id,claim,sentence,evidence,role
0,1 in 5 million in UK have abnormal PrP positivity.,"OBJECTIVES To carry out a further survey of archived appendix samples to understand better the differences between existing estimates of the prevalence of subclinical infection with prions after the bovine spongiform encephalopathy epizootic and to see whether a broader birth cohort was affected, and to understand better the implications for the management of blood and blood products and for the handling of surgical instruments.   
",False,OBJECTIVE
1,1 in 5 million in UK have abnormal PrP positivity.,"DESIGN Irreversibly unlinked and anonymised large scale survey of archived appendix samples.   
",False,METHODS
2,1 in 5 million in UK have abnormal PrP positivity.,"SETTING Archived appendix samples from the pathology departments of 41 UK hospitals participating in the earlier survey, and additional hospitals in regions with lower levels of participation in that survey.   ",False,METHODS
3,1 in 5 million in UK have abnormal PrP positivity.,"SAMPLE 32,441 archived appendix samples fixed in formalin and embedded in paraffin and tested for the presence of abnormal prion protein (PrP).   
",False,METHODS
4,1 in 5 million in UK have abnormal PrP positivity.,"RESULTS Of the 32,441 appendix samples 16 were positive for abnormal PrP, indicating an overall prevalence of 493 per million population (95% confidence interval 282 to 801 per million).",True,RESULTS
5,1 in 5 million in UK have abnormal PrP positivity.,"The prevalence in those born in 1941-60 (733 per million, 269 to 1596 per million) did not differ significantly from those born between 1961 and 1985 (412 per million, 198 to 758 per million) and was similar in both sexes and across the three broad geographical areas sampled.",False,RESULTS
6,1 in 5 million in UK have abnormal PrP positivity.,"Genetic testing of the positive specimens for the genotype at PRNP codon 129 revealed a high proportion that were valine homozygous compared with the frequency in the normal population, and in stark contrast with confirmed clinical cases of vCJD, all of which were methionine homozygous at PRNP codon 129.   
",False,RESULTS
7,1 in 5 million in UK have abnormal PrP positivity.,"CONCLUSIONS This study corroborates previous studies and suggests a high prevalence of infection with abnormal PrP, indicating vCJD carrier status in the population compared with the 177 vCJD cases to date.",False,CONCLUSIONS
8,1 in 5 million in UK have abnormal PrP positivity.,These findings have important implications for the management of blood and blood products and for the handling of surgical instruments.,False,CONCLUSIONS
9,32% of liver transplantation programs required patients to discontinue methadone treatment in 2001.,ContextChronic hepatitis C is the leading cause for liver transplantation in the United States.,False,BACKGROUND
10,32% of liver transplantation programs required patients to discontinue methadone treatment in 2001.,"Intravenous drug use, the major risk factor, accounts for approximately 60% of hepatitis C virus transmission.",False,BACKGROUND
11,32% of liver transplantation programs required patients to discontinue methadone treatment in 2001.,Information from the United Network of Organ Sharing (UNOS) does not address substance use among liver transplantation patients.,False,BACKGROUND
12,32% of liver transplantation programs required patients to discontinue methadone treatment in 2001.,ObjectiveTo identify addiction-related criteria for admission to the UNOS liver transplantation waiting list and posttransplantation problems experienced by patients who are prescribed maintenance methadone.,False,OBJECTIVE
13,32% of liver transplantation programs required patients to discontinue methadone treatment in 2001.,"Design, Setting, and ParticipantsMail survey of all 97 adult US liver transplantation programs (belonging to UNOS) in March 2000 with telephone follow-up conducted in May and June 2000.Main Outcome MeasuresPrograms' acceptance and management of patients with past or present substance use disorder.",False,METHODS
14,32% of liver transplantation programs required patients to discontinue methadone treatment in 2001.,"ResultsOf the 97 programs surveyed, 87 (90%) responded.",False,METHODS
15,32% of liver transplantation programs required patients to discontinue methadone treatment in 2001.,"All accept applicants with a history of alcoholism or other addictions, including heroin dependence.",False,METHODS
16,32% of liver transplantation programs required patients to discontinue methadone treatment in 2001.,Eighty-eight percent of the responding programs require at least 6 months of abstinence from alcohol; 83% from illicit drugs.,False,RESULTS
17,32% of liver transplantation programs required patients to discontinue methadone treatment in 2001.,Ninety-four percent have addiction treatment requirements.,False,RESULTS
18,32% of liver transplantation programs required patients to discontinue methadone treatment in 2001.,Consultations from substance abuse specialists are obtained by 86%.,False,RESULTS
19,32% of liver transplantation programs required patients to discontinue methadone treatment in 2001.,Patients receiving methadone maintenance are accepted by 56% of the responding programs.,False,RESULTS
20,32% of liver transplantation programs required patients to discontinue methadone treatment in 2001.,Approximately 180 patients receiving methadone maintenance are reported to have undergone liver transplantation.,False,RESULTS
21,32% of liver transplantation programs required patients to discontinue methadone treatment in 2001.,ConclusionsMost liver transplantation programs have established policies for patients with substance use disorders.,False,CONCLUSIONS
22,32% of liver transplantation programs required patients to discontinue methadone treatment in 2001.,Opiate-dependent patients receiving opiate replacement therapy seem underrepresented in transplantation programs.,False,CONCLUSIONS
23,32% of liver transplantation programs required patients to discontinue methadone treatment in 2001.,Little anecdotal evidence for negative impact of opiate replacement therapy on liver transplantation outcome was found.,False,CONCLUSIONS
24,32% of liver transplantation programs required patients to discontinue methadone treatment in 2001.,Policies requiring discontinuation of methadone in 32% of all programs contradict the evidence base for efficacy of long-term replacement therapies and potentially result in relapse of previously stable patients.,True,CONCLUSIONS
25,40mg/day dosage of folic acid and 2mg/day dosage of vitamin B12 does not affect chronic kidney disease (CKD) progression.,CONTEXT High plasma homocysteine levels are a risk factor for mortality and vascular disease in observational studies of patients with chronic kidney disease.,False,OBJECTIVE
26,40mg/day dosage of folic acid and 2mg/day dosage of vitamin B12 does not affect chronic kidney disease (CKD) progression.,"Folic acid and B vitamins decrease homocysteine levels in this population but whether they lower mortality is unknown.   
",False,OBJECTIVE
27,40mg/day dosage of folic acid and 2mg/day dosage of vitamin B12 does not affect chronic kidney disease (CKD) progression.,"OBJECTIVE To determine whether high doses of folic acid and B vitamins administered daily reduce mortality in patients with chronic kidney disease.   
",False,OBJECTIVE
28,40mg/day dosage of folic acid and 2mg/day dosage of vitamin B12 does not affect chronic kidney disease (CKD) progression.,"DESIGN, SETTING, AND PARTICIPANTS Double-blind randomized controlled trial (2001-2006) in 36 US Department of Veterans Affairs medical centers.",False,METHODS
29,40mg/day dosage of folic acid and 2mg/day dosage of vitamin B12 does not affect chronic kidney disease (CKD) progression.,"Median follow-up was 3.2 years for 2056 participants aged 21 years or older with advanced chronic kidney disease (estimated creatinine clearance < or =30 mL/min) (n = 1305) or end-stage renal disease (n = 751) and high homocysteine levels (> or = 15 micromol/L).   
",False,METHODS
30,40mg/day dosage of folic acid and 2mg/day dosage of vitamin B12 does not affect chronic kidney disease (CKD) progression.,"INTERVENTION Participants received a daily capsule containing 40 mg of folic acid, 100 mg of pyridoxine hydrochloride (vitamin B6), and 2 mg of cyanocobalamin (vitamin B12) or a placebo.   
",False,METHODS
31,40mg/day dosage of folic acid and 2mg/day dosage of vitamin B12 does not affect chronic kidney disease (CKD) progression.,MAIN OUTCOME MEASURES The primary outcome was all-cause mortality.,False,METHODS
32,40mg/day dosage of folic acid and 2mg/day dosage of vitamin B12 does not affect chronic kidney disease (CKD) progression.,"Secondary outcomes included myocardial infarction (MI), stroke, amputation of all or part of a lower extremity, a composite of these 3 plus all-cause mortality, time to initiation of dialysis, and time to thrombosis of arteriovenous access in hemodialysis patients.   
",False,METHODS
33,40mg/day dosage of folic acid and 2mg/day dosage of vitamin B12 does not affect chronic kidney disease (CKD) progression.,RESULTS Mean baseline homocysteine level was 24.0 micromol/L in the vitamin group and 24.2 micromol/L in the placebo group.,True,RESULTS
34,40mg/day dosage of folic acid and 2mg/day dosage of vitamin B12 does not affect chronic kidney disease (CKD) progression.,"It was lowered 6.3 micromol/L (25.8%; P < .001) in the vitamin group and 0.4 micromol/L (1.7%; P = .14) in the placebo group at 3 months, but there was no significant effect on mortality (448 vitamin group deaths vs 436 placebo group deaths) (hazard ratio [HR], 1.04; 95% CI, 0.91-1.18).",False,RESULTS
35,40mg/day dosage of folic acid and 2mg/day dosage of vitamin B12 does not affect chronic kidney disease (CKD) progression.,"No significant effects were demonstrated for secondary outcomes or adverse events: there were 129 MIs in the vitamin group vs 150 for placebo (HR, 0.86; 95% CI, 0.67-1.08), 37 strokes in the vitamin group vs 41 for placebo (HR, 0.90; 95% CI, 0.58-1.40), and 60 amputations in the vitamin group vs 53 for placebo (HR, 1.14; 95% CI, 0.79-1.64).",False,RESULTS
36,40mg/day dosage of folic acid and 2mg/day dosage of vitamin B12 does not affect chronic kidney disease (CKD) progression.,"In addition, the composite of MI, stroke, and amputations plus mortality (P = .85), time to dialysis (P = .38), and time to thrombosis in hemodialysis patients (P = .97) did not differ between the vitamin and placebo groups.   
",False,RESULTS
37,40mg/day dosage of folic acid and 2mg/day dosage of vitamin B12 does not affect chronic kidney disease (CKD) progression.,"CONCLUSION Treatment with high doses of folic acid and B vitamins did not improve survival or reduce the incidence of vascular disease in patients with advanced chronic kidney disease or end-stage renal disease.   
",True,CONCLUSIONS
38,40mg/day dosage of folic acid and 2mg/day dosage of vitamin B12 does not affect chronic kidney disease (CKD) progression.,TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00032435.,False,CONCLUSIONS
39,76-85% of people with severe mental disorder receive no treatment in low and middle income countries.,"CONTEXT Little is known about the extent or severity of untreated mental disorders, especially in less-developed countries.   
",False,BACKGROUND
40,76-85% of people with severe mental disorder receive no treatment in low and middle income countries.,"OBJECTIVE To estimate prevalence, severity, and treatment of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) mental disorders in 14 countries (6 less developed, 8 developed) in the World Health Organization (WHO) World Mental Health (WMH) Survey Initiative.   
",False,OBJECTIVE
41,76-85% of people with severe mental disorder receive no treatment in low and middle income countries.,"DESIGN, SETTING, AND PARTICIPANTS Face-to-face household surveys of 60 463 community adults conducted from 2001-2003 in 14 countries in the Americas, Europe, the Middle East, Africa, and Asia.   
",False,METHODS
42,76-85% of people with severe mental disorder receive no treatment in low and middle income countries.,"MAIN OUTCOME MEASURES The DSM-IV disorders, severity, and treatment were assessed with the WMH version of the WHO Composite International Diagnostic Interview (WMH-CIDI), a fully structured, lay-administered psychiatric diagnostic interview.   
",False,METHODS
43,76-85% of people with severe mental disorder receive no treatment in low and middle income countries.,"RESULTS The prevalence of having any WMH-CIDI/DSM-IV disorder in the prior year varied widely, from 4.3% in Shanghai to 26.4% in the United States, with an interquartile range (IQR) of 9.1%-16.9%.",False,RESULTS
44,76-85% of people with severe mental disorder receive no treatment in low and middle income countries.,"Between 33.1% (Colombia) and 80.9% (Nigeria) of 12-month cases were mild (IQR, 40.2%-53.3%).",False,RESULTS
45,76-85% of people with severe mental disorder receive no treatment in low and middle income countries.,Serious disorders were associated with substantial role disability.,False,RESULTS
46,76-85% of people with severe mental disorder receive no treatment in low and middle income countries.,"Although disorder severity was correlated with probability of treatment in almost all countries, 35.5% to 50.3% of serious cases in developed countries and 76.3% to 85.4% in less-developed countries received no treatment in the 12 months before the interview.",True,RESULTS
47,76-85% of people with severe mental disorder receive no treatment in low and middle income countries.,"Due to the high prevalence of mild and subthreshold cases, the number of those who received treatment far exceeds the number of untreated serious cases in every country.   
",False,CONCLUSIONS
48,76-85% of people with severe mental disorder receive no treatment in low and middle income countries.,CONCLUSIONS Reallocation of treatment resources could substantially decrease the problem of unmet need for treatment of mental disorders among serious cases.,False,CONCLUSIONS
49,76-85% of people with severe mental disorder receive no treatment in low and middle income countries.,Structural barriers exist to this reallocation.,False,CONCLUSIONS
50,76-85% of people with severe mental disorder receive no treatment in low and middle income countries.,"Careful consideration needs to be given to the value of treating some mild cases, especially those at risk for progressing to more serious disorders.",False,CONCLUSIONS
51,A T helper 2 cell (Th2) environment impedes disease development in patients with systemic lupus erythematosus (SLE).,"In systemic lupus erythematosus (SLE), self-reactive antibodies can target the kidney (lupus nephritis), leading to functional failure and possible mortality.",False,BACKGROUND
52,A T helper 2 cell (Th2) environment impedes disease development in patients with systemic lupus erythematosus (SLE).,"We report that activation of basophils by autoreactive IgE causes their homing to lymph nodes, promoting T helper type 2 (T(H)2) cell differentiation and enhancing the production of self-reactive antibodies that cause lupus-like nephritis in mice lacking the Src family protein tyrosine kinase Lyn (Lyn(-/-) mice).",True,BACKGROUND
53,A T helper 2 cell (Th2) environment impedes disease development in patients with systemic lupus erythematosus (SLE).,"Individuals with SLE also have elevated serum IgE, self-reactive IgEs and activated basophils that express CD62 ligand (CD62L) and the major histocompatibility complex (MHC) class II molecule human leukocyte antigen-DR (HLA-DR), parameters that are associated with increased disease activity and active lupus nephritis.",True,RESULTS
54,A T helper 2 cell (Th2) environment impedes disease development in patients with systemic lupus erythematosus (SLE).,Basophils were also present in the lymph nodes and spleen of subjects with SLE.,False,RESULTS
55,A T helper 2 cell (Th2) environment impedes disease development in patients with systemic lupus erythematosus (SLE).,"Thus, in Lyn(-/-) mice, basophils and IgE autoantibodies amplify autoantibody production that leads to lupus nephritis, and in individuals with SLE IgE autoantibodies and activated basophils are factors associated with disease activity and nephritis.",True,RESULTS
56,A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.,"CONTEXT The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor-positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and endoxifen.",False,OBJECTIVE
57,A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.,"The formation of active metabolites is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6) enzyme.   
",False,OBJECTIVE
58,A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.,"OBJECTIVE To determine whether CYP2D6 variation is associated with clinical outcomes in women receiving adjuvant tamoxifen.   
",False,OBJECTIVE
59,A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.,"DESIGN, SETTING, AND PATIENTS Retrospective analysis of German and US cohorts of patients treated with adjuvant tamoxifen for early stage breast cancer.",False,METHODS
60,A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.,The 1325 patients had diagnoses between 1986 and 2005 of stage I through III breast cancer and were mainly postmenopausal (95.4%).,False,METHODS
61,A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.,"Last follow-up was in December 2008; inclusion criteria were hormone receptor positivity, no metastatic disease at diagnosis, adjuvant tamoxifen therapy, and no chemotherapy.",False,METHODS
62,A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.,"DNA from tumor tissue or blood was genotyped for CYP2D6 variants associated with reduced (*10, *41) or absent (*3, *4, *5) enzyme activity.",False,METHODS
63,A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.,"Women were classified as having an extensive (n=609), heterozygous extensive/intermediate (n=637), or poor (n=79) CYP2D6 metabolism.   
",False,METHODS
64,A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.,"MAIN OUTCOME MEASURES Time to recurrence, event-free survival, disease-free survival, and overall survival.   
",False,METHODS
65,A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.,RESULTS Median follow-up was 6.3 years.,False,RESULTS
66,A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.,"At 9 years of follow-up, the recurrence rates were 14.9% for extensive metabolizers, 20.9% for heterozygous extensive/intermediate metabolizers, and 29.0% for poor metabolizers, and all-cause mortality rates were 16.7%, 18.0%, and 22.8%, respectively.",True,RESULTS
67,A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.,"Compared with extensive metabolizers, there was a significantly increased risk of recurrence for heterozygous extensive/intermediate metabolizers (time to recurrence adjusted hazard ratio [HR], 1.40; 95% confidence interval [CI], 1.04-1.90) and for poor metabolizers (time to recurrence HR, 1.90; 95% CI, 1.10-3.28).",True,RESULTS
68,A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.,"Compared with extensive metabolizers, those with decreased CYP2D6 activity (heterozygous extensive/intermediate and poor metabolism) had worse event-free survival (HR, 1.33; 95% CI, 1.06-1.68) and disease-free survival (HR, 1.29; 95% CI, 1.03-1.61), but there was no significant difference in overall survival (HR, 1.15; 95% CI, 0.88-1.51).   
",True,RESULTS
69,A breast cancer patient's capacity to metabolize tamoxifen influences treatment outcome.,"CONCLUSION Among women with breast cancer treated with tamoxifen, there was an association between CYP2D6 variation and clinical outcomes, such that the presence of 2 functional CYP2D6 alleles was associated with better clinical outcomes and the presence of nonfunctional or reduced-function alleles with worse outcomes.",True,CONCLUSIONS
70,A country's Vaccine Alliance (GAVI) eligibility is not indictivate of accelerated adoption of the Hub vaccine.,BACKGROUND Adoption of new and underutilized vaccines by national immunization programs is an essential step towards reducing child mortality.,False,BACKGROUND
71,A country's Vaccine Alliance (GAVI) eligibility is not indictivate of accelerated adoption of the Hub vaccine.,Policy decisions to adopt new vaccines in high mortality countries often lag behind decisions in high-income countries.,False,BACKGROUND
72,A country's Vaccine Alliance (GAVI) eligibility is not indictivate of accelerated adoption of the Hub vaccine.,"Using the case of Haemophilus influenzae type b (Hib) vaccine, this paper endeavors to explain these delays through the analysis of country-level economic, epidemiological, programmatic and policy-related factors, as well as the role of the Global Alliance for Vaccines and Immunisation (GAVI Alliance).   
",False,BACKGROUND
73,A country's Vaccine Alliance (GAVI) eligibility is not indictivate of accelerated adoption of the Hub vaccine.,METHODS AND FINDINGS Data for 147 countries from 1990 to 2007 were analyzed in accelerated failure time models to identify factors that are associated with the time to decision to adopt Hib vaccine.,False,METHODS
74,A country's Vaccine Alliance (GAVI) eligibility is not indictivate of accelerated adoption of the Hub vaccine.,"In multivariable models that control for Gross National Income, region, and burden of Hib disease, the receipt of GAVI support speeded the time to decision by a factor of 0.37 (95% CI 0.18-0.76), or 63%.",False,RESULTS
75,A country's Vaccine Alliance (GAVI) eligibility is not indictivate of accelerated adoption of the Hub vaccine.,The presence of two or more neighboring country adopters accelerated decisions to adopt by a factor of 0.50 (95% CI 0.33-0.75).,False,RESULTS
76,A country's Vaccine Alliance (GAVI) eligibility is not indictivate of accelerated adoption of the Hub vaccine.,"For each 1% increase in vaccine price, decisions to adopt are delayed by a factor of 1.02 (95% CI 1.00-1.04).",False,RESULTS
77,A country's Vaccine Alliance (GAVI) eligibility is not indictivate of accelerated adoption of the Hub vaccine.,"Global recommendations and local studies were not associated with time to decision.   
",False,RESULTS
78,A country's Vaccine Alliance (GAVI) eligibility is not indictivate of accelerated adoption of the Hub vaccine.,CONCLUSIONS This study substantiates previous findings related to vaccine price and presents new evidence to suggest that GAVI eligibility is associated with accelerated decisions to adopt Hib vaccine.,True,CONCLUSIONS
79,A country's Vaccine Alliance (GAVI) eligibility is not indictivate of accelerated adoption of the Hub vaccine.,"The influence of neighboring country decisions was also highly significant, suggesting that approaches to support the adoption of new vaccines should consider supply- and demand-side factors.",False,CONCLUSIONS
80,A deficiency of folate increases blood levels of homocysteine.,BACKGROUND Lowering serum homocysteine levels with folic acid is expected to reduce mortality from ischemic heart disease.,False,BACKGROUND
81,A deficiency of folate increases blood levels of homocysteine.,"Homocysteine reduction is known to be maximal at a folic acid dosage of 1 mg/d, but the effect of lower doses (relevant to food fortification) is unclear.   
",False,BACKGROUND
82,A deficiency of folate increases blood levels of homocysteine.,"METHODS We randomized 151 patients with ischemic heart disease to 1 of 5 dosages of folic acid (0.2, 0.4, 0.6, 0.8, and 1.0 mg/d) or placebo.",False,METHODS
83,A deficiency of folate increases blood levels of homocysteine.,"Fasting blood samples for serum homocysteine and serum folate analysis were taken initially, after 3 months of supplementation, and 3 months after folic acid use was discontinued.   
",False,METHODS
84,A deficiency of folate increases blood levels of homocysteine.,"RESULTS Median serum homocysteine level decreased with increasing folic acid dosage, to a maximum at 0.8 mg of folic acid per day, when the homocysteine reduction (placebo adjusted) was 2.7 micromol/L (23%), similar to the known effect of folic acid dosages of 1 mg/d and above.",True,RESULTS
85,A deficiency of folate increases blood levels of homocysteine.,"The higher a person's initial serum homocysteine level, the greater was the response to folic acid, but there were statistically significant reductions regardless of the initial level.",False,RESULTS
86,A deficiency of folate increases blood levels of homocysteine.,Serum folate level increased approximately linearly (5.5 nmol/L for every 0.1 mg of folic acid).,False,RESULTS
87,A deficiency of folate increases blood levels of homocysteine.,"Within-person fluctuations over time in serum homocysteine levels, measured in the placebo group, were large compared with the effect of folic acid, indicating that monitoring of the reduction in an individual is impractical.   
",False,CONCLUSIONS
88,A deficiency of folate increases blood levels of homocysteine.,CONCLUSIONS A dosage of folic acid of 0.8 mg/d appears necessary to achieve the maximum reduction in serum homocysteine level across the range of homocysteine levels in the population.,False,CONCLUSIONS
89,A deficiency of folate increases blood levels of homocysteine.,Current US food fortification levels will achieve only a small proportion of the achievable homocysteine reduction.,False,CONCLUSIONS
90,A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.,"Importance Despite lack of evidence of their utility, biomarkers of ovarian reserve are being promoted as potential markers of reproductive potential.",False,BACKGROUND
91,A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.,Objective To determine the associations between biomarkers of ovarian reserve and reproductive potential among women of late reproductive age.,False,OBJECTIVE
92,A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.,"Design, Setting, and Participants Prospective time-to-pregnancy cohort study (2008 to date of last follow-up in March 2016) of women (N = 981) aged 30 to 44 years without a history of infertility who had been trying to conceive for 3 months or less, recruited from the community in the Raleigh-Durham, North Carolina, area.",False,METHODS
93,A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.,"Exposures Early-follicular-phase serum level of antimüllerian hormone (AMH), follicle-stimulating hormone (FSH), and inhibin B and urinary level of FSH.",False,METHODS
94,A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.,Main Outcomes and Measures The primary outcomes were the cumulative probability of conception by 6 and 12 cycles of attempt and relative fecundability (probability of conception in a given menstrual cycle).,False,METHODS
95,A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.,Conception was defined as a positive pregnancy test result.,False,METHODS
96,A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.,"Results A total of 750 women (mean age, 33.3 [SD, 3.2] years; 77% white; 36% overweight or obese) provided a blood and urine sample and were included in the analysis.",False,RESULTS
97,A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.,"After adjusting for age, body mass index, race, current smoking status, and recent hormonal contraceptive use, women with low AMH values (<0.7 ng/mL [n = 84]) did not have a significantly different predicted probability of conceiving by 6 cycles of attempt (65%; 95% CI, 50%-75%) compared with women (n = 579) with normal values (62%; 95% CI, 57%-66%) or by 12 cycles of attempt (84% [95% CI, 70%-91%] vs 75% [95% CI, 70%-79%], respectively).",True,RESULTS
98,A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.,"Women with high serum FSH values (>10 mIU/mL [n = 83]) did not have a significantly different predicted probability of conceiving after 6 cycles of attempt (63%; 95% CI, 50%-73%) compared with women (n = 654) with normal values (62%; 95% CI, 57%-66%) or after 12 cycles of attempt (82% [95% CI, 70%-89%] vs 75% [95% CI, 70%-78%], respectively).",True,RESULTS
99,A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.,"Women with high urinary FSH values (>11.5 mIU/mg creatinine [n = 69]) did not have a significantly different predicted probability of conceiving after 6 cycles of attempt (61%; 95% CI, 46%-74%) compared with women (n = 660) with normal values (62%; 95% CI, 58%-66%) or after 12 cycles of attempt (70% [95% CI, 54%-80%] vs 76% [95% CI, 72%-80%], respectively).",True,RESULTS
100,A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.,"Inhibin B levels (n = 737) were not associated with the probability of conceiving in a given cycle (hazard ratio per 1-pg/mL increase, 0.999; 95% CI, 0.997-1.001).",True,RESULTS
101,A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.,"Conclusions and Relevance Among women aged 30 to 44 years without a history of infertility who had been trying to conceive for 3 months or less, biomarkers indicating diminished ovarian reserve compared with normal ovarian reserve were not associated with reduced fertility.",True,CONCLUSIONS
102,A diminished ovarian reserve does not solely indicate infertility in an a priori non-infertile population.,These findings do not support the use of urinary or blood follicle-stimulating hormone tests or antimüllerian hormone levels to assess natural fertility for women with these characteristics.,False,CONCLUSIONS
103,"A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.","Importance Despite lack of evidence of their utility, biomarkers of ovarian reserve are being promoted as potential markers of reproductive potential.",False,BACKGROUND
104,"A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.",Objective To determine the associations between biomarkers of ovarian reserve and reproductive potential among women of late reproductive age.,False,OBJECTIVE
105,"A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.","Design, Setting, and Participants Prospective time-to-pregnancy cohort study (2008 to date of last follow-up in March 2016) of women (N = 981) aged 30 to 44 years without a history of infertility who had been trying to conceive for 3 months or less, recruited from the community in the Raleigh-Durham, North Carolina, area.",False,METHODS
106,"A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.","Exposures Early-follicular-phase serum level of antimüllerian hormone (AMH), follicle-stimulating hormone (FSH), and inhibin B and urinary level of FSH.",False,METHODS
107,"A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.",Main Outcomes and Measures The primary outcomes were the cumulative probability of conception by 6 and 12 cycles of attempt and relative fecundability (probability of conception in a given menstrual cycle).,False,METHODS
108,"A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.",Conception was defined as a positive pregnancy test result.,False,METHODS
109,"A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.","Results A total of 750 women (mean age, 33.3 [SD, 3.2] years; 77% white; 36% overweight or obese) provided a blood and urine sample and were included in the analysis.",False,RESULTS
110,"A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.","After adjusting for age, body mass index, race, current smoking status, and recent hormonal contraceptive use, women with low AMH values (<0.7 ng/mL [n = 84]) did not have a significantly different predicted probability of conceiving by 6 cycles of attempt (65%; 95% CI, 50%-75%) compared with women (n = 579) with normal values (62%; 95% CI, 57%-66%) or by 12 cycles of attempt (84% [95% CI, 70%-91%] vs 75% [95% CI, 70%-79%], respectively).",True,RESULTS
111,"A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.","Women with high serum FSH values (>10 mIU/mL [n = 83]) did not have a significantly different predicted probability of conceiving after 6 cycles of attempt (63%; 95% CI, 50%-73%) compared with women (n = 654) with normal values (62%; 95% CI, 57%-66%) or after 12 cycles of attempt (82% [95% CI, 70%-89%] vs 75% [95% CI, 70%-78%], respectively).",True,RESULTS
112,"A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.","Women with high urinary FSH values (>11.5 mIU/mg creatinine [n = 69]) did not have a significantly different predicted probability of conceiving after 6 cycles of attempt (61%; 95% CI, 46%-74%) compared with women (n = 660) with normal values (62%; 95% CI, 58%-66%) or after 12 cycles of attempt (70% [95% CI, 54%-80%] vs 76% [95% CI, 72%-80%], respectively).",True,RESULTS
113,"A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.","Inhibin B levels (n = 737) were not associated with the probability of conceiving in a given cycle (hazard ratio per 1-pg/mL increase, 0.999; 95% CI, 0.997-1.001).",True,RESULTS
114,"A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.","Conclusions and Relevance Among women aged 30 to 44 years without a history of infertility who had been trying to conceive for 3 months or less, biomarkers indicating diminished ovarian reserve compared with normal ovarian reserve were not associated with reduced fertility.",True,CONCLUSIONS
115,"A diminished ovarian reserve is a very strong indicator of infertility, even in an a priori non-infertile population.",These findings do not support the use of urinary or blood follicle-stimulating hormone tests or antimüllerian hormone levels to assess natural fertility for women with these characteristics.,False,CONCLUSIONS
116,A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.,BACKGROUND The heritable haemoglobinopathy alpha(+)-thalassaemia is caused by the reduced synthesis of alpha-globin chains that form part of normal adult haemoglobin (Hb).,False,OBJECTIVE
117,A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.,Individuals homozygous for alpha(+)-thalassaemia have microcytosis and an increased erythrocyte count.,True,OBJECTIVE
118,A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.,"Alpha(+)-thalassaemia homozygosity confers considerable protection against severe malaria, including severe malarial anaemia (SMA) (Hb concentration < 50 g/l), but does not influence parasite count.",False,OBJECTIVE
119,A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.,"We tested the hypothesis that the erythrocyte indices associated with alpha(+)-thalassaemia homozygosity provide a haematological benefit during acute malaria.   
",False,OBJECTIVE
120,A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.,METHODS AND FINDINGS Data from children living on the north coast of Papua New Guinea who had participated in a case-control study of the protection afforded by alpha(+)-thalassaemia against severe malaria were reanalysed to assess the genotype-specific reduction in erythrocyte count and Hb levels associated with acute malarial disease.,False,METHODS
121,A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.,We observed a reduction in median erythrocyte count of approximately 1.5 x 10(12)/l in all children with acute falciparum malaria relative to values in community children (p < 0.001).,False,RESULTS
122,A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.,We developed a simple mathematical model of the linear relationship between Hb concentration and erythrocyte count.,False,RESULTS
123,A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.,This model predicted that children homozygous for alpha(+)-thalassaemia lose less Hb than children of normal genotype for a reduction in erythrocyte count of >1.1 x 10(12)/l as a result of the reduced mean cell Hb in homozygous alpha(+)-thalassaemia.,False,RESULTS
124,A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.,"In addition, children homozygous for alpha(+)-thalassaemia require a 10% greater reduction in erythrocyte count than children of normal genotype (p = 0.02) for Hb concentration to fall to 50 g/l, the cutoff for SMA.",False,RESULTS
125,A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.,"We estimated that the haematological profile in children homozygous for alpha(+)-thalassaemia reduces the risk of SMA during acute malaria compared to children of normal genotype (relative risk 0.52; 95% confidence interval [CI] 0.24-1.12, p = 0.09).   
",True,RESULTS
126,A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.,CONCLUSIONS The increased erythrocyte count and microcytosis in children homozygous for alpha(+)-thalassaemia may contribute substantially to their protection against SMA.,True,CONCLUSIONS
127,A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.,A lower concentration of Hb per erythrocyte and a larger population of erythrocytes may be a biologically advantageous strategy against the significant reduction in erythrocyte count that occurs during acute infection with the malaria parasite Plasmodium falciparum.,False,CONCLUSIONS
128,A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.,"This haematological profile may reduce the risk of anaemia by other Plasmodium species, as well as other causes of anaemia.",False,CONCLUSIONS
129,A high microerythrocyte count protects against severe anemia in homozygous alpha (+)- thalassemia trait subjects.,Other host polymorphisms that induce an increased erythrocyte count and microcytosis may confer a similar advantage.,False,CONCLUSIONS
130,A mutation in HNF4A leads to an increased risk of developing diabetes by the age of 14 years.,Background  Macrosomia is associated with considerable neonatal and maternal morbidity.,False,OBJECTIVE
131,A mutation in HNF4A leads to an increased risk of developing diabetes by the age of 14 years.,Factors that predict macrosomia are poorly understood.,False,OBJECTIVE
132,A mutation in HNF4A leads to an increased risk of developing diabetes by the age of 14 years.,The increased rate of macrosomia in the offspring of pregnant women with diabetes and in congenital hyperinsulinaemia is mediated by increased foetal insulin secretion.,False,OBJECTIVE
133,A mutation in HNF4A leads to an increased risk of developing diabetes by the age of 14 years.,"We assessed the in utero and neonatal role of two key regulators of pancreatic insulin secretion by studying birthweight and the incidence of neonatal hypoglycaemia in patients with heterozygous mutations in the maturity-onset diabetes of the young (MODY) genes HNF4A (encoding HNF-4α) and HNF1A/TCF1 (encoding HNF-1α), and the effect of pancreatic deletion of Hnf4a on foetal and neonatal insulin secretion in mice.",True,OBJECTIVE
134,A single nucleotide variant the gene DGKK is strongly associated with increased risk of hypospadias.,Hypospadias is a common congenital malformation of the male external genitalia.,False,BACKGROUND
135,A single nucleotide variant the gene DGKK is strongly associated with increased risk of hypospadias.,"We performed a genome-wide association study using pooled DNA from 436 individuals with hypospadias (cases) and 494 controls of European descent and selected the highest ranked SNPs for individual genotyping in the discovery sample, an additional Dutch sample of 133 cases and their parents, and a Swedish series of 266 cases and 402 controls.",False,METHODS
136,A single nucleotide variant the gene DGKK is strongly associated with increased risk of hypospadias.,"Individual genotyping of two SNPs (rs1934179 and rs7063116) in DGKK, encoding diacylglycerol kinase κ, produced compelling evidence for association with hypospadias in the discovery sample (allele-specific odds ratio (OR) = 2.5, P = 2.5 × 10−11 and OR = 2.3, P = 2.9 × 10−9, respectively) and in the Dutch (OR = 3.9, P = 2.4 × 10−5 and OR = 3.8, P = 3.4 × 10−5) and Swedish (OR = 2.5, P = 2.6 × 10−8 and OR = 2.2, P = 2.7 × 10−6) replication samples.",True,RESULTS
137,A single nucleotide variant the gene DGKK is strongly associated with increased risk of hypospadias.,"Expression studies showed expression of DGKK in preputial tissue of cases and controls, which was lower in carriers of the risk allele of rs1934179 (P = 0.047).",False,RESULTS
138,A single nucleotide variant the gene DGKK is strongly associated with increased risk of hypospadias.,We propose DGKK as a major risk gene for hypospadias.,False,CONCLUSIONS
139,A strong bias in the phage genome locations where the spacers were derived has been observed in many CRISPR subtypes that confer the immunity to phage.,Clustered regularly interspaced short palindromic repeats (CRISPR)-Cas systems provide adaptive immunity against phage via spacer-encoded CRISPR RNAs that are complementary to invasive nucleic acids.,False,BACKGROUND
140,A strong bias in the phage genome locations where the spacers were derived has been observed in many CRISPR subtypes that confer the immunity to phage.,"Here, we challenge Streptococcus thermophilus with a bacteriophage, and used PCR-based metagenomics to monitor phage-derived spacers daily for 15 days in two experiments.",False,METHODS
141,A strong bias in the phage genome locations where the spacers were derived has been observed in many CRISPR subtypes that confer the immunity to phage.,"Spacers that target the host chromosome are infrequent and strongly selected against, suggesting autoimmunity is lethal.",False,METHODS
142,A strong bias in the phage genome locations where the spacers were derived has been observed in many CRISPR subtypes that confer the immunity to phage.,"In experiments that recover over half a million spacers, we observe early dominance by a few spacer sub-populations and rapid oscillations in sub-population abundances.",False,RESULTS
143,A strong bias in the phage genome locations where the spacers were derived has been observed in many CRISPR subtypes that confer the immunity to phage.,"In two CRISPR systems and in replicate experiments, a few spacers account for the majority of spacer sequences.",False,RESULTS
144,A strong bias in the phage genome locations where the spacers were derived has been observed in many CRISPR subtypes that confer the immunity to phage.,"Nearly all phage locations targeted by the acquired spacers have a proto-spacer adjacent motif (PAM), indicating PAMs are involved in spacer acquisition.",False,RESULTS
145,A strong bias in the phage genome locations where the spacers were derived has been observed in many CRISPR subtypes that confer the immunity to phage.,We detect a strong and reproducible bias in the phage genome locations from which spacers derive.,True,CONCLUSIONS
146,A strong bias in the phage genome locations where the spacers were derived has been observed in many CRISPR subtypes that confer the immunity to phage.,This may reflect selection for specific spacers based on location and effectiveness.,False,CONCLUSIONS
147,ALDH1 expression is associated with poorer prognosis for breast cancer primary tumors.,Application of stem cell biology to breast cancer research has been limited by the lack of simple methods for identification and isolation of normal and malignant stem cells.,False,BACKGROUND
148,ALDH1 expression is associated with poorer prognosis for breast cancer primary tumors.,"Utilizing in vitro and in vivo experimental systems, we show that normal and cancer human mammary epithelial cells with increased aldehyde dehydrogenase activity (ALDH) have stem/progenitor properties.",False,BACKGROUND
149,ALDH1 expression is associated with poorer prognosis for breast cancer primary tumors.,These cells contain the subpopulation of normal breast epithelium with the broadest lineage differentiation potential and greatest growth capacity in a xenotransplant model.,False,BACKGROUND
150,ALDH1 expression is associated with poorer prognosis for breast cancer primary tumors.,"In breast carcinomas, high ALDH activity identifies the tumorigenic cell fraction, capable of self-renewal and of generating tumors that recapitulate the heterogeneity of the parental tumor.",False,BACKGROUND
151,ALDH1 expression is associated with poorer prognosis for breast cancer primary tumors.,"In a series of 577 breast carcinomas, expression of ALDH1 detected by immunostaining correlated with poor prognosis.",True,BACKGROUND
152,ALDH1 expression is associated with poorer prognosis for breast cancer primary tumors.,These findings offer an important new tool for the study of normal and malignant breast stem cells and facilitate the clinical application of stem cell concepts.,False,BACKGROUND
153,AMP-activated protein kinase (AMPK) activation reduces inflammation-related fibrosis in the lungs.,"Fibrosis is a pathological result of a dysfunctional repair response to tissue injury and occurs in a number of organs, including the lungs1.",False,BACKGROUND
154,AMP-activated protein kinase (AMPK) activation reduces inflammation-related fibrosis in the lungs.,Cellular metabolism regulates tissue repair and remodelling responses to injury2-4.,False,BACKGROUND
155,AMP-activated protein kinase (AMPK) activation reduces inflammation-related fibrosis in the lungs.,AMPK is a critical sensor of cellular bioenergetics and controls the switch from anabolic to catabolic metabolism5.,False,BACKGROUND
156,AMP-activated protein kinase (AMPK) activation reduces inflammation-related fibrosis in the lungs.,"However, the role of AMPK in fibrosis is not well understood.",False,BACKGROUND
157,AMP-activated protein kinase (AMPK) activation reduces inflammation-related fibrosis in the lungs.,"Here, we demonstrate that in humans with idiopathic pulmonary fibrosis (IPF) and in an experimental mouse model of lung fibrosis, AMPK activity is lower in fibrotic regions associated with metabolically active and apoptosis-resistant myofibroblasts.",False,RESULTS
158,AMP-activated protein kinase (AMPK) activation reduces inflammation-related fibrosis in the lungs.,"Pharmacological activation of AMPK in myofibroblasts from lungs of humans with IPF display lower fibrotic activity, along with enhanced mitochondrial biogenesis and normalization of sensitivity to apoptosis.",True,RESULTS
159,AMP-activated protein kinase (AMPK) activation reduces inflammation-related fibrosis in the lungs.,"In a bleomycin model of lung fibrosis in mice, metformin therapeutically accelerates the resolution of well-established fibrosis in an AMPK-dependent manner.",True,CONCLUSIONS
160,AMP-activated protein kinase (AMPK) activation reduces inflammation-related fibrosis in the lungs.,"These studies implicate deficient AMPK activation in non-resolving, pathologic fibrotic processes, and support a role for metformin (or other AMPK activators) to reverse established fibrosis by facilitating deactivation and apoptosis of myofibroblasts.",True,CONCLUSIONS
161,APOE4 expression in iPSC-derived neurons results in decreased tau phosphorylation.,"Efforts to develop drugs for Alzheimer's disease (AD) have shown promise in animal studies, only to fail in human trials, suggesting a pressing need to study AD in human model systems.",False,BACKGROUND
162,APOE4 expression in iPSC-derived neurons results in decreased tau phosphorylation.,"Using human neurons derived from induced pluripotent stem cells that expressed apolipoprotein E4 (ApoE4), a variant of the APOE gene product and the major genetic risk factor for AD, we demonstrated that ApoE4-expressing neurons had higher levels of tau phosphorylation, unrelated to their increased production of amyloid-β (Aβ) peptides, and that they displayed GABAergic neuron degeneration.",True,BACKGROUND
163,APOE4 expression in iPSC-derived neurons results in decreased tau phosphorylation.,"ApoE4 increased Aβ production in human, but not in mouse, neurons.",False,RESULTS
164,APOE4 expression in iPSC-derived neurons results in decreased tau phosphorylation.,"Converting ApoE4 to ApoE3 by gene editing rescued these phenotypes, indicating the specific effects of ApoE4.",False,RESULTS
165,APOE4 expression in iPSC-derived neurons results in decreased tau phosphorylation.,"Neurons that lacked APOE behaved similarly to those expressing ApoE3, and the introduction of ApoE4 expression recapitulated the pathological phenotypes, suggesting a gain of toxic effects from ApoE4.",False,RESULTS
166,APOE4 expression in iPSC-derived neurons results in decreased tau phosphorylation.,"Treatment of ApoE4-expressing neurons with a small-molecule structure corrector ameliorated the detrimental effects, thus showing that correcting the pathogenic conformation of ApoE4 is a viable therapeutic approach for ApoE4-related AD.",False,CONCLUSIONS
167,ART has no effect on the infectiveness of HIV-positive people.,BACKGROUND Many mathematical models have investigated the impact of expanding access to antiretroviral therapy (ART) on new HIV infections.,False,BACKGROUND
168,ART has no effect on the infectiveness of HIV-positive people.,Comparing results and conclusions across models is challenging because models have addressed slightly different questions and have reported different outcome metrics.,False,BACKGROUND
169,ART has no effect on the infectiveness of HIV-positive people.,"This study compares the predictions of several mathematical models simulating the same ART intervention programmes to determine the extent to which models agree about the epidemiological impact of expanded ART.   
",False,BACKGROUND
170,ART has no effect on the infectiveness of HIV-positive people.,METHODS AND FINDINGS Twelve independent mathematical models evaluated a set of standardised ART intervention scenarios in South Africa and reported a common set of outputs.,False,METHODS
171,ART has no effect on the infectiveness of HIV-positive people.,"Intervention scenarios systematically varied the CD4 count threshold for treatment eligibility, access to treatment, and programme retention.",False,METHODS
172,ART has no effect on the infectiveness of HIV-positive people.,"For a scenario in which 80% of HIV-infected individuals start treatment on average 1 y after their CD4 count drops below 350 cells/µl and 85% remain on treatment after 3 y, the models projected that HIV incidence would be 35% to 54% lower 8 y after the introduction of ART, compared to a counterfactual scenario in which there is no ART.",True,RESULTS
173,ART has no effect on the infectiveness of HIV-positive people.,More variation existed in the estimated long-term (38 y) reductions in incidence.,False,RESULTS
174,ART has no effect on the infectiveness of HIV-positive people.,"The impact of optimistic interventions including immediate ART initiation varied widely across models, maintaining substantial uncertainty about the theoretical prospect for elimination of HIV from the population using ART alone over the next four decades.",False,RESULTS
175,ART has no effect on the infectiveness of HIV-positive people.,The number of person-years of ART per infection averted over 8 y ranged between 5.8 and 18.7.,False,RESULTS
176,ART has no effect on the infectiveness of HIV-positive people.,"Considering the actual scale-up of ART in South Africa, seven models estimated that current HIV incidence is 17% to 32% lower than it would have been in the absence of ART.",True,RESULTS
177,ART has no effect on the infectiveness of HIV-positive people.,"Differences between model assumptions about CD4 decline and HIV transmissibility over the course of infection explained only a modest amount of the variation in model results.   
",False,RESULTS
178,ART has no effect on the infectiveness of HIV-positive people.,"CONCLUSIONS Mathematical models evaluating the impact of ART vary substantially in structure, complexity, and parameter choices, but all suggest that ART, at high levels of access and with high adherence, has the potential to substantially reduce new HIV infections.",True,CONCLUSIONS
179,ART has no effect on the infectiveness of HIV-positive people.,"There was broad agreement regarding the short-term epidemiologic impact of ambitious treatment scale-up, but more variation in longer term projections and in the efficiency with which treatment can reduce new infections.",False,CONCLUSIONS
180,ART has no effect on the infectiveness of HIV-positive people.,Differences between model predictions could not be explained by differences in model structure or parameterization that were hypothesized to affect intervention impact.,False,CONCLUSIONS
181,ART substantially reduces infectiveness of HIV-positive people.,BACKGROUND Many mathematical models have investigated the impact of expanding access to antiretroviral therapy (ART) on new HIV infections.,False,BACKGROUND
182,ART substantially reduces infectiveness of HIV-positive people.,Comparing results and conclusions across models is challenging because models have addressed slightly different questions and have reported different outcome metrics.,False,BACKGROUND
183,ART substantially reduces infectiveness of HIV-positive people.,"This study compares the predictions of several mathematical models simulating the same ART intervention programmes to determine the extent to which models agree about the epidemiological impact of expanded ART.   
",False,BACKGROUND
184,ART substantially reduces infectiveness of HIV-positive people.,METHODS AND FINDINGS Twelve independent mathematical models evaluated a set of standardised ART intervention scenarios in South Africa and reported a common set of outputs.,False,METHODS
185,ART substantially reduces infectiveness of HIV-positive people.,"Intervention scenarios systematically varied the CD4 count threshold for treatment eligibility, access to treatment, and programme retention.",False,METHODS
186,ART substantially reduces infectiveness of HIV-positive people.,"For a scenario in which 80% of HIV-infected individuals start treatment on average 1 y after their CD4 count drops below 350 cells/µl and 85% remain on treatment after 3 y, the models projected that HIV incidence would be 35% to 54% lower 8 y after the introduction of ART, compared to a counterfactual scenario in which there is no ART.",True,RESULTS
187,ART substantially reduces infectiveness of HIV-positive people.,More variation existed in the estimated long-term (38 y) reductions in incidence.,False,RESULTS
188,ART substantially reduces infectiveness of HIV-positive people.,"The impact of optimistic interventions including immediate ART initiation varied widely across models, maintaining substantial uncertainty about the theoretical prospect for elimination of HIV from the population using ART alone over the next four decades.",False,RESULTS
189,ART substantially reduces infectiveness of HIV-positive people.,The number of person-years of ART per infection averted over 8 y ranged between 5.8 and 18.7.,False,RESULTS
190,ART substantially reduces infectiveness of HIV-positive people.,"Considering the actual scale-up of ART in South Africa, seven models estimated that current HIV incidence is 17% to 32% lower than it would have been in the absence of ART.",True,RESULTS
191,ART substantially reduces infectiveness of HIV-positive people.,"Differences between model assumptions about CD4 decline and HIV transmissibility over the course of infection explained only a modest amount of the variation in model results.   
",False,RESULTS
192,ART substantially reduces infectiveness of HIV-positive people.,"CONCLUSIONS Mathematical models evaluating the impact of ART vary substantially in structure, complexity, and parameter choices, but all suggest that ART, at high levels of access and with high adherence, has the potential to substantially reduce new HIV infections.",True,CONCLUSIONS
193,ART substantially reduces infectiveness of HIV-positive people.,"There was broad agreement regarding the short-term epidemiologic impact of ambitious treatment scale-up, but more variation in longer term projections and in the efficiency with which treatment can reduce new infections.",False,CONCLUSIONS
194,ART substantially reduces infectiveness of HIV-positive people.,Differences between model predictions could not be explained by differences in model structure or parameterization that were hypothesized to affect intervention impact.,False,CONCLUSIONS
195,Activated Cdk5 phosphorylates the ATM protein in response to DNA damage.,"The phosphatidylinositol-3-kinase-like kinase ATM (ataxia-telangiectasia mutated) has a central role in coordinating DNA damage responses, including cell-cycle checkpoint control, DNA repair and apoptosis.",False,BACKGROUND
196,Activated Cdk5 phosphorylates the ATM protein in response to DNA damage.,Mutations of ATM cause a spectrum of defects ranging from neurodegeneration to cancer predisposition.,False,BACKGROUND
197,Activated Cdk5 phosphorylates the ATM protein in response to DNA damage.,"However, the mechanism by which DNA damage activates ATM is poorly understood.",False,BACKGROUND
198,Activated Cdk5 phosphorylates the ATM protein in response to DNA damage.,"Here we show that Cdk5 (cyclin-dependent kinase 5), activated by DNA damage, directly phosphorylates ATM at Ser 794 in post-mitotic neurons.",True,BACKGROUND
199,Activated Cdk5 phosphorylates the ATM protein in response to DNA damage.,"Phosphorylation at Ser 794 precedes, and is required for, ATM autophosphorylation at Ser 1981, and activates ATM kinase activity.",False,RESULTS
200,Activated Cdk5 phosphorylates the ATM protein in response to DNA damage.,The Cdk5-ATM signal regulates phosphorylation and function of the ATM targets p53 and H2AX.,False,RESULTS
201,Activated Cdk5 phosphorylates the ATM protein in response to DNA damage.,"Interruption of the Cdk5-ATM pathway attenuates DNA-damage-induced neuronal cell cycle re-entry and expression of the p53 targets PUMA and Bax, protecting neurons from death.",False,CONCLUSIONS
202,Activated Cdk5 phosphorylates the ATM protein in response to DNA damage.,"Thus, activation of Cdk5 by DNA damage serves as a critical signal to initiate the ATM response and regulate ATM-dependent cellular processes.",True,CONCLUSIONS
203,Activated Cdk5 regulates DNA damage-induced neuronal death.,"The phosphatidylinositol-3-kinase-like kinase ATM (ataxia-telangiectasia mutated) has a central role in coordinating DNA damage responses, including cell-cycle checkpoint control, DNA repair and apoptosis.",False,BACKGROUND
204,Activated Cdk5 regulates DNA damage-induced neuronal death.,Mutations of ATM cause a spectrum of defects ranging from neurodegeneration to cancer predisposition.,False,BACKGROUND
205,Activated Cdk5 regulates DNA damage-induced neuronal death.,"However, the mechanism by which DNA damage activates ATM is poorly understood.",False,BACKGROUND
206,Activated Cdk5 regulates DNA damage-induced neuronal death.,"Here we show that Cdk5 (cyclin-dependent kinase 5), activated by DNA damage, directly phosphorylates ATM at Ser 794 in post-mitotic neurons.",False,BACKGROUND
207,Activated Cdk5 regulates DNA damage-induced neuronal death.,"Phosphorylation at Ser 794 precedes, and is required for, ATM autophosphorylation at Ser 1981, and activates ATM kinase activity.",False,RESULTS
208,Activated Cdk5 regulates DNA damage-induced neuronal death.,The Cdk5-ATM signal regulates phosphorylation and function of the ATM targets p53 and H2AX.,False,RESULTS
209,Activated Cdk5 regulates DNA damage-induced neuronal death.,"Interruption of the Cdk5-ATM pathway attenuates DNA-damage-induced neuronal cell cycle re-entry and expression of the p53 targets PUMA and Bax, protecting neurons from death.",True,CONCLUSIONS
210,Activated Cdk5 regulates DNA damage-induced neuronal death.,"Thus, activation of Cdk5 by DNA damage serves as a critical signal to initiate the ATM response and regulate ATM-dependent cellular processes.",False,CONCLUSIONS
211,Activation of PPM1D enhances p53 function.,Gliomas arising in the brainstem and thalamus are devastating tumors that are difficult to surgically resect.,False,BACKGROUND
212,Activation of PPM1D enhances p53 function.,"To determine the genetic and epigenetic landscape of these tumors, we performed exomic sequencing of 14 brainstem gliomas (BSGs) and 12 thalamic gliomas.",False,METHODS
213,Activation of PPM1D enhances p53 function.,We also performed targeted mutational analysis of an additional 24 such tumors and genome-wide methylation profiling of 45 gliomas.,False,METHODS
214,Activation of PPM1D enhances p53 function.,"This study led to the discovery of tumor-specific mutations in PPM1D, encoding wild-type p53-induced protein phosphatase 1D (WIP1), in 37.5% of the BSGs that harbored hallmark H3F3A mutations encoding p.",False,RESULTS
215,Activation of PPM1D enhances p53 function.,Lys27Met substitutions.,False,RESULTS
216,Activation of PPM1D enhances p53 function.,PPM1D mutations were mutually exclusive with TP53 mutations in BSG and attenuated p53 activation in vitro.,True,RESULTS
217,Activation of PPM1D enhances p53 function.,PPM1D mutations were truncating alterations in exon 6 that enhanced the ability of PPM1D to suppress the activation of the DNA damage response checkpoint protein CHK2.,True,CONCLUSIONS
218,Activation of PPM1D enhances p53 function.,These results define PPM1D as a frequent target of somatic mutation and as a potential therapeutic target in brainstem gliomas.,False,CONCLUSIONS
219,Activation of PPM1D enhances p53 function.,Improved sequencing technologies offer unprecedented opportunities for investigating the role of rare genetic variation in common disease.,False,BACKGROUND
220,Activation of PPM1D enhances p53 function.,"However, there are considerable challenges with respect to study design, data analysis and replication.",False,BACKGROUND
221,Activation of PPM1D enhances p53 function.,"Using pooled next-generation sequencing of 507 genes implicated in the repair of DNA in 1,150 samples, an analytical strategy focused on protein-truncating variants (PTVs) and a large-scale sequencing case–control replication experiment in 13,642 individuals, here we show that rare PTVs in the p53-inducible protein phosphatase PPM1D are associated with predisposition to breast cancer and ovarian cancer.",False,METHODS
222,Activation of PPM1D enhances p53 function.,"PPM1D PTV mutations were present in 25 out of 7,781 cases versus 1 out of 5,861 controls (P = 1.12 × 10−5), including 18 mutations in 6,912 individuals with breast cancer (P = 2.42 × 10−4) and 12 mutations in 1,121 individuals with ovarian cancer (P = 3.10 × 10−9).",False,RESULTS
223,Activation of PPM1D enhances p53 function.,"Notably, all of the identified PPM1D PTVs were mosaic in lymphocyte DNA and clustered within a 370-base-pair region in the final exon of the gene, carboxy-terminal to the phosphatase catalytic domain.",False,RESULTS
224,Activation of PPM1D enhances p53 function.,"Functional studies demonstrate that the mutations result in enhanced suppression of p53 in response to ionizing radiation exposure, suggesting that the mutant alleles encode hyperactive PPM1D isoforms.",True,CONCLUSIONS
225,Activation of PPM1D enhances p53 function.,"Thus, although the mutations cause premature protein truncation, they do not result in the simple loss-of-function effect typically associated with this class of variant, but instead probably have a gain-of-function effect.",False,CONCLUSIONS
226,Activation of PPM1D enhances p53 function.,Our results have implications for the detection and management of breast and ovarian cancer risk.,False,CONCLUSIONS
227,Activation of PPM1D enhances p53 function.,"More generally, these data provide new insights into the role of rare and of mosaic genetic variants in common conditions, and the use of sequencing in their identification.",False,CONCLUSIONS
228,Activation of the Rac1 homolog CED-10 kills viable cells in SRGP-1 mutant Caenorhabditis elegans.,Multicellular animals rapidly clear dying cells from their bodies.,False,BACKGROUND
229,Activation of the Rac1 homolog CED-10 kills viable cells in SRGP-1 mutant Caenorhabditis elegans.,Many of the pathways that mediate this cell removal are conserved through evolution.,False,BACKGROUND
230,Activation of the Rac1 homolog CED-10 kills viable cells in SRGP-1 mutant Caenorhabditis elegans.,"Here, we identify srgp-1 as a negative regulator of cell clearance in both Caenorhabditis elegans and mammalian cells.",False,BACKGROUND
231,Activation of the Rac1 homolog CED-10 kills viable cells in SRGP-1 mutant Caenorhabditis elegans.,"Loss of srgp-1 function results in improved engulfment of apoptotic cells, whereas srgp-1 overexpression inhibits apoptotic cell corpse removal.",False,BACKGROUND
232,Activation of the Rac1 homolog CED-10 kills viable cells in SRGP-1 mutant Caenorhabditis elegans.,We show that SRGP-1 functions in engulfing cells and functions as a GTPase activating protein (GAP) for CED-10 (Rac1).,True,BACKGROUND
233,Activation of the Rac1 homolog CED-10 kills viable cells in SRGP-1 mutant Caenorhabditis elegans.,"Interestingly, loss of srgp-1 function promotes not only the clearance of already dead cells, but also the removal of cells that have been brought to the verge of death through sublethal apoptotic, necrotic or cytotoxic insults.",True,BACKGROUND
234,Activation of the Rac1 homolog CED-10 kills viable cells in SRGP-1 mutant Caenorhabditis elegans.,"In contrast, impaired engulfment allows damaged cells to escape clearance, which results in increased long-term survival.",False,BACKGROUND
235,Activation of the Rac1 homolog CED-10 kills viable cells in SRGP-1 mutant Caenorhabditis elegans.,"We propose that C. elegans uses the engulfment machinery as part of a primitive, but evolutionarily conserved, survey mechanism that identifies and removes unfit cells within a tissue.",False,BACKGROUND
236,Active Ly49Q induces neutrophil polarization.,Neutrophils rapidly undergo polarization and directional movement to infiltrate the sites of infection and inflammation.,False,BACKGROUND
237,Active Ly49Q induces neutrophil polarization.,"Here, we show that an inhibitory MHC I receptor, Ly49Q, was crucial for the swift polarization of and tissue infiltration by neutrophils.",True,BACKGROUND
238,Active Ly49Q induces neutrophil polarization.,"During the steady state, Ly49Q inhibited neutrophil adhesion by preventing focal-complex formation, likely by inhibiting Src and PI3 kinases.",False,RESULTS
239,Active Ly49Q induces neutrophil polarization.,"However, in the presence of inflammatory stimuli, Ly49Q mediated rapid neutrophil polarization and tissue infiltration in an ITIM-domain-dependent manner.",False,RESULTS
240,Active Ly49Q induces neutrophil polarization.,These opposite functions appeared to be mediated by distinct use of effector phosphatase SHP-1 and SHP-2.,False,RESULTS
241,Active Ly49Q induces neutrophil polarization.,Ly49Q-dependent polarization and migration were affected by Ly49Q regulation of membrane raft functions.,False,RESULTS
242,Active Ly49Q induces neutrophil polarization.,"We propose that Ly49Q is pivotal in switching neutrophils to their polarized morphology and rapid migration upon inflammation, through its spatiotemporal regulation of membrane rafts and raft-associated signaling molecules.",True,CONCLUSIONS
243,Active Ly49Q prevents neutrophil polarization.,Neutrophils rapidly undergo polarization and directional movement to infiltrate the sites of infection and inflammation.,False,BACKGROUND
244,Active Ly49Q prevents neutrophil polarization.,"Here, we show that an inhibitory MHC I receptor, Ly49Q, was crucial for the swift polarization of and tissue infiltration by neutrophils.",True,BACKGROUND
245,Active Ly49Q prevents neutrophil polarization.,"During the steady state, Ly49Q inhibited neutrophil adhesion by preventing focal-complex formation, likely by inhibiting Src and PI3 kinases.",False,RESULTS
246,Active Ly49Q prevents neutrophil polarization.,"However, in the presence of inflammatory stimuli, Ly49Q mediated rapid neutrophil polarization and tissue infiltration in an ITIM-domain-dependent manner.",False,RESULTS
247,Active Ly49Q prevents neutrophil polarization.,These opposite functions appeared to be mediated by distinct use of effector phosphatase SHP-1 and SHP-2.,False,RESULTS
248,Active Ly49Q prevents neutrophil polarization.,Ly49Q-dependent polarization and migration were affected by Ly49Q regulation of membrane raft functions.,False,RESULTS
249,Active Ly49Q prevents neutrophil polarization.,"We propose that Ly49Q is pivotal in switching neutrophils to their polarized morphology and rapid migration upon inflammation, through its spatiotemporal regulation of membrane rafts and raft-associated signaling molecules.",True,CONCLUSIONS
250,Active caspase-11 participate in regulating phagosome-lysosome fusion.,Inflammasomes are multiprotein complexes that include members of the NLR (nucleotide-binding domain leucine-rich repeat containing) family and caspase-1.,False,BACKGROUND
251,Active caspase-11 participate in regulating phagosome-lysosome fusion.,"Once bacterial molecules are sensed within the macrophage, the inflammasome is assembled, mediating the activation of caspase-1.",False,BACKGROUND
252,Active caspase-11 participate in regulating phagosome-lysosome fusion.,"Caspase-11 mediates caspase-1 activation in response to lipopolysaccharide and bacterial toxins, and yet its role during bacterial infection is unknown.",False,BACKGROUND
253,Active caspase-11 participate in regulating phagosome-lysosome fusion.,"Here, we demonstrated that caspase-11 was dispensable for caspase-1 activation in response to Legionella, Salmonella, Francisella, and Listeria.",False,RESULTS
254,Active caspase-11 participate in regulating phagosome-lysosome fusion.,We also determined that active mouse caspase-11 was required for restriction of L. pneumophila infection.,False,RESULTS
255,Active caspase-11 participate in regulating phagosome-lysosome fusion.,"Similarly, human caspase-4 and caspase-5, homologs of mouse caspase-11, cooperated to restrict L. pneumophila infection in human macrophages.",False,RESULTS
256,Active caspase-11 participate in regulating phagosome-lysosome fusion.,Caspase-11 promoted the fusion of the L. pneumophila vacuole with lysosomes by modulating actin polymerization through cofilin.,False,RESULTS
257,Active caspase-11 participate in regulating phagosome-lysosome fusion.,"However, caspase-11 was dispensable for the fusion of lysosomes with phagosomes containing nonpathogenic bacteria, uncovering a fundamental difference in the trafficking of phagosomes according to their cargo.",True,CONCLUSIONS
258,Active caspase-11 protein promotes pyroptosis.,Inflammasomes are multiprotein complexes that include members of the NLR (nucleotide-binding domain leucine-rich repeat containing) family and caspase-1.,False,BACKGROUND
259,Active caspase-11 protein promotes pyroptosis.,"Once bacterial molecules are sensed within the macrophage, the inflammasome is assembled, mediating the activation of caspase-1.",False,BACKGROUND
260,Active caspase-11 protein promotes pyroptosis.,"Caspase-11 mediates caspase-1 activation in response to lipopolysaccharide and bacterial toxins, and yet its role during bacterial infection is unknown.",False,BACKGROUND
261,Active caspase-11 protein promotes pyroptosis.,"Here, we demonstrated that caspase-11 was dispensable for caspase-1 activation in response to Legionella, Salmonella, Francisella, and Listeria.",True,RESULTS
262,Active caspase-11 protein promotes pyroptosis.,We also determined that active mouse caspase-11 was required for restriction of L. pneumophila infection.,True,RESULTS
263,Active caspase-11 protein promotes pyroptosis.,"Similarly, human caspase-4 and caspase-5, homologs of mouse caspase-11, cooperated to restrict L. pneumophila infection in human macrophages.",False,RESULTS
264,Active caspase-11 protein promotes pyroptosis.,Caspase-11 promoted the fusion of the L. pneumophila vacuole with lysosomes by modulating actin polymerization through cofilin.,False,RESULTS
265,Active caspase-11 protein promotes pyroptosis.,"However, caspase-11 was dispensable for the fusion of lysosomes with phagosomes containing nonpathogenic bacteria, uncovering a fundamental difference in the trafficking of phagosomes according to their cargo.",False,CONCLUSIONS
266,Adult tissue-resident macrophages are seeded before birth.,"Mononuclear phagocytes, including monocytes, macrophages, and dendritic cells, contribute to tissue integrity as well as to innate and adaptive immune defense.",False,BACKGROUND
267,Adult tissue-resident macrophages are seeded before birth.,Emerging evidence for labor division indicates that manipulation of these cells could bear therapeutic potential.,False,BACKGROUND
268,Adult tissue-resident macrophages are seeded before birth.,"However, specific ontogenies of individual populations and the overall functional organization of this cellular network are not well defined.",False,BACKGROUND
269,Adult tissue-resident macrophages are seeded before birth.,Here we report a fate-mapping study of the murine monocyte and macrophage compartment taking advantage of constitutive and conditional CX(3)CR1 promoter-driven Cre recombinase expression.,False,RESULTS
270,Adult tissue-resident macrophages are seeded before birth.,"We have demonstrated that major tissue-resident macrophage populations, including liver Kupffer cells and lung alveolar, splenic, and peritoneal macrophages, are established prior to birth and maintain themselves subsequently during adulthood independent of replenishment by blood monocytes.",True,CONCLUSIONS
271,Adult tissue-resident macrophages are seeded before birth.,"Furthermore, we have established that short-lived Ly6C(+) monocytes constitute obligatory steady-state precursors of blood-resident Ly6C(-) cells and that the abundance of Ly6C(+) blood monocytes dynamically controls the circulation lifespan of their progeny.",False,CONCLUSIONS
272,Adult tissue-resident macrophages are seeded before birth.,Macrophages are distributed in tissues throughout the body and contribute to both homeostasis and disease.,False,BACKGROUND
273,Adult tissue-resident macrophages are seeded before birth.,"Recently, it has become evident that most adult tissue macrophages originate during embryonic development and not from circulating monocytes.",True,BACKGROUND
274,Adult tissue-resident macrophages are seeded before birth.,"Each tissue has its own composition of embryonically derived and adult-derived macrophages, but it is unclear whether macrophages of distinct origins are functionally interchangeable or have unique roles at steady state.",False,BACKGROUND
275,Adult tissue-resident macrophages are seeded before birth.,This new understanding also prompts reconsideration of the function of circulating monocytes.,False,BACKGROUND
276,Adult tissue-resident macrophages are seeded before birth.,"Classical Ly6c(hi) monocytes patrol the extravascular space in resting organs, and Ly6c(lo) nonclassical monocytes patrol the vasculature.",False,BACKGROUND
277,Adult tissue-resident macrophages are seeded before birth.,"Inflammation triggers monocytes to differentiate into macrophages, but whether resident and newly recruited macrophages possess similar functions during inflammation is unclear.",False,BACKGROUND
278,Adult tissue-resident macrophages are seeded before birth.,"Here, we define the tools used for identifying the complex origin of tissue macrophages and discuss the relative contributions of tissue niche versus ontological origin to the regulation of macrophage functions during steady state and inflammation.",False,BACKGROUND
279,Adult tissue-resident macrophages are seeded before birth.,"Mononuclear phagocytes, including monocytes, macrophages, and dendritic cells, contribute to tissue integrity as well as to innate and adaptive immune defense.",False,BACKGROUND
280,Adult tissue-resident macrophages are seeded before birth.,Emerging evidence for labor division indicates that manipulation of these cells could bear therapeutic potential.,False,BACKGROUND
281,Adult tissue-resident macrophages are seeded before birth.,"However, specific ontogenies of individual populations and the overall functional organization of this cellular network are not well defined.",False,BACKGROUND
282,Adult tissue-resident macrophages are seeded before birth.,Here we report a fate-mapping study of the murine monocyte and macrophage compartment taking advantage of constitutive and conditional CX(3)CR1 promoter-driven Cre recombinase expression.,False,RESULTS
283,Adult tissue-resident macrophages are seeded before birth.,"We have demonstrated that major tissue-resident macrophage populations, including liver Kupffer cells and lung alveolar, splenic, and peritoneal macrophages, are established prior to birth and maintain themselves subsequently during adulthood independent of replenishment by blood monocytes.",True,CONCLUSIONS
284,Adult tissue-resident macrophages are seeded before birth.,"Furthermore, we have established that short-lived Ly6C(+) monocytes constitute obligatory steady-state precursors of blood-resident Ly6C(-) cells and that the abundance of Ly6C(+) blood monocytes dynamically controls the circulation lifespan of their progeny.",False,CONCLUSIONS
285,Adult tissue-resident macrophages are seeded before birth.,Macrophages are distributed in tissues throughout the body and contribute to both homeostasis and disease.,False,BACKGROUND
286,Adult tissue-resident macrophages are seeded before birth.,"Recently, it has become evident that most adult tissue macrophages originate during embryonic development and not from circulating monocytes.",True,BACKGROUND
287,Adult tissue-resident macrophages are seeded before birth.,"Each tissue has its own composition of embryonically derived and adult-derived macrophages, but it is unclear whether macrophages of distinct origins are functionally interchangeable or have unique roles at steady state.",False,BACKGROUND
288,Adult tissue-resident macrophages are seeded before birth.,This new understanding also prompts reconsideration of the function of circulating monocytes.,False,BACKGROUND
289,Adult tissue-resident macrophages are seeded before birth.,"Classical Ly6c(hi) monocytes patrol the extravascular space in resting organs, and Ly6c(lo) nonclassical monocytes patrol the vasculature.",False,BACKGROUND
290,Adult tissue-resident macrophages are seeded before birth.,"Inflammation triggers monocytes to differentiate into macrophages, but whether resident and newly recruited macrophages possess similar functions during inflammation is unclear.",False,BACKGROUND
291,Adult tissue-resident macrophages are seeded before birth.,"Here, we define the tools used for identifying the complex origin of tissue macrophages and discuss the relative contributions of tissue niche versus ontological origin to the regulation of macrophage functions during steady state and inflammation.",False,BACKGROUND
292,Adult tissue-resident macrophages possess a self-renewing capacity.,"Mononuclear phagocytes, including monocytes, macrophages, and dendritic cells, contribute to tissue integrity as well as to innate and adaptive immune defense.",False,BACKGROUND
293,Adult tissue-resident macrophages possess a self-renewing capacity.,Emerging evidence for labor division indicates that manipulation of these cells could bear therapeutic potential.,False,BACKGROUND
294,Adult tissue-resident macrophages possess a self-renewing capacity.,"However, specific ontogenies of individual populations and the overall functional organization of this cellular network are not well defined.",False,BACKGROUND
295,Adult tissue-resident macrophages possess a self-renewing capacity.,Here we report a fate-mapping study of the murine monocyte and macrophage compartment taking advantage of constitutive and conditional CX(3)CR1 promoter-driven Cre recombinase expression.,False,RESULTS
296,Adult tissue-resident macrophages possess a self-renewing capacity.,"We have demonstrated that major tissue-resident macrophage populations, including liver Kupffer cells and lung alveolar, splenic, and peritoneal macrophages, are established prior to birth and maintain themselves subsequently during adulthood independent of replenishment by blood monocytes.",True,CONCLUSIONS
297,Adult tissue-resident macrophages possess a self-renewing capacity.,"Furthermore, we have established that short-lived Ly6C(+) monocytes constitute obligatory steady-state precursors of blood-resident Ly6C(-) cells and that the abundance of Ly6C(+) blood monocytes dynamically controls the circulation lifespan of their progeny.",False,CONCLUSIONS
298,Aggravated inflammation is dependent on NLRP3 inflammasome activation.,"Development of the acute and chronic inflammatory responses known as gout and pseudogout are associated with the deposition of monosodium urate (MSU) or calcium pyrophosphate dihydrate (CPPD) crystals, respectively, in joints and periarticular tissues.",False,BACKGROUND
299,Aggravated inflammation is dependent on NLRP3 inflammasome activation.,"Although MSU crystals were first identified as the aetiological agent of gout in the eighteenth century and more recently as a ‘danger signal’ released from dying cells, little is known about the molecular mechanisms underlying MSU- or CPPD-induced inflammation.",False,BACKGROUND
300,Aggravated inflammation is dependent on NLRP3 inflammasome activation.,"Here we show that MSU and CPPD engage the caspase-1-activating NALP3 (also called cryopyrin) inflammasome, resulting in the production of active interleukin (IL)-1β and IL-18.",True,BACKGROUND
301,Aggravated inflammation is dependent on NLRP3 inflammasome activation.,"Macrophages from mice deficient in various components of the inflammasome such as caspase-1, ASC and NALP3 are defective in crystal-induced IL-1β activation.",True,RESULTS
302,Aggravated inflammation is dependent on NLRP3 inflammasome activation.,"Moreover, an impaired neutrophil influx is found in an in vivo model of crystal-induced peritonitis in inflammasome-deficient mice or mice deficient in the IL-1β receptor (IL-1R).",False,RESULTS
303,Aggravated inflammation is dependent on NLRP3 inflammasome activation.,"These findings provide insight into the molecular processes underlying the inflammatory conditions of gout and pseudogout, and further support a pivotal role of the inflammasome in several autoinflammatory diseases.",False,RESULTS
304,Alirocumab treatment reduces apo(a) fractional clearance rate.,"BACKGROUND Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), lowers plasma low-density lipoprotein (LDL) cholesterol and apolipoprotein B100 (apoB).",False,BACKGROUND
305,Alirocumab treatment reduces apo(a) fractional clearance rate.,"Although studies in mice and cells have identified increased hepatic LDL receptors as the basis for LDL lowering by PCSK9 inhibitors, there have been no human studies characterizing the effects of PCSK9 inhibitors on lipoprotein metabolism.",False,BACKGROUND
306,Alirocumab treatment reduces apo(a) fractional clearance rate.,"In particular, it is not known whether inhibition of PCSK9 has any effects on very low-density lipoprotein or intermediate-density lipoprotein (IDL) metabolism.",False,BACKGROUND
307,Alirocumab treatment reduces apo(a) fractional clearance rate.,Inhibition of PCSK9 also results in reductions of plasma lipoprotein (a) levels.,False,BACKGROUND
308,Alirocumab treatment reduces apo(a) fractional clearance rate.,"The regulation of plasma Lp(a) levels, including the role of LDL receptors in the clearance of Lp(a), is poorly defined, and no mechanistic studies of the Lp(a) lowering by alirocumab in humans have been published to date.   
",False,BACKGROUND
309,Alirocumab treatment reduces apo(a) fractional clearance rate.,"METHODS Eighteen (10 F, 8 mol/L) participants completed a placebo-controlled, 2-period study.",False,METHODS
310,Alirocumab treatment reduces apo(a) fractional clearance rate.,"They received 2 doses of placebo, 2 weeks apart, followed by 5 doses of 150 mg of alirocumab, 2 weeks apart.",False,METHODS
311,Alirocumab treatment reduces apo(a) fractional clearance rate.,"At the end of each period, fractional clearance rates (FCRs) and production rates (PRs) of apoB and apo(a) were determined.",False,METHODS
312,Alirocumab treatment reduces apo(a) fractional clearance rate.,"In 10 participants, postprandial triglycerides and apoB48 levels were measured.   
",False,METHODS
313,Alirocumab treatment reduces apo(a) fractional clearance rate.,"RESULTS Alirocumab reduced ultracentrifugally isolated LDL-C by 55.1%, LDL-apoB by 56.3%, and plasma Lp(a) by 18.7%.",True,RESULTS
314,Alirocumab treatment reduces apo(a) fractional clearance rate.,The fall in LDL-apoB was caused by an 80.4% increase in LDL-apoB FCR and a 23.9% reduction in LDL-apoB PR.,True,RESULTS
315,Alirocumab treatment reduces apo(a) fractional clearance rate.,The latter was due to a 46.1% increase in IDL-apoB FCR coupled with a 27.2% decrease in conversion of IDL to LDL.,False,RESULTS
316,Alirocumab treatment reduces apo(a) fractional clearance rate.,The FCR of apo(a) tended to increase (24.6%) without any change in apo(a) PR.,True,RESULTS
317,Alirocumab treatment reduces apo(a) fractional clearance rate.,"Alirocumab had no effects on FCRs or PRs of very low-density lipoproteins-apoB and very low-density lipoproteins triglycerides or on postprandial plasma triglycerides or apoB48 concentrations.   
",False,RESULTS
318,Alirocumab treatment reduces apo(a) fractional clearance rate.,CONCLUSIONS Alirocumab decreased LDL-C and LDL-apoB by increasing IDL- and LDL-apoB FCRs and decreasing LDL-apoB PR.,True,CONCLUSIONS
319,Alirocumab treatment reduces apo(a) fractional clearance rate.,These results are consistent with increases in LDL receptors available to clear IDL and LDL from blood during PCSK9 inhibition.,False,CONCLUSIONS
320,Alirocumab treatment reduces apo(a) fractional clearance rate.,The increase in apo(a) FCR during alirocumab treatment suggests that increased LDL receptors may also play a role in the reduction of plasma Lp(a).   ,True,CONCLUSIONS
321,Alirocumab treatment reduces apo(a) fractional clearance rate.,CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov.,False,BACKGROUND
322,Alirocumab treatment reduces apo(a) fractional clearance rate.,Unique identifier: NCT01959971.,False,BACKGROUND
323,Allogeneic mechanical circulatory support is not as effective as autologous mechanical circulatory support for treating acute myocardial infarction.,CONTEXT Mesenchymal stem cells (MSCs) are under evaluation as a therapy for ischemic cardiomyopathy (ICM).,False,OBJECTIVE
324,Allogeneic mechanical circulatory support is not as effective as autologous mechanical circulatory support for treating acute myocardial infarction.,"Both autologous and allogeneic MSC therapies are possible; however, their safety and efficacy have not been compared.   
",False,OBJECTIVE
325,Allogeneic mechanical circulatory support is not as effective as autologous mechanical circulatory support for treating acute myocardial infarction.,"OBJECTIVE To test whether allogeneic MSCs are as safe and effective as autologous MSCs in patients with left ventricular (LV) dysfunction due to ICM.   
",False,OBJECTIVE
326,Allogeneic mechanical circulatory support is not as effective as autologous mechanical circulatory support for treating acute myocardial infarction.,"DESIGN, SETTING, AND PATIENTS A phase 1/2 randomized comparison (POSEIDON study) in a US tertiary-care referral hospital of allogeneic and autologous MSCs in 30 patients with LV dysfunction due to ICM between April 2, 2010, and September 14, 2011, with 13-month follow-up.   
",False,METHODS
327,Allogeneic mechanical circulatory support is not as effective as autologous mechanical circulatory support for treating acute myocardial infarction.,"INTERVENTION Twenty million, 100 million, or 200 million cells (5 patients in each cell type per dose level) were delivered by transendocardial stem cell injection into 10 LV sites.   
",False,METHODS
328,Allogeneic mechanical circulatory support is not as effective as autologous mechanical circulatory support for treating acute myocardial infarction.,MAIN OUTCOME MEASURES Thirty-day postcatheterization incidence of predefined treatment-emergent serious adverse events (SAEs).,False,METHODS
329,Allogeneic mechanical circulatory support is not as effective as autologous mechanical circulatory support for treating acute myocardial infarction.,"Efficacy assessments included 6-minute walk test, exercise peak VO2, Minnesota Living with Heart Failure Questionnaire (MLHFQ), New York Heart Association class, LV volumes, ejection fraction (EF), early enhancement defect (EED; infarct size), and sphericity index.   
",False,METHODS
330,Allogeneic mechanical circulatory support is not as effective as autologous mechanical circulatory support for treating acute myocardial infarction.,"RESULTS Within 30 days, 1 patient in each group (treatment-emergent SAE rate, 6.7%) was hospitalized for heart failure, less than the prespecified stopping event rate of 25%.",False,RESULTS
331,Allogeneic mechanical circulatory support is not as effective as autologous mechanical circulatory support for treating acute myocardial infarction.,The 1-year incidence of SAEs was 33.3% (n = 5) in the allogeneic group and 53.3% (n = 8) in the autologous group (P = .46).,True,RESULTS
332,Allogeneic mechanical circulatory support is not as effective as autologous mechanical circulatory support for treating acute myocardial infarction.,"At 1 year, there were no ventricular arrhythmia SAEs observed among allogeneic recipients compared with 4 patients (26.7%) in the autologous group (P = .10).",True,RESULTS
333,Allogeneic mechanical circulatory support is not as effective as autologous mechanical circulatory support for treating acute myocardial infarction.,"Relative to baseline, autologous but not allogeneic MSC therapy was associated with an improvement in the 6-minute walk test and the MLHFQ score, but neither improved exercise VO2 max.",False,RESULTS
334,Allogeneic mechanical circulatory support is not as effective as autologous mechanical circulatory support for treating acute myocardial infarction.,"Allogeneic and autologous MSCs reduced mean EED by −33.21% (95% CI, −43.61% to −22.81%; P < .001) and sphericity index but did not increase EF.",True,RESULTS
335,Allogeneic mechanical circulatory support is not as effective as autologous mechanical circulatory support for treating acute myocardial infarction.,Allogeneic MSCs reduced LV end-diastolic volumes.,False,RESULTS
336,Allogeneic mechanical circulatory support is not as effective as autologous mechanical circulatory support for treating acute myocardial infarction.,Low-dose concentration MSCs (20 million cells) produced greatest reductions in LV volumes and increased EF.,False,RESULTS
337,Allogeneic mechanical circulatory support is not as effective as autologous mechanical circulatory support for treating acute myocardial infarction.,"Allogeneic MSCs did not stimulate significant donor-specific alloimmune reactions.   
",False,RESULTS
338,Allogeneic mechanical circulatory support is not as effective as autologous mechanical circulatory support for treating acute myocardial infarction.,"CONCLUSIONS In this early-stage study of patients with ICM, transendocardial injection of allogeneic and autologous MSCs without a placebo control were both associated with low rates of treatment-emergent SAEs, including immunologic reactions.",True,CONCLUSIONS
339,Allogeneic mechanical circulatory support is not as effective as autologous mechanical circulatory support for treating acute myocardial infarction.,"In aggregate, MSC injection favorably affected patient functional capacity, quality of life, and ventricular remodeling.   
",False,CONCLUSIONS
340,Allogeneic mechanical circulatory support is not as effective as autologous mechanical circulatory support for treating acute myocardial infarction.,TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01087996.,False,CONCLUSIONS
341,Alteration of origin firing causes changes in termination zones of Okazaki fragments.,"Many fundamental aspects of DNA replication, such as the exact locations where DNA synthesis is initiated and terminated, how frequently origins are used, and how fork progression is influenced by transcription, are poorly understood.",False,BACKGROUND
342,Alteration of origin firing causes changes in termination zones of Okazaki fragments.,"Via the deep sequencing of Okazaki fragments, we comprehensively document replication fork directionality throughout the S. cerevisiae genome, which permits the systematic analysis of initiation, origin efficiency, fork progression, and termination.",False,BACKGROUND
343,Alteration of origin firing causes changes in termination zones of Okazaki fragments.,We show that leading-strand initiation preferentially occurs within a nucleosome-free region at replication origins.,False,BACKGROUND
344,Alteration of origin firing causes changes in termination zones of Okazaki fragments.,"Using a strain in which late origins can be induced to fire early, we show that replication termination is a largely passive phenomenon that does not rely on cis-acting sequences or replication fork pausing.",True,BACKGROUND
345,Alteration of origin firing causes changes in termination zones of Okazaki fragments.,"The replication profile is predominantly determined by the kinetics of origin firing, allowing us to reconstruct chromosome-wide timing profiles from an asynchronous culture.",False,BACKGROUND
346,Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.,"OBJECTIVE To determine the relative accuracy of clinic measurements and home blood pressure monitoring compared with ambulatory blood pressure monitoring as a reference standard for the diagnosis of hypertension.   
",False,OBJECTIVE
347,Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.,DESIGN Systematic review with meta-analysis with hierarchical summary receiver operating characteristic models.,False,METHODS
348,Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.,"Methodological quality was appraised, including evidence of validation of blood pressure measurement equipment.   
",False,METHODS
349,Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.,"DATA SOURCES Medline (from 1966), Embase (from 1980), Cochrane Database of Systematic Reviews, DARE, Medion, ARIF, and TRIP up to May 2010.",False,METHODS
350,Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.,"Eligibility criteria for selecting studies Eligible studies examined diagnosis of hypertension in adults of all ages using home and/or clinic blood pressure measurement compared with those made using ambulatory monitoring that clearly defined thresholds to diagnose hypertension.   
",False,METHODS
351,Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.,"RESULTS The 20 eligible studies used various thresholds for the diagnosis of hypertension, and only seven studies (clinic) and three studies (home) could be directly compared with ambulatory monitoring.",False,RESULTS
352,Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.,"Compared with ambulatory monitoring thresholds of 135/85 mm Hg, clinic measurements over 140/90 mm Hg had mean sensitivity and specificity of 74.6% (95% confidence interval 60.7% to 84.8%) and 74.6% (47.9% to 90.4%), respectively, whereas home measurements over 135/85 mm Hg had mean sensitivity and specificity of 85.7% (78.0% to 91.0%) and 62.4% (48.0% to 75.0%).   
",True,RESULTS
353,Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.,CONCLUSIONS Neither clinic nor home measurement had sufficient sensitivity or specificity to be recommended as a single diagnostic test.,False,CONCLUSIONS
354,Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.,"If ambulatory monitoring is taken as the reference standard, then treatment decisions based on clinic or home blood pressure alone might result in substantial overdiagnosis.",True,CONCLUSIONS
355,Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.,"Ambulatory monitoring before the start of lifelong drug treatment might lead to more appropriate targeting of treatment, particularly around the diagnostic threshold.",True,CONCLUSIONS
356,Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.,"BACKGROUND The diagnosis of hypertension has traditionally been based on blood-pressure measurements in the clinic, but home and ambulatory measurements better correlate with cardiovascular outcome, and ambulatory monitoring is more accurate than both clinic and home monitoring in diagnosing hypertension.",True,BACKGROUND
357,Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.,"We aimed to compare the cost-effectiveness of different diagnostic strategies for hypertension.   
",False,BACKGROUND
358,Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.,METHODS We did a Markov model-based probabilistic cost-effectiveness analysis.,False,METHODS
359,Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.,We used a hypothetical primary-care population aged 40 years or older with a screening blood-pressure measurement greater than 140/90 mm Hg and risk-factor prevalence equivalent to the general population.,False,METHODS
360,Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.,"We compared three diagnostic strategies-further blood pressure measurement in the clinic, at home, and with an ambulatory monitor-in terms of lifetime costs, quality-adjusted life years, and cost-effectiveness.   
",False,METHODS
361,Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.,FINDINGS Ambulatory monitoring was the most cost-effective strategy for the diagnosis of hypertension for men and women of all ages.,False,RESULTS
362,Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.,It was cost-saving for all groups (from -£56 [95% CI -105 to -10] in men aged 75 years to -£323 [-389 to -222] in women aged 40 years) and resulted in more quality-adjusted life years for men and women older than 50 years (from 0·006 [0·000 to 0·015] for women aged 60 years to 0·022 [0·012 to 0·035] for men aged 70 years).,False,RESULTS
363,Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.,"This finding was robust when assessed with a wide range of deterministic sensitivity analyses around the base case, but was sensitive if home monitoring was judged to have equal test performance to ambulatory monitoring or if treatment was judged effective irrespective of whether an individual was hypertensive.   
",False,RESULTS
364,Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.,INTERPRETATION Ambulatory monitoring as a diagnostic strategy for hypertension after an initial raised reading in the clinic would reduce misdiagnosis and save costs.,True,CONCLUSIONS
365,Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.,Additional costs from ambulatory monitoring are counterbalanced by cost savings from better targeted treatment.,False,CONCLUSIONS
366,Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.,"Ambulatory monitoring is recommended for most patients before the start of antihypertensive drugs.   
",False,CONCLUSIONS
367,Ambulatory blood pressure monitoring is inaccurate at diagnosing hypertension.,FUNDING National Institute for Health Research and the National Institute for Health and Clinical Excellence.,False,CONCLUSIONS
368,Amitriptyline is an effective treatment for chronic tension-type headaches.,CONTEXT Chronic tension-type headaches are characterized by near-daily headaches and often are difficult to manage in primary practice.,False,BACKGROUND
369,Amitriptyline is an effective treatment for chronic tension-type headaches.,"Behavioral and pharmacological therapies each appear modestly effective, but data are lacking on their separate and combined effects.   
",False,BACKGROUND
370,Amitriptyline is an effective treatment for chronic tension-type headaches.,"OBJECTIVE To evaluate the clinical efficacy of behavioral and pharmacological therapies, singly and combined, for chronic tension-type headaches.   
",False,OBJECTIVE
371,Amitriptyline is an effective treatment for chronic tension-type headaches.,"DESIGN AND SETTING Randomized placebo-controlled trial conducted from August 1995 to January 1998 at 2 outpatient sites in Ohio.   
",False,METHODS
372,Amitriptyline is an effective treatment for chronic tension-type headaches.,"PARTICIPANTS Two hundred three adults (mean age, 37 years; 76% women) with diagnosis of chronic tension-type headaches (mean, 26 headache d/mo).   
",False,METHODS
373,Amitriptyline is an effective treatment for chronic tension-type headaches.,"INTERVENTIONS Participants were randomly assigned to receive tricyclic antidepressant (amitriptyline hydrochloride, up to 100 mg/d, or nortriptyline hydrochloride, up to 75 mg/d) medication (n = 53), placebo (n = 48), stress management (eg, relaxation, cognitive coping) therapy (3 sessions and 2 telephone contacts) plus placebo (n = 49), or stress management therapy plus antidepressant medication (n = 53).   
",False,METHODS
374,Amitriptyline is an effective treatment for chronic tension-type headaches.,"MAIN OUTCOME MEASURES Monthly headache index scores calculated as the mean of pain ratings (0-10 scale) recorded by participants in a daily diary 4 times per day; number of days per month with at least moderate pain (pain rating >/=5), analgesic medication use, and Headache Disability Inventory scores, compared by intervention group.   
",False,METHODS
375,Amitriptyline is an effective treatment for chronic tension-type headaches.,"RESULTS Tricyclic antidepressant medication and stress management therapy each produced larger reductions in headache activity, analgesic medication use, and headache-related disability than placebo, but antidepressant medication yielded more rapid improvements in headache activity.",True,RESULTS
376,Amitriptyline is an effective treatment for chronic tension-type headaches.,"Combined therapy was more likely to produce clinically significant (>/=50%) reductions in headache index scores (64% of participants) than antidepressant medication (38% of participants; P =.006), stress management therapy (35%; P =.003), or placebo (29%; P =.001).",True,RESULTS
377,Amitriptyline is an effective treatment for chronic tension-type headaches.,"On other measures the combined therapy and its 2 component therapies produced similar outcomes.   
",False,RESULTS
378,Amitriptyline is an effective treatment for chronic tension-type headaches.,CONCLUSIONS Our results indicate that antidepressant medication and stress management therapy are each modestly effective in treating chronic tension-type headaches.,True,CONCLUSIONS
379,Amitriptyline is an effective treatment for chronic tension-type headaches.,Combined therapy may improve outcome relative to monotherapy.,False,CONCLUSIONS
380,Amitriptyline is an effective treatment for chronic tension-type headaches.,"The tricyclic antidepressant, amitriptyline, is an effective drug for the treatment of chronic tension-type headache and for other chronic pain syndromes, but it is also effective in the prophylaxis of an episodic type of headache such as migraine.",True,BACKGROUND
381,Amitriptyline is an effective treatment for chronic tension-type headaches.,"However, its efficacy in episodic tension-type headache has not yet been clarified.",False,BACKGROUND
382,Amitriptyline is an effective treatment for chronic tension-type headaches.,We compared the efficacy of amitriptyline (25 mg/day) in 82 nondepressed patients with either chronic or episodic tension-type headache in an open-label study.,False,METHODS
383,Amitriptyline is an effective treatment for chronic tension-type headaches.,"Amitriptyline significantly reduced (P < 0.05) frequency and duration of headache as well as analgesic consumption in chronic, but not in episodic, tension-type headache.",True,RESULTS
384,Amitriptyline is an effective treatment for chronic tension-type headaches.,"Further placebo-controlled trials, possibly with higher doses of amitriptyline, might confirm if the different pattern of response to amitriptyline can be explained in terms of different involvement of central nociception and of peripheral myofascial factors in the chronic and in the episodic forms of tension-type headache.",False,RESULTS
385,Amitriptyline is an effective treatment for chronic tension-type headaches.,Amitriptyline is the medication of first choice in the treatment of chronic tension-type headache.,True,BACKGROUND
386,Amitriptyline is an effective treatment for chronic tension-type headaches.,In 197 patients with chronic tension-type headache (87M and 110F with a mean age of 38 +/-,False,METHODS
387,Amitriptyline is an effective treatment for chronic tension-type headaches.,"13 (18-68)) efficacy and tolerability of 60-90 mg amitriptylinoxide (AO) were compared with 50-75 mg amitriptyline (AM) and placebo (PL) in a double-blind, parallel-group trial consisting of a four weeks' baseline phase and 12 weeks of treatment.",False,METHODS
388,Amitriptyline is an effective treatment for chronic tension-type headaches.,The primary study endpoint was a reduction of at least 50% of the product of headache duration and frequency and a reduction of at least 50% in headache intensity.,True,METHODS
389,Amitriptyline is an effective treatment for chronic tension-type headaches.,Statistics used were Fisher's exact test and analysis of variance.,False,METHODS
390,Amitriptyline is an effective treatment for chronic tension-type headaches.,"No significant difference emerged between AO, AM and PL with respect to the primary study endpoint.",False,RESULTS
391,Amitriptyline is an effective treatment for chronic tension-type headaches.,"Treatment response occurred in 30.3% of the AO, 22.4% of the AM and 21.9% of the PL group.",False,RESULTS
392,Amitriptyline is an effective treatment for chronic tension-type headaches.,"A reduction in headache duration and frequency of at least 50% was found in 39.4% on AO, in 25.4% on AM and in 26.6% on PL (PAO-PL = .1384, PAM-PL = 1.000, PAO-AM = .0973).",True,RESULTS
393,Amitriptyline is an effective treatment for chronic tension-type headaches.,"A reduction in headache intensity of at least 50% was found in 31.8% on AO, in 26.9% on AM and in 26.6% on PL (PAO-PL = .5657, PAM-PL = 1.000, PAO-AM = .5715).",True,RESULTS
394,Amitriptyline is an effective treatment for chronic tension-type headaches.,Trend analysis with respect to a significant reduction of headache intensity (p < 0.05) and the product of headache duration and frequency revealed a superior effect of AO.(ABSTRACT TRUNCATED AT 250 WORDS),False,RESULTS
395,An M2-like phenotype in brown adipose tissue macrophages is quickly induced by cold exposure.,"All homeotherms use thermogenesis to maintain their core body temperature, ensuring that cellular functions and physiological processes can continue in cold environments.",False,BACKGROUND
396,An M2-like phenotype in brown adipose tissue macrophages is quickly induced by cold exposure.,"In the prevailing model of thermogenesis, when the hypothalamus senses cold temperatures it triggers sympathetic discharge, resulting in the release of noradrenaline in brown adipose tissue and white adipose tissue.",False,BACKGROUND
397,An M2-like phenotype in brown adipose tissue macrophages is quickly induced by cold exposure.,"Acting via the β(3)-adrenergic receptors, noradrenaline induces lipolysis in white adipocytes, whereas it stimulates the expression of thermogenic genes, such as PPAR-γ coactivator 1a (Ppargc1a), uncoupling protein 1 (Ucp1) and acyl-CoA synthetase long-chain family member 1 (Acsl1), in brown adipocytes.",False,BACKGROUND
398,An M2-like phenotype in brown adipose tissue macrophages is quickly induced by cold exposure.,"However, the precise nature of all the cell types involved in this efferent loop is not well established.",False,BACKGROUND
399,An M2-like phenotype in brown adipose tissue macrophages is quickly induced by cold exposure.,Here we report in mice an unexpected requirement for the interleukin-4 (IL-4)-stimulated program of alternative macrophage activation in adaptive thermogenesis.,False,BACKGROUND
400,An M2-like phenotype in brown adipose tissue macrophages is quickly induced by cold exposure.,"Exposure to cold temperature rapidly promoted alternative activation of adipose tissue macrophages, which secrete catecholamines to induce thermogenic gene expression in brown adipose tissue and lipolysis in white adipose tissue.",True,RESULTS
401,An M2-like phenotype in brown adipose tissue macrophages is quickly induced by cold exposure.,"Absence of alternatively activated macrophages impaired metabolic adaptations to cold, whereas administration of IL-4 increased thermogenic gene expression, fatty acid mobilization and energy expenditure, all in a macrophage-dependent manner.",False,RESULTS
402,An M2-like phenotype in brown adipose tissue macrophages is quickly induced by cold exposure.,"Thus, we have discovered a role for alternatively activated macrophages in the orchestration of an important mammalian stress response, the response to cold.",False,RESULTS
403,Androgenetic haploid mouse embryonic stem cells (ESCs) can be derived and genetically manipulated in vitro.,Haploid cells are amenable for genetic analysis.,False,BACKGROUND
404,Androgenetic haploid mouse embryonic stem cells (ESCs) can be derived and genetically manipulated in vitro.,Recent success in the derivation of mouse haploid embryonic stem cells (haESCs) via parthenogenesis has enabled genetic screening in mammalian cells.,False,BACKGROUND
405,Androgenetic haploid mouse embryonic stem cells (ESCs) can be derived and genetically manipulated in vitro.,"However, successful generation of live animals from these haESCs, which is needed to extend the genetic analysis to the organism level, has not been achieved.",False,BACKGROUND
406,Androgenetic haploid mouse embryonic stem cells (ESCs) can be derived and genetically manipulated in vitro.,"Here, we report the derivation of haESCs from androgenetic blastocysts.",False,BACKGROUND
407,Androgenetic haploid mouse embryonic stem cells (ESCs) can be derived and genetically manipulated in vitro.,"These cells, designated as AG-haESCs, partially maintain paternal imprints, express classical ESC pluripotency markers, and contribute to various tissues, including the germline, upon injection into diploid blastocysts.",False,RESULTS
408,Androgenetic haploid mouse embryonic stem cells (ESCs) can be derived and genetically manipulated in vitro.,"Strikingly, live mice can be obtained upon injection of AG-haESCs into MII oocytes, and these mice bear haESC-carried genetic traits and develop into fertile adults.",True,RESULTS
409,Androgenetic haploid mouse embryonic stem cells (ESCs) can be derived and genetically manipulated in vitro.,"Furthermore, gene targeting via homologous recombination is feasible in the AG-haESCs.",False,RESULTS
410,Androgenetic haploid mouse embryonic stem cells (ESCs) can be derived and genetically manipulated in vitro.,Our results demonstrate that AG-haESCs can be used as a genetically tractable fertilization agent for the production of live animals via injection into oocytes.,True,CONCLUSIONS
411,Angiotensin converting enzyme inhibitors are associated with decreased risk for functional renal insufficiency.,Angiotensin converting enzyme (ACE) inhibitors are now one of the most frequently used classes of antihypertensive drugs.,False,BACKGROUND
412,Angiotensin converting enzyme inhibitors are associated with decreased risk for functional renal insufficiency.,"Beyond their utility in the management of hypertension, their use has been extended to the long-term management of patients with congestive heart failure (CHF), as well as diabetic and nondiabetic nephropathies.",False,BACKGROUND
413,Angiotensin converting enzyme inhibitors are associated with decreased risk for functional renal insufficiency.,"Although ACE inhibitor therapy usually improves renal blood flow (RBF) and sodium excretion rates in CHF and reduces the rate of progressive renal injury in chronic renal disease, its use can also be associated with a syndrome of “functional renal insufficiency” and/or hyperkalemia.",True,BACKGROUND
414,Angiotensin converting enzyme inhibitors are associated with decreased risk for functional renal insufficiency.,"This form of acute renal failure (ARF) most commonly develops shortly after initiation of ACE inhibitor therapy but can be observed after months or years of therapy, even in the absence of prior ill effects.",False,BACKGROUND
415,Angiotensin converting enzyme inhibitors are associated with decreased risk for functional renal insufficiency.,ARF is most likely to occur when renal perfusion pressure cannot be sustained because of substantial decreases in mean arterial pressure (MAP) or when glomerular filtration rate (GFR) is highly angiotensin II (Ang II) dependent.,False,BACKGROUND
416,Angiotensin converting enzyme inhibitors are associated with decreased risk for functional renal insufficiency.,Conditions that predict an adverse hemodynamic effect of ACE inhibitors in patients with CHF are preexisting hypotension and low cardiac filling pressures.,False,BACKGROUND
417,Angiotensin converting enzyme inhibitors are associated with decreased risk for functional renal insufficiency.,"The GFR is especially dependent on Ang II during extracellular fluid (ECF) volume depletion, high-grade bilateral renal artery stenosis, or stenosis of a dominant or single kidney, as in a renal transplant recipient.",False,BACKGROUND
418,Angiotensin converting enzyme inhibitors are associated with decreased risk for functional renal insufficiency.,"Understanding the pathophysiological mechanisms and the common risk factors for ACE inhibitor–induced functional ARF is critical, because preventive strategies for ARF exist, and if effectively used, they may permit use of these compounds in a less restricted fashion.  ",True,BACKGROUND
419,Angiotensin converting enzyme inhibitors are associated with decreased risk for functional renal insufficiency.,"Under normal physiological conditions, renal autoregulation adjusts renal vascular resistance, so that RBF and GFR remain constant over a wide range of MAPs.1 The intrinsic renal autoregulation mechanism is adjusted by Ang II and the sympathetic nervous system.",False,BACKGROUND
420,Angiotensin converting enzyme inhibitors are associated with decreased risk for functional renal insufficiency.,When renal perfusion pressure falls (as in …,False,BACKGROUND
421,Anthrax spores are very difficult to dispose once they are dispersed.,"CONTEXT Bioterrorist attacks involving letters and mail-handling systems in Washington, DC, resulted in Bacillus anthracis (anthrax) spore contamination in the Hart Senate Office Building and other facilities in the US Capitol's vicinity.   
",False,BACKGROUND
422,Anthrax spores are very difficult to dispose once they are dispersed.,"OBJECTIVE To provide information about the nature and extent of indoor secondary aerosolization of B anthracis spores.   
",False,OBJECTIVE
423,Anthrax spores are very difficult to dispose once they are dispersed.,"DESIGN Stationary and personal air samples, surface dust, and swab samples were collected under semiquiescent (minimal activities) and then simulated active office conditions to estimate secondary aerosolization of B anthracis spores.",False,METHODS
424,Anthrax spores are very difficult to dispose once they are dispersed.,"Nominal size characteristics, airborne concentrations, and surface contamination of B anthracis particles (colony-forming units) were evaluated.   
",False,METHODS
425,Anthrax spores are very difficult to dispose once they are dispersed.,"RESULTS Viable B anthracis spores reaerosolized under semiquiescent conditions, with a marked increase in reaerosolization during simulated active office conditions.",False,RESULTS
426,Anthrax spores are very difficult to dispose once they are dispersed.,Increases were observed for B anthracis collected on open sheep blood agar plates (P<.001) and personal air monitors (P =.01) during active office conditions.,False,RESULTS
427,Anthrax spores are very difficult to dispose once they are dispersed.,More than 80% of the B anthracis particles collected on stationary monitors were within an alveolar respirable size range of 0.95 to 3.5 micro m.   CONCLUSIONS Bacillus anthracis spores used in a recent terrorist incident reaerosolized under common office activities.,True,CONCLUSIONS
428,Anthrax spores are very difficult to dispose once they are dispersed.,"These findings have important implications for appropriate respiratory protection, remediation, and reoccupancy of contaminated office environments.",False,CONCLUSIONS
429,Anthrax spores remain deadly until affected areas are decontaminated.,"CONTEXT Bioterrorist attacks involving letters and mail-handling systems in Washington, DC, resulted in Bacillus anthracis (anthrax) spore contamination in the Hart Senate Office Building and other facilities in the US Capitol's vicinity.   
",False,BACKGROUND
430,Anthrax spores remain deadly until affected areas are decontaminated.,"OBJECTIVE To provide information about the nature and extent of indoor secondary aerosolization of B anthracis spores.   
",False,OBJECTIVE
431,Anthrax spores remain deadly until affected areas are decontaminated.,"DESIGN Stationary and personal air samples, surface dust, and swab samples were collected under semiquiescent (minimal activities) and then simulated active office conditions to estimate secondary aerosolization of B anthracis spores.",False,METHODS
432,Anthrax spores remain deadly until affected areas are decontaminated.,"Nominal size characteristics, airborne concentrations, and surface contamination of B anthracis particles (colony-forming units) were evaluated.   
",False,METHODS
433,Anthrax spores remain deadly until affected areas are decontaminated.,"RESULTS Viable B anthracis spores reaerosolized under semiquiescent conditions, with a marked increase in reaerosolization during simulated active office conditions.",False,RESULTS
434,Anthrax spores remain deadly until affected areas are decontaminated.,Increases were observed for B anthracis collected on open sheep blood agar plates (P<.001) and personal air monitors (P =.01) during active office conditions.,False,RESULTS
435,Anthrax spores remain deadly until affected areas are decontaminated.,More than 80% of the B anthracis particles collected on stationary monitors were within an alveolar respirable size range of 0.95 to 3.5 micro m.   CONCLUSIONS Bacillus anthracis spores used in a recent terrorist incident reaerosolized under common office activities.,True,CONCLUSIONS
436,Anthrax spores remain deadly until affected areas are decontaminated.,"These findings have important implications for appropriate respiratory protection, remediation, and reoccupancy of contaminated office environments.",False,CONCLUSIONS
437,Antidepressants increase the severity of migraines.,"OBJECTIVE To evaluate the efficacy and relative adverse effects of tricyclic antidepressants in the treatment of migraine, tension-type, and mixed headaches.   
",False,OBJECTIVE
438,Antidepressants increase the severity of migraines.,"DESIGN Meta-analysis.   
",False,METHODS
439,Antidepressants increase the severity of migraines.,"DATA SOURCES Medline, Embase, the Cochrane Trials Registry, and PsycLIT.",False,METHODS
440,Antidepressants increase the severity of migraines.,"Studies reviewed Randomised trials of adults receiving tricyclics as only treatment for a minimum of four weeks.   
",False,METHODS
441,Antidepressants increase the severity of migraines.,"DATA EXTRACTION Frequency of headaches (number of headache attacks for migraine and number of days with headache for tension-type headaches), intensity of headache, and headache index.   
",False,METHODS
442,Antidepressants increase the severity of migraines.,RESULTS 37 studies met the inclusion criteria.,False,RESULTS
443,Antidepressants increase the severity of migraines.,"Tricyclics significantly reduced the number of days with tension-type headache and number of headache attacks from migraine than placebo (average standardised mean difference -1.29, 95% confidence interval -2.18 to -0.39 and -0.70, -0.93 to -0.48) but not compared with selective serotonin reuptake inhibitors (-0.80, -2.63 to 0.02 and -0.20, -0.60 to 0.19).",True,RESULTS
444,Antidepressants increase the severity of migraines.,"The effect of tricyclics increased with longer duration of treatment (β=-0.11, 95% confidence interval -0.63 to -0.15; P<0.0005).",False,RESULTS
445,Antidepressants increase the severity of migraines.,"Tricyclics were also more likely to reduce the intensity of headaches by at least 50% than either placebo (tension-type: relative risk 1.41, 95% confidence interval 1.02 to 1.89; migraine: 1.80, 1.24 to 2.62) or selective serotonin reuptake inhibitors (1.73, 1.34 to 2.22 and 1.72, 1.15 to 2.55).",True,RESULTS
446,Antidepressants increase the severity of migraines.,"Tricyclics were more likely to cause adverse effects than placebo (1.53, 95% confidence interval 1.11 to 2.12) and selective serotonin reuptake inhibitors (2.22, 1.52 to 3.32), including dry mouth (P<0.0005 for both), drowsiness (P<0.0005 for both), and weight gain (P<0.001 for both), but did not increase dropout rates (placebo: 1.22, 0.83 to 1.80, selective serotonin reuptake inhibitors: 1.16, 0.81 to 2.97).   
",False,RESULTS
447,Antidepressants increase the severity of migraines.,"CONCLUSIONS Tricyclic antidepressants are effective in preventing migraine and tension-type headaches and are more effective than selective serotonin reuptake inhibitors, although with greater adverse effects.",True,CONCLUSIONS
448,Antidepressants increase the severity of migraines.,The effectiveness of tricyclics seems to increase over time.,False,CONCLUSIONS
449,Antidepressants reduce the severity of migraines.,"OBJECTIVE To evaluate the efficacy and relative adverse effects of tricyclic antidepressants in the treatment of migraine, tension-type, and mixed headaches.   
",False,OBJECTIVE
450,Antidepressants reduce the severity of migraines.,"DESIGN Meta-analysis.   
",False,METHODS
451,Antidepressants reduce the severity of migraines.,"DATA SOURCES Medline, Embase, the Cochrane Trials Registry, and PsycLIT.",False,METHODS
452,Antidepressants reduce the severity of migraines.,"Studies reviewed Randomised trials of adults receiving tricyclics as only treatment for a minimum of four weeks.   
",False,METHODS
453,Antidepressants reduce the severity of migraines.,"DATA EXTRACTION Frequency of headaches (number of headache attacks for migraine and number of days with headache for tension-type headaches), intensity of headache, and headache index.   
",False,METHODS
454,Antidepressants reduce the severity of migraines.,RESULTS 37 studies met the inclusion criteria.,False,RESULTS
455,Antidepressants reduce the severity of migraines.,"Tricyclics significantly reduced the number of days with tension-type headache and number of headache attacks from migraine than placebo (average standardised mean difference -1.29, 95% confidence interval -2.18 to -0.39 and -0.70, -0.93 to -0.48) but not compared with selective serotonin reuptake inhibitors (-0.80, -2.63 to 0.02 and -0.20, -0.60 to 0.19).",True,RESULTS
456,Antidepressants reduce the severity of migraines.,"The effect of tricyclics increased with longer duration of treatment (β=-0.11, 95% confidence interval -0.63 to -0.15; P<0.0005).",False,RESULTS
457,Antidepressants reduce the severity of migraines.,"Tricyclics were also more likely to reduce the intensity of headaches by at least 50% than either placebo (tension-type: relative risk 1.41, 95% confidence interval 1.02 to 1.89; migraine: 1.80, 1.24 to 2.62) or selective serotonin reuptake inhibitors (1.73, 1.34 to 2.22 and 1.72, 1.15 to 2.55).",True,RESULTS
458,Antidepressants reduce the severity of migraines.,"Tricyclics were more likely to cause adverse effects than placebo (1.53, 95% confidence interval 1.11 to 2.12) and selective serotonin reuptake inhibitors (2.22, 1.52 to 3.32), including dry mouth (P<0.0005 for both), drowsiness (P<0.0005 for both), and weight gain (P<0.001 for both), but did not increase dropout rates (placebo: 1.22, 0.83 to 1.80, selective serotonin reuptake inhibitors: 1.16, 0.81 to 2.97).   
",False,RESULTS
459,Antidepressants reduce the severity of migraines.,"CONCLUSIONS Tricyclic antidepressants are effective in preventing migraine and tension-type headaches and are more effective than selective serotonin reuptake inhibitors, although with greater adverse effects.",True,CONCLUSIONS
460,Antidepressants reduce the severity of migraines.,The effectiveness of tricyclics seems to increase over time.,False,CONCLUSIONS
461,Antimicrobial agents are less effective due to the pressure of antimicrobial usage.,"Overusing antibiotics is not the only cause and reducing use is not the only solution   W arning signs of antimicrobial resistance, chinks in the antimicrobial armour, began to appear in the middle of the last century, and by the 1990s various reports had signalled the dangers of excessive or inappropriate use of antibiotics in clinical medicine and of the use of antibiotics in animal feed as growth promoters.1–3 Overuse of antimicrobials emerged as the main culprit, and reducing their use was seen as the answer.",True,BACKGROUND
462,Antimicrobial agents are less effective due to the pressure of antimicrobial usage.,But it may not be that simple.  ,False,BACKGROUND
463,Antimicrobial agents are less effective due to the pressure of antimicrobial usage.,"The idea that reducing antibiotic use would redress the problem formed part of a positive response on the part of the United Kingdom government to the House of Lords report,1 including a public information campaign, surveillance of resistance along the food chain, targets with respect to hospital acquired infections, and setting up of an overarching advisory body on all aspects of antibiotic use.",False,BACKGROUND
464,Antimicrobial agents are less effective due to the pressure of antimicrobial usage.,"However, the concept of overuse has proved too simplistic, for, although the evidence of overprescribing as the …",False,BACKGROUND
465,Antimicrobial agents are more effective due to the pressure of antimicrobial usage.,"Overusing antibiotics is not the only cause and reducing use is not the only solution   W arning signs of antimicrobial resistance, chinks in the antimicrobial armour, began to appear in the middle of the last century, and by the 1990s various reports had signalled the dangers of excessive or inappropriate use of antibiotics in clinical medicine and of the use of antibiotics in animal feed as growth promoters.1–3 Overuse of antimicrobials emerged as the main culprit, and reducing their use was seen as the answer.",True,BACKGROUND
466,Antimicrobial agents are more effective due to the pressure of antimicrobial usage.,But it may not be that simple.  ,False,BACKGROUND
467,Antimicrobial agents are more effective due to the pressure of antimicrobial usage.,"The idea that reducing antibiotic use would redress the problem formed part of a positive response on the part of the United Kingdom government to the House of Lords report,1 including a public information campaign, surveillance of resistance along the food chain, targets with respect to hospital acquired infections, and setting up of an overarching advisory body on all aspects of antibiotic use.",False,BACKGROUND
468,Antimicrobial agents are more effective due to the pressure of antimicrobial usage.,"However, the concept of overuse has proved too simplistic, for, although the evidence of overprescribing as the …",False,BACKGROUND
469,Antiretroviral therapy increases rates of tuberculosis across a broad range of CD4 strata.,"BACKGROUND Human immunodeficiency virus (HIV) infection is the strongest risk factor for developing tuberculosis and has fuelled its resurgence, especially in sub-Saharan Africa.",False,BACKGROUND
470,Antiretroviral therapy increases rates of tuberculosis across a broad range of CD4 strata.,"In 2010, there were an estimated 1.1 million incident cases of tuberculosis among the 34 million people living with HIV worldwide.",False,BACKGROUND
471,Antiretroviral therapy increases rates of tuberculosis across a broad range of CD4 strata.,Antiretroviral therapy has substantial potential to prevent HIV-associated tuberculosis.,False,BACKGROUND
472,Antiretroviral therapy increases rates of tuberculosis across a broad range of CD4 strata.,"We conducted a systematic review of studies that analysed the impact of antiretroviral therapy on the incidence of tuberculosis in adults with HIV infection.   
",False,BACKGROUND
473,Antiretroviral therapy increases rates of tuberculosis across a broad range of CD4 strata.,"METHODS AND FINDINGS PubMed, Embase, African Index Medicus, LILACS, and clinical trial registries were systematically searched.",False,METHODS
474,Antiretroviral therapy increases rates of tuberculosis across a broad range of CD4 strata.,"Randomised controlled trials, prospective cohort studies, and retrospective cohort studies were included if they compared tuberculosis incidence by antiretroviral therapy status in HIV-infected adults for a median of over 6 mo in developing countries.",False,METHODS
475,Antiretroviral therapy increases rates of tuberculosis across a broad range of CD4 strata.,"For the meta-analyses there were four categories based on CD4 counts at antiretroviral therapy initiation: (1) less than 200 cells/µl, (2) 200 to 350 cells/µl, (3) greater than 350 cells/µl, and (4) any CD4 count.",False,METHODS
476,Antiretroviral therapy increases rates of tuberculosis across a broad range of CD4 strata.,Eleven studies met the inclusion criteria.,False,RESULTS
477,Antiretroviral therapy increases rates of tuberculosis across a broad range of CD4 strata.,"Antiretroviral therapy is strongly associated with a reduction in the incidence of tuberculosis in all baseline CD4 count categories: (1) less than 200 cells/µl (hazard ratio [HR] 0.16, 95% confidence interval [CI] 0.07 to 0.36), (2) 200 to 350 cells/µl (HR 0.34, 95% CI 0.19 to 0.60), (3) greater than 350 cells/µl (HR 0.43, 95% CI 0.30 to 0.63), and (4) any CD4 count (HR 0.35, 95% CI 0.28 to 0.44).",True,RESULTS
478,Antiretroviral therapy increases rates of tuberculosis across a broad range of CD4 strata.,"There was no evidence of hazard ratio modification with respect to baseline CD4 count category (p = 0.20).   
",False,RESULTS
479,Antiretroviral therapy increases rates of tuberculosis across a broad range of CD4 strata.,CONCLUSIONS Antiretroviral therapy is strongly associated with a reduction in the incidence of tuberculosis across all CD4 count strata.,True,CONCLUSIONS
480,Antiretroviral therapy increases rates of tuberculosis across a broad range of CD4 strata.,Earlier initiation of antiretroviral therapy may be a key component of global and national strategies to control the HIV-associated tuberculosis syndemic.   ,False,CONCLUSIONS
481,Antiretroviral therapy increases rates of tuberculosis across a broad range of CD4 strata.,REVIEW REGISTRATION International Prospective Register of Systematic Reviews CRD42011001209 Please see later in the article for the Editors' Summary.,False,CONCLUSIONS
482,Asymptomatic visual impairment screening in elderly populations leads to improved vision.,"OBJECTIVE To assess whether population screening for impaired vision among older people in the community leads to improvements in vision.   
",False,OBJECTIVE
483,Asymptomatic visual impairment screening in elderly populations leads to improved vision.,DESIGN Systematic review of randomised controlled trials of population screening in the community that included any assessment of vision or visual function with at least 6 months' follow up.   ,False,METHODS
484,Asymptomatic visual impairment screening in elderly populations leads to improved vision.,"SUBJECTS Adults aged 65 or over.   
",False,METHODS
485,Asymptomatic visual impairment screening in elderly populations leads to improved vision.,"MAIN OUTCOME MEASURE Proportions with visual impairment in intervention and control groups with any method of assessing visual impairment.   
",False,METHODS
486,Asymptomatic visual impairment screening in elderly populations leads to improved vision.,RESULTS There were no trials that primarily assessed visual screening.,False,METHODS
487,Asymptomatic visual impairment screening in elderly populations leads to improved vision.,Outcome data on vision were available for 3494 people in five trials of multiphasic assessment.,False,METHODS
488,Asymptomatic visual impairment screening in elderly populations leads to improved vision.,"All the trials used self reported measures for vision impairment, both as screening tools and as outcome measures.",False,METHODS
489,Asymptomatic visual impairment screening in elderly populations leads to improved vision.,The inclusion of a visual screening component in the assessment did not result in improvements in self reported visual problems (pooled odds ratio 1.04:95% confidence interval 0.89 to 1.22).,True,RESULTS
490,Asymptomatic visual impairment screening in elderly populations leads to improved vision.,"A small reduction (11%) in the number of older people with self reported visual problems cannot be excluded.   
",False,CONCLUSIONS
491,Asymptomatic visual impairment screening in elderly populations leads to improved vision.,CONCLUSIONS Screening of asymptomatic older people in the community is not justified on present evidence.,True,CONCLUSIONS
492,Asymptomatic visual impairment screening in elderly populations leads to improved vision.,Visual impairment in this age group can usually be reduced with treatment.,False,CONCLUSIONS
493,Asymptomatic visual impairment screening in elderly populations leads to improved vision.,It is unclear why no benefit was seen.,False,CONCLUSIONS
494,Asymptomatic visual impairment screening in elderly populations leads to improved vision.,Further work is needed to clarify what interventions are appropriate for older people with unreported impairment of vision.,False,CONCLUSIONS
495,Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.,"CONTEXT Antibody-based induction therapy plus calcineurin inhibitors (CNIs) reduce acute rejection rates in kidney recipients; however, opportunistic infections and toxic CNI effects remain challenging.",False,OBJECTIVE
496,Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.,"Reportedly, mesenchymal stem cells (MSCs) have successfully treated graft-vs-host disease.   
",False,OBJECTIVE
497,Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.,"OBJECTIVE To assess autologous MSCs as replacement of antibody induction for patients with end-stage renal disease who undergo ABO-compatible, cross-match-negative kidney transplants from a living-related donor.   
",False,OBJECTIVE
498,Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.,"DESIGN, SETTING, AND PATIENTS One hundred fifty-nine patients were enrolled in this single-site, prospective, open-label, randomized study from February 2008-May 2009, when recruitment was completed.   
",False,METHODS
499,Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.,INTERVENTION Patients were inoculated with marrow-derived autologous MSC (1-2 x 10(6)/kg) at kidney reperfusion and two weeks later.,False,METHODS
500,Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.,"Fifty-three patients received standard-dose and 52 patients received low-dose CNIs (80% of standard); 51 patients in the control group received anti-IL-2 receptor antibody plus standard-dose CNIs.   
",False,METHODS
501,Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.,"MAIN OUTCOME MEASURES The primary measure was 1-year incidence of acute rejection and renal function (estimated glomerular filtration rate [eGFR]); the secondary measure was patient and graft survival and incidence of adverse events.   
",False,METHODS
502,Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.,RESULTS Patient and graft survival at 13 to 30 months was similar in all groups.,False,RESULTS
503,Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.,"After 6 months, 4 of 53 patients (7.5%) in the autologous MSC plus standard-dose CNI group (95% CI, 0.4%-14.7%; P = .04) and 4 of 52 patients (7.7%) in the low-dose group (95% CI, 0.5%-14.9%; P = .046) compared with 11 of 51 controls (21.6%; 95% CI, 10.5%-32.6%) had biopsy-confirmed acute rejection.",True,RESULTS
504,Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.,"None of the patients in either autologous MSC group had glucorticoid-resistant rejection, whereas 4 patients (7.8%) in the control group did (95% CI, 0.6%-15.1%; overall P = .02).",False,RESULTS
505,Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.,Renal function recovered faster among both MSC groups showing increased eGFR levels during the first month after surgery than the control group.,True,RESULTS
506,Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.,"Patients receiving standard-dose CNI had a mean difference of 6.2 mL/min per 1.73 m(2) (95% CI, 0.4-11.9; P=.04) and those in the low-dose CNI of 10.0 mL/min per 1.73 m(2) (95% CI, 3.8-16.2; P=.002).",False,RESULTS
507,Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.,"Also, during the 1-year follow-up, combined analysis of MSC-treated groups revealed significantly decreased risk of opportunistic infections than the control group (hazard ratio, 0.42; 95% CI, 0.20-0.85, P=.02)   CONCLUSION Among patients undergoing renal transplant, the use of autologous MSCs compared with anti-IL-2 receptor antibody induction therapy resulted in lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated renal function at 1 year.   
",True,CONCLUSIONS
508,Autologous transplantation of mesenchymal stem cells has better graft function than induction therapy with anti-interleukin-2 receptor antibodies.,TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00658073.,False,CONCLUSIONS
509,Autophagy deficiency in the liver increases vulnerability to insulin resistance.,"Despite growing interest and a recent surge in papers, the role of autophagy in glucose and lipid metabolism is unclear.",False,BACKGROUND
510,Autophagy deficiency in the liver increases vulnerability to insulin resistance.,We produced mice with skeletal muscle–specific deletion of Atg7 (encoding autophagy-related 7).,False,BACKGROUND
511,Autophagy deficiency in the liver increases vulnerability to insulin resistance.,"Unexpectedly, these mice showed decreased fat mass and were protected from diet-induced obesity and insulin resistance; this phenotype was accompanied by increased fatty acid oxidation and browning of white adipose tissue (WAT) owing to induction of fibroblast growth factor 21 (Fgf21).",True,RESULTS
512,Autophagy deficiency in the liver increases vulnerability to insulin resistance.,"Mitochondrial dysfunction induced by autophagy deficiency increased Fgf21 expression through induction of Atf4, a master regulator of the integrated stress response.",False,RESULTS
513,Autophagy deficiency in the liver increases vulnerability to insulin resistance.,Mitochondrial respiratory chain inhibitors also induced Fgf21 in an Atf4-dependent manner.,False,RESULTS
514,Autophagy deficiency in the liver increases vulnerability to insulin resistance.,"We also observed induction of Fgf21, resistance to diet-induced obesity and amelioration of insulin resistance in mice with autophagy deficiency in the liver, another insulin target tissue.",True,RESULTS
515,Autophagy deficiency in the liver increases vulnerability to insulin resistance.,"These findings suggest that autophagy deficiency and subsequent mitochondrial dysfunction promote Fgf21 expression, a hormone we consequently term a 'mitokine', and together these processes promote protection from diet-induced obesity and insulin resistance.",True,CONCLUSIONS
516,B cells go though plasmablast differentiation and antibody production by continuous expression of EBI2.,Humoral immunity depends on both rapid and long-term antibody production against invading pathogens.,False,BACKGROUND
517,B cells go though plasmablast differentiation and antibody production by continuous expression of EBI2.,"This is achieved by the generation of spatially distinct extrafollicular plasmablast and follicular germinal center (GC) B cell populations, but the signals that guide responding B cells to these alternative compartments have not been fully elucidated.",False,BACKGROUND
518,B cells go though plasmablast differentiation and antibody production by continuous expression of EBI2.,"Here, we show that expression of the orphan G protein-coupled receptor Epstein-Barr virus-induced gene 2 (EBI2, also known as GPR183) by activated B cells was essential for their movement to extrafollicular sites and induction of early plasmablast responses.",True,RESULTS
519,B cells go though plasmablast differentiation and antibody production by continuous expression of EBI2.,"Conversely, downregulation of EBI2 enabled B cells to access the center of follicles and promoted efficient GC formation.",False,RESULTS
520,B cells go though plasmablast differentiation and antibody production by continuous expression of EBI2.,EBI2 therefore provides a previously uncharacterized dimension to B cell migration that is crucial for coordinating rapid versus long-term antibody responses.,True,CONCLUSIONS
521,BCL-2 activation antagonizes the apoptotic effects of c-Myc.,"Resistance to apoptosis, often achieved by the overexpression of antiapoptotic proteins, is common and perhaps required in the genesis of cancer.",False,BACKGROUND
522,BCL-2 activation antagonizes the apoptotic effects of c-Myc.,"However, it remains uncertain whether apoptotic defects are essential for tumor maintenance.",False,BACKGROUND
523,BCL-2 activation antagonizes the apoptotic effects of c-Myc.,"To test this, we generated mice expressing a conditional BCL-2 gene and constitutive c-myc that develop lymphoblastic leukemia.",False,BACKGROUND
524,BCL-2 activation antagonizes the apoptotic effects of c-Myc.,"Eliminating BCL-2 yielded rapid loss of leukemic cells and significantly prolonged survival, formally validating BCL-2 as a rational target for cancer therapy.",True,BACKGROUND
525,BCL-2 activation antagonizes the apoptotic effects of c-Myc.,"Loss of this single molecule resulted in cell death, despite or perhaps attributable to the presence of other oncogenic events.",False,BACKGROUND
526,BCL-2 activation antagonizes the apoptotic effects of c-Myc.,This suggests a generalizable model in which aberrations inherent to cancer generate tonic death signals that would otherwise kill the cell if not opposed by a requisite apoptotic defect(s).,False,BACKGROUND
527,BCL-2 promotes the apoptotic effects of c-Myc.,"Resistance to apoptosis, often achieved by the overexpression of antiapoptotic proteins, is common and perhaps required in the genesis of cancer.",False,BACKGROUND
528,BCL-2 promotes the apoptotic effects of c-Myc.,"However, it remains uncertain whether apoptotic defects are essential for tumor maintenance.",False,BACKGROUND
529,BCL-2 promotes the apoptotic effects of c-Myc.,"To test this, we generated mice expressing a conditional BCL-2 gene and constitutive c-myc that develop lymphoblastic leukemia.",False,BACKGROUND
530,BCL-2 promotes the apoptotic effects of c-Myc.,"Eliminating BCL-2 yielded rapid loss of leukemic cells and significantly prolonged survival, formally validating BCL-2 as a rational target for cancer therapy.",True,BACKGROUND
531,BCL-2 promotes the apoptotic effects of c-Myc.,"Loss of this single molecule resulted in cell death, despite or perhaps attributable to the presence of other oncogenic events.",False,BACKGROUND
532,BCL-2 promotes the apoptotic effects of c-Myc.,This suggests a generalizable model in which aberrations inherent to cancer generate tonic death signals that would otherwise kill the cell if not opposed by a requisite apoptotic defect(s).,False,BACKGROUND
533,BLM gene encodes RecQ-class DNA helicase.,"The Bloom's syndrome (BS) gene, BLM, plays an important role in the maintenance of genomic stability in somatic cells.",False,BACKGROUND
534,BLM gene encodes RecQ-class DNA helicase.,A candidate for BLM was identified by direct selection of a cDNA derived from a 250 kb segment of the genome to which BLM had been assigned by somatic crossover point mapping.,False,METHODS
535,BLM gene encodes RecQ-class DNA helicase.,"In this novel mapping method, cells were used from persons with BS that had undergone intragenic recombination within BLM.",False,METHODS
536,BLM gene encodes RecQ-class DNA helicase.,"cDNA analysis of the candidate gene identified a 4437 bp cDNA that encodes a 1417 amino acid peptide with homology to the RecQ helicases, a subfamily of DExH box-containing DNA and RNA helicases.",True,RESULTS
537,BLM gene encodes RecQ-class DNA helicase.,The presence of chain-terminating mutations in the candidate gene in persons with BS proved that it was BLM.,False,RESULTS
538,BRCA 1 mutation carriers' risk of breast and ovarian cancer depends on where the mutation is located.,"IMPORTANCE Limited information about the relationship between specific mutations in BRCA1 or BRCA2 (BRCA1/2) and cancer risk exists.   
",False,BACKGROUND
539,BRCA 1 mutation carriers' risk of breast and ovarian cancer depends on where the mutation is located.,"OBJECTIVE To identify mutation-specific cancer risks for carriers of BRCA1/2.   
",False,OBJECTIVE
540,BRCA 1 mutation carriers' risk of breast and ovarian cancer depends on where the mutation is located.,"DESIGN, SETTING, AND PARTICIPANTS Observational study of women who were ascertained between 1937 and 2011 (median, 1999) and found to carry disease-associated BRCA1 or BRCA2 mutations.",False,METHODS
541,BRCA 1 mutation carriers' risk of breast and ovarian cancer depends on where the mutation is located.,"The international sample comprised 19,581 carriers of BRCA1 mutations and 11,900 carriers of BRCA2 mutations from 55 centers in 33 countries on 6 continents.",False,METHODS
542,BRCA 1 mutation carriers' risk of breast and ovarian cancer depends on where the mutation is located.,"We estimated hazard ratios for breast and ovarian cancer based on mutation type, function, and nucleotide position.",False,METHODS
543,BRCA 1 mutation carriers' risk of breast and ovarian cancer depends on where the mutation is located.,"We also estimated RHR, the ratio of breast vs ovarian cancer hazard ratios.",False,METHODS
544,BRCA 1 mutation carriers' risk of breast and ovarian cancer depends on where the mutation is located.,A value of RHR greater than 1 indicated elevated breast cancer risk; a value of RHR less than 1 indicated elevated ovarian cancer risk.   ,False,METHODS
545,BRCA 1 mutation carriers' risk of breast and ovarian cancer depends on where the mutation is located.,"EXPOSURES Mutations of BRCA1 or BRCA2.   
",False,METHODS
546,BRCA 1 mutation carriers' risk of breast and ovarian cancer depends on where the mutation is located.,"MAIN OUTCOMES AND MEASURES Breast and ovarian cancer risks.   
",False,METHODS
547,BRCA 1 mutation carriers' risk of breast and ovarian cancer depends on where the mutation is located.,"RESULTS Among BRCA1 mutation carriers, 9052 women (46%) were diagnosed with breast cancer, 2317 (12%) with ovarian cancer, 1041 (5%) with breast and ovarian cancer, and 7171 (37%) without cancer.",False,RESULTS
548,BRCA 1 mutation carriers' risk of breast and ovarian cancer depends on where the mutation is located.,"Among BRCA2 mutation carriers, 6180 women (52%) were diagnosed with breast cancer, 682 (6%) with ovarian cancer, 272 (2%) with breast and ovarian cancer, and 4766 (40%) without cancer.",False,RESULTS
549,BRCA 1 mutation carriers' risk of breast and ovarian cancer depends on where the mutation is located.,"In BRCA1, we identified 3 breast cancer cluster regions (BCCRs) located at c.179 to c.505 (BCCR1; RHR = 1.46; 95% CI, 1.22-1.74; P = 2 × 10(-6)), c.4328 to c.4945 (BCCR2; RHR = 1.34; 95% CI, 1.01-1.78; P = .04), and c. 5261 to c.5563 (BCCR2', RHR = 1.38; 95% CI, 1.22-1.55; P = 6 × 10(-9)).",False,RESULTS
550,BRCA 1 mutation carriers' risk of breast and ovarian cancer depends on where the mutation is located.,"We also identified an ovarian cancer cluster region (OCCR) from c.1380 to c.4062 (approximately exon 11) with RHR = 0.62 (95% CI, 0.56-0.70; P = 9 × 10(-17)).",False,RESULTS
551,BRCA 1 mutation carriers' risk of breast and ovarian cancer depends on where the mutation is located.,"In BRCA2, we observed multiple BCCRs spanning c.1 to c.596 (BCCR1; RHR = 1.71; 95% CI, 1.06-2.78; P = .03), c.772 to c.1806 (BCCR1'; RHR = 1.63; 95% CI, 1.10-2.40; P = .01), and c.7394 to c.8904 (BCCR2; RHR = 2.31; 95% CI, 1.69-3.16; P = .00002).",False,RESULTS
552,BRCA 1 mutation carriers' risk of breast and ovarian cancer depends on where the mutation is located.,"We also identified 3 OCCRs: the first (OCCR1) spanned c.3249 to c.5681 that was adjacent to c.5946delT (6174delT; RHR = 0.51; 95% CI, 0.44-0.60; P = 6 × 10(-17)).",False,RESULTS
553,BRCA 1 mutation carriers' risk of breast and ovarian cancer depends on where the mutation is located.,"The second OCCR spanned c.6645 to c.7471 (OCCR2; RHR = 0.57; 95% CI, 0.41-0.80; P = .001).",False,RESULTS
554,BRCA 1 mutation carriers' risk of breast and ovarian cancer depends on where the mutation is located.,"Mutations conferring nonsense-mediated decay were associated with differential breast or ovarian cancer risks and an earlier age of breast cancer diagnosis for both BRCA1 and BRCA2 mutation carriers.   
",True,CONCLUSIONS
555,BRCA 1 mutation carriers' risk of breast and ovarian cancer depends on where the mutation is located.,CONCLUSIONS AND RELEVANCE Breast and ovarian cancer risks varied by type and location of BRCA1/2 mutations.,True,CONCLUSIONS
556,BRCA 1 mutation carriers' risk of breast and ovarian cancer depends on where the mutation is located.,"With appropriate validation, these data may have implications for risk assessment and cancer prevention decision making for carriers of BRCA1 and BRCA2 mutations.",False,CONCLUSIONS
557,Bacterial meningitis can be diagnosed on the basis of positive cerebrospinal fluid (CSF) cultures.,"CONTEXT Diagnostic lumbar punctures (LPs), commonly used to rule out meningitis, are associated with adverse events.   
",False,BACKGROUND
558,Bacterial meningitis can be diagnosed on the basis of positive cerebrospinal fluid (CSF) cultures.,"OBJECTIVE To systematically review the evidence about diagnostic LP techniques that may decrease the risk of adverse events and the evidence about test accuracy of cerebrospinal fluid (CSF) analysis in adult patients with suspected bacterial meningitis.   
",False,OBJECTIVE
559,Bacterial meningitis can be diagnosed on the basis of positive cerebrospinal fluid (CSF) cultures.,"DATA SOURCES We searched the Cochrane Library, MEDLINE (using Ovid and PubMed) from 1966 to January 2006 and EMBASE from 1980 to January 2006 without language restrictions to identify relevant studies and identified others from the bibliographies of retrieved articles.   ",False,METHODS
560,Bacterial meningitis can be diagnosed on the basis of positive cerebrospinal fluid (CSF) cultures.,STUDY SELECTION We included randomized trials of patients aged 18 years or older undergoing interventions to facilitate a successful diagnostic LP or to potentially reduce adverse events.,False,METHODS
561,Bacterial meningitis can be diagnosed on the basis of positive cerebrospinal fluid (CSF) cultures.,"Studies assessing the accuracy of biochemical analysis of the CSF for possible bacterial meningitis were also identified.   
",False,METHODS
562,Bacterial meningitis can be diagnosed on the basis of positive cerebrospinal fluid (CSF) cultures.,DATA EXTRACTION Two investigators independently appraised study quality and extracted relevant data.,False,METHODS
563,Bacterial meningitis can be diagnosed on the basis of positive cerebrospinal fluid (CSF) cultures.,"For studies of the LP technique, data on the intervention and the outcome were extracted.",False,METHODS
564,Bacterial meningitis can be diagnosed on the basis of positive cerebrospinal fluid (CSF) cultures.,"For studies of the laboratory diagnosis of bacterial meningitis, data on the reference standard and test accuracy were extracted.   
",False,METHODS
565,Bacterial meningitis can be diagnosed on the basis of positive cerebrospinal fluid (CSF) cultures.,DATA SYNTHESIS We found 15 randomized trials.,False,RESULTS
566,Bacterial meningitis can be diagnosed on the basis of positive cerebrospinal fluid (CSF) cultures.,A random-effects model was used for quantitative synthesis.,False,RESULTS
567,Bacterial meningitis can be diagnosed on the basis of positive cerebrospinal fluid (CSF) cultures.,"Five studies of 587 patients compared atraumatic needles with standard needles and found a nonsignificant decrease in the odds of headache with an atraumatic needle (absolute risk reduction [ARR], 12.3%; 95% confidence interval [CI], -1.72% to 26.2%).",False,RESULTS
568,Bacterial meningitis can be diagnosed on the basis of positive cerebrospinal fluid (CSF) cultures.,"Reinsertion of the stylet before needle removal decreased the risk of headache (ARR, 11.3%; 95% CI, 6.50%-16.2%).",False,RESULTS
569,Bacterial meningitis can be diagnosed on the basis of positive cerebrospinal fluid (CSF) cultures.,"The combined results from 4 studies of 717 patients showed a nonsignificant decrease in headache in patients who were mobilized after LP (ARR, 2.9%; 95% CI, -3.4 to 9.3%).",False,RESULTS
570,Bacterial meningitis can be diagnosed on the basis of positive cerebrospinal fluid (CSF) cultures.,Four studies on the accuracy of biochemical analysis of CSF in patients with suspected meningitis met inclusion criteria.,False,RESULTS
571,Bacterial meningitis can be diagnosed on the basis of positive cerebrospinal fluid (CSF) cultures.,"A CSF-blood glucose ratio of 0.4 or less (likelihood ratio [LR], 18; 95% CI, 12-27]), CSF white blood cell count of 500/muL or higher (LR, 15; 95% CI, 10-22), and CSF lactate level of 31.53 mg/dL or more (> or =3.5 mmol/L; LR, 21; 95% CI, 14-32) accurately diagnosed bacterial meningitis.   
",True,RESULTS
572,Bacterial meningitis can be diagnosed on the basis of positive cerebrospinal fluid (CSF) cultures.,"CONCLUSIONS These data suggest that small-gauge, atraumatic needles may decrease the risk of headache after diagnostic LP.",False,CONCLUSIONS
573,Bacterial meningitis can be diagnosed on the basis of positive cerebrospinal fluid (CSF) cultures.,Reinsertion of the stylet before needle removal should occur and patients do not require bed rest after the procedure.,False,CONCLUSIONS
574,Bacterial meningitis can be diagnosed on the basis of positive cerebrospinal fluid (CSF) cultures.,Future research should focus on evaluating interventions to optimize the success of a diagnostic LP and to enhance training in procedural skills.,False,CONCLUSIONS
575,Bariatric surgery increases rates of colorectal cancer.,BACKGROUND Bariatric surgery is becoming a more widespread treatment for obesity.,False,BACKGROUND
576,Bariatric surgery increases rates of colorectal cancer.,Comprehensive evidence of the long-term effects of contemporary surgery on a broad range of clinical outcomes in large populations treated in routine clinical practice is lacking.,False,BACKGROUND
577,Bariatric surgery increases rates of colorectal cancer.,"The objective of this study was to measure the association between bariatric surgery, weight, body mass index, and obesity-related co-morbidities.   
",False,BACKGROUND
578,Bariatric surgery increases rates of colorectal cancer.,METHODS AND FINDINGS This was an observational retrospective cohort study using data from the United Kingdom Clinical Practice Research Datalink.,False,METHODS
579,Bariatric surgery increases rates of colorectal cancer.,"All 3,882 patients registered in the database and with bariatric surgery on or before 31 December 2014 were included and matched by propensity score to 3,882 obese patients without surgery.",False,METHODS
580,Bariatric surgery increases rates of colorectal cancer.,"The main outcome measures were change in weight and body mass index over 4 y; incident diagnoses of type 2 diabetes mellitus (T2DM), hypertension, angina, myocardial infarction (MI), stroke, fractures, obstructive sleep apnoea, and cancer; mortality; and resolution of hypertension and T2DM.",False,METHODS
581,Bariatric surgery increases rates of colorectal cancer.,"Weight measures were available for 3,847 patients between 1 and 4 mo, 2,884 patients between 5 and 12 mo, and 2,258 patients between 13 and 48 mo post-procedure.",False,RESULTS
582,Bariatric surgery increases rates of colorectal cancer.,"Bariatric surgery patients exhibited rapid weight loss for the first four postoperative months, at a rate of 4.98 kg/mo (95% CI 4.88-5.08).",False,RESULTS
583,Bariatric surgery increases rates of colorectal cancer.,Slower weight loss was sustained to the end of 4 y. Gastric bypass (6.56 kg/mo) and sleeve gastrectomy (6.29 kg/mo) were associated with greater initial weight reduction than gastric banding (2.77 kg/mo).,False,RESULTS
584,Bariatric surgery increases rates of colorectal cancer.,"Protective hazard ratios (HRs) were detected for bariatric surgery for incident T2DM, 0.68 (95% CI 0.55-0.83); hypertension, 0.35 (95% CI 0.27-0.45); angina, 0.59 (95% CI 0.40-0.87);MI, 0.28 (95% CI 0.10-0.74); and obstructive sleep apnoea, 0.55 (95% CI 0.40-0.87).",False,RESULTS
585,Bariatric surgery increases rates of colorectal cancer.,"Strong associations were found between bariatric surgery and the resolution of T2DM, with a HR of 9.29 (95% CI 6.84-12.62), and between bariatric surgery and the resolution of hypertension, with a HR of 5.64 (95% CI 2.65-11.99).",False,RESULTS
586,Bariatric surgery increases rates of colorectal cancer.,"No association was detected between bariatric surgery and fractures, cancer, or stroke.",True,RESULTS
587,Bariatric surgery increases rates of colorectal cancer.,"Effect estimates for mortality found no protective association with bariatric surgery overall, with a HR of 0.97 (95% CI 0.66-1.43).",False,RESULTS
588,Bariatric surgery increases rates of colorectal cancer.,"The data used were recorded for the management of patients in primary care and may be subject to inaccuracy, which would tend to lead to underestimates of true relative effect sizes.   
",False,CONCLUSIONS
589,Bariatric surgery increases rates of colorectal cancer.,"CONCLUSIONS Bariatric surgery as delivered in the UK healthcare system is associated with dramatic weight loss, sustained at least 4 y after surgery.",False,CONCLUSIONS
590,Bariatric surgery increases rates of colorectal cancer.,"This weight loss is accompanied by substantial improvements in pre-existing T2DM and hypertension, as well as a reduced risk of incident T2DM, hypertension, angina, MI, and obstructive sleep apnoea.",False,CONCLUSIONS
591,Bariatric surgery increases rates of colorectal cancer.,Widening the availability of bariatric surgery could lead to substantial health benefits for many people who are morbidly obese.,False,CONCLUSIONS
592,Bariatric surgery increases rates of postmenopausal breast cancer.,BACKGROUND Bariatric surgery is becoming a more widespread treatment for obesity.,False,BACKGROUND
593,Bariatric surgery increases rates of postmenopausal breast cancer.,Comprehensive evidence of the long-term effects of contemporary surgery on a broad range of clinical outcomes in large populations treated in routine clinical practice is lacking.,False,BACKGROUND
594,Bariatric surgery increases rates of postmenopausal breast cancer.,"The objective of this study was to measure the association between bariatric surgery, weight, body mass index, and obesity-related co-morbidities.   
",False,BACKGROUND
595,Bariatric surgery increases rates of postmenopausal breast cancer.,METHODS AND FINDINGS This was an observational retrospective cohort study using data from the United Kingdom Clinical Practice Research Datalink.,False,METHODS
596,Bariatric surgery increases rates of postmenopausal breast cancer.,"All 3,882 patients registered in the database and with bariatric surgery on or before 31 December 2014 were included and matched by propensity score to 3,882 obese patients without surgery.",False,METHODS
597,Bariatric surgery increases rates of postmenopausal breast cancer.,"The main outcome measures were change in weight and body mass index over 4 y; incident diagnoses of type 2 diabetes mellitus (T2DM), hypertension, angina, myocardial infarction (MI), stroke, fractures, obstructive sleep apnoea, and cancer; mortality; and resolution of hypertension and T2DM.",False,METHODS
598,Bariatric surgery increases rates of postmenopausal breast cancer.,"Weight measures were available for 3,847 patients between 1 and 4 mo, 2,884 patients between 5 and 12 mo, and 2,258 patients between 13 and 48 mo post-procedure.",False,RESULTS
599,Bariatric surgery increases rates of postmenopausal breast cancer.,"Bariatric surgery patients exhibited rapid weight loss for the first four postoperative months, at a rate of 4.98 kg/mo (95% CI 4.88-5.08).",False,RESULTS
600,Bariatric surgery increases rates of postmenopausal breast cancer.,Slower weight loss was sustained to the end of 4 y. Gastric bypass (6.56 kg/mo) and sleeve gastrectomy (6.29 kg/mo) were associated with greater initial weight reduction than gastric banding (2.77 kg/mo).,False,RESULTS
601,Bariatric surgery increases rates of postmenopausal breast cancer.,"Protective hazard ratios (HRs) were detected for bariatric surgery for incident T2DM, 0.68 (95% CI 0.55-0.83); hypertension, 0.35 (95% CI 0.27-0.45); angina, 0.59 (95% CI 0.40-0.87);MI, 0.28 (95% CI 0.10-0.74); and obstructive sleep apnoea, 0.55 (95% CI 0.40-0.87).",False,RESULTS
602,Bariatric surgery increases rates of postmenopausal breast cancer.,"Strong associations were found between bariatric surgery and the resolution of T2DM, with a HR of 9.29 (95% CI 6.84-12.62), and between bariatric surgery and the resolution of hypertension, with a HR of 5.64 (95% CI 2.65-11.99).",False,RESULTS
603,Bariatric surgery increases rates of postmenopausal breast cancer.,"No association was detected between bariatric surgery and fractures, cancer, or stroke.",True,RESULTS
604,Bariatric surgery increases rates of postmenopausal breast cancer.,"Effect estimates for mortality found no protective association with bariatric surgery overall, with a HR of 0.97 (95% CI 0.66-1.43).",False,RESULTS
605,Bariatric surgery increases rates of postmenopausal breast cancer.,"The data used were recorded for the management of patients in primary care and may be subject to inaccuracy, which would tend to lead to underestimates of true relative effect sizes.   
",False,CONCLUSIONS
606,Bariatric surgery increases rates of postmenopausal breast cancer.,"CONCLUSIONS Bariatric surgery as delivered in the UK healthcare system is associated with dramatic weight loss, sustained at least 4 y after surgery.",False,CONCLUSIONS
607,Bariatric surgery increases rates of postmenopausal breast cancer.,"This weight loss is accompanied by substantial improvements in pre-existing T2DM and hypertension, as well as a reduced risk of incident T2DM, hypertension, angina, MI, and obstructive sleep apnoea.",False,CONCLUSIONS
608,Bariatric surgery increases rates of postmenopausal breast cancer.,Widening the availability of bariatric surgery could lead to substantial health benefits for many people who are morbidly obese.,False,CONCLUSIONS
609,Bariatric surgery leads to negative outcomes in mental health.,IMPORTANCE Bariatric surgery is associated with sustained weight loss and improved physical health status for severely obese individuals.,False,BACKGROUND
610,Bariatric surgery leads to negative outcomes in mental health.,"Mental health conditions may be common among patients seeking bariatric surgery; however, the prevalence of these conditions and whether they are associated with postoperative outcomes remains unknown.   
",False,BACKGROUND
611,Bariatric surgery leads to negative outcomes in mental health.,"OBJECTIVE To determine the prevalence of mental health conditions among bariatric surgery candidates and recipients, to evaluate the association between preoperative mental health conditions and health outcomes following bariatric surgery, and to evaluate the association between surgery and the clinical course of mental health conditions.   
",False,OBJECTIVE
612,Bariatric surgery leads to negative outcomes in mental health.,"DATA SOURCES We searched PubMed, MEDLINE on OVID, and PsycINFO for studies published between January 1988 and November 2015.",False,METHODS
613,Bariatric surgery leads to negative outcomes in mental health.,"Study quality was assessed using an adapted tool for risk of bias; quality of evidence was rated based on GRADE (Grading of Recommendations Assessment, Development and Evaluation) criteria.   
",False,METHODS
614,Bariatric surgery leads to negative outcomes in mental health.,"FINDINGS We identified 68 publications meeting inclusion criteria: 59 reporting the prevalence of preoperative mental health conditions (65,363 patients) and 27 reporting associations between preoperative mental health conditions and postoperative outcomes (50,182 patients).",False,RESULTS
615,Bariatric surgery leads to negative outcomes in mental health.,"Among patients seeking and undergoing bariatric surgery, the most common mental health conditions, based on random-effects estimates of prevalence, were depression (19% [95% CI, 14%-25%]) and binge eating disorder (17% [95% CI, 13%-21%]).",False,RESULTS
616,Bariatric surgery leads to negative outcomes in mental health.,There was conflicting evidence regarding the association between preoperative mental health conditions and postoperative weight loss.,False,RESULTS
617,Bariatric surgery leads to negative outcomes in mental health.,Neither depression nor binge eating disorder was consistently associated with differences in weight outcomes.,False,RESULTS
618,Bariatric surgery leads to negative outcomes in mental health.,"Bariatric surgery was, however, consistently associated with postoperative decreases in the prevalence of depression (7 studies; 8%-74% decrease) and the severity of depressive symptoms (6 studies; 40%-70% decrease).   
",True,RESULTS
619,Bariatric surgery leads to negative outcomes in mental health.,"CONCLUSIONS AND RELEVANCE Mental health conditions are common among bariatric surgery patients-in particular, depression and binge eating disorder.",False,CONCLUSIONS
620,Bariatric surgery leads to negative outcomes in mental health.,There is inconsistent evidence regarding the association between preoperative mental health conditions and postoperative weight loss.,False,CONCLUSIONS
621,Bariatric surgery leads to negative outcomes in mental health.,Moderate-quality evidence supports an association between bariatric surgery and lower rates of depression postoperatively.,True,CONCLUSIONS
622,Bariatric surgery leads to positive outcomes in mental health.,IMPORTANCE Bariatric surgery is associated with sustained weight loss and improved physical health status for severely obese individuals.,False,BACKGROUND
623,Bariatric surgery leads to positive outcomes in mental health.,"Mental health conditions may be common among patients seeking bariatric surgery; however, the prevalence of these conditions and whether they are associated with postoperative outcomes remains unknown.   
",False,BACKGROUND
624,Bariatric surgery leads to positive outcomes in mental health.,"OBJECTIVE To determine the prevalence of mental health conditions among bariatric surgery candidates and recipients, to evaluate the association between preoperative mental health conditions and health outcomes following bariatric surgery, and to evaluate the association between surgery and the clinical course of mental health conditions.   
",False,OBJECTIVE
625,Bariatric surgery leads to positive outcomes in mental health.,"DATA SOURCES We searched PubMed, MEDLINE on OVID, and PsycINFO for studies published between January 1988 and November 2015.",False,METHODS
626,Bariatric surgery leads to positive outcomes in mental health.,"Study quality was assessed using an adapted tool for risk of bias; quality of evidence was rated based on GRADE (Grading of Recommendations Assessment, Development and Evaluation) criteria.   
",False,METHODS
627,Bariatric surgery leads to positive outcomes in mental health.,"FINDINGS We identified 68 publications meeting inclusion criteria: 59 reporting the prevalence of preoperative mental health conditions (65,363 patients) and 27 reporting associations between preoperative mental health conditions and postoperative outcomes (50,182 patients).",False,RESULTS
628,Bariatric surgery leads to positive outcomes in mental health.,"Among patients seeking and undergoing bariatric surgery, the most common mental health conditions, based on random-effects estimates of prevalence, were depression (19% [95% CI, 14%-25%]) and binge eating disorder (17% [95% CI, 13%-21%]).",False,RESULTS
629,Bariatric surgery leads to positive outcomes in mental health.,There was conflicting evidence regarding the association between preoperative mental health conditions and postoperative weight loss.,False,RESULTS
630,Bariatric surgery leads to positive outcomes in mental health.,Neither depression nor binge eating disorder was consistently associated with differences in weight outcomes.,False,RESULTS
631,Bariatric surgery leads to positive outcomes in mental health.,"Bariatric surgery was, however, consistently associated with postoperative decreases in the prevalence of depression (7 studies; 8%-74% decrease) and the severity of depressive symptoms (6 studies; 40%-70% decrease).   
",True,RESULTS
632,Bariatric surgery leads to positive outcomes in mental health.,"CONCLUSIONS AND RELEVANCE Mental health conditions are common among bariatric surgery patients-in particular, depression and binge eating disorder.",False,CONCLUSIONS
633,Bariatric surgery leads to positive outcomes in mental health.,There is inconsistent evidence regarding the association between preoperative mental health conditions and postoperative weight loss.,False,CONCLUSIONS
634,Bariatric surgery leads to positive outcomes in mental health.,Moderate-quality evidence supports an association between bariatric surgery and lower rates of depression postoperatively.,True,CONCLUSIONS
635,Bariatric surgery reduces colorectal cancer.,BACKGROUND Bariatric surgery is becoming a more widespread treatment for obesity.,False,BACKGROUND
636,Bariatric surgery reduces colorectal cancer.,Comprehensive evidence of the long-term effects of contemporary surgery on a broad range of clinical outcomes in large populations treated in routine clinical practice is lacking.,False,BACKGROUND
637,Bariatric surgery reduces colorectal cancer.,"The objective of this study was to measure the association between bariatric surgery, weight, body mass index, and obesity-related co-morbidities.   
",False,BACKGROUND
638,Bariatric surgery reduces colorectal cancer.,METHODS AND FINDINGS This was an observational retrospective cohort study using data from the United Kingdom Clinical Practice Research Datalink.,False,METHODS
639,Bariatric surgery reduces colorectal cancer.,"All 3,882 patients registered in the database and with bariatric surgery on or before 31 December 2014 were included and matched by propensity score to 3,882 obese patients without surgery.",False,METHODS
640,Bariatric surgery reduces colorectal cancer.,"The main outcome measures were change in weight and body mass index over 4 y; incident diagnoses of type 2 diabetes mellitus (T2DM), hypertension, angina, myocardial infarction (MI), stroke, fractures, obstructive sleep apnoea, and cancer; mortality; and resolution of hypertension and T2DM.",False,METHODS
641,Bariatric surgery reduces colorectal cancer.,"Weight measures were available for 3,847 patients between 1 and 4 mo, 2,884 patients between 5 and 12 mo, and 2,258 patients between 13 and 48 mo post-procedure.",False,RESULTS
642,Bariatric surgery reduces colorectal cancer.,"Bariatric surgery patients exhibited rapid weight loss for the first four postoperative months, at a rate of 4.98 kg/mo (95% CI 4.88-5.08).",False,RESULTS
643,Bariatric surgery reduces colorectal cancer.,Slower weight loss was sustained to the end of 4 y. Gastric bypass (6.56 kg/mo) and sleeve gastrectomy (6.29 kg/mo) were associated with greater initial weight reduction than gastric banding (2.77 kg/mo).,False,RESULTS
644,Bariatric surgery reduces colorectal cancer.,"Protective hazard ratios (HRs) were detected for bariatric surgery for incident T2DM, 0.68 (95% CI 0.55-0.83); hypertension, 0.35 (95% CI 0.27-0.45); angina, 0.59 (95% CI 0.40-0.87);MI, 0.28 (95% CI 0.10-0.74); and obstructive sleep apnoea, 0.55 (95% CI 0.40-0.87).",False,RESULTS
645,Bariatric surgery reduces colorectal cancer.,"Strong associations were found between bariatric surgery and the resolution of T2DM, with a HR of 9.29 (95% CI 6.84-12.62), and between bariatric surgery and the resolution of hypertension, with a HR of 5.64 (95% CI 2.65-11.99).",False,RESULTS
646,Bariatric surgery reduces colorectal cancer.,"No association was detected between bariatric surgery and fractures, cancer, or stroke.",True,RESULTS
647,Bariatric surgery reduces colorectal cancer.,"Effect estimates for mortality found no protective association with bariatric surgery overall, with a HR of 0.97 (95% CI 0.66-1.43).",False,RESULTS
648,Bariatric surgery reduces colorectal cancer.,"The data used were recorded for the management of patients in primary care and may be subject to inaccuracy, which would tend to lead to underestimates of true relative effect sizes.   
",False,CONCLUSIONS
649,Bariatric surgery reduces colorectal cancer.,"CONCLUSIONS Bariatric surgery as delivered in the UK healthcare system is associated with dramatic weight loss, sustained at least 4 y after surgery.",False,CONCLUSIONS
650,Bariatric surgery reduces colorectal cancer.,"This weight loss is accompanied by substantial improvements in pre-existing T2DM and hypertension, as well as a reduced risk of incident T2DM, hypertension, angina, MI, and obstructive sleep apnoea.",False,CONCLUSIONS
651,Bariatric surgery reduces colorectal cancer.,Widening the availability of bariatric surgery could lead to substantial health benefits for many people who are morbidly obese.,False,CONCLUSIONS
652,Bariatric surgery reduces postmenopausal breast cancer.,BACKGROUND Bariatric surgery is becoming a more widespread treatment for obesity.,False,BACKGROUND
653,Bariatric surgery reduces postmenopausal breast cancer.,Comprehensive evidence of the long-term effects of contemporary surgery on a broad range of clinical outcomes in large populations treated in routine clinical practice is lacking.,False,BACKGROUND
654,Bariatric surgery reduces postmenopausal breast cancer.,"The objective of this study was to measure the association between bariatric surgery, weight, body mass index, and obesity-related co-morbidities.   
",False,BACKGROUND
655,Bariatric surgery reduces postmenopausal breast cancer.,METHODS AND FINDINGS This was an observational retrospective cohort study using data from the United Kingdom Clinical Practice Research Datalink.,False,METHODS
656,Bariatric surgery reduces postmenopausal breast cancer.,"All 3,882 patients registered in the database and with bariatric surgery on or before 31 December 2014 were included and matched by propensity score to 3,882 obese patients without surgery.",False,METHODS
657,Bariatric surgery reduces postmenopausal breast cancer.,"The main outcome measures were change in weight and body mass index over 4 y; incident diagnoses of type 2 diabetes mellitus (T2DM), hypertension, angina, myocardial infarction (MI), stroke, fractures, obstructive sleep apnoea, and cancer; mortality; and resolution of hypertension and T2DM.",False,METHODS
658,Bariatric surgery reduces postmenopausal breast cancer.,"Weight measures were available for 3,847 patients between 1 and 4 mo, 2,884 patients between 5 and 12 mo, and 2,258 patients between 13 and 48 mo post-procedure.",False,RESULTS
659,Bariatric surgery reduces postmenopausal breast cancer.,"Bariatric surgery patients exhibited rapid weight loss for the first four postoperative months, at a rate of 4.98 kg/mo (95% CI 4.88-5.08).",False,RESULTS
660,Bariatric surgery reduces postmenopausal breast cancer.,Slower weight loss was sustained to the end of 4 y. Gastric bypass (6.56 kg/mo) and sleeve gastrectomy (6.29 kg/mo) were associated with greater initial weight reduction than gastric banding (2.77 kg/mo).,False,RESULTS
661,Bariatric surgery reduces postmenopausal breast cancer.,"Protective hazard ratios (HRs) were detected for bariatric surgery for incident T2DM, 0.68 (95% CI 0.55-0.83); hypertension, 0.35 (95% CI 0.27-0.45); angina, 0.59 (95% CI 0.40-0.87);MI, 0.28 (95% CI 0.10-0.74); and obstructive sleep apnoea, 0.55 (95% CI 0.40-0.87).",False,RESULTS
662,Bariatric surgery reduces postmenopausal breast cancer.,"Strong associations were found between bariatric surgery and the resolution of T2DM, with a HR of 9.29 (95% CI 6.84-12.62), and between bariatric surgery and the resolution of hypertension, with a HR of 5.64 (95% CI 2.65-11.99).",False,RESULTS
663,Bariatric surgery reduces postmenopausal breast cancer.,"No association was detected between bariatric surgery and fractures, cancer, or stroke.",True,RESULTS
664,Bariatric surgery reduces postmenopausal breast cancer.,"Effect estimates for mortality found no protective association with bariatric surgery overall, with a HR of 0.97 (95% CI 0.66-1.43).",False,RESULTS
665,Bariatric surgery reduces postmenopausal breast cancer.,"The data used were recorded for the management of patients in primary care and may be subject to inaccuracy, which would tend to lead to underestimates of true relative effect sizes.   
",False,CONCLUSIONS
666,Bariatric surgery reduces postmenopausal breast cancer.,"CONCLUSIONS Bariatric surgery as delivered in the UK healthcare system is associated with dramatic weight loss, sustained at least 4 y after surgery.",False,CONCLUSIONS
667,Bariatric surgery reduces postmenopausal breast cancer.,"This weight loss is accompanied by substantial improvements in pre-existing T2DM and hypertension, as well as a reduced risk of incident T2DM, hypertension, angina, MI, and obstructive sleep apnoea.",False,CONCLUSIONS
668,Bariatric surgery reduces postmenopausal breast cancer.,Widening the availability of bariatric surgery could lead to substantial health benefits for many people who are morbidly obese.,False,CONCLUSIONS
669,Basophils promote disease development in patients with systemic lupus erythematosus (SLE).,"In systemic lupus erythematosus (SLE), self-reactive antibodies can target the kidney (lupus nephritis), leading to functional failure and possible mortality.",False,BACKGROUND
670,Basophils promote disease development in patients with systemic lupus erythematosus (SLE).,"We report that activation of basophils by autoreactive IgE causes their homing to lymph nodes, promoting T helper type 2 (T(H)2) cell differentiation and enhancing the production of self-reactive antibodies that cause lupus-like nephritis in mice lacking the Src family protein tyrosine kinase Lyn (Lyn(-/-) mice).",True,BACKGROUND
671,Basophils promote disease development in patients with systemic lupus erythematosus (SLE).,"Individuals with SLE also have elevated serum IgE, self-reactive IgEs and activated basophils that express CD62 ligand (CD62L) and the major histocompatibility complex (MHC) class II molecule human leukocyte antigen-DR (HLA-DR), parameters that are associated with increased disease activity and active lupus nephritis.",True,RESULTS
672,Basophils promote disease development in patients with systemic lupus erythematosus (SLE).,Basophils were also present in the lymph nodes and spleen of subjects with SLE.,False,RESULTS
673,Basophils promote disease development in patients with systemic lupus erythematosus (SLE).,"Thus, in Lyn(-/-) mice, basophils and IgE autoantibodies amplify autoantibody production that leads to lupus nephritis, and in individuals with SLE IgE autoantibodies and activated basophils are factors associated with disease activity and nephritis.",True,RESULTS
674,Binding of p53 to enhancer regions (p53BERs) regulates the activity of p53 transcription and cell cycle arrest through the production of p53-dependent eRNAs.,Binding within or nearby target genes involved in cell proliferation and survival enables the p53 tumor suppressor gene to regulate their transcription and cell-cycle progression.,False,BACKGROUND
675,Binding of p53 to enhancer regions (p53BERs) regulates the activity of p53 transcription and cell cycle arrest through the production of p53-dependent eRNAs.,"Using genome-wide chromatin-binding profiles, we describe binding of p53 also to regions located distantly from any known p53 target gene.",False,BACKGROUND
676,Binding of p53 to enhancer regions (p53BERs) regulates the activity of p53 transcription and cell cycle arrest through the production of p53-dependent eRNAs.,"Interestingly, many of these regions possess conserved p53-binding sites and all known hallmarks of enhancer regions.",False,BACKGROUND
677,Binding of p53 to enhancer regions (p53BERs) regulates the activity of p53 transcription and cell cycle arrest through the production of p53-dependent eRNAs.,We demonstrate that these p53-bound enhancer regions (p53BERs) indeed contain enhancer activity and interact intrachromosomally with multiple neighboring genes to convey long-distance p53-dependent transcription regulation.,False,RESULTS
678,Binding of p53 to enhancer regions (p53BERs) regulates the activity of p53 transcription and cell cycle arrest through the production of p53-dependent eRNAs.,"Furthermore, p53BERs produce, in a p53-dependent manner, enhancer RNAs (eRNAs) that are required for efficient transcriptional enhancement of interacting target genes and induction of a p53-dependent cell-cycle arrest.",True,RESULTS
679,Binding of p53 to enhancer regions (p53BERs) regulates the activity of p53 transcription and cell cycle arrest through the production of p53-dependent eRNAs.,"Thus, our results ascribe transcription enhancement activity to p53 with the capacity to regulate multiple genes from a single genomic binding site.",False,CONCLUSIONS
680,Binding of p53 to enhancer regions (p53BERs) regulates the activity of p53 transcription and cell cycle arrest through the production of p53-dependent eRNAs.,"Moreover, eRNA production from p53BERs is required for efficient p53 transcription enhancement.",True,CONCLUSIONS
681,Birth-weight is negatively associated with breast cancer.,"BACKGROUND Birth size, perhaps a proxy for prenatal environment, might be a correlate of subsequent breast cancer risk, but findings from epidemiological studies have been inconsistent.",False,BACKGROUND
682,Birth-weight is negatively associated with breast cancer.,"We re-analysed individual participant data from published and unpublished studies to obtain more precise estimates of the magnitude and shape of the birth size-breast cancer association.   
",False,BACKGROUND
683,Birth-weight is negatively associated with breast cancer.,"METHODS AND FINDINGS Studies were identified through computer-assisted and manual searches, and personal communication with investigators.",False,METHODS
684,Birth-weight is negatively associated with breast cancer.,"Individual participant data from 32 studies, comprising 22,058 breast cancer cases, were obtained.",False,METHODS
685,Birth-weight is negatively associated with breast cancer.,"Random effect models were used, if appropriate, to combine study-specific estimates of effect.",False,METHODS
686,Birth-weight is negatively associated with breast cancer.,"Birth weight was positively associated with breast cancer risk in studies based on birth records (pooled relative risk [RR] per one standard deviation [SD] [= 0.5 kg] increment in birth weight: 1.06; 95% confidence interval [CI] 1.02-1.09) and parental recall when the participants were children (1.02; 95% CI 0.99-1.05), but not in those based on adult self-reports, or maternal recall during the woman's adulthood (0.98; 95% CI 0.95-1.01) (p for heterogeneity between data sources = 0.003).",True,RESULTS
687,Birth-weight is negatively associated with breast cancer.,"Relative to women who weighed 3.000-3.499 kg, the risk was 0.96 (CI 0.80-1.16) in those who weighed < 2.500 kg, and 1.12 (95% CI 1.00-1.25) in those who weighed > or = 4.000 kg (p for linear trend = 0.001) in birth record data.",True,RESULTS
688,Birth-weight is negatively associated with breast cancer.,"Birth length and head circumference from birth records were also positively associated with breast cancer risk (pooled RR per one SD increment: 1.06 [95% CI 1.03-1.10] and 1.09 [95% CI 1.03-1.15], respectively).",False,RESULTS
689,Birth-weight is negatively associated with breast cancer.,Simultaneous adjustment for these three birth size variables showed that length was the strongest independent predictor of risk.,False,RESULTS
690,Birth-weight is negatively associated with breast cancer.,The birth size effects did not appear to be confounded or mediated by established breast cancer risk factors and were not modified by age or menopausal status.,False,RESULTS
691,Birth-weight is negatively associated with breast cancer.,"The cumulative incidence of breast cancer per 100 women by age 80 y in the study populations was estimated to be 10.0, 10.0, 10.4, and 11.5 in those who were, respectively, in the bottom, second, third, and top fourths of the birth length distribution.   
",False,RESULTS
692,Birth-weight is negatively associated with breast cancer.,"CONCLUSIONS This pooled analysis of individual participant data is consistent with birth size, and in particular birth length, being an independent correlate of breast cancer risk in adulthood.",True,CONCLUSIONS
693,Birth-weight is negatively associated with breast cancer.,Breast cancer may originate in utero.,False,BACKGROUND
694,Birth-weight is negatively associated with breast cancer.,We reviewed the available evidence on the association between birthweight and the risk of breast cancer.,False,BACKGROUND
695,Birth-weight is negatively associated with breast cancer.,"To date, 26 research papers addressing this issue have been published.",False,RESULTS
696,Birth-weight is negatively associated with breast cancer.,"The majority of studies identified a positive link between birthweight and premenopausal, but not postmenopausal, breast cancer.",False,RESULTS
697,Birth-weight is negatively associated with breast cancer.,The relative risk estimate for breast cancer comparing women with high birthweight to women with low birthweight combining all studies including both pre- and postmenopausal breast cancer was 1.23 (95% confidence interval 1.13-1.34).,True,RESULTS
698,Birth-weight is negatively associated with breast cancer.,The mechanisms underlying this association likely include elevated levels of growth factors that may increase the number of susceptible stem cells in the mammary gland or initiate tumors through DNA mutations.,False,RESULTS
699,Birth-weight is negatively associated with breast cancer.,"Loss of imprinting (LOI) of growth hormone genes relevant for intrauterine growth, such as insulin-like growth factor 2 (IGF2), leads to abnormally high levels of these hormones evidenced by high birthweight.",False,CONCLUSIONS
700,Birth-weight is negatively associated with breast cancer.,LOI of IGF2 has also been found in mammary tumor tissue.,False,CONCLUSIONS
701,Birth-weight is negatively associated with breast cancer.,The role of environmental factors that stimulate such epigenetic regulation of gene expression remains to be elucidated.,False,CONCLUSIONS
702,Birth-weight is negatively associated with breast cancer.,BACKGROUND Emerging evidence suggests an association between female prenatal experience and her subsequent risk of developing breast cancer.,False,OBJECTIVE
703,Birth-weight is negatively associated with breast cancer.,"Potential underlying mechanisms include variation in amounts of maternal endogenous sex hormones and growth hormones, germ-cell mutations, formation of cancer stem-cells, and other genetic or epigenetic events.",False,OBJECTIVE
704,Birth-weight is negatively associated with breast cancer.,"We reviewed and summarised quantitatively the available data on intrauterine exposures and risk of breast cancer.   
",False,OBJECTIVE
705,Birth-weight is negatively associated with breast cancer.,METHODS We systematically searched for studies that assessed association between perinatal factors and risk of breast cancer.,False,METHODS
706,Birth-weight is negatively associated with breast cancer.,"We reviewed separately each of the perinatal factors, including birthweight, birth length, parental age at delivery, gestational age, intrauterine exposure to diethylstilbestrol, twin membership, maternal pre-eclampsia or eclampsia, and other factors.   
",False,METHODS
707,Birth-weight is negatively associated with breast cancer.,"FINDINGS We identified 57 studies published between Oct 1, 1980, and June 21, 2007.",False,RESULTS
708,Birth-weight is negatively associated with breast cancer.,"Increased risk of breast cancer was noted with increased birthweight (relative risk [RR] 1.15 [95% CI 1.09-1.21]), birth length (1.28 [1.11-1.48]), higher maternal age (1.13 [1.02-1.25]), and paternal age (1.12 [1.05-1.19]).",True,RESULTS
709,Birth-weight is negatively associated with breast cancer.,Decreased risk of breast cancer was noted for maternal pre-eclampsia and eclampsia (0.48 [0.30-0.78]) and twin membership (0.93 [0.87-1.00]).,False,RESULTS
710,Birth-weight is negatively associated with breast cancer.,"No association was noted between risk of breast cancer and gestational age at birth (0.95 [0.71-1.26]) or maternal diethylstilbestrol treatment (1.40 [0.86-2.28]).   
",False,RESULTS
711,Birth-weight is negatively associated with breast cancer.,INTERPRETATION The intrauterine environment contributes to the predisposition of women to breast cancer in adulthood.,False,CONCLUSIONS
712,Birth-weight is negatively associated with breast cancer.,The in-utero mechanisms responsible for such predisposition need to be elucidated.,False,CONCLUSIONS
713,Birth-weight is negatively associated with breast cancer.,"INTRODUCTION Various perinatal factors, including birth weight, birth order, maternal age, gestational age, twin status, and parental smoking, have been postulated to affect breast cancer risk in daughters by altering the hormonal environment of the developing fetal mammary glands.",False,BACKGROUND
714,Birth-weight is negatively associated with breast cancer.,"Despite ample biologic plausibility, epidemiologic studies to date have yielded conflicting results.",False,BACKGROUND
715,Birth-weight is negatively associated with breast cancer.,"We investigated the associations between perinatal factors and subsequent breast cancer risk through meta-analyses.   
",False,BACKGROUND
716,Birth-weight is negatively associated with breast cancer.,"METHODS We reviewed breast cancer studies published from January 1966 to February 2007 that included data on birth weight, birth order, maternal age, gestational age, twin status, and maternal or paternal smoking.",False,METHODS
717,Birth-weight is negatively associated with breast cancer.,"Meta-analyses using random effect models were employed to summarize the results.   
",False,METHODS
718,Birth-weight is negatively associated with breast cancer.,"RESULTS We found that heavier birth weights were associated with increased breast cancer risk, with studies involving five categories of birth weight identifying odds ratios (ORs) of 1.24 (95% confidence interval [CI] 1.04 to 1.48) for 4,000 g or more and 1.15 (95% CI 1.04 to 1.26) for 3,500 g to 3,999 g, relative to a birth weight of 2,500 to 2,599 g. These studies provided no support for a J-shaped relationship of birthweight to risk.",True,RESULTS
719,Birth-weight is negatively associated with breast cancer.,"Support for an association with birthweight was also derived from studies based on three birth weight categories (OR 1.15 [95% CI 1.01 to 1.31] for > or =4,000 g relative to <3,000 g) and two birth weight categories (OR 1.09 [95% CI 1.02 to 1.18] for > or =3,000 g relative to <3,000 g).",False,RESULTS
720,Birth-weight is negatively associated with breast cancer.,"Women born to older mothers and twins were also at some increased risk, but the results were heterogeneous across studies and publication years.",False,RESULTS
721,Birth-weight is negatively associated with breast cancer.,"Birth order, prematurity, and maternal smoking were unrelated to breast cancer risk.   
",False,CONCLUSIONS
722,Birth-weight is negatively associated with breast cancer.,CONCLUSION Our findings provide some support for the hypothesis that in utero exposures reflective of higher endogenous hormone levels could affect risk for development of breast cancer in adulthood.,True,CONCLUSIONS
723,Blocking the interaction between TDP-43 and respiratory complex I proteins ND3 and ND6 prevents TDP-43-induced neuronal loss.,"Genetic mutations in TAR DNA-binding protein 43 (TARDBP, also known as TDP-43) cause amyotrophic lateral sclerosis (ALS), and an increase in the presence of TDP-43 (encoded by TARDBP) in the cytoplasm is a prominent histopathological feature of degenerating neurons in various neurodegenerative diseases.",False,BACKGROUND
724,Blocking the interaction between TDP-43 and respiratory complex I proteins ND3 and ND6 prevents TDP-43-induced neuronal loss.,"However, the molecular mechanisms by which TDP-43 contributes to ALS pathophysiology remain elusive.",False,BACKGROUND
725,Blocking the interaction between TDP-43 and respiratory complex I proteins ND3 and ND6 prevents TDP-43-induced neuronal loss.,Here we have found that TDP-43 accumulates in the mitochondria of neurons in subjects with ALS or frontotemporal dementia (FTD).,False,BACKGROUND
726,Blocking the interaction between TDP-43 and respiratory complex I proteins ND3 and ND6 prevents TDP-43-induced neuronal loss.,Disease-associated mutations increase TDP-43 mitochondrial localization.,False,RESULTS
727,Blocking the interaction between TDP-43 and respiratory complex I proteins ND3 and ND6 prevents TDP-43-induced neuronal loss.,"In mitochondria, wild-type (WT) and mutant TDP-43 preferentially bind mitochondria-transcribed messenger RNAs (mRNAs) encoding respiratory complex I subunits ND3 and ND6, impair their expression and specifically cause complex I disassembly.",False,RESULTS
728,Blocking the interaction between TDP-43 and respiratory complex I proteins ND3 and ND6 prevents TDP-43-induced neuronal loss.,"The suppression of TDP-43 mitochondrial localization abolishes WT and mutant TDP-43-induced mitochondrial dysfunction and neuronal loss, and improves phenotypes of transgenic mutant TDP-43 mice.",True,CONCLUSIONS
729,Blocking the interaction between TDP-43 and respiratory complex I proteins ND3 and ND6 prevents TDP-43-induced neuronal loss.,"Thus, our studies link TDP-43 toxicity directly to mitochondrial bioenergetics and propose the targeting of TDP-43 mitochondrial localization as a promising therapeutic approach for neurodegeneration.",False,CONCLUSIONS
730,Bone marrow cells don't contribute to adult macrophage compartments.,"Despite accumulating evidence suggesting local self-maintenance of tissue macrophages in the steady state, the dogma remains that tissue macrophages derive from monocytes.",False,BACKGROUND
731,Bone marrow cells don't contribute to adult macrophage compartments.,"Using parabiosis and fate-mapping approaches, we confirmed that monocytes do not show significant contribution to tissue macrophages in the steady state.",False,BACKGROUND
732,Bone marrow cells don't contribute to adult macrophage compartments.,"Similarly, we found that after depletion of lung macrophages, the majority of repopulation occurred by stochastic cellular proliferation in situ in a macrophage colony-stimulating factor (M-Csf)- and granulocyte macrophage (GM)-CSF-dependent manner but independently of interleukin-4.",False,RESULTS
733,Bone marrow cells don't contribute to adult macrophage compartments.,"We also found that after bone marrow transplantation, host macrophages retained the capacity to expand when the development of donor macrophages was compromised.",True,RESULTS
734,Bone marrow cells don't contribute to adult macrophage compartments.,Expansion of host macrophages was functional and prevented the development of alveolar proteinosis in mice transplanted with GM-Csf-receptor-deficient progenitors.,False,CONCLUSIONS
735,Bone marrow cells don't contribute to adult macrophage compartments.,"Collectively, these results indicate that tissue-resident macrophages and circulating monocytes should be classified as mononuclear phagocyte lineages that are independently maintained in the steady state.",False,CONCLUSIONS
736,Broadly HIV-1 Neutralizing Antibodies (bnAb) 10EB have no affinity for phospholipids.,Characterization of human monoclonal antibodies is providing considerable insight into mechanisms of broad HIV-1 neutralization.,False,BACKGROUND
737,Broadly HIV-1 Neutralizing Antibodies (bnAb) 10EB have no affinity for phospholipids.,"Here we report an HIV-1 gp41 membrane-proximal external region (MPER)-specific antibody, named 10E8, which neutralizes ∼98% of tested viruses.",False,BACKGROUND
738,Broadly HIV-1 Neutralizing Antibodies (bnAb) 10EB have no affinity for phospholipids.,An analysis of sera from 78 healthy HIV-1-infected donors demonstrated that 27% contained MPER-specific antibodies and 8% contained 10E8-like specificities.,False,RESULTS
739,Broadly HIV-1 Neutralizing Antibodies (bnAb) 10EB have no affinity for phospholipids.,"In contrast to other neutralizing MPER antibodies, 10E8 did not bind phospholipids, was not autoreactive, and bound cell-surface envelope.",True,RESULTS
740,Broadly HIV-1 Neutralizing Antibodies (bnAb) 10EB have no affinity for phospholipids.,The structure of 10E8 in complex with the complete MPER revealed a site of vulnerability comprising a narrow stretch of highly conserved gp41-hydrophobic residues and a critical arginine or lysine just before the transmembrane region.,False,RESULTS
741,Broadly HIV-1 Neutralizing Antibodies (bnAb) 10EB have no affinity for phospholipids.,Analysis of resistant HIV-1 variants confirmed the importance of these residues for neutralization.,False,CONCLUSIONS
742,Broadly HIV-1 Neutralizing Antibodies (bnAb) 10EB have no affinity for phospholipids.,"The highly conserved MPER is a target of potent, non-self-reactive neutralizing antibodies, suggesting that HIV-1 vaccines should aim to induce antibodies to this region of HIV-1 envelope glycoprotein.",False,CONCLUSIONS
743,C2 works synergistically with A-769662 to activate dephosphorylated AMPK.,The metabolic stress-sensing enzyme AMP-activated protein kinase (AMPK) is responsible for regulating metabolism in response to energy supply and demand.,False,BACKGROUND
744,C2 works synergistically with A-769662 to activate dephosphorylated AMPK.,Drugs that activate AMPK may be useful in the treatment of metabolic diseases including type 2 diabetes.,False,BACKGROUND
745,C2 works synergistically with A-769662 to activate dephosphorylated AMPK.,"We have determined the crystal structure of AMPK in complex with its activator 5-(5-hydroxyl-isoxazol-3-yl)-furan-2-phosphonic acid (C2), revealing two C2-binding sites in the γ-subunit distinct from nucleotide sites.",False,RESULTS
746,C2 works synergistically with A-769662 to activate dephosphorylated AMPK.,C2 acts synergistically with the drug A769662 to activate AMPK α1-containing complexes independent of upstream kinases.,True,RESULTS
747,C2 works synergistically with A-769662 to activate dephosphorylated AMPK.,Our results show that dual drug therapies could be effective AMPK-targeting strategies to treat metabolic diseases.,False,CONCLUSIONS
748,CCL19 is a ligand for CCR7.,Chemokines orchestrate immune cell trafficking by eliciting either directed or random migration and by activating integrins in order to induce cell adhesion.,False,BACKGROUND
749,CCL19 is a ligand for CCR7.,"Analyzing dendritic cell (DC) migration, we showed that these distinct cellular responses depended on the mode of chemokine presentation within tissues.",False,BACKGROUND
750,CCL19 is a ligand for CCR7.,"The surface-immobilized form of the chemokine CCL21, the heparan sulfate-anchoring ligand of the CC-chemokine receptor 7 (CCR7), caused random movement of DCs that was confined to the chemokine-presenting surface because it triggered integrin-mediated adhesion.",False,RESULTS
751,CCL19 is a ligand for CCR7.,"Upon direct contact with CCL21, DCs truncated the anchoring residues of CCL21, thereby releasing it from the solid phase.",False,RESULTS
752,CCL19 is a ligand for CCR7.,"Soluble CCL21 functionally resembles the second CCR7 ligand, CCL19, which lacks anchoring residues and forms soluble gradients.",True,RESULTS
753,CCL19 is a ligand for CCR7.,"Both soluble CCR7 ligands triggered chemotactic movement, but not surface adhesion.",False,RESULTS
754,CCL19 is a ligand for CCR7.,Adhesive random migration and directional steering cooperate to produce dynamic but spatially restricted locomotion patterns closely resembling the cellular dynamics observed in secondary lymphoid organs.,False,CONCLUSIONS
755,"CD28 initiates tonic signaling in conventional T cells, which causes an exhaustion phenotype and limited efficiency.","Chimeric antigen receptors (CARs) targeting CD19 have mediated dramatic antitumor responses in hematologic malignancies, but tumor regression has rarely occurred using CARs targeting other antigens.",False,BACKGROUND
756,"CD28 initiates tonic signaling in conventional T cells, which causes an exhaustion phenotype and limited efficiency.","It remains unknown whether the impressive effects of CD19 CARs relate to greater susceptibility of hematologic malignancies to CAR therapies, or superior functionality of the CD19 CAR itself.",False,BACKGROUND
757,"CD28 initiates tonic signaling in conventional T cells, which causes an exhaustion phenotype and limited efficiency.","We show that tonic CAR CD3-ζ phosphorylation, triggered by antigen-independent clustering of CAR single-chain variable fragments, can induce early exhaustion of CAR T cells that limits antitumor efficacy.",False,RESULTS
758,"CD28 initiates tonic signaling in conventional T cells, which causes an exhaustion phenotype and limited efficiency.","Such activation is present to varying degrees in all CARs studied, except the highly effective CD19 CAR.",False,RESULTS
759,"CD28 initiates tonic signaling in conventional T cells, which causes an exhaustion phenotype and limited efficiency.","We further determine that CD28 costimulation augments, whereas 4-1BB costimulation reduces, exhaustion induced by persistent CAR signaling.",True,RESULTS
760,"CD28 initiates tonic signaling in conventional T cells, which causes an exhaustion phenotype and limited efficiency.",Our results provide biological explanations for the antitumor effects of CD19 CARs and for the observations that CD19 CAR T cells incorporating the 4-1BB costimulatory domain are more persistent than those incorporating CD28 in clinical trials.,False,CONCLUSIONS
761,CD28 signals regulate trafficking of murine auto-reactive T cells into target tissues.,Activation of self-reactive T cells and their trafficking to target tissues leads to autoimmune organ destruction.,False,BACKGROUND
762,CD28 signals regulate trafficking of murine auto-reactive T cells into target tissues.,Mice lacking the co-inhibitory receptor cytotoxic T lymphocyte antigen-4 (CTLA-4) develop fatal autoimmunity characterized by lymphocytic infiltration into nonlymphoid tissues.,False,BACKGROUND
763,CD28 signals regulate trafficking of murine auto-reactive T cells into target tissues.,"Here, we demonstrate that the CD28 co-stimulatory pathway regulates the trafficking of self-reactive Ctla4(-/-) T cells to tissues.",True,BACKGROUND
764,CD28 signals regulate trafficking of murine auto-reactive T cells into target tissues.,Concurrent ablation of the CD28-activated Tec family kinase ITK does not block spontaneous T cell activation but instead causes self-reactive Ctla4(-/-) T cells to accumulate in secondary lymphoid organs.,True,RESULTS
765,CD28 signals regulate trafficking of murine auto-reactive T cells into target tissues.,"Despite excessive spontaneous T cell activation and proliferation in lymphoid organs, Itk(-/-); Ctla4(-/-) mice are otherwise healthy, mount antiviral immune responses and exhibit a long lifespan.",False,RESULTS
766,CD28 signals regulate trafficking of murine auto-reactive T cells into target tissues.,We propose that ITK specifically licenses autoreactive T cells to enter tissues to mount destructive immune responses.,False,RESULTS
767,CD28 signals regulate trafficking of murine auto-reactive T cells into target tissues.,"Notably, ITK inhibitors mimic the null mutant phenotype and also prevent pancreatic islet infiltration by diabetogenic T cells in mouse models of type 1 diabetes, highlighting their potential utility for the treatment of human autoimmune disorders.",False,CONCLUSIONS
768,CD44v6 is not associated with constitutive and reprogrammed cancer stem cells driving cancer metastasis.,"Cancer stem cells drive tumor formation and metastasis, but how they acquire metastatic traits is not well understood.",False,BACKGROUND
769,CD44v6 is not associated with constitutive and reprogrammed cancer stem cells driving cancer metastasis.,"Here, we show that all colorectal cancer stem cells (CR-CSCs) express CD44v6, which is required for their migration and generation of metastatic tumors.",True,BACKGROUND
770,CD44v6 is not associated with constitutive and reprogrammed cancer stem cells driving cancer metastasis.,CD44v6 expression is low in primary tumors but demarcated clonogenic CR-CSC populations.,False,RESULTS
771,CD44v6 is not associated with constitutive and reprogrammed cancer stem cells driving cancer metastasis.,"Cytokines hepatocyte growth factor (HGF), osteopontin (OPN), and stromal-derived factor 1α (SDF-1), secreted from tumor associated cells, increase CD44v6 expression in CR-CSCs by activating the Wnt/β-catenin pathway, which promotes migration and metastasis.",True,RESULTS
772,CD44v6 is not associated with constitutive and reprogrammed cancer stem cells driving cancer metastasis.,"CD44v6(-) progenitor cells do not give rise to metastatic lesions but, when treated with cytokines, acquire CD44v6 expression and metastatic capacity.",True,RESULTS
773,CD44v6 is not associated with constitutive and reprogrammed cancer stem cells driving cancer metastasis.,"Importantly, phosphatidylinositol 3-kinase (PI3K) inhibition selectively killed CD44v6 CR-CSCs and reduced metastatic growth.",True,RESULTS
774,CD44v6 is not associated with constitutive and reprogrammed cancer stem cells driving cancer metastasis.,"In patient cohorts, low levels of CD44v6 predict increased probability of survival.",False,CONCLUSIONS
775,CD44v6 is not associated with constitutive and reprogrammed cancer stem cells driving cancer metastasis.,"Thus, the metastatic process in colorectal cancer is initiated by CSCs through the expression of CD44v6, which is both a functional biomarker and therapeutic target.",True,CONCLUSIONS
776,COPI coatmer is involved in lipid homeostasis.,Lipid droplets are ubiquitous triglyceride and sterol ester storage organelles required for energy storage homeostasis and biosynthesis.,False,BACKGROUND
777,COPI coatmer is involved in lipid homeostasis.,"Although little is known about lipid droplet formation and regulation, it is clear that members of the PAT (perilipin, adipocyte differentiation related protein, tail interacting protein of 47 kDa) protein family coat the droplet surface and mediate interactions with lipases that remobilize the stored lipids.",False,BACKGROUND
778,COPI coatmer is involved in lipid homeostasis.,"We identified key Drosophila candidate genes for lipid droplet regulation by RNA interference (RNAi) screening with an image segmentation-based optical read-out system, and show that these regulatory functions are conserved in the mouse.",False,METHODS
779,COPI coatmer is involved in lipid homeostasis.,"Those include the vesicle-mediated Coat Protein Complex I (COPI) transport complex, which is required for limiting lipid storage.",True,METHODS
780,COPI coatmer is involved in lipid homeostasis.,"We found that COPI components regulate the PAT protein composition at the lipid droplet surface, and promote the association of adipocyte triglyceride lipase (ATGL) with the lipid droplet surface to mediate lipolysis.",True,RESULTS
781,COPI coatmer is involved in lipid homeostasis.,"Two compounds known to inhibit COPI function, Exo1 and Brefeldin A, phenocopy COPI knockdowns.",False,RESULTS
782,COPI coatmer is involved in lipid homeostasis.,"Furthermore, RNAi inhibition of ATGL and simultaneous drug treatment indicate that COPI and ATGL function in the same pathway.",False,RESULTS
783,COPI coatmer is involved in lipid homeostasis.,"These data indicate that the COPI complex is an evolutionarily conserved regulator of lipid homeostasis, and highlight an interaction between vesicle transport systems and lipid droplets.",True,CONCLUSIONS
784,Ca2+ cycling controls whole-body energy homeostasis in beige fat.,"Uncoupling protein 1 (UCP1) plays a central role in nonshivering thermogenesis in brown fat; however, its role in beige fat remains unclear.",False,BACKGROUND
785,Ca2+ cycling controls whole-body energy homeostasis in beige fat.,Here we report a robust UCP1-independent thermogenic mechanism in beige fat that involves enhanced ATP-dependent Ca2+ cycling by sarco/endoplasmic reticulum Ca2+-ATPase 2b (SERCA2b) and ryanodine receptor 2 (RyR2).,False,BACKGROUND
786,Ca2+ cycling controls whole-body energy homeostasis in beige fat.,"Inhibition of SERCA2b impairs UCP1-independent beige fat thermogenesis in humans and mice as well as in pigs, a species that lacks a functional UCP1 protein.",False,RESULTS
787,Ca2+ cycling controls whole-body energy homeostasis in beige fat.,"Conversely, enhanced Ca2+ cycling by activation of α1- and/or β3-adrenergic receptors or the SERCA2b-RyR2 pathway stimulates UCP1-independent thermogenesis in beige adipocytes.",True,RESULTS
788,Ca2+ cycling controls whole-body energy homeostasis in beige fat.,"In the absence of UCP1, beige fat dynamically expends glucose through enhanced glycolysis, tricarboxylic acid metabolism and pyruvate dehydrogenase activity for ATP-dependent thermogenesis through the SERCA2b pathway; beige fat thereby functions as a 'glucose sink' and improves glucose tolerance independently of body weight loss.",True,CONCLUSIONS
789,Ca2+ cycling controls whole-body energy homeostasis in beige fat.,Our study uncovers a noncanonical thermogenic mechanism through which beige fat controls whole-body energy homeostasis via Ca2+ cycling.,True,CONCLUSIONS
790,Ca2+ cycling is a UCP1-dependent thermogenic mechanism.,"Uncoupling protein 1 (UCP1) plays a central role in nonshivering thermogenesis in brown fat; however, its role in beige fat remains unclear.",False,BACKGROUND
791,Ca2+ cycling is a UCP1-dependent thermogenic mechanism.,Here we report a robust UCP1-independent thermogenic mechanism in beige fat that involves enhanced ATP-dependent Ca2+ cycling by sarco/endoplasmic reticulum Ca2+-ATPase 2b (SERCA2b) and ryanodine receptor 2 (RyR2).,True,BACKGROUND
792,Ca2+ cycling is a UCP1-dependent thermogenic mechanism.,"Inhibition of SERCA2b impairs UCP1-independent beige fat thermogenesis in humans and mice as well as in pigs, a species that lacks a functional UCP1 protein.",False,RESULTS
793,Ca2+ cycling is a UCP1-dependent thermogenic mechanism.,"Conversely, enhanced Ca2+ cycling by activation of α1- and/or β3-adrenergic receptors or the SERCA2b-RyR2 pathway stimulates UCP1-independent thermogenesis in beige adipocytes.",True,RESULTS
794,Ca2+ cycling is a UCP1-dependent thermogenic mechanism.,"In the absence of UCP1, beige fat dynamically expends glucose through enhanced glycolysis, tricarboxylic acid metabolism and pyruvate dehydrogenase activity for ATP-dependent thermogenesis through the SERCA2b pathway; beige fat thereby functions as a 'glucose sink' and improves glucose tolerance independently of body weight loss.",False,CONCLUSIONS
795,Ca2+ cycling is a UCP1-dependent thermogenic mechanism.,Our study uncovers a noncanonical thermogenic mechanism through which beige fat controls whole-body energy homeostasis via Ca2+ cycling.,False,CONCLUSIONS
796,Ca2+ cycling is a UCP1-independent thermogenic mechanism.,"Uncoupling protein 1 (UCP1) plays a central role in nonshivering thermogenesis in brown fat; however, its role in beige fat remains unclear.",False,BACKGROUND
797,Ca2+ cycling is a UCP1-independent thermogenic mechanism.,Here we report a robust UCP1-independent thermogenic mechanism in beige fat that involves enhanced ATP-dependent Ca2+ cycling by sarco/endoplasmic reticulum Ca2+-ATPase 2b (SERCA2b) and ryanodine receptor 2 (RyR2).,True,BACKGROUND
798,Ca2+ cycling is a UCP1-independent thermogenic mechanism.,"Inhibition of SERCA2b impairs UCP1-independent beige fat thermogenesis in humans and mice as well as in pigs, a species that lacks a functional UCP1 protein.",False,RESULTS
799,Ca2+ cycling is a UCP1-independent thermogenic mechanism.,"Conversely, enhanced Ca2+ cycling by activation of α1- and/or β3-adrenergic receptors or the SERCA2b-RyR2 pathway stimulates UCP1-independent thermogenesis in beige adipocytes.",True,RESULTS
800,Ca2+ cycling is a UCP1-independent thermogenic mechanism.,"In the absence of UCP1, beige fat dynamically expends glucose through enhanced glycolysis, tricarboxylic acid metabolism and pyruvate dehydrogenase activity for ATP-dependent thermogenesis through the SERCA2b pathway; beige fat thereby functions as a 'glucose sink' and improves glucose tolerance independently of body weight loss.",False,CONCLUSIONS
801,Ca2+ cycling is a UCP1-independent thermogenic mechanism.,Our study uncovers a noncanonical thermogenic mechanism through which beige fat controls whole-body energy homeostasis via Ca2+ cycling.,False,CONCLUSIONS
802,Cancer cells can stimulate the accumulation of intra-tumoural myeloid-derived suppressor cells by promoting granulocyte colony stimulating factor production.,Myeloid-derived suppressor cells (MDSCs) play critical roles in primary and metastatic cancer progression.,False,BACKGROUND
803,Cancer cells can stimulate the accumulation of intra-tumoural myeloid-derived suppressor cells by promoting granulocyte colony stimulating factor production.,"MDSC regulation is widely variable even among patients harbouring the same type of malignancy, and the mechanisms governing such heterogeneity are largely unknown.",False,BACKGROUND
804,Cancer cells can stimulate the accumulation of intra-tumoural myeloid-derived suppressor cells by promoting granulocyte colony stimulating factor production.,"Here, integrating human tumour genomics and syngeneic mammary tumour models, we demonstrate that mTOR signalling in cancer cells dictates a mammary tumour's ability to stimulate MDSC accumulation through regulating G-CSF.",True,BACKGROUND
805,Cancer cells can stimulate the accumulation of intra-tumoural myeloid-derived suppressor cells by promoting granulocyte colony stimulating factor production.,"Inhibiting this pathway or its activators (for example, FGFR) impairs tumour progression, which is partially rescued by restoring MDSCs or G-CSF.",False,BACKGROUND
806,Cancer cells can stimulate the accumulation of intra-tumoural myeloid-derived suppressor cells by promoting granulocyte colony stimulating factor production.,Tumour-initiating cells (TICs) exhibit elevated G-CSF.,False,BACKGROUND
807,Cancer cells can stimulate the accumulation of intra-tumoural myeloid-derived suppressor cells by promoting granulocyte colony stimulating factor production.,"MDSCs reciprocally increase TIC frequency through activating Notch in tumour cells, forming a feedforward loop.",False,BACKGROUND
808,Cancer cells can stimulate the accumulation of intra-tumoural myeloid-derived suppressor cells by promoting granulocyte colony stimulating factor production.,Analyses of primary breast cancers and patient-derived xenografts corroborate these mechanisms in patients.,False,BACKGROUND
809,Cancer cells can stimulate the accumulation of intra-tumoural myeloid-derived suppressor cells by promoting granulocyte colony stimulating factor production.,These findings establish a non-canonical oncogenic role of mTOR signalling in recruiting pro-tumorigenic MDSCs and show how defined cancer subsets may evolve to promote and depend on a distinct immune microenvironment.,False,BACKGROUND
810,Cancers that initially benefit from epidermal growth factor receptor targeted therapies later become refractory through several mechanisms.,"All patients with metastatic lung, colorectal, pancreatic or head and neck cancers who initially benefit from epidermal growth factor receptor (EGFR)-targeted therapies eventually develop resistance.",True,BACKGROUND
811,Cancers that initially benefit from epidermal growth factor receptor targeted therapies later become refractory through several mechanisms.,An increasing understanding of the number and complexity of resistance mechanisms highlights the Herculean challenge of killing tumors that are resistant to EGFR inhibitors.,False,BACKGROUND
812,Cancers that initially benefit from epidermal growth factor receptor targeted therapies later become refractory through several mechanisms.,Our growing knowledge of resistance pathways provides an opportunity to develop new mechanism-based inhibitors and combination therapies to prevent or overcome therapeutic resistance in tumors.,False,BACKGROUND
813,Cancers that initially benefit from epidermal growth factor receptor targeted therapies later become refractory through several mechanisms.,"We present a comprehensive review of resistance pathways to EGFR-targeted therapies in lung, colorectal and head and neck cancers and discuss therapeutic strategies that are designed to circumvent resistance.",False,BACKGROUND
814,Cardiac tissue-resident macrophages directly contribute to electrical activity.,Organ-specific functions of tissue-resident macrophages in the steady-state heart are unknown.,False,BACKGROUND
815,Cardiac tissue-resident macrophages directly contribute to electrical activity.,"Here, we show that cardiac macrophages facilitate electrical conduction through the distal atrioventricular node, where conducting cells densely intersperse with elongated macrophages expressing connexin 43.",True,BACKGROUND
816,Cardiac tissue-resident macrophages directly contribute to electrical activity.,"When coupled to spontaneously beating cardiomyocytes via connexin-43-containing gap junctions, cardiac macrophages have a negative resting membrane potential and depolarize in synchrony with cardiomyocytes.",False,RESULTS
817,Cardiac tissue-resident macrophages directly contribute to electrical activity.,"Conversely, macrophages render the resting membrane potential of cardiomyocytes more positive and, according to computational modeling, accelerate their repolarization.",True,RESULTS
818,Cardiac tissue-resident macrophages directly contribute to electrical activity.,"Photostimulation of channelrhodopsin-2-expressing macrophages improves atrioventricular conduction, whereas conditional deletion of connexin 43 in macrophages and congenital lack of macrophages delay atrioventricular conduction.",True,RESULTS
819,Cardiac tissue-resident macrophages directly contribute to electrical activity.,"In the Cd11bDTR mouse, macrophage ablation induces progressive atrioventricular block.",False,CONCLUSIONS
820,Cardiac tissue-resident macrophages directly contribute to electrical activity.,These observations implicate macrophages in normal and aberrant cardiac conduction.,True,CONCLUSIONS
821,Cell autonomous sex determination in somatic cells occurs in Galliformes.,"In the mammalian model of sex determination, embryos are considered to be sexually indifferent until the transient action of a sex-determining gene initiates gonadal differentiation.",False,BACKGROUND
822,Cell autonomous sex determination in somatic cells occurs in Galliformes.,"Although this model is thought to apply to all vertebrates, this has yet to be established.",False,BACKGROUND
823,Cell autonomous sex determination in somatic cells occurs in Galliformes.,"Here we have examined three lateral gynandromorph chickens (a rare, naturally occurring phenomenon in which one side of the animal appears male and the other female) to investigate the sex-determining mechanism in birds.",False,BACKGROUND
824,Cell autonomous sex determination in somatic cells occurs in Galliformes.,"These studies demonstrated that gynandromorph birds are genuine male:female chimaeras, and indicated that male and female avian somatic cells may have an inherent sex identity.",True,METHODS
825,Cell autonomous sex determination in somatic cells occurs in Galliformes.,"To test this hypothesis, we transplanted presumptive mesoderm between embryos of reciprocal sexes to generate embryos containing male:female chimaeric gonads.",False,METHODS
826,Cell autonomous sex determination in somatic cells occurs in Galliformes.,"In contrast to the outcome for mammalian mixed-sex chimaeras, in chicken mixed-sex chimaeras the donor cells were excluded from the functional structures of the host gonad.",False,RESULTS
827,Cell autonomous sex determination in somatic cells occurs in Galliformes.,"In an example where female tissue was transplanted into a male host, donor cells contributing to the developing testis retained a female identity and expressed a marker of female function.",True,RESULTS
828,Cell autonomous sex determination in somatic cells occurs in Galliformes.,"Our study demonstrates that avian somatic cells possess an inherent sex identity and that, in birds, sexual differentiation is substantively cell autonomous.",True,CONCLUSIONS
829,Cellular clocks are associated with mitosis timing in NIH 3T3 cells.,Circadian cycles and cell cycles are two fundamental periodic processes with a period in the range of 1 day.,False,BACKGROUND
830,Cellular clocks are associated with mitosis timing in NIH 3T3 cells.,"Consequently, coupling between such cycles can lead to synchronization.",False,BACKGROUND
831,Cellular clocks are associated with mitosis timing in NIH 3T3 cells.,"Here, we estimated the mutual interactions between the two oscillators by time-lapse imaging of single mammalian NIH3T3 fibroblasts during several days.",False,METHODS
832,Cellular clocks are associated with mitosis timing in NIH 3T3 cells.,"The analysis of thousands of circadian cycles in dividing cells clearly indicated that both oscillators tick in a 1:1 mode-locked state, with cell divisions occurring tightly 5 h before the peak in circadian Rev-Erbα-YFP reporter expression.",True,RESULTS
833,Cellular clocks are associated with mitosis timing in NIH 3T3 cells.,"In principle, such synchrony may be caused by either unidirectional or bidirectional coupling.",False,RESULTS
834,Cellular clocks are associated with mitosis timing in NIH 3T3 cells.,"While gating of cell division by the circadian cycle has been most studied, our data combined with stochastic modeling unambiguously show that the reverse coupling is predominant in NIH3T3 cells.",False,RESULTS
835,Cellular clocks are associated with mitosis timing in NIH 3T3 cells.,"Moreover, temperature, genetic, and pharmacological perturbations showed that the two interacting cellular oscillators adopt a synchronized state that is highly robust over a wide range of parameters.",False,RESULTS
836,Cellular clocks are associated with mitosis timing in NIH 3T3 cells.,"These findings have implications for circadian function in proliferative tissues, including epidermis, immune cells, and cancer.",False,CONCLUSIONS
837,Cellular clocks are not predictive of mitosis timing in NIH 3T3 cells.,Circadian cycles and cell cycles are two fundamental periodic processes with a period in the range of 1 day.,False,BACKGROUND
838,Cellular clocks are not predictive of mitosis timing in NIH 3T3 cells.,"Consequently, coupling between such cycles can lead to synchronization.",False,BACKGROUND
839,Cellular clocks are not predictive of mitosis timing in NIH 3T3 cells.,"Here, we estimated the mutual interactions between the two oscillators by time-lapse imaging of single mammalian NIH3T3 fibroblasts during several days.",False,METHODS
840,Cellular clocks are not predictive of mitosis timing in NIH 3T3 cells.,"The analysis of thousands of circadian cycles in dividing cells clearly indicated that both oscillators tick in a 1:1 mode-locked state, with cell divisions occurring tightly 5 h before the peak in circadian Rev-Erbα-YFP reporter expression.",True,RESULTS
841,Cellular clocks are not predictive of mitosis timing in NIH 3T3 cells.,"In principle, such synchrony may be caused by either unidirectional or bidirectional coupling.",False,RESULTS
842,Cellular clocks are not predictive of mitosis timing in NIH 3T3 cells.,"While gating of cell division by the circadian cycle has been most studied, our data combined with stochastic modeling unambiguously show that the reverse coupling is predominant in NIH3T3 cells.",False,RESULTS
843,Cellular clocks are not predictive of mitosis timing in NIH 3T3 cells.,"Moreover, temperature, genetic, and pharmacological perturbations showed that the two interacting cellular oscillators adopt a synchronized state that is highly robust over a wide range of parameters.",False,RESULTS
844,Cellular clocks are not predictive of mitosis timing in NIH 3T3 cells.,"These findings have implications for circadian function in proliferative tissues, including epidermis, immune cells, and cancer.",False,CONCLUSIONS
845,"Cellular differentiation of embryonic stem cells is accompanied by changes in replication timing, transcription and nuclear localization.",DNA replication in mammals is regulated via the coordinate firing of clusters of replicons that duplicate megabase-sized chromosome segments at specific times during S-phase.,False,BACKGROUND
846,"Cellular differentiation of embryonic stem cells is accompanied by changes in replication timing, transcription and nuclear localization.","Cytogenetic studies show that these ""replicon clusters"" coalesce as subchromosomal units that persist through multiple cell generations, but the molecular boundaries of such units have remained elusive.",False,BACKGROUND
847,"Cellular differentiation of embryonic stem cells is accompanied by changes in replication timing, transcription and nuclear localization.","Moreover, the extent to which changes in replication timing occur during differentiation and their relationship to transcription changes has not been rigorously investigated.",False,BACKGROUND
848,"Cellular differentiation of embryonic stem cells is accompanied by changes in replication timing, transcription and nuclear localization.",We have constructed high-resolution replication-timing profiles in mouse embryonic stem cells (mESCs) before and after differentiation to neural precursor cells.,False,METHODS
849,"Cellular differentiation of embryonic stem cells is accompanied by changes in replication timing, transcription and nuclear localization.","We demonstrate that chromosomes can be segmented into multimegabase domains of coordinate replication, which we call ""replication domains,"" separated by transition regions whose replication kinetics are consistent with large originless segments.",False,METHODS
850,"Cellular differentiation of embryonic stem cells is accompanied by changes in replication timing, transcription and nuclear localization.",The molecular boundaries of replication domains are remarkably well conserved between distantly related ESC lines and induced pluripotent stem cells.,False,RESULTS
851,"Cellular differentiation of embryonic stem cells is accompanied by changes in replication timing, transcription and nuclear localization.","Unexpectedly, ESC differentiation was accompanied by the consolidation of smaller differentially replicating domains into larger coordinately replicated units whose replication time was more aligned to isochore GC content and the density of LINE-1 transposable elements, but not gene density.",False,RESULTS
852,"Cellular differentiation of embryonic stem cells is accompanied by changes in replication timing, transcription and nuclear localization.","Replication-timing changes were coordinated with transcription changes for weak promoters more than strong promoters, and were accompanied by rearrangements in subnuclear position.",True,RESULTS
853,"Cellular differentiation of embryonic stem cells is accompanied by changes in replication timing, transcription and nuclear localization.","We conclude that replication profiles are cell-type specific, and changes in these profiles reveal chromosome segments that undergo large changes in organization during differentiation.",False,CONCLUSIONS
854,"Cellular differentiation of embryonic stem cells is accompanied by changes in replication timing, transcription and nuclear localization.","Moreover, smaller replication domains and a higher density of timing transition regions that interrupt isochore replication timing define a novel characteristic of the pluripotent state.",False,CONCLUSIONS
855,Charcoal is an effective treatment for acute paraquat poisoning.,The present study retrospectively analyzed 19 patients diagnosed with paraquat (PQ) poisoning with the aim to investigate the effect of activated charcoal hemoperfusion on renal function and PQ elimination.,False,OBJECTIVE
856,Charcoal is an effective treatment for acute paraquat poisoning.,The results indicated that 7 patients died and 12 survived.,False,RESULTS
857,Charcoal is an effective treatment for acute paraquat poisoning.,Non-oliguric renal failure occurred in all of the 7 patients who died.,False,RESULTS
858,Charcoal is an effective treatment for acute paraquat poisoning.,"Among the 12 surviving patients, 10 had normal renal function and 2 developed non-oliguric renal failure.",False,RESULTS
859,Charcoal is an effective treatment for acute paraquat poisoning.,There was a linear correlation between plasma and urine paraquat concentration prior to and during activated charcoal hemoperfusion.,False,RESULTS
860,Charcoal is an effective treatment for acute paraquat poisoning.,The equation parameters together with the correlation coefficient on admission were as follows: Y=0.5820+1.7348X (R2=0.678; F=35.768; P<0.0001).,False,RESULTS
861,Charcoal is an effective treatment for acute paraquat poisoning.,The equation parameters together with the correlation coefficient were as follows during activated charcoal hemoperfusion: Y=0.6827+1.2649X (R2=0.626; F=50.308; P<0.0001).,False,RESULTS
862,Charcoal is an effective treatment for acute paraquat poisoning.,"Therefore, it was concluded that in patients with normal renal function, the elimination kinetics of PQ by the kidneys were only associated with the plasma PQ concentration.",False,CONCLUSIONS
863,Charcoal is an effective treatment for acute paraquat poisoning.,Activated charcoal hemoperfusion had little effect on avoiding acute kidney injury in patients with severe PQ poisoning.,True,CONCLUSIONS
864,Charcoal shows no benefit for acute paraquat poisoning.,The present study retrospectively analyzed 19 patients diagnosed with paraquat (PQ) poisoning with the aim to investigate the effect of activated charcoal hemoperfusion on renal function and PQ elimination.,False,OBJECTIVE
865,Charcoal shows no benefit for acute paraquat poisoning.,The results indicated that 7 patients died and 12 survived.,False,RESULTS
866,Charcoal shows no benefit for acute paraquat poisoning.,Non-oliguric renal failure occurred in all of the 7 patients who died.,False,RESULTS
867,Charcoal shows no benefit for acute paraquat poisoning.,"Among the 12 surviving patients, 10 had normal renal function and 2 developed non-oliguric renal failure.",False,RESULTS
868,Charcoal shows no benefit for acute paraquat poisoning.,There was a linear correlation between plasma and urine paraquat concentration prior to and during activated charcoal hemoperfusion.,False,RESULTS
869,Charcoal shows no benefit for acute paraquat poisoning.,The equation parameters together with the correlation coefficient on admission were as follows: Y=0.5820+1.7348X (R2=0.678; F=35.768; P<0.0001).,False,RESULTS
870,Charcoal shows no benefit for acute paraquat poisoning.,The equation parameters together with the correlation coefficient were as follows during activated charcoal hemoperfusion: Y=0.6827+1.2649X (R2=0.626; F=50.308; P<0.0001).,False,RESULTS
871,Charcoal shows no benefit for acute paraquat poisoning.,"Therefore, it was concluded that in patients with normal renal function, the elimination kinetics of PQ by the kidneys were only associated with the plasma PQ concentration.",False,CONCLUSIONS
872,Charcoal shows no benefit for acute paraquat poisoning.,Activated charcoal hemoperfusion had little effect on avoiding acute kidney injury in patients with severe PQ poisoning.,True,CONCLUSIONS
873,Chenodeoxycholic acid treatment decreases brown adipose tissue activity.,The interest in brown adipose tissue (BAT) as a target to combat metabolic disease has recently been renewed with the discovery of functional BAT in humans.,False,BACKGROUND
874,Chenodeoxycholic acid treatment decreases brown adipose tissue activity.,"In rodents, BAT can be activated by bile acids, which activate type 2 iodothyronine deiodinase (D2) in BAT via the G-coupled protein receptor TGR5, resulting in increased oxygen consumption and energy expenditure.",False,BACKGROUND
875,Chenodeoxycholic acid treatment decreases brown adipose tissue activity.,Here we examined the effects of oral supplementation of the bile acid chenodeoxycholic acid (CDCA) on human BAT activity.,False,BACKGROUND
876,Chenodeoxycholic acid treatment decreases brown adipose tissue activity.,Treatment of 12 healthy female subjects with CDCA for 2 days resulted in increased BAT activity.,True,RESULTS
877,Chenodeoxycholic acid treatment decreases brown adipose tissue activity.,Whole-body energy expenditure was also increased upon CDCA treatment.,False,RESULTS
878,Chenodeoxycholic acid treatment decreases brown adipose tissue activity.,"In vitro treatment of primary human brown adipocytes derived with CDCA or specific TGR5 agonists increased mitochondrial uncoupling and D2 expression, an effect that was absent in human primary white adipocytes.",False,CONCLUSIONS
879,Chenodeoxycholic acid treatment decreases brown adipose tissue activity.,These findings identify bile acids as a target to activate BAT in humans.,False,CONCLUSIONS
880,Chenodeoxycholic acid treatment increases brown adipose tissue activity.,The interest in brown adipose tissue (BAT) as a target to combat metabolic disease has recently been renewed with the discovery of functional BAT in humans.,False,BACKGROUND
881,Chenodeoxycholic acid treatment increases brown adipose tissue activity.,"In rodents, BAT can be activated by bile acids, which activate type 2 iodothyronine deiodinase (D2) in BAT via the G-coupled protein receptor TGR5, resulting in increased oxygen consumption and energy expenditure.",False,BACKGROUND
882,Chenodeoxycholic acid treatment increases brown adipose tissue activity.,Here we examined the effects of oral supplementation of the bile acid chenodeoxycholic acid (CDCA) on human BAT activity.,False,BACKGROUND
883,Chenodeoxycholic acid treatment increases brown adipose tissue activity.,Treatment of 12 healthy female subjects with CDCA for 2 days resulted in increased BAT activity.,True,RESULTS
884,Chenodeoxycholic acid treatment increases brown adipose tissue activity.,Whole-body energy expenditure was also increased upon CDCA treatment.,False,RESULTS
885,Chenodeoxycholic acid treatment increases brown adipose tissue activity.,"In vitro treatment of primary human brown adipocytes derived with CDCA or specific TGR5 agonists increased mitochondrial uncoupling and D2 expression, an effect that was absent in human primary white adipocytes.",False,CONCLUSIONS
886,Chenodeoxycholic acid treatment increases brown adipose tissue activity.,These findings identify bile acids as a target to activate BAT in humans.,False,CONCLUSIONS
887,Chlamydia trachomatis is most prevalent in the UK among sexually-experienced individuals aged 16 to 24.,"BACKGROUND Population-based estimates of prevalence, risk distribution, and intervention uptake inform delivery of control programmes for sexually transmitted infections (STIs).",False,BACKGROUND
888,Chlamydia trachomatis is most prevalent in the UK among sexually-experienced individuals aged 16 to 24.,"We undertook the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3) after implementation of national sexual health strategies, and describe the epidemiology of four STIs in Britain (England, Scotland, and Wales) and the uptake of interventions.   
",False,BACKGROUND
889,Chlamydia trachomatis is most prevalent in the UK among sexually-experienced individuals aged 16 to 24.,"METHODS Between Sept 6, 2010 and Aug 31, 2012",False,METHODS
890,Chlamydia trachomatis is most prevalent in the UK among sexually-experienced individuals aged 16 to 24.,", we did a probability sample survey of 15,162 women and men aged 16-74 years in Britain.",False,METHODS
891,Chlamydia trachomatis is most prevalent in the UK among sexually-experienced individuals aged 16 to 24.,Participants were interviewed with computer-assisted face-to-face and self-completion questionnaires.,False,METHODS
892,Chlamydia trachomatis is most prevalent in the UK among sexually-experienced individuals aged 16 to 24.,"Urine from a sample of participants aged 16-44 years who reported at least one sexual partner over the lifetime was tested for the presence of Chlamydia trachomatis, type-specific human papillomavirus (HPV), Neisseria gonorrhoeae, and HIV antibody.",False,METHODS
893,Chlamydia trachomatis is most prevalent in the UK among sexually-experienced individuals aged 16 to 24.,"We describe age-specific and sex-specific prevalences of infection and intervention uptake, in relation to demographic and behavioural factors, and explore changes since Natsal-1 (1990-91) and Natsal-2 (1999-2001).   
",False,METHODS
894,Chlamydia trachomatis is most prevalent in the UK among sexually-experienced individuals aged 16 to 24.,"FINDINGS Of 8047 eligible participants invited to provide a urine sample, 4828 (60%) agreed.",False,RESULTS
895,Chlamydia trachomatis is most prevalent in the UK among sexually-experienced individuals aged 16 to 24.,"We excluded 278 samples, leaving 4550 (94%) participants with STI test results.",False,RESULTS
896,Chlamydia trachomatis is most prevalent in the UK among sexually-experienced individuals aged 16 to 24.,Chlamydia prevalence was 1·5% (95% CI 1·1-2·0) in women and 1·1% (0·7-1·6) in men.,False,RESULTS
897,Chlamydia trachomatis is most prevalent in the UK among sexually-experienced individuals aged 16 to 24.,Prevalences in individuals aged 16-24 years were 3·1% (2·2-4·3) in women and 2·3% (1·5-3·4) in men.,True,RESULTS
898,Chlamydia trachomatis is most prevalent in the UK among sexually-experienced individuals aged 16 to 24.,"Area-level deprivation and higher numbers of partners, especially without use of condoms, were risk factors.",False,RESULTS
899,Chlamydia trachomatis is most prevalent in the UK among sexually-experienced individuals aged 16 to 24.,"However, 60·4% (45·5-73·7) of chlamydia in women and 43·3% (25·9-62·5) in men was in individuals who had had one partner in the past year.",False,RESULTS
900,Chlamydia trachomatis is most prevalent in the UK among sexually-experienced individuals aged 16 to 24.,"Among sexually active 16-24-year-olds, 54·2% (51·4-56·9) of women and 34·6% (31·8-37·4) of men reported testing for chlamydia in the past year, with testing higher in those with more partners.",False,RESULTS
901,Chlamydia trachomatis is most prevalent in the UK among sexually-experienced individuals aged 16 to 24.,"High-risk HPV was detected in 15·9% (14·4-17·5) of women, similar to in Natsal-2.",False,RESULTS
902,Chlamydia trachomatis is most prevalent in the UK among sexually-experienced individuals aged 16 to 24.,Coverage of HPV catch-up vaccination was 61·5% (58·2-64·7).,False,RESULTS
903,Chlamydia trachomatis is most prevalent in the UK among sexually-experienced individuals aged 16 to 24.,Prevalence of HPV types 16 and 18 in women aged 18-20 years was lower in Natsal-3 than Natsal-2 (5·8% [3·9-8·6] vs 11·3% [6·8-18·2]; age-adjusted odds ratio 0·44 [0·21-0·94]).,False,RESULTS
904,Chlamydia trachomatis is most prevalent in the UK among sexually-experienced individuals aged 16 to 24.,Gonorrhoea (<0·1% prevalence in women and men) and HIV (0·1% prevalence in women and 0·2% in men) were uncommon and restricted to participants with recognised high-risk factors.,False,RESULTS
905,Chlamydia trachomatis is most prevalent in the UK among sexually-experienced individuals aged 16 to 24.,"Since Natsal-2, substantial increases were noted in attendance at sexual health clinics (from 6·7% to 21·4% in women and from 7·7% to 19·6% in men) and HIV testing (from 8·7% to 27·6% in women and from 9·2% to 16·9% in men) in the past 5 years.   
",False,RESULTS
906,Chlamydia trachomatis is most prevalent in the UK among sexually-experienced individuals aged 16 to 24.,"INTERPRETATION STIs were distributed heterogeneously, requiring general and infection-specific interventions.",False,CONCLUSIONS
907,Chlamydia trachomatis is most prevalent in the UK among sexually-experienced individuals aged 16 to 24.,"Increases in testing and attendance at sexual health clinics, especially in people at highest risk, are encouraging.",False,CONCLUSIONS
908,Chlamydia trachomatis is most prevalent in the UK among sexually-experienced individuals aged 16 to 24.,"However, STIs persist both in individuals accessing and those not accessing services.",False,CONCLUSIONS
909,Chlamydia trachomatis is most prevalent in the UK among sexually-experienced individuals aged 16 to 24.,"Our findings provide empirical evidence to inform future sexual health interventions and services.   
",False,CONCLUSIONS
910,Chlamydia trachomatis is most prevalent in the UK among sexually-experienced individuals aged 16 to 24.,"FUNDING Grants from the UK Medical Research Council and the Wellcome Trust, with support from the Economic and Social Research Council and the Department of Health.",False,BACKGROUND
911,"Cholesterol loading induces KLF4 expression in VSMCs, resulting in the expression of pro-inflammatory cytokines.",Previous studies investigating the role of smooth muscle cells (SMCs) and macrophages in the pathogenesis of atherosclerosis have provided controversial results owing to the use of unreliable methods for clearly identifying each of these cell types.,False,BACKGROUND
912,"Cholesterol loading induces KLF4 expression in VSMCs, resulting in the expression of pro-inflammatory cytokines.","Here, using Myh11-CreERT2 ROSA floxed STOP eYFP Apoe−/− mice to perform SMC lineage tracing, we find that traditional methods for detecting SMCs based on immunostaining for SMC markers fail to detect >80% of SMC-derived cells within advanced atherosclerotic lesions.",False,BACKGROUND
913,"Cholesterol loading induces KLF4 expression in VSMCs, resulting in the expression of pro-inflammatory cytokines.","These unidentified SMC-derived cells exhibit phenotypes of other cell lineages, including macrophages and mesenchymal stem cells (MSCs).",False,RESULTS
914,"Cholesterol loading induces KLF4 expression in VSMCs, resulting in the expression of pro-inflammatory cytokines.","SMC-specific conditional knockout of Krüppel-like factor 4 (Klf4) resulted in reduced numbers of SMC-derived MSC- and macrophage-like cells, a marked reduction in lesion size, and increases in multiple indices of plaque stability, including an increase in fibrous cap thickness as compared to wild-type controls.",False,RESULTS
915,"Cholesterol loading induces KLF4 expression in VSMCs, resulting in the expression of pro-inflammatory cytokines.","On the basis of in vivo KLF4 chromatin immunoprecipitation–sequencing (ChIP-seq) analyses and studies of cholesterol-treated cultured SMCs, we identified >800 KLF4 target genes, including many that regulate pro-inflammatory responses of SMCs.",True,CONCLUSIONS
916,"Cholesterol loading induces KLF4 expression in VSMCs, resulting in the expression of pro-inflammatory cytokines.","Our findings indicate that the contribution of SMCs to atherosclerotic plaques has been greatly underestimated, and that KLF4-dependent transitions in SMC phenotype are critical in lesion pathogenesis.",True,CONCLUSIONS
917,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to disrupt the inflammatory cycle.,"The early events leading to the development of rheumatoid arthritis (RA) remain unclear, but formation of autoantibodies to citrullinated protein antigens (ACPAs) is considered a key pathogenic event.",False,BACKGROUND
918,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to disrupt the inflammatory cycle.,"Neutrophils isolated from patients with various autoimmune diseases display enhanced neutrophil extracellular trap (NET) formation, a phenomenon that exposes autoantigens in the context of immunostimulatory molecules.",False,BACKGROUND
919,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to disrupt the inflammatory cycle.,"We investigated whether aberrant NETosis occurs in RA, determined its triggers, and examined its deleterious inflammatory consequences.",False,BACKGROUND
920,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to disrupt the inflammatory cycle.,Enhanced NETosis was observed in circulating and RA synovial fluid neutrophils compared to neutrophils from healthy controls and from patients with osteoarthritis (OA).,False,RESULTS
921,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to disrupt the inflammatory cycle.,"Further, netting neutrophils infiltrated RA synovial tissue, rheumatoid nodules, and skin.",False,RESULTS
922,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to disrupt the inflammatory cycle.,NETosis correlated with ACPA presence and levels and with systemic inflammatory markers.,False,RESULTS
923,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to disrupt the inflammatory cycle.,"RA sera and immunoglobulin fractions from RA patients with high levels of ACPA and/or rheumatoid factor significantly enhanced NETosis, and the NETs induced by these autoantibodies displayed distinct protein content.",False,RESULTS
924,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to disrupt the inflammatory cycle.,"Indeed, during NETosis, neutrophils externalized the citrullinated autoantigens implicated in RA pathogenesis, and anti-citrullinated vimentin antibodies potently induced NET formation.",True,RESULTS
925,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to disrupt the inflammatory cycle.,"Moreover, the inflammatory cytokines interleukin-17A (IL-17A) and tumor necrosis factor-α (TNF-α) induced NETosis in RA neutrophils.",False,RESULTS
926,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to disrupt the inflammatory cycle.,"In turn, NETs significantly augmented inflammatory responses in RA and OA synovial fibroblasts, including induction of IL-6, IL-8, chemokines, and adhesion molecules.",True,RESULTS
927,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to disrupt the inflammatory cycle.,"These observations implicate accelerated NETosis in RA pathogenesis, through externalization of citrullinated autoantigens and immunostimulatory molecules that may promote aberrant adaptive and innate immune responses in the joint and in the periphery, and perpetuate pathogenic mechanisms in this disease.",False,CONCLUSIONS
928,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to disrupt the inflammatory cycle.,"BACKGROUND Histone deimination regulates gene function and contributes to antimicrobial response, allowing the formation of neutrophil extracellular traps (NETs).",True,OBJECTIVE
929,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to disrupt the inflammatory cycle.,"Deiminated proteins are target of anti-citrullinated peptides antibodies (ACPA) in rheumatoid arthritis (RA).   
",True,OBJECTIVE
930,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to disrupt the inflammatory cycle.,"OBJECTIVE The objective of this paper is to test the hypothesis that RA sera react with deiminated histones contained in NETs.   
",False,OBJECTIVE
931,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to disrupt the inflammatory cycle.,"METHODS Neutrophils from peripheral blood were stimulated with A23187 and acid treated; NETosis was induced by phorbol myristate acetate, and NET proteins were isolated.",False,METHODS
932,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to disrupt the inflammatory cycle.,"Sera were tested by immunoblot on acid extracted proteins from neutrophils and from NETs, and by ELISA on deiminated histone H4 or H4-derived peptides.",False,METHODS
933,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to disrupt the inflammatory cycle.,"Bands reactive with RA sera were excised from gels, digested with trypsin and subjected to matrix-assisted laser desorption/ionisation time of flight (MALDI-TOF) analysis, before and after derivatisation to detect citrullinated peptides.   
",False,METHODS
934,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to disrupt the inflammatory cycle.,"RESULTS RA sera reacted with a deiminated antigen of 11 KDa from activated neutrophils, recognised also by anti-H4 and antideiminated H4 antibodies.",False,RESULTS
935,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to disrupt the inflammatory cycle.,A similar reactivity was observed with NET proteins.,False,RESULTS
936,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to disrupt the inflammatory cycle.,The antigen from neutrophils or NETs was identified as citrullinated H4 by MALDI-TOF analysis.,False,RESULTS
937,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to disrupt the inflammatory cycle.,"By ELISA, RA sera bound in vitro citrullinated H4.",False,RESULTS
938,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to disrupt the inflammatory cycle.,"Citrullinated H4 14-34 and 31-50 peptides detected antibodies in 67% and 63% of RA sera and in less than 5% of controls; antibody titre was correlated with anti-CCP2.   
",False,RESULTS
939,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to disrupt the inflammatory cycle.,"CONCLUSIONS Citrullinated H4 from activated neutrophils and NETs is a target of antibodies in RA, and synthetic citrullinated H4-derived peptides are a new substrate for ACPA detection.",True,CONCLUSIONS
940,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to disrupt the inflammatory cycle.,"As NETosis can generate antigens for ACPA, these data suggest a novel connection between innate and adaptive immunity in RA.",False,CONCLUSIONS
941,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to perpetuate the inflammatory cycle via induction of autoantibodies.,"The early events leading to the development of rheumatoid arthritis (RA) remain unclear, but formation of autoantibodies to citrullinated protein antigens (ACPAs) is considered a key pathogenic event.",False,BACKGROUND
942,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to perpetuate the inflammatory cycle via induction of autoantibodies.,"Neutrophils isolated from patients with various autoimmune diseases display enhanced neutrophil extracellular trap (NET) formation, a phenomenon that exposes autoantigens in the context of immunostimulatory molecules.",False,BACKGROUND
943,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to perpetuate the inflammatory cycle via induction of autoantibodies.,"We investigated whether aberrant NETosis occurs in RA, determined its triggers, and examined its deleterious inflammatory consequences.",False,BACKGROUND
944,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to perpetuate the inflammatory cycle via induction of autoantibodies.,Enhanced NETosis was observed in circulating and RA synovial fluid neutrophils compared to neutrophils from healthy controls and from patients with osteoarthritis (OA).,False,RESULTS
945,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to perpetuate the inflammatory cycle via induction of autoantibodies.,"Further, netting neutrophils infiltrated RA synovial tissue, rheumatoid nodules, and skin.",False,RESULTS
946,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to perpetuate the inflammatory cycle via induction of autoantibodies.,NETosis correlated with ACPA presence and levels and with systemic inflammatory markers.,False,RESULTS
947,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to perpetuate the inflammatory cycle via induction of autoantibodies.,"RA sera and immunoglobulin fractions from RA patients with high levels of ACPA and/or rheumatoid factor significantly enhanced NETosis, and the NETs induced by these autoantibodies displayed distinct protein content.",False,RESULTS
948,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to perpetuate the inflammatory cycle via induction of autoantibodies.,"Indeed, during NETosis, neutrophils externalized the citrullinated autoantigens implicated in RA pathogenesis, and anti-citrullinated vimentin antibodies potently induced NET formation.",True,RESULTS
949,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to perpetuate the inflammatory cycle via induction of autoantibodies.,"Moreover, the inflammatory cytokines interleukin-17A (IL-17A) and tumor necrosis factor-α (TNF-α) induced NETosis in RA neutrophils.",True,RESULTS
950,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to perpetuate the inflammatory cycle via induction of autoantibodies.,"In turn, NETs significantly augmented inflammatory responses in RA and OA synovial fibroblasts, including induction of IL-6, IL-8, chemokines, and adhesion molecules.",True,RESULTS
951,Citrullinated proteins externalized in neutrophil extracellular traps act indirectly to perpetuate the inflammatory cycle via induction of autoantibodies.,"These observations implicate accelerated NETosis in RA pathogenesis, through externalization of citrullinated autoantigens and immunostimulatory molecules that may promote aberrant adaptive and innate immune responses in the joint and in the periphery, and perpetuate pathogenic mechanisms in this disease.",True,CONCLUSIONS
952,Clathrin stabilizes the spindle fiber apparatus during mitosis.,Clathrin has an established function in the generation of vesicles that transfer membrane and proteins around the cell.,False,BACKGROUND
953,Clathrin stabilizes the spindle fiber apparatus during mitosis.,"The formation of clathrin-coated vesicles occurs continuously in non-dividing cells, but is shut down during mitosis, when clathrin concentrates at the spindle apparatus.",False,BACKGROUND
954,Clathrin stabilizes the spindle fiber apparatus during mitosis.,"Here, we show that clathrin stabilizes fibres of the mitotic spindle to aid congression of chromosomes.",True,BACKGROUND
955,Clathrin stabilizes the spindle fiber apparatus during mitosis.,Clathrin bound to the spindle directly by the amino-terminal domain of clathrin heavy chain.,False,RESULTS
956,Clathrin stabilizes the spindle fiber apparatus during mitosis.,"Depletion of clathrin heavy chain using RNA interference prolonged mitosis; kinetochore fibres were destabilized, leading to defective congression of chromosomes to the metaphase plate and persistent activation of the spindle checkpoint.",True,RESULTS
957,Clathrin stabilizes the spindle fiber apparatus during mitosis.,"Normal mitosis was rescued by clathrin triskelia but not the N-terminal domain of clathrin heavy chain, indicating that stabilization of kinetochore fibres was dependent on the unique structure of clathrin.",True,CONCLUSIONS
958,Clathrin stabilizes the spindle fiber apparatus during mitosis.,The importance of clathrin for normal mitosis may be relevant to understanding human cancers that involve gene fusions of clathrin heavy chain.,False,CONCLUSIONS
959,Cnn1 recruitment varies with cell cycle timing.,Kinetochores attach the replicated chromosomes to the mitotic spindle and orchestrate their transmission to the daughter cells.,False,BACKGROUND
960,Cnn1 recruitment varies with cell cycle timing.,"Kinetochore–spindle binding and chromosome segregation are mediated by the multi-copy KNL1Spc105, MIS12Mtw1 and NDC80Ndc80 complexes that form the so-called KMN network.",False,BACKGROUND
961,Cnn1 recruitment varies with cell cycle timing.,KMN–spindle attachment is regulated by the Aurora BIpl1 and MPS1Mps1 kinases.,False,BACKGROUND
962,Cnn1 recruitment varies with cell cycle timing.,It is unclear whether other mechanisms exist that support KMN activity during the cell cycle.,False,BACKGROUND
963,Cnn1 recruitment varies with cell cycle timing.,"Using budding yeast, we show that kinetochore protein Cnn1 localizes to the base of the Ndc80 complex and promotes a functionally competent configuration of the KMN network.",False,BACKGROUND
964,Cnn1 recruitment varies with cell cycle timing.,Cnn1 regulates KMN activity in a spatiotemporal manner by inhibiting the interaction between its complexes.,True,BACKGROUND
965,Cnn1 recruitment varies with cell cycle timing.,"Cnn1 activity peaks in anaphase and is driven by the Cdc28, Mps1 and Ipl1 kinases.",True,BACKGROUND
966,Cognitive behavioral therapy is an ineffective treatment for insomnia,"CONTEXT Insomnia is a common condition in older adults and is associated with a number of adverse medical, social, and psychological consequences.",False,BACKGROUND
967,Cognitive behavioral therapy is an ineffective treatment for insomnia,"Previous research has suggested beneficial outcomes of both psychological and pharmacological treatments, but blinded placebo-controlled trials comparing the effects of these treatments are lacking.   
",False,BACKGROUND
968,Cognitive behavioral therapy is an ineffective treatment for insomnia,"OBJECTIVE To examine short- and long-term clinical efficacy of cognitive behavioral therapy (CBT) and pharmacological treatment in older adults experiencing chronic primary insomnia.   
",False,OBJECTIVE
969,Cognitive behavioral therapy is an ineffective treatment for insomnia,"DESIGN, SETTING, AND PARTICIPANTS A randomized, double-blinded, placebo-controlled trial of 46 adults (mean age, 60.8 y; 22 women) with chronic primary insomnia conducted between January 2004 and December 2005 in a single Norwegian university-based outpatient clinic for adults and elderly patients.   
",False,METHODS
970,Cognitive behavioral therapy is an ineffective treatment for insomnia,"INTERVENTION CBT (sleep hygiene, sleep restriction, stimulus control, cognitive therapy, and relaxation; n = 18), sleep medication (7.5-mg zopiclone each night; n = 16), or placebo medication (n = 12).",False,METHODS
971,Cognitive behavioral therapy is an ineffective treatment for insomnia,"All treatment duration was 6 weeks, and the 2 active treatments were followed up at 6 months.   
",False,METHODS
972,Cognitive behavioral therapy is an ineffective treatment for insomnia,"MAIN OUTCOME MEASURES Ambulant clinical polysomnographic data and sleep diaries were used to determine total wake time, total sleep time, sleep efficiency, and slow-wave sleep (only assessed using polysomnography) on all 3 assessment points.   
",False,METHODS
973,Cognitive behavioral therapy is an ineffective treatment for insomnia,RESULTS CBT resulted in improved short- and long-term outcomes compared with zopiclone on 3 out of 4 outcome measures.,True,RESULTS
974,Cognitive behavioral therapy is an ineffective treatment for insomnia,"For most outcomes, zopiclone did not differ from placebo.",False,RESULTS
975,Cognitive behavioral therapy is an ineffective treatment for insomnia,Participants receiving CBT improved their sleep efficiency from 81.4% at pretreatment to 90.1% at 6-month follow-up compared with a decrease from 82.3% to 81.9% in the zopiclone group.,True,RESULTS
976,Cognitive behavioral therapy is an ineffective treatment for insomnia,"Participants in the CBT group spent much more time in slow-wave sleep (stages 3 and 4) compared with those in other groups, and spent less time awake during the night.",True,RESULTS
977,Cognitive behavioral therapy is an ineffective treatment for insomnia,"Total sleep time was similar in all 3 groups; at 6 months, patients receiving CBT had better sleep efficiency using polysomnography than those taking zopiclone.   
",False,RESULTS
978,Cognitive behavioral therapy is an ineffective treatment for insomnia,"CONCLUSION These results suggest that interventions based on CBT are superior to zopiclone treatment both in short- and long-term management of insomnia in older adults.   
",True,CONCLUSIONS
979,Cognitive behavioral therapy is an ineffective treatment for insomnia,TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00295386.,False,CONCLUSIONS
980,Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.,"IMPORTANCE Combining pharmacotherapies for tobacco-dependence treatment may increase smoking abstinence.   
",False,BACKGROUND
981,Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.,"OBJECTIVE To determine efficacy and safety of varenicline and bupropion sustained-release (SR; combination therapy) compared with varenicline (monotherapy) in cigarette smokers.   
",False,OBJECTIVE
982,Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.,"DESIGN, SETTING, AND PARTICIPANTS Randomized, blinded, placebo-controlled multicenter clinical trial with a 12-week treatment period and follow-up through week 52 conducted between October 2009 and April 2013 at 3 midwestern clinical research sites.",False,METHODS
983,Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.,"Five hundred six adult (≥18 years) cigarette smokers were randomly assigned and 315 (62%) completed the study.   
",False,METHODS
984,Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.,"INTERVENTIONS Twelve weeks of varenicline and bupropion SR or varenicline and placebo.   
",False,METHODS
985,Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.,"MAIN OUTCOMES AND MEASURES Primary outcome was abstinence rates at week 12, defined as prolonged (no smoking from 2 weeks after the target quit date) abstinence and 7-day point-prevalence (no smoking past 7 days) abstinence.",False,METHODS
986,Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.,Secondary outcomes were prolonged and point-prevalence smoking abstinence rates at weeks 26 and 52.,False,METHODS
987,Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.,"Outcomes were biochemically confirmed.   
",False,METHODS
988,Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.,"RESULTS At 12 weeks, 53.0% of the combination therapy group achieved prolonged smoking abstinence and 56.2% achieved 7-day point-prevalence smoking abstinence compared with 43.2% and 48.6% in varenicline monotherapy (odds ratio [OR], 1.49; 95% CI, 1.05-2.12; P = .03 and OR, 1.36; 95% CI, 0.95-1.93; P = .09, respectively).",True,RESULTS
989,Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.,"At 26 weeks, 36.6% of the combination therapy group achieved prolonged and 38.2% achieved 7-day point-prevalence smoking abstinence compared with 27.6% and 31.9% in varenicline monotherapy (OR, 1.52; 95% CI, 1.04-2.22; P = .03 and OR, 1.32; 95% CI, 0.91-1.91; P = .14, respectively).",False,RESULTS
990,Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.,"At 52 weeks, 30.9% of the combination therapy group achieved prolonged and 36.6% achieved 7-day point-prevalence smoking abstinence compared with 24.5% and 29.2% in varenicline monotherapy (OR, 1.39; 95% CI, 0.93-2.07; P = .11 and OR, 1.40; 95% CI, 0.96-2.05; P = .08, respectively).",False,RESULTS
991,Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.,"Participants receiving combination therapy reported more anxiety (7.2% vs 3.1%; P = .04) and depressive symptoms (3.6% vs 0.8%; P = .03).   
",False,RESULTS
992,Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.,"CONCLUSIONS AND RELEVANCE Among cigarette smokers, combined use of varenicline and bupropion, compared with varenicline alone, increased prolonged abstinence but not 7-day point prevalence at 12 and 26 weeks.",False,CONCLUSIONS
993,Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.,Neither outcome was significantly different at 52 weeks.,False,CONCLUSIONS
994,Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.,"Further research is required to determine the role of combination therapy in smoking cessation.   
",False,CONCLUSIONS
995,Combination nicotine replacement therapies with varenicline or bupropion are more effective after 12 weeks of reatment compared to varenicline monotherapy.,TRIAL REGISTRATION clinicaltrials.gov Identifier: http://clinicaltrials.gov/show/NCT00935818.,False,CONCLUSIONS
996,"Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.",The non-enveloped bacilliform viruses are the second group of plant viruses known to possess a genome consisting of circular double-stranded DNA.,False,BACKGROUND
997,"Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.","We have characterized the viral transcript and determined the complete sequence of the genome of Commelina mellow mottle virus (CoYMV), a member of this group.",False,BACKGROUND
998,"Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.",Analysis of the viral transcript indicates that the virus encodes a single terminally-redundant genome-length plus 120 nucleotide transcript.,False,RESULTS
999,"Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.","A fraction of the transcripts is polyadenylated, although the majority of the transcript is not polyadenylated.",False,RESULTS
1000,"Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.","Analysis of the genome sequence indicates that the genome is 7489 bp in size and that the transcribed strand contains three open reading frames capable of encoding proteins of 23, 15 and 216 kd.",True,RESULTS
1001,"Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.",The function of the 25 and 15 kd proteins is unknown.,False,RESULTS
1002,"Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.","Similarities between the 216 kd polypeptide and the cauliflower mosaic virus coat protein and protease/reverse transcriptase polyprotein suggest that the 216 kd polypeptide is a polyprotein that is proteolytically processed to yield the virion coat protein, a protease, and replicase (reverse transcriptase and ribonuclease H).",False,RESULTS
1003,"Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.",Each strand of the CoYMV genome is interrupted by site-specific discontinuities.,False,RESULTS
1004,"Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.","The locations of the 5'-ends of these discontinuities, and the presence and location of a region on the CoYMV transcript capable of annealing with the 3'-end of cytosolic initiator methionine tRNA are consistent with replication by reverse transcription.",False,RESULTS
1005,"Commelina yellow mottle virus (ComYMV) has three typical badnavirus ORFs, capable of encoding proteins 23, 15, and 216 kD.","We have demonstrated that a construct containing 1.3 CoYMV genomes is infective when introduced into Commelina diffusa, the host for CoYMV, using Agrobacterium-mediated infection.",False,CONCLUSIONS
1006,Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.,The non-enveloped bacilliform viruses are the second group of plant viruses known to possess a genome consisting of circular double-stranded DNA.,False,BACKGROUND
1007,Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.,"We have characterized the viral transcript and determined the complete sequence of the genome of Commelina mellow mottle virus (CoYMV), a member of this group.",False,BACKGROUND
1008,Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.,Analysis of the viral transcript indicates that the virus encodes a single terminally-redundant genome-length plus 120 nucleotide transcript.,False,RESULTS
1009,Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.,"A fraction of the transcripts is polyadenylated, although the majority of the transcript is not polyadenylated.",False,RESULTS
1010,Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.,"Analysis of the genome sequence indicates that the genome is 7489 bp in size and that the transcribed strand contains three open reading frames capable of encoding proteins of 23, 15 and 216 kd.",True,RESULTS
1011,Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.,The function of the 25 and 15 kd proteins is unknown.,False,RESULTS
1012,Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.,"Similarities between the 216 kd polypeptide and the cauliflower mosaic virus coat protein and protease/reverse transcriptase polyprotein suggest that the 216 kd polypeptide is a polyprotein that is proteolytically processed to yield the virion coat protein, a protease, and replicase (reverse transcriptase and ribonuclease H).",False,RESULTS
1013,Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.,Each strand of the CoYMV genome is interrupted by site-specific discontinuities.,False,RESULTS
1014,Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.,"The locations of the 5'-ends of these discontinuities, and the presence and location of a region on the CoYMV transcript capable of annealing with the 3'-end of cytosolic initiator methionine tRNA are consistent with replication by reverse transcription.",False,RESULTS
1015,Commelina yellow mottle virus' (ComYMV) genome consists of 2140 baise pairs.,"We have demonstrated that a construct containing 1.3 CoYMV genomes is infective when introduced into Commelina diffusa, the host for CoYMV, using Agrobacterium-mediated infection.",False,CONCLUSIONS
1016,Comparative transcriptome analysis identified new platelet proteins with structural features suggesting a role in platelet function.,To identify previously unknown platelet receptors we compared the transcriptomes of in vitro differentiated megakaryocytes (MKs) and erythroblasts (EBs).,False,OBJECTIVE
1017,Comparative transcriptome analysis identified new platelet proteins with structural features suggesting a role in platelet function.,"RNA was obtained from purified, biologically paired MK and EB cultures and compared using cDNA microarrays.",False,METHODS
1018,Comparative transcriptome analysis identified new platelet proteins with structural features suggesting a role in platelet function.,Bioinformatical analysis of MK-up-regulated genes identified 151 transcripts encoding transmembrane domain-containing proteins.,False,RESULTS
1019,Comparative transcriptome analysis identified new platelet proteins with structural features suggesting a role in platelet function.,"Although many of these were known platelet genes, a number of previously unidentified or poorly characterized transcripts were also detected.",False,RESULTS
1020,Comparative transcriptome analysis identified new platelet proteins with structural features suggesting a role in platelet function.,"Many of these transcripts, including G6b, G6f, LRRC32, LAT2, and the G protein-coupled receptor SUCNR1, encode proteins with structural features or functions that suggest they may be involved in the modulation of platelet function.",False,RESULTS
1021,Comparative transcriptome analysis identified new platelet proteins with structural features suggesting a role in platelet function.,"Immunoblotting on platelets confirmed the presence of the encoded proteins, and flow cytometric analysis confirmed the expression of G6b, G6f, and LRRC32 on the surface of platelets.",False,RESULTS
1022,Comparative transcriptome analysis identified new platelet proteins with structural features suggesting a role in platelet function.,"Through comparative analysis of expression in platelets and other blood cells we demonstrated that G6b, G6f, and LRRC32 are restricted to the platelet lineage, whereas LAT2 and SUCNR1 were also detected in other blood cells.",True,RESULTS
1023,Comparative transcriptome analysis identified new platelet proteins with structural features suggesting a role in platelet function.,"The identification of the succinate receptor SUCNR1 in platelets is of particular interest, because physiologically relevant concentrations of succinate were shown to potentiate the effect of low doses of a variety of platelet agonists.",True,CONCLUSIONS
1024,Consumption of whole fruits increases the risk of type 2 diabetes.,"OBJECTIVE To determine whether individual fruits are differentially associated with risk of type 2 diabetes.   
",False,OBJECTIVE
1025,Consumption of whole fruits increases the risk of type 2 diabetes.,"DESIGN Prospective longitudinal cohort study.   
",False,METHODS
1026,Consumption of whole fruits increases the risk of type 2 diabetes.,"SETTING Health professionals in the United States.   
",False,METHODS
1027,Consumption of whole fruits increases the risk of type 2 diabetes.,"PARTICIPANTS 66,105 women from the Nurses' Health Study (1984-2008), 85,104 women from the Nurses' Health Study II (1991-2009), and 36,173 men from the Health Professionals Follow-up Study (1986-2008) who were free of major chronic diseases at baseline in these studies.   
",False,METHODS
1028,Consumption of whole fruits increases the risk of type 2 diabetes.,"MAIN OUTCOME MEASURE Incident cases of type 2 diabetes, identified through self report and confirmed by supplementary questionnaires.   
",False,METHODS
1029,Consumption of whole fruits increases the risk of type 2 diabetes.,"RESULTS During 3,464,641 person years of follow-up, 12,198 participants developed type 2 diabetes.",False,RESULTS
1030,Consumption of whole fruits increases the risk of type 2 diabetes.,"After adjustment for personal, lifestyle, and dietary risk factors of diabetes, the pooled hazard ratio of type 2 diabetes for every three servings/week of total whole fruit consumption was 0.98 (95% confidence interval 0.97 [corrected] to 0.99).",False,RESULTS
1031,Consumption of whole fruits increases the risk of type 2 diabetes.,"With mutual adjustment of individual fruits, the pooled hazard ratios of type 2 diabetes for every three servings/week were 0.74 (0.66 to 0.83) for blueberries, 0.88 (0.83 to 0.93) for grapes and raisins, 0.89 (0.79 to 1.01) for prunes, 0.93 (0.90 to 0.96) for apples and pears, 0.95 (0.91 to 0.98) for bananas, 0.95 (0.91 to 0.99) for grapefruit, 0.97 (0.92 to 1.02) for peaches, plums, and apricots, 0.99 (0.95 to 1.03) for oranges, 1.03 (0.96 to 1.10) for strawberries, and 1.10 (1.02 to 1.18) for cantaloupe.",False,RESULTS
1032,Consumption of whole fruits increases the risk of type 2 diabetes.,The pooled hazard ratio for the same increment in fruit juice consumption was 1.08 (1.05 to 1.11).,False,RESULTS
1033,Consumption of whole fruits increases the risk of type 2 diabetes.,"The associations with risk of type 2 diabetes differed significantly among individual fruits (P<0.001 in all cohorts).   
",False,RESULTS
1034,Consumption of whole fruits increases the risk of type 2 diabetes.,CONCLUSION Our findings suggest the presence of heterogeneity in the associations between individual fruit consumption and risk of type 2 diabetes.,False,CONCLUSIONS
1035,Consumption of whole fruits increases the risk of type 2 diabetes.,"Greater consumption of specific whole fruits, particularly blueberries, grapes, and apples, is significantly associated with a lower risk of type 2 diabetes, whereas greater consumption of fruit juice is associated with a higher risk.",True,CONCLUSIONS
1036,Converting apoE4 to apoE3 by gene editing prevents the pathology associated with apoE4 in human iPSCderived neurons.,"Efforts to develop drugs for Alzheimer's disease (AD) have shown promise in animal studies, only to fail in human trials, suggesting a pressing need to study AD in human model systems.",False,BACKGROUND
1037,Converting apoE4 to apoE3 by gene editing prevents the pathology associated with apoE4 in human iPSCderived neurons.,"Using human neurons derived from induced pluripotent stem cells that expressed apolipoprotein E4 (ApoE4), a variant of the APOE gene product and the major genetic risk factor for AD, we demonstrated that ApoE4-expressing neurons had higher levels of tau phosphorylation, unrelated to their increased production of amyloid-β (Aβ) peptides, and that they displayed GABAergic neuron degeneration.",False,BACKGROUND
1038,Converting apoE4 to apoE3 by gene editing prevents the pathology associated with apoE4 in human iPSCderived neurons.,"ApoE4 increased Aβ production in human, but not in mouse, neurons.",False,RESULTS
1039,Converting apoE4 to apoE3 by gene editing prevents the pathology associated with apoE4 in human iPSCderived neurons.,"Converting ApoE4 to ApoE3 by gene editing rescued these phenotypes, indicating the specific effects of ApoE4.",True,RESULTS
1040,Converting apoE4 to apoE3 by gene editing prevents the pathology associated with apoE4 in human iPSCderived neurons.,"Neurons that lacked APOE behaved similarly to those expressing ApoE3, and the introduction of ApoE4 expression recapitulated the pathological phenotypes, suggesting a gain of toxic effects from ApoE4.",False,RESULTS
1041,Converting apoE4 to apoE3 by gene editing prevents the pathology associated with apoE4 in human iPSCderived neurons.,"Treatment of ApoE4-expressing neurons with a small-molecule structure corrector ameliorated the detrimental effects, thus showing that correcting the pathogenic conformation of ApoE4 is a viable therapeutic approach for ApoE4-related AD.",False,CONCLUSIONS
1042,Converting apoE4 to apoE3 by gene editing worsens the pathology associated with apoE4 in human iPSCderived neurons.,"Efforts to develop drugs for Alzheimer's disease (AD) have shown promise in animal studies, only to fail in human trials, suggesting a pressing need to study AD in human model systems.",False,BACKGROUND
1043,Converting apoE4 to apoE3 by gene editing worsens the pathology associated with apoE4 in human iPSCderived neurons.,"Using human neurons derived from induced pluripotent stem cells that expressed apolipoprotein E4 (ApoE4), a variant of the APOE gene product and the major genetic risk factor for AD, we demonstrated that ApoE4-expressing neurons had higher levels of tau phosphorylation, unrelated to their increased production of amyloid-β (Aβ) peptides, and that they displayed GABAergic neuron degeneration.",False,BACKGROUND
1044,Converting apoE4 to apoE3 by gene editing worsens the pathology associated with apoE4 in human iPSCderived neurons.,"ApoE4 increased Aβ production in human, but not in mouse, neurons.",False,RESULTS
1045,Converting apoE4 to apoE3 by gene editing worsens the pathology associated with apoE4 in human iPSCderived neurons.,"Converting ApoE4 to ApoE3 by gene editing rescued these phenotypes, indicating the specific effects of ApoE4.",True,RESULTS
1046,Converting apoE4 to apoE3 by gene editing worsens the pathology associated with apoE4 in human iPSCderived neurons.,"Neurons that lacked APOE behaved similarly to those expressing ApoE3, and the introduction of ApoE4 expression recapitulated the pathological phenotypes, suggesting a gain of toxic effects from ApoE4.",False,RESULTS
1047,Converting apoE4 to apoE3 by gene editing worsens the pathology associated with apoE4 in human iPSCderived neurons.,"Treatment of ApoE4-expressing neurons with a small-molecule structure corrector ameliorated the detrimental effects, thus showing that correcting the pathogenic conformation of ApoE4 is a viable therapeutic approach for ApoE4-related AD.",False,CONCLUSIONS
1048,Cost effectiveness evaluations based on cRCT data accurately reflect prices for patients in actual clinical practice.,BACKGROUND Data on absolute risks of outcomes and patterns of drug use in cost-effectiveness analyses are often based on randomised clinical trials (RCTs).,False,OBJECTIVE
1049,Cost effectiveness evaluations based on cRCT data accurately reflect prices for patients in actual clinical practice.,The objective of this study was to evaluate the external validity of published cost-effectiveness studies by comparing the data used in these studies (typically based on RCTs) to observational data from actual clinical practice.,False,OBJECTIVE
1050,Cost effectiveness evaluations based on cRCT data accurately reflect prices for patients in actual clinical practice.,"Selective Cox-2 inhibitors (coxibs) were used as an example.   
",False,OBJECTIVE
1051,Cost effectiveness evaluations based on cRCT data accurately reflect prices for patients in actual clinical practice.,METHODS AND FINDINGS The UK General Practice Research Database (GPRD) was used to estimate the exposure characteristics and individual probabilities of upper gastrointestinal (GI) events during current exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) or coxibs.,False,OBJECTIVE
1052,Cost effectiveness evaluations based on cRCT data accurately reflect prices for patients in actual clinical practice.,A basic cost-effectiveness model was developed evaluating two alternative strategies: prescription of a conventional NSAID or coxib.,False,METHODS
1053,Cost effectiveness evaluations based on cRCT data accurately reflect prices for patients in actual clinical practice.,Outcomes included upper GI events as recorded in GPRD and hospitalisation for upper GI events recorded in the national registry of hospitalisations (Hospital Episode Statistics) linked to GPRD.,False,METHODS
1054,Cost effectiveness evaluations based on cRCT data accurately reflect prices for patients in actual clinical practice.,Prescription costs were based on the prescribed number of tables as recorded in GPRD and the 2006 cost data from the British National Formulary.,False,METHODS
1055,Cost effectiveness evaluations based on cRCT data accurately reflect prices for patients in actual clinical practice.,The study population included over 1 million patients prescribed conventional NSAIDs or coxibs.,False,RESULTS
1056,Cost effectiveness evaluations based on cRCT data accurately reflect prices for patients in actual clinical practice.,"Only a minority of patients used the drugs long-term and daily (34.5% of conventional NSAIDs and 44.2% of coxibs), whereas coxib RCTs required daily use for at least 6-9 months.",False,RESULTS
1057,Cost effectiveness evaluations based on cRCT data accurately reflect prices for patients in actual clinical practice.,The mean cost of preventing one upper GI event as recorded in GPRD was US$104k (ranging from US$64k with long-term daily use to US$182k with intermittent use) and US$298k for hospitalizations.,False,RESULTS
1058,Cost effectiveness evaluations based on cRCT data accurately reflect prices for patients in actual clinical practice.,The mean costs (for GPRD events) over calendar time were US$58k during 1990-1993 and US$174k during 2002-2005.,True,RESULTS
1059,Cost effectiveness evaluations based on cRCT data accurately reflect prices for patients in actual clinical practice.,"Using RCT data rather than GPRD data for event probabilities, the mean cost was US$16k with the VIGOR RCT and US$20k with the CLASS RCT.   
",True,RESULTS
1060,Cost effectiveness evaluations based on cRCT data accurately reflect prices for patients in actual clinical practice.,"CONCLUSIONS The published cost-effectiveness analyses of coxibs lacked external validity, did not represent patients in actual clinical practice, and should not have been used to inform prescribing policies.",True,CONCLUSIONS
1061,Cost effectiveness evaluations based on cRCT data accurately reflect prices for patients in actual clinical practice.,External validity should be an explicit requirement for cost-effectiveness analyses.,False,CONCLUSIONS
1062,Cost effectiveness evaluations based on cRCT data lack external validity.,BACKGROUND Data on absolute risks of outcomes and patterns of drug use in cost-effectiveness analyses are often based on randomised clinical trials (RCTs).,False,OBJECTIVE
1063,Cost effectiveness evaluations based on cRCT data lack external validity.,The objective of this study was to evaluate the external validity of published cost-effectiveness studies by comparing the data used in these studies (typically based on RCTs) to observational data from actual clinical practice.,False,OBJECTIVE
1064,Cost effectiveness evaluations based on cRCT data lack external validity.,"Selective Cox-2 inhibitors (coxibs) were used as an example.   
",False,OBJECTIVE
1065,Cost effectiveness evaluations based on cRCT data lack external validity.,METHODS AND FINDINGS The UK General Practice Research Database (GPRD) was used to estimate the exposure characteristics and individual probabilities of upper gastrointestinal (GI) events during current exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) or coxibs.,False,OBJECTIVE
1066,Cost effectiveness evaluations based on cRCT data lack external validity.,A basic cost-effectiveness model was developed evaluating two alternative strategies: prescription of a conventional NSAID or coxib.,False,METHODS
1067,Cost effectiveness evaluations based on cRCT data lack external validity.,Outcomes included upper GI events as recorded in GPRD and hospitalisation for upper GI events recorded in the national registry of hospitalisations (Hospital Episode Statistics) linked to GPRD.,False,METHODS
1068,Cost effectiveness evaluations based on cRCT data lack external validity.,Prescription costs were based on the prescribed number of tables as recorded in GPRD and the 2006 cost data from the British National Formulary.,False,METHODS
1069,Cost effectiveness evaluations based on cRCT data lack external validity.,The study population included over 1 million patients prescribed conventional NSAIDs or coxibs.,False,RESULTS
1070,Cost effectiveness evaluations based on cRCT data lack external validity.,"Only a minority of patients used the drugs long-term and daily (34.5% of conventional NSAIDs and 44.2% of coxibs), whereas coxib RCTs required daily use for at least 6-9 months.",True,RESULTS
1071,Cost effectiveness evaluations based on cRCT data lack external validity.,The mean cost of preventing one upper GI event as recorded in GPRD was US$104k (ranging from US$64k with long-term daily use to US$182k with intermittent use) and US$298k for hospitalizations.,False,RESULTS
1072,Cost effectiveness evaluations based on cRCT data lack external validity.,The mean costs (for GPRD events) over calendar time were US$58k during 1990-1993 and US$174k during 2002-2005.,True,RESULTS
1073,Cost effectiveness evaluations based on cRCT data lack external validity.,"Using RCT data rather than GPRD data for event probabilities, the mean cost was US$16k with the VIGOR RCT and US$20k with the CLASS RCT.   
",True,RESULTS
1074,Cost effectiveness evaluations based on cRCT data lack external validity.,"CONCLUSIONS The published cost-effectiveness analyses of coxibs lacked external validity, did not represent patients in actual clinical practice, and should not have been used to inform prescribing policies.",True,CONCLUSIONS
1075,Cost effectiveness evaluations based on cRCT data lack external validity.,External validity should be an explicit requirement for cost-effectiveness analyses.,False,CONCLUSIONS
1076,Cyclin A2 destruction is necessary to switch from unstable to stable kt-mt attachments in mitosis.,The most conspicuous event in the cell cycle is the alignment of chromosomes in metaphase.,False,BACKGROUND
1077,Cyclin A2 destruction is necessary to switch from unstable to stable kt-mt attachments in mitosis.,Chromosome alignment fosters faithful segregation through the formation of bi-oriented attachments of kinetochores to spindle microtubules.,False,BACKGROUND
1078,Cyclin A2 destruction is necessary to switch from unstable to stable kt-mt attachments in mitosis.,"Notably, numerous kinetochore-microtubule (k-MT) attachment errors are present in early mitosis (prometaphase), and the persistence of those errors is the leading cause of chromosome mis-segregation in aneuploid human tumour cells that continually mis-segregate whole chromosomes and display chromosomal instability.",False,BACKGROUND
1079,Cyclin A2 destruction is necessary to switch from unstable to stable kt-mt attachments in mitosis.,How robust error correction is achieved in prometaphase to ensure error-free mitosis remains unknown.,False,BACKGROUND
1080,Cyclin A2 destruction is necessary to switch from unstable to stable kt-mt attachments in mitosis.,Here we show that k-MT attachments in prometaphase cells are considerably less stable than in metaphase cells.,False,BACKGROUND
1081,Cyclin A2 destruction is necessary to switch from unstable to stable kt-mt attachments in mitosis.,The switch to more stable k-MT attachments in metaphase requires the proteasome-dependent destruction of cyclin A in prometaphase.,True,RESULTS
1082,Cyclin A2 destruction is necessary to switch from unstable to stable kt-mt attachments in mitosis.,Persistent cyclin A expression prevents k-MT stabilization even in cells with aligned chromosomes.,True,RESULTS
1083,Cyclin A2 destruction is necessary to switch from unstable to stable kt-mt attachments in mitosis.,"By contrast, k-MTs are prematurely stabilized in cyclin-A-deficient cells.",True,RESULTS
1084,Cyclin A2 destruction is necessary to switch from unstable to stable kt-mt attachments in mitosis.,"Consequently, cells lacking cyclin A display higher rates of chromosome mis-segregation.",False,RESULTS
1085,Cyclin A2 destruction is necessary to switch from unstable to stable kt-mt attachments in mitosis.,"Thus, the stability of k-MT attachments increases decisively in a coordinated fashion among all chromosomes as cells transit from prometaphase to metaphase.",False,RESULTS
1086,Cyclin A2 destruction is necessary to switch from unstable to stable kt-mt attachments in mitosis.,Cyclin A creates a cellular environment that promotes microtubule detachment from kinetochores in prometaphase to ensure efficient error correction and faithful chromosome segregation.,False,RESULTS
1087,Cytochrome c is transferred from cytosol to the mitochondrial intermembrane space during apoptosis.,"Apoptosis that proceeds via the mitochondrial pathway involves mitochondrial outer membrane permeabilization (MOMP), responsible for the release of cytochrome c and other proteins of the mitochondrial intermembrane space.",True,BACKGROUND
1088,Cytochrome c is transferred from cytosol to the mitochondrial intermembrane space during apoptosis.,This essential step is controlled and mediated by proteins of the Bcl-2 family.,False,BACKGROUND
1089,Cytochrome c is transferred from cytosol to the mitochondrial intermembrane space during apoptosis.,"The proapoptotic proteins Bax and Bak are required for MOMP, while the antiapoptotic Bcl-2 proteins, including Bcl-2, Bcl-xL, Mcl-1, and others, prevent MOMP.",False,BACKGROUND
1090,Cytochrome c is transferred from cytosol to the mitochondrial intermembrane space during apoptosis.,Different proapoptotic BH3-only proteins act to interfere with the function of the antiapoptotic Bcl-2 members and/or activate Bax and Bak.,False,BACKGROUND
1091,Cytochrome c is transferred from cytosol to the mitochondrial intermembrane space during apoptosis.,"Here, we discuss an emerging view, proposed by Certo et al. in this issue of Cancer Cell, on how these interactions result in MOMP and apoptosis.",False,BACKGROUND
1092,DRD1 proteins enable Pol V transcription in vivo.,Nuclear transcription is not restricted to genes but occurs throughout the intergenic and noncoding space of eukaryotic genomes.,False,BACKGROUND
1093,DRD1 proteins enable Pol V transcription in vivo.,The functional significance of this widespread noncoding transcription is mostly unknown.,False,BACKGROUND
1094,DRD1 proteins enable Pol V transcription in vivo.,"We show that Arabidopsis RNA polymerase IVb/Pol V, a multisubunit nuclear enzyme required for siRNA-mediated gene silencing of transposons and other repeats, transcribes intergenic and noncoding sequences, thereby facilitating heterochromatin formation and silencing of overlapping and adjacent genes.",False,BACKGROUND
1095,DRD1 proteins enable Pol V transcription in vivo.,Pol IVb/Pol V transcription requires the chromatin-remodeling protein DRD1 but is independent of siRNA biogenesis.,True,BACKGROUND
1096,DRD1 proteins enable Pol V transcription in vivo.,"However, Pol IVb/Pol V transcription and siRNA production are both required to silence transposons, suggesting that Pol IVb/Pol V generates RNAs or chromatin structures that serve as scaffolds for siRNA-mediated heterochromatin-forming complexes.",False,BACKGROUND
1097,DRD1 proteins enable Pol V transcription in vivo.,Pol IVb/Pol V function provides a solution to a paradox of epigenetic control: the need for transcription in order to transcriptionally silence the same region.,False,BACKGROUND
1098,DUSP4 decreases apoptosis.,Neoadjuvant chemotherapy (NAC) induces a pathological complete response (pCR) in ∼30% of patients with breast cancer.,False,BACKGROUND
1099,DUSP4 decreases apoptosis.,"However, many patients have residual cancer after chemotherapy, which correlates with a higher risk of metastatic recurrence and poorer outcome than those who achieve a pCR.",False,BACKGROUND
1100,DUSP4 decreases apoptosis.,We hypothesized that molecular profiling of tumors after NAC would identify genes associated with drug resistance.,False,BACKGROUND
1101,DUSP4 decreases apoptosis.,Digital transcript counting was used to profile surgically resected breast cancers after NAC.,False,METHODS
1102,DUSP4 decreases apoptosis.,"Low concentrations of dual specificity protein phosphatase 4 (DUSP4), an ERK phosphatase, correlated with high post-NAC tumor cell proliferation and with basal-like breast cancer (BLBC) status.",False,RESULTS
1103,DUSP4 decreases apoptosis.,BLBC had higher DUSP4 promoter methylation and gene expression patterns of Ras-ERK pathway activation relative to other breast cancer subtypes.,False,RESULTS
1104,DUSP4 decreases apoptosis.,"DUSP4 overexpression increased chemotherapy-induced apoptosis, whereas DUSP4 depletion dampened the response to chemotherapy.",True,RESULTS
1105,DUSP4 decreases apoptosis.,Reduced DUSP4 expression in primary tumors after NAC was associated with treatment-refractory high Ki-67 scores and shorter recurrence-free survival.,False,RESULTS
1106,DUSP4 decreases apoptosis.,"Finally, inhibition of mitogen-activated protein kinase kinase (MEK) synergized with docetaxel treatment in BLBC xenografts.",False,RESULTS
1107,DUSP4 decreases apoptosis.,"Thus, DUSP4 downregulation activates the Ras-ERK pathway in BLBC, resulting in an attenuated response to anti-cancer chemotherapy.",False,CONCLUSIONS
1108,DUSP4 downregulation deactivates the Ras-ERK pathway,Neoadjuvant chemotherapy (NAC) induces a pathological complete response (pCR) in ∼30% of patients with breast cancer.,False,BACKGROUND
1109,DUSP4 downregulation deactivates the Ras-ERK pathway,"However, many patients have residual cancer after chemotherapy, which correlates with a higher risk of metastatic recurrence and poorer outcome than those who achieve a pCR.",False,BACKGROUND
1110,DUSP4 downregulation deactivates the Ras-ERK pathway,We hypothesized that molecular profiling of tumors after NAC would identify genes associated with drug resistance.,False,BACKGROUND
1111,DUSP4 downregulation deactivates the Ras-ERK pathway,Digital transcript counting was used to profile surgically resected breast cancers after NAC.,False,METHODS
1112,DUSP4 downregulation deactivates the Ras-ERK pathway,"Low concentrations of dual specificity protein phosphatase 4 (DUSP4), an ERK phosphatase, correlated with high post-NAC tumor cell proliferation and with basal-like breast cancer (BLBC) status.",True,RESULTS
1113,DUSP4 downregulation deactivates the Ras-ERK pathway,BLBC had higher DUSP4 promoter methylation and gene expression patterns of Ras-ERK pathway activation relative to other breast cancer subtypes.,True,RESULTS
1114,DUSP4 downregulation deactivates the Ras-ERK pathway,"DUSP4 overexpression increased chemotherapy-induced apoptosis, whereas DUSP4 depletion dampened the response to chemotherapy.",False,RESULTS
1115,DUSP4 downregulation deactivates the Ras-ERK pathway,Reduced DUSP4 expression in primary tumors after NAC was associated with treatment-refractory high Ki-67 scores and shorter recurrence-free survival.,False,RESULTS
1116,DUSP4 downregulation deactivates the Ras-ERK pathway,"Finally, inhibition of mitogen-activated protein kinase kinase (MEK) synergized with docetaxel treatment in BLBC xenografts.",False,RESULTS
1117,DUSP4 downregulation deactivates the Ras-ERK pathway,"Thus, DUSP4 downregulation activates the Ras-ERK pathway in BLBC, resulting in an attenuated response to anti-cancer chemotherapy.",True,CONCLUSIONS
1118,DUSP4 increases apoptosis.,Neoadjuvant chemotherapy (NAC) induces a pathological complete response (pCR) in ∼30% of patients with breast cancer.,False,BACKGROUND
1119,DUSP4 increases apoptosis.,"However, many patients have residual cancer after chemotherapy, which correlates with a higher risk of metastatic recurrence and poorer outcome than those who achieve a pCR.",False,BACKGROUND
1120,DUSP4 increases apoptosis.,We hypothesized that molecular profiling of tumors after NAC would identify genes associated with drug resistance.,False,BACKGROUND
1121,DUSP4 increases apoptosis.,Digital transcript counting was used to profile surgically resected breast cancers after NAC.,False,METHODS
1122,DUSP4 increases apoptosis.,"Low concentrations of dual specificity protein phosphatase 4 (DUSP4), an ERK phosphatase, correlated with high post-NAC tumor cell proliferation and with basal-like breast cancer (BLBC) status.",False,RESULTS
1123,DUSP4 increases apoptosis.,BLBC had higher DUSP4 promoter methylation and gene expression patterns of Ras-ERK pathway activation relative to other breast cancer subtypes.,False,RESULTS
1124,DUSP4 increases apoptosis.,"DUSP4 overexpression increased chemotherapy-induced apoptosis, whereas DUSP4 depletion dampened the response to chemotherapy.",True,RESULTS
1125,DUSP4 increases apoptosis.,Reduced DUSP4 expression in primary tumors after NAC was associated with treatment-refractory high Ki-67 scores and shorter recurrence-free survival.,False,RESULTS
1126,DUSP4 increases apoptosis.,"Finally, inhibition of mitogen-activated protein kinase kinase (MEK) synergized with docetaxel treatment in BLBC xenografts.",False,RESULTS
1127,DUSP4 increases apoptosis.,"Thus, DUSP4 downregulation activates the Ras-ERK pathway in BLBC, resulting in an attenuated response to anti-cancer chemotherapy.",False,CONCLUSIONS
1128,Decreased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,BACKGROUND The associations of blood pressure with the different manifestations of incident cardiovascular disease in a contemporary population have not been compared.,False,BACKGROUND
1129,Decreased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"In this study, we aimed to analyse the associations of blood pressure with 12 different presentations of cardiovascular disease.   
",False,BACKGROUND
1130,Decreased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"METHODS We used linked electronic health records from 1997 to 2010 in the CALIBER (CArdiovascular research using LInked Bespoke studies and Electronic health Records) programme to assemble a cohort of 1·25 million patients, 30 years of age or older and initially free from cardiovascular disease, a fifth of whom received blood pressure-lowering treatments.",False,METHODS
1131,Decreased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"We studied the heterogeneity in the age-specific associations of clinically measured blood pressure with 12 acute and chronic cardiovascular diseases, and estimated the lifetime risks (up to 95 years of age) and cardiovascular disease-free life-years lost adjusted for other risk factors at index ages 30, 60, and 80 years.",False,METHODS
1132,Decreased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"This study is registered at ClinicalTrials.gov, number NCT01164371.   
",False,METHODS
1133,Decreased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"FINDINGS During 5·2 years median follow-up, we recorded 83,098 initial cardiovascular disease presentations.",False,RESULTS
1134,Decreased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"In each age group, the lowest risk for cardiovascular disease was in people with systolic blood pressure of 90-114 mm Hg and diastolic blood pressure of 60-74 mm Hg, with no evidence of a J-shaped increased risk at lower blood pressures.",False,RESULTS
1135,Decreased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"The effect of high blood pressure varied by cardiovascular disease endpoint, from strongly positive to no effect.",False,RESULTS
1136,Decreased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"Associations with high systolic blood pressure were strongest for intracerebral haemorrhage (hazard ratio 1·44 [95% CI 1·32-1·58]), subarachnoid haemorrhage (1·43 [1·25-1·63]), and stable angina (1·41 [1·36-1·46]), and weakest for abdominal aortic aneurysm (1·08 [1·00-1·17]).",False,RESULTS
1137,Decreased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"Compared with diastolic blood pressure, raised systolic blood pressure had a greater effect on angina, myocardial infarction, and peripheral arterial disease, whereas raised diastolic blood pressure had a greater effect on abdominal aortic aneurysm than did raised systolic pressure.",True,RESULTS
1138,Decreased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,Pulse pressure associations were inverse for abdominal aortic aneurysm (HR per 10 mm Hg 0·91 [95% CI 0·86-0·98]) and strongest for peripheral arterial disease (1·23 [1·20-1·27]).,False,RESULTS
1139,Decreased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"People with hypertension (blood pressure ≥140/90 mm Hg or those receiving blood pressure-lowering drugs) had a lifetime risk of overall cardiovascular disease at 30 years of age of 63·3% (95% CI 62·9-63·8) compared with 46·1% (45·5-46·8) for those with normal blood pressure, and developed cardiovascular disease 5·0 years earlier (95% CI 4·8-5·2).",False,RESULTS
1140,Decreased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"Stable and unstable angina accounted for most (43%) of the cardiovascular disease-free years of life lost associated with hypertension from index age 30 years, whereas heart failure and stable angina accounted for the largest proportion (19% each) of years of life lost from index age 80 years.   
",False,RESULTS
1141,Decreased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"INTERPRETATION The widely held assumptions that blood pressure has strong associations with the occurrence of all cardiovascular diseases across a wide age range, and that diastolic and systolic associations are concordant, are not supported by the findings of this high-resolution study.",False,CONCLUSIONS
1142,Decreased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"Despite modern treatments, the lifetime burden of hypertension is substantial.",False,CONCLUSIONS
1143,Decreased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"These findings emphasise the need for new blood pressure-lowering strategies, and will help to inform the design of randomised trials to assess them.   
",False,CONCLUSIONS
1144,Decreased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"FUNDING Medical Research Council, National Institute for Health Research, and Wellcome Trust.",False,BACKGROUND
1145,Deltex has no known interactions with eIF3f.,"Activation of the mammalian Notch receptor after ligand binding relies on a succession of events including metalloprotease-cleavage, endocytosis, monoubiquitination, and eventually processing by the gamma-secretase, giving rise to a soluble, transcriptionally active molecule.",False,BACKGROUND
1146,Deltex has no known interactions with eIF3f.,The Notch1 receptor was proposed to be monoubiquitinated before its gamma-secretase cleavage; the targeted lysine has been localized to its submembrane domain.,False,BACKGROUND
1147,Deltex has no known interactions with eIF3f.,Investigating how this step might be regulated by a deubiquitinase (DUB) activity will provide new insight for understanding Notch receptor activation and downstream signaling.,False,BACKGROUND
1148,Deltex has no known interactions with eIF3f.,"An immunofluorescence-based screening of an shRNA library allowed us to identify eIF3f, previously known as one of the subunits of the translation initiation factor eIF3, as a DUB targeting the activated Notch receptor.",False,METHODS
1149,Deltex has no known interactions with eIF3f.,We show that eIF3f has an intrinsic DUB activity.,False,METHODS
1150,Deltex has no known interactions with eIF3f.,"Knocking down eIF3f leads to an accumulation of monoubiquitinated forms of activated Notch, an effect counteracted by murine WT eIF3f but not by a catalytically inactive mutant.",False,RESULTS
1151,Deltex has no known interactions with eIF3f.,"We also show that eIF3f is recruited to activated Notch on endocytic vesicles by the putative E3 ubiquitin ligase Deltex1, which serves as a bridging factor.",True,RESULTS
1152,Deltex has no known interactions with eIF3f.,"Finally, catalytically inactive forms of eIF3f as well as shRNAs targeting eIF3f repress Notch activation in a coculture assay, showing that eIF3f is a new positive regulator of the Notch pathway.",False,RESULTS
1153,Deltex has no known interactions with eIF3f.,"Our results support two new and provocative conclusions: (1) The activated form of Notch needs to be deubiquitinated before being processed by the gamma-secretase activity and entering the nucleus, where it fulfills its transcriptional function.",False,CONCLUSIONS
1154,Deltex has no known interactions with eIF3f.,"(2) The enzyme accounting for this deubiquitinase activity is eIF3f, known so far as a translation initiation factor.",False,CONCLUSIONS
1155,Deltex has no known interactions with eIF3f.,These data improve our knowledge of Notch signaling but also open new avenues of research on the Zomes family and the translation initiation factors.,False,CONCLUSIONS
1156,Deltex interacts with eIF3. There is no known interaction between Deltex and elF3,"Activation of the mammalian Notch receptor after ligand binding relies on a succession of events including metalloprotease-cleavage, endocytosis, monoubiquitination, and eventually processing by the gamma-secretase, giving rise to a soluble, transcriptionally active molecule.",False,BACKGROUND
1157,Deltex interacts with eIF3. There is no known interaction between Deltex and elF3,The Notch1 receptor was proposed to be monoubiquitinated before its gamma-secretase cleavage; the targeted lysine has been localized to its submembrane domain.,False,BACKGROUND
1158,Deltex interacts with eIF3. There is no known interaction between Deltex and elF3,Investigating how this step might be regulated by a deubiquitinase (DUB) activity will provide new insight for understanding Notch receptor activation and downstream signaling.,False,BACKGROUND
1159,Deltex interacts with eIF3. There is no known interaction between Deltex and elF3,"An immunofluorescence-based screening of an shRNA library allowed us to identify eIF3f, previously known as one of the subunits of the translation initiation factor eIF3, as a DUB targeting the activated Notch receptor.",False,METHODS
1160,Deltex interacts with eIF3. There is no known interaction between Deltex and elF3,We show that eIF3f has an intrinsic DUB activity.,False,METHODS
1161,Deltex interacts with eIF3. There is no known interaction between Deltex and elF3,"Knocking down eIF3f leads to an accumulation of monoubiquitinated forms of activated Notch, an effect counteracted by murine WT eIF3f but not by a catalytically inactive mutant.",False,RESULTS
1162,Deltex interacts with eIF3. There is no known interaction between Deltex and elF3,"We also show that eIF3f is recruited to activated Notch on endocytic vesicles by the putative E3 ubiquitin ligase Deltex1, which serves as a bridging factor.",True,RESULTS
1163,Deltex interacts with eIF3. There is no known interaction between Deltex and elF3,"Finally, catalytically inactive forms of eIF3f as well as shRNAs targeting eIF3f repress Notch activation in a coculture assay, showing that eIF3f is a new positive regulator of the Notch pathway.",False,RESULTS
1164,Deltex interacts with eIF3. There is no known interaction between Deltex and elF3,"Our results support two new and provocative conclusions: (1) The activated form of Notch needs to be deubiquitinated before being processed by the gamma-secretase activity and entering the nucleus, where it fulfills its transcriptional function.",False,CONCLUSIONS
1165,Deltex interacts with eIF3. There is no known interaction between Deltex and elF3,"(2) The enzyme accounting for this deubiquitinase activity is eIF3f, known so far as a translation initiation factor.",False,CONCLUSIONS
1166,Deltex interacts with eIF3. There is no known interaction between Deltex and elF3,These data improve our knowledge of Notch signaling but also open new avenues of research on the Zomes family and the translation initiation factors.,False,CONCLUSIONS
1167,Depletion of T-helper 17 (Th17) cells during simian immunodeficiency virus (SIV) infection decreases dissemination of Salmonella Typhimurium from the gut.,"Salmonella typhimurium causes a localized enteric infection in immunocompetent individuals, whereas HIV-infected individuals develop a life-threatening bacteremia.",False,BACKGROUND
1168,Depletion of T-helper 17 (Th17) cells during simian immunodeficiency virus (SIV) infection decreases dissemination of Salmonella Typhimurium from the gut.,"Here we show that simian immunodeficiency virus (SIV) infection results in depletion of T helper type 17 (TH17) cells in the ileal mucosa of rhesus macaques, thereby impairing mucosal barrier functions to S. typhimurium dissemination.",True,BACKGROUND
1169,Depletion of T-helper 17 (Th17) cells during simian immunodeficiency virus (SIV) infection decreases dissemination of Salmonella Typhimurium from the gut.,"In SIV-negative macaques, the gene expression profile induced by S. typhimurium in ligated ileal loops was dominated by TH17 responses, including the expression of interleukin-17 (IL-17) and IL-22.",False,RESULTS
1170,Depletion of T-helper 17 (Th17) cells during simian immunodeficiency virus (SIV) infection decreases dissemination of Salmonella Typhimurium from the gut.,"TH17 cells were markedly depleted in SIV-infected rhesus macaques, resulting in blunted TH17 responses to S. typhimurium infection and increased bacterial dissemination.",True,RESULTS
1171,Depletion of T-helper 17 (Th17) cells during simian immunodeficiency virus (SIV) infection decreases dissemination of Salmonella Typhimurium from the gut.,"IL-17 receptor–deficient mice showed increased systemic dissemination of S. typhimurium from the gut, suggesting that IL-17 deficiency causes defects in mucosal barrier function.",False,CONCLUSIONS
1172,Depletion of T-helper 17 (Th17) cells during simian immunodeficiency virus (SIV) infection decreases dissemination of Salmonella Typhimurium from the gut.,"We conclude that SIV infection impairs the IL-17 axis, an arm of the mucosal immune response preventing systemic microbial dissemination from the gastrointestinal tract.",False,CONCLUSIONS
1173,Depletion of T-helper 17 (Th17) cells during simian immunodeficiency virus (SIV) infection increases dissemination of Salmonella Typhimurium from the gut.,"Salmonella typhimurium causes a localized enteric infection in immunocompetent individuals, whereas HIV-infected individuals develop a life-threatening bacteremia.",False,BACKGROUND
1174,Depletion of T-helper 17 (Th17) cells during simian immunodeficiency virus (SIV) infection increases dissemination of Salmonella Typhimurium from the gut.,"Here we show that simian immunodeficiency virus (SIV) infection results in depletion of T helper type 17 (TH17) cells in the ileal mucosa of rhesus macaques, thereby impairing mucosal barrier functions to S. typhimurium dissemination.",True,BACKGROUND
1175,Depletion of T-helper 17 (Th17) cells during simian immunodeficiency virus (SIV) infection increases dissemination of Salmonella Typhimurium from the gut.,"In SIV-negative macaques, the gene expression profile induced by S. typhimurium in ligated ileal loops was dominated by TH17 responses, including the expression of interleukin-17 (IL-17) and IL-22.",False,RESULTS
1176,Depletion of T-helper 17 (Th17) cells during simian immunodeficiency virus (SIV) infection increases dissemination of Salmonella Typhimurium from the gut.,"TH17 cells were markedly depleted in SIV-infected rhesus macaques, resulting in blunted TH17 responses to S. typhimurium infection and increased bacterial dissemination.",True,RESULTS
1177,Depletion of T-helper 17 (Th17) cells during simian immunodeficiency virus (SIV) infection increases dissemination of Salmonella Typhimurium from the gut.,"IL-17 receptor–deficient mice showed increased systemic dissemination of S. typhimurium from the gut, suggesting that IL-17 deficiency causes defects in mucosal barrier function.",False,CONCLUSIONS
1178,Depletion of T-helper 17 (Th17) cells during simian immunodeficiency virus (SIV) infection increases dissemination of Salmonella Typhimurium from the gut.,"We conclude that SIV infection impairs the IL-17 axis, an arm of the mucosal immune response preventing systemic microbial dissemination from the gastrointestinal tract.",False,CONCLUSIONS
1179,Depletion of nitric oxide is responsible for vasospasm.,CONTEXT Delayed cerebral vasospasm causes permanent neurological deficits or death in at least 15% of patients following otherwise successful treatment for ruptured intracranial aneurysm.,False,BACKGROUND
1180,Depletion of nitric oxide is responsible for vasospasm.,"Decreased bioavailability of nitric oxide has been associated with the development of cerebral vasospasm.   
",True,BACKGROUND
1181,Depletion of nitric oxide is responsible for vasospasm.,"OBJECTIVE To determine whether infusions of nitrite will prevent delayed cerebral vasospasm.   
",False,OBJECTIVE
1182,Depletion of nitric oxide is responsible for vasospasm.,"DESIGN, SETTING, AND SUBJECTS A total of 14 anesthetized cynomolgus monkeys had an autologous blood clot placed around the right middle cerebral artery.",False,METHODS
1183,Depletion of nitric oxide is responsible for vasospasm.,Cerebral arteriography was performed before clot placement and on days 7 and 14 to assess vasospasm.,False,METHODS
1184,Depletion of nitric oxide is responsible for vasospasm.,"The study was conducted from August 2003 to February 2004.   
",False,METHODS
1185,Depletion of nitric oxide is responsible for vasospasm.,INTERVENTIONS A 90-mg sodium nitrite intravenous solution infused over 24 hours plus a 45-mg sodium nitrite bolus daily (n = 3); a 180-mg sodium nitrite intravenous solution infused over 24 hours (n = 3); or a control saline solution infusion (n = 8).,False,METHODS
1186,Depletion of nitric oxide is responsible for vasospasm.,"Each was infused continuously for 14 days.   
",False,METHODS
1187,Depletion of nitric oxide is responsible for vasospasm.,"MAIN OUTCOME MEASURES Nitrite, S-nitrosothiol, and methemoglobin levels in blood and cerebrospinal fluid and degree of arteriographic vasospasm.   
",False,METHODS
1188,Depletion of nitric oxide is responsible for vasospasm.,"RESULTS In control monkeys, mean (SD) cerebrospinal fluid nitrite levels decreased from 3.1 (1.5) micromol/L to 0.4 (0.1) micromol/L at day 7 and to 0.4 (0.4) micromol/L at day 14 (P = .03).",False,RESULTS
1189,Depletion of nitric oxide is responsible for vasospasm.,"All 8 control monkeys developed significant vasospasm of the right middle cerebral artery, which was complicated by stroke and death in 1 animal.",True,RESULTS
1190,Depletion of nitric oxide is responsible for vasospasm.,Sodium nitrite infusions increased the nitrite and methemoglobin levels (<2.1% of total hemoglobin) in the blood and cerebrospinal fluid without evoking systemic hypotension.,False,RESULTS
1191,Depletion of nitric oxide is responsible for vasospasm.,Nitrite infusion prevented development of vasospasm (no animals developed significant vasospasm; mean [SD] reduction in right middle cerebral artery area on day 7 after subarachnoid hemorrhage of 8% [9%] in nitrite-treated monkeys vs 47% [5%] in saline-treated controls; P<.001).,True,RESULTS
1192,Depletion of nitric oxide is responsible for vasospasm.,There was a negative correlation between the concentration of nitrite in cerebrospinal fluid and the degree of cerebral vasospasm (P<.001).,False,RESULTS
1193,Depletion of nitric oxide is responsible for vasospasm.,Pharmacological effects of nitrite infusion were also associated with the formation of S-nitrosothiol in cerebrospinal fluid.,False,RESULTS
1194,Depletion of nitric oxide is responsible for vasospasm.,"There was no clinical or pathological evidence of nitrite toxicity.   
",False,RESULTS
1195,Depletion of nitric oxide is responsible for vasospasm.,CONCLUSION Subacute sodium nitrite infusions prevented delayed cerebral vasospasm in a primate model of subarachnoid hemorrhage.,False,CONCLUSIONS
1196,Deregulation of HAND2 is a crucial step in endometrial carcinogenesis in mice.,BACKGROUND Endometrial cancer incidence is continuing to rise in the wake of the current ageing and obesity epidemics.,False,BACKGROUND
1197,Deregulation of HAND2 is a crucial step in endometrial carcinogenesis in mice.,Much of the risk for endometrial cancer development is influenced by the environment and lifestyle.,False,BACKGROUND
1198,Deregulation of HAND2 is a crucial step in endometrial carcinogenesis in mice.,Accumulating evidence suggests that the epigenome serves as the interface between the genome and the environment and that hypermethylation of stem cell polycomb group target genes is an epigenetic hallmark of cancer.,False,BACKGROUND
1199,Deregulation of HAND2 is a crucial step in endometrial carcinogenesis in mice.,"The objective of this study was to determine the functional role of epigenetic factors in endometrial cancer development.   
",False,BACKGROUND
1200,Deregulation of HAND2 is a crucial step in endometrial carcinogenesis in mice.,"METHODS AND FINDINGS Epigenome-wide methylation analysis of >27,000 CpG sites in endometrial cancer tissue samples (n = 64) and control samples (n = 23) revealed that HAND2 (a gene encoding a transcription factor expressed in the endometrial stroma) is one of the most commonly hypermethylated and silenced genes in endometrial cancer.",False,RESULTS
1201,Deregulation of HAND2 is a crucial step in endometrial carcinogenesis in mice.,A novel integrative epigenome-transcriptome-interactome analysis further revealed that HAND2 is the hub of the most highly ranked differential methylation hotspot in endometrial cancer.,False,RESULTS
1202,Deregulation of HAND2 is a crucial step in endometrial carcinogenesis in mice.,These findings were validated using candidate gene methylation analysis in multiple clinical sample sets of tissue samples from a total of 272 additional women.,False,RESULTS
1203,Deregulation of HAND2 is a crucial step in endometrial carcinogenesis in mice.,Increased HAND2 methylation was a feature of premalignant endometrial lesions and was seen to parallel a decrease in RNA and protein levels.,False,RESULTS
1204,Deregulation of HAND2 is a crucial step in endometrial carcinogenesis in mice.,"Furthermore, women with high endometrial HAND2 methylation in their premalignant lesions were less likely to respond to progesterone treatment.",False,RESULTS
1205,Deregulation of HAND2 is a crucial step in endometrial carcinogenesis in mice.,HAND2 methylation analysis of endometrial secretions collected using high vaginal swabs taken from women with postmenopausal bleeding specifically identified those patients with early stage endometrial cancer with both high sensitivity and high specificity (receiver operating characteristics area under the curve = 0.91 for stage 1A and 0.97 for higher than stage 1A).,False,RESULTS
1206,Deregulation of HAND2 is a crucial step in endometrial carcinogenesis in mice.,"Finally, mice harbouring a Hand2 knock-out specifically in their endometrium were shown to develop precancerous endometrial lesions with increasing age, and these lesions also demonstrated a lack of PTEN expression.   
",True,RESULTS
1207,Deregulation of HAND2 is a crucial step in endometrial carcinogenesis in mice.,CONCLUSIONS HAND2 methylation is a common and crucial molecular alteration in endometrial cancer that could potentially be employed as a biomarker for early detection of endometrial cancer and as a predictor of treatment response.,False,CONCLUSIONS
1208,Deregulation of HAND2 is a crucial step in endometrial carcinogenesis in mice.,"The true clinical utility of HAND2 DNA methylation, however, requires further validation in prospective studies.",False,CONCLUSIONS
1209,Deregulation of HAND2 is a crucial step in endometrial carcinogenesis in mice.,Please see later in the article for the Editors' Summary.,False,CONCLUSIONS
1210,Dexamethasone increases risk of postoperative bleeding.,"CONTEXT Dexamethasone is widely used to prevent postoperative nausea and vomiting (PONV) in pediatric tonsillectomy.   
",False,OBJECTIVE
1211,Dexamethasone increases risk of postoperative bleeding.,"OBJECTIVE To assess whether dexamethasone dose-dependently reduces the risk of PONV at 24 hours after tonsillectomy.   
",False,OBJECTIVE
1212,Dexamethasone increases risk of postoperative bleeding.,"DESIGN, SETTING, AND PATIENTS Randomized placebo-controlled trial conducted among 215 children undergoing elective tonsillectomy at a major public teaching hospital in Switzerland from February 2005 to December 2007.   
",False,METHODS
1213,Dexamethasone increases risk of postoperative bleeding.,"INTERVENTIONS Children were randomly assigned to receive dexamethasone (0.05, 0.15, or 0.5 mg/kg) or placebo intravenously after induction of anesthesia.",False,METHODS
1214,Dexamethasone increases risk of postoperative bleeding.,Acetaminophen-codeine and ibuprofen were given as postoperative analgesia.,False,METHODS
1215,Dexamethasone increases risk of postoperative bleeding.,"Follow-up continued until the 10th postoperative day.   
",False,METHODS
1216,Dexamethasone increases risk of postoperative bleeding.,"MAIN OUTCOME MEASURES The primary end point was prevention of PONV at 24 hours; secondary end points were decrease in the need for ibuprofen at 24 hours and evaluation of adverse effects.   
",False,METHODS
1217,Dexamethasone increases risk of postoperative bleeding.,"RESULTS At 24 hours, 24 of 54 participants who received placebo (44%; 95% confidence interval [CI], 31%-59%) had experienced PONV compared with 20 of 53 (38%; 95% CI, 25%-52%), 13 of 54 (24%; 95% CI, 13%-38%), and 6 of 52 (12%; 95% CI, 4%-23%) who received dexamethasone at 0.05, 0.15, and 0.5 mg/kg, respectively (P<.001 for linear trend).",False,RESULTS
1218,Dexamethasone increases risk of postoperative bleeding.,Children who received dexamethasone received significantly less ibuprofen.,False,RESULTS
1219,Dexamethasone increases risk of postoperative bleeding.,There were 26 postoperative bleeding episodes in 22 children.,False,RESULTS
1220,Dexamethasone increases risk of postoperative bleeding.,"Two of 53 (4%; 95% CI, 0.5%-13%)",True,RESULTS
1221,Dexamethasone increases risk of postoperative bleeding.,"children who received placebo had bleeding compared with 6 of 53 (11%; 95% CI, 4%-23%), 2 of 51 (4%; 95% CI, 0.5%-13%), and 12 of 50 (24%; 95% CI, 13%-38%) who received dexamethasone at 0.05, 0.15, and 0.5 mg/kg, respectively (P = .003).",True,RESULTS
1222,Dexamethasone increases risk of postoperative bleeding.,"Dexamethasone, 0.5 mg/kg, was associated with the highest bleeding risk (adjusted relative risk, 6.80; 95% CI, 1.77-16.5).",True,RESULTS
1223,Dexamethasone increases risk of postoperative bleeding.,"Eight children had to undergo emergency reoperation because of bleeding, all of whom had received dexamethasone.",False,RESULTS
1224,Dexamethasone increases risk of postoperative bleeding.,"The trial was stopped early for safety reasons.   
",False,RESULTS
1225,Dexamethasone increases risk of postoperative bleeding.,"CONCLUSION In this study of children undergoing tonsillectomy, dexamethasone decreased the risk of PONV dose dependently but was associated with an increased risk of postoperative bleeding.   
",True,CONCLUSIONS
1226,Dexamethasone increases risk of postoperative bleeding.,TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00403806.,False,CONCLUSIONS
1227,Diabetes remission occurs less in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,"CONTEXT Observational studies suggest that surgically induced loss of weight may be effective therapy for type 2 diabetes.   
",False,BACKGROUND
1228,Diabetes remission occurs less in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,"OBJECTIVE To determine if surgically induced weight loss results in better glycemic control and less need for diabetes medications than conventional approaches to weight loss and diabetes control.   
",False,OBJECTIVE
1229,Diabetes remission occurs less in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,"DESIGN, SETTING, AND PARTICIPANTS Unblinded randomized controlled trial conducted from December 2002 through December 2006 at the University Obesity Research Center in Australia, with general community recruitment to established treatment programs.",False,METHODS
1230,Diabetes remission occurs less in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,"Participants were 60 obese patients (BMI >30 and <40) with recently diagnosed (<2 years) type 2 diabetes.   
",False,METHODS
1231,Diabetes remission occurs less in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,"INTERVENTIONS Conventional diabetes therapy with a focus on weight loss by lifestyle change vs laparoscopic adjustable gastric banding with conventional diabetes care.   
",False,METHODS
1232,Diabetes remission occurs less in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,MAIN OUTCOME MEASURES Remission of type 2 diabetes (fasting glucose level <126 mg/dL [7.0 mmol/L] and glycated hemoglobin [HbA1c] value <6.2% while taking no glycemic therapy).,False,METHODS
1233,Diabetes remission occurs less in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,Secondary measures included weight and components of the metabolic syndrome.,False,METHODS
1234,Diabetes remission occurs less in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,"Analysis was by intention-to-treat.   
",False,METHODS
1235,Diabetes remission occurs less in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,"RESULTS Of the 60 patients enrolled, 55 (92%) completed the 2-year follow-up.",False,RESULTS
1236,Diabetes remission occurs less in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,Remission of type 2 diabetes was achieved by 22 (73%) in the surgical group and 4 (13%) in the conventional-therapy group.,True,RESULTS
1237,Diabetes remission occurs less in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,"Relative risk of remission for the surgical group was 5.5 (95% confidence interval, 2.2-14.0).",True,RESULTS
1238,Diabetes remission occurs less in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,"Surgical and conventional-therapy groups lost a mean (SD) of 20.7% (8.6%) and 1.7% (5.2%) of weight, respectively, at 2 years (P < .001).",False,RESULTS
1239,Diabetes remission occurs less in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,"Remission of type 2 diabetes was related to weight loss (R2 = 0.46, P < .001) and lower baseline HbA1c levels (combined R2 = 0.52, P < .001).",False,RESULTS
1240,Diabetes remission occurs less in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,"There were no serious complications in either group.   
",False,RESULTS
1241,Diabetes remission occurs less in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,CONCLUSIONS Participants randomized to surgical therapy were more likely to achieve remission of type 2 diabetes through greater weight loss.,True,CONCLUSIONS
1242,Diabetes remission occurs less in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,"These results need to be confirmed in a larger, more diverse population and have long-term efficacy assessed.   
",False,CONCLUSIONS
1243,Diabetes remission occurs less in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,TRIAL REGISTRATION actr.org Identifier: ACTRN012605000159651.,False,CONCLUSIONS
1244,Diabetes remission occurs more in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,"CONTEXT Observational studies suggest that surgically induced loss of weight may be effective therapy for type 2 diabetes.   
",False,BACKGROUND
1245,Diabetes remission occurs more in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,"OBJECTIVE To determine if surgically induced weight loss results in better glycemic control and less need for diabetes medications than conventional approaches to weight loss and diabetes control.   
",False,OBJECTIVE
1246,Diabetes remission occurs more in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,"DESIGN, SETTING, AND PARTICIPANTS Unblinded randomized controlled trial conducted from December 2002 through December 2006 at the University Obesity Research Center in Australia, with general community recruitment to established treatment programs.",False,METHODS
1247,Diabetes remission occurs more in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,"Participants were 60 obese patients (BMI >30 and <40) with recently diagnosed (<2 years) type 2 diabetes.   
",False,METHODS
1248,Diabetes remission occurs more in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,"INTERVENTIONS Conventional diabetes therapy with a focus on weight loss by lifestyle change vs laparoscopic adjustable gastric banding with conventional diabetes care.   
",False,METHODS
1249,Diabetes remission occurs more in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,MAIN OUTCOME MEASURES Remission of type 2 diabetes (fasting glucose level <126 mg/dL [7.0 mmol/L] and glycated hemoglobin [HbA1c] value <6.2% while taking no glycemic therapy).,False,METHODS
1250,Diabetes remission occurs more in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,Secondary measures included weight and components of the metabolic syndrome.,False,METHODS
1251,Diabetes remission occurs more in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,"Analysis was by intention-to-treat.   
",False,METHODS
1252,Diabetes remission occurs more in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,"RESULTS Of the 60 patients enrolled, 55 (92%) completed the 2-year follow-up.",False,RESULTS
1253,Diabetes remission occurs more in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,Remission of type 2 diabetes was achieved by 22 (73%) in the surgical group and 4 (13%) in the conventional-therapy group.,True,RESULTS
1254,Diabetes remission occurs more in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,"Relative risk of remission for the surgical group was 5.5 (95% confidence interval, 2.2-14.0).",True,RESULTS
1255,Diabetes remission occurs more in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,"Surgical and conventional-therapy groups lost a mean (SD) of 20.7% (8.6%) and 1.7% (5.2%) of weight, respectively, at 2 years (P < .001).",False,RESULTS
1256,Diabetes remission occurs more in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,"Remission of type 2 diabetes was related to weight loss (R2 = 0.46, P < .001) and lower baseline HbA1c levels (combined R2 = 0.52, P < .001).",False,RESULTS
1257,Diabetes remission occurs more in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,"There were no serious complications in either group.   
",False,RESULTS
1258,Diabetes remission occurs more in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,CONCLUSIONS Participants randomized to surgical therapy were more likely to achieve remission of type 2 diabetes through greater weight loss.,True,CONCLUSIONS
1259,Diabetes remission occurs more in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,"These results need to be confirmed in a larger, more diverse population and have long-term efficacy assessed.   
",False,CONCLUSIONS
1260,Diabetes remission occurs more in people treated with conventional therapy than in people treated with laparoscopic adjustable gastric banding surgery.,TRIAL REGISTRATION actr.org Identifier: ACTRN012605000159651.,False,CONCLUSIONS
1261,Diabetic patients with acute coronary syndrome experience decreased short-term and long-term risk for bleeding events.,"BACKGROUND Although unstable coronary artery disease is the most common reason for admission to a coronary care unit, the long-term prognosis of patients with this diagnosis is unknown.",False,BACKGROUND
1262,Diabetic patients with acute coronary syndrome experience decreased short-term and long-term risk for bleeding events.,"This is particularly true for patients with diabetes mellitus, who are known to have a high morbidity and mortality after an acute myocardial infarction.   
",False,BACKGROUND
1263,Diabetic patients with acute coronary syndrome experience decreased short-term and long-term risk for bleeding events.,METHODS AND RESULTS Prospectively collected data from 6 different countries in the Organization to Assess Strategies for Ischemic Syndromes (OASIS) registry were analyzed to determine the 2-year prognosis of diabetic and nondiabetic patients who were hospitalized with unstable angina or non-Q-wave myocardial infarction.,False,METHODS
1264,Diabetic patients with acute coronary syndrome experience decreased short-term and long-term risk for bleeding events.,"Overall, 1718 of 8013 registry patients (21%) had diabetes.",False,RESULTS
1265,Diabetic patients with acute coronary syndrome experience decreased short-term and long-term risk for bleeding events.,"Diabetic patients had a higher rate of coronary bypass surgery than nondiabetic patients (23% versus 20%, P:<0.001) but had similar rates of catheterization and angioplasty.",False,RESULTS
1266,Diabetic patients with acute coronary syndrome experience decreased short-term and long-term risk for bleeding events.,"Diabetes independently predicted mortality (relative risk [RR], 1.57; 95% CI, 1.38 to 1.81; P:<0.001), as well as cardiovascular death, new myocardial infarction, stroke, and new congestive heart failure.",True,RESULTS
1267,Diabetic patients with acute coronary syndrome experience decreased short-term and long-term risk for bleeding events.,"Moreover, compared with their nondiabetic counterparts, women had a significantly higher risk than men (RR, 1.98; 95% CI, 1.60 to 2.44; and RR, 1.28; 95% CI, 1.06 to 1.56, respectively).",False,RESULTS
1268,Diabetic patients with acute coronary syndrome experience decreased short-term and long-term risk for bleeding events.,"Interestingly, diabetic patients without prior cardiovascular disease had the same event rates for all outcomes as nondiabetic patients with previous vascular disease.   
",False,RESULTS
1269,Diabetic patients with acute coronary syndrome experience decreased short-term and long-term risk for bleeding events.,CONCLUSIONS Hospitalization for unstable angina or non-Q-wave myocardial infarction predicts a high 2-year morbidity and mortality; this is especially evident for patients with diabetes.,False,CONCLUSIONS
1270,Diabetic patients with acute coronary syndrome experience decreased short-term and long-term risk for bleeding events.,Diabetic patients with no previous cardiovascular disease have the same long-term morbidity and mortality as nondiabetic patients with established cardiovascular disease after hospitalization for unstable coronary artery disease.,False,CONCLUSIONS
1271,Differentiation of progenitor cells to myeloid cells is skewed upon activation of insulin signaling.,"The Drosophila lymph gland is a haematopoietic organ in which progenitor cells, which are most akin to the common myeloid progenitor in mammals, proliferate and differentiate into three types of mature cell--plasmatocytes, crystal cells and lamellocytes--the functions of which are reminiscent of mammalian myeloid cells.",False,BACKGROUND
1272,Differentiation of progenitor cells to myeloid cells is skewed upon activation of insulin signaling.,"During the first and early second instars of larval development, the lymph gland contains only progenitors, whereas in the third instar, a medial region of the primary lobe of the lymph gland called the medullary zone contains these progenitors, and maturing blood cells are found juxtaposed in a peripheral region designated the cortical zone.",False,METHODS
1273,Differentiation of progenitor cells to myeloid cells is skewed upon activation of insulin signaling.,A third group of cells referred to as the posterior signalling centre functions as a haematopoietic niche.,False,METHODS
1274,Differentiation of progenitor cells to myeloid cells is skewed upon activation of insulin signaling.,"Similarly to mammalian myeloid cells, Drosophila blood cells respond to multiple stresses including hypoxia, infection and oxidative stress.",False,RESULTS
1275,Differentiation of progenitor cells to myeloid cells is skewed upon activation of insulin signaling.,"However, how systemic signals are sensed by myeloid progenitors to regulate cell-fate determination has not been well described.",False,RESULTS
1276,Differentiation of progenitor cells to myeloid cells is skewed upon activation of insulin signaling.,"Here, we show that the haematopoietic progenitors of Drosophila are direct targets of systemic (insulin) and nutritional (essential amino acid) signals, and that these systemic signals maintain the progenitors by promoting Wingless (WNT in mammals) signalling.",True,CONCLUSIONS
1277,Differentiation of progenitor cells to myeloid cells is skewed upon activation of insulin signaling.,We expect that this study will promote investigation of such possible direct signal sensing mechanisms by mammalian myeloid progenitors.,False,CONCLUSIONS
1278,Differentiation of progenitor cells to myeloid cells is skewed when insulin signaling is suppressed.,"The Drosophila lymph gland is a haematopoietic organ in which progenitor cells, which are most akin to the common myeloid progenitor in mammals, proliferate and differentiate into three types of mature cell--plasmatocytes, crystal cells and lamellocytes--the functions of which are reminiscent of mammalian myeloid cells.",False,BACKGROUND
1279,Differentiation of progenitor cells to myeloid cells is skewed when insulin signaling is suppressed.,"During the first and early second instars of larval development, the lymph gland contains only progenitors, whereas in the third instar, a medial region of the primary lobe of the lymph gland called the medullary zone contains these progenitors, and maturing blood cells are found juxtaposed in a peripheral region designated the cortical zone.",False,METHODS
1280,Differentiation of progenitor cells to myeloid cells is skewed when insulin signaling is suppressed.,A third group of cells referred to as the posterior signalling centre functions as a haematopoietic niche.,False,METHODS
1281,Differentiation of progenitor cells to myeloid cells is skewed when insulin signaling is suppressed.,"Similarly to mammalian myeloid cells, Drosophila blood cells respond to multiple stresses including hypoxia, infection and oxidative stress.",False,RESULTS
1282,Differentiation of progenitor cells to myeloid cells is skewed when insulin signaling is suppressed.,"However, how systemic signals are sensed by myeloid progenitors to regulate cell-fate determination has not been well described.",False,RESULTS
1283,Differentiation of progenitor cells to myeloid cells is skewed when insulin signaling is suppressed.,"Here, we show that the haematopoietic progenitors of Drosophila are direct targets of systemic (insulin) and nutritional (essential amino acid) signals, and that these systemic signals maintain the progenitors by promoting Wingless (WNT in mammals) signalling.",True,CONCLUSIONS
1284,Differentiation of progenitor cells to myeloid cells is skewed when insulin signaling is suppressed.,We expect that this study will promote investigation of such possible direct signal sensing mechanisms by mammalian myeloid progenitors.,False,CONCLUSIONS
1285,Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.,"Importance Despite lack of evidence of their utility, biomarkers of ovarian reserve are being promoted as potential markers of reproductive potential.",False,BACKGROUND
1286,Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.,Objective To determine the associations between biomarkers of ovarian reserve and reproductive potential among women of late reproductive age.,False,OBJECTIVE
1287,Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.,"Design, Setting, and Participants Prospective time-to-pregnancy cohort study (2008 to date of last follow-up in March 2016) of women (N = 981) aged 30 to 44 years without a history of infertility who had been trying to conceive for 3 months or less, recruited from the community in the Raleigh-Durham, North Carolina, area.",False,METHODS
1288,Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.,"Exposures Early-follicular-phase serum level of antimüllerian hormone (AMH), follicle-stimulating hormone (FSH), and inhibin B and urinary level of FSH.",False,METHODS
1289,Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.,Main Outcomes and Measures The primary outcomes were the cumulative probability of conception by 6 and 12 cycles of attempt and relative fecundability (probability of conception in a given menstrual cycle).,False,METHODS
1290,Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.,Conception was defined as a positive pregnancy test result.,False,METHODS
1291,Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.,"Results A total of 750 women (mean age, 33.3 [SD, 3.2] years; 77% white; 36% overweight or obese) provided a blood and urine sample and were included in the analysis.",False,RESULTS
1292,Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.,"After adjusting for age, body mass index, race, current smoking status, and recent hormonal contraceptive use, women with low AMH values (<0.7 ng/mL [n = 84]) did not have a significantly different predicted probability of conceiving by 6 cycles of attempt (65%; 95% CI, 50%-75%) compared with women (n = 579) with normal values (62%; 95% CI, 57%-66%) or by 12 cycles of attempt (84% [95% CI, 70%-91%] vs 75% [95% CI, 70%-79%], respectively).",True,RESULTS
1293,Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.,"Women with high serum FSH values (>10 mIU/mL [n = 83]) did not have a significantly different predicted probability of conceiving after 6 cycles of attempt (63%; 95% CI, 50%-73%) compared with women (n = 654) with normal values (62%; 95% CI, 57%-66%) or after 12 cycles of attempt (82% [95% CI, 70%-89%] vs 75% [95% CI, 70%-78%], respectively).",True,RESULTS
1294,Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.,"Women with high urinary FSH values (>11.5 mIU/mg creatinine [n = 69]) did not have a significantly different predicted probability of conceiving after 6 cycles of attempt (61%; 95% CI, 46%-74%) compared with women (n = 660) with normal values (62%; 95% CI, 58%-66%) or after 12 cycles of attempt (70% [95% CI, 54%-80%] vs 76% [95% CI, 72%-80%], respectively).",True,RESULTS
1295,Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.,"Inhibin B levels (n = 737) were not associated with the probability of conceiving in a given cycle (hazard ratio per 1-pg/mL increase, 0.999; 95% CI, 0.997-1.001).",False,RESULTS
1296,Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.,"Conclusions and Relevance Among women aged 30 to 44 years without a history of infertility who had been trying to conceive for 3 months or less, biomarkers indicating diminished ovarian reserve compared with normal ovarian reserve were not associated with reduced fertility.",True,CONCLUSIONS
1297,Diminished ovarian reserve is a reliable indicator of infertility in a non-infertile population.,These findings do not support the use of urinary or blood follicle-stimulating hormone tests or antimüllerian hormone levels to assess natural fertility for women with these characteristics.,False,CONCLUSIONS
1298,Drosophila supracellular actomyosin structures are found at boundaries in wing imaginal discs.,Subdividing proliferating tissues into compartments is an evolutionarily conserved strategy of animal development [1-6].,False,BACKGROUND
1299,Drosophila supracellular actomyosin structures are found at boundaries in wing imaginal discs.,Signals across boundaries between compartments can result in local expression of secreted proteins organizing growth and patterning of tissues [1-6].,False,BACKGROUND
1300,Drosophila supracellular actomyosin structures are found at boundaries in wing imaginal discs.,Sharp and straight interfaces between compartments are crucial for stabilizing the position of such organizers and therefore for precise implementation of body plans.,False,BACKGROUND
1301,Drosophila supracellular actomyosin structures are found at boundaries in wing imaginal discs.,"Maintaining boundaries in proliferating tissues requires mechanisms to counteract cell rearrangements caused by cell division; however, the nature of such mechanisms remains unclear.",False,BACKGROUND
1302,Drosophila supracellular actomyosin structures are found at boundaries in wing imaginal discs.,Here we quantitatively analyzed cell morphology and the response to the laser ablation of cell bonds in the vicinity of the anteroposterior compartment boundary in developing Drosophila wings.,False,METHODS
1303,Drosophila supracellular actomyosin structures are found at boundaries in wing imaginal discs.,We found that mechanical tension is approximately 2.5-fold increased on cell bonds along this compartment boundary as compared to the remaining tissue.,False,RESULTS
1304,Drosophila supracellular actomyosin structures are found at boundaries in wing imaginal discs.,"Cell bond tension is decreased in the presence of Y-27632 [7], an inhibitor of Rho-kinase whose main effector is Myosin II [8].",False,RESULTS
1305,Drosophila supracellular actomyosin structures are found at boundaries in wing imaginal discs.,Simulations using a vertex model [9] demonstrate that a 2.5-fold increase in local cell bond tension suffices to guide the rearrangement of cells after cell division to maintain compartment boundaries.,False,RESULTS
1306,Drosophila supracellular actomyosin structures are found at boundaries in wing imaginal discs.,Our results provide a physical mechanism in which the local increase in Myosin II-dependent cell bond tension directs cell sorting at compartment boundaries.,True,CONCLUSIONS
1307,Drosophila supracellular actomyosin structures are found at boundaries in wing imaginal discs.,"As organisms develop, their tissues can become separated into distinct cell populations through the establishment of compartment boundaries.",False,BACKGROUND
1308,Drosophila supracellular actomyosin structures are found at boundaries in wing imaginal discs.,"Compartment boundaries have been discovered in a wide variety of tissues, but in many cases the molecular mechanisms that separate cells remain poorly understood.",False,BACKGROUND
1309,Drosophila supracellular actomyosin structures are found at boundaries in wing imaginal discs.,"In the Drosophila wing, a stripe of Notch activation maintains the dorsal-ventral compartment boundary, through a process that depends on the actin cytoskeleton.",False,BACKGROUND
1310,Drosophila supracellular actomyosin structures are found at boundaries in wing imaginal discs.,"Here, we show that the dorsal-ventral boundary exhibits a distinct accumulation of Myosin II, and that this accumulation is regulated downstream of Notch signaling.",True,RESULTS
1311,Drosophila supracellular actomyosin structures are found at boundaries in wing imaginal discs.,"Conversely, the dorsal-ventral boundary is depleted for the Par-3 homologue Bazooka.",False,RESULTS
1312,Drosophila supracellular actomyosin structures are found at boundaries in wing imaginal discs.,We further show that mutations in the Myosin heavy chain subunit encoded by zipper can impair dorsal-ventral compartmentalization without affecting anterior-posterior compartmentalization.,False,CONCLUSIONS
1313,Drosophila supracellular actomyosin structures are found at boundaries in wing imaginal discs.,"These observations identify a distinct accumulation and requirement for Myosin activity in dorsal-ventral compartmentalization, and suggest a novel mechanism in which contractile tension along an F-actin cable at the compartment boundary contributes to compartmentalization.",False,CONCLUSIONS
1314,Dscam1 acts as a hypervariable pattern-recognition receptor for the immune system.,Activation of the insect innate immune system is dependent on a limited number of pattern recognition receptors (PRRs) capable of interacting with pathogen-associated molecular pattern.,False,BACKGROUND
1315,Dscam1 acts as a hypervariable pattern-recognition receptor for the immune system.,"Here we report a novel role of an alternatively spliced hypervariable immunoglobulin domain-encoding gene, Dscam, in generating a broad range of PRRs implicated in immune defense in the malaria vector Anopheles gambiae.",True,BACKGROUND
1316,Dscam1 acts as a hypervariable pattern-recognition receptor for the immune system.,"The mosquito Down syndrome cell adhesion molecule gene, AgDscam, has a complex genome organization with 101 exons that can produce over 31,000 potential alternative splice forms with different combinations of adhesive domains and interaction specificities.",False,RESULTS
1317,Dscam1 acts as a hypervariable pattern-recognition receptor for the immune system.,AgDscam responds to infection by producing pathogen challenge-specific splice form repertoires.,True,RESULTS
1318,Dscam1 acts as a hypervariable pattern-recognition receptor for the immune system.,Transient silencing of AgDscam compromises the mosquito's resistance to infections with bacteria and the malaria parasite Plasmodium.,False,CONCLUSIONS
1319,Dscam1 acts as a hypervariable pattern-recognition receptor for the immune system.,AgDscam is mediating phagocytosis of bacteria with which it can associate and defend against in a splice form–specific manner.,True,CONCLUSIONS
1320,Dscam1 acts as a hypervariable pattern-recognition receptor for the immune system.,AgDscam is a hypervariable PRR of the A. gambiae innate immune system.,True,CONCLUSIONS
1321,ERAP1 SNPs are epistatic to HLA alleles for ankylosing spondylitis.,"Ankylosing spondylitis (AS) is a common, highly heritable, inflammatory arthritis for which HLA-B*27 is the major genetic risk factor, although its role in the aetiology of AS remains elusive.",False,BACKGROUND
1322,ERAP1 SNPs are epistatic to HLA alleles for ankylosing spondylitis.,"To better understand the genetic basis of the MHC susceptibility loci, we genotyped 7,264 MHC SNPs in 22,647 AS cases and controls of European descent.",False,METHODS
1323,ERAP1 SNPs are epistatic to HLA alleles for ankylosing spondylitis.,"We impute SNPs, classical HLA alleles and amino-acid residues within HLA proteins, and tested these for association to AS status.",False,METHODS
1324,ERAP1 SNPs are epistatic to HLA alleles for ankylosing spondylitis.,"Here we show that in addition to effects due to HLA-B*27 alleles, several other HLA-B alleles also affect susceptibility.",False,RESULTS
1325,ERAP1 SNPs are epistatic to HLA alleles for ankylosing spondylitis.,"After controlling for the associated haplotypes in HLA-B, we observe independent associations with variants in the HLA-A, HLA-DPB1 and HLA-DRB1 loci.",False,RESULTS
1326,ERAP1 SNPs are epistatic to HLA alleles for ankylosing spondylitis.,We also demonstrate that the ERAP1 SNP rs30187 association is not restricted only to carriers of HLA-B*27 but also found in HLA-B*40:01 carriers independently of HLA-B*27 genotype.,True,RESULTS
1327,Early patent ductus ateriosus (PDA) screening decreases in-hospital mortality.,IMPORTANCE There is currently no consensus for the screening and treatment of patent ductus arteriosus (PDA) in extremely preterm infants.,False,OBJECTIVE
1328,Early patent ductus ateriosus (PDA) screening decreases in-hospital mortality.,"Less pharmacological closure and more supportive management have been observed without evidence to support these changes.   
",False,OBJECTIVE
1329,Early patent ductus ateriosus (PDA) screening decreases in-hospital mortality.,"OBJECTIVE To evaluate the association between early screening echocardiography for PDA and in-hospital mortality.   
",False,OBJECTIVE
1330,Early patent ductus ateriosus (PDA) screening decreases in-hospital mortality.,"DESIGN, SETTING, AND PARTICIPANTS Comparison of screened and not screened preterm infants enrolled in the EPIPAGE 2 national prospective population-based cohort study that included all preterm infants born at less than 29 weeks of gestation and hospitalized in 68 neonatal intensive care units in France from April through December 2011.",False,METHODS
1331,Early patent ductus ateriosus (PDA) screening decreases in-hospital mortality.,"Two main analyses were performed to adjust for potential selection bias, one using propensity score matching and one using neonatal unit preference for early screening echocardiography as an instrumental variable.   ",False,METHODS
1332,Early patent ductus ateriosus (PDA) screening decreases in-hospital mortality.,"EXPOSURES Early screening echocardiography before day 3 of life.   
",False,METHODS
1333,Early patent ductus ateriosus (PDA) screening decreases in-hospital mortality.,MAIN OUTCOMES AND MEASURES The primary outcome was death between day 3 and discharge.,False,METHODS
1334,Early patent ductus ateriosus (PDA) screening decreases in-hospital mortality.,"The secondary outcomes were major neonatal morbidities (pulmonary hemorrhage, severe bronchopulmonary dysplasia, severe cerebral lesions, and necrotizing enterocolitis).   
",False,METHODS
1335,Early patent ductus ateriosus (PDA) screening decreases in-hospital mortality.,"RESULTS Among the 1513 preterm infants with data available to determine exposure, 847 were screened for PDA and 666 were not; 605 infants from each group could be paired.",False,RESULTS
1336,Early patent ductus ateriosus (PDA) screening decreases in-hospital mortality.,"Exposed infants were treated for PDA more frequently during their hospitalization than nonexposed infants (55.1% vs 43.1%; odds ratio [OR], 1.62 [95% CI, 1.31 to 2.00]; absolute risk reduction [ARR] in events per 100 infants, -12.0 [95% CI, -17.3 to -6.7).",False,RESULTS
1337,Early patent ductus ateriosus (PDA) screening decreases in-hospital mortality.,"Exposed infants had a lower hospital death rate (14.2% vs 18.5% ; OR, 0.73 [95% CI, 0.54 to 0.98]; ARR, 4.3 [95% CI, 0.3 to 8.3]) and a lower rate of pulmonary hemorrhage (5.6% vs 8.9%; OR, 0.60 [95% CI, 0.38 to 0.95]; ARR, 3.3 [95% CI, 0.4 to 6.3]).",True,RESULTS
1338,Early patent ductus ateriosus (PDA) screening decreases in-hospital mortality.,"No differences in rates of necrotizing enterocolitis, severe bronchopulmonary dysplasia, or severe cerebral lesions were observed.",False,RESULTS
1339,Early patent ductus ateriosus (PDA) screening decreases in-hospital mortality.,"In the overall cohort, instrumental variable analysis yielded an adjusted OR for in-hospital mortality of 0.62 [95% CI, 0.37 to 1.04].   
",False,RESULTS
1340,Early patent ductus ateriosus (PDA) screening decreases in-hospital mortality.,"CONCLUSIONS AND RELEVANCE In this national population-based cohort of extremely preterm infants, screening echocardiography before day 3 of life was associated with lower in-hospital mortality and likelihood of pulmonary hemorrhage but not with differences in necrotizing enterocolitis, severe bronchopulmonary dysplasia, or severe cerebral lesions.",True,CONCLUSIONS
1341,Early patent ductus ateriosus (PDA) screening decreases in-hospital mortality.,"However, results of the instrumental variable analysis leave some ambiguity in the interpretation, and longer-term evaluation is needed to provide clarity.",False,CONCLUSIONS
1342,Early patent ductus ateriosus (PDA) screening increases in-hospital mortality.,IMPORTANCE There is currently no consensus for the screening and treatment of patent ductus arteriosus (PDA) in extremely preterm infants.,False,OBJECTIVE
1343,Early patent ductus ateriosus (PDA) screening increases in-hospital mortality.,"Less pharmacological closure and more supportive management have been observed without evidence to support these changes.   
",False,OBJECTIVE
1344,Early patent ductus ateriosus (PDA) screening increases in-hospital mortality.,"OBJECTIVE To evaluate the association between early screening echocardiography for PDA and in-hospital mortality.   
",False,OBJECTIVE
1345,Early patent ductus ateriosus (PDA) screening increases in-hospital mortality.,"DESIGN, SETTING, AND PARTICIPANTS Comparison of screened and not screened preterm infants enrolled in the EPIPAGE 2 national prospective population-based cohort study that included all preterm infants born at less than 29 weeks of gestation and hospitalized in 68 neonatal intensive care units in France from April through December 2011.",False,METHODS
1346,Early patent ductus ateriosus (PDA) screening increases in-hospital mortality.,"Two main analyses were performed to adjust for potential selection bias, one using propensity score matching and one using neonatal unit preference for early screening echocardiography as an instrumental variable.   ",False,METHODS
1347,Early patent ductus ateriosus (PDA) screening increases in-hospital mortality.,"EXPOSURES Early screening echocardiography before day 3 of life.   
",False,METHODS
1348,Early patent ductus ateriosus (PDA) screening increases in-hospital mortality.,MAIN OUTCOMES AND MEASURES The primary outcome was death between day 3 and discharge.,False,METHODS
1349,Early patent ductus ateriosus (PDA) screening increases in-hospital mortality.,"The secondary outcomes were major neonatal morbidities (pulmonary hemorrhage, severe bronchopulmonary dysplasia, severe cerebral lesions, and necrotizing enterocolitis).   
",False,METHODS
1350,Early patent ductus ateriosus (PDA) screening increases in-hospital mortality.,"RESULTS Among the 1513 preterm infants with data available to determine exposure, 847 were screened for PDA and 666 were not; 605 infants from each group could be paired.",False,RESULTS
1351,Early patent ductus ateriosus (PDA) screening increases in-hospital mortality.,"Exposed infants were treated for PDA more frequently during their hospitalization than nonexposed infants (55.1% vs 43.1%; odds ratio [OR], 1.62 [95% CI, 1.31 to 2.00]; absolute risk reduction [ARR] in events per 100 infants, -12.0 [95% CI, -17.3 to -6.7).",False,RESULTS
1352,Early patent ductus ateriosus (PDA) screening increases in-hospital mortality.,"Exposed infants had a lower hospital death rate (14.2% vs 18.5% ; OR, 0.73 [95% CI, 0.54 to 0.98]; ARR, 4.3 [95% CI, 0.3 to 8.3]) and a lower rate of pulmonary hemorrhage (5.6% vs 8.9%; OR, 0.60 [95% CI, 0.38 to 0.95]; ARR, 3.3 [95% CI, 0.4 to 6.3]).",True,RESULTS
1353,Early patent ductus ateriosus (PDA) screening increases in-hospital mortality.,"No differences in rates of necrotizing enterocolitis, severe bronchopulmonary dysplasia, or severe cerebral lesions were observed.",False,RESULTS
1354,Early patent ductus ateriosus (PDA) screening increases in-hospital mortality.,"In the overall cohort, instrumental variable analysis yielded an adjusted OR for in-hospital mortality of 0.62 [95% CI, 0.37 to 1.04].   
",False,RESULTS
1355,Early patent ductus ateriosus (PDA) screening increases in-hospital mortality.,"CONCLUSIONS AND RELEVANCE In this national population-based cohort of extremely preterm infants, screening echocardiography before day 3 of life was associated with lower in-hospital mortality and likelihood of pulmonary hemorrhage but not with differences in necrotizing enterocolitis, severe bronchopulmonary dysplasia, or severe cerebral lesions.",True,CONCLUSIONS
1356,Early patent ductus ateriosus (PDA) screening increases in-hospital mortality.,"However, results of the instrumental variable analysis leave some ambiguity in the interpretation, and longer-term evaluation is needed to provide clarity.",False,CONCLUSIONS
1357,"Ectopic expression of Sall4, Nanog, Esrrb, and Lin28 generates induced pluripotent stem cells from mouse embryonic fibroblasts more efficiently than other factor combinations.","Induced pluripotent stem cells (iPSCs) are commonly generated by transduction of Oct4, Sox2, Klf4, and Myc (OSKM) into cells.",False,BACKGROUND
1358,"Ectopic expression of Sall4, Nanog, Esrrb, and Lin28 generates induced pluripotent stem cells from mouse embryonic fibroblasts more efficiently than other factor combinations.","Although iPSCs are pluripotent, they frequently exhibit high variation in terms of quality, as measured in mice by chimera contribution and tetraploid complementation.",False,BACKGROUND
1359,"Ectopic expression of Sall4, Nanog, Esrrb, and Lin28 generates induced pluripotent stem cells from mouse embryonic fibroblasts more efficiently than other factor combinations.",Reliably high-quality iPSCs will be needed for future therapeutic applications.,False,BACKGROUND
1360,"Ectopic expression of Sall4, Nanog, Esrrb, and Lin28 generates induced pluripotent stem cells from mouse embryonic fibroblasts more efficiently than other factor combinations.","Here, we show that one major determinant of iPSC quality is the combination of reprogramming factors used.",False,BACKGROUND
1361,"Ectopic expression of Sall4, Nanog, Esrrb, and Lin28 generates induced pluripotent stem cells from mouse embryonic fibroblasts more efficiently than other factor combinations.","Based on tetraploid complementation, we found that ectopic expression of Sall4, Nanog, Esrrb, and Lin28 (SNEL) in mouse embryonic fibroblasts (MEFs) generated high-quality iPSCs more efficiently than other combinations of factors including OSKM.",True,RESULTS
1362,"Ectopic expression of Sall4, Nanog, Esrrb, and Lin28 generates induced pluripotent stem cells from mouse embryonic fibroblasts more efficiently than other factor combinations.","Although differentially methylated regions, transcript number of master regulators, establishment of specific superenhancers, and global aneuploidy were comparable between high- and low-quality lines, aberrant gene expression, trisomy of chromosome 8, and abnormal H2A.X deposition were distinguishing features that could potentially also be applicable to human.",False,RESULTS
1363,Egr2 regulates the homeostasis of B and T cells.,Lymphocytes provide optimal responses against pathogens with minimal inflammatory pathology.,False,BACKGROUND
1364,Egr2 regulates the homeostasis of B and T cells.,"However, the intrinsic mechanisms regulating these responses are unknown.",False,BACKGROUND
1365,Egr2 regulates the homeostasis of B and T cells.,"Here, we report that deletion of both transcription factors Egr2 and Egr3 in lymphocytes resulted in a lethal autoimmune syndrome with excessive serum proinflammatory cytokines but also impaired antigen receptor-induced proliferation of B and T cells.",True,BACKGROUND
1366,Egr2 regulates the homeostasis of B and T cells.,Egr2- and Egr3-defective B and T cells had hyperactive signal transducer and activator of transcription-1 (STAT1) and STAT3 while antigen receptor-induced activation of transcription factor AP-1 was severely impaired.,True,RESULTS
1367,Egr2 regulates the homeostasis of B and T cells.,"We discovered that Egr2 and/or Egr3 directly induced expression of suppressor of cytokine signaling-1 (SOCS1) and SOCS3, inhibitors of STAT1 and STAT3, and also blocked the function of Batf, an AP-1 inhibitor, in B and T cells.",True,RESULTS
1368,Egr2 regulates the homeostasis of B and T cells.,"Thus, Egr2 and Egr3 regulate B and T cell function in adaptive immune responses and homeostasis by promoting antigen receptor signaling and controlling inflammation.",True,RESULTS
1369,Egr3 regulates the homeostasis of B and T cells.,Lymphocytes provide optimal responses against pathogens with minimal inflammatory pathology.,False,BACKGROUND
1370,Egr3 regulates the homeostasis of B and T cells.,"However, the intrinsic mechanisms regulating these responses are unknown.",False,BACKGROUND
1371,Egr3 regulates the homeostasis of B and T cells.,"Here, we report that deletion of both transcription factors Egr2 and Egr3 in lymphocytes resulted in a lethal autoimmune syndrome with excessive serum proinflammatory cytokines but also impaired antigen receptor-induced proliferation of B and T cells.",True,BACKGROUND
1372,Egr3 regulates the homeostasis of B and T cells.,Egr2- and Egr3-defective B and T cells had hyperactive signal transducer and activator of transcription-1 (STAT1) and STAT3 while antigen receptor-induced activation of transcription factor AP-1 was severely impaired.,True,RESULTS
1373,Egr3 regulates the homeostasis of B and T cells.,"We discovered that Egr2 and/or Egr3 directly induced expression of suppressor of cytokine signaling-1 (SOCS1) and SOCS3, inhibitors of STAT1 and STAT3, and also blocked the function of Batf, an AP-1 inhibitor, in B and T cells.",True,RESULTS
1374,Egr3 regulates the homeostasis of B and T cells.,"Thus, Egr2 and Egr3 regulate B and T cell function in adaptive immune responses and homeostasis by promoting antigen receptor signaling and controlling inflammation.",True,RESULTS
1375,Eilat virus (EILV) produced in mosquitos elicits rapid and long-lasting neutralizing antibodies in nonhuman primates.,"Traditionally, vaccine development involves tradeoffs between immunogenicity and safety.",False,BACKGROUND
1376,Eilat virus (EILV) produced in mosquitos elicits rapid and long-lasting neutralizing antibodies in nonhuman primates.,Live-attenuated vaccines typically offer rapid and durable immunity but have reduced safety when compared to inactivated vaccines.,False,BACKGROUND
1377,Eilat virus (EILV) produced in mosquitos elicits rapid and long-lasting neutralizing antibodies in nonhuman primates.,"In contrast, the inability of inactivated vaccines to replicate enhances safety at the expense of immunogenicity, often necessitating multiple doses and boosters.",False,BACKGROUND
1378,Eilat virus (EILV) produced in mosquitos elicits rapid and long-lasting neutralizing antibodies in nonhuman primates.,"To overcome these tradeoffs, we developed the insect-specific alphavirus, Eilat virus (EILV), as a vaccine platform.",False,BACKGROUND
1379,Eilat virus (EILV) produced in mosquitos elicits rapid and long-lasting neutralizing antibodies in nonhuman primates.,"To address the chikungunya fever (CHIKF) pandemic, we used an EILV cDNA clone to design a chimeric virus containing the chikungunya virus (CHIKV) structural proteins.",False,METHODS
1380,Eilat virus (EILV) produced in mosquitos elicits rapid and long-lasting neutralizing antibodies in nonhuman primates.,"The recombinant EILV/CHIKV was structurally identical at 10 Å to wild-type CHIKV, as determined by single-particle cryo-electron microscopy, and it mimicked the early stages of CHIKV replication in vertebrate cells from attachment and entry to viral RNA delivery.",False,RESULTS
1381,Eilat virus (EILV) produced in mosquitos elicits rapid and long-lasting neutralizing antibodies in nonhuman primates.,"Yet the recombinant virus remained completely defective for productive replication, providing a high degree of safety.",False,RESULTS
1382,Eilat virus (EILV) produced in mosquitos elicits rapid and long-lasting neutralizing antibodies in nonhuman primates.,A single dose of EILV/CHIKV produced in mosquito cells elicited rapid (within 4 d) and long-lasting (>290 d) neutralizing antibodies that provided complete protection in two different mouse models.,True,RESULTS
1383,Eilat virus (EILV) produced in mosquitos elicits rapid and long-lasting neutralizing antibodies in nonhuman primates.,"In nonhuman primates, EILV/CHIKV elicited rapid and robust immunity that protected against viremia and telemetrically monitored fever.",True,CONCLUSIONS
1384,Eilat virus (EILV) produced in mosquitos elicits rapid and long-lasting neutralizing antibodies in nonhuman primates.,Our EILV platform represents the first structurally native application of an insect-specific virus in preclinical vaccine development and highlights the potential application of such viruses in vaccinology.,False,CONCLUSIONS
1385,Elevated cell-free mitochondrial DNA levels are associated with mortality.,BACKGROUND Mitochondrial DNA (mtDNA) is a critical activator of inflammation and the innate immune system.,False,BACKGROUND
1386,Elevated cell-free mitochondrial DNA levels are associated with mortality.,"However, mtDNA level has not been tested for its role as a biomarker in the intensive care unit (ICU).",False,BACKGROUND
1387,Elevated cell-free mitochondrial DNA levels are associated with mortality.,"We hypothesized that circulating cell-free mtDNA levels would be associated with mortality and improve risk prediction in ICU patients.   
",False,BACKGROUND
1388,Elevated cell-free mitochondrial DNA levels are associated with mortality.,"METHODS AND FINDINGS Analyses of mtDNA levels were performed on blood samples obtained from two prospective observational cohort studies of ICU patients (the Brigham and Women's Hospital Registry of Critical Illness [BWH RoCI, n = 200] and Molecular Epidemiology of Acute Respiratory Distress Syndrome [ME ARDS, n = 243]).",False,METHODS
1389,Elevated cell-free mitochondrial DNA levels are associated with mortality.,mtDNA levels in plasma were assessed by measuring the copy number of the NADH dehydrogenase 1 gene using quantitative real-time PCR.,False,METHODS
1390,Elevated cell-free mitochondrial DNA levels are associated with mortality.,"Medical ICU patients with an elevated mtDNA level (≥3,200 copies/µl plasma) had increased odds of dying within 28 d of ICU admission in both the BWH RoCI (odds ratio [OR] 7.5, 95% CI 3.6-15.8, p = 1×10(-7)) and ME ARDS (OR 8.4, 95% CI 2.9-24.2, p = 9×10(-5)) cohorts, while no evidence for association was noted in non-medical ICU patients.",True,RESULTS
1391,Elevated cell-free mitochondrial DNA levels are associated with mortality.,"The addition of an elevated mtDNA level improved the net reclassification index (NRI) of 28-d mortality among medical ICU patients when added to clinical models in both the BWH RoCI (NRI 79%, standard error 14%, p<1×10(-4)) and ME ARDS (NRI 55%, standard error 20%, p = 0.007) cohorts.",False,RESULTS
1392,Elevated cell-free mitochondrial DNA levels are associated with mortality.,"In the BWH RoCI cohort, those with an elevated mtDNA level had an increased risk of death, even in analyses limited to patients with sepsis or acute respiratory distress syndrome.",True,RESULTS
1393,Elevated cell-free mitochondrial DNA levels are associated with mortality.,"Study limitations include the lack of data elucidating the concise pathological roles of mtDNA in the patients, and the limited numbers of measurements for some of biomarkers.   
",False,CONCLUSIONS
1394,Elevated cell-free mitochondrial DNA levels are associated with mortality.,"CONCLUSIONS Increased mtDNA levels are associated with ICU mortality, and inclusion of mtDNA level improves risk prediction in medical ICU patients.",True,CONCLUSIONS
1395,Elevated cell-free mitochondrial DNA levels are associated with mortality.,Our data suggest that mtDNA could serve as a viable plasma biomarker in medical ICU patients.,False,CONCLUSIONS
1396,Energy balance requires hypothalamic glutamate neurotransmission.,The melanocortin receptor 4 (MC4R) is a well-established mediator of body weight homeostasis.,False,BACKGROUND
1397,Energy balance requires hypothalamic glutamate neurotransmission.,"However, the neurotransmitter(s) that mediate MC4R function remain largely unknown; as a result, little is known about the second-order neurons of the MC4R neural pathway.",False,BACKGROUND
1398,Energy balance requires hypothalamic glutamate neurotransmission.,"Single-minded 1 (Sim1)-expressing brain regions, which include the paraventricular nucleus of hypothalamus (PVH), represent key brain sites that mediate melanocortin action.",False,METHODS
1399,Energy balance requires hypothalamic glutamate neurotransmission.,We conditionally restored MC4R expression in Sim1 neurons in the background of Mc4r-null mice.,False,METHODS
1400,Energy balance requires hypothalamic glutamate neurotransmission.,The restoration dramatically reduced obesity in Mc4r-null mice.,False,RESULTS
1401,Energy balance requires hypothalamic glutamate neurotransmission.,The anti-obesity effect was completely reversed by selective disruption of glutamate release from those same Sim1 neurons.,True,RESULTS
1402,Energy balance requires hypothalamic glutamate neurotransmission.,The reversal was caused by lower energy expenditure and hyperphagia.,False,RESULTS
1403,Energy balance requires hypothalamic glutamate neurotransmission.,"Corroboratively, selective disruption of glutamate release from adult PVH neurons led to rapid obesity development via reduced energy expenditure and hyperphagia.",True,RESULTS
1404,Energy balance requires hypothalamic glutamate neurotransmission.,"Thus, this study establishes glutamate as the primary neurotransmitter that mediates MC4Rs on Sim1 neurons in body weight regulation.",True,CONCLUSIONS
1405,Energy balance requires hypothalamic glutamate neurotransmission.,AgRP neuron activity drives feeding and weight gain whereas that of nearby POMC neurons does the opposite.,False,BACKGROUND
1406,Energy balance requires hypothalamic glutamate neurotransmission.,"However, the role of excitatory glutamatergic input in controlling these neurons is unknown.",False,BACKGROUND
1407,Energy balance requires hypothalamic glutamate neurotransmission.,"To address this question, we generated mice lacking NMDA receptors (NMDARs) on either AgRP or POMC neurons.",False,BACKGROUND
1408,Energy balance requires hypothalamic glutamate neurotransmission.,"Deletion of NMDARs from AgRP neurons markedly reduced weight, body fat and food intake whereas deletion from POMC neurons had no effect.",True,RESULTS
1409,Energy balance requires hypothalamic glutamate neurotransmission.,"Activation of AgRP neurons by fasting, as assessed by c-Fos, Agrp and Npy mRNA expression, AMPA receptor-mediated EPSCs, depolarization and firing rates, required NMDARs.",True,RESULTS
1410,Energy balance requires hypothalamic glutamate neurotransmission.,"Furthermore, AgRP but not POMC neurons have dendritic spines and increased glutamatergic input onto AgRP neurons caused by fasting was paralleled by an increase in spines, suggesting fasting induced synaptogenesis and spinogenesis.",True,CONCLUSIONS
1411,Energy balance requires hypothalamic glutamate neurotransmission.,Thus glutamatergic synaptic transmission and its modulation by NMDARs play key roles in controlling AgRP neurons and determining the cellular and behavioral response to fasting.,True,CONCLUSIONS
1412,Energy balance requires hypothalamic glutamate neurotransmission.,The importance of neuropeptides in the hypothalamus has been experimentally established.,False,BACKGROUND
1413,Energy balance requires hypothalamic glutamate neurotransmission.,"Due to difficulties in assessing function in vivo, the roles of the fast-acting neurotransmitters glutamate and GABA are largely unknown.",False,BACKGROUND
1414,Energy balance requires hypothalamic glutamate neurotransmission.,"Synaptic vesicular transporters (VGLUTs for glutamate and VGAT for GABA) are required for vesicular uptake and, consequently, synaptic release of neurotransmitters.",False,BACKGROUND
1415,Energy balance requires hypothalamic glutamate neurotransmission.,Ventromedial hypothalamic (VMH) neurons are predominantly glutamatergic and express VGLUT2.,False,BACKGROUND
1416,Energy balance requires hypothalamic glutamate neurotransmission.,"To evaluate the role of glutamate release from VMH neurons, we generated mice lacking VGLUT2 selectively in SF1 neurons (a major subset of VMH neurons).",False,BACKGROUND
1417,Energy balance requires hypothalamic glutamate neurotransmission.,These mice have hypoglycemia during fasting secondary to impaired fasting-induced increases in the glucose-raising pancreatic hormone glucagon and impaired induction in liver of mRNAs encoding PGC-1alpha and the gluconeogenic enzymes PEPCK and G6Pase.,False,RESULTS
1418,Energy balance requires hypothalamic glutamate neurotransmission.,"Similarly, these mice have defective counterregulatory responses to insulin-induced hypoglycemia and 2-deoxyglucose (an antimetabolite).",False,RESULTS
1419,Energy balance requires hypothalamic glutamate neurotransmission.,"Thus, glutamate release from VMH neurons is an important component of the neurocircuitry that functions to prevent hypoglycemia.",True,RESULTS
1420,Energy balance requires hypothalamic glutamate neurotransmission.,"Glial cells perform critical functions that alter the metabolism and activity of neurons, and there is increasing interest in their role in appetite and energy balance.",False,BACKGROUND
1421,Energy balance requires hypothalamic glutamate neurotransmission.,"Leptin, a key regulator of appetite and metabolism, has previously been reported to influence glial structural proteins and morphology.",False,BACKGROUND
1422,Energy balance requires hypothalamic glutamate neurotransmission.,"Here, we demonstrate that metabolic status and leptin also modify astrocyte-specific glutamate and glucose transporters, indicating that metabolic signals influence synaptic efficacy and glucose uptake and, ultimately, neuronal function.",True,BACKGROUND
1423,Energy balance requires hypothalamic glutamate neurotransmission.,We found that basal and glucose-stimulated electrical activity of hypothalamic proopiomelanocortin (POMC) neurons in mice were altered in the offspring of mothers fed a high-fat diet.,True,RESULTS
1424,Energy balance requires hypothalamic glutamate neurotransmission.,"In adulthood, increased body weight and fasting also altered the expression of glucose and glutamate transporters.",True,RESULTS
1425,Energy balance requires hypothalamic glutamate neurotransmission.,These results demonstrate that whole-organism metabolism alters hypothalamic glial cell activity and suggest that these cells play an important role in the pathology of obesity.,False,CONCLUSIONS
1426,Enhanced early production of inflammatory chemokines damages viral control in the lung.,Inflammation induced by recognition of pathogen-associated molecular patterns markedly affects subsequent adaptive responses.,False,BACKGROUND
1427,Enhanced early production of inflammatory chemokines damages viral control in the lung.,We asked whether the adaptive immune system can also affect the character and magnitude of innate inflammatory responses.,False,BACKGROUND
1428,Enhanced early production of inflammatory chemokines damages viral control in the lung.,"We found that the response of memory, but not naive, CD4+ T cells enhances production of multiple innate inflammatory cytokines and chemokines (IICs) in the lung and that, during influenza infection, this leads to early control of virus.",True,RESULTS
1429,Enhanced early production of inflammatory chemokines damages viral control in the lung.,Memory CD4+ T cell–induced IICs and viral control require cognate antigen recognition and are optimal when memory cells are either T helper type 1 (TH1) or TH17 polarized but are independent of interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) production and do not require activation of conserved pathogen recognition pathways.,False,RESULTS
1430,Enhanced early production of inflammatory chemokines damages viral control in the lung.,This represents a previously undescribed mechanism by which memory CD4+ T cells induce an early innate response that enhances immune protection against pathogens.,False,CONCLUSIONS
1431,Environmental factors can influence the development of breast cancer.,"BACKGROUND Information is scarce about the combined effects on breast cancer incidence of low-penetrance genetic susceptibility polymorphisms and environmental factors (reproductive, behavioural, and anthropometric risk factors for breast cancer).",False,BACKGROUND
1432,Environmental factors can influence the development of breast cancer.,"To test for evidence of gene-environment interactions, we compared genotypic relative risks for breast cancer across the other risk factors in a large UK prospective study.   
",False,BACKGROUND
1433,Environmental factors can influence the development of breast cancer.,"METHODS We tested gene-environment interactions in 7610 women who developed breast cancer and 10 196 controls without the disease, studying the effects of 12 polymorphisms (FGFR2-rs2981582, TNRC9-rs3803662, 2q35-rs13387042, MAP3K1-rs889312, 8q24-rs13281615, 2p-rs4666451, 5p12-rs981782, CASP8-rs1045485, LSP1-rs3817198, 5q-rs30099, TGFB1-rs1982073, and ATM-rs1800054) in relation to prospectively collected information about ten established environmental risk factors (age at menarche, parity, age at first birth, breastfeeding, menopausal status, age at menopause, use of hormone replacement therapy, body-mass index, height, and alcohol consumption).   
",True,METHODS
1434,Environmental factors can influence the development of breast cancer.,FINDINGS After allowance for multiple testing none of the 120 comparisons yielded significant evidence of a gene-environment interaction.,False,RESULTS
1435,Environmental factors can influence the development of breast cancer.,"By contrast with previous suggestions, there was little evidence that the genotypic relative risks were affected by use of hormone replacement therapy, either overall or for oestrogen-receptor-positive disease.",False,RESULTS
1436,Environmental factors can influence the development of breast cancer.,"Only one of the 12 polymorphisms was correlated with any of the ten other risk factors: carriers of the high-risk C allele of MAP3K1-rs889312 were significantly shorter than non-carriers (mean height 162.4 cm [95% CI 162.1-162.7] vs 163.1 cm [162.9-163.2]; p=0.01 after allowance for multiple testing).   
",False,RESULTS
1437,Environmental factors can influence the development of breast cancer.,"INTERPRETATION Risks of breast cancer associated with low-penetrance susceptibility polymorphisms do not vary significantly with these ten established environmental risk factors.   
",True,CONCLUSIONS
1438,Environmental factors can influence the development of breast cancer.,FUNDING Cancer Research UK and the UK Medical Research Council.,False,CONCLUSIONS
1439,Environmentally-induced senescence is mimicked in disease modeling by adding specific molecules to the culture system.,"Reprogramming somatic cells to induced pluripotent stem cells (iPSCs) resets their identity back to an embryonic age and, thus, presents a significant hurdle for modeling late-onset disorders.",False,BACKGROUND
1440,Environmentally-induced senescence is mimicked in disease modeling by adding specific molecules to the culture system.,"In this study, we describe a strategy for inducing aging-related features in human iPSC-derived lineages and apply it to the modeling of Parkinson's disease (PD).",True,BACKGROUND
1441,Environmentally-induced senescence is mimicked in disease modeling by adding specific molecules to the culture system.,"Our approach involves expression of progerin, a truncated form of lamin A associated with premature aging.",True,RESULTS
1442,Environmentally-induced senescence is mimicked in disease modeling by adding specific molecules to the culture system.,"We found that expression of progerin in iPSC-derived fibroblasts and neurons induces multiple aging-related markers and characteristics, including dopamine-specific phenotypes such as neuromelanin accumulation.",False,RESULTS
1443,Environmentally-induced senescence is mimicked in disease modeling by adding specific molecules to the culture system.,"Induced aging in PD iPSC-derived dopamine neurons revealed disease phenotypes that require both aging and genetic susceptibility, such as pronounced dendrite degeneration, progressive loss of tyrosine hydroxylase (TH) expression, and enlarged mitochondria or Lewy-body-precursor inclusions.",True,CONCLUSIONS
1444,Environmentally-induced senescence is mimicked in disease modeling by adding specific molecules to the culture system.,"Thus, our study suggests that progerin-induced aging can be used to reveal late-onset age-related disease features in hiPSC-based disease models.",True,CONCLUSIONS
1445,Excess gestational weight gain is associated with obesity-related pregnancy outcomes.,"OBJECTIVE To evaluate the effects of dietary and lifestyle interventions in pregnancy on maternal and fetal weight and to quantify the effects of these interventions on obstetric outcomes.   
",False,OBJECTIVE
1446,Excess gestational weight gain is associated with obesity-related pregnancy outcomes.,"DESIGN Systematic review and meta-analysis.   
",False,METHODS
1447,Excess gestational weight gain is associated with obesity-related pregnancy outcomes.,DATA SOURCES Major databases from inception to January 2012 without language restrictions.   ,False,METHODS
1448,Excess gestational weight gain is associated with obesity-related pregnancy outcomes.,"STUDY SELECTION Randomised controlled trials that evaluated any dietary or lifestyle interventions with potential to influence maternal weight during pregnancy and outcomes of pregnancy.   
",False,METHODS
1449,Excess gestational weight gain is associated with obesity-related pregnancy outcomes.,"DATA SYNTHESIS Results summarised as relative risks for dichotomous data and mean differences for continuous data.   
",False,METHODS
1450,Excess gestational weight gain is associated with obesity-related pregnancy outcomes.,"RESULTS We identified 44 relevant randomised controlled trials (7278 women) evaluating three categories of interventions: diet, physical activity, and a mixed approach.",False,RESULTS
1451,Excess gestational weight gain is associated with obesity-related pregnancy outcomes.,"Overall, there was 1.42 kg reduction (95% confidence interval 0.95 to 1.89 kg) in gestational weight gain with any intervention compared with control.",False,RESULTS
1452,Excess gestational weight gain is associated with obesity-related pregnancy outcomes.,"With all interventions combined, there were no significant differences in birth weight (mean difference -50 g, -100 to 0 g) and the incidence of large for gestational age (relative risk 0.85, 0.66 to 1.09) or small for gestational age (1.00, 0.78 to 1.28) babies between the groups, though by itself physical activity was associated with reduced birth weight (mean difference -60 g, -120 to -10 g).",False,RESULTS
1453,Excess gestational weight gain is associated with obesity-related pregnancy outcomes.,"Interventions were associated with a reduced the risk of pre-eclampsia (0.74, 0.60 to 0.92) and shoulder dystocia (0.39, 0.22 to 0.70), with no significant effect on other critically important outcomes.",True,RESULTS
1454,Excess gestational weight gain is associated with obesity-related pregnancy outcomes.,"Dietary intervention resulted in the largest reduction in maternal gestational weight gain (3.84 kg, 2.45 to 5.22 kg), with improved pregnancy outcomes compared with other interventions.",False,RESULTS
1455,Excess gestational weight gain is associated with obesity-related pregnancy outcomes.,"The overall evidence rating was low to very low for important outcomes such as pre-eclampsia, gestational diabetes, gestational hypertension, and preterm delivery.   
",False,RESULTS
1456,Excess gestational weight gain is associated with obesity-related pregnancy outcomes.,CONCLUSIONS Dietary and lifestyle interventions in pregnancy can reduce maternal gestational weight gain and improve outcomes for both mother and baby.,True,CONCLUSIONS
1457,Excess gestational weight gain is associated with obesity-related pregnancy outcomes.,"Among the interventions, those based on diet are the most effective and are associated with reductions in maternal gestational weight gain and improved obstetric outcomes.",True,CONCLUSIONS
1458,Exercise increases cancer mortality rates among Chinese citizens.,"BACKGROUND Although cigarette smoking, excessive alcohol drinking, obesity, and several other well-studied unhealthy lifestyle-related factors each have been linked to the risk of multiple chronic diseases and premature death, little is known about the combined impact on mortality outcomes, in particular among Chinese and other non-Western populations.",False,BACKGROUND
1459,Exercise increases cancer mortality rates among Chinese citizens.,"The objective of this study was to quantify the overall impact of lifestyle-related factors beyond that of active cigarette smoking and alcohol consumption on all-cause and cause-specific mortality in Chinese women.   
",False,BACKGROUND
1460,Exercise increases cancer mortality rates among Chinese citizens.,"METHODS AND FINDINGS We used data from the Shanghai Women's Health Study, an ongoing population-based prospective cohort study in China.",False,METHODS
1461,Exercise increases cancer mortality rates among Chinese citizens.,"Participants included 71,243 women aged 40 to 70 years enrolled during 1996-2000 who never smoked or drank alcohol regularly.",False,METHODS
1462,Exercise increases cancer mortality rates among Chinese citizens.,"A healthy lifestyle score was created on the basis of five lifestyle-related factors shown to be independently associated with mortality outcomes (normal weight, lower waist-hip ratio, daily exercise, never exposed to spouse's smoking, higher daily fruit and vegetable intake).",False,METHODS
1463,Exercise increases cancer mortality rates among Chinese citizens.,The score ranged from zero (least healthy) to five (most healthy) points.,False,METHODS
1464,Exercise increases cancer mortality rates among Chinese citizens.,"During an average follow-up of 9 years, 2,860 deaths occurred, including 775 from cardiovascular disease (CVD) and 1,351 from cancer.",False,RESULTS
1465,Exercise increases cancer mortality rates among Chinese citizens.,Adjusted hazard ratios for mortality decreased progressively with an increasing number of healthy lifestyle factors.,False,RESULTS
1466,Exercise increases cancer mortality rates among Chinese citizens.,"Compared to women with a score of zero, hazard ratios (95% confidence intervals) for women with four to five factors were 0.57 (0.44-0.74) for total mortality, 0.29 (0.16-0.54) for CVD mortality, and 0.76 (0.54-1.06) for cancer mortality.",True,RESULTS
1467,Exercise increases cancer mortality rates among Chinese citizens.,The inverse association between the healthy lifestyle score and mortality was seen consistently regardless of chronic disease status at baseline.,False,RESULTS
1468,Exercise increases cancer mortality rates among Chinese citizens.,"The population attributable risks for not having 4-5 healthy lifestyle factors were 33% for total deaths, 59% for CVD deaths, and 19% for cancer deaths.   
",True,RESULTS
1469,Exercise increases cancer mortality rates among Chinese citizens.,"CONCLUSIONS In this first study, to our knowledge, to quantify the combined impact of lifestyle-related factors on mortality outcomes in Chinese women, a healthier lifestyle pattern-including being of normal weight, lower central adiposity, participation in physical activity, nonexposure to spousal smoking, and higher fruit and vegetable intake-was associated with reductions in total and cause-specific mortality among lifetime nonsmoking and nondrinking women, supporting the importance of overall lifestyle modification in disease prevention.",True,CONCLUSIONS
1470,Exercise increases cancer mortality rates among Chinese citizens.,Please see later in the article for the Editors' Summary.,False,CONCLUSIONS
1471,Exercise reduces cancer mortality rates among Chinese citizens.,"BACKGROUND Although cigarette smoking, excessive alcohol drinking, obesity, and several other well-studied unhealthy lifestyle-related factors each have been linked to the risk of multiple chronic diseases and premature death, little is known about the combined impact on mortality outcomes, in particular among Chinese and other non-Western populations.",False,BACKGROUND
1472,Exercise reduces cancer mortality rates among Chinese citizens.,"The objective of this study was to quantify the overall impact of lifestyle-related factors beyond that of active cigarette smoking and alcohol consumption on all-cause and cause-specific mortality in Chinese women.   
",False,BACKGROUND
1473,Exercise reduces cancer mortality rates among Chinese citizens.,"METHODS AND FINDINGS We used data from the Shanghai Women's Health Study, an ongoing population-based prospective cohort study in China.",False,METHODS
1474,Exercise reduces cancer mortality rates among Chinese citizens.,"Participants included 71,243 women aged 40 to 70 years enrolled during 1996-2000 who never smoked or drank alcohol regularly.",False,METHODS
1475,Exercise reduces cancer mortality rates among Chinese citizens.,"A healthy lifestyle score was created on the basis of five lifestyle-related factors shown to be independently associated with mortality outcomes (normal weight, lower waist-hip ratio, daily exercise, never exposed to spouse's smoking, higher daily fruit and vegetable intake).",False,METHODS
1476,Exercise reduces cancer mortality rates among Chinese citizens.,The score ranged from zero (least healthy) to five (most healthy) points.,False,METHODS
1477,Exercise reduces cancer mortality rates among Chinese citizens.,"During an average follow-up of 9 years, 2,860 deaths occurred, including 775 from cardiovascular disease (CVD) and 1,351 from cancer.",False,RESULTS
1478,Exercise reduces cancer mortality rates among Chinese citizens.,Adjusted hazard ratios for mortality decreased progressively with an increasing number of healthy lifestyle factors.,False,RESULTS
1479,Exercise reduces cancer mortality rates among Chinese citizens.,"Compared to women with a score of zero, hazard ratios (95% confidence intervals) for women with four to five factors were 0.57 (0.44-0.74) for total mortality, 0.29 (0.16-0.54) for CVD mortality, and 0.76 (0.54-1.06) for cancer mortality.",True,RESULTS
1480,Exercise reduces cancer mortality rates among Chinese citizens.,The inverse association between the healthy lifestyle score and mortality was seen consistently regardless of chronic disease status at baseline.,False,RESULTS
1481,Exercise reduces cancer mortality rates among Chinese citizens.,"The population attributable risks for not having 4-5 healthy lifestyle factors were 33% for total deaths, 59% for CVD deaths, and 19% for cancer deaths.   
",True,RESULTS
1482,Exercise reduces cancer mortality rates among Chinese citizens.,"CONCLUSIONS In this first study, to our knowledge, to quantify the combined impact of lifestyle-related factors on mortality outcomes in Chinese women, a healthier lifestyle pattern-including being of normal weight, lower central adiposity, participation in physical activity, nonexposure to spousal smoking, and higher fruit and vegetable intake-was associated with reductions in total and cause-specific mortality among lifetime nonsmoking and nondrinking women, supporting the importance of overall lifestyle modification in disease prevention.",True,CONCLUSIONS
1483,Exercise reduces cancer mortality rates among Chinese citizens.,Please see later in the article for the Editors' Summary.,False,CONCLUSIONS
1484,Exposure to fine particulate air pollution is unrelated to anxiety prevalence.,"OBJECTIVE To determine whether higher past exposure to particulate air pollution is associated with prevalent high symptoms of anxiety.   
",False,OBJECTIVE
1485,Exposure to fine particulate air pollution is unrelated to anxiety prevalence.,"DESIGN Observational cohort study.   
",False,METHODS
1486,Exposure to fine particulate air pollution is unrelated to anxiety prevalence.,"SETTING Nurses' Health Study.   
",False,METHODS
1487,Exposure to fine particulate air pollution is unrelated to anxiety prevalence.,"PARTICIPANTS 71,271 women enrolled in the Nurses' Health Study residing throughout the contiguous United States who had valid estimates on exposure to particulate matter for at least one exposure period of interest and data on anxiety symptoms.   
",False,METHODS
1488,Exposure to fine particulate air pollution is unrelated to anxiety prevalence.,"MAIN OUTCOME MEASURES Meaningfully high symptoms of anxiety, defined as a score of 6 points or greater on the phobic anxiety subscale of the Crown-Crisp index, administered in 2004.   
",False,METHODS
1489,Exposure to fine particulate air pollution is unrelated to anxiety prevalence.,"RESULTS The 71,271 eligible women were aged between 57 and 85 years (mean 70 years) at the time of assessment of anxiety symptoms, with a prevalence of high anxiety symptoms of 15%.",False,METHODS
1490,Exposure to fine particulate air pollution is unrelated to anxiety prevalence.,"Exposure to particulate matter was characterized using estimated average exposure to particulate matter <2.5 μm in diameter (PM2.5) and 2.5 to 10 μm in diameter (PM2.5-10) in the one month, three months, six months, one year, and 15 years prior to assessment of anxiety symptoms, and residential distance to the nearest major road two years prior to assessment.",False,METHODS
1491,Exposure to fine particulate air pollution is unrelated to anxiety prevalence.,"Significantly increased odds of high anxiety symptoms were observed with higher exposure to PM2.5 for multiple averaging periods (for example, odds ratio per 10 µg/m(3) increase in prior one month average PM2.5: 1.12, 95% confidence interval 1.06 to 1.19; in prior 12 month average PM2.5: 1.15, 1.06 to 1.26).",True,RESULTS
1492,Exposure to fine particulate air pollution is unrelated to anxiety prevalence.,Models including multiple exposure windows suggested short term averaging periods were more relevant than long term averaging periods.,False,RESULTS
1493,Exposure to fine particulate air pollution is unrelated to anxiety prevalence.,There was no association between anxiety and exposure to PM2.5-10.,False,RESULTS
1494,Exposure to fine particulate air pollution is unrelated to anxiety prevalence.,"Residential proximity to major roads was not related to anxiety symptoms in a dose dependent manner.   
",False,RESULTS
1495,Exposure to fine particulate air pollution is unrelated to anxiety prevalence.,"CONCLUSIONS Exposure to fine particulate matter (PM2.5) was associated with high symptoms of anxiety, with more recent exposures potentially more relevant than more distant exposures.",True,CONCLUSIONS
1496,Exposure to fine particulate air pollution is unrelated to anxiety prevalence.,Research evaluating whether reductions in exposure to ambient PM2.5 would reduce the population level burden of clinically relevant symptoms of anxiety is warranted.,False,CONCLUSIONS
1497,Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.,CONTEXT Exogenous estrogen use may lower risk of dementia in postmenopausal women.,False,BACKGROUND
1498,Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.,"A relationship between long-term exposure to endogenous estrogens and incident dementia has been hypothesized but not studied.   
",False,BACKGROUND
1499,Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.,"OBJECTIVE To determine whether a longer reproductive period, as an indicator of longer exposure to endogenous estrogens, is associated with lower risk of dementia and Alzheimer disease (AD) in women who have natural menopause.   
",False,OBJECTIVE
1500,Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.,"DESIGN AND SETTING The Rotterdam Study, a population-based prospective cohort study conducted in the Netherlands.   
",False,METHODS
1501,Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.,"PARTICIPANTS A total of 3601 women aged 55 years or older who did not have dementia at baseline (1990-1993) and had information on age at menarche, age at menopause, and type of menopause.",False,METHODS
1502,Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.,"Participants were reexamined in 1993-1994 and 1997-1999 and were continuously monitored for development of dementia.   
",False,METHODS
1503,Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.,"MAIN OUTCOME MEASURES Incidence of dementia, based on Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition criteria, and AD, based on National Institute of Neurological Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria, compared by quartiles of reproductive period among women with natural menopause.   
",False,METHODS
1504,Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.,"RESULTS During 21 046 person-years of follow-up (median follow-up, 6.3 years), 199 women developed dementia, including 159 who developed AD.",False,RESULTS
1505,Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.,"After adjusting for age, dementia was not clearly associated with length of reproductive period.",False,RESULTS
1506,Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.,"However, after adjusting for multiple covariates, women with natural menopause and more reproductive years had an increased risk of dementia (adjusted rate ratio [RR] for women with >39 reproductive years [highest quartile] compared with <34 reproductive years [lowest quartile], 1.78; 95% confidence interval [CI], 1.12-2.84).",False,RESULTS
1507,Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.,"The adjusted RR per year of increase was 1.04 (95% CI, 1.01-1.08).",False,RESULTS
1508,Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.,"For risk of AD, the adjusted RRs were 1.51 (95% CI, 0.91-2.50) and 1.03 (95% CI, 1.00-1.07), respectively.",False,RESULTS
1509,Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.,"Risk of dementia associated with a longer reproductive period was most pronounced in APOE epsilon4 carriers (adjusted RR for >39 reproductive years compared with <34 reproductive years, 4.20 [95% CI, 1.97-8.92] for dementia and 3.42 [95% CI, 1.51-7.75] for AD), whereas in noncarriers, no clear association with dementia or AD was observed.   
",True,RESULTS
1510,Female carriers of the Apolipoprotein E4 (APOE4) allele have decreased risk for dementia.,CONCLUSION Our findings do not support the hypothesis that a longer reproductive period reduces risk of dementia in women who have natural menopause.,False,CONCLUSIONS
1511,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.,CONTEXT Exogenous estrogen use may lower risk of dementia in postmenopausal women.,False,BACKGROUND
1512,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.,"A relationship between long-term exposure to endogenous estrogens and incident dementia has been hypothesized but not studied.   
",False,BACKGROUND
1513,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.,"OBJECTIVE To determine whether a longer reproductive period, as an indicator of longer exposure to endogenous estrogens, is associated with lower risk of dementia and Alzheimer disease (AD) in women who have natural menopause.   
",False,OBJECTIVE
1514,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.,"DESIGN AND SETTING The Rotterdam Study, a population-based prospective cohort study conducted in the Netherlands.   
",False,METHODS
1515,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.,"PARTICIPANTS A total of 3601 women aged 55 years or older who did not have dementia at baseline (1990-1993) and had information on age at menarche, age at menopause, and type of menopause.",False,METHODS
1516,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.,"Participants were reexamined in 1993-1994 and 1997-1999 and were continuously monitored for development of dementia.   
",False,METHODS
1517,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.,"MAIN OUTCOME MEASURES Incidence of dementia, based on Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition criteria, and AD, based on National Institute of Neurological Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria, compared by quartiles of reproductive period among women with natural menopause.   
",False,METHODS
1518,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.,"RESULTS During 21 046 person-years of follow-up (median follow-up, 6.3 years), 199 women developed dementia, including 159 who developed AD.",False,RESULTS
1519,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.,"After adjusting for age, dementia was not clearly associated with length of reproductive period.",False,RESULTS
1520,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.,"However, after adjusting for multiple covariates, women with natural menopause and more reproductive years had an increased risk of dementia (adjusted rate ratio [RR] for women with >39 reproductive years [highest quartile] compared with <34 reproductive years [lowest quartile], 1.78; 95% confidence interval [CI], 1.12-2.84).",False,RESULTS
1521,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.,"The adjusted RR per year of increase was 1.04 (95% CI, 1.01-1.08).",False,RESULTS
1522,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.,"For risk of AD, the adjusted RRs were 1.51 (95% CI, 0.91-2.50) and 1.03 (95% CI, 1.00-1.07), respectively.",False,RESULTS
1523,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.,"Risk of dementia associated with a longer reproductive period was most pronounced in APOE epsilon4 carriers (adjusted RR for >39 reproductive years compared with <34 reproductive years, 4.20 [95% CI, 1.97-8.92] for dementia and 3.42 [95% CI, 1.51-7.75] for AD), whereas in noncarriers, no clear association with dementia or AD was observed.   
",True,RESULTS
1524,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for Alzheimer's disease.,CONCLUSION Our findings do not support the hypothesis that a longer reproductive period reduces risk of dementia in women who have natural menopause.,False,CONCLUSIONS
1525,Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.,CONTEXT Exogenous estrogen use may lower risk of dementia in postmenopausal women.,False,BACKGROUND
1526,Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.,"A relationship between long-term exposure to endogenous estrogens and incident dementia has been hypothesized but not studied.   
",False,BACKGROUND
1527,Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.,"OBJECTIVE To determine whether a longer reproductive period, as an indicator of longer exposure to endogenous estrogens, is associated with lower risk of dementia and Alzheimer disease (AD) in women who have natural menopause.   
",False,OBJECTIVE
1528,Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.,"DESIGN AND SETTING The Rotterdam Study, a population-based prospective cohort study conducted in the Netherlands.   
",False,METHODS
1529,Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.,"PARTICIPANTS A total of 3601 women aged 55 years or older who did not have dementia at baseline (1990-1993) and had information on age at menarche, age at menopause, and type of menopause.",False,METHODS
1530,Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.,"Participants were reexamined in 1993-1994 and 1997-1999 and were continuously monitored for development of dementia.   
",False,METHODS
1531,Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.,"MAIN OUTCOME MEASURES Incidence of dementia, based on Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition criteria, and AD, based on National Institute of Neurological Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria, compared by quartiles of reproductive period among women with natural menopause.   
",False,METHODS
1532,Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.,"RESULTS During 21 046 person-years of follow-up (median follow-up, 6.3 years), 199 women developed dementia, including 159 who developed AD.",False,RESULTS
1533,Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.,"After adjusting for age, dementia was not clearly associated with length of reproductive period.",False,RESULTS
1534,Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.,"However, after adjusting for multiple covariates, women with natural menopause and more reproductive years had an increased risk of dementia (adjusted rate ratio [RR] for women with >39 reproductive years [highest quartile] compared with <34 reproductive years [lowest quartile], 1.78; 95% confidence interval [CI], 1.12-2.84).",False,RESULTS
1535,Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.,"The adjusted RR per year of increase was 1.04 (95% CI, 1.01-1.08).",False,RESULTS
1536,Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.,"For risk of AD, the adjusted RRs were 1.51 (95% CI, 0.91-2.50) and 1.03 (95% CI, 1.00-1.07), respectively.",False,RESULTS
1537,Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.,"Risk of dementia associated with a longer reproductive period was most pronounced in APOE epsilon4 carriers (adjusted RR for >39 reproductive years compared with <34 reproductive years, 4.20 [95% CI, 1.97-8.92] for dementia and 3.42 [95% CI, 1.51-7.75] for AD), whereas in noncarriers, no clear association with dementia or AD was observed.   
",True,RESULTS
1538,Female carriers of the Apolipoprotein E4 (APOE4) allele have longer lifetime exposure to estrogen due to an increased reproductive period.,CONCLUSION Our findings do not support the hypothesis that a longer reproductive period reduces risk of dementia in women who have natural menopause.,False,CONCLUSIONS
1539,Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.,CONTEXT Exogenous estrogen use may lower risk of dementia in postmenopausal women.,False,BACKGROUND
1540,Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.,"A relationship between long-term exposure to endogenous estrogens and incident dementia has been hypothesized but not studied.   
",False,BACKGROUND
1541,Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.,"OBJECTIVE To determine whether a longer reproductive period, as an indicator of longer exposure to endogenous estrogens, is associated with lower risk of dementia and Alzheimer disease (AD) in women who have natural menopause.   
",False,OBJECTIVE
1542,Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.,"DESIGN AND SETTING The Rotterdam Study, a population-based prospective cohort study conducted in the Netherlands.   
",False,METHODS
1543,Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.,"PARTICIPANTS A total of 3601 women aged 55 years or older who did not have dementia at baseline (1990-1993) and had information on age at menarche, age at menopause, and type of menopause.",False,METHODS
1544,Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.,"Participants were reexamined in 1993-1994 and 1997-1999 and were continuously monitored for development of dementia.   
",False,METHODS
1545,Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.,"MAIN OUTCOME MEASURES Incidence of dementia, based on Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition criteria, and AD, based on National Institute of Neurological Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria, compared by quartiles of reproductive period among women with natural menopause.   
",False,METHODS
1546,Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.,"RESULTS During 21 046 person-years of follow-up (median follow-up, 6.3 years), 199 women developed dementia, including 159 who developed AD.",False,RESULTS
1547,Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.,"After adjusting for age, dementia was not clearly associated with length of reproductive period.",False,RESULTS
1548,Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.,"However, after adjusting for multiple covariates, women with natural menopause and more reproductive years had an increased risk of dementia (adjusted rate ratio [RR] for women with >39 reproductive years [highest quartile] compared with <34 reproductive years [lowest quartile], 1.78; 95% confidence interval [CI], 1.12-2.84).",False,RESULTS
1549,Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.,"The adjusted RR per year of increase was 1.04 (95% CI, 1.01-1.08).",False,RESULTS
1550,Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.,"For risk of AD, the adjusted RRs were 1.51 (95% CI, 0.91-2.50) and 1.03 (95% CI, 1.00-1.07), respectively.",False,RESULTS
1551,Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.,"Risk of dementia associated with a longer reproductive period was most pronounced in APOE epsilon4 carriers (adjusted RR for >39 reproductive years compared with <34 reproductive years, 4.20 [95% CI, 1.97-8.92] for dementia and 3.42 [95% CI, 1.51-7.75] for AD), whereas in noncarriers, no clear association with dementia or AD was observed.   
",True,RESULTS
1552,Female carriers of the Apolipoprotein E4 (APOE4) allele have shorter lifetime exposure to estrogen due to a decreased reproductive period.,CONCLUSION Our findings do not support the hypothesis that a longer reproductive period reduces risk of dementia in women who have natural menopause.,False,CONCLUSIONS
1553,Fibroblast growth factor 21 protects against atherosclerosis by modulating adiponectin and SREBP2 levels.,BACKGROUND Fibroblast growth factor 21 (FGF21) is a metabolic hormone with pleiotropic effects on glucose and lipid metabolism and insulin sensitivity.,False,BACKGROUND
1554,Fibroblast growth factor 21 protects against atherosclerosis by modulating adiponectin and SREBP2 levels.,"It acts as a key downstream target of both peroxisome proliferator-activated receptor α and γ, the agonists of which have been used for lipid lowering and insulin sensitization, respectively.",False,BACKGROUND
1555,Fibroblast growth factor 21 protects against atherosclerosis by modulating adiponectin and SREBP2 levels.,"However, the role of FGF21 in the cardiovascular system remains elusive.   
",False,BACKGROUND
1556,Fibroblast growth factor 21 protects against atherosclerosis by modulating adiponectin and SREBP2 levels.,METHODS AND RESULTS The roles of FGF21 in atherosclerosis were investigated by evaluating the impact of FGF21 deficiency and replenishment with recombinant FGF21 in apolipoprotein E(-/-) mice.,False,METHODS
1557,Fibroblast growth factor 21 protects against atherosclerosis by modulating adiponectin and SREBP2 levels.,"FGF21 deficiency causes a marked exacerbation of atherosclerotic plaque formation and premature death in apolipoprotein E(-/-) mice, which is accompanied by hypoadiponectinemia and severe hypercholesterolemia.",False,RESULTS
1558,Fibroblast growth factor 21 protects against atherosclerosis by modulating adiponectin and SREBP2 levels.,"Replenishment of FGF21 protects against atherosclerosis in apolipoprotein E(-/-)mice via 2 independent mechanisms, inducing the adipocyte production of adiponectin, which in turn acts on the blood vessels to inhibit neointima formation and macrophage inflammation, and suppressing the hepatic expression of the transcription factor sterol regulatory element-binding protein-2, thereby leading to reduced cholesterol synthesis and attenuation of hypercholesterolemia.",True,RESULTS
1559,Fibroblast growth factor 21 protects against atherosclerosis by modulating adiponectin and SREBP2 levels.,Chronic treatment with adiponectin partially reverses atherosclerosis without obvious effects on hypercholesterolemia in FGF21-deficient apolipoprotein E(-/-) mice.,False,RESULTS
1560,Fibroblast growth factor 21 protects against atherosclerosis by modulating adiponectin and SREBP2 levels.,"By contrast, the cholesterol-lowering effects of FGF21 are abrogated by hepatic expression of sterol regulatory element-binding protein-2.   
",False,RESULTS
1561,Fibroblast growth factor 21 protects against atherosclerosis by modulating adiponectin and SREBP2 levels.,"CONCLUSIONS FGF21 protects against atherosclerosis via fine tuning the multiorgan crosstalk among liver, adipose tissue, and blood vessels.",False,CONCLUSIONS
1562,Forkhead 0 (fox0) transcription factors are involved in apoptosis.,"The forkhead O (FoxO) family of transcription factors participates in diverse physiologic processes, including induction of cell-cycle arrest, stress resistance, differentiation, apoptosis, and metabolism.",True,BACKGROUND
1563,Forkhead 0 (fox0) transcription factors are involved in apoptosis.,"Several recent studies indicate that FoxO-dependent signaling is required for long-term regenerative potential of the hematopoietic stem cell (HSC) compartment through regulation of HSC response to physiologic oxidative stress, quiescence, and survival.",False,BACKGROUND
1564,Forkhead 0 (fox0) transcription factors are involved in apoptosis.,These observations link FoxO function in mammalian systems with the evolutionarily conserved role of FoxO in promotion of stress resistance and longevity in lower phylogenetic systems.,False,BACKGROUND
1565,Forkhead 0 (fox0) transcription factors are involved in apoptosis.,"Furthermore, these findings have implications for aging in higher organisms and in malignant stem cell biology, and suggest that FoxOs may play an important role in the maintenance and integrity of stem cell compartments in a broad spectrum of tissues.",False,BACKGROUND
1566,Forkhead 0 (fox0) transcription factors are involved in cellular differentiation.,"The forkhead O (FoxO) family of transcription factors participates in diverse physiologic processes, including induction of cell-cycle arrest, stress resistance, differentiation, apoptosis, and metabolism.",True,BACKGROUND
1567,Forkhead 0 (fox0) transcription factors are involved in cellular differentiation.,"Several recent studies indicate that FoxO-dependent signaling is required for long-term regenerative potential of the hematopoietic stem cell (HSC) compartment through regulation of HSC response to physiologic oxidative stress, quiescence, and survival.",False,BACKGROUND
1568,Forkhead 0 (fox0) transcription factors are involved in cellular differentiation.,These observations link FoxO function in mammalian systems with the evolutionarily conserved role of FoxO in promotion of stress resistance and longevity in lower phylogenetic systems.,False,BACKGROUND
1569,Forkhead 0 (fox0) transcription factors are involved in cellular differentiation.,"Furthermore, these findings have implications for aging in higher organisms and in malignant stem cell biology, and suggest that FoxOs may play an important role in the maintenance and integrity of stem cell compartments in a broad spectrum of tissues.",False,BACKGROUND
1570,FoxO3a activation in neuronal death is inhibited by reactive oxygen species (ROS).,The Sir2 deacetylase modulates organismal life-span in various species.,False,BACKGROUND
1571,FoxO3a activation in neuronal death is inhibited by reactive oxygen species (ROS).,"However, the molecular mechanisms by which Sir2 increases longevity are largely unknown.",False,BACKGROUND
1572,FoxO3a activation in neuronal death is inhibited by reactive oxygen species (ROS).,"We show that in mammalian cells, the Sir2 homolog SIRT1 appears to control the cellular response to stress by regulating the FOXO family of Forkhead transcription factors, a family of proteins that function as sensors of the insulin signaling pathway and as regulators of organismal longevity.",False,RESULTS
1573,FoxO3a activation in neuronal death is inhibited by reactive oxygen species (ROS).,"SIRT1 and the FOXO transcription factor FOXO3 formed a complex in cells in response to oxidative stress, and SIRT1 deacetylated FOXO3 in vitro and within cells.",False,RESULTS
1574,FoxO3a activation in neuronal death is inhibited by reactive oxygen species (ROS).,SIRT1 had a dual effect on FOXO3 function: SIRT1 increased FOXO3's ability to induce cell cycle arrest and resistance to oxidative stress but inhibited FOXO3's ability to induce cell death.,False,CONCLUSIONS
1575,FoxO3a activation in neuronal death is inhibited by reactive oxygen species (ROS).,"Thus, one way in which members of the Sir2 family of proteins may increase organismal longevity is by tipping FOXO-dependent responses away from apoptosis and toward stress resistance.",True,CONCLUSIONS
1576,Foxk2 regulates autophagy genes in muscle cells and fibroblast cells.,Autophagy is the primary catabolic process triggered in response to starvation.,False,BACKGROUND
1577,Foxk2 regulates autophagy genes in muscle cells and fibroblast cells.,"Although autophagic regulation within the cytosolic compartment is well established, it is becoming clear that nuclear events also regulate the induction or repression of autophagy.",False,BACKGROUND
1578,Foxk2 regulates autophagy genes in muscle cells and fibroblast cells.,"Nevertheless, a thorough understanding of the mechanisms by which sequence-specific transcription factors modulate expression of genes required for autophagy is lacking.",False,BACKGROUND
1579,Foxk2 regulates autophagy genes in muscle cells and fibroblast cells.,"Here, we identify Foxk proteins (Foxk1 and Foxk2) as transcriptional repressors of autophagy in muscle cells and fibroblasts.",True,BACKGROUND
1580,Foxk2 regulates autophagy genes in muscle cells and fibroblast cells.,"Interestingly, Foxk1/2 serve to counter-balance another forkhead transcription factor, Foxo3, which induces an overlapping set of autophagic and atrophic targets in muscle.",False,RESULTS
1581,Foxk2 regulates autophagy genes in muscle cells and fibroblast cells.,Foxk1/2 specifically recruits Sin3A-HDAC complexes to restrict acetylation of histone H4 and expression of critical autophagy genes.,True,RESULTS
1582,Foxk2 regulates autophagy genes in muscle cells and fibroblast cells.,"Remarkably, mTOR promotes the transcriptional activity of Foxk1 by facilitating nuclear entry to specifically limit basal levels of autophagy in nutrient-rich conditions.",False,CONCLUSIONS
1583,Foxk2 regulates autophagy genes in muscle cells and fibroblast cells.,"Our study highlights an ancient, conserved mechanism whereby nutritional status is interpreted by mTOR to restrict autophagy by repressing essential autophagy genes through Foxk-Sin3-mediated transcriptional control.",False,CONCLUSIONS
1584,G-CSF increases the expansion and infiltration of MDSCs into tumors.,Myeloid-derived suppressor cells (MDSCs) play critical roles in primary and metastatic cancer progression.,False,BACKGROUND
1585,G-CSF increases the expansion and infiltration of MDSCs into tumors.,"MDSC regulation is widely variable even among patients harbouring the same type of malignancy, and the mechanisms governing such heterogeneity are largely unknown.",False,BACKGROUND
1586,G-CSF increases the expansion and infiltration of MDSCs into tumors.,"Here, integrating human tumour genomics and syngeneic mammary tumour models, we demonstrate that mTOR signalling in cancer cells dictates a mammary tumour's ability to stimulate MDSC accumulation through regulating G-CSF.",True,BACKGROUND
1587,G-CSF increases the expansion and infiltration of MDSCs into tumors.,"Inhibiting this pathway or its activators (for example, FGFR) impairs tumour progression, which is partially rescued by restoring MDSCs or G-CSF.",False,BACKGROUND
1588,G-CSF increases the expansion and infiltration of MDSCs into tumors.,Tumour-initiating cells (TICs) exhibit elevated G-CSF.,False,BACKGROUND
1589,G-CSF increases the expansion and infiltration of MDSCs into tumors.,"MDSCs reciprocally increase TIC frequency through activating Notch in tumour cells, forming a feedforward loop.",False,BACKGROUND
1590,G-CSF increases the expansion and infiltration of MDSCs into tumors.,Analyses of primary breast cancers and patient-derived xenografts corroborate these mechanisms in patients.,False,BACKGROUND
1591,G-CSF increases the expansion and infiltration of MDSCs into tumors.,These findings establish a non-canonical oncogenic role of mTOR signalling in recruiting pro-tumorigenic MDSCs and show how defined cancer subsets may evolve to promote and depend on a distinct immune microenvironment.,False,BACKGROUND
1592,GATA3 regulates cell cycle progression in bone marrow hematopoietic stem cells.,Maintaining hematopoietic stem cell (HSC) quiescence is a critical property for the life-long generation of blood cells.,False,BACKGROUND
1593,GATA3 regulates cell cycle progression in bone marrow hematopoietic stem cells.,"Approximately 75% of cells in a highly enriched long-term repopulating HSC (LT-HSC) pool (Lin(-)Sca1(+)c-Kit(hi)CD150(+)CD48(-)) are quiescent, with only a small percentage of the LT-HSCs in cycle.",False,BACKGROUND
1594,GATA3 regulates cell cycle progression in bone marrow hematopoietic stem cells.,Transcription factor GATA-3 is known to be vital for the development of T cells at multiple stages in the thymus and for Th2 differentiation in the peripheral organs.,False,BACKGROUND
1595,GATA3 regulates cell cycle progression in bone marrow hematopoietic stem cells.,"Although it is well documented that GATA-3 is expressed in HSCs, a role for GATA-3 in any prethymic progenitor cell has not been established.",False,BACKGROUND
1596,GATA3 regulates cell cycle progression in bone marrow hematopoietic stem cells.,"In the present study, we show that Gata3-null mutant mice generate fewer LT-HSCs and that fewer Gata3-null LT-HSCs are in cycle.",False,BACKGROUND
1597,GATA3 regulates cell cycle progression in bone marrow hematopoietic stem cells.,"Furthermore, Gata3 mutant hematopoietic progenitor cells fail to be recruited into an increased cycling state after 5-fluorouracil-induced myelosuppression.",True,BACKGROUND
1598,GATA3 regulates cell cycle progression in bone marrow hematopoietic stem cells.,"Therefore, GATA-3 is required for the maintenance of a normal number of LT-HSCs and for their entry into the cell cycle.",True,BACKGROUND
1599,GATA3 regulates self-renewal capacity in bone marrow hematopoietic stem cells.,Maintaining hematopoietic stem cell (HSC) quiescence is a critical property for the life-long generation of blood cells.,False,BACKGROUND
1600,GATA3 regulates self-renewal capacity in bone marrow hematopoietic stem cells.,"Approximately 75% of cells in a highly enriched long-term repopulating HSC (LT-HSC) pool (Lin(-)Sca1(+)c-Kit(hi)CD150(+)CD48(-)) are quiescent, with only a small percentage of the LT-HSCs in cycle.",False,BACKGROUND
1601,GATA3 regulates self-renewal capacity in bone marrow hematopoietic stem cells.,Transcription factor GATA-3 is known to be vital for the development of T cells at multiple stages in the thymus and for Th2 differentiation in the peripheral organs.,False,BACKGROUND
1602,GATA3 regulates self-renewal capacity in bone marrow hematopoietic stem cells.,"Although it is well documented that GATA-3 is expressed in HSCs, a role for GATA-3 in any prethymic progenitor cell has not been established.",False,BACKGROUND
1603,GATA3 regulates self-renewal capacity in bone marrow hematopoietic stem cells.,"In the present study, we show that Gata3-null mutant mice generate fewer LT-HSCs and that fewer Gata3-null LT-HSCs are in cycle.",True,BACKGROUND
1604,GATA3 regulates self-renewal capacity in bone marrow hematopoietic stem cells.,"Furthermore, Gata3 mutant hematopoietic progenitor cells fail to be recruited into an increased cycling state after 5-fluorouracil-induced myelosuppression.",False,BACKGROUND
1605,GATA3 regulates self-renewal capacity in bone marrow hematopoietic stem cells.,"Therefore, GATA-3 is required for the maintenance of a normal number of LT-HSCs and for their entry into the cell cycle.",True,BACKGROUND
1606,Gastric infection with Helicobacter pylori decreases risk of gastric cancer in humans.,"OBJECTIVE To investigate the association between gastric cancer and prior infection with Helicobacter pylori.   
",False,OBJECTIVE
1607,Gastric infection with Helicobacter pylori decreases risk of gastric cancer in humans.,"DESIGN Case-control comparison of prevalence of IgG antibodies to H pylori in blood samples collected prospectively, before diagnosis of gastric cancer in the cases.",False,METHODS
1608,Gastric infection with Helicobacter pylori decreases risk of gastric cancer in humans.,Presence of H pylori antibody (greater than 10 micrograms IgG/ml) determined by enzyme linked immunosorbent assay (ELISA).   ,False,METHODS
1609,Gastric infection with Helicobacter pylori decreases risk of gastric cancer in humans.,"SUBJECTS 29 men with a subsequent diagnosis of gastric cancer and 116 aged matched controls selected from over 22,000 middle aged men participating in two ongoing cohort studies (the British United Provident Association study and the Caerphilly collaborative heart disease study), who had provided blood samples during 1975-1982.   
",False,RESULTS
1610,Gastric infection with Helicobacter pylori decreases risk of gastric cancer in humans.,RESULTS 20 of the 29 cases (69%) and 54 of the 116 controls (47%) were positive for H pylori specific antibody.,False,RESULTS
1611,Gastric infection with Helicobacter pylori decreases risk of gastric cancer in humans.,"The median specific IgG concentration was significantly higher in the cases than controls (90 micrograms/ml v 3.6 micrograms/ml, p less than 0.01).",False,RESULTS
1612,Gastric infection with Helicobacter pylori decreases risk of gastric cancer in humans.,"The estimated odds ratio for the risk of gastric cancer in those with a history of infection with H pylori was 2.77 (95% confidence interval 1.04 to 7.97, 2p = 0.039).   
",True,RESULTS
1613,Gastric infection with Helicobacter pylori decreases risk of gastric cancer in humans.,CONCLUSIONS H pylori infection may be an important cause of gastric cancer; between 35% and 55% of all cases may be associated with such an infection.,True,CONCLUSIONS
1614,Gastric infection with Helicobacter pylori increases risk of gastric cancer in humans.,"OBJECTIVE To investigate the association between gastric cancer and prior infection with Helicobacter pylori.   
",False,OBJECTIVE
1615,Gastric infection with Helicobacter pylori increases risk of gastric cancer in humans.,"DESIGN Case-control comparison of prevalence of IgG antibodies to H pylori in blood samples collected prospectively, before diagnosis of gastric cancer in the cases.",False,METHODS
1616,Gastric infection with Helicobacter pylori increases risk of gastric cancer in humans.,Presence of H pylori antibody (greater than 10 micrograms IgG/ml) determined by enzyme linked immunosorbent assay (ELISA).   ,False,METHODS
1617,Gastric infection with Helicobacter pylori increases risk of gastric cancer in humans.,"SUBJECTS 29 men with a subsequent diagnosis of gastric cancer and 116 aged matched controls selected from over 22,000 middle aged men participating in two ongoing cohort studies (the British United Provident Association study and the Caerphilly collaborative heart disease study), who had provided blood samples during 1975-1982.   
",False,RESULTS
1618,Gastric infection with Helicobacter pylori increases risk of gastric cancer in humans.,RESULTS 20 of the 29 cases (69%) and 54 of the 116 controls (47%) were positive for H pylori specific antibody.,False,RESULTS
1619,Gastric infection with Helicobacter pylori increases risk of gastric cancer in humans.,"The median specific IgG concentration was significantly higher in the cases than controls (90 micrograms/ml v 3.6 micrograms/ml, p less than 0.01).",False,RESULTS
1620,Gastric infection with Helicobacter pylori increases risk of gastric cancer in humans.,"The estimated odds ratio for the risk of gastric cancer in those with a history of infection with H pylori was 2.77 (95% confidence interval 1.04 to 7.97, 2p = 0.039).   
",True,RESULTS
1621,Gastric infection with Helicobacter pylori increases risk of gastric cancer in humans.,CONCLUSIONS H pylori infection may be an important cause of gastric cancer; between 35% and 55% of all cases may be associated with such an infection.,True,CONCLUSIONS
1622,General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.,"OBJECTIVE To evaluate if a specific exercise strategy, targeting the rotator cuff and scapula stabilisers, improves shoulder function and pain more than unspecific exercises in patients with subacromial impingement syndrome, thereby decreasing the need for arthroscopic subacromial decompression.   
",False,OBJECTIVE
1623,General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.,"DESIGN Randomised, participant and single assessor blinded, controlled study.   
",False,METHODS
1624,General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.,"SETTING Department of orthopaedics in a Swedish university hospital.   
",False,METHODS
1625,General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.,"PARTICIPANTS 102 patients with long standing (over six months) persistent subacromial impingement syndrome in whom earlier conservative treatment had failed, recruited through orthopaedic specialists.   
",False,METHODS
1626,General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.,INTERVENTIONS The specific exercise strategy consisted of strengthening eccentric exercises for the rotator cuff and concentric/eccentric exercises for the scapula stabilisers in combination with manual mobilisation.,False,METHODS
1627,General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.,The control exercise programme consisted of unspecific movement exercises for the neck and shoulder.,False,METHODS
1628,General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.,Patients in both groups received five to six individual guided treatment sessions during 12 weeks.,False,METHODS
1629,General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.,"In between these supervised sessions the participants performed home exercises once or twice a day for 12 weeks.   
",False,METHODS
1630,General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.,MAIN OUTCOME MEASURES The primary outcome was the Constant-Murley shoulder assessment score evaluating shoulder function and pain.,False,METHODS
1631,General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.,"Secondary outcomes were patients' global impression of change because of treatment and decision regarding surgery.   
",False,METHODS
1632,General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.,"RESULTS Most (97, 95%) participants completed the 12 week study.",False,RESULTS
1633,General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.,There was a significantly greater improvement in the Constant-Murley score in the specific exercise group than in the control exercise group (24 points (95% confidence interval 19 to 28.0) v 9 points (5 to 13); mean difference between group: 15 points (8.5 to 20.6)).,True,RESULTS
1634,General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.,"Significantly more patients in the specific exercise group reported successful outcome (defined as large improvement or recovered) in the patients' global assessment of change because of treatment: 69% (35/51) v 24% (11/46); odds ratio 7.6, 3.1 to 18.9; P<0.001.",False,RESULTS
1635,General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.,"A significantly lower proportion of patients in the specific exercise group subsequently chose to undergo surgery: 20% (10/51) v 63% (29/46); odds ratio 7.7, 3.1 to 19.4; P<0.001).   
",False,RESULTS
1636,General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.,"CONCLUSION A specific exercise strategy, focusing on strengthening eccentric exercises for the rotator cuff and concentric/eccentric exercises for the scapula stabilisers, is effective in reducing pain and improving shoulder function in patients with persistent subacromial impingement syndrome.",False,CONCLUSIONS
1637,General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.,"By extension, this exercise strategy reduces the need for arthroscopic subacromial decompression within the three month timeframe used in the study.   
",False,CONCLUSIONS
1638,General exercise therapy is more effective than rotator cuff exercises in reducing pain and improving function of the shoulder.,TRIAL REGISTRATION Clinical trials NCT01037673.,False,CONCLUSIONS
1639,General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.,"OBJECTIVE To evaluate if a specific exercise strategy, targeting the rotator cuff and scapula stabilisers, improves shoulder function and pain more than unspecific exercises in patients with subacromial impingement syndrome, thereby decreasing the need for arthroscopic subacromial decompression.   
",False,OBJECTIVE
1640,General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.,"DESIGN Randomised, participant and single assessor blinded, controlled study.   
",False,METHODS
1641,General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.,"SETTING Department of orthopaedics in a Swedish university hospital.   
",False,METHODS
1642,General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.,"PARTICIPANTS 102 patients with long standing (over six months) persistent subacromial impingement syndrome in whom earlier conservative treatment had failed, recruited through orthopaedic specialists.   
",False,METHODS
1643,General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.,INTERVENTIONS The specific exercise strategy consisted of strengthening eccentric exercises for the rotator cuff and concentric/eccentric exercises for the scapula stabilisers in combination with manual mobilisation.,False,METHODS
1644,General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.,The control exercise programme consisted of unspecific movement exercises for the neck and shoulder.,False,METHODS
1645,General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.,Patients in both groups received five to six individual guided treatment sessions during 12 weeks.,False,METHODS
1646,General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.,"In between these supervised sessions the participants performed home exercises once or twice a day for 12 weeks.   
",False,METHODS
1647,General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.,MAIN OUTCOME MEASURES The primary outcome was the Constant-Murley shoulder assessment score evaluating shoulder function and pain.,False,METHODS
1648,General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.,"Secondary outcomes were patients' global impression of change because of treatment and decision regarding surgery.   
",False,METHODS
1649,General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.,"RESULTS Most (97, 95%) participants completed the 12 week study.",False,RESULTS
1650,General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.,There was a significantly greater improvement in the Constant-Murley score in the specific exercise group than in the control exercise group (24 points (95% confidence interval 19 to 28.0) v 9 points (5 to 13); mean difference between group: 15 points (8.5 to 20.6)).,True,RESULTS
1651,General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.,"Significantly more patients in the specific exercise group reported successful outcome (defined as large improvement or recovered) in the patients' global assessment of change because of treatment: 69% (35/51) v 24% (11/46); odds ratio 7.6, 3.1 to 18.9; P<0.001.",True,RESULTS
1652,General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.,"A significantly lower proportion of patients in the specific exercise group subsequently chose to undergo surgery: 20% (10/51) v 63% (29/46); odds ratio 7.7, 3.1 to 19.4; P<0.001).   
",False,RESULTS
1653,General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.,"CONCLUSION A specific exercise strategy, focusing on strengthening eccentric exercises for the rotator cuff and concentric/eccentric exercises for the scapula stabilisers, is effective in reducing pain and improving shoulder function in patients with persistent subacromial impingement syndrome.",True,CONCLUSIONS
1654,General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.,"By extension, this exercise strategy reduces the need for arthroscopic subacromial decompression within the three month timeframe used in the study.   
",False,CONCLUSIONS
1655,General exercise therapy is more effective than scapular stabilizer exercises in reducing pain and improving function of the shoulder.,TRIAL REGISTRATION Clinical trials NCT01037673.,False,CONCLUSIONS
1656,Genes involved in pre-mRNA splicing have a significant impact on genome stability.,"Signaling pathways that respond to DNA damage are essential for the maintenance of genome stability and are linked to many diseases, including cancer.",False,BACKGROUND
1657,Genes involved in pre-mRNA splicing have a significant impact on genome stability.,"Here, a genome-wide siRNA screen was employed to identify additional genes involved in genome stabilization by monitoring phosphorylation of the histone variant H2AX, an early mark of DNA damage.",False,BACKGROUND
1658,Genes involved in pre-mRNA splicing have a significant impact on genome stability.,We identified hundreds of genes whose downregulation led to elevated levels of H2AX phosphorylation (gammaH2AX) and revealed links to cellular complexes and to genes with unclassified functions.,False,RESULTS
1659,Genes involved in pre-mRNA splicing have a significant impact on genome stability.,"We demonstrate a widespread role for mRNA-processing factors in preventing DNA damage, which in some cases is caused by aberrant RNA-DNA structures.",True,RESULTS
1660,Genes involved in pre-mRNA splicing have a significant impact on genome stability.,"Furthermore, we connect increased gammaH2AX levels to the neurological disorder Charcot-Marie-Tooth (CMT) syndrome, and we find a role for several CMT proteins in the DNA-damage response.",False,CONCLUSIONS
1661,Genes involved in pre-mRNA splicing have a significant impact on genome stability.,These data indicate that preservation of genome stability is mediated by a larger network of biological processes than previously appreciated.,False,CONCLUSIONS
1662,Genetic deficiency of mast cells leads to decreased weight gain in a mouse model of diet-induced obesity.,"Although mast cell functions have classically been related to allergic responses, recent studies indicate that these cells contribute to other common diseases such as multiple sclerosis, rheumatoid arthritis, atherosclerosis, aortic aneurysm and cancer.",False,BACKGROUND
1663,Genetic deficiency of mast cells leads to decreased weight gain in a mouse model of diet-induced obesity.,This study presents evidence that mast cells also contribute to diet-induced obesity and diabetes.,False,BACKGROUND
1664,Genetic deficiency of mast cells leads to decreased weight gain in a mouse model of diet-induced obesity.,"For example, white adipose tissue (WAT) from obese humans and mice contain more mast cells than WAT from their lean counterparts.",False,BACKGROUND
1665,Genetic deficiency of mast cells leads to decreased weight gain in a mouse model of diet-induced obesity.,"Furthermore, in the context of mice on a Western diet, genetically induced deficiency of mast cells, or their pharmacological stabilization, reduces body weight gain and levels of inflammatory cytokines, chemokines and proteases in serum and WAT, in concert with improved glucose homeostasis and energy expenditure.",True,BACKGROUND
1666,Genetic deficiency of mast cells leads to decreased weight gain in a mouse model of diet-induced obesity.,Mechanistic studies reveal that mast cells contribute to WAT and muscle angiogenesis and associated cell apoptosis and cathepsin activity.,False,RESULTS
1667,Genetic deficiency of mast cells leads to decreased weight gain in a mouse model of diet-induced obesity.,"Adoptive transfer experiments of cytokine-deficient mast cells show that these cells, by producing interleukin-6 (IL-6) and interferon-gamma (IFN-gamma), contribute to mouse adipose tissue cysteine protease cathepsin expression, apoptosis and angiogenesis, thereby promoting diet-induced obesity and glucose intolerance.",False,RESULTS
1668,Genetic deficiency of mast cells leads to decreased weight gain in a mouse model of diet-induced obesity.,Our results showing reduced obesity and diabetes in mice treated with clinically available mast cell-stabilizing agents suggest the potential of developing new therapies for these common human metabolic disorders.,False,CONCLUSIONS
1669,Genetic deletion of JAM-A increases gut permeability.,"Mice lacking junctional adhesion molecule A (JAM-A, encoded by F11r) exhibit enhanced intestinal epithelial permeability, bacterial translocation, and elevated colonic lymphocyte numbers, yet do not develop colitis.",True,BACKGROUND
1670,Genetic deletion of JAM-A increases gut permeability.,"To investigate the contribution of adaptive immune compensation in response to increased intestinal epithelial permeability, we examined the susceptibility of F11r(-/-)Rag1(-/-) mice to acute colitis.",False,BACKGROUND
1671,Genetic deletion of JAM-A increases gut permeability.,"Although negligible contributions of adaptive immunity in F11r(+/+)Rag1(-/-) mice were observed, F11r(-/-)Rag1(-/-) mice exhibited increased microflora-dependent colitis.",False,RESULTS
1672,Genetic deletion of JAM-A increases gut permeability.,Elimination of T cell subsets and cytokine analyses revealed a protective role for TGF-β-producing CD4(+) T cells in F11r(-/-) mice.,False,RESULTS
1673,Genetic deletion of JAM-A increases gut permeability.,"Additionally, loss of JAM-A resulted in elevated mucosal and serum IgA that was dependent upon CD4(+) T cells and TGF-β.",False,RESULTS
1674,Genetic deletion of JAM-A increases gut permeability.,"Absence of IgA in F11r(+/+)Igha(-/-) mice did not affect disease, whereas F11r(-/-)Igha(-/-) mice displayed markedly increased susceptibility to acute injury-induced colitis.",False,RESULTS
1675,Genetic deletion of JAM-A increases gut permeability.,These data establish a role for adaptive immune-mediated protection from acute colitis under conditions of intestinal epithelial barrier compromise.,False,CONCLUSIONS
1676,Genomic aberrations of metastases provide information for targeted therapy.,"Human tumors show a high level of genetic heterogeneity, but the processes that influence the timing and route of metastatic dissemination of the subclones are unknown.",False,BACKGROUND
1677,Genomic aberrations of metastases provide information for targeted therapy.,"Here we have used whole-exome sequencing of 103 matched benign, malignant and metastatic skin tumors from genetically heterogeneous mice to demonstrate that most metastases disseminate synchronously from the primary tumor, supporting parallel rather than linear evolution as the predominant model of metastasis.",False,BACKGROUND
1678,Genomic aberrations of metastases provide information for targeted therapy.,"Shared mutations between primary carcinomas and their matched metastases have the distinct A-to-T signature of the initiating carcinogen dimethylbenzanthracene, but non-shared mutations are primarily G-to-T, a signature associated with oxidative stress.",False,BACKGROUND
1679,Genomic aberrations of metastases provide information for targeted therapy.,The existence of carcinomas that either did or did not metastasize in the same host animal suggests that there are tumor-intrinsic factors that influence metastatic seeding.,False,BACKGROUND
1680,Genomic aberrations of metastases provide information for targeted therapy.,"We also demonstrate the importance of germline polymorphisms in determining allele-specific mutations, and we identify somatic genetic alterations that are specifically related to initiation of carcinogenesis by Hras or Kras mutations.",False,BACKGROUND
1681,Genomic aberrations of metastases provide information for targeted therapy.,Mouse tumors that mimic the genetic heterogeneity of human cancers can aid our understanding of the clonal evolution of metastasis and provide a realistic model for the testing of novel therapies.,True,BACKGROUND
1682,Genomic sequences involved in alternative splicing responsible for Hutchinson-Gilford progeria syndrome (HGPS) are abundant in the ''progerinonly'' allele of Lmna knock-in models.,"Hutchinson-Gilford progeria syndrome (HGPS) is a childhood premature aging disease caused by a spontaneous point mutation in lamin A (encoded by LMNA), one of the major architectural elements of the mammalian cell nucleus.",True,BACKGROUND
1683,Genomic sequences involved in alternative splicing responsible for Hutchinson-Gilford progeria syndrome (HGPS) are abundant in the ''progerinonly'' allele of Lmna knock-in models.,"The HGPS mutation activates an aberrant cryptic splice site in LMNA pre-mRNA, leading to synthesis of a truncated lamin A protein and concomitant reduction in wild-type lamin A. Fibroblasts from individuals with HGPS have severe morphological abnormalities in nuclear envelope structure.",False,BACKGROUND
1684,Genomic sequences involved in alternative splicing responsible for Hutchinson-Gilford progeria syndrome (HGPS) are abundant in the ''progerinonly'' allele of Lmna knock-in models.,Here we show that the cellular disease phenotype is reversible in cells from individuals with HGPS.,False,BACKGROUND
1685,Genomic sequences involved in alternative splicing responsible for Hutchinson-Gilford progeria syndrome (HGPS) are abundant in the ''progerinonly'' allele of Lmna knock-in models.,Introduction of wild-type lamin A protein does not rescue the cellular disease symptoms.,False,RESULTS
1686,Genomic sequences involved in alternative splicing responsible for Hutchinson-Gilford progeria syndrome (HGPS) are abundant in the ''progerinonly'' allele of Lmna knock-in models.,The mutant LMNA mRNA and lamin A protein can be efficiently eliminated by correction of the aberrant splicing event using a modified oligonucleotide targeted to the activated cryptic splice site.,True,RESULTS
1687,Genomic sequences involved in alternative splicing responsible for Hutchinson-Gilford progeria syndrome (HGPS) are abundant in the ''progerinonly'' allele of Lmna knock-in models.,"Upon splicing correction, HGPS fibroblasts assume normal nuclear morphology, the aberrant nuclear distribution and cellular levels of lamina-associated proteins are rescued, defects in heterochromatin-specific histone modifications are corrected and proper expression of several misregulated genes is reestablished.",True,RESULTS
1688,Genomic sequences involved in alternative splicing responsible for Hutchinson-Gilford progeria syndrome (HGPS) are abundant in the ''progerinonly'' allele of Lmna knock-in models.,Our results establish proof of principle for the correction of the premature aging phenotype in individuals with HGPS.,False,CONCLUSIONS
1689,Glial calcium waves influence seizures.,Seizures in focal epilepsies are sustained by a highly synchronous neuronal discharge that arises at restricted brain sites and subsequently spreads to large portions of the brain.,False,OBJECTIVE
1690,Glial calcium waves influence seizures.,"Despite intense experimental research in this field, the earlier cellular events that initiate and sustain a focal seizure are still not well defined.",False,OBJECTIVE
1691,Glial calcium waves influence seizures.,Their identification is central to understand the pathophysiology of focal epilepsies and to develop new pharmacological therapies for drug-resistant forms of epilepsy.,False,OBJECTIVE
1692,Glial calcium waves influence seizures.,The prominent involvement of astrocytes in ictogenesis was recently proposed.,False,OBJECTIVE
1693,Glial calcium waves influence seizures.,We test here whether a cooperation between astrocytes and neurons is a prerequisite to support ictal (seizure-like) and interictal epileptiform events.,False,OBJECTIVE
1694,Glial calcium waves influence seizures.,Simultaneous patch-clamp recording and Ca2+ imaging techniques were performed in a new in vitro model of focal seizures induced by local applications of N-methyl-D-aspartic acid (NMDA) in rat entorhinal cortex slices.,False,METHODS
1695,Glial calcium waves influence seizures.,"We found that a Ca2+ elevation in astrocytes correlates with both the initial development and the maintenance of a focal, seizure-like discharge.",True,RESULTS
1696,Glial calcium waves influence seizures.,A delayed astrocyte activation during ictal discharges was also observed in other models (including the whole in vitro isolated guinea pig brain) in which the site of generation of seizure activity cannot be precisely monitored.,False,RESULTS
1697,Glial calcium waves influence seizures.,"In contrast, interictal discharges were not associated with Ca2+ changes in astrocytes.",False,RESULTS
1698,Glial calcium waves influence seizures.,"Selective inhibition or stimulation of astrocyte Ca2+ signalling blocked or enhanced, respectively, ictal discharges, but did not affect interictal discharge generation.",False,RESULTS
1699,Glial calcium waves influence seizures.,Our data reveal that neurons engage astrocytes in a recurrent excitatory loop (possibly involving gliotransmission) that promotes seizure ignition and sustains the ictal discharge.,True,CONCLUSIONS
1700,Glial calcium waves influence seizures.,This neuron-astrocyte interaction may represent a novel target to develop effective therapeutic strategies to control seizures.,False,CONCLUSIONS
1701,"Glioblastoma multiforme (GBM) is characterized by extensive invasion, rapid growth, necrosis, and angiogenesis.","Although GBP1 (guanylate binding protein 1) was among the first interferon-inducible proteins identified, its function is still largely unknown.",False,BACKGROUND
1702,"Glioblastoma multiforme (GBM) is characterized by extensive invasion, rapid growth, necrosis, and angiogenesis.",Epidermal growth factor receptor (EGFR) activation by amplification or mutation is one of the most frequent genetic lesions in a variety of human tumors.,False,BACKGROUND
1703,"Glioblastoma multiforme (GBM) is characterized by extensive invasion, rapid growth, necrosis, and angiogenesis.","These include glioblastoma multiforme (GBM), which is characterized by independent but interrelated features of extensive invasion into normal brain parenchyma, rapid growth, necrosis, and angiogenesis.",True,BACKGROUND
1704,"Glioblastoma multiforme (GBM) is characterized by extensive invasion, rapid growth, necrosis, and angiogenesis.","In this study, we show that EGFR activation promoted GBP1 expression in GBM cell lines through a signaling pathway involving Src and p38 mitogen-activated protein kinase.",False,METHODS
1705,"Glioblastoma multiforme (GBM) is characterized by extensive invasion, rapid growth, necrosis, and angiogenesis.","Moreover, we identified YY1 (Yin Yang 1) as the downstream transcriptional regulator regulating EGFR-driven GBP1 expression.",False,METHODS
1706,"Glioblastoma multiforme (GBM) is characterized by extensive invasion, rapid growth, necrosis, and angiogenesis.",GBP1 was required for EGFR-mediated MMP1 (matrix metalloproteinase 1) expression and glioma cell invasion in vitro.,False,RESULTS
1707,"Glioblastoma multiforme (GBM) is characterized by extensive invasion, rapid growth, necrosis, and angiogenesis.","Although deregulation of GBP1 expression did not affect glioma cell proliferation, overexpression of GBP1 enhanced glioma cell invasion through MMP1 induction, which required its C-terminal helical domain and was independent of its GTPase activity.",False,RESULTS
1708,"Glioblastoma multiforme (GBM) is characterized by extensive invasion, rapid growth, necrosis, and angiogenesis.",Reducing GBP1 levels by RNA interference in invasive GBM cells also markedly inhibited their ability to infiltrate the brain parenchyma of mice.,False,RESULTS
1709,"Glioblastoma multiforme (GBM) is characterized by extensive invasion, rapid growth, necrosis, and angiogenesis.","GBP1 expression was high and positively correlated with EGFR expression in human GBM tumors and cell lines, particularly those of the neural subtype.",False,CONCLUSIONS
1710,"Glioblastoma multiforme (GBM) is characterized by extensive invasion, rapid growth, necrosis, and angiogenesis.","Together, these findings establish GBP1 as a previously unknown link between EGFR activity and MMP1 expression and nominate it as a novel potential therapeutic target for inhibiting GBM invasion.",False,CONCLUSIONS
1711,Gpr124 increases BBB breakdown in mouse models of ischemic stroke.,"Although blood–brain barrier (BBB) compromise is central to the etiology of diverse central nervous system (CNS) disorders, endothelial receptor proteins that control BBB function are poorly defined.",False,BACKGROUND
1712,Gpr124 increases BBB breakdown in mouse models of ischemic stroke.,"The endothelial G-protein-coupled receptor (GPCR) Gpr124 has been reported to be required for normal forebrain angiogenesis and BBB function in mouse embryos, but the role of this receptor in adult animals is unknown.",False,BACKGROUND
1713,Gpr124 increases BBB breakdown in mouse models of ischemic stroke.,"Here Gpr124 conditional knockout (CKO) in the endothelia of adult mice did not affect homeostatic BBB integrity, but resulted in BBB disruption and microvascular hemorrhage in mouse models of both ischemic stroke and glioblastoma, accompanied by reduced cerebrovascular canonical Wnt–β-catenin signaling.",True,RESULTS
1714,Gpr124 increases BBB breakdown in mouse models of ischemic stroke.,"Constitutive activation of Wnt–β-catenin signaling fully corrected the BBB disruption and hemorrhage defects of Gpr124-CKO mice, with rescue of the endothelial gene tight junction, pericyte coverage and extracellular-matrix deficits.",False,RESULTS
1715,Gpr124 increases BBB breakdown in mouse models of ischemic stroke.,We thus identify Gpr124 as an endothelial GPCR specifically required for endothelial Wnt signaling and BBB integrity under pathological conditions in adult mice.,False,CONCLUSIONS
1716,Gpr124 increases BBB breakdown in mouse models of ischemic stroke.,This finding implicates Gpr124 as a potential therapeutic target for human CNS disorders characterized by BBB disruption.,False,CONCLUSIONS
1717,Gpr124 suppresses BBB breakdown in mouse models of ischemic stroke.,"Although blood–brain barrier (BBB) compromise is central to the etiology of diverse central nervous system (CNS) disorders, endothelial receptor proteins that control BBB function are poorly defined.",False,BACKGROUND
1718,Gpr124 suppresses BBB breakdown in mouse models of ischemic stroke.,"The endothelial G-protein-coupled receptor (GPCR) Gpr124 has been reported to be required for normal forebrain angiogenesis and BBB function in mouse embryos, but the role of this receptor in adult animals is unknown.",False,BACKGROUND
1719,Gpr124 suppresses BBB breakdown in mouse models of ischemic stroke.,"Here Gpr124 conditional knockout (CKO) in the endothelia of adult mice did not affect homeostatic BBB integrity, but resulted in BBB disruption and microvascular hemorrhage in mouse models of both ischemic stroke and glioblastoma, accompanied by reduced cerebrovascular canonical Wnt–β-catenin signaling.",True,RESULTS
1720,Gpr124 suppresses BBB breakdown in mouse models of ischemic stroke.,"Constitutive activation of Wnt–β-catenin signaling fully corrected the BBB disruption and hemorrhage defects of Gpr124-CKO mice, with rescue of the endothelial gene tight junction, pericyte coverage and extracellular-matrix deficits.",False,RESULTS
1721,Gpr124 suppresses BBB breakdown in mouse models of ischemic stroke.,We thus identify Gpr124 as an endothelial GPCR specifically required for endothelial Wnt signaling and BBB integrity under pathological conditions in adult mice.,False,CONCLUSIONS
1722,Gpr124 suppresses BBB breakdown in mouse models of ischemic stroke.,This finding implicates Gpr124 as a potential therapeutic target for human CNS disorders characterized by BBB disruption.,False,CONCLUSIONS
1723,Guanine nucleotide exchange factors (GEFs) mediate RhoA activation in response to tensional forces on fibronectin-binding integrins.,How individual cells respond to mechanical forces is of considerable interest to biologists as force affects many aspects of cell behaviour.,False,BACKGROUND
1724,Guanine nucleotide exchange factors (GEFs) mediate RhoA activation in response to tensional forces on fibronectin-binding integrins.,"The application of force on integrins triggers cytoskeletal rearrangements and growth of the associated adhesion complex, resulting in increased cellular stiffness, also known as reinforcement.",False,BACKGROUND
1725,Guanine nucleotide exchange factors (GEFs) mediate RhoA activation in response to tensional forces on fibronectin-binding integrins.,"Although RhoA has been shown to play a role during reinforcement, the molecular mechanisms that regulate its activity are unknown.",False,BACKGROUND
1726,Guanine nucleotide exchange factors (GEFs) mediate RhoA activation in response to tensional forces on fibronectin-binding integrins.,"By combining biochemical and biophysical approaches, we identified two guanine nucleotide exchange factors (GEFs), LARG and GEF-H1, as key molecules that regulate the cellular adaptation to force.",True,RESULTS
1727,Guanine nucleotide exchange factors (GEFs) mediate RhoA activation in response to tensional forces on fibronectin-binding integrins.,We show that stimulation of integrins with tensional force triggers activation of these two GEFs and their recruitment to adhesion complexes.,False,RESULTS
1728,Guanine nucleotide exchange factors (GEFs) mediate RhoA activation in response to tensional forces on fibronectin-binding integrins.,"Surprisingly, activation of LARG and GEF-H1 involves distinct signalling pathways.",False,CONCLUSIONS
1729,Guanine nucleotide exchange factors (GEFs) mediate RhoA activation in response to tensional forces on fibronectin-binding integrins.,"Our results reveal that LARG is activated by the Src family tyrosine kinase Fyn, whereas GEF-H1 catalytic activity is enhanced by ERK downstream of a signalling cascade that includes FAK and Ras.",False,CONCLUSIONS
1730,H.pylori-mediated gastric cancer occurs due to the accumulation of mutations in host epithelial cells.,Infection with Helicobacter pylori (H. pylori) is a risk factor for the development of gastric cancer.,False,BACKGROUND
1731,H.pylori-mediated gastric cancer occurs due to the accumulation of mutations in host epithelial cells.,"Here we show that infection of gastric epithelial cells with 'cag' pathogenicity island (cagPAI)-positive H. pylori induced aberrant expression of activation-induced cytidine deaminase (AID), a member of the cytidine-deaminase family that acts as a DNA- and RNA-editing enzyme, via the IκB kinase–dependent nuclear factor-κB activation pathway.",False,BACKGROUND
1732,H.pylori-mediated gastric cancer occurs due to the accumulation of mutations in host epithelial cells.,H. pylori–mediated upregulation of AID resulted in the accumulation of nucleotide alterations in the TP53 tumor suppressor gene in gastric cells in vitro.,True,BACKGROUND
1733,H.pylori-mediated gastric cancer occurs due to the accumulation of mutations in host epithelial cells.,Our findings provide evidence that aberrant AID expression caused by H. pylori infection might be a mechanism of mutation accumulation in the gastric mucosa during H. pylori–associated gastric carcinogenesis.,True,BACKGROUND
1734,HAND2 methylation is a key step in early endometrial carcinogenesis.,BACKGROUND Endometrial cancer incidence is continuing to rise in the wake of the current ageing and obesity epidemics.,False,BACKGROUND
1735,HAND2 methylation is a key step in early endometrial carcinogenesis.,Much of the risk for endometrial cancer development is influenced by the environment and lifestyle.,False,BACKGROUND
1736,HAND2 methylation is a key step in early endometrial carcinogenesis.,Accumulating evidence suggests that the epigenome serves as the interface between the genome and the environment and that hypermethylation of stem cell polycomb group target genes is an epigenetic hallmark of cancer.,False,BACKGROUND
1737,HAND2 methylation is a key step in early endometrial carcinogenesis.,"The objective of this study was to determine the functional role of epigenetic factors in endometrial cancer development.   
",False,BACKGROUND
1738,HAND2 methylation is a key step in early endometrial carcinogenesis.,"METHODS AND FINDINGS Epigenome-wide methylation analysis of >27,000 CpG sites in endometrial cancer tissue samples (n = 64) and control samples (n = 23) revealed that HAND2 (a gene encoding a transcription factor expressed in the endometrial stroma) is one of the most commonly hypermethylated and silenced genes in endometrial cancer.",True,RESULTS
1739,HAND2 methylation is a key step in early endometrial carcinogenesis.,A novel integrative epigenome-transcriptome-interactome analysis further revealed that HAND2 is the hub of the most highly ranked differential methylation hotspot in endometrial cancer.,False,RESULTS
1740,HAND2 methylation is a key step in early endometrial carcinogenesis.,These findings were validated using candidate gene methylation analysis in multiple clinical sample sets of tissue samples from a total of 272 additional women.,False,RESULTS
1741,HAND2 methylation is a key step in early endometrial carcinogenesis.,Increased HAND2 methylation was a feature of premalignant endometrial lesions and was seen to parallel a decrease in RNA and protein levels.,True,RESULTS
1742,HAND2 methylation is a key step in early endometrial carcinogenesis.,"Furthermore, women with high endometrial HAND2 methylation in their premalignant lesions were less likely to respond to progesterone treatment.",False,RESULTS
1743,HAND2 methylation is a key step in early endometrial carcinogenesis.,HAND2 methylation analysis of endometrial secretions collected using high vaginal swabs taken from women with postmenopausal bleeding specifically identified those patients with early stage endometrial cancer with both high sensitivity and high specificity (receiver operating characteristics area under the curve = 0.91 for stage 1A and 0.97 for higher than stage 1A).,True,RESULTS
1744,HAND2 methylation is a key step in early endometrial carcinogenesis.,"Finally, mice harbouring a Hand2 knock-out specifically in their endometrium were shown to develop precancerous endometrial lesions with increasing age, and these lesions also demonstrated a lack of PTEN expression.   
",False,RESULTS
1745,HAND2 methylation is a key step in early endometrial carcinogenesis.,CONCLUSIONS HAND2 methylation is a common and crucial molecular alteration in endometrial cancer that could potentially be employed as a biomarker for early detection of endometrial cancer and as a predictor of treatment response.,True,CONCLUSIONS
1746,HAND2 methylation is a key step in early endometrial carcinogenesis.,"The true clinical utility of HAND2 DNA methylation, however, requires further validation in prospective studies.",False,CONCLUSIONS
1747,HAND2 methylation is a key step in early endometrial carcinogenesis.,Please see later in the article for the Editors' Summary.,False,CONCLUSIONS
1748,Having a main partner improves HIV outcomes.,"OBJECTIVES To explore the association between a stable partnership and clinical outcome in HIV infected patients receiving highly active antiretroviral therapy (HAART).   
",False,OBJECTIVE
1749,Having a main partner improves HIV outcomes.,"DESIGN Prospective cohort study of adults with HIV (Swiss HIV cohort study).   
",False,METHODS
1750,Having a main partner improves HIV outcomes.,"SETTING Seven outpatient clinics throughout Switzerland.   
",False,METHODS
1751,Having a main partner improves HIV outcomes.,"PARTICIPANTS The 3736 patients in the cohort who started HAART before 2002 (median age 36 years, 29% female, median follow up 3.6 years).   
",False,METHODS
1752,Having a main partner improves HIV outcomes.,"MAIN OUTCOME MEASURES Time to AIDS or death (primary endpoint), death alone, increases in CD4 cell count of at least 50 and 100 above baseline, optimal viral suppression (a viral load below 400 copies/ml), and viral rebound.   
",False,METHODS
1753,Having a main partner improves HIV outcomes.,RESULTS During follow up 2985 (80%) participants reported a stable partnership on at least one occasion.,False,RESULTS
1754,Having a main partner improves HIV outcomes.,"When starting HAART, 52% (545/1042) of participants reported a stable partnership; after five years of follow up 46% (190/412) of participants reported a stable partnership.",False,RESULTS
1755,Having a main partner improves HIV outcomes.,"In an analysis stratified by previous antiretroviral therapy and clinical stage when starting HAART (US Centers for Disease Control and Prevention group A, B, or C), the adjusted hazard ratio for progression to AIDS or death was 0.79 (95% confidence interval 0.63 to 0.98) for participants with a stable partnership compared with those without.",True,RESULTS
1756,Having a main partner improves HIV outcomes.,"Adjusted hazards ratios for other endpoints were 0.59 (0.44 to 0.79) for progression to death, 1.15 (1.06 to 1.24) for an increase in CD4 cells of 100 counts/microl or more, and 1.06 (0.98 to 1.14) for optimal viral suppression.   
",False,RESULTS
1757,Having a main partner improves HIV outcomes.,CONCLUSIONS A stable partnership is associated with a slower rate of progression to AIDS or death in HIV infected patients receiving HAART.,True,CONCLUSIONS
1758,Having a main partner worsens HIV outcomes.,"OBJECTIVES To explore the association between a stable partnership and clinical outcome in HIV infected patients receiving highly active antiretroviral therapy (HAART).   
",False,OBJECTIVE
1759,Having a main partner worsens HIV outcomes.,"DESIGN Prospective cohort study of adults with HIV (Swiss HIV cohort study).   
",False,METHODS
1760,Having a main partner worsens HIV outcomes.,"SETTING Seven outpatient clinics throughout Switzerland.   
",False,METHODS
1761,Having a main partner worsens HIV outcomes.,"PARTICIPANTS The 3736 patients in the cohort who started HAART before 2002 (median age 36 years, 29% female, median follow up 3.6 years).   
",False,METHODS
1762,Having a main partner worsens HIV outcomes.,"MAIN OUTCOME MEASURES Time to AIDS or death (primary endpoint), death alone, increases in CD4 cell count of at least 50 and 100 above baseline, optimal viral suppression (a viral load below 400 copies/ml), and viral rebound.   
",False,METHODS
1763,Having a main partner worsens HIV outcomes.,RESULTS During follow up 2985 (80%) participants reported a stable partnership on at least one occasion.,False,RESULTS
1764,Having a main partner worsens HIV outcomes.,"When starting HAART, 52% (545/1042) of participants reported a stable partnership; after five years of follow up 46% (190/412) of participants reported a stable partnership.",False,RESULTS
1765,Having a main partner worsens HIV outcomes.,"In an analysis stratified by previous antiretroviral therapy and clinical stage when starting HAART (US Centers for Disease Control and Prevention group A, B, or C), the adjusted hazard ratio for progression to AIDS or death was 0.79 (95% confidence interval 0.63 to 0.98) for participants with a stable partnership compared with those without.",True,RESULTS
1766,Having a main partner worsens HIV outcomes.,"Adjusted hazards ratios for other endpoints were 0.59 (0.44 to 0.79) for progression to death, 1.15 (1.06 to 1.24) for an increase in CD4 cells of 100 counts/microl or more, and 1.06 (0.98 to 1.14) for optimal viral suppression.   
",False,RESULTS
1767,Having a main partner worsens HIV outcomes.,CONCLUSIONS A stable partnership is associated with a slower rate of progression to AIDS or death in HIV infected patients receiving HAART.,True,CONCLUSIONS
1768,HbA1c consistently overestimates glycemic control in black individuals with Sickle cell trait (SCT).,"Importance Hemoglobin A1c (HbA1c) reflects past glucose concentrations, but this relationship may differ between those with sickle cell trait (SCT) and those without it.",False,BACKGROUND
1769,HbA1c consistently overestimates glycemic control in black individuals with Sickle cell trait (SCT).,Objective To evaluate the association between SCT and HbA1c for given levels of fasting or 2-hour glucose levels among African Americans.,False,OBJECTIVE
1770,HbA1c consistently overestimates glycemic control in black individuals with Sickle cell trait (SCT).,"Design, Setting, and Participants Retrospective cohort study using data collected from 7938 participants in 2 community-based cohorts, the Coronary Artery Risk Development in Young Adults (CARDIA) study and the Jackson Heart Study (JHS).",False,METHODS
1771,HbA1c consistently overestimates glycemic control in black individuals with Sickle cell trait (SCT).,"From the CARDIA study, 2637 patients contributed a maximum of 2 visits (2005-2011); from the JHS, 5301 participants contributed a maximum of 3 visits (2000-2013).",False,METHODS
1772,HbA1c consistently overestimates glycemic control in black individuals with Sickle cell trait (SCT).,All visits were scheduled at approximately 5-year intervals.,False,METHODS
1773,HbA1c consistently overestimates glycemic control in black individuals with Sickle cell trait (SCT).,"Participants without SCT data, those without any concurrent HbA1c and glucose measurements, and those with hemoglobin variants HbSS, HbCC, or HbAC were excluded.",False,METHODS
1774,HbA1c consistently overestimates glycemic control in black individuals with Sickle cell trait (SCT).,"Analysis of the primary outcome was conducted using generalized estimating equations (GEE) to examine the association of SCT with HbA1c levels, controlling for fasting or 2-hour glucose measures.",False,METHODS
1775,HbA1c consistently overestimates glycemic control in black individuals with Sickle cell trait (SCT).,Exposures Presence of SCT.,False,METHODS
1776,HbA1c consistently overestimates glycemic control in black individuals with Sickle cell trait (SCT).,Main Outcomes and Measures Hemoglobin A1c stratified by the presence or absence of SCT was the primary outcome measure.,False,METHODS
1777,HbA1c consistently overestimates glycemic control in black individuals with Sickle cell trait (SCT).,"Results The analytic sample included 4620 participants (mean age, 52.3 [SD, 11.8] years; 2835 women [61.3%]; 367 [7.9%] with SCT) with 9062 concurrent measures of fasting glucose and HbA1c levels.",False,RESULTS
1778,HbA1c consistently overestimates glycemic control in black individuals with Sickle cell trait (SCT).,"In unadjusted GEE analyses, for a given fasting glucose, HbA1c values were statistically significantly lower in those with (5.72%) vs those without (6.01%) SCT (mean HbA1c difference, −0.29%; 95% CI, −0.35% to −0.23%).",True,RESULTS
1779,HbA1c consistently overestimates glycemic control in black individuals with Sickle cell trait (SCT).,"Findings were similar in models adjusted for key risk factors and in analyses using 2001 concurrent measures of 2-hour glucose and HbA1c concentration for those with SCT (mean, 5.35%) vs those without SCT (mean, 5.65%) for a mean HbA1c difference of −0.30% (95% CI, −0.39% to −0.21%).",True,RESULTS
1780,HbA1c consistently overestimates glycemic control in black individuals with Sickle cell trait (SCT).,The HbA1c difference by SCT was greater at higher fasting (P = .02 for interaction) and 2-hour (P = .03) glucose concentrations.,False,RESULTS
1781,HbA1c consistently overestimates glycemic control in black individuals with Sickle cell trait (SCT).,The prevalence of prediabetes and diabetes was statistically significantly lower among participants with SCT when defined using HbA1c values (29.2% vs 48.6% for prediabetes and 3.8% vs 7.3% for diabetes in 572 observations from participants with SCT and 6877 observations from participants without SCT; P<.001 for both comparisons).,True,RESULTS
1782,HbA1c consistently overestimates glycemic control in black individuals with Sickle cell trait (SCT).,"Conclusions and Relevance Among African Americans from 2 large, well-established cohorts, participants with SCT had lower levels of HbA1c at any given concentration of fasting or 2-hour glucose compared with participants without SCT.",True,CONCLUSIONS
1783,HbA1c consistently overestimates glycemic control in black individuals with Sickle cell trait (SCT).,These findings suggest that HbA1c may systematically underestimate past glycemia in black patients with SCT and may require further evaluation.,True,CONCLUSIONS
1784,Headaches are correlated with cognitive impairment.,"OBJECTIVE To evaluate the association of overall and specific headaches with volume of white matter hyperintensities, brain infarcts, and cognition.   
",False,OBJECTIVE
1785,Headaches are correlated with cognitive impairment.,"DESIGN Population based, cross sectional study.   
",False,METHODS
1786,Headaches are correlated with cognitive impairment.,"SETTING Epidemiology of Vascular Ageing study, Nantes, France.   
",False,METHODS
1787,Headaches are correlated with cognitive impairment.,"PARTICIPANTS 780 participants (mean age 69, 58.5% women) with detailed headache assessment.   
",False,METHODS
1788,Headaches are correlated with cognitive impairment.,MAIN OUTCOME MEASURES Brain scans were evaluated for volume of white matter hyperintensities (by fully automated imaging processing) and for classification of infarcts (by visual reading with a standardised assessment grid).,False,METHODS
1789,Headaches are correlated with cognitive impairment.,"Cognitive function was assessed by a battery of tests including the mini-mental state examination.   
",False,METHODS
1790,Headaches are correlated with cognitive impairment.,"RESULTS 163 (20.9%) participants reported a history of severe headache and 116 had migraine, of whom 17 (14.7%) reported aura symptoms.",False,RESULTS
1791,Headaches are correlated with cognitive impairment.,An association was found between any history of severe headache and increasing volume of white matter hyperintensities.,False,RESULTS
1792,Headaches are correlated with cognitive impairment.,"The adjusted odds ratio of being in the highest third for total volume of white matter hyperintensities was 2.0 (95% confidence interval 1.3 to 3.1, P for trend 0.002) for participants with any history of severe headache when compared with participants without severe headache being in the lowest third.",False,RESULTS
1793,Headaches are correlated with cognitive impairment.,The association pattern was similar for all headache types.,False,RESULTS
1794,Headaches are correlated with cognitive impairment.,"Migraine with aura was the only headache type strongly associated with volume of deep white matter hyperintensities (highest third odds ratio 12.4, 1.6 to 99.4, P for trend 0.005) and with brain infarcts (3.4, 1.2 to 9.3).",False,RESULTS
1795,Headaches are correlated with cognitive impairment.,The location of infarcts was predominantly outside the cerebellum and brain stem.,False,RESULTS
1796,Headaches are correlated with cognitive impairment.,"Evidence was lacking for cognitive impairment for any headache type with or without brain lesions.   
",True,RESULTS
1797,Headaches are correlated with cognitive impairment.,"CONCLUSIONS In this population based study, any history of severe headache was associated with an increased volume of white matter hyperintensities.",False,CONCLUSIONS
1798,Headaches are correlated with cognitive impairment.,Migraine with aura was the only headache type associated with brain infarcts.,False,CONCLUSIONS
1799,Headaches are correlated with cognitive impairment.,Evidence that headache of any type by itself or in combination with brain lesions was associated with cognitive impairment was lacking.,False,CONCLUSIONS
1800,Healthy volunteers exhibit rapid and transient increase of cellular ATP after being bolus-injected with fructose.,CONTEXT The mechanisms that drive progression from fatty liver to steatohepatitis and cirrhosis are unknown.,False,BACKGROUND
1801,Healthy volunteers exhibit rapid and transient increase of cellular ATP after being bolus-injected with fructose.,"In animal models, obese mice with fatty livers are vulnerable to liver adenosine triphosphate (ATP) depletion and necrosis, suggesting that altered hepatic energy homeostasis may be involved.   
",False,BACKGROUND
1802,Healthy volunteers exhibit rapid and transient increase of cellular ATP after being bolus-injected with fructose.,"OBJECTIVE To determine if patients with fatty liver disease exhibit impaired recovery from hepatic ATP depletion.   
",False,OBJECTIVE
1803,Healthy volunteers exhibit rapid and transient increase of cellular ATP after being bolus-injected with fructose.,DESIGN Laboratory analysis of liver ATP stores monitored by nuclear magnetic resonance spectroscopy before and after transient hepatic ATP depletion was induced by fructose injection.,False,METHODS
1804,Healthy volunteers exhibit rapid and transient increase of cellular ATP after being bolus-injected with fructose.,"The study was conducted between July 15 and August 30, 1998.   
",False,METHODS
1805,Healthy volunteers exhibit rapid and transient increase of cellular ATP after being bolus-injected with fructose.,"SETTING University hospital.   
",False,METHODS
1806,Healthy volunteers exhibit rapid and transient increase of cellular ATP after being bolus-injected with fructose.,"PATIENTS Eight consecutive adults with biopsy-proven nonalcoholic steatohepatitis and 7 healthy age- and sex-matched controls.   
",False,METHODS
1807,Healthy volunteers exhibit rapid and transient increase of cellular ATP after being bolus-injected with fructose.,"MAIN OUTCOME MEASURE Level of ATP 1 hour after fructose infusion in patients vs controls.   
",False,METHODS
1808,Healthy volunteers exhibit rapid and transient increase of cellular ATP after being bolus-injected with fructose.,"RESULTS In patients, serum aminotransferase levels were increased (P = .02 vs controls); albumin and bilirubin values were normal and clinical evidence of portal hypertension was absent in both groups.",False,RESULTS
1809,Healthy volunteers exhibit rapid and transient increase of cellular ATP after being bolus-injected with fructose.,"However, 2 patients had moderate fibrosis and 1 had cirrhosis on liver biopsy.",False,RESULTS
1810,Healthy volunteers exhibit rapid and transient increase of cellular ATP after being bolus-injected with fructose.,"Mean serum glucose, cholesterol, and triglyceride levels were similar between groups but patients weighed significantly more than controls (P = .02).",False,RESULTS
1811,Healthy volunteers exhibit rapid and transient increase of cellular ATP after being bolus-injected with fructose.,Liver ATP levels were similar in the 2 groups before fructose infusion and decreased similarly in both after fructose infusion (P = .01 vs initial ATP levels).,True,RESULTS
1812,Healthy volunteers exhibit rapid and transient increase of cellular ATP after being bolus-injected with fructose.,"However, controls replenished their hepatic ATP stores during the 1-hour follow-up period (P<.02 vs minimum ATP) but patients did not.",False,RESULTS
1813,Healthy volunteers exhibit rapid and transient increase of cellular ATP after being bolus-injected with fructose.,"Hence, patients' hepatic ATP levels were lower than those of controls at the end of the study (P = .04).",False,RESULTS
1814,Healthy volunteers exhibit rapid and transient increase of cellular ATP after being bolus-injected with fructose.,"Body mass index (BMI) correlated inversely with ATP recovery, even in controls (R = -0.768; P = .07).",False,RESULTS
1815,Healthy volunteers exhibit rapid and transient increase of cellular ATP after being bolus-injected with fructose.,"Although BMI was greater in patients than controls (P = .02) and correlated strongly with fatty liver and serum aminotransferase elevations, neither of the latter 2 parameters nor the histologic severity of fibrosis strongly predicted hepatic ATP recovery.   
",False,RESULTS
1816,Healthy volunteers exhibit rapid and transient increase of cellular ATP after being bolus-injected with fructose.,CONCLUSIONS These data suggest that recovery from hepatic ATP depletion becomes progressively less efficient as body mass increases in healthy controls and is severely impaired in patients with obesity-related nonalcoholic steatohepatitis.,False,CONCLUSIONS
1817,Helicobacter pylori-induced aberrant NF-kB-dependent expression of activation-induced cytidine deaminase contributes to the mutagenesis of host DNA.,Infection with Helicobacter pylori (H. pylori) is a risk factor for the development of gastric cancer.,False,BACKGROUND
1818,Helicobacter pylori-induced aberrant NF-kB-dependent expression of activation-induced cytidine deaminase contributes to the mutagenesis of host DNA.,"Here we show that infection of gastric epithelial cells with 'cag' pathogenicity island (cagPAI)-positive H. pylori induced aberrant expression of activation-induced cytidine deaminase (AID), a member of the cytidine-deaminase family that acts as a DNA- and RNA-editing enzyme, via the IκB kinase–dependent nuclear factor-κB activation pathway.",True,BACKGROUND
1819,Helicobacter pylori-induced aberrant NF-kB-dependent expression of activation-induced cytidine deaminase contributes to the mutagenesis of host DNA.,H. pylori–mediated upregulation of AID resulted in the accumulation of nucleotide alterations in the TP53 tumor suppressor gene in gastric cells in vitro.,False,BACKGROUND
1820,Helicobacter pylori-induced aberrant NF-kB-dependent expression of activation-induced cytidine deaminase contributes to the mutagenesis of host DNA.,Our findings provide evidence that aberrant AID expression caused by H. pylori infection might be a mechanism of mutation accumulation in the gastric mucosa during H. pylori–associated gastric carcinogenesis.,True,BACKGROUND
1821,Helminths interfere with immune system control of coinfections by microbial pathogens 16.,"Tuberculosis and helminthic infections coexist in many parts of the world, yet the impact of helminth-elicited Th2 responses on the ability of the host to control Mycobacterium tuberculosis (Mtb) infection has not been fully explored.",False,BACKGROUND
1822,Helminths interfere with immune system control of coinfections by microbial pathogens 16.,We show that mice infected with the intestinal helminth Nippostrongylus brasiliensis (Nb) exhibit a transitory impairment of resistance to airborne Mtb infection.,True,BACKGROUND
1823,Helminths interfere with immune system control of coinfections by microbial pathogens 16.,"Furthermore, a second dose of Nb infection substantially increases the bacterial burden in the lungs of co-infected mice.",True,BACKGROUND
1824,Helminths interfere with immune system control of coinfections by microbial pathogens 16.,"Interestingly, the Th2 response in the co-infected animals did not impair the onset and development of the protective Mtb-specific Th1 cellular immune responses.",False,RESULTS
1825,Helminths interfere with immune system control of coinfections by microbial pathogens 16.,"However, the helminth-induced Th2 environment resulted in the accumulation of alternatively activated macrophages (AAMs) in the lung.",False,RESULTS
1826,Helminths interfere with immune system control of coinfections by microbial pathogens 16.,"Co-infected mice lacking interleukin (IL) 4Rα exhibited improved ability to control Mtb infection, which was accompanied by significantly reduced accumulation of AAMs.",False,RESULTS
1827,Helminths interfere with immune system control of coinfections by microbial pathogens 16.,"Moreover, IL-4Rα(-/-) mice adoptively transferred with wild-type macrophages had a significantly higher Mtb load in their lungs compared with those that received IL-4Rα(-/-) macrophages, suggesting a direct contribution for the IL-4R pathway to the heightened susceptibility of co-infected animals.",False,RESULTS
1828,Helminths interfere with immune system control of coinfections by microbial pathogens 16.,"The Th2 response can thus enhance the intracellular persistence of Mtb, in part by mediating the alternative activation of macrophages via the IL-4Rα signaling pathway.",True,CONCLUSIONS
1829,High levels of CRP lead to a higher risk of exacerbations in chronic obstructive pulmonary disease (COPD).,"IMPORTANCE Exacerbations of respiratory symptoms in chronic obstructive pulmonary disease (COPD) have profound and long-lasting adverse effects on patients.   
",False,BACKGROUND
1830,High levels of CRP lead to a higher risk of exacerbations in chronic obstructive pulmonary disease (COPD).,"OBJECTIVE To test the hypothesis that elevated levels of inflammatory biomarkers in individuals with stable COPD are associated with an increased risk of having exacerbations.   
",False,OBJECTIVE
1831,High levels of CRP lead to a higher risk of exacerbations in chronic obstructive pulmonary disease (COPD).,"DESIGN, SETTING, AND PARTICIPANTS Prospective cohort study examining 61,650 participants with spirometry measurements from the Copenhagen City Heart Study (2001-2003) and the Copenhagen General Population Study (2003-2008).",False,METHODS
1832,High levels of CRP lead to a higher risk of exacerbations in chronic obstructive pulmonary disease (COPD).,"Of these, 6574 had COPD, defined as a ratio between forced expiratory volume in 1 second (FEV1) and forced vital capacity below 0.7.   
",False,METHODS
1833,High levels of CRP lead to a higher risk of exacerbations in chronic obstructive pulmonary disease (COPD).,MAIN OUTCOMES AND MEASURES Baseline levels of C-reactive protein (CRP) and fibrinogen and leukocyte count were measured in participants at a time when they were not experiencing symptoms of exacerbations.,False,METHODS
1834,High levels of CRP lead to a higher risk of exacerbations in chronic obstructive pulmonary disease (COPD).,Exacerbations were recorded and defined as short-course treatment with oral corticosteroids alone or in combination with an antibiotic or as a hospital admission due to COPD.,False,METHODS
1835,High levels of CRP lead to a higher risk of exacerbations in chronic obstructive pulmonary disease (COPD).,"Levels of CRP and fibrinogen and leukocyte count were defined as high or low according to cut points of 3 mg/L, 14 μmol/L, and 9 ×10(9)/L, respectively.   
",False,METHODS
1836,High levels of CRP lead to a higher risk of exacerbations in chronic obstructive pulmonary disease (COPD).,"RESULTS During follow-up, 3083 exacerbations were recorded (mean, 0.5/participant).",False,RESULTS
1837,High levels of CRP lead to a higher risk of exacerbations in chronic obstructive pulmonary disease (COPD).,"In the first year of follow-up, multivariable-adjusted odds ratios for having frequent exacerbations were 1.2 (95% CI, 0.7-2.2; 17 events/1000 person-years) for individuals with 1 high biomarker, 1.7 (95% CI, 0.9-3.2; 32 events/1000 person-years) for individuals with 2 high biomarkers, and 3.7 (95% CI, 1.9-7.4; 81 events/1000 person-years) for individuals with 3 high biomarkers compared with individuals who had no elevated biomarkers (9 events/1000 person-years; trend: P = 2 × 10(-5)).",True,RESULTS
1838,High levels of CRP lead to a higher risk of exacerbations in chronic obstructive pulmonary disease (COPD).,"Corresponding hazard ratios using maximum follow-up time were 1.4 (95% CI, 1.1-1.8), 1.6 (95% CI, 1.3-2.2), and 2.5 (95% CI, 1.8-3.4), respectively (trend: P = 1 × 10(-8)).",False,RESULTS
1839,High levels of CRP lead to a higher risk of exacerbations in chronic obstructive pulmonary disease (COPD).,"The addition of inflammatory biomarkers to a basic model including age, sex, FEV1 percent predicted, smoking, use of any inhaled medication, body mass index, history of previous exacerbations, and time since most recent prior exacerbation improved the C statistics from 0.71 to 0.73 (comparison: P = 9 × 10(-5)).",False,RESULTS
1840,High levels of CRP lead to a higher risk of exacerbations in chronic obstructive pulmonary disease (COPD).,"Relative risks were consistent in those with milder COPD, in those with no history of frequent exacerbations, and in the 2 studies separately.",False,RESULTS
1841,High levels of CRP lead to a higher risk of exacerbations in chronic obstructive pulmonary disease (COPD).,"The highest 5-year absolute risks of having frequent exacerbations in those with 3 high biomarkers (vs no high biomarkers) were 62% (vs 24%) for those with Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades C-D (n = 558), 98% (vs 64%) in those with a history of frequent exacerbations (n = 127), and 52% (vs 15%) for those with GOLD grades 3-4 (n = 465).   
",False,RESULTS
1842,High levels of CRP lead to a higher risk of exacerbations in chronic obstructive pulmonary disease (COPD).,"CONCLUSIONS AND RELEVANCE Simultaneously elevated levels of CRP and fibrinogen and leukocyte count in individuals with COPD were associated with increased risk of having exacerbations, even in those with milder COPD and in those without previous exacerbations.",True,CONCLUSIONS
1843,High levels of CRP lead to a higher risk of exacerbations in chronic obstructive pulmonary disease (COPD).,Further investigation is needed to determine the clinical value of these biomarkers for risk stratification.,False,CONCLUSIONS
1844,"Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are negatively correlated with cardiovascular events in humans.","Intestinal microbiota metabolism of choline and phosphatidylcholine produces trimethylamine (TMA), which is further metabolized to a proatherogenic species, trimethylamine-N-oxide (TMAO).",False,BACKGROUND
1845,"Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are negatively correlated with cardiovascular events in humans.","We demonstrate here that metabolism by intestinal microbiota of dietary L-carnitine, a trimethylamine abundant in red meat, also produces TMAO and accelerates atherosclerosis in mice.",True,BACKGROUND
1846,"Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are negatively correlated with cardiovascular events in humans.",Omnivorous human subjects produced more TMAO than did vegans or vegetarians following ingestion of L-carnitine through a microbiota-dependent mechanism.,False,RESULTS
1847,"Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are negatively correlated with cardiovascular events in humans.",The presence of specific bacterial taxa in human feces was associated with both plasma TMAO concentration and dietary status.,False,RESULTS
1848,"Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are negatively correlated with cardiovascular events in humans.","Plasma L-carnitine levels in subjects undergoing cardiac evaluation (n = 2,595) predicted increased risks for both prevalent cardiovascular disease (CVD) and incident major adverse cardiac events (myocardial infarction, stroke or death), but only among subjects with concurrently high TMAO levels.",False,RESULTS
1849,"Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are negatively correlated with cardiovascular events in humans.","Chronic dietary L-carnitine supplementation in mice altered cecal microbial composition, markedly enhanced synthesis of TMA and TMAO, and increased atherosclerosis, but this did not occur if intestinal microbiota was concurrently suppressed.",True,RESULTS
1850,"Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are negatively correlated with cardiovascular events in humans.","In mice with an intact intestinal microbiota, dietary supplementation with TMAO or either carnitine or choline reduced in vivo reverse cholesterol transport.",False,CONCLUSIONS
1851,"Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are negatively correlated with cardiovascular events in humans.",Intestinal microbiota may thus contribute to the well-established link between high levels of red meat consumption and CVD risk.,False,CONCLUSIONS
1852,"Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are positively correlated with cardiovascular events in humans.","Intestinal microbiota metabolism of choline and phosphatidylcholine produces trimethylamine (TMA), which is further metabolized to a proatherogenic species, trimethylamine-N-oxide (TMAO).",False,BACKGROUND
1853,"Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are positively correlated with cardiovascular events in humans.","We demonstrate here that metabolism by intestinal microbiota of dietary L-carnitine, a trimethylamine abundant in red meat, also produces TMAO and accelerates atherosclerosis in mice.",True,BACKGROUND
1854,"Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are positively correlated with cardiovascular events in humans.",Omnivorous human subjects produced more TMAO than did vegans or vegetarians following ingestion of L-carnitine through a microbiota-dependent mechanism.,False,RESULTS
1855,"Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are positively correlated with cardiovascular events in humans.",The presence of specific bacterial taxa in human feces was associated with both plasma TMAO concentration and dietary status.,False,RESULTS
1856,"Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are positively correlated with cardiovascular events in humans.","Plasma L-carnitine levels in subjects undergoing cardiac evaluation (n = 2,595) predicted increased risks for both prevalent cardiovascular disease (CVD) and incident major adverse cardiac events (myocardial infarction, stroke or death), but only among subjects with concurrently high TMAO levels.",False,RESULTS
1857,"Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are positively correlated with cardiovascular events in humans.","Chronic dietary L-carnitine supplementation in mice altered cecal microbial composition, markedly enhanced synthesis of TMA and TMAO, and increased atherosclerosis, but this did not occur if intestinal microbiota was concurrently suppressed.",True,RESULTS
1858,"Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are positively correlated with cardiovascular events in humans.","In mice with an intact intestinal microbiota, dietary supplementation with TMAO or either carnitine or choline reduced in vivo reverse cholesterol transport.",False,CONCLUSIONS
1859,"Higher plasma levels of I-carnitine, when associated with trimethylamine N-oxide, are positively correlated with cardiovascular events in humans.",Intestinal microbiota may thus contribute to the well-established link between high levels of red meat consumption and CVD risk.,False,CONCLUSIONS
1860,Human embryonic stem cells give rise to cell types from all three embryonic germ layers.,Somatic cell nuclear transfer (SCNT) technology has recently been used to generate animals with a common genetic composition.,False,BACKGROUND
1861,Human embryonic stem cells give rise to cell types from all three embryonic germ layers.,"In this study, we report the derivation of a pluripotent embryonic stem (ES) cell line (SCNT-hES-1) from a cloned human blastocyst.",False,BACKGROUND
1862,Human embryonic stem cells give rise to cell types from all three embryonic germ layers.,The SCNT-hES-1 cells displayed typical ES cell morphology and cell surface markers and were capable of differentiating into embryoid bodies in vitro and of forming teratomas in vivo containing cell derivatives from all three embryonic germ layers in severe combined immunodeficient mice.,True,RESULTS
1863,Human embryonic stem cells give rise to cell types from all three embryonic germ layers.,"After continuous proliferation for more than 70 passages, SCNT-hES-1 cells maintained normal karyotypes and were genetically identical to the somatic nuclear donor cells.",False,RESULTS
1864,Human embryonic stem cells give rise to cell types from all three embryonic germ layers.,"Although we cannot completely exclude the possibility that the cells had a parthenogenetic origin, imprinting analyses support a SCNT origin of the derived human ES cells.",False,RESULTS
1865,Human embryonic stem cells give rise to cell types from all three embryonic germ layers.,Embryonic stem (ES) cell lines derived from human blastocysts have the developmental potential to form derivatives of all three embryonic germ layers even after prolonged culture.,True,BACKGROUND
1866,Human embryonic stem cells give rise to cell types from all three embryonic germ layers.,"Here we describe the clonal derivation of two human ES cell lines, H9.1 and H9.2.",False,BACKGROUND
1867,Human embryonic stem cells give rise to cell types from all three embryonic germ layers.,"At the time of the clonal derivation of the H9.1 and H9.2 ES cell lines, the parental ES cell line, H9, had already been continuously cultured for 6 months.",False,RESULTS
1868,Human embryonic stem cells give rise to cell types from all three embryonic germ layers.,"After an additional 8 months of culture, H9.1 and H9.2 ES cell lines continued to: (1) actively proliferate, (2) express high levels of telomerase, and (3) retain normal karyotypes.",False,RESULTS
1869,Human embryonic stem cells give rise to cell types from all three embryonic germ layers.,"Telomere lengths, while somewhat variable, were maintained between 8 and 12 kb in high-passage H9.1 and H9.2 cells.",False,RESULTS
1870,Human embryonic stem cells give rise to cell types from all three embryonic germ layers.,High-passage H9.1 and H9.2 cells both formed teratomas in SCID-beige mice that included differentiated derivatives of all three embryonic germ layers.,True,RESULTS
1871,Human embryonic stem cells give rise to cell types from all three embryonic germ layers.,"These results demonstrate the pluripotency of single human ES cells, the maintenance of pluripotency during an extended period of culture, and the long-term self-renewing properties of cultured human ES cells.",False,CONCLUSIONS
1872,Human embryonic stem cells give rise to cell types from all three embryonic germ layers.,"The remarkable developmental potential, proliferative capacity, and karyotypic stability of human ES cells distinguish them from adult cells.",False,CONCLUSIONS
1873,Human embryonic stem cells give rise to cell types from all three embryonic germ layers.,Embryonic stem cells have the ability to remain undifferentiated and proliferate indefinitely in vitro while maintaining the potential to differentiate into derivatives of all three embryonic germ layers.,True,BACKGROUND
1874,Human embryonic stem cells give rise to cell types from all three embryonic germ layers.,"These cells have, therefore, potential for in vitro differentiation studies, gene function, and so on.",False,BACKGROUND
1875,Human embryonic stem cells give rise to cell types from all three embryonic germ layers.,The aim of this study was to produce a human embryonic stem cell line.,False,BACKGROUND
1876,Human embryonic stem cells give rise to cell types from all three embryonic germ layers.,An inner cell mass of a human blastocyst was separated and cultured on mouse embryonic fibroblasts in embryonic stem cell medium with related additives.,False,METHODS
1877,Human embryonic stem cells give rise to cell types from all three embryonic germ layers.,The established line was evaluated by morphology; passaging; freezing and thawing; alkaline phosphatase; Oct-4 expression; anti-surface markers including Tra-1-60 and Tra-1-81; and karyotype and spontaneous differentiation.,False,METHODS
1878,Human embryonic stem cells give rise to cell types from all three embryonic germ layers.,Differentiated cardiomyocytes and neurons were evaluated by transmission electron microscopy and immunocytochemistry.,False,METHODS
1879,Human embryonic stem cells give rise to cell types from all three embryonic germ layers.,"Here, we report the derivation of a new embryonic stem cell line (Royan H1) from a human blastocyst that remains undifferentiated in morphology during continuous passaging for more than 30 passages, maintains a normal XX karyotype, is viable after freezing and thawing, and expresses alkaline phosphatase, Oct-4, Tra-1-60, and Tra-1-81.",False,RESULTS
1880,Human embryonic stem cells give rise to cell types from all three embryonic germ layers.,These cells remain undifferentiated when grown on mouse embryonic fibroblast feeder layers in the presence or absence of recombinant human leukemia inhibitory factor.,False,RESULTS
1881,Human embryonic stem cells give rise to cell types from all three embryonic germ layers.,Royan H1 cells can differentiate in vitro in the absence of feeder cells and can produce embryoid bodies that can further differentiate into beating cardiomyocytes as well as neurons.,False,RESULTS
1882,Human embryonic stem cells give rise to cell types from all three embryonic germ layers.,These results define Royan H1 cells as a new human embryonic stem cell line.,False,CONCLUSIONS
1883,"Human embryonic stem cells give rise to cell types from the outer embryonic germ layer, but not the other two layers.",Somatic cell nuclear transfer (SCNT) technology has recently been used to generate animals with a common genetic composition.,False,BACKGROUND
1884,"Human embryonic stem cells give rise to cell types from the outer embryonic germ layer, but not the other two layers.","In this study, we report the derivation of a pluripotent embryonic stem (ES) cell line (SCNT-hES-1) from a cloned human blastocyst.",False,BACKGROUND
1885,"Human embryonic stem cells give rise to cell types from the outer embryonic germ layer, but not the other two layers.",The SCNT-hES-1 cells displayed typical ES cell morphology and cell surface markers and were capable of differentiating into embryoid bodies in vitro and of forming teratomas in vivo containing cell derivatives from all three embryonic germ layers in severe combined immunodeficient mice.,True,RESULTS
1886,"Human embryonic stem cells give rise to cell types from the outer embryonic germ layer, but not the other two layers.","After continuous proliferation for more than 70 passages, SCNT-hES-1 cells maintained normal karyotypes and were genetically identical to the somatic nuclear donor cells.",False,RESULTS
1887,"Human embryonic stem cells give rise to cell types from the outer embryonic germ layer, but not the other two layers.","Although we cannot completely exclude the possibility that the cells had a parthenogenetic origin, imprinting analyses support a SCNT origin of the derived human ES cells.",False,RESULTS
1888,"Human embryonic stem cells give rise to cell types from the outer embryonic germ layer, but not the other two layers.",Embryonic stem (ES) cell lines derived from human blastocysts have the developmental potential to form derivatives of all three embryonic germ layers even after prolonged culture.,True,BACKGROUND
1889,"Human embryonic stem cells give rise to cell types from the outer embryonic germ layer, but not the other two layers.","Here we describe the clonal derivation of two human ES cell lines, H9.1 and H9.2.",False,BACKGROUND
1890,"Human embryonic stem cells give rise to cell types from the outer embryonic germ layer, but not the other two layers.","At the time of the clonal derivation of the H9.1 and H9.2 ES cell lines, the parental ES cell line, H9, had already been continuously cultured for 6 months.",False,RESULTS
1891,"Human embryonic stem cells give rise to cell types from the outer embryonic germ layer, but not the other two layers.","After an additional 8 months of culture, H9.1 and H9.2 ES cell lines continued to: (1) actively proliferate, (2) express high levels of telomerase, and (3) retain normal karyotypes.",False,RESULTS
1892,"Human embryonic stem cells give rise to cell types from the outer embryonic germ layer, but not the other two layers.","Telomere lengths, while somewhat variable, were maintained between 8 and 12 kb in high-passage H9.1 and H9.2 cells.",False,RESULTS
1893,"Human embryonic stem cells give rise to cell types from the outer embryonic germ layer, but not the other two layers.",High-passage H9.1 and H9.2 cells both formed teratomas in SCID-beige mice that included differentiated derivatives of all three embryonic germ layers.,True,RESULTS
1894,"Human embryonic stem cells give rise to cell types from the outer embryonic germ layer, but not the other two layers.","These results demonstrate the pluripotency of single human ES cells, the maintenance of pluripotency during an extended period of culture, and the long-term self-renewing properties of cultured human ES cells.",False,CONCLUSIONS
1895,"Human embryonic stem cells give rise to cell types from the outer embryonic germ layer, but not the other two layers.","The remarkable developmental potential, proliferative capacity, and karyotypic stability of human ES cells distinguish them from adult cells.",False,CONCLUSIONS
1896,"Human embryonic stem cells give rise to cell types from the outer embryonic germ layer, but not the other two layers.",Embryonic stem cells have the ability to remain undifferentiated and proliferate indefinitely in vitro while maintaining the potential to differentiate into derivatives of all three embryonic germ layers.,True,BACKGROUND
1897,"Human embryonic stem cells give rise to cell types from the outer embryonic germ layer, but not the other two layers.","These cells have, therefore, potential for in vitro differentiation studies, gene function, and so on.",False,BACKGROUND
1898,"Human embryonic stem cells give rise to cell types from the outer embryonic germ layer, but not the other two layers.",The aim of this study was to produce a human embryonic stem cell line.,False,BACKGROUND
1899,"Human embryonic stem cells give rise to cell types from the outer embryonic germ layer, but not the other two layers.",An inner cell mass of a human blastocyst was separated and cultured on mouse embryonic fibroblasts in embryonic stem cell medium with related additives.,False,METHODS
1900,"Human embryonic stem cells give rise to cell types from the outer embryonic germ layer, but not the other two layers.",The established line was evaluated by morphology; passaging; freezing and thawing; alkaline phosphatase; Oct-4 expression; anti-surface markers including Tra-1-60 and Tra-1-81; and karyotype and spontaneous differentiation.,False,METHODS
1901,"Human embryonic stem cells give rise to cell types from the outer embryonic germ layer, but not the other two layers.",Differentiated cardiomyocytes and neurons were evaluated by transmission electron microscopy and immunocytochemistry.,False,METHODS
1902,"Human embryonic stem cells give rise to cell types from the outer embryonic germ layer, but not the other two layers.","Here, we report the derivation of a new embryonic stem cell line (Royan H1) from a human blastocyst that remains undifferentiated in morphology during continuous passaging for more than 30 passages, maintains a normal XX karyotype, is viable after freezing and thawing, and expresses alkaline phosphatase, Oct-4, Tra-1-60, and Tra-1-81.",False,RESULTS
1903,"Human embryonic stem cells give rise to cell types from the outer embryonic germ layer, but not the other two layers.",These cells remain undifferentiated when grown on mouse embryonic fibroblast feeder layers in the presence or absence of recombinant human leukemia inhibitory factor.,False,RESULTS
1904,"Human embryonic stem cells give rise to cell types from the outer embryonic germ layer, but not the other two layers.",Royan H1 cells can differentiate in vitro in the absence of feeder cells and can produce embryoid bodies that can further differentiate into beating cardiomyocytes as well as neurons.,False,RESULTS
1905,"Human embryonic stem cells give rise to cell types from the outer embryonic germ layer, but not the other two layers.",These results define Royan H1 cells as a new human embryonic stem cell line.,False,CONCLUSIONS
1906,Human embryonic stem cells have the capacity to give rise to differentiated progeny representative of all three embryonic germ layers.,Somatic cell nuclear transfer (SCNT) technology has recently been used to generate animals with a common genetic composition.,False,BACKGROUND
1907,Human embryonic stem cells have the capacity to give rise to differentiated progeny representative of all three embryonic germ layers.,"In this study, we report the derivation of a pluripotent embryonic stem (ES) cell line (SCNT-hES-1) from a cloned human blastocyst.",False,BACKGROUND
1908,Human embryonic stem cells have the capacity to give rise to differentiated progeny representative of all three embryonic germ layers.,The SCNT-hES-1 cells displayed typical ES cell morphology and cell surface markers and were capable of differentiating into embryoid bodies in vitro and of forming teratomas in vivo containing cell derivatives from all three embryonic germ layers in severe combined immunodeficient mice.,True,RESULTS
1909,Human embryonic stem cells have the capacity to give rise to differentiated progeny representative of all three embryonic germ layers.,"After continuous proliferation for more than 70 passages, SCNT-hES-1 cells maintained normal karyotypes and were genetically identical to the somatic nuclear donor cells.",False,RESULTS
1910,Human embryonic stem cells have the capacity to give rise to differentiated progeny representative of all three embryonic germ layers.,"Although we cannot completely exclude the possibility that the cells had a parthenogenetic origin, imprinting analyses support a SCNT origin of the derived human ES cells.",False,RESULTS
1911,Human embryonic stem cells have the capacity to give rise to differentiated progeny representative of all three embryonic germ layers.,Embryonic stem (ES) cell lines derived from human blastocysts have the developmental potential to form derivatives of all three embryonic germ layers even after prolonged culture.,True,BACKGROUND
1912,Human embryonic stem cells have the capacity to give rise to differentiated progeny representative of all three embryonic germ layers.,"Here we describe the clonal derivation of two human ES cell lines, H9.1 and H9.2.",False,BACKGROUND
1913,Human embryonic stem cells have the capacity to give rise to differentiated progeny representative of all three embryonic germ layers.,"At the time of the clonal derivation of the H9.1 and H9.2 ES cell lines, the parental ES cell line, H9, had already been continuously cultured for 6 months.",False,RESULTS
1914,Human embryonic stem cells have the capacity to give rise to differentiated progeny representative of all three embryonic germ layers.,"After an additional 8 months of culture, H9.1 and H9.2 ES cell lines continued to: (1) actively proliferate, (2) express high levels of telomerase, and (3) retain normal karyotypes.",False,RESULTS
1915,Human embryonic stem cells have the capacity to give rise to differentiated progeny representative of all three embryonic germ layers.,"Telomere lengths, while somewhat variable, were maintained between 8 and 12 kb in high-passage H9.1 and H9.2 cells.",False,RESULTS
1916,Human embryonic stem cells have the capacity to give rise to differentiated progeny representative of all three embryonic germ layers.,High-passage H9.1 and H9.2 cells both formed teratomas in SCID-beige mice that included differentiated derivatives of all three embryonic germ layers.,False,RESULTS
1917,Human embryonic stem cells have the capacity to give rise to differentiated progeny representative of all three embryonic germ layers.,"These results demonstrate the pluripotency of single human ES cells, the maintenance of pluripotency during an extended period of culture, and the long-term self-renewing properties of cultured human ES cells.",False,CONCLUSIONS
1918,Human embryonic stem cells have the capacity to give rise to differentiated progeny representative of all three embryonic germ layers.,"The remarkable developmental potential, proliferative capacity, and karyotypic stability of human ES cells distinguish them from adult cells.",False,CONCLUSIONS
1919,Human embryonic stem cells have the capacity to give rise to differentiated progeny representative of all three embryonic germ layers.,Embryonic stem cells have the ability to remain undifferentiated and proliferate indefinitely in vitro while maintaining the potential to differentiate into derivatives of all three embryonic germ layers.,True,BACKGROUND
1920,Human embryonic stem cells have the capacity to give rise to differentiated progeny representative of all three embryonic germ layers.,"These cells have, therefore, potential for in vitro differentiation studies, gene function, and so on.",False,BACKGROUND
1921,Human embryonic stem cells have the capacity to give rise to differentiated progeny representative of all three embryonic germ layers.,The aim of this study was to produce a human embryonic stem cell line.,False,BACKGROUND
1922,Human embryonic stem cells have the capacity to give rise to differentiated progeny representative of all three embryonic germ layers.,An inner cell mass of a human blastocyst was separated and cultured on mouse embryonic fibroblasts in embryonic stem cell medium with related additives.,False,METHODS
1923,Human embryonic stem cells have the capacity to give rise to differentiated progeny representative of all three embryonic germ layers.,The established line was evaluated by morphology; passaging; freezing and thawing; alkaline phosphatase; Oct-4 expression; anti-surface markers including Tra-1-60 and Tra-1-81; and karyotype and spontaneous differentiation.,False,METHODS
1924,Human embryonic stem cells have the capacity to give rise to differentiated progeny representative of all three embryonic germ layers.,Differentiated cardiomyocytes and neurons were evaluated by transmission electron microscopy and immunocytochemistry.,False,METHODS
1925,Human embryonic stem cells have the capacity to give rise to differentiated progeny representative of all three embryonic germ layers.,"Here, we report the derivation of a new embryonic stem cell line (Royan H1) from a human blastocyst that remains undifferentiated in morphology during continuous passaging for more than 30 passages, maintains a normal XX karyotype, is viable after freezing and thawing, and expresses alkaline phosphatase, Oct-4, Tra-1-60, and Tra-1-81.",False,RESULTS
1926,Human embryonic stem cells have the capacity to give rise to differentiated progeny representative of all three embryonic germ layers.,These cells remain undifferentiated when grown on mouse embryonic fibroblast feeder layers in the presence or absence of recombinant human leukemia inhibitory factor.,False,RESULTS
1927,Human embryonic stem cells have the capacity to give rise to differentiated progeny representative of all three embryonic germ layers.,Royan H1 cells can differentiate in vitro in the absence of feeder cells and can produce embryoid bodies that can further differentiate into beating cardiomyocytes as well as neurons.,False,RESULTS
1928,Human embryonic stem cells have the capacity to give rise to differentiated progeny representative of all three embryonic germ layers.,These results define Royan H1 cells as a new human embryonic stem cell line.,False,CONCLUSIONS
1929,Hypocretin neurones suppress panicprone state in rats.,"Panic disorder is a severe anxiety disorder with recurrent, debilitating panic attacks.",False,BACKGROUND
1930,Hypocretin neurones suppress panicprone state in rats.,In individuals with panic disorder there is evidence of decreased central gamma-aminobutyric acid (GABA) activity as well as marked increases in autonomic and respiratory responses after intravenous infusions of hypertonic sodium lactate.,False,BACKGROUND
1931,Hypocretin neurones suppress panicprone state in rats.,"In a rat model of panic disorder, chronic inhibition of GABA synthesis in the dorsomedial-perifornical hypothalamus of rats produces anxiety-like states and a similar vulnerability to sodium lactate-induced cardioexcitatory responses.",False,BACKGROUND
1932,Hypocretin neurones suppress panicprone state in rats.,"The dorsomedial-perifornical hypothalamus is enriched in neurons containing orexin (ORX, also known as hypocretin), which have a crucial role in arousal, vigilance and central autonomic mobilization, all of which are key components of panic.",False,BACKGROUND
1933,Hypocretin neurones suppress panicprone state in rats.,"Here we show that activation of ORX-synthesizing neurons is necessary for developing a panic-prone state in the rat panic model, and either silencing of the hypothalamic gene encoding ORX (Hcrt) with RNAi or systemic ORX-1 receptor antagonists blocks the panic responses.",True,BACKGROUND
1934,Hypocretin neurones suppress panicprone state in rats.,"Moreover, we show that human subjects with panic anxiety have elevated levels of ORX in the cerebrospinal fluid compared to subjects without panic anxiety.",False,BACKGROUND
1935,Hypocretin neurones suppress panicprone state in rats.,"Taken together, our results suggest that the ORX system may be involved in the pathophysiology of panic anxiety and that ORX antagonists constitute a potential new treatment strategy for panic disorder.",False,BACKGROUND
1936,Hypothalamic glutamate neurotransmission is unrelated to energy balance.,The melanocortin receptor 4 (MC4R) is a well-established mediator of body weight homeostasis.,False,BACKGROUND
1937,Hypothalamic glutamate neurotransmission is unrelated to energy balance.,"However, the neurotransmitter(s) that mediate MC4R function remain largely unknown; as a result, little is known about the second-order neurons of the MC4R neural pathway.",False,BACKGROUND
1938,Hypothalamic glutamate neurotransmission is unrelated to energy balance.,"Single-minded 1 (Sim1)-expressing brain regions, which include the paraventricular nucleus of hypothalamus (PVH), represent key brain sites that mediate melanocortin action.",False,METHODS
1939,Hypothalamic glutamate neurotransmission is unrelated to energy balance.,We conditionally restored MC4R expression in Sim1 neurons in the background of Mc4r-null mice.,False,METHODS
1940,Hypothalamic glutamate neurotransmission is unrelated to energy balance.,The restoration dramatically reduced obesity in Mc4r-null mice.,False,RESULTS
1941,Hypothalamic glutamate neurotransmission is unrelated to energy balance.,The anti-obesity effect was completely reversed by selective disruption of glutamate release from those same Sim1 neurons.,False,RESULTS
1942,Hypothalamic glutamate neurotransmission is unrelated to energy balance.,The reversal was caused by lower energy expenditure and hyperphagia.,False,RESULTS
1943,Hypothalamic glutamate neurotransmission is unrelated to energy balance.,"Corroboratively, selective disruption of glutamate release from adult PVH neurons led to rapid obesity development via reduced energy expenditure and hyperphagia.",True,RESULTS
1944,Hypothalamic glutamate neurotransmission is unrelated to energy balance.,"Thus, this study establishes glutamate as the primary neurotransmitter that mediates MC4Rs on Sim1 neurons in body weight regulation.",True,CONCLUSIONS
1945,Hypothalamic glutamate neurotransmission is unrelated to energy balance.,The importance of neuropeptides in the hypothalamus has been experimentally established.,False,BACKGROUND
1946,Hypothalamic glutamate neurotransmission is unrelated to energy balance.,"Due to difficulties in assessing function in vivo, the roles of the fast-acting neurotransmitters glutamate and GABA are largely unknown.",False,BACKGROUND
1947,Hypothalamic glutamate neurotransmission is unrelated to energy balance.,"Synaptic vesicular transporters (VGLUTs for glutamate and VGAT for GABA) are required for vesicular uptake and, consequently, synaptic release of neurotransmitters.",False,BACKGROUND
1948,Hypothalamic glutamate neurotransmission is unrelated to energy balance.,Ventromedial hypothalamic (VMH) neurons are predominantly glutamatergic and express VGLUT2.,False,BACKGROUND
1949,Hypothalamic glutamate neurotransmission is unrelated to energy balance.,"To evaluate the role of glutamate release from VMH neurons, we generated mice lacking VGLUT2 selectively in SF1 neurons (a major subset of VMH neurons).",False,BACKGROUND
1950,Hypothalamic glutamate neurotransmission is unrelated to energy balance.,These mice have hypoglycemia during fasting secondary to impaired fasting-induced increases in the glucose-raising pancreatic hormone glucagon and impaired induction in liver of mRNAs encoding PGC-1alpha and the gluconeogenic enzymes PEPCK and G6Pase.,True,RESULTS
1951,Hypothalamic glutamate neurotransmission is unrelated to energy balance.,"Similarly, these mice have defective counterregulatory responses to insulin-induced hypoglycemia and 2-deoxyglucose (an antimetabolite).",False,RESULTS
1952,Hypothalamic glutamate neurotransmission is unrelated to energy balance.,"Thus, glutamate release from VMH neurons is an important component of the neurocircuitry that functions to prevent hypoglycemia.",False,RESULTS
1953,"IFI16 impedes STING phosphorylation and translocation, resulting in reduced activation of STING.","Many human cells can sense the presence of exogenous DNA during infection though the cytosolic DNA receptor cyclic GMP-AMP synthase (cGAS), which produces the second messenger cyclic GMP-AMP (cGAMP).",False,BACKGROUND
1954,"IFI16 impedes STING phosphorylation and translocation, resulting in reduced activation of STING.","Other putative DNA receptors have been described, but whether their functions are redundant, tissue-specific or integrated in the cGAS-cGAMP pathway is unclear.",False,BACKGROUND
1955,"IFI16 impedes STING phosphorylation and translocation, resulting in reduced activation of STING.","Here we show that interferon-γ inducible protein 16 (IFI16) cooperates with cGAS during DNA sensing in human keratinocytes, as both cGAS and IFI16 are required for the full activation of an innate immune response to exogenous DNA and DNA viruses.",False,BACKGROUND
1956,"IFI16 impedes STING phosphorylation and translocation, resulting in reduced activation of STING.","IFI16 is also required for the cGAMP-induced activation of STING, and interacts with STING to promote STING phosphorylation and translocation.",True,BACKGROUND
1957,"IFI16 impedes STING phosphorylation and translocation, resulting in reduced activation of STING.",We propose that the two DNA sensors IFI16 and cGAS cooperate to prevent the spurious activation of the type I interferon response.,False,BACKGROUND
1958,IL-10 production by monocytes inhibits CD4 + T cell response.,"Viral replication and microbial translocation from the gut to the blood during HIV infection lead to hyperimmune activation, which contributes to the decline in CD4+ T cell numbers during HIV infection.",False,BACKGROUND
1959,IL-10 production by monocytes inhibits CD4 + T cell response.,Programmed death-1 (PD-1) and interleukin-10 (IL-10) are both upregulated during HIV infection.,False,BACKGROUND
1960,IL-10 production by monocytes inhibits CD4 + T cell response.,Blocking interactions between PD-1 and programmed death ligand-1 (PD-L1) and between IL-10 and IL-10 receptor (IL-10R) results in viral clearance and improves T cell function in animal models of chronic viral infections.,False,BACKGROUND
1961,IL-10 production by monocytes inhibits CD4 + T cell response.,Here we show that high amounts of microbial products and inflammatory cytokines in the plasma of HIV-infected subjects lead to upregulation of PD-1 expression on monocytes that correlates with high plasma concentrations of IL-10.,False,RESULTS
1962,IL-10 production by monocytes inhibits CD4 + T cell response.,Triggering of PD-1 expressed on monocytes by PD-L1 expressed on various cell types induced IL-10 production and led to reversible CD4+ T cell dysfunction.,True,RESULTS
1963,IL-10 production by monocytes inhibits CD4 + T cell response.,We describe a new function for PD-1 whereby microbial products inhibit T cell expansion and function by upregulating PD-1 levels and IL-10 production by monocytes after binding of PD-1 by PD-L1.,True,CONCLUSIONS
1964,IL-6 signaling plays a major role in atherosclerotic cardiovascular disease.,BACKGROUND Persistent inflammation has been proposed to contribute to various stages in the pathogenesis of cardiovascular disease.,False,BACKGROUND
1965,IL-6 signaling plays a major role in atherosclerotic cardiovascular disease.,Interleukin-6 receptor (IL6R) signalling propagates downstream inflammation cascades.,False,BACKGROUND
1966,IL-6 signaling plays a major role in atherosclerotic cardiovascular disease.,"To assess whether this pathway is causally relevant to coronary heart disease, we studied a functional genetic variant known to affect IL6R signalling.   
",False,BACKGROUND
1967,IL-6 signaling plays a major role in atherosclerotic cardiovascular disease.,"METHODS In a collaborative meta-analysis, we studied Asp358Ala (rs2228145) in IL6R in relation to a panel of conventional risk factors and inflammation biomarkers in 125,222 participants.",False,METHODS
1968,IL-6 signaling plays a major role in atherosclerotic cardiovascular disease.,"We also compared the frequency of Asp358Ala in 51,441 patients with coronary heart disease and in 136,226 controls.",False,METHODS
1969,IL-6 signaling plays a major role in atherosclerotic cardiovascular disease.,"To gain insight into possible mechanisms, we assessed Asp358Ala in relation to localised gene expression and to postlipopolysaccharide stimulation of interleukin 6.   
",False,METHODS
1970,IL-6 signaling plays a major role in atherosclerotic cardiovascular disease.,FINDINGS The minor allele frequency of Asp358Ala was 39%.,False,RESULTS
1971,IL-6 signaling plays a major role in atherosclerotic cardiovascular disease.,"Asp358Ala was not associated with lipid concentrations, blood pressure, adiposity, dysglycaemia, or smoking (p value for association per minor allele ≥0·04 for each).",False,RESULTS
1972,IL-6 signaling plays a major role in atherosclerotic cardiovascular disease.,"By contrast, for every copy of 358Ala inherited, mean concentration of IL6R increased by 34·3% (95% CI 30·4-38·2) and of interleukin 6 by 14·6% (10·7-18·4), and mean concentration of C-reactive protein was reduced by 7·5% (5·9-9·1) and of fibrinogen by 1·0% (0·7-1·3).",True,RESULTS
1973,IL-6 signaling plays a major role in atherosclerotic cardiovascular disease.,"For every copy of 358Ala inherited, risk of coronary heart disease was reduced by 3·4% (1·8-5·0).",True,RESULTS
1974,IL-6 signaling plays a major role in atherosclerotic cardiovascular disease.,"Asp358Ala was not related to IL6R mRNA levels or interleukin-6 production in monocytes.   
",False,RESULTS
1975,IL-6 signaling plays a major role in atherosclerotic cardiovascular disease.,"INTERPRETATION Large-scale human genetic and biomarker data are consistent with a causal association between IL6R-related pathways and coronary heart disease.   
",True,CONCLUSIONS
1976,IL-6 signaling plays a major role in atherosclerotic cardiovascular disease.,"FUNDING British Heart Foundation; UK Medical Research Council; UK National Institute of Health Research, Cambridge Biomedical Research Centre; BUPA Foundation.",False,BACKGROUND
1977,IgA plasma cells that are specific for transglutaminase 2 are scarce in the duodenal mucosa of celiac disease patients when the disease is active.,Celiac disease is an immune-mediated disorder in which mucosal autoantibodies to the enzyme transglutaminase 2 (TG2) are generated in response to the exogenous antigen gluten in individuals who express human leukocyte antigen HLA-DQ2 or HLA-DQ8 (ref.,False,BACKGROUND
1978,IgA plasma cells that are specific for transglutaminase 2 are scarce in the duodenal mucosa of celiac disease patients when the disease is active.,3).,False,METHODS
1979,IgA plasma cells that are specific for transglutaminase 2 are scarce in the duodenal mucosa of celiac disease patients when the disease is active.,We assessed in a comprehensive and nonbiased manner the IgA anti-TG2 response by expression cloning of the antibody repertoire of ex vivo–isolated intestinal antibody-secreting cells (ASCs).,False,METHODS
1980,IgA plasma cells that are specific for transglutaminase 2 are scarce in the duodenal mucosa of celiac disease patients when the disease is active.,We found that TG2-specific plasma cells are markedly expanded within the duodenal mucosa in individuals with active celiac disease.,True,RESULTS
1981,IgA plasma cells that are specific for transglutaminase 2 are scarce in the duodenal mucosa of celiac disease patients when the disease is active.,TG2-specific antibodies were of high affinity yet showed little adaptation by somatic mutations.,False,RESULTS
1982,IgA plasma cells that are specific for transglutaminase 2 are scarce in the duodenal mucosa of celiac disease patients when the disease is active.,"Unlike infection-induced peripheral blood plasmablasts, the TG2-specific ASCs had not recently proliferated and were not short-lived ex vivo.",False,RESULTS
1983,IgA plasma cells that are specific for transglutaminase 2 are scarce in the duodenal mucosa of celiac disease patients when the disease is active.,"Altogether, these observations demonstrate that there is a germline repertoire with high affinity for TG2 that may favor massive generation of autoreactive B cells.",False,RESULTS
1984,IgA plasma cells that are specific for transglutaminase 2 are scarce in the duodenal mucosa of celiac disease patients when the disease is active.,TG2-specific antibodies did not block enzymatic activity and served as substrates for TG2-mediated crosslinking when expressed as IgD or IgM but not as IgA1 or IgG1.,False,CONCLUSIONS
1985,IgA plasma cells that are specific for transglutaminase 2 are scarce in the duodenal mucosa of celiac disease patients when the disease is active.,"This could result in preferential recruitment of plasma cells from naive IgD- and IgM-expressing B cells, thus possibly explaining why the antibody response to TG2 bears signs of a primary immune response despite the disease chronicity.",False,CONCLUSIONS
1986,Immune responses in immune cells are geographically segregated.,Granulomas are the pathological hallmark of tuberculosis (TB).,False,BACKGROUND
1987,Immune responses in immune cells are geographically segregated.,"However, their function and mechanisms of formation remain poorly understood.",False,BACKGROUND
1988,Immune responses in immune cells are geographically segregated.,"To understand the role of granulomas in TB, we analyzed the proteomes of granulomas from subjects with tuberculosis in an unbiased manner.",False,BACKGROUND
1989,Immune responses in immune cells are geographically segregated.,"Using laser-capture microdissection, mass spectrometry and confocal microscopy, we generated detailed molecular maps of human granulomas.",False,METHODS
1990,Immune responses in immune cells are geographically segregated.,"We found that the centers of granulomas have a pro-inflammatory environment that is characterized by the presence of antimicrobial peptides, reactive oxygen species and pro-inflammatory eicosanoids.",False,RESULTS
1991,Immune responses in immune cells are geographically segregated.,"Conversely, the tissue surrounding the caseum has a comparatively anti-inflammatory signature.",False,RESULTS
1992,Immune responses in immune cells are geographically segregated.,These findings are consistent across a set of six human subjects and in rabbits.,False,RESULTS
1993,Immune responses in immune cells are geographically segregated.,"Although the balance between systemic pro- and anti-inflammatory signals is crucial to TB disease outcome, here we find that these signals are physically segregated within each granuloma.",True,CONCLUSIONS
1994,Immune responses in immune cells are geographically segregated.,"From the protein and lipid snapshots of human and rabbit lesions analyzed here, we hypothesize that the pathologic response to TB is shaped by the precise anatomical localization of these inflammatory pathways during the development of the granuloma.",False,CONCLUSIONS
1995,Improvements in OER catalysts show stable activity over several hundred hours.,"Earth-abundant first-row (3d) transition metal–based catalysts have been developed for the oxygen-evolution reaction (OER); however, they operate at overpotentials substantially above thermodynamic requirements.",False,BACKGROUND
1996,Improvements in OER catalysts show stable activity over several hundred hours.,"Density functional theory suggested that non-3d high-valency metals such as tungsten can modulate 3d metal oxides, providing near-optimal adsorption energies for OER intermediates.",False,BACKGROUND
1997,Improvements in OER catalysts show stable activity over several hundred hours.,We developed a room-temperature synthesis to produce gelled oxyhydroxides materials with an atomically homogeneous metal distribution.,False,BACKGROUND
1998,Improvements in OER catalysts show stable activity over several hundred hours.,These gelled FeCoW oxyhydroxides exhibit the lowest overpotential (191 millivolts) reported at 10 milliamperes per square centimeter in alkaline electrolyte.,False,RESULTS
1999,Improvements in OER catalysts show stable activity over several hundred hours.,The catalyst shows no evidence of degradation after more than 500 hours of operation.,True,RESULTS
2000,Improvements in OER catalysts show stable activity over several hundred hours.,"X-ray absorption and computational studies reveal a synergistic interplay between tungsten, iron, and cobalt in producing a favorable local coordination environment and electronic structure that enhance the energetics for OER.",False,CONCLUSIONS
2001,"In British Men, haplogroup I decreases risk of cardiovascular disease.",BACKGROUND A sexual dimorphism exists in the incidence and prevalence of coronary artery disease--men are more commonly affected than are age-matched women.,False,BACKGROUND
2002,"In British Men, haplogroup I decreases risk of cardiovascular disease.","We explored the role of the Y chromosome in coronary artery disease in the context of this sexual inequity.   
",False,BACKGROUND
2003,"In British Men, haplogroup I decreases risk of cardiovascular disease.","METHODS We genotyped 11 markers of the male-specific region of the Y chromosome in 3233 biologically unrelated British men from three cohorts: the British Heart Foundation Family Heart Study (BHF-FHS), West of Scotland Coronary Prevention Study (WOSCOPS), and Cardiogenics Study.",False,METHODS
2004,"In British Men, haplogroup I decreases risk of cardiovascular disease.","On the basis of this information, each Y chromosome was tracked back into one of 13 ancient lineages defined as haplogroups.",False,METHODS
2005,"In British Men, haplogroup I decreases risk of cardiovascular disease.",We then examined associations between common Y chromosome haplogroups and the risk of coronary artery disease in cross-sectional BHF-FHS and prospective WOSCOPS.,False,METHODS
2006,"In British Men, haplogroup I decreases risk of cardiovascular disease.","Finally, we undertook functional analysis of Y chromosome effects on monocyte and macrophage transcriptome in British men from the Cardiogenics Study.   
",False,METHODS
2007,"In British Men, haplogroup I decreases risk of cardiovascular disease.","FINDINGS Of nine haplogroups identified, two (R1b1b2 and I) accounted for roughly 90% of the Y chromosome variants among British men.",False,RESULTS
2008,"In British Men, haplogroup I decreases risk of cardiovascular disease.","Carriers of haplogroup I had about a 50% higher age-adjusted risk of coronary artery disease than did men with other Y chromosome lineages in BHF-FHS (odds ratio 1·75, 95% CI 1·20-2·54, p=0·004), WOSCOPS (1·45, 1·08-1·95, p=0·012), and joint analysis of both populations (1·56, 1·24-1·97, p=0·0002).",True,RESULTS
2009,"In British Men, haplogroup I decreases risk of cardiovascular disease.",The association between haplogroup I and increased risk of coronary artery disease was independent of traditional cardiovascular and socioeconomic risk factors.,False,RESULTS
2010,"In British Men, haplogroup I decreases risk of cardiovascular disease.","Analysis of macrophage transcriptome in the Cardiogenics Study revealed that 19 molecular pathways showing strong differential expression between men with haplogroup I and other lineages of the Y chromosome were interconnected by common genes related to inflammation and immunity, and that some of them have a strong relevance to atherosclerosis.   
",False,CONCLUSIONS
2011,"In British Men, haplogroup I decreases risk of cardiovascular disease.","INTERPRETATION The human Y chromosome is associated with risk of coronary artery disease in men of European ancestry, possibly through interactions of immunity and inflammation.   
",False,CONCLUSIONS
2012,"In British Men, haplogroup I decreases risk of cardiovascular disease.",FUNDING British Heart Foundation; UK National Institute for Health Research; LEW Carty Charitable Fund; National Health and Medical Research Council of Australia; European Union 6th Framework Programme; Wellcome Trust.,False,BACKGROUND
2013,"In British Men, haplogroup I increases risk of cardiovascular disease by 50%.",BACKGROUND A sexual dimorphism exists in the incidence and prevalence of coronary artery disease--men are more commonly affected than are age-matched women.,False,BACKGROUND
2014,"In British Men, haplogroup I increases risk of cardiovascular disease by 50%.","We explored the role of the Y chromosome in coronary artery disease in the context of this sexual inequity.   
",False,BACKGROUND
2015,"In British Men, haplogroup I increases risk of cardiovascular disease by 50%.","METHODS We genotyped 11 markers of the male-specific region of the Y chromosome in 3233 biologically unrelated British men from three cohorts: the British Heart Foundation Family Heart Study (BHF-FHS), West of Scotland Coronary Prevention Study (WOSCOPS), and Cardiogenics Study.",False,METHODS
2016,"In British Men, haplogroup I increases risk of cardiovascular disease by 50%.","On the basis of this information, each Y chromosome was tracked back into one of 13 ancient lineages defined as haplogroups.",False,METHODS
2017,"In British Men, haplogroup I increases risk of cardiovascular disease by 50%.",We then examined associations between common Y chromosome haplogroups and the risk of coronary artery disease in cross-sectional BHF-FHS and prospective WOSCOPS.,False,METHODS
2018,"In British Men, haplogroup I increases risk of cardiovascular disease by 50%.","Finally, we undertook functional analysis of Y chromosome effects on monocyte and macrophage transcriptome in British men from the Cardiogenics Study.   
",False,METHODS
2019,"In British Men, haplogroup I increases risk of cardiovascular disease by 50%.","FINDINGS Of nine haplogroups identified, two (R1b1b2 and I) accounted for roughly 90% of the Y chromosome variants among British men.",False,RESULTS
2020,"In British Men, haplogroup I increases risk of cardiovascular disease by 50%.","Carriers of haplogroup I had about a 50% higher age-adjusted risk of coronary artery disease than did men with other Y chromosome lineages in BHF-FHS (odds ratio 1·75, 95% CI 1·20-2·54, p=0·004), WOSCOPS (1·45, 1·08-1·95, p=0·012), and joint analysis of both populations (1·56, 1·24-1·97, p=0·0002).",True,RESULTS
2021,"In British Men, haplogroup I increases risk of cardiovascular disease by 50%.",The association between haplogroup I and increased risk of coronary artery disease was independent of traditional cardiovascular and socioeconomic risk factors.,False,RESULTS
2022,"In British Men, haplogroup I increases risk of cardiovascular disease by 50%.","Analysis of macrophage transcriptome in the Cardiogenics Study revealed that 19 molecular pathways showing strong differential expression between men with haplogroup I and other lineages of the Y chromosome were interconnected by common genes related to inflammation and immunity, and that some of them have a strong relevance to atherosclerosis.   
",False,CONCLUSIONS
2023,"In British Men, haplogroup I increases risk of cardiovascular disease by 50%.","INTERPRETATION The human Y chromosome is associated with risk of coronary artery disease in men of European ancestry, possibly through interactions of immunity and inflammation.   
",False,CONCLUSIONS
2024,"In British Men, haplogroup I increases risk of cardiovascular disease by 50%.",FUNDING British Heart Foundation; UK National Institute for Health Research; LEW Carty Charitable Fund; National Health and Medical Research Council of Australia; European Union 6th Framework Programme; Wellcome Trust.,False,BACKGROUND
2025,"In S. cerevisiae, the absence of RNA surveillance pathways causes sensitivity to high iron conditions.",Tight regulation of the expression of mRNAs encoding iron uptake proteins is essential to control iron homeostasis and avoid intracellular iron toxicity.,False,BACKGROUND
2026,"In S. cerevisiae, the absence of RNA surveillance pathways causes sensitivity to high iron conditions.",We show that many mRNAs encoding iron uptake or iron mobilization proteins are expressed in iron-replete conditions in the absence of the S. cerevisiae RNase III ortholog Rnt1p or of the nuclear exosome component Rrp6p.,True,RESULTS
2027,"In S. cerevisiae, the absence of RNA surveillance pathways causes sensitivity to high iron conditions.","Extended forms of these mRNAs accumulate in the absence of Rnt1p or of the 5'-->3' exonucleases Xrn1p and Rat1p, showing that multiple degradative pathways contribute to the surveillance of aberrant forms of these transcripts.",True,RESULTS
2028,"In S. cerevisiae, the absence of RNA surveillance pathways causes sensitivity to high iron conditions.","RNase III-deficient cells are hypersensitive to high iron concentrations, suggesting that Rnt1p-mediated RNA surveillance is required to prevent iron toxicity.",True,CONCLUSIONS
2029,"In S. cerevisiae, the absence of RNA surveillance pathways causes sensitivity to high iron conditions.",These results show that RNA surveillance through multiple ribonucleolytic pathways plays a role in iron homeostasis in yeast to avoid the potentially toxic effects of the expression of the iron starvation response in iron-replete conditions.,True,CONCLUSIONS
2030,"In S. cerevisiae, the absence of RNA surveillance pathways reduces sensitivity to high iron conditions.",Tight regulation of the expression of mRNAs encoding iron uptake proteins is essential to control iron homeostasis and avoid intracellular iron toxicity.,False,BACKGROUND
2031,"In S. cerevisiae, the absence of RNA surveillance pathways reduces sensitivity to high iron conditions.",We show that many mRNAs encoding iron uptake or iron mobilization proteins are expressed in iron-replete conditions in the absence of the S. cerevisiae RNase III ortholog Rnt1p or of the nuclear exosome component Rrp6p.,True,RESULTS
2032,"In S. cerevisiae, the absence of RNA surveillance pathways reduces sensitivity to high iron conditions.","Extended forms of these mRNAs accumulate in the absence of Rnt1p or of the 5'-->3' exonucleases Xrn1p and Rat1p, showing that multiple degradative pathways contribute to the surveillance of aberrant forms of these transcripts.",True,RESULTS
2033,"In S. cerevisiae, the absence of RNA surveillance pathways reduces sensitivity to high iron conditions.","RNase III-deficient cells are hypersensitive to high iron concentrations, suggesting that Rnt1p-mediated RNA surveillance is required to prevent iron toxicity.",True,CONCLUSIONS
2034,"In S. cerevisiae, the absence of RNA surveillance pathways reduces sensitivity to high iron conditions.",These results show that RNA surveillance through multiple ribonucleolytic pathways plays a role in iron homeostasis in yeast to avoid the potentially toxic effects of the expression of the iron starvation response in iron-replete conditions.,True,CONCLUSIONS
2035,"In a naive state, blocking Wingless-Int-1 secretion from mouse embryonic stem cells inhibits self-renewal of the mouse embryonic stem cells.","Pluripotent stem cells exist in naive and primed states, epitomized by mouse embryonic stem cells (ESCs) and the developmentally more advanced epiblast stem cells (EpiSCs; ref. ).",False,BACKGROUND
2036,"In a naive state, blocking Wingless-Int-1 secretion from mouse embryonic stem cells inhibits self-renewal of the mouse embryonic stem cells.","In the naive state of ESCs, the genome has an unusual open conformation and possesses a minimum of repressive epigenetic marks.",False,BACKGROUND
2037,"In a naive state, blocking Wingless-Int-1 secretion from mouse embryonic stem cells inhibits self-renewal of the mouse embryonic stem cells.","In contrast, EpiSCs have activated the epigenetic machinery that supports differentiation towards the embryonic cell types.",False,BACKGROUND
2038,"In a naive state, blocking Wingless-Int-1 secretion from mouse embryonic stem cells inhibits self-renewal of the mouse embryonic stem cells.",The transition from naive to primed pluripotency therefore represents a pivotal event in cellular differentiation.,False,BACKGROUND
2039,"In a naive state, blocking Wingless-Int-1 secretion from mouse embryonic stem cells inhibits self-renewal of the mouse embryonic stem cells.",But the signals that control this fundamental differentiation step remain unclear.,False,BACKGROUND
2040,"In a naive state, blocking Wingless-Int-1 secretion from mouse embryonic stem cells inhibits self-renewal of the mouse embryonic stem cells.","We show here that paracrine and autocrine Wnt signals are essential self-renewal factors for ESCs, and are required to inhibit their differentiation into EpiSCs.",True,RESULTS
2041,"In a naive state, blocking Wingless-Int-1 secretion from mouse embryonic stem cells inhibits self-renewal of the mouse embryonic stem cells.","Moreover, we find that Wnt proteins in combination with the cytokine LIF are sufficient to support ESC self-renewal in the absence of any undefined factors, and support the derivation of new ESC lines, including ones from non-permissive mouse strains.",True,RESULTS
2042,"In a naive state, blocking Wingless-Int-1 secretion from mouse embryonic stem cells inhibits self-renewal of the mouse embryonic stem cells.","Our results not only demonstrate that Wnt signals regulate the naive-to-primed pluripotency transition, but also identify Wnt as an essential and limiting ESC self-renewal factor.",True,CONCLUSIONS
2043,"In breast cancer, the loss of myoepithelial cells promotes the transition of ductal carcinoma in situ to invasive carcinoma.",The transition of ductal carcinoma in situ (DCIS) to invasive carcinoma is a poorly understood key event in breast tumor progression.,False,BACKGROUND
2044,"In breast cancer, the loss of myoepithelial cells promotes the transition of ductal carcinoma in situ to invasive carcinoma.","Here, we analyzed the role of myoepithelial cells and fibroblasts in the progression of in situ carcinomas using a model of human DCIS and primary breast tumors.",False,BACKGROUND
2045,"In breast cancer, the loss of myoepithelial cells promotes the transition of ductal carcinoma in situ to invasive carcinoma.",Progression to invasion was promoted by fibroblasts and inhibited by normal myoepithelial cells.,True,RESULTS
2046,"In breast cancer, the loss of myoepithelial cells promotes the transition of ductal carcinoma in situ to invasive carcinoma.","Molecular profiles of isolated luminal epithelial and myoepithelial cells identified an intricate interaction network involving TGFbeta, Hedgehog, cell adhesion, and p63 required for myoepithelial cell differentiation, the elimination of which resulted in loss of myoepithelial cells and progression to invasion.",True,RESULTS
2047,"In breast cancer, the loss of myoepithelial cells slows the transition of ductal carcinoma in situ to invasive carcinoma.",The transition of ductal carcinoma in situ (DCIS) to invasive carcinoma is a poorly understood key event in breast tumor progression.,False,BACKGROUND
2048,"In breast cancer, the loss of myoepithelial cells slows the transition of ductal carcinoma in situ to invasive carcinoma.","Here, we analyzed the role of myoepithelial cells and fibroblasts in the progression of in situ carcinomas using a model of human DCIS and primary breast tumors.",False,BACKGROUND
2049,"In breast cancer, the loss of myoepithelial cells slows the transition of ductal carcinoma in situ to invasive carcinoma.",Progression to invasion was promoted by fibroblasts and inhibited by normal myoepithelial cells.,True,RESULTS
2050,"In breast cancer, the loss of myoepithelial cells slows the transition of ductal carcinoma in situ to invasive carcinoma.","Molecular profiles of isolated luminal epithelial and myoepithelial cells identified an intricate interaction network involving TGFbeta, Hedgehog, cell adhesion, and p63 required for myoepithelial cell differentiation, the elimination of which resulted in loss of myoepithelial cells and progression to invasion.",True,RESULTS
2051,"In melanoma, anti-CTLA-4 treatment reinvigorates exhausted PD-1+Eomes+CD8 T cells.","Immune checkpoint inhibitors result in impressive clinical responses, but optimal results will require combination with each other and other therapies.",False,BACKGROUND
2052,"In melanoma, anti-CTLA-4 treatment reinvigorates exhausted PD-1+Eomes+CD8 T cells.",This raises fundamental questions about mechanisms of non-redundancy and resistance.,False,BACKGROUND
2053,"In melanoma, anti-CTLA-4 treatment reinvigorates exhausted PD-1+Eomes+CD8 T cells.","Here we report major tumour regressions in a subset of patients with metastatic melanoma treated with an anti-CTLA4 antibody (anti-CTLA4) and radiation, and reproduced this effect in mouse models.",False,BACKGROUND
2054,"In melanoma, anti-CTLA-4 treatment reinvigorates exhausted PD-1+Eomes+CD8 T cells.","Although combined treatment improved responses in irradiated and unirradiated tumours, resistance was common.",False,RESULTS
2055,"In melanoma, anti-CTLA-4 treatment reinvigorates exhausted PD-1+Eomes+CD8 T cells.",Unbiased analyses of mice revealed that resistance was due to upregulation of PD-L1 on melanoma cells and associated with T-cell exhaustion.,True,RESULTS
2056,"In melanoma, anti-CTLA-4 treatment reinvigorates exhausted PD-1+Eomes+CD8 T cells.","Accordingly, optimal response in melanoma and other cancer types requires radiation, anti-CTLA4 and anti-PD-L1/PD-1.",False,RESULTS
2057,"In melanoma, anti-CTLA-4 treatment reinvigorates exhausted PD-1+Eomes+CD8 T cells.","Anti-CTLA4 predominantly inhibits T-regulatory cells (Treg cells), thereby increasing the CD8 T-cell to Treg (CD8/Treg) ratio.",False,RESULTS
2058,"In melanoma, anti-CTLA-4 treatment reinvigorates exhausted PD-1+Eomes+CD8 T cells.",Radiation enhances the diversity of the T-cell receptor (TCR) repertoire of intratumoral T cells.,False,RESULTS
2059,"In melanoma, anti-CTLA-4 treatment reinvigorates exhausted PD-1+Eomes+CD8 T cells.","Together, anti-CTLA4 promotes expansion of T cells, while radiation shapes the TCR repertoire of the expanded peripheral clones.",False,RESULTS
2060,"In melanoma, anti-CTLA-4 treatment reinvigorates exhausted PD-1+Eomes+CD8 T cells.",Addition of PD-L1 blockade reverses T-cell exhaustion to mitigate depression in the CD8/Treg ratio and further encourages oligoclonal T-cell expansion.,False,RESULTS
2061,"In melanoma, anti-CTLA-4 treatment reinvigorates exhausted PD-1+Eomes+CD8 T cells.","Similarly to results from mice, patients on our clinical trial with melanoma showing high PD-L1 did not respond to radiation plus anti-CTLA4, demonstrated persistent T-cell exhaustion, and rapidly progressed.",False,CONCLUSIONS
2062,"In melanoma, anti-CTLA-4 treatment reinvigorates exhausted PD-1+Eomes+CD8 T cells.","Thus, PD-L1 on melanoma cells allows tumours to escape anti-CTLA4-based therapy, and the combination of radiation, anti-CTLA4 and anti-PD-L1 promotes response and immunity through distinct mechanisms.",False,CONCLUSIONS
2063,"In patients with congenital heart defects, β-blockers significantly improve clinical heart failure outcomes.","CONTEXT Although beta-blockers improve symptoms and survival in adults with heart failure, little is known about these medications in children and adolescents.   
",False,OBJECTIVE
2064,"In patients with congenital heart defects, β-blockers significantly improve clinical heart failure outcomes.","OBJECTIVE To prospectively evaluate the effects of carvedilol in children and adolescents with symptomatic systemic ventricular systolic dysfunction.   
",False,OBJECTIVE
2065,"In patients with congenital heart defects, β-blockers significantly improve clinical heart failure outcomes.","DESIGN, SETTING, AND PARTICIPANTS A multicenter, randomized, double-blind, placebo-controlled study of 161 children and adolescents with symptomatic systolic heart failure from 26 US centers.",False,METHODS
2066,"In patients with congenital heart defects, β-blockers significantly improve clinical heart failure outcomes.","In addition to treatment with conventional heart failure medications, patients were assigned to receive placebo or carvedilol.",False,METHODS
2067,"In patients with congenital heart defects, β-blockers significantly improve clinical heart failure outcomes.","Enrollment began in June 2000 and the last dose was given in May 2005 (each patient received medication for 8 months).   
",False,METHODS
2068,"In patients with congenital heart defects, β-blockers significantly improve clinical heart failure outcomes.","INTERVENTIONS Patients were randomized in a 1:1:1 ratio to twice-daily dosing with placebo, low-dose carvedilol (0.2 mg/kg per dose if weight <62.5 kg or 12.5 mg per dose if weight > or =62.5 kg), or high-dose carvedilol (0.4 mg/kg per dose if weight <62.5 kg or 25 mg per dose if weight > or =62.5 kg) and were stratified according to whether each patient's systemic ventricle was a left ventricle or not.   
",False,METHODS
2069,"In patients with congenital heart defects, β-blockers significantly improve clinical heart failure outcomes.",MAIN OUTCOME MEASURES The primary outcome was a composite measure of heart failure outcomes in patients receiving carvedilol (low- and high-dose combined) vs placebo.,False,METHODS
2070,"In patients with congenital heart defects, β-blockers significantly improve clinical heart failure outcomes.","Secondary efficacy variables included individual components of this composite, echocardiographic measures, and plasma b-type natriuretic peptide levels.   
",False,METHODS
2071,"In patients with congenital heart defects, β-blockers significantly improve clinical heart failure outcomes.","RESULTS There was no statistically significant difference between groups for the composite end point based on the percentage of patients who improved, worsened, or were unchanged.",False,RESULTS
2072,"In patients with congenital heart defects, β-blockers significantly improve clinical heart failure outcomes.","Among 54 patients assigned to placebo, 30 improved (56%), 16 worsened (30%), and 8 were unchanged (15%); among 103 patients assigned to carvedilol, 58 improved (56%), 25 worsened (24%), and 20 were unchanged (19%).",False,RESULTS
2073,"In patients with congenital heart defects, β-blockers significantly improve clinical heart failure outcomes.",The rates of worsening were lower than expected.,False,RESULTS
2074,"In patients with congenital heart defects, β-blockers significantly improve clinical heart failure outcomes.","The odds ratio for worsened outcome for patients in the combined carvedilol group vs the placebo group was 0.79 (95% CI, 0.36-1.59; P = .47).",False,RESULTS
2075,"In patients with congenital heart defects, β-blockers significantly improve clinical heart failure outcomes.","A prespecified subgroup analysis noted significant interaction between treatment and ventricular morphology (P = .02), indicating a possible differential effect of treatment between patients with a systemic left ventricle (beneficial trend) and those whose systemic ventricle was not a left ventricle (nonbeneficial trend).   
",False,RESULTS
2076,"In patients with congenital heart defects, β-blockers significantly improve clinical heart failure outcomes.",CONCLUSIONS These preliminary results suggest that carvedilol does not significantly improve clinical heart failure outcomes in children and adolescents with symptomatic systolic heart failure.,True,CONCLUSIONS
2077,"In patients with congenital heart defects, β-blockers significantly improve clinical heart failure outcomes.","However, given the lower than expected event rates, the trial may have been underpowered.",False,CONCLUSIONS
2078,"In patients with congenital heart defects, β-blockers significantly improve clinical heart failure outcomes.","There may be a differential effect of carvedilol in children and adolescents based on ventricular morphology.   
",False,CONCLUSIONS
2079,"In patients with congenital heart defects, β-blockers significantly improve clinical heart failure outcomes.",TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00052026.,False,CONCLUSIONS
2080,"In pediatric tissue, most T cells are naive T cell emigrants from the thymus.",It is unclear how the immune response in early life becomes appropriately stimulated to provide protection while also avoiding excessive activation as a result of diverse new antigens.,False,BACKGROUND
2081,"In pediatric tissue, most T cells are naive T cell emigrants from the thymus.",T cells are integral to adaptive immunity; mouse studies indicate that tissue localization of T cell subsets is important for both protective immunity and immunoregulation.,False,BACKGROUND
2082,"In pediatric tissue, most T cells are naive T cell emigrants from the thymus.","In humans, however, the early development and function of T cells in tissues remain unexplored.",False,BACKGROUND
2083,"In pediatric tissue, most T cells are naive T cell emigrants from the thymus.","We present here an analysis of lymphoid and mucosal tissue T cells derived from pediatric organ donors in the first two years of life, as compared to adult organ donors, revealing early compartmentalization of T cell differentiation and regulation.",False,METHODS
2084,"In pediatric tissue, most T cells are naive T cell emigrants from the thymus.","Whereas adult tissues contain a predominance of memory T cells, in pediatric blood and tissues the main subset consists of naive recent thymic emigrants, with effector memory T cells (T(EM)) found only in the lungs and small intestine.",True,RESULTS
2085,"In pediatric tissue, most T cells are naive T cell emigrants from the thymus.","Additionally, regulatory T (T(reg)) cells comprise a high proportion (30-40%) of CD4(+) T cells in pediatric tissues but are present at much lower frequencies (1-10%) in adult tissues.",False,RESULTS
2086,"In pediatric tissue, most T cells are naive T cell emigrants from the thymus.","Pediatric tissue T(reg) cells suppress endogenous T cell activation, and early T cell functionality is confined to the mucosal sites that have the lowest T(reg):T(EM) cell ratios, which suggests control in situ of immune responses in early life.",False,CONCLUSIONS
2087,"In rhesus macaques, daily subcutaneous injections of tenofovir protects against rectally transmitted simian-human immunodeficiency virus.","BACKGROUND In the absence of an effective vaccine, HIV continues to spread globally, emphasizing the need for novel strategies to limit its transmission.",False,BACKGROUND
2088,"In rhesus macaques, daily subcutaneous injections of tenofovir protects against rectally transmitted simian-human immunodeficiency virus.",Pre-exposure prophylaxis (PrEP) with antiretroviral drugs could prove to be an effective intervention strategy if highly efficacious and cost-effective PrEP modalities are identified.,False,BACKGROUND
2089,"In rhesus macaques, daily subcutaneous injections of tenofovir protects against rectally transmitted simian-human immunodeficiency virus.","We evaluated daily and intermittent PrEP regimens of increasing antiviral activity in a macaque model that closely resembles human transmission.   
",False,BACKGROUND
2090,"In rhesus macaques, daily subcutaneous injections of tenofovir protects against rectally transmitted simian-human immunodeficiency virus.",METHODS AND FINDINGS We used a repeat-exposure macaque model with 14 weekly rectal virus challenges.,False,METHODS
2091,"In rhesus macaques, daily subcutaneous injections of tenofovir protects against rectally transmitted simian-human immunodeficiency virus.","Three drug treatments were given once daily, each to a different group of six rhesus macaques.",False,METHODS
2092,"In rhesus macaques, daily subcutaneous injections of tenofovir protects against rectally transmitted simian-human immunodeficiency virus.","Group 1 was treated subcutaneously with a human-equivalent dose of emtricitabine (FTC), group 2 received orally the human-equivalent dosing of both FTC and tenofovir-disoproxil fumarate (TDF), and group 3 received subcutaneously a similar dosing of FTC and a higher dose of tenofovir.",False,METHODS
2093,"In rhesus macaques, daily subcutaneous injections of tenofovir protects against rectally transmitted simian-human immunodeficiency virus.",A fourth group of six rhesus macaques (group 4) received intermittently a PrEP regimen similar to group 3 only 2 h before and 24 h after each weekly virus challenge.,False,METHODS
2094,"In rhesus macaques, daily subcutaneous injections of tenofovir protects against rectally transmitted simian-human immunodeficiency virus.",Results were compared to 18 control macaques that did not receive any drug treatment.,False,METHODS
2095,"In rhesus macaques, daily subcutaneous injections of tenofovir protects against rectally transmitted simian-human immunodeficiency virus.","The risk of infection in macaques treated in groups 1 and 2 was 3.8- and 7.8-fold lower than in untreated macaques (p = 0.02 and p = 0.008, respectively).",False,RESULTS
2096,"In rhesus macaques, daily subcutaneous injections of tenofovir protects against rectally transmitted simian-human immunodeficiency virus.",All six macaques in group 3 were protected.,True,RESULTS
2097,"In rhesus macaques, daily subcutaneous injections of tenofovir protects against rectally transmitted simian-human immunodeficiency virus.",Breakthrough infections had blunted acute viremias; drug resistance was seen in two of six animals.,False,RESULTS
2098,"In rhesus macaques, daily subcutaneous injections of tenofovir protects against rectally transmitted simian-human immunodeficiency virus.","All six animals in group 4 that received intermittent PrEP were protected.   
",False,RESULTS
2099,"In rhesus macaques, daily subcutaneous injections of tenofovir protects against rectally transmitted simian-human immunodeficiency virus.",CONCLUSIONS This model suggests that single drugs for daily PrEP can be protective but a combination of antiretroviral drugs may be required to increase the level of protection.,False,CONCLUSIONS
2100,"In rhesus macaques, daily subcutaneous injections of tenofovir protects against rectally transmitted simian-human immunodeficiency virus.",Short but potent intermittent PrEP can provide protection comparable to that of daily PrEP in this SHIV/macaque model.,False,CONCLUSIONS
2101,"In rhesus macaques, daily subcutaneous injections of tenofovir protects against rectally transmitted simian-human immunodeficiency virus.",These findings support PrEP trials for HIV prevention in humans and identify promising PrEP modalities.,False,CONCLUSIONS
2102,"In young and middle-aged adults, current or remote uses of ADHD medications increase the risk of serious cardiovascular events.",CONTEXT More than 1.5 million US adults use stimulants and other medications labeled for treatment of attention-deficit/hyperactivity disorder (ADHD).,False,BACKGROUND
2103,"In young and middle-aged adults, current or remote uses of ADHD medications increase the risk of serious cardiovascular events.","These agents can increase heart rate and blood pressure, raising concerns about their cardiovascular safety.   
",False,BACKGROUND
2104,"In young and middle-aged adults, current or remote uses of ADHD medications increase the risk of serious cardiovascular events.","OBJECTIVE To examine whether current use of medications prescribed primarily to treat ADHD is associated with increased risk of serious cardiovascular events in young and middle-aged adults.   
",False,OBJECTIVE
2105,"In young and middle-aged adults, current or remote uses of ADHD medications increase the risk of serious cardiovascular events.","DESIGN, SETTING, AND PARTICIPANTS Retrospective, population-based cohort study using electronic health care records from 4 study sites (OptumInsight Epidemiology, Tennessee Medicaid, Kaiser Permanente California, and the HMO Research Network), starting in 1986 at 1 site and ending in 2005 at all sites, with additional covariate assessment using 2007 survey data.",False,METHODS
2106,"In young and middle-aged adults, current or remote uses of ADHD medications increase the risk of serious cardiovascular events.","Participants were adults aged 25 through 64 years with dispensed prescriptions for methylphenidate, amphetamine, or atomoxetine at baseline.",False,METHODS
2107,"In young and middle-aged adults, current or remote uses of ADHD medications increase the risk of serious cardiovascular events.","Each medication user (n = 150,359) was matched to 2 nonusers on study site, birth year, sex, and calendar year (443,198 total users and nonusers).   
",False,METHODS
2108,"In young and middle-aged adults, current or remote uses of ADHD medications increase the risk of serious cardiovascular events.","MAIN OUTCOME MEASURES Serious cardiovascular events, including myocardial infarction (MI), sudden cardiac death (SCD), or stroke, with comparison between current or new users and remote users to account for potential healthy-user bias.   
",False,METHODS
2109,"In young and middle-aged adults, current or remote uses of ADHD medications increase the risk of serious cardiovascular events.","RESULTS During 806,182 person-years of follow-up (median, 1.3 years per person), 1357 cases of MI, 296 cases of SCD, and 575 cases of stroke occurred.",False,RESULTS
2110,"In young and middle-aged adults, current or remote uses of ADHD medications increase the risk of serious cardiovascular events.","There were 107,322 person-years of current use (median, 0.33 years), with a crude incidence per 1000 person-years of 1.34 (95% CI, 1.14-1.57) for MI, 0.30 (95% CI, 0.20-0.42) for SCD, and 0.56 (95% CI, 0.43-0.72) for stroke.",False,RESULTS
2111,"In young and middle-aged adults, current or remote uses of ADHD medications increase the risk of serious cardiovascular events.","The multivariable-adjusted rate ratio (RR) of serious cardiovascular events for current use vs nonuse of ADHD medications was 0.83 (95% CI, 0.72-0.96).",True,RESULTS
2112,"In young and middle-aged adults, current or remote uses of ADHD medications increase the risk of serious cardiovascular events.","Among new users of ADHD medications, the adjusted RR was 0.77 (95% CI, 0.63-0.94).",True,RESULTS
2113,"In young and middle-aged adults, current or remote uses of ADHD medications increase the risk of serious cardiovascular events.","The adjusted RR for current use vs remote use was 1.03 (95% CI, 0.86-1.24); for new use vs remote use, the adjusted RR was 1.02 (95% CI, 0.82-1.28); the upper limit of 1.28 corresponds to an additional 0.19 events per 1000 person-years at ages 25-44 years and 0.77 events per 1000 person-years at ages 45-64 years.   
",False,RESULTS
2114,"In young and middle-aged adults, current or remote uses of ADHD medications increase the risk of serious cardiovascular events.","CONCLUSIONS Among young and middle-aged adults, current or new use of ADHD medications, compared with nonuse or remote use, was not associated with an increased risk of serious cardiovascular events.",True,CONCLUSIONS
2115,"In young and middle-aged adults, current or remote uses of ADHD medications increase the risk of serious cardiovascular events.",Apparent protective associations likely represent healthy-user bias.,False,CONCLUSIONS
2116,Incidence of 10/66 dementia is higher than the incidence of DSM-IV dementia.,BACKGROUND Results of the few cohort studies from countries with low incomes or middle incomes suggest a lower incidence of dementia than in high-income countries.,False,BACKGROUND
2117,Incidence of 10/66 dementia is higher than the incidence of DSM-IV dementia.,"We assessed incidence of dementia according to criteria from the 10/66 Dementia Research Group and Diagnostic and Statistical Manual of Mental Disorders (DSM) IV, the effect of dementia at baseline on mortality, and the independent effects of age, sex, socioeconomic position, and indicators of cognitive reserve.   
",False,BACKGROUND
2118,Incidence of 10/66 dementia is higher than the incidence of DSM-IV dementia.,"METHODS We did a population-based cohort study of all people aged 65 years and older living in urban sites in Cuba, the Dominican Republic, and Venezuela, and rural and urban sites in Peru, Mexico, and China, with ascertainment of incident 10/66 and DSM-IV dementia 3-5 years after cohort inception.",False,METHODS
2119,Incidence of 10/66 dementia is higher than the incidence of DSM-IV dementia.,"We used questionnaires to obtain information about age in years, sex, educational level, literacy, occupational attainment, and number of household assets.",False,METHODS
2120,Incidence of 10/66 dementia is higher than the incidence of DSM-IV dementia.,We obtained information about mortality from all sites.,False,METHODS
2121,Incidence of 10/66 dementia is higher than the incidence of DSM-IV dementia.,"For participants who had died, we interviewed a friend or relative to ascertain the likelihood that they had dementia before death.   
",False,METHODS
2122,Incidence of 10/66 dementia is higher than the incidence of DSM-IV dementia.,"FINDINGS 12,887 participants were interviewed at baseline.",False,RESULTS
2123,Incidence of 10/66 dementia is higher than the incidence of DSM-IV dementia.,"11,718 were free of dementia, of whom 8137 (69%) were reinterviewed, contributing 34,718 person-years of follow-up.",False,RESULTS
2124,Incidence of 10/66 dementia is higher than the incidence of DSM-IV dementia.,"Incidence for 10/66 dementia varied between 18·2 and 30·4 per 1000 person-years, and were 1·4-2·7 times higher than were those for DSM-IV dementia (9·9-15·7 per 1000 person-years).",True,RESULTS
2125,Incidence of 10/66 dementia is higher than the incidence of DSM-IV dementia.,Mortality hazards were 1·56-5·69 times higher in individuals with dementia at baseline than in those who were dementia-free.,False,RESULTS
2126,Incidence of 10/66 dementia is higher than the incidence of DSM-IV dementia.,Informant reports suggested a high incidence of dementia before death; overall incidence might be 4-19% higher if these data were included.,False,RESULTS
2127,Incidence of 10/66 dementia is higher than the incidence of DSM-IV dementia.,"10/66 dementia incidence was independently associated with increased age (HR 1·67; 95% CI 1·56-1·79), female sex (0·72; 0·61-0·84), and low education (0·89; 0·81-0·97), but not with occupational attainment (1·04; 0·95-1·13).   
",False,RESULTS
2128,Incidence of 10/66 dementia is higher than the incidence of DSM-IV dementia.,"INTERPRETATION Our results provide supportive evidence for the cognitive reserve hypothesis, showing that in middle-income countries as in high-income countries, education, literacy, verbal fluency, and motor sequencing confer substantial protection against the onset of dementia.   
",False,CONCLUSIONS
2129,Incidence of 10/66 dementia is higher than the incidence of DSM-IV dementia.,"FUNDING Wellcome Trust Health Consequences of Population Change Programme, WHO, US Alzheimer's Association, FONACIT/ CDCH/ UCV.",False,BACKGROUND
2130,Incidence of 10/66 dementia is lower than the incidence of DSM-IV dementia.,BACKGROUND Results of the few cohort studies from countries with low incomes or middle incomes suggest a lower incidence of dementia than in high-income countries.,False,BACKGROUND
2131,Incidence of 10/66 dementia is lower than the incidence of DSM-IV dementia.,"We assessed incidence of dementia according to criteria from the 10/66 Dementia Research Group and Diagnostic and Statistical Manual of Mental Disorders (DSM) IV, the effect of dementia at baseline on mortality, and the independent effects of age, sex, socioeconomic position, and indicators of cognitive reserve.   
",False,BACKGROUND
2132,Incidence of 10/66 dementia is lower than the incidence of DSM-IV dementia.,"METHODS We did a population-based cohort study of all people aged 65 years and older living in urban sites in Cuba, the Dominican Republic, and Venezuela, and rural and urban sites in Peru, Mexico, and China, with ascertainment of incident 10/66 and DSM-IV dementia 3-5 years after cohort inception.",False,METHODS
2133,Incidence of 10/66 dementia is lower than the incidence of DSM-IV dementia.,"We used questionnaires to obtain information about age in years, sex, educational level, literacy, occupational attainment, and number of household assets.",False,METHODS
2134,Incidence of 10/66 dementia is lower than the incidence of DSM-IV dementia.,We obtained information about mortality from all sites.,False,METHODS
2135,Incidence of 10/66 dementia is lower than the incidence of DSM-IV dementia.,"For participants who had died, we interviewed a friend or relative to ascertain the likelihood that they had dementia before death.   
",False,METHODS
2136,Incidence of 10/66 dementia is lower than the incidence of DSM-IV dementia.,"FINDINGS 12,887 participants were interviewed at baseline.",False,RESULTS
2137,Incidence of 10/66 dementia is lower than the incidence of DSM-IV dementia.,"11,718 were free of dementia, of whom 8137 (69%) were reinterviewed, contributing 34,718 person-years of follow-up.",False,RESULTS
2138,Incidence of 10/66 dementia is lower than the incidence of DSM-IV dementia.,"Incidence for 10/66 dementia varied between 18·2 and 30·4 per 1000 person-years, and were 1·4-2·7 times higher than were those for DSM-IV dementia (9·9-15·7 per 1000 person-years).",True,RESULTS
2139,Incidence of 10/66 dementia is lower than the incidence of DSM-IV dementia.,Mortality hazards were 1·56-5·69 times higher in individuals with dementia at baseline than in those who were dementia-free.,False,RESULTS
2140,Incidence of 10/66 dementia is lower than the incidence of DSM-IV dementia.,Informant reports suggested a high incidence of dementia before death; overall incidence might be 4-19% higher if these data were included.,False,RESULTS
2141,Incidence of 10/66 dementia is lower than the incidence of DSM-IV dementia.,"10/66 dementia incidence was independently associated with increased age (HR 1·67; 95% CI 1·56-1·79), female sex (0·72; 0·61-0·84), and low education (0·89; 0·81-0·97), but not with occupational attainment (1·04; 0·95-1·13).   
",False,RESULTS
2142,Incidence of 10/66 dementia is lower than the incidence of DSM-IV dementia.,"INTERPRETATION Our results provide supportive evidence for the cognitive reserve hypothesis, showing that in middle-income countries as in high-income countries, education, literacy, verbal fluency, and motor sequencing confer substantial protection against the onset of dementia.   
",False,CONCLUSIONS
2143,Incidence of 10/66 dementia is lower than the incidence of DSM-IV dementia.,"FUNDING Wellcome Trust Health Consequences of Population Change Programme, WHO, US Alzheimer's Association, FONACIT/ CDCH/ UCV.",False,BACKGROUND
2144,Incidence of heart failure increased by 10% in women since 1979.,"CONTEXT The epidemic of heart failure has yet to be fully investigated, and data on incidence, survival, and sex-specific temporal trends in community-based populations are limited.   
",False,BACKGROUND
2145,Incidence of heart failure increased by 10% in women since 1979.,"OBJECTIVE To test the hypothesis that the incidence of heart failure has declined and survival after heart failure diagnosis has improved over time but that secular trends have diverged by sex.   
",False,OBJECTIVE
2146,Incidence of heart failure increased by 10% in women since 1979.,"DESIGN, SETTING, AND PARTICIPANTS Population-based cohort study using the resources of the Rochester Epidemiology Project conducted in Olmsted County, Minnesota.",False,METHODS
2147,Incidence of heart failure increased by 10% in women since 1979.,"Patients were 4537 Olmsted County residents (57% women; mean [SD] age, 74 [14] years) with a diagnosis of heart failure between 1979 and 2000.",False,METHODS
2148,Incidence of heart failure increased by 10% in women since 1979.,"Framingham criteria and clinical criteria were used to validate the diagnosis   MAIN OUTCOME MEASURES Incidence of heart failure and survival after heart failure diagnosis.   
",False,METHODS
2149,Incidence of heart failure increased by 10% in women since 1979.,"RESULTS The incidence of heart failure was higher among men (378/100 000 persons; 95% confidence interval [CI], 361-395 for men; 289/100 000 persons; 95% CI, 277-300 for women) and did not change over time among men or women.",True,RESULTS
2150,Incidence of heart failure increased by 10% in women since 1979.,"After a mean follow-up of 4.2 years (range, 0-23.8 years), 3347 deaths occurred, including 1930 among women and 1417 among men.",False,RESULTS
2151,Incidence of heart failure increased by 10% in women since 1979.,"Survival after heart failure diagnosis was worse among men than women (relative risk, 1.33; 95% CI, 1.24-1.43) but overall improved over time (5-year age-adjusted survival, 43% in 1979-1984 vs 52% in 1996-2000, P<.001).",False,RESULTS
2152,Incidence of heart failure increased by 10% in women since 1979.,"However, men and younger persons experienced larger survival gains, contrasting with less or no improvement for women and elderly persons.   
",False,RESULTS
2153,Incidence of heart failure increased by 10% in women since 1979.,"CONCLUSION In this community-based cohort, the incidence of heart failure has not declined during 2 decades, but survival after onset of heart failure has increased overall, with less improvement among women and elderly persons.",False,CONCLUSIONS
2154,Incidence of sepsis has fallen substantially from 2009 to 2014.,Importance Estimates from claims-based analyses suggest that the incidence of sepsis is increasing and mortality rates from sepsis are decreasing.,False,BACKGROUND
2155,Incidence of sepsis has fallen substantially from 2009 to 2014.,"However, estimates from claims data may lack clinical fidelity and can be affected by changing diagnosis and coding practices over time.",False,BACKGROUND
2156,Incidence of sepsis has fallen substantially from 2009 to 2014.,Objective To estimate the US national incidence of sepsis and trends using detailed clinical data from the electronic health record (EHR) systems of diverse hospitals.,False,OBJECTIVE
2157,Incidence of sepsis has fallen substantially from 2009 to 2014.,"Design, Setting, and Population Retrospective cohort study of adult patients admitted to 409 academic, community, and federal hospitals from 2009-2014.",False,METHODS
2158,Incidence of sepsis has fallen substantially from 2009 to 2014.,"Exposures Sepsis was identified using clinical indicators of presumed infection and concurrent acute organ dysfunction, adapting Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) criteria for objective and consistent EHR-based surveillance.",False,METHODS
2159,Incidence of sepsis has fallen substantially from 2009 to 2014.,"Main Outcomes and Measures Sepsis incidence, outcomes, and trends from 2009-2014 were calculated using regression models and compared with claims-based estimates using International Classification of Diseases, Ninth Revision, Clinical Modification codes for severe sepsis or septic shock.",False,METHODS
2160,Incidence of sepsis has fallen substantially from 2009 to 2014.,Case-finding criteria were validated against Sepsis-3 criteria using medical record reviews.,False,METHODS
2161,Incidence of sepsis has fallen substantially from 2009 to 2014.,"Results A total of 173 690 sepsis cases (mean age, 66.5 [SD, 15.5] y; 77 660 [42.4%] women) were identified using clinical criteria among 2 901 019 adults admitted to study hospitals in 2014 (6.0% incidence).",False,RESULTS
2162,Incidence of sepsis has fallen substantially from 2009 to 2014.,"Of these, 26 061 (15.0%) died in the hospital and 10 731 (6.2%) were discharged to hospice.",False,RESULTS
2163,Incidence of sepsis has fallen substantially from 2009 to 2014.,"From 2009-2014, sepsis incidence using clinical criteria was stable (+0.6% relative change/y [95% CI, −2.3% to 3.5%], P = .67) whereas incidence per claims increased (+10.3%/y [95% CI, 7.2% to 13.3%], P < .001).",True,RESULTS
2164,Incidence of sepsis has fallen substantially from 2009 to 2014.,"In-hospital mortality using clinical criteria declined (−3.3%/y [95% CI, −5.6% to −1.0%], P = .004), but there was no significant change in the combined outcome of death or discharge to hospice (−1.3%/y [95% CI, −3.2% to 0.6%], P = .19).",False,RESULTS
2165,Incidence of sepsis has fallen substantially from 2009 to 2014.,"In contrast, mortality using claims declined significantly (−7.0%/y [95% CI, −8.8% to −5.2%], P < .001), as did death or discharge to hospice (−4.5%/y [95% CI, −6.1% to −2.8%], P < .001).",False,RESULTS
2166,Incidence of sepsis has fallen substantially from 2009 to 2014.,"Clinical criteria were more sensitive in identifying sepsis than claims (69.7% [95% CI, 52.9% to 92.0%] vs 32.3% [95% CI, 24.4% to 43.0%], P < .001), with comparable positive predictive value (70.4% [95% CI, 64.0% to 76.8%] vs 75.2% [95% CI, 69.8% to 80.6%], P = .23).",False,RESULTS
2167,Incidence of sepsis has fallen substantially from 2009 to 2014.,"Conclusions and Relevance In clinical data from 409 hospitals, sepsis was present in 6% of adult hospitalizations, and in contrast to claims-based analyses, neither the incidence of sepsis nor the combined outcome of death or discharge to hospice changed significantly between 2009-2014.",True,CONCLUSIONS
2168,Incidence of sepsis has fallen substantially from 2009 to 2014.,The findings also suggest that EHR-based clinical data provide more objective estimates than claims-based data for sepsis surveillance.,False,CONCLUSIONS
2169,Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).,"CONTEXT Pharmacist review of medication orders in the intensive care unit (ICU) has been shown to prevent errors, and pharmacist consultation has reduced drug costs.",False,BACKGROUND
2170,Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).,"However, whether pharmacist participation in the ICU at the time of drug prescribing reduces adverse events has not been studied.   
",False,BACKGROUND
2171,Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).,"OBJECTIVE To measure the effect of pharmacist participation on medical rounds in the ICU on the rate of preventable adverse drug events (ADEs) caused by ordering errors.   
",False,OBJECTIVE
2172,Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).,"DESIGN Before-after comparison between phase 1 (baseline) and phase 2 (after intervention implemented) and phase 2 comparison with a control unit that did not receive the intervention.   
",False,METHODS
2173,Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).,"SETTING A medical ICU (study unit) and a coronary care unit (control unit) in a large urban teaching hospital.   
",False,METHODS
2174,Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).,"PATIENTS Seventy-five patients randomly selected from each of 3 groups: all admissions to the study unit from February 1, 1993, through July 31, 1993 (baseline) and all admissions to the study unit (postintervention) and control unit from October 1, 1994, through July 7, 1995.",False,METHODS
2175,Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).,"In addition, 50 patients were selected at random from the control unit during the baseline period.   
",False,METHODS
2176,Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).,"INTERVENTION A senior pharmacist made rounds with the ICU team and remained in the ICU for consultation in the morning, and was available on call throughout the day.   
",False,METHODS
2177,Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).,"MAIN OUTCOME MEASURES Preventable ADEs due to ordering (prescribing) errors and the number, type, and acceptance of interventions made by the pharmacist.",False,METHODS
2178,Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).,Preventable ADEs were identified by review of medical records of the randomly selected patients during both preintervention and postintervention phases.,False,METHODS
2179,Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).,"Pharmacists recorded all recommendations, which were then analyzed by type and acceptance.   
",False,METHODS
2180,Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).,"RESULTS The rate of preventable ordering ADEs decreased by 66% from 10.4 per 1000 patient-days (95% confidence interval [CI], 7-14) before the intervention to 3.5 (95% CI, 1-5; P<.001) after the intervention.",True,RESULTS
2181,Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).,"In the control unit, the rate was essentially unchanged during the same time periods: 10.9 (95% CI, 6-16) and 12.4 (95% CI, 8-17) per 1000 patient-days.",False,RESULTS
2182,Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).,"The pharmacist made 366 recommendations related to drug ordering, of which 362 (99%) were accepted by physicians.   
",False,RESULTS
2183,Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).,CONCLUSIONS The presence of a pharmacist on rounds as a full member of the patient care team in a medical ICU was associated with a substantially lower rate of ADEs caused by prescribing errors.,True,CONCLUSIONS
2184,Including pharmacists in rounding teams does not alter the incidence of adverse drug events (ADEs).,Nearly all the changes were readily accepted by physicians.,False,CONCLUSIONS
2185,Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).,"CONTEXT Pharmacist review of medication orders in the intensive care unit (ICU) has been shown to prevent errors, and pharmacist consultation has reduced drug costs.",False,BACKGROUND
2186,Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).,"However, whether pharmacist participation in the ICU at the time of drug prescribing reduces adverse events has not been studied.   
",False,BACKGROUND
2187,Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).,"OBJECTIVE To measure the effect of pharmacist participation on medical rounds in the ICU on the rate of preventable adverse drug events (ADEs) caused by ordering errors.   
",False,OBJECTIVE
2188,Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).,"DESIGN Before-after comparison between phase 1 (baseline) and phase 2 (after intervention implemented) and phase 2 comparison with a control unit that did not receive the intervention.   
",False,METHODS
2189,Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).,"SETTING A medical ICU (study unit) and a coronary care unit (control unit) in a large urban teaching hospital.   
",False,METHODS
2190,Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).,"PATIENTS Seventy-five patients randomly selected from each of 3 groups: all admissions to the study unit from February 1, 1993, through July 31, 1993 (baseline) and all admissions to the study unit (postintervention) and control unit from October 1, 1994, through July 7, 1995.",False,METHODS
2191,Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).,"In addition, 50 patients were selected at random from the control unit during the baseline period.   
",False,METHODS
2192,Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).,"INTERVENTION A senior pharmacist made rounds with the ICU team and remained in the ICU for consultation in the morning, and was available on call throughout the day.   
",False,METHODS
2193,Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).,"MAIN OUTCOME MEASURES Preventable ADEs due to ordering (prescribing) errors and the number, type, and acceptance of interventions made by the pharmacist.",False,METHODS
2194,Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).,Preventable ADEs were identified by review of medical records of the randomly selected patients during both preintervention and postintervention phases.,False,METHODS
2195,Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).,"Pharmacists recorded all recommendations, which were then analyzed by type and acceptance.   
",False,METHODS
2196,Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).,"RESULTS The rate of preventable ordering ADEs decreased by 66% from 10.4 per 1000 patient-days (95% confidence interval [CI], 7-14) before the intervention to 3.5 (95% CI, 1-5; P<.001) after the intervention.",True,RESULTS
2197,Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).,"In the control unit, the rate was essentially unchanged during the same time periods: 10.9 (95% CI, 6-16) and 12.4 (95% CI, 8-17) per 1000 patient-days.",False,RESULTS
2198,Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).,"The pharmacist made 366 recommendations related to drug ordering, of which 362 (99%) were accepted by physicians.   
",False,RESULTS
2199,Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).,CONCLUSIONS The presence of a pharmacist on rounds as a full member of the patient care team in a medical ICU was associated with a substantially lower rate of ADEs caused by prescribing errors.,True,CONCLUSIONS
2200,Including pharmacists in rounding teams reduces the incidence of adverse drug events (ADEs).,Nearly all the changes were readily accepted by physicians.,False,CONCLUSIONS
2201,Increased LDL receptors plays a role in the reduction of plasma Lp(a).,"BACKGROUND Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), lowers plasma low-density lipoprotein (LDL) cholesterol and apolipoprotein B100 (apoB).",False,BACKGROUND
2202,Increased LDL receptors plays a role in the reduction of plasma Lp(a).,"Although studies in mice and cells have identified increased hepatic LDL receptors as the basis for LDL lowering by PCSK9 inhibitors, there have been no human studies characterizing the effects of PCSK9 inhibitors on lipoprotein metabolism.",False,BACKGROUND
2203,Increased LDL receptors plays a role in the reduction of plasma Lp(a).,"In particular, it is not known whether inhibition of PCSK9 has any effects on very low-density lipoprotein or intermediate-density lipoprotein (IDL) metabolism.",False,BACKGROUND
2204,Increased LDL receptors plays a role in the reduction of plasma Lp(a).,Inhibition of PCSK9 also results in reductions of plasma lipoprotein (a) levels.,False,BACKGROUND
2205,Increased LDL receptors plays a role in the reduction of plasma Lp(a).,"The regulation of plasma Lp(a) levels, including the role of LDL receptors in the clearance of Lp(a), is poorly defined, and no mechanistic studies of the Lp(a) lowering by alirocumab in humans have been published to date.   
",False,BACKGROUND
2206,Increased LDL receptors plays a role in the reduction of plasma Lp(a).,"METHODS Eighteen (10 F, 8 mol/L) participants completed a placebo-controlled, 2-period study.",False,METHODS
2207,Increased LDL receptors plays a role in the reduction of plasma Lp(a).,"They received 2 doses of placebo, 2 weeks apart, followed by 5 doses of 150 mg of alirocumab, 2 weeks apart.",False,METHODS
2208,Increased LDL receptors plays a role in the reduction of plasma Lp(a).,"At the end of each period, fractional clearance rates (FCRs) and production rates (PRs) of apoB and apo(a) were determined.",False,METHODS
2209,Increased LDL receptors plays a role in the reduction of plasma Lp(a).,"In 10 participants, postprandial triglycerides and apoB48 levels were measured.   
",False,METHODS
2210,Increased LDL receptors plays a role in the reduction of plasma Lp(a).,"RESULTS Alirocumab reduced ultracentrifugally isolated LDL-C by 55.1%, LDL-apoB by 56.3%, and plasma Lp(a) by 18.7%.",True,RESULTS
2211,Increased LDL receptors plays a role in the reduction of plasma Lp(a).,The fall in LDL-apoB was caused by an 80.4% increase in LDL-apoB FCR and a 23.9% reduction in LDL-apoB PR.,True,RESULTS
2212,Increased LDL receptors plays a role in the reduction of plasma Lp(a).,The latter was due to a 46.1% increase in IDL-apoB FCR coupled with a 27.2% decrease in conversion of IDL to LDL.,True,RESULTS
2213,Increased LDL receptors plays a role in the reduction of plasma Lp(a).,The FCR of apo(a) tended to increase (24.6%) without any change in apo(a) PR.,False,RESULTS
2214,Increased LDL receptors plays a role in the reduction of plasma Lp(a).,"Alirocumab had no effects on FCRs or PRs of very low-density lipoproteins-apoB and very low-density lipoproteins triglycerides or on postprandial plasma triglycerides or apoB48 concentrations.   
",False,RESULTS
2215,Increased LDL receptors plays a role in the reduction of plasma Lp(a).,CONCLUSIONS Alirocumab decreased LDL-C and LDL-apoB by increasing IDL- and LDL-apoB FCRs and decreasing LDL-apoB PR.,False,CONCLUSIONS
2216,Increased LDL receptors plays a role in the reduction of plasma Lp(a).,These results are consistent with increases in LDL receptors available to clear IDL and LDL from blood during PCSK9 inhibition.,False,CONCLUSIONS
2217,Increased LDL receptors plays a role in the reduction of plasma Lp(a).,The increase in apo(a) FCR during alirocumab treatment suggests that increased LDL receptors may also play a role in the reduction of plasma Lp(a).   ,True,CONCLUSIONS
2218,Increased LDL receptors plays a role in the reduction of plasma Lp(a).,CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov.,False,BACKGROUND
2219,Increased LDL receptors plays a role in the reduction of plasma Lp(a).,Unique identifier: NCT01959971.,False,BACKGROUND
2220,Increased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,BACKGROUND The associations of blood pressure with the different manifestations of incident cardiovascular disease in a contemporary population have not been compared.,False,BACKGROUND
2221,Increased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"In this study, we aimed to analyse the associations of blood pressure with 12 different presentations of cardiovascular disease.   
",False,BACKGROUND
2222,Increased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"METHODS We used linked electronic health records from 1997 to 2010 in the CALIBER (CArdiovascular research using LInked Bespoke studies and Electronic health Records) programme to assemble a cohort of 1·25 million patients, 30 years of age or older and initially free from cardiovascular disease, a fifth of whom received blood pressure-lowering treatments.",False,METHODS
2223,Increased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"We studied the heterogeneity in the age-specific associations of clinically measured blood pressure with 12 acute and chronic cardiovascular diseases, and estimated the lifetime risks (up to 95 years of age) and cardiovascular disease-free life-years lost adjusted for other risk factors at index ages 30, 60, and 80 years.",False,METHODS
2224,Increased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"This study is registered at ClinicalTrials.gov, number NCT01164371.   
",False,METHODS
2225,Increased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"FINDINGS During 5·2 years median follow-up, we recorded 83,098 initial cardiovascular disease presentations.",False,RESULTS
2226,Increased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"In each age group, the lowest risk for cardiovascular disease was in people with systolic blood pressure of 90-114 mm Hg and diastolic blood pressure of 60-74 mm Hg, with no evidence of a J-shaped increased risk at lower blood pressures.",False,RESULTS
2227,Increased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"The effect of high blood pressure varied by cardiovascular disease endpoint, from strongly positive to no effect.",False,RESULTS
2228,Increased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"Associations with high systolic blood pressure were strongest for intracerebral haemorrhage (hazard ratio 1·44 [95% CI 1·32-1·58]), subarachnoid haemorrhage (1·43 [1·25-1·63]), and stable angina (1·41 [1·36-1·46]), and weakest for abdominal aortic aneurysm (1·08 [1·00-1·17]).",False,RESULTS
2229,Increased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"Compared with diastolic blood pressure, raised systolic blood pressure had a greater effect on angina, myocardial infarction, and peripheral arterial disease, whereas raised diastolic blood pressure had a greater effect on abdominal aortic aneurysm than did raised systolic pressure.",True,RESULTS
2230,Increased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,Pulse pressure associations were inverse for abdominal aortic aneurysm (HR per 10 mm Hg 0·91 [95% CI 0·86-0·98]) and strongest for peripheral arterial disease (1·23 [1·20-1·27]).,False,RESULTS
2231,Increased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"People with hypertension (blood pressure ≥140/90 mm Hg or those receiving blood pressure-lowering drugs) had a lifetime risk of overall cardiovascular disease at 30 years of age of 63·3% (95% CI 62·9-63·8) compared with 46·1% (45·5-46·8) for those with normal blood pressure, and developed cardiovascular disease 5·0 years earlier (95% CI 4·8-5·2).",False,RESULTS
2232,Increased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"Stable and unstable angina accounted for most (43%) of the cardiovascular disease-free years of life lost associated with hypertension from index age 30 years, whereas heart failure and stable angina accounted for the largest proportion (19% each) of years of life lost from index age 80 years.   
",False,RESULTS
2233,Increased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"INTERPRETATION The widely held assumptions that blood pressure has strong associations with the occurrence of all cardiovascular diseases across a wide age range, and that diastolic and systolic associations are concordant, are not supported by the findings of this high-resolution study.",False,CONCLUSIONS
2234,Increased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"Despite modern treatments, the lifetime burden of hypertension is substantial.",False,CONCLUSIONS
2235,Increased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"These findings emphasise the need for new blood pressure-lowering strategies, and will help to inform the design of randomised trials to assess them.   
",False,CONCLUSIONS
2236,Increased diastolic blood pressure (DBP) is associated with abdominal aortic aneurysm.,"FUNDING Medical Research Council, National Institute for Health Research, and Wellcome Trust.",False,BACKGROUND
2237,Increased microtubule acetylation exacerbates LRRK2 Roc-COR domain mutation induced locomotor deficits.,Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common genetic cause of Parkinson's disease.,False,BACKGROUND
2238,Increased microtubule acetylation exacerbates LRRK2 Roc-COR domain mutation induced locomotor deficits.,LRRK2 is a multifunctional protein affecting many cellular processes and has been described to bind microtubules.,False,BACKGROUND
2239,Increased microtubule acetylation exacerbates LRRK2 Roc-COR domain mutation induced locomotor deficits.,"Defective microtubule-based axonal transport is hypothesized to contribute to Parkinson's disease, but whether LRRK2 mutations affect this process to mediate pathogenesis is not known.",False,BACKGROUND
2240,Increased microtubule acetylation exacerbates LRRK2 Roc-COR domain mutation induced locomotor deficits.,"Here we find that LRRK2 containing pathogenic Roc-COR domain mutations (R1441C, Y1699C) preferentially associates with deacetylated microtubules, and inhibits axonal transport in primary neurons and in Drosophila, causing locomotor deficits in vivo.",False,RESULTS
2241,Increased microtubule acetylation exacerbates LRRK2 Roc-COR domain mutation induced locomotor deficits.,"In vitro, increasing microtubule acetylation using deacetylase inhibitors or the tubulin acetylase αTAT1 prevents association of mutant LRRK2 with microtubules, and the deacetylase inhibitor trichostatin A (TSA) restores axonal transport.",True,RESULTS
2242,Increased microtubule acetylation exacerbates LRRK2 Roc-COR domain mutation induced locomotor deficits.,"In vivo knockdown of the deacetylases HDAC6 and Sirt2, or administration of TSA rescues both axonal transport and locomotor behavior.",False,CONCLUSIONS
2243,Increased microtubule acetylation exacerbates LRRK2 Roc-COR domain mutation induced locomotor deficits.,"Thus, this study reveals a pathogenic mechanism and a potential intervention for Parkinson's disease.",False,CONCLUSIONS
2244,Increased microtubule acetylation repairs interference of axonal transport caused by LRRK2 Roc-COR domain mutations.,Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common genetic cause of Parkinson's disease.,False,BACKGROUND
2245,Increased microtubule acetylation repairs interference of axonal transport caused by LRRK2 Roc-COR domain mutations.,LRRK2 is a multifunctional protein affecting many cellular processes and has been described to bind microtubules.,False,BACKGROUND
2246,Increased microtubule acetylation repairs interference of axonal transport caused by LRRK2 Roc-COR domain mutations.,"Defective microtubule-based axonal transport is hypothesized to contribute to Parkinson's disease, but whether LRRK2 mutations affect this process to mediate pathogenesis is not known.",False,BACKGROUND
2247,Increased microtubule acetylation repairs interference of axonal transport caused by LRRK2 Roc-COR domain mutations.,"Here we find that LRRK2 containing pathogenic Roc-COR domain mutations (R1441C, Y1699C) preferentially associates with deacetylated microtubules, and inhibits axonal transport in primary neurons and in Drosophila, causing locomotor deficits in vivo.",False,RESULTS
2248,Increased microtubule acetylation repairs interference of axonal transport caused by LRRK2 Roc-COR domain mutations.,"In vitro, increasing microtubule acetylation using deacetylase inhibitors or the tubulin acetylase αTAT1 prevents association of mutant LRRK2 with microtubules, and the deacetylase inhibitor trichostatin A (TSA) restores axonal transport.",True,RESULTS
2249,Increased microtubule acetylation repairs interference of axonal transport caused by LRRK2 Roc-COR domain mutations.,"In vivo knockdown of the deacetylases HDAC6 and Sirt2, or administration of TSA rescues both axonal transport and locomotor behavior.",True,CONCLUSIONS
2250,Increased microtubule acetylation repairs interference of axonal transport caused by LRRK2 Roc-COR domain mutations.,"Thus, this study reveals a pathogenic mechanism and a potential intervention for Parkinson's disease.",False,CONCLUSIONS
2251,Increased microtubule acetylation worsens interference of axonal transport caused by LRRK2 Roc-COR domain mutations.,Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common genetic cause of Parkinson's disease.,False,BACKGROUND
2252,Increased microtubule acetylation worsens interference of axonal transport caused by LRRK2 Roc-COR domain mutations.,LRRK2 is a multifunctional protein affecting many cellular processes and has been described to bind microtubules.,False,BACKGROUND
2253,Increased microtubule acetylation worsens interference of axonal transport caused by LRRK2 Roc-COR domain mutations.,"Defective microtubule-based axonal transport is hypothesized to contribute to Parkinson's disease, but whether LRRK2 mutations affect this process to mediate pathogenesis is not known.",False,BACKGROUND
2254,Increased microtubule acetylation worsens interference of axonal transport caused by LRRK2 Roc-COR domain mutations.,"Here we find that LRRK2 containing pathogenic Roc-COR domain mutations (R1441C, Y1699C) preferentially associates with deacetylated microtubules, and inhibits axonal transport in primary neurons and in Drosophila, causing locomotor deficits in vivo.",False,RESULTS
2255,Increased microtubule acetylation worsens interference of axonal transport caused by LRRK2 Roc-COR domain mutations.,"In vitro, increasing microtubule acetylation using deacetylase inhibitors or the tubulin acetylase αTAT1 prevents association of mutant LRRK2 with microtubules, and the deacetylase inhibitor trichostatin A (TSA) restores axonal transport.",True,RESULTS
2256,Increased microtubule acetylation worsens interference of axonal transport caused by LRRK2 Roc-COR domain mutations.,"In vivo knockdown of the deacetylases HDAC6 and Sirt2, or administration of TSA rescues both axonal transport and locomotor behavior.",True,CONCLUSIONS
2257,Increased microtubule acetylation worsens interference of axonal transport caused by LRRK2 Roc-COR domain mutations.,"Thus, this study reveals a pathogenic mechanism and a potential intervention for Parkinson's disease.",False,CONCLUSIONS
2258,Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.,"CONTEXT Many observational studies have shown that physical activity reduces the risk of cognitive decline; however, evidence from randomized trials is lacking.   
",False,OBJECTIVE
2259,Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.,"OBJECTIVE To determine whether physical activity reduces the rate of cognitive decline among older adults at risk.   
",False,OBJECTIVE
2260,Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.,"DESIGN AND SETTING Randomized controlled trial of a 24-week physical activity intervention conducted between 2004 and 2007 in metropolitan Perth, Western Australia.",False,METHODS
2261,Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.,"Assessors of cognitive function were blinded to group membership.   
",False,METHODS
2262,Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.,PARTICIPANTS We recruited volunteers who reported memory problems but did not meet criteria for dementia.,False,METHODS
2263,Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.,"Three hundred eleven individuals aged 50 years or older were screened for eligibility, 89 were not eligible, and 52 refused to participate.",False,METHODS
2264,Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.,"A total of 170 participants were randomized and 138 participants completed the 18-month assessment.   
",False,METHODS
2265,Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.,"INTERVENTION Participants were randomly allocated to an education and usual care group or to a 24-week home-based program of physical activity.   
",False,METHODS
2266,Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.,"MAIN OUTCOME MEASURE Change in Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) scores (possible range, 0-70) over 18 months.   
",False,METHODS
2267,Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.,"RESULTS In an intent-to-treat analysis, participants in the intervention group improved 0.26 points (95% confidence interval, -0.89 to 0.54) and those in the usual care group deteriorated 1.04 points (95% confidence interval, 0.32 to 1.82) on the ADAS-Cog at the end of the intervention.",True,RESULTS
2268,Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.,"The absolute difference of the outcome measure between the intervention and control groups was -1.3 points (95% confidence interval,-2.38 to -0.22) at the end of the intervention.",False,RESULTS
2269,Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.,"At 18 months, participants in the intervention group improved 0.73 points (95% confidence interval, -1.27 to 0.03) on the ADAS-Cog, and those in the usual care group improved 0.04 points (95% confidence interval, -0.46 to 0.88).",False,RESULTS
2270,Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.,"Word list delayed recall and Clinical Dementia Rating sum of boxes improved modestly as well, whereas word list total immediate recall, digit symbol coding, verbal fluency, Beck depression score, and Medical Outcomes 36-Item Short-Form physical and mental component summaries did not change significantly.   
",False,RESULTS
2271,Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.,"CONCLUSIONS In this study of adults with subjective memory impairment, a 6-month program of physical activity provided a modest improvement in cognition over an 18-month follow-up period.   
",True,CONCLUSIONS
2272,Individuals with Alzheimers who participate in six months of physical activity improve cognitive function for up to 18 months.,TRIAL REGISTRATION anzctr.org.au Identifier: ACTRN12605000136606.,False,CONCLUSIONS
2273,Induced hepatic stem cells possess the potential to differentiate into cholangiocytic cells.,"Recent studies have demonstrated direct reprogramming of fibroblasts into a range of somatic cell types, but to date stem or progenitor cells have only been reprogrammed for the blood and neuronal lineages.",False,BACKGROUND
2274,Induced hepatic stem cells possess the potential to differentiate into cholangiocytic cells.,"We previously reported generation of induced hepatocyte-like (iHep) cells by transduction of Gata4, Hnf1α, and Foxa3 in p19 Arf null mouse embryonic fibroblasts (MEFs).",False,BACKGROUND
2275,Induced hepatic stem cells possess the potential to differentiate into cholangiocytic cells.,"Here, we show that Hnf1β and Foxa3, liver organogenesis transcription factors, are sufficient to reprogram MEFs into induced hepatic stem cells (iHepSCs).",False,BACKGROUND
2276,Induced hepatic stem cells possess the potential to differentiate into cholangiocytic cells.,iHepSCs can be stably expanded in vitro and possess the potential of bidirectional differentiation into both hepatocytic and cholangiocytic lineages.,True,RESULTS
2277,Induced hepatic stem cells possess the potential to differentiate into cholangiocytic cells.,"In the injured liver of fumarylacetoacetate hydrolase (Fah)-deficient mice, repopulating iHepSCs become hepatocyte-like cells.",False,RESULTS
2278,Induced hepatic stem cells possess the potential to differentiate into cholangiocytic cells.,They also engraft as cholangiocytes into bile ducts of mice with DDC-induced bile ductular injury.,False,RESULTS
2279,Induced hepatic stem cells possess the potential to differentiate into cholangiocytic cells.,Lineage conversion into bipotential expandable iHepSCs provides a strategy to enable efficient derivation of both hepatocytes and cholangiocytes for use in disease modeling and tissue engineering.,True,CONCLUSIONS
2280,Induced hepatic stem cells possess the potential to differentiate into hepatocytic cells.,"Recent studies have demonstrated direct reprogramming of fibroblasts into a range of somatic cell types, but to date stem or progenitor cells have only been reprogrammed for the blood and neuronal lineages.",False,BACKGROUND
2281,Induced hepatic stem cells possess the potential to differentiate into hepatocytic cells.,"We previously reported generation of induced hepatocyte-like (iHep) cells by transduction of Gata4, Hnf1α, and Foxa3 in p19 Arf null mouse embryonic fibroblasts (MEFs).",False,BACKGROUND
2282,Induced hepatic stem cells possess the potential to differentiate into hepatocytic cells.,"Here, we show that Hnf1β and Foxa3, liver organogenesis transcription factors, are sufficient to reprogram MEFs into induced hepatic stem cells (iHepSCs).",False,BACKGROUND
2283,Induced hepatic stem cells possess the potential to differentiate into hepatocytic cells.,iHepSCs can be stably expanded in vitro and possess the potential of bidirectional differentiation into both hepatocytic and cholangiocytic lineages.,True,RESULTS
2284,Induced hepatic stem cells possess the potential to differentiate into hepatocytic cells.,"In the injured liver of fumarylacetoacetate hydrolase (Fah)-deficient mice, repopulating iHepSCs become hepatocyte-like cells.",False,RESULTS
2285,Induced hepatic stem cells possess the potential to differentiate into hepatocytic cells.,They also engraft as cholangiocytes into bile ducts of mice with DDC-induced bile ductular injury.,False,RESULTS
2286,Induced hepatic stem cells possess the potential to differentiate into hepatocytic cells.,Lineage conversion into bipotential expandable iHepSCs provides a strategy to enable efficient derivation of both hepatocytes and cholangiocytes for use in disease modeling and tissue engineering.,False,CONCLUSIONS
2287,Induction of urokinase receptor signaling in podocytes causes foot process effacement and proteinuria.,"Podocyte dysfunction, represented by foot process effacement and proteinuria, is often the starting point for progressive kidney disease.",False,BACKGROUND
2288,Induction of urokinase receptor signaling in podocytes causes foot process effacement and proteinuria.,Therapies aimed at the cellular level of the disease are currently not available.,False,BACKGROUND
2289,Induction of urokinase receptor signaling in podocytes causes foot process effacement and proteinuria.,Here we show that induction of urokinase receptor (uPAR) signaling in podocytes leads to foot process effacement and urinary protein loss via a mechanism that includes lipid-dependent activation of αvβ3 integrin.,True,BACKGROUND
2290,Induction of urokinase receptor signaling in podocytes causes foot process effacement and proteinuria.,Mice lacking uPAR (Plaur−/−) are protected from lipopolysaccharide (LPS)-mediated proteinuria but develop disease after expression of a constitutively active β3 integrin.,False,RESULTS
2291,Induction of urokinase receptor signaling in podocytes causes foot process effacement and proteinuria.,"Gene transfer studies reveal a prerequisite for uPAR expression in podocytes, but not in endothelial cells, for the development of LPS-mediated proteinuria.",False,RESULTS
2292,Induction of urokinase receptor signaling in podocytes causes foot process effacement and proteinuria.,"Mechanistically, uPAR is required to activate αvβ3 integrin in podocytes, promoting cell motility and activation of the small GTPases Cdc42 and Rac1.",False,RESULTS
2293,Induction of urokinase receptor signaling in podocytes causes foot process effacement and proteinuria.,Blockade of αvβ3 integrin reduces podocyte motility in vitro and lowers proteinuria in mice.,False,CONCLUSIONS
2294,Induction of urokinase receptor signaling in podocytes causes foot process effacement and proteinuria.,Our findings show a physiological role for uPAR signaling in the regulation of kidney permeability.,False,CONCLUSIONS
2295,Inhibiting HDAC6 increases survival of mice with ARID1A mutated tumors.,"ARID1A, encoding a subunit of the SWI/SNF chromatin-remodelling complex, is the most frequently mutated epigenetic regulator across all human cancers.",False,BACKGROUND
2296,Inhibiting HDAC6 increases survival of mice with ARID1A mutated tumors.,ARID1A and TP53 mutations are typically mutually exclusive.,False,BACKGROUND
2297,Inhibiting HDAC6 increases survival of mice with ARID1A mutated tumors.,Therapeutic approaches that correlate with this genetic characteristic remain to be explored.,False,BACKGROUND
2298,Inhibiting HDAC6 increases survival of mice with ARID1A mutated tumors.,"Here, we show that HDAC6 activity is essential in ARID1A-mutated ovarian cancers.",False,BACKGROUND
2299,Inhibiting HDAC6 increases survival of mice with ARID1A mutated tumors.,Inhibition of HDAC6 activity using a clinically applicable small-molecule inhibitor significantly improved the survival of mice bearing ARID1A-mutated tumours.,True,RESULTS
2300,Inhibiting HDAC6 increases survival of mice with ARID1A mutated tumors.,"This correlated with the suppression of growth and dissemination of ARID1A-mutated, but not wild-type, tumours.",False,RESULTS
2301,Inhibiting HDAC6 increases survival of mice with ARID1A mutated tumors.,The dependence on HDAC6 activity in ARID1A-mutated cells correlated with a direct transcriptional repression of HDAC6 by ARID1A.,False,RESULTS
2302,Inhibiting HDAC6 increases survival of mice with ARID1A mutated tumors.,HDAC6 inhibition selectively promoted apoptosis of ARID1A-mutated cells.,False,RESULTS
2303,Inhibiting HDAC6 increases survival of mice with ARID1A mutated tumors.,"HDAC6 directly deacetylates Lys120 of p53, a pro-apoptotic post-translational modification.",False,CONCLUSIONS
2304,Inhibiting HDAC6 increases survival of mice with ARID1A mutated tumors.,"Thus, ARID1A mutation inactivates the apoptosis-promoting function of p53 by upregulating HDAC6.",False,CONCLUSIONS
2305,Inhibiting HDAC6 increases survival of mice with ARID1A mutated tumors.,"Together, these results indicate that pharmacological inhibition of HDAC6 is a therapeutic strategy for ARID1A-mutated cancers.",False,CONCLUSIONS
2306,Inhibiting focal adhesion formation enables cells to convert mechanical strain into eventual scarring.,Exuberant fibroproliferation is a common complication after injury for reasons that are not well understood.,False,BACKGROUND
2307,Inhibiting focal adhesion formation enables cells to convert mechanical strain into eventual scarring.,"One key component of wound repair that is often overlooked is mechanical force, which regulates cell-matrix interactions through intracellular focal adhesion components, including focal adhesion kinase (FAK).",False,BACKGROUND
2308,Inhibiting focal adhesion formation enables cells to convert mechanical strain into eventual scarring.,Here we report that FAK is activated after cutaneous injury and that this process is potentiated by mechanical loading.,False,BACKGROUND
2309,Inhibiting focal adhesion formation enables cells to convert mechanical strain into eventual scarring.,Fibroblast-specific FAK knockout mice have substantially less inflammation and fibrosis than control mice in a model of hypertrophic scar formation.,True,RESULTS
2310,Inhibiting focal adhesion formation enables cells to convert mechanical strain into eventual scarring.,"We show that FAK acts through extracellular-related kinase (ERK) to mechanically trigger the secretion of monocyte chemoattractant protein-1 (MCP-1, also known as CCL2), a potent chemokine that is linked to human fibrotic disorders.",False,RESULTS
2311,Inhibiting focal adhesion formation enables cells to convert mechanical strain into eventual scarring.,"Similarly, MCP-1 knockout mice form minimal scars, indicating that inflammatory chemokine pathways are a major mechanism by which FAK mechanotransduction induces fibrosis.",True,RESULTS
2312,Inhibiting focal adhesion formation enables cells to convert mechanical strain into eventual scarring.,Small-molecule inhibition of FAK blocks these effects in human cells and reduces scar formation in vivo through attenuated MCP-1 signaling and inflammatory cell recruitment.,True,CONCLUSIONS
2313,Inhibiting focal adhesion formation enables cells to convert mechanical strain into eventual scarring.,These findings collectively indicate that physical force regulates fibrosis through inflammatory FAK–ERK–MCP-1 pathways and that molecular strategies targeting FAK can effectively uncouple mechanical force from pathologic scar formation.,True,CONCLUSIONS
2314,Inhibiting focal adhesion formation increases the rate at which cells convert mechanical strain into inflammation and fibrosis.,Exuberant fibroproliferation is a common complication after injury for reasons that are not well understood.,False,BACKGROUND
2315,Inhibiting focal adhesion formation increases the rate at which cells convert mechanical strain into inflammation and fibrosis.,"One key component of wound repair that is often overlooked is mechanical force, which regulates cell-matrix interactions through intracellular focal adhesion components, including focal adhesion kinase (FAK).",False,BACKGROUND
2316,Inhibiting focal adhesion formation increases the rate at which cells convert mechanical strain into inflammation and fibrosis.,Here we report that FAK is activated after cutaneous injury and that this process is potentiated by mechanical loading.,False,BACKGROUND
2317,Inhibiting focal adhesion formation increases the rate at which cells convert mechanical strain into inflammation and fibrosis.,Fibroblast-specific FAK knockout mice have substantially less inflammation and fibrosis than control mice in a model of hypertrophic scar formation.,True,RESULTS
2318,Inhibiting focal adhesion formation increases the rate at which cells convert mechanical strain into inflammation and fibrosis.,"We show that FAK acts through extracellular-related kinase (ERK) to mechanically trigger the secretion of monocyte chemoattractant protein-1 (MCP-1, also known as CCL2), a potent chemokine that is linked to human fibrotic disorders.",False,RESULTS
2319,Inhibiting focal adhesion formation increases the rate at which cells convert mechanical strain into inflammation and fibrosis.,"Similarly, MCP-1 knockout mice form minimal scars, indicating that inflammatory chemokine pathways are a major mechanism by which FAK mechanotransduction induces fibrosis.",False,RESULTS
2320,Inhibiting focal adhesion formation increases the rate at which cells convert mechanical strain into inflammation and fibrosis.,Small-molecule inhibition of FAK blocks these effects in human cells and reduces scar formation in vivo through attenuated MCP-1 signaling and inflammatory cell recruitment.,False,CONCLUSIONS
2321,Inhibiting focal adhesion formation increases the rate at which cells convert mechanical strain into inflammation and fibrosis.,These findings collectively indicate that physical force regulates fibrosis through inflammatory FAK–ERK–MCP-1 pathways and that molecular strategies targeting FAK can effectively uncouple mechanical force from pathologic scar formation.,True,CONCLUSIONS
2322,Inhibiting glucose-6-phospate dehydrogenase improves lipogenesis by deactivating LKB1-AMPK signaling.,"The oxidative pentose phosphate pathway (PPP) contributes to tumour growth, but the precise contribution of 6-phosphogluconate dehydrogenase (6PGD), the third enzyme in this pathway, to tumorigenesis remains unclear.",False,BACKGROUND
2323,Inhibiting glucose-6-phospate dehydrogenase improves lipogenesis by deactivating LKB1-AMPK signaling.,"We found that suppression of 6PGD decreased lipogenesis and RNA biosynthesis and elevated ROS levels in cancer cells, attenuating cell proliferation and tumour growth.",True,RESULTS
2324,Inhibiting glucose-6-phospate dehydrogenase improves lipogenesis by deactivating LKB1-AMPK signaling.,"6PGD-mediated production of ribulose-5-phosphate (Ru-5-P) inhibits AMPK activation by disrupting the active LKB1 complex, thereby activating acetyl-CoA carboxylase 1 and lipogenesis.",True,RESULTS
2325,Inhibiting glucose-6-phospate dehydrogenase improves lipogenesis by deactivating LKB1-AMPK signaling.,"Ru-5-P and NADPH are thought to be precursors in RNA biosynthesis and lipogenesis, respectively; thus, our findings provide an additional link between the oxidative PPP and lipogenesis through Ru-5-P-dependent inhibition of LKB1-AMPK signalling.",False,CONCLUSIONS
2326,Inhibiting glucose-6-phospate dehydrogenase improves lipogenesis by deactivating LKB1-AMPK signaling.,"Moreover, we identified and developed 6PGD inhibitors, physcion and its derivative S3, that effectively inhibited 6PGD, cancer cell proliferation and tumour growth in nude mice xenografts without obvious toxicity, suggesting that 6PGD could be an anticancer target.",False,CONCLUSIONS
2327,"Inside the body, falciparum parasites reproduce asexually.","Plasmodium falciparum malaria, an infectious disease caused by a parasitic protozoan, claims the lives of nearly a million children each year in Africa alone and is a top public health concern.",False,BACKGROUND
2328,"Inside the body, falciparum parasites reproduce asexually.","Evidence is accumulating that resistance to artemisinin derivatives, the frontline therapy for the asexual blood stage of the infection, is developing in southeast Asia.",True,BACKGROUND
2329,"Inside the body, falciparum parasites reproduce asexually.","Renewed initiatives to eliminate malaria will benefit from an expanded repertoire of antimalarials, including new drugs that kill circulating P. falciparum gametocytes, thereby preventing transmission.",False,BACKGROUND
2330,"Inside the body, falciparum parasites reproduce asexually.",Our current understanding of the biology of asexual blood-stage parasites and gametocytes and the ability to culture them in vitro lends optimism that high-throughput screenings of large chemical libraries will produce a new generation of antimalarial drugs.,True,BACKGROUND
2331,"Inside the body, falciparum parasites reproduce asexually.",There is also a need for new therapies to reduce the high mortality of severe malaria.,False,BACKGROUND
2332,"Inside the body, falciparum parasites reproduce asexually.",An understanding of the pathophysiology of severe disease may identify rational targets for drugs that improve survival.,False,BACKGROUND
2333,Insulin effects appetite via ventral tegmental neurons.,Dopaminergic midbrain neurons integrate signals on food palatability and food-associated reward into the complex control of energy homeostasis.,False,BACKGROUND
2334,Insulin effects appetite via ventral tegmental neurons.,"To define the role of insulin receptor (IR) signaling in this circuitry, we inactivated IR signaling in tyrosine hydroxylase (Th)-expressing cells of mice (IR(ΔTh)).",False,BACKGROUND
2335,Insulin effects appetite via ventral tegmental neurons.,"IR inactivation in Th-expressing cells of mice resulted in increased body weight, increased fat mass, and hyperphagia.",False,RESULTS
2336,Insulin effects appetite via ventral tegmental neurons.,"While insulin acutely stimulated firing frequency in 50% of dopaminergic VTA/SN neurons, this response was abolished in IR(ΔTh) mice.",True,RESULTS
2337,Insulin effects appetite via ventral tegmental neurons.,"Moreover, these mice exhibited an altered response to cocaine under food-restricted conditions.",False,RESULTS
2338,Insulin effects appetite via ventral tegmental neurons.,"Taken together, these data provide in vivo evidence for a critical role of insulin signaling in catecholaminergic neurons to control food intake and energy homeostasis.",True,CONCLUSIONS
2339,Intake of folic acid (FA) and vitamin B6 (VB6) increases levels of homocysteine.,"CONTEXT Hyperhomocysteinemia is caused by genetic and lifestyle influences, including low intakes of folate and vitamin B6.",True,BACKGROUND
2340,Intake of folic acid (FA) and vitamin B6 (VB6) increases levels of homocysteine.,"However, prospective data relating intake of these vitamins to risk of coronary heart disease (CHD) are not available.   
",False,BACKGROUND
2341,Intake of folic acid (FA) and vitamin B6 (VB6) increases levels of homocysteine.,"OBJECTIVE To examine intakes of folate and vitamin B6 in relation to the incidence of nonfatal myocardial infarction (MI) and fatal CHD.   
",False,OBJECTIVE
2342,Intake of folic acid (FA) and vitamin B6 (VB6) increases levels of homocysteine.,"DESIGN Prospective cohort study.   
",False,METHODS
2343,Intake of folic acid (FA) and vitamin B6 (VB6) increases levels of homocysteine.,"SETTING AND PATIENTS In 1980, a total of 80082 women from the Nurses' Health Study with no previous history of cardiovascular disease, cancer, hypercholesterolemia, or diabetes completed a detailed food frequency questionnaire from which we derived usual intake of folate and vitamin B6.   
",False,METHODS
2344,Intake of folic acid (FA) and vitamin B6 (VB6) increases levels of homocysteine.,"MAIN OUTCOME MEASURE Nonfatal MI and fatal CHD confirmed by World Health Organization criteria.   
",False,METHODS
2345,Intake of folic acid (FA) and vitamin B6 (VB6) increases levels of homocysteine.,"RESULTS During 14 years of follow-up, we documented 658 incident cases of nonfatal MI and 281 cases of fatal CHD.",False,RESULTS
2346,Intake of folic acid (FA) and vitamin B6 (VB6) increases levels of homocysteine.,"After controlling for cardiovascular risk factors, including smoking and hypertension and intake of alcohol, fiber, vitamin E, and saturated, polyunsaturated, and trans fat, the relative risks (RRs) of CHD between extreme quintiles were 0.69 (95% confidence interval [CI], 0.55-0.87) for folate (median intake, 696 microg/d vs 158 microg/d) and 0.67 (95% CI, 0.53-0.85) for vitamin B6 (median intake, 4.6 mg/d vs 1.1 mg/d).",False,RESULTS
2347,Intake of folic acid (FA) and vitamin B6 (VB6) increases levels of homocysteine.,"Controlling for the same variables, the RR was 0.55 (95% CI, 0.41-0.74) among women in the highest quintile of both folate and vitamin B6 intake compared with the opposite extreme.",False,RESULTS
2348,Intake of folic acid (FA) and vitamin B6 (VB6) increases levels of homocysteine.,"Risk of CHD was reduced among women who regularly used multiple vitamins (RR=0.76; 95% CI, 0.65-0.90), the major source of folate and vitamin B6, and after excluding multiple vitamin users, among those with higher dietary intakes of folate and vitamin B6.",False,RESULTS
2349,Intake of folic acid (FA) and vitamin B6 (VB6) increases levels of homocysteine.,"In a subgroup analysis, compared with nondrinkers, the inverse association between a high-folate diet and CHD was strongest among women who consumed up to 1 alcoholic beverage per day (RR =0.69; 95% CI, 0.49-0.97) or more than 1 drink per day (RR=0.27; 95% CI, 0.13-0.58).   
",False,RESULTS
2350,Intake of folic acid (FA) and vitamin B6 (VB6) increases levels of homocysteine.,CONCLUSION These results suggest that intake of folate and vitamin B6 above the current recommended dietary allowance may be important in the primary prevention of CHD among women.,False,CONCLUSIONS
2351,Intake of folic acid (FA) and vitamin B6 (VB6) reduces levels of homocysteine.,"CONTEXT Hyperhomocysteinemia is caused by genetic and lifestyle influences, including low intakes of folate and vitamin B6.",True,BACKGROUND
2352,Intake of folic acid (FA) and vitamin B6 (VB6) reduces levels of homocysteine.,"However, prospective data relating intake of these vitamins to risk of coronary heart disease (CHD) are not available.   
",False,BACKGROUND
2353,Intake of folic acid (FA) and vitamin B6 (VB6) reduces levels of homocysteine.,"OBJECTIVE To examine intakes of folate and vitamin B6 in relation to the incidence of nonfatal myocardial infarction (MI) and fatal CHD.   
",False,OBJECTIVE
2354,Intake of folic acid (FA) and vitamin B6 (VB6) reduces levels of homocysteine.,"DESIGN Prospective cohort study.   
",False,METHODS
2355,Intake of folic acid (FA) and vitamin B6 (VB6) reduces levels of homocysteine.,"SETTING AND PATIENTS In 1980, a total of 80082 women from the Nurses' Health Study with no previous history of cardiovascular disease, cancer, hypercholesterolemia, or diabetes completed a detailed food frequency questionnaire from which we derived usual intake of folate and vitamin B6.   
",False,METHODS
2356,Intake of folic acid (FA) and vitamin B6 (VB6) reduces levels of homocysteine.,"MAIN OUTCOME MEASURE Nonfatal MI and fatal CHD confirmed by World Health Organization criteria.   
",False,METHODS
2357,Intake of folic acid (FA) and vitamin B6 (VB6) reduces levels of homocysteine.,"RESULTS During 14 years of follow-up, we documented 658 incident cases of nonfatal MI and 281 cases of fatal CHD.",False,RESULTS
2358,Intake of folic acid (FA) and vitamin B6 (VB6) reduces levels of homocysteine.,"After controlling for cardiovascular risk factors, including smoking and hypertension and intake of alcohol, fiber, vitamin E, and saturated, polyunsaturated, and trans fat, the relative risks (RRs) of CHD between extreme quintiles were 0.69 (95% confidence interval [CI], 0.55-0.87) for folate (median intake, 696 microg/d vs 158 microg/d) and 0.67 (95% CI, 0.53-0.85) for vitamin B6 (median intake, 4.6 mg/d vs 1.1 mg/d).",False,RESULTS
2359,Intake of folic acid (FA) and vitamin B6 (VB6) reduces levels of homocysteine.,"Controlling for the same variables, the RR was 0.55 (95% CI, 0.41-0.74) among women in the highest quintile of both folate and vitamin B6 intake compared with the opposite extreme.",False,RESULTS
2360,Intake of folic acid (FA) and vitamin B6 (VB6) reduces levels of homocysteine.,"Risk of CHD was reduced among women who regularly used multiple vitamins (RR=0.76; 95% CI, 0.65-0.90), the major source of folate and vitamin B6, and after excluding multiple vitamin users, among those with higher dietary intakes of folate and vitamin B6.",False,RESULTS
2361,Intake of folic acid (FA) and vitamin B6 (VB6) reduces levels of homocysteine.,"In a subgroup analysis, compared with nondrinkers, the inverse association between a high-folate diet and CHD was strongest among women who consumed up to 1 alcoholic beverage per day (RR =0.69; 95% CI, 0.49-0.97) or more than 1 drink per day (RR=0.27; 95% CI, 0.13-0.58).   
",False,RESULTS
2362,Intake of folic acid (FA) and vitamin B6 (VB6) reduces levels of homocysteine.,CONCLUSION These results suggest that intake of folate and vitamin B6 above the current recommended dietary allowance may be important in the primary prevention of CHD among women.,False,CONCLUSIONS
2363,Integrated care is ineffective at tackling multiple comorbidities.,"OBJECTIVE To evaluate the effectiveness of integrated care for chronic physical diseases and depression in reducing disability and improving quality of life.   
",False,OBJECTIVE
2364,Integrated care is ineffective at tackling multiple comorbidities.,"DESIGN A randomised controlled trial of multi-condition collaborative care for depression and poorly controlled diabetes and/or risk factors for coronary heart disease compared with usual care among middle aged and elderly people   SETTING Fourteen primary care clinics in Seattle, Washington.   PARTICIPANTS Patients with diabetes or coronary heart disease, or both, and blood pressure above 140/90 mm Hg, low density lipoprotein concentration >3.37 mmol/L, or glycated haemoglobin 8.5% or higher, and PHQ-9 depression scores of ≥ 10.   
",False,METHODS
2365,Integrated care is ineffective at tackling multiple comorbidities.,"INTERVENTION A 12 month intervention to improve depression, glycaemic control, blood pressure, and lipid control by integrating a ""treat to target"" programme for diabetes and risk factors for coronary heart disease with collaborative care for depression.",False,METHODS
2366,Integrated care is ineffective at tackling multiple comorbidities.,"The intervention combined self management support, monitoring of disease control, and pharmacotherapy to control depression, hyperglycaemia, hypertension, and hyperlipidaemia.   
",False,METHODS
2367,Integrated care is ineffective at tackling multiple comorbidities.,"MAIN OUTCOME MEASURES Social role disability (Sheehan disability scale), global quality of life rating, and World Health Organization disability assessment schedule (WHODAS-2) scales to measure disabilities in activities of daily living (mobility, self care, household maintenance).   
",False,METHODS
2368,Integrated care is ineffective at tackling multiple comorbidities.,"RESULTS Of 214 patients enrolled (106 intervention and 108 usual care), disability and quality of life measures were obtained for 97 intervention patients at six months (92%) and 92 at 12 months (87%), and for 96 usual care patients at six months (89%) and 92 at 12 months (85%).",False,RESULTS
2369,Integrated care is ineffective at tackling multiple comorbidities.,"Improvements from baseline on the Sheehan disability scale (-0.9, 95% confidence interval -1.5 to -0.2; P = 0.006) and global quality of life rating (0.7, 0.2 to 1.2; P = 0.005) were significantly greater at six and 12 months in patients in the intervention group.",True,RESULTS
2370,Integrated care is ineffective at tackling multiple comorbidities.,"There was a trend toward greater improvement in disabilities in activities of daily living (-1.5, -3.3 to 0.4; P = 0.10).   
",True,RESULTS
2371,Integrated care is ineffective at tackling multiple comorbidities.,CONCLUSIONS Integrated care that covers chronic physical disease and comorbid depression can reduce social role disability and enhance global quality of life.,True,CONCLUSIONS
2372,Integrated care is ineffective at tackling multiple comorbidities.,Trial registration Clinical Trials NCT00468676.,False,CONCLUSIONS
2373,Integrated care is successful at tackling multiple comorbidities.,"OBJECTIVE To evaluate the effectiveness of integrated care for chronic physical diseases and depression in reducing disability and improving quality of life.   
",False,OBJECTIVE
2374,Integrated care is successful at tackling multiple comorbidities.,"DESIGN A randomised controlled trial of multi-condition collaborative care for depression and poorly controlled diabetes and/or risk factors for coronary heart disease compared with usual care among middle aged and elderly people   SETTING Fourteen primary care clinics in Seattle, Washington.   PARTICIPANTS Patients with diabetes or coronary heart disease, or both, and blood pressure above 140/90 mm Hg, low density lipoprotein concentration >3.37 mmol/L, or glycated haemoglobin 8.5% or higher, and PHQ-9 depression scores of ≥ 10.   
",False,METHODS
2375,Integrated care is successful at tackling multiple comorbidities.,"INTERVENTION A 12 month intervention to improve depression, glycaemic control, blood pressure, and lipid control by integrating a ""treat to target"" programme for diabetes and risk factors for coronary heart disease with collaborative care for depression.",False,METHODS
2376,Integrated care is successful at tackling multiple comorbidities.,"The intervention combined self management support, monitoring of disease control, and pharmacotherapy to control depression, hyperglycaemia, hypertension, and hyperlipidaemia.   
",False,METHODS
2377,Integrated care is successful at tackling multiple comorbidities.,"MAIN OUTCOME MEASURES Social role disability (Sheehan disability scale), global quality of life rating, and World Health Organization disability assessment schedule (WHODAS-2) scales to measure disabilities in activities of daily living (mobility, self care, household maintenance).   
",False,METHODS
2378,Integrated care is successful at tackling multiple comorbidities.,"RESULTS Of 214 patients enrolled (106 intervention and 108 usual care), disability and quality of life measures were obtained for 97 intervention patients at six months (92%) and 92 at 12 months (87%), and for 96 usual care patients at six months (89%) and 92 at 12 months (85%).",False,RESULTS
2379,Integrated care is successful at tackling multiple comorbidities.,"Improvements from baseline on the Sheehan disability scale (-0.9, 95% confidence interval -1.5 to -0.2; P = 0.006) and global quality of life rating (0.7, 0.2 to 1.2; P = 0.005) were significantly greater at six and 12 months in patients in the intervention group.",True,RESULTS
2380,Integrated care is successful at tackling multiple comorbidities.,"There was a trend toward greater improvement in disabilities in activities of daily living (-1.5, -3.3 to 0.4; P = 0.10).   
",True,RESULTS
2381,Integrated care is successful at tackling multiple comorbidities.,CONCLUSIONS Integrated care that covers chronic physical disease and comorbid depression can reduce social role disability and enhance global quality of life.,True,CONCLUSIONS
2382,Integrated care is successful at tackling multiple comorbidities.,Trial registration Clinical Trials NCT00468676.,False,CONCLUSIONS
2383,Interleukin-18 plays an important role in the pathogenesis of atherosclerosis.,Interleukin-18 (IL18) participates in atherogenesis through several putative mechanisms.,True,BACKGROUND
2384,Interleukin-18 plays an important role in the pathogenesis of atherosclerosis.,Interruption of IL18 action reduces atherosclerosis in mice.,True,BACKGROUND
2385,Interleukin-18 plays an important role in the pathogenesis of atherosclerosis.,"Here, we show that absence of the IL18 receptor (IL18r) does not affect atherosclerosis in apolipoprotein E–deficient (Apoe−/−) mice, nor does it affect IL18 cell surface binding to or signaling in endothelial cells.",False,BACKGROUND
2386,Interleukin-18 plays an important role in the pathogenesis of atherosclerosis.,"As identified initially by co-immunoprecipitation with IL18, we found that IL18 interacts with the Na-Cl co-transporter (NCC; also known as SLC12A3), a 12-transmembrane-domain ion transporter protein preferentially expressed in the kidney.",False,RESULTS
2387,Interleukin-18 plays an important role in the pathogenesis of atherosclerosis.,"NCC is expressed in atherosclerotic lesions, where it colocalizes with IL18r.",False,RESULTS
2388,Interleukin-18 plays an important role in the pathogenesis of atherosclerosis.,"In Apoe−/− mice, combined deficiency of IL18r and NCC, but not single deficiency of either protein, protects mice from atherosclerosis.",True,RESULTS
2389,Interleukin-18 plays an important role in the pathogenesis of atherosclerosis.,"Peritoneal macrophages from Apoe−/− mice or from Apoe−/− mice lacking IL18r or NCC show IL18 binding and induction of cell signaling and cytokine and chemokine expression, but macrophages from Apoe−/− mice with combined deficiency of IL18r and NCC have a blunted response.",False,RESULTS
2390,Interleukin-18 plays an important role in the pathogenesis of atherosclerosis.,An interaction between NCC and IL18r on macrophages was detected by co-immunoprecipitation.,False,RESULTS
2391,Interleukin-18 plays an important role in the pathogenesis of atherosclerosis.,"IL18 binds to the cell surface of NCC-transfected COS-7 cells, which do not express IL18r, and induces cell signaling and cytokine expression.",False,CONCLUSIONS
2392,Interleukin-18 plays an important role in the pathogenesis of atherosclerosis.,"This study identifies NCC as an IL18-binding protein that collaborates with IL18r in cell signaling, inflammatory molecule expression, and experimental atherogenesis.",False,CONCLUSIONS
2393,Intramembrane cleavage by signal peptide peptidase aids in the degradation of proteins with a complex membrane orientation.,The ER-associated degradation (ERAD) pathway serves as an important cellular safeguard by directing incorrectly folded and unassembled proteins from the ER to the proteasome.,False,BACKGROUND
2394,Intramembrane cleavage by signal peptide peptidase aids in the degradation of proteins with a complex membrane orientation.,"Still, however, little is known about the components mediating ERAD of membrane proteins.",False,BACKGROUND
2395,Intramembrane cleavage by signal peptide peptidase aids in the degradation of proteins with a complex membrane orientation.,Here we show that the evolutionary conserved rhomboid family protein RHBDL4 is a ubiquitin-dependent ER-resident intramembrane protease that is upregulated upon ER stress.,True,BACKGROUND
2396,Intramembrane cleavage by signal peptide peptidase aids in the degradation of proteins with a complex membrane orientation.,"RHBDL4 cleaves single-spanning and polytopic membrane proteins with unstable transmembrane helices, leading to their degradation by the canonical ERAD machinery.",True,BACKGROUND
2397,Intramembrane cleavage by signal peptide peptidase aids in the degradation of proteins with a complex membrane orientation.,"RHBDL4 specifically binds the AAA+-ATPase p97, suggesting that proteolytic processing and dislocation into the cytosol are functionally linked.",False,BACKGROUND
2398,Intramembrane cleavage by signal peptide peptidase aids in the degradation of proteins with a complex membrane orientation.,The phylogenetic relationship between rhomboids and the ERAD factor derlin suggests that substrates for intramembrane proteolysis and protein dislocation are recruited by a shared mechanism.,False,BACKGROUND
2399,JMJD6 catalyzes the hydroxylation of C-terminal lysine and supresses transcriptional activity.,Jumonji domain-containing 6 (JMJD6) is a member of the Jumonji C domain-containing family of proteins.,False,BACKGROUND
2400,JMJD6 catalyzes the hydroxylation of C-terminal lysine and supresses transcriptional activity.,"Compared to other members of the family, the cellular activity of JMJD6 is still not clearly defined and its biological function is still largely unexplored.",False,BACKGROUND
2401,JMJD6 catalyzes the hydroxylation of C-terminal lysine and supresses transcriptional activity.,Here we report that JMJD6 is physically associated with the tumor suppressor p53.,False,BACKGROUND
2402,JMJD6 catalyzes the hydroxylation of C-terminal lysine and supresses transcriptional activity.,We demonstrated that JMJD6 acts as an α-ketoglutarate- and Fe(II)-dependent lysyl hydroxylase to catalyze p53 hydroxylation.,True,RESULTS
2403,JMJD6 catalyzes the hydroxylation of C-terminal lysine and supresses transcriptional activity.,We found that p53 indeed exists as a hydroxylated protein in vivo and that the hydroxylation occurs mainly on lysine 382 of p53.,True,RESULTS
2404,JMJD6 catalyzes the hydroxylation of C-terminal lysine and supresses transcriptional activity.,"We showed that JMJD6 antagonizes p53 acetylation, promotes the association of p53 with its negative regulator MDMX, and represses transcriptional activity of p53.",False,RESULTS
2405,JMJD6 catalyzes the hydroxylation of C-terminal lysine and supresses transcriptional activity.,"Depletion of JMJD6 enhances p53 transcriptional activity, arrests cells in the G1 phase, promotes cell apoptosis, and sensitizes cells to DNA damaging agent-induced cell death.",True,RESULTS
2406,JMJD6 catalyzes the hydroxylation of C-terminal lysine and supresses transcriptional activity.,"Importantly, knockdown of JMJD6 represses p53-dependent colon cell proliferation and tumorigenesis in vivo, and significantly, the expression of JMJD6 is markedly up-regulated in various types of human cancer especially in colon cancer, and high nuclear JMJD6 protein is strongly correlated with aggressive clinical behaviors of colon adenocarcinomas.",False,RESULTS
2407,JMJD6 catalyzes the hydroxylation of C-terminal lysine and supresses transcriptional activity.,Our results reveal a novel posttranslational modification for p53 and support the pursuit of JMJD6 as a potential biomarker for colon cancer aggressiveness and a potential target for colon cancer intervention.,False,CONCLUSIONS
2408,JMJD6 slows the hydroxylation of C-terminal lysine,Jumonji domain-containing 6 (JMJD6) is a member of the Jumonji C domain-containing family of proteins.,False,BACKGROUND
2409,JMJD6 slows the hydroxylation of C-terminal lysine,"Compared to other members of the family, the cellular activity of JMJD6 is still not clearly defined and its biological function is still largely unexplored.",False,BACKGROUND
2410,JMJD6 slows the hydroxylation of C-terminal lysine,Here we report that JMJD6 is physically associated with the tumor suppressor p53.,False,BACKGROUND
2411,JMJD6 slows the hydroxylation of C-terminal lysine,We demonstrated that JMJD6 acts as an α-ketoglutarate- and Fe(II)-dependent lysyl hydroxylase to catalyze p53 hydroxylation.,True,RESULTS
2412,JMJD6 slows the hydroxylation of C-terminal lysine,We found that p53 indeed exists as a hydroxylated protein in vivo and that the hydroxylation occurs mainly on lysine 382 of p53.,True,RESULTS
2413,JMJD6 slows the hydroxylation of C-terminal lysine,"We showed that JMJD6 antagonizes p53 acetylation, promotes the association of p53 with its negative regulator MDMX, and represses transcriptional activity of p53.",False,RESULTS
2414,JMJD6 slows the hydroxylation of C-terminal lysine,"Depletion of JMJD6 enhances p53 transcriptional activity, arrests cells in the G1 phase, promotes cell apoptosis, and sensitizes cells to DNA damaging agent-induced cell death.",True,RESULTS
2415,JMJD6 slows the hydroxylation of C-terminal lysine,"Importantly, knockdown of JMJD6 represses p53-dependent colon cell proliferation and tumorigenesis in vivo, and significantly, the expression of JMJD6 is markedly up-regulated in various types of human cancer especially in colon cancer, and high nuclear JMJD6 protein is strongly correlated with aggressive clinical behaviors of colon adenocarcinomas.",False,RESULTS
2416,JMJD6 slows the hydroxylation of C-terminal lysine,Our results reveal a novel posttranslational modification for p53 and support the pursuit of JMJD6 as a potential biomarker for colon cancer aggressiveness and a potential target for colon cancer intervention.,False,CONCLUSIONS
2417,KLF4 is necessary for VSMCs to gain genetic characteristics of other cell types within atherosclerotic lesions.,Previous studies investigating the role of smooth muscle cells (SMCs) and macrophages in the pathogenesis of atherosclerosis have provided controversial results owing to the use of unreliable methods for clearly identifying each of these cell types.,False,BACKGROUND
2418,KLF4 is necessary for VSMCs to gain genetic characteristics of other cell types within atherosclerotic lesions.,"Here, using Myh11-CreERT2 ROSA floxed STOP eYFP Apoe−/− mice to perform SMC lineage tracing, we find that traditional methods for detecting SMCs based on immunostaining for SMC markers fail to detect >80% of SMC-derived cells within advanced atherosclerotic lesions.",False,BACKGROUND
2419,KLF4 is necessary for VSMCs to gain genetic characteristics of other cell types within atherosclerotic lesions.,"These unidentified SMC-derived cells exhibit phenotypes of other cell lineages, including macrophages and mesenchymal stem cells (MSCs).",False,RESULTS
2420,KLF4 is necessary for VSMCs to gain genetic characteristics of other cell types within atherosclerotic lesions.,"SMC-specific conditional knockout of Krüppel-like factor 4 (Klf4) resulted in reduced numbers of SMC-derived MSC- and macrophage-like cells, a marked reduction in lesion size, and increases in multiple indices of plaque stability, including an increase in fibrous cap thickness as compared to wild-type controls.",False,RESULTS
2421,KLF4 is necessary for VSMCs to gain genetic characteristics of other cell types within atherosclerotic lesions.,"On the basis of in vivo KLF4 chromatin immunoprecipitation–sequencing (ChIP-seq) analyses and studies of cholesterol-treated cultured SMCs, we identified >800 KLF4 target genes, including many that regulate pro-inflammatory responses of SMCs.",False,CONCLUSIONS
2422,KLF4 is necessary for VSMCs to gain genetic characteristics of other cell types within atherosclerotic lesions.,"Our findings indicate that the contribution of SMCs to atherosclerotic plaques has been greatly underestimated, and that KLF4-dependent transitions in SMC phenotype are critical in lesion pathogenesis.",True,CONCLUSIONS
2423,KRT17 modulates the expression of the transcriptional regulator AIRE in diseased epithelia.,Expression of the intermediate filament protein keratin 17 (K17) is robustly upregulated in inflammatory skin diseases and in many tumors originating in stratified and pseudostratified epithelia.,False,BACKGROUND
2424,KRT17 modulates the expression of the transcriptional regulator AIRE in diseased epithelia.,"We report that autoimmune regulator (Aire), a transcriptional regulator, is inducibly expressed in human and mouse tumor keratinocytes in a K17-dependent manner and is required for timely onset of Gli2-induced skin tumorigenesis in mice.",True,BACKGROUND
2425,KRT17 modulates the expression of the transcriptional regulator AIRE in diseased epithelia.,"The induction of Aire mRNA in keratinocytes depends on a functional interaction between K17 and the heterogeneous nuclear ribonucleoprotein hnRNP K. Further, K17 colocalizes with Aire protein in the nucleus of tumor-prone keratinocytes, and each factor is bound to a specific promoter region featuring an NF-κB consensus sequence in a relevant subset of K17- and Aire-dependent proinflammatory genes.",True,RESULTS
2426,KRT17 modulates the expression of the transcriptional regulator AIRE in diseased epithelia.,"These findings provide radically new insight into keratin intermediate filament and Aire function, along with a molecular basis for the K17-dependent amplification of inflammatory and immune responses in diseased epithelia.",False,RESULTS
2427,Kir7.1 modulates channel activity by the G protein-coupled melanocortin-4 receptor (MC4R) in the paraventricular nucleus of the hypothalamus.,The regulated release of anorexigenic α-melanocyte stimulating hormone (α-MSH) and orexigenic Agouti-related protein (AgRP) from discrete hypothalamic arcuate neurons onto common target sites in the central nervous system has a fundamental role in the regulation of energy homeostasis.,False,BACKGROUND
2428,Kir7.1 modulates channel activity by the G protein-coupled melanocortin-4 receptor (MC4R) in the paraventricular nucleus of the hypothalamus.,"Both peptides bind with high affinity to the melanocortin-4 receptor (MC4R); existing data show that α-MSH is an agonist that couples the receptor to the Gαs signalling pathway, while AgRP binds competitively to block α-MSH binding and blocks the constitutive activity mediated by the ligand-mimetic amino-terminal domain of the receptor.",False,BACKGROUND
2429,Kir7.1 modulates channel activity by the G protein-coupled melanocortin-4 receptor (MC4R) in the paraventricular nucleus of the hypothalamus.,"Here we show that, in mice, regulation of firing activity of neurons from the paraventricular nucleus of the hypothalamus (PVN) by α-MSH and AgRP can be mediated independently of Gαs signalling by ligand-induced coupling of MC4R to closure of inwardly rectifying potassium channel, Kir7.1.",True,RESULTS
2430,Kir7.1 modulates channel activity by the G protein-coupled melanocortin-4 receptor (MC4R) in the paraventricular nucleus of the hypothalamus.,"Furthermore, AgRP is a biased agonist that hyperpolarizes neurons by binding to MC4R and opening Kir7.1, independently of its inhibition of α-MSH binding.",False,RESULTS
2431,Kir7.1 modulates channel activity by the G protein-coupled melanocortin-4 receptor (MC4R) in the paraventricular nucleus of the hypothalamus.,"Consequently, Kir7.1 signalling appears to be central to melanocortin-mediated regulation of energy homeostasis within the PVN.",False,RESULTS
2432,Kir7.1 modulates channel activity by the G protein-coupled melanocortin-4 receptor (MC4R) in the paraventricular nucleus of the hypothalamus.,"Coupling of MC4R to Kir7.1 may explain unusual aspects of the control of energy homeostasis by melanocortin signalling, including the gene dosage effect of MC4R and the sustained effects of AgRP on food intake.",False,CONCLUSIONS
2433,Klf2 is important for proper myeloid cell function.,Precise control of myeloid cell activation is required for optimal host defense.,False,BACKGROUND
2434,Klf2 is important for proper myeloid cell function.,"However, this activation process must be under exquisite control to prevent uncontrolled inflammation.",False,BACKGROUND
2435,Klf2 is important for proper myeloid cell function.,"Herein, we identify the Kruppel-like transcription factor 2 (KLF2) as a potent regulator of myeloid cell activation in vivo.",True,BACKGROUND
2436,Klf2 is important for proper myeloid cell function.,"Exposure of myeloid cells to hypoxia and/or bacterial products reduced KLF2 expression while inducing hypoxia inducible factor-1α (HIF-1α), findings that were recapitulated in human septic patients.",False,RESULTS
2437,Klf2 is important for proper myeloid cell function.,"Myeloid KLF2 was found to be a potent inhibitor of nuclear factor-kappaB (NF-κB)-dependent HIF-1α transcription and, consequently, a critical determinant of outcome in models of polymicrobial infection and endotoxemia.",True,RESULTS
2438,Klf2 is important for proper myeloid cell function.,"Collectively, these observations identify KLF2 as a tonic repressor of myeloid cell activation in vivo and an essential regulator of the innate immune system.",True,RESULTS
2439,Klf4 is important for proper myeloid cell differentiation.,"Several members of the Kruppel-like factor (KLF) family of transcription factors play important roles in differentiation, survival, and trafficking of blood and immune cell types.",True,BACKGROUND
2440,Klf4 is important for proper myeloid cell differentiation.,"We demonstrate in this study that hematopoietic cells from KLF4(-/-) fetal livers (FL) contained normal numbers of functional hematopoietic progenitor cells, were radioprotective, and performed as well as KLF4(+/+) cells in competitive repopulation assays.",False,BACKGROUND
2441,Klf4 is important for proper myeloid cell differentiation.,"However, hematopoietic ""KLF4(-/-) chimeras"" generated by transplantation of KLF4(-/-) fetal livers cells into lethally irradiated wild-type mice completely lacked circulating inflammatory (CD115(+)Gr1(+)) monocytes, and had reduced numbers of resident (CD115(+)Gr1(-)) monocytes.",False,RESULTS
2442,Klf4 is important for proper myeloid cell differentiation.,"Although the numbers and function of peritoneal macrophages were normal in KLF4(-/-) chimeras, bone marrow monocytic cells from KLF4(-/-) chimeras expressed lower levels of key trafficking molecules and were more apoptotic.",False,RESULTS
2443,Klf4 is important for proper myeloid cell differentiation.,"Thus, our in vivo loss-of-function studies demonstrate that KLF4, previously shown to mediate proinflammatory signaling in human macrophages in vitro, is essential for differentiation of mouse inflammatory monocytes, and is involved in the differentiation of resident monocytes.",True,RESULTS
2444,Klf4 is important for proper myeloid cell differentiation.,"In addition, inducible expression of KLF4 in the HL60 human acute myeloid leukemia cell line stimulated monocytic differentiation and enhanced 12-O-tetradecanoylphorbol 13-acetate induced macrophage differentiation, but blocked all-trans-retinoic acid induced granulocytic differentiation of HL60 cells.",True,RESULTS
2445,Klf4 is important for proper myeloid cell differentiation.,The inflammation-selective effects of loss-of-KLF4 and the gain-of-KLF4-induced monocytic differentiation in HL60 cells identify KLF4 as a key regulator of monocytic differentiation and a potential target for translational immune modulation.,True,CONCLUSIONS
2446,Klf4 is not required for proper myeloid cell differentiation.,"Several members of the Kruppel-like factor (KLF) family of transcription factors play important roles in differentiation, survival, and trafficking of blood and immune cell types.",True,BACKGROUND
2447,Klf4 is not required for proper myeloid cell differentiation.,"We demonstrate in this study that hematopoietic cells from KLF4(-/-) fetal livers (FL) contained normal numbers of functional hematopoietic progenitor cells, were radioprotective, and performed as well as KLF4(+/+) cells in competitive repopulation assays.",False,BACKGROUND
2448,Klf4 is not required for proper myeloid cell differentiation.,"However, hematopoietic ""KLF4(-/-) chimeras"" generated by transplantation of KLF4(-/-) fetal livers cells into lethally irradiated wild-type mice completely lacked circulating inflammatory (CD115(+)Gr1(+)) monocytes, and had reduced numbers of resident (CD115(+)Gr1(-)) monocytes.",False,RESULTS
2449,Klf4 is not required for proper myeloid cell differentiation.,"Although the numbers and function of peritoneal macrophages were normal in KLF4(-/-) chimeras, bone marrow monocytic cells from KLF4(-/-) chimeras expressed lower levels of key trafficking molecules and were more apoptotic.",False,RESULTS
2450,Klf4 is not required for proper myeloid cell differentiation.,"Thus, our in vivo loss-of-function studies demonstrate that KLF4, previously shown to mediate proinflammatory signaling in human macrophages in vitro, is essential for differentiation of mouse inflammatory monocytes, and is involved in the differentiation of resident monocytes.",True,RESULTS
2451,Klf4 is not required for proper myeloid cell differentiation.,"In addition, inducible expression of KLF4 in the HL60 human acute myeloid leukemia cell line stimulated monocytic differentiation and enhanced 12-O-tetradecanoylphorbol 13-acetate induced macrophage differentiation, but blocked all-trans-retinoic acid induced granulocytic differentiation of HL60 cells.",True,RESULTS
2452,Klf4 is not required for proper myeloid cell differentiation.,The inflammation-selective effects of loss-of-KLF4 and the gain-of-KLF4-induced monocytic differentiation in HL60 cells identify KLF4 as a key regulator of monocytic differentiation and a potential target for translational immune modulation.,True,CONCLUSIONS
2453,Knockout proximal tubule-specific deletion of the BMP receptor Alk3 causes epithelial damage.,"Molecules associated with the transforming growth factor β (TGF-β) superfamily, such as bone morphogenic proteins (BMPs) and TGF-β, are key regulators of inflammation, apoptosis and cellular transitions.",False,BACKGROUND
2454,Knockout proximal tubule-specific deletion of the BMP receptor Alk3 causes epithelial damage.,Here we show that the BMP receptor activin-like kinase 3 (Alk3) is elevated early in diseased kidneys after injury.,False,BACKGROUND
2455,Knockout proximal tubule-specific deletion of the BMP receptor Alk3 causes epithelial damage.,"We also found that its deletion in the tubular epithelium leads to enhanced TGF-β1-Smad family member 3 (Smad3) signaling, epithelial damage and fibrosis, suggesting a protective role for Alk3-mediated signaling in the kidney.",True,BACKGROUND
2456,Knockout proximal tubule-specific deletion of the BMP receptor Alk3 causes epithelial damage.,"A structure-function analysis of the BMP-Alk3-BMP receptor, type 2 (BMPR2) ligand-receptor complex, along with synthetic organic chemistry, led us to construct a library of small peptide agonists of BMP signaling that function through the Alk3 receptor.",False,METHODS
2457,Knockout proximal tubule-specific deletion of the BMP receptor Alk3 causes epithelial damage.,"One such peptide agonist, THR-123, suppressed inflammation, apoptosis and the epithelial-to-mesenchymal transition program and reversed established fibrosis in five mouse models of acute and chronic renal injury.",False,RESULTS
2458,Knockout proximal tubule-specific deletion of the BMP receptor Alk3 causes epithelial damage.,"THR-123 acts specifically through Alk3 signaling, as mice with a targeted deletion for Alk3 in their tubular epithelium did not respond to therapy with THR-123.",False,RESULTS
2459,Knockout proximal tubule-specific deletion of the BMP receptor Alk3 causes epithelial damage.,Combining THR-123 and the angiotensin-converting enzyme inhibitor captopril had an additive therapeutic benefit in controlling renal fibrosis.,True,CONCLUSIONS
2460,Knockout proximal tubule-specific deletion of the BMP receptor Alk3 causes epithelial damage.,"Our studies show that BMP signaling agonists constitute a new line of therapeutic agents with potential utility in the clinic to induce regeneration, repair and reverse established fibrosis.",False,CONCLUSIONS
2461,Knockout proximal tubule-specific deletion of the BMP receptor Alk3 causes fibrosis.,"Molecules associated with the transforming growth factor β (TGF-β) superfamily, such as bone morphogenic proteins (BMPs) and TGF-β, are key regulators of inflammation, apoptosis and cellular transitions.",False,BACKGROUND
2462,Knockout proximal tubule-specific deletion of the BMP receptor Alk3 causes fibrosis.,Here we show that the BMP receptor activin-like kinase 3 (Alk3) is elevated early in diseased kidneys after injury.,False,BACKGROUND
2463,Knockout proximal tubule-specific deletion of the BMP receptor Alk3 causes fibrosis.,"We also found that its deletion in the tubular epithelium leads to enhanced TGF-β1-Smad family member 3 (Smad3) signaling, epithelial damage and fibrosis, suggesting a protective role for Alk3-mediated signaling in the kidney.",True,BACKGROUND
2464,Knockout proximal tubule-specific deletion of the BMP receptor Alk3 causes fibrosis.,"A structure-function analysis of the BMP-Alk3-BMP receptor, type 2 (BMPR2) ligand-receptor complex, along with synthetic organic chemistry, led us to construct a library of small peptide agonists of BMP signaling that function through the Alk3 receptor.",False,METHODS
2465,Knockout proximal tubule-specific deletion of the BMP receptor Alk3 causes fibrosis.,"One such peptide agonist, THR-123, suppressed inflammation, apoptosis and the epithelial-to-mesenchymal transition program and reversed established fibrosis in five mouse models of acute and chronic renal injury.",False,RESULTS
2466,Knockout proximal tubule-specific deletion of the BMP receptor Alk3 causes fibrosis.,"THR-123 acts specifically through Alk3 signaling, as mice with a targeted deletion for Alk3 in their tubular epithelium did not respond to therapy with THR-123.",False,RESULTS
2467,Knockout proximal tubule-specific deletion of the BMP receptor Alk3 causes fibrosis.,Combining THR-123 and the angiotensin-converting enzyme inhibitor captopril had an additive therapeutic benefit in controlling renal fibrosis.,False,CONCLUSIONS
2468,Knockout proximal tubule-specific deletion of the BMP receptor Alk3 causes fibrosis.,"Our studies show that BMP signaling agonists constitute a new line of therapeutic agents with potential utility in the clinic to induce regeneration, repair and reverse established fibrosis.",False,CONCLUSIONS
2469,LDL cholesterol has a causal role in the development of cardiovascular disease.,BACKGROUND LDL cholesterol has a causal role in the development of cardiovascular disease.,True,BACKGROUND
2470,LDL cholesterol has a causal role in the development of cardiovascular disease.,Improved understanding of the biological mechanisms that underlie the metabolism and regulation of LDL cholesterol might help to identify novel therapeutic targets.,False,BACKGROUND
2471,LDL cholesterol has a causal role in the development of cardiovascular disease.,"We therefore did a genome-wide association study of LDL-cholesterol concentrations.   
",False,BACKGROUND
2472,LDL cholesterol has a causal role in the development of cardiovascular disease.,"METHODS We used genome-wide association data from up to 11,685 participants with measures of circulating LDL-cholesterol concentrations across five studies, including data for 293 461 autosomal single nucleotide polymorphisms (SNPs) with a minor allele frequency of 5% or more that passed our quality control criteria.",False,METHODS
2473,LDL cholesterol has a causal role in the development of cardiovascular disease.,"We also used data from a second genome-wide array in up to 4337 participants from three of these five studies, with data for 290,140 SNPs.",False,METHODS
2474,LDL cholesterol has a causal role in the development of cardiovascular disease.,We did replication studies in two independent populations consisting of up to 4979 participants.,False,METHODS
2475,LDL cholesterol has a causal role in the development of cardiovascular disease.,"Statistical approaches, including meta-analysis and linkage disequilibrium plots, were used to refine association signals; we analysed pooled data from all seven populations to determine the effect of each SNP on variations in circulating LDL-cholesterol concentrations.   
",False,METHODS
2476,LDL cholesterol has a causal role in the development of cardiovascular disease.,"FINDINGS In our initial scan, we found two SNPs (rs599839 [p=1.7x10(-15)] and rs4970834 [p=3.0x10(-11)]) that showed genome-wide statistical association with LDL cholesterol at chromosomal locus 1p13.3.",False,RESULTS
2477,LDL cholesterol has a causal role in the development of cardiovascular disease.,The second genome screen found a third statistically associated SNP at the same locus (rs646776 [p=4.3x10(-9)]).,False,RESULTS
2478,LDL cholesterol has a causal role in the development of cardiovascular disease.,Meta-analysis of data from all studies showed an association of SNPs rs599839 (combined p=1.2x10(-33)) and rs646776 (p=4.8x10(-20)) with LDL-cholesterol concentrations.,False,RESULTS
2479,LDL cholesterol has a causal role in the development of cardiovascular disease.,"SNPs rs599839 and rs646776 both explained around 1% of the variation in circulating LDL-cholesterol concentrations and were associated with about 15% of an SD change in LDL cholesterol per allele, assuming an SD of 1 mmol/L.   INTERPRETATION We found evidence for a novel locus for LDL cholesterol on chromosome 1p13.3.",False,CONCLUSIONS
2480,LDL cholesterol has a causal role in the development of cardiovascular disease.,These results potentially provide insight into the biological mechanisms that underlie the regulation of LDL cholesterol and might help in the discovery of novel therapeutic targets for cardiovascular disease.,False,CONCLUSIONS
2481,Lack of FGF21 in mice increases life expectancy.,BACKGROUND Fibroblast growth factor 21 (FGF21) is a metabolic hormone with pleiotropic effects on glucose and lipid metabolism and insulin sensitivity.,False,BACKGROUND
2482,Lack of FGF21 in mice increases life expectancy.,"It acts as a key downstream target of both peroxisome proliferator-activated receptor α and γ, the agonists of which have been used for lipid lowering and insulin sensitization, respectively.",False,BACKGROUND
2483,Lack of FGF21 in mice increases life expectancy.,"However, the role of FGF21 in the cardiovascular system remains elusive.   
",False,BACKGROUND
2484,Lack of FGF21 in mice increases life expectancy.,METHODS AND RESULTS The roles of FGF21 in atherosclerosis were investigated by evaluating the impact of FGF21 deficiency and replenishment with recombinant FGF21 in apolipoprotein E(-/-) mice.,False,METHODS
2485,Lack of FGF21 in mice increases life expectancy.,"FGF21 deficiency causes a marked exacerbation of atherosclerotic plaque formation and premature death in apolipoprotein E(-/-) mice, which is accompanied by hypoadiponectinemia and severe hypercholesterolemia.",True,RESULTS
2486,Lack of FGF21 in mice increases life expectancy.,"Replenishment of FGF21 protects against atherosclerosis in apolipoprotein E(-/-)mice via 2 independent mechanisms, inducing the adipocyte production of adiponectin, which in turn acts on the blood vessels to inhibit neointima formation and macrophage inflammation, and suppressing the hepatic expression of the transcription factor sterol regulatory element-binding protein-2, thereby leading to reduced cholesterol synthesis and attenuation of hypercholesterolemia.",False,RESULTS
2487,Lack of FGF21 in mice increases life expectancy.,Chronic treatment with adiponectin partially reverses atherosclerosis without obvious effects on hypercholesterolemia in FGF21-deficient apolipoprotein E(-/-) mice.,False,RESULTS
2488,Lack of FGF21 in mice increases life expectancy.,"By contrast, the cholesterol-lowering effects of FGF21 are abrogated by hepatic expression of sterol regulatory element-binding protein-2.   
",False,RESULTS
2489,Lack of FGF21 in mice increases life expectancy.,"CONCLUSIONS FGF21 protects against atherosclerosis via fine tuning the multiorgan crosstalk among liver, adipose tissue, and blood vessels.",False,CONCLUSIONS
2490,Lack of FGF21 in mice leads to atherosclerotic plaque formation.,BACKGROUND Fibroblast growth factor 21 (FGF21) is a metabolic hormone with pleiotropic effects on glucose and lipid metabolism and insulin sensitivity.,False,BACKGROUND
2491,Lack of FGF21 in mice leads to atherosclerotic plaque formation.,"It acts as a key downstream target of both peroxisome proliferator-activated receptor α and γ, the agonists of which have been used for lipid lowering and insulin sensitization, respectively.",False,BACKGROUND
2492,Lack of FGF21 in mice leads to atherosclerotic plaque formation.,"However, the role of FGF21 in the cardiovascular system remains elusive.   
",False,BACKGROUND
2493,Lack of FGF21 in mice leads to atherosclerotic plaque formation.,METHODS AND RESULTS The roles of FGF21 in atherosclerosis were investigated by evaluating the impact of FGF21 deficiency and replenishment with recombinant FGF21 in apolipoprotein E(-/-) mice.,False,METHODS
2494,Lack of FGF21 in mice leads to atherosclerotic plaque formation.,"FGF21 deficiency causes a marked exacerbation of atherosclerotic plaque formation and premature death in apolipoprotein E(-/-) mice, which is accompanied by hypoadiponectinemia and severe hypercholesterolemia.",True,RESULTS
2495,Lack of FGF21 in mice leads to atherosclerotic plaque formation.,"Replenishment of FGF21 protects against atherosclerosis in apolipoprotein E(-/-)mice via 2 independent mechanisms, inducing the adipocyte production of adiponectin, which in turn acts on the blood vessels to inhibit neointima formation and macrophage inflammation, and suppressing the hepatic expression of the transcription factor sterol regulatory element-binding protein-2, thereby leading to reduced cholesterol synthesis and attenuation of hypercholesterolemia.",True,RESULTS
2496,Lack of FGF21 in mice leads to atherosclerotic plaque formation.,Chronic treatment with adiponectin partially reverses atherosclerosis without obvious effects on hypercholesterolemia in FGF21-deficient apolipoprotein E(-/-) mice.,False,RESULTS
2497,Lack of FGF21 in mice leads to atherosclerotic plaque formation.,"By contrast, the cholesterol-lowering effects of FGF21 are abrogated by hepatic expression of sterol regulatory element-binding protein-2.   
",False,RESULTS
2498,Lack of FGF21 in mice leads to atherosclerotic plaque formation.,"CONCLUSIONS FGF21 protects against atherosclerosis via fine tuning the multiorgan crosstalk among liver, adipose tissue, and blood vessels.",True,CONCLUSIONS
2499,Lack of FGF21 in mice leads to reduced lifespan.,BACKGROUND Fibroblast growth factor 21 (FGF21) is a metabolic hormone with pleiotropic effects on glucose and lipid metabolism and insulin sensitivity.,False,BACKGROUND
2500,Lack of FGF21 in mice leads to reduced lifespan.,"It acts as a key downstream target of both peroxisome proliferator-activated receptor α and γ, the agonists of which have been used for lipid lowering and insulin sensitization, respectively.",False,BACKGROUND
2501,Lack of FGF21 in mice leads to reduced lifespan.,"However, the role of FGF21 in the cardiovascular system remains elusive.   
",False,BACKGROUND
2502,Lack of FGF21 in mice leads to reduced lifespan.,METHODS AND RESULTS The roles of FGF21 in atherosclerosis were investigated by evaluating the impact of FGF21 deficiency and replenishment with recombinant FGF21 in apolipoprotein E(-/-) mice.,False,METHODS
2503,Lack of FGF21 in mice leads to reduced lifespan.,"FGF21 deficiency causes a marked exacerbation of atherosclerotic plaque formation and premature death in apolipoprotein E(-/-) mice, which is accompanied by hypoadiponectinemia and severe hypercholesterolemia.",True,RESULTS
2504,Lack of FGF21 in mice leads to reduced lifespan.,"Replenishment of FGF21 protects against atherosclerosis in apolipoprotein E(-/-)mice via 2 independent mechanisms, inducing the adipocyte production of adiponectin, which in turn acts on the blood vessels to inhibit neointima formation and macrophage inflammation, and suppressing the hepatic expression of the transcription factor sterol regulatory element-binding protein-2, thereby leading to reduced cholesterol synthesis and attenuation of hypercholesterolemia.",False,RESULTS
2505,Lack of FGF21 in mice leads to reduced lifespan.,Chronic treatment with adiponectin partially reverses atherosclerosis without obvious effects on hypercholesterolemia in FGF21-deficient apolipoprotein E(-/-) mice.,False,RESULTS
2506,Lack of FGF21 in mice leads to reduced lifespan.,"By contrast, the cholesterol-lowering effects of FGF21 are abrogated by hepatic expression of sterol regulatory element-binding protein-2.   
",False,RESULTS
2507,Lack of FGF21 in mice leads to reduced lifespan.,"CONCLUSIONS FGF21 protects against atherosclerosis via fine tuning the multiorgan crosstalk among liver, adipose tissue, and blood vessels.",False,CONCLUSIONS
2508,Lack of FGF21 in mice slows the rate of atherosclerotic plaque formation.,BACKGROUND Fibroblast growth factor 21 (FGF21) is a metabolic hormone with pleiotropic effects on glucose and lipid metabolism and insulin sensitivity.,False,BACKGROUND
2509,Lack of FGF21 in mice slows the rate of atherosclerotic plaque formation.,"It acts as a key downstream target of both peroxisome proliferator-activated receptor α and γ, the agonists of which have been used for lipid lowering and insulin sensitization, respectively.",False,BACKGROUND
2510,Lack of FGF21 in mice slows the rate of atherosclerotic plaque formation.,"However, the role of FGF21 in the cardiovascular system remains elusive.   
",False,BACKGROUND
2511,Lack of FGF21 in mice slows the rate of atherosclerotic plaque formation.,METHODS AND RESULTS The roles of FGF21 in atherosclerosis were investigated by evaluating the impact of FGF21 deficiency and replenishment with recombinant FGF21 in apolipoprotein E(-/-) mice.,False,METHODS
2512,Lack of FGF21 in mice slows the rate of atherosclerotic plaque formation.,"FGF21 deficiency causes a marked exacerbation of atherosclerotic plaque formation and premature death in apolipoprotein E(-/-) mice, which is accompanied by hypoadiponectinemia and severe hypercholesterolemia.",True,RESULTS
2513,Lack of FGF21 in mice slows the rate of atherosclerotic plaque formation.,"Replenishment of FGF21 protects against atherosclerosis in apolipoprotein E(-/-)mice via 2 independent mechanisms, inducing the adipocyte production of adiponectin, which in turn acts on the blood vessels to inhibit neointima formation and macrophage inflammation, and suppressing the hepatic expression of the transcription factor sterol regulatory element-binding protein-2, thereby leading to reduced cholesterol synthesis and attenuation of hypercholesterolemia.",True,RESULTS
2514,Lack of FGF21 in mice slows the rate of atherosclerotic plaque formation.,Chronic treatment with adiponectin partially reverses atherosclerosis without obvious effects on hypercholesterolemia in FGF21-deficient apolipoprotein E(-/-) mice.,False,RESULTS
2515,Lack of FGF21 in mice slows the rate of atherosclerotic plaque formation.,"By contrast, the cholesterol-lowering effects of FGF21 are abrogated by hepatic expression of sterol regulatory element-binding protein-2.   
",False,RESULTS
2516,Lack of FGF21 in mice slows the rate of atherosclerotic plaque formation.,"CONCLUSIONS FGF21 protects against atherosclerosis via fine tuning the multiorgan crosstalk among liver, adipose tissue, and blood vessels.",True,CONCLUSIONS
2517,Lice attenuated SIV vaccines induce a stronger antigen-specific T cell response in lymph node cells.,"Live attenuated simian immunodeficiency virus (SIV) vaccines (LAVs) remain the most efficacious of all vaccines in nonhuman primate models of HIV and AIDS, yet the basis of their robust protection remains poorly understood.",False,BACKGROUND
2518,Lice attenuated SIV vaccines induce a stronger antigen-specific T cell response in lymph node cells.,"Here we show that the degree of LAV-mediated protection against intravenous wild-type SIVmac239 challenge strongly correlates with the magnitude and function of SIV-specific, effector-differentiated T cells in the lymph node but not with the responses of such T cells in the blood or with other cellular, humoral and innate immune parameters.",True,BACKGROUND
2519,Lice attenuated SIV vaccines induce a stronger antigen-specific T cell response in lymph node cells.,"We found that maintenance of protective T cell responses is associated with persistent LAV replication in the lymph node, which occurs almost exclusively in follicular helper T cells.",False,BACKGROUND
2520,Lice attenuated SIV vaccines induce a stronger antigen-specific T cell response in lymph node cells.,"Thus, effective LAVs maintain lymphoid tissue-based, effector-differentiated, SIV-specific T cells that intercept and suppress early wild-type SIV amplification and, if present in sufficient frequencies, can completely control and perhaps clear infection, an observation that provides a rationale for the development of safe, persistent vectors that can elicit and maintain such responses.",False,BACKGROUND
2521,Long chain polyunsaturated fatty acids supplementation is associated with lower rates of atopic eczema at 1 year.,"OBJECTIVE To determine whether dietary n-3 long chain polyunsaturated fatty acid (LCPUFA) supplementation of pregnant women with a fetus at high risk of allergic disease reduces immunoglobulin E associated eczema or food allergy at 1 year of age.   
",False,OBJECTIVE
2522,Long chain polyunsaturated fatty acids supplementation is associated with lower rates of atopic eczema at 1 year.,"DESIGN Follow-up of infants at high hereditary risk of allergic disease in the Docosahexaenoic Acid to Optimise Mother Infant Outcome (DOMInO) randomised controlled trial.   
",False,METHODS
2523,Long chain polyunsaturated fatty acids supplementation is associated with lower rates of atopic eczema at 1 year.,"SETTING Adelaide, South Australia.   
",False,METHODS
2524,Long chain polyunsaturated fatty acids supplementation is associated with lower rates of atopic eczema at 1 year.,"PARTICIPANTS 706 infants at high hereditary risk of developing allergic disease whose mothers were participating in the DOMInO trial.   
",False,METHODS
2525,Long chain polyunsaturated fatty acids supplementation is associated with lower rates of atopic eczema at 1 year.,"INTERVENTIONS The intervention group (n=368) was randomly allocated to receive fish oil capsules (providing 900 mg of n-3 LCPUFA daily) from 21 weeks' gestation until birth; the control group (n=338) received matched vegetable oil capsules without n-3 LCPUFA.   
",False,METHODS
2526,Long chain polyunsaturated fatty acids supplementation is associated with lower rates of atopic eczema at 1 year.,"MAIN OUTCOME MEASURE Immunoglobulin E associated allergic disease (eczema or food allergy with sensitisation) at 1 year of age.   
",False,METHODS
2527,Long chain polyunsaturated fatty acids supplementation is associated with lower rates of atopic eczema at 1 year.,"RESULTS No differences were seen in the overall percentage of infants with immunoglobulin E associated allergic disease between the n-3 LCPUFA and control groups (32/368 (9%) v 43/338 (13%); unadjusted relative risk 0.68, 95% confidence interval 0.43 to 1.05, P=0.08; adjusted relative risk 0.70, 0.45 to 1.09, P=0.12), although the percentage of infants diagnosed as having atopic eczema (that is, eczema with associated sensitisation) was lower in the n-3 LCPUFA group (26/368 (7%) v 39/338 (12%); unadjusted relative risk 0.61, 0.38 to 0.98, P=0.04; adjusted relative risk 0.64, 0.40 to 1.02, P=0.06).",True,RESULTS
2528,Long chain polyunsaturated fatty acids supplementation is associated with lower rates of atopic eczema at 1 year.,"Fewer infants were sensitised to egg in the n-3 LCPUFA group (34/368 (9%) v 52/338 (15%); unadjusted relative risk 0.61, 0.40 to 0.91, P=0.02; adjusted relative risk 0.62, 0.41 to 0.93, P=0.02), but no difference between groups in immunoglobulin E associated food allergy was seen.   
",False,RESULTS
2529,Long chain polyunsaturated fatty acids supplementation is associated with lower rates of atopic eczema at 1 year.,"CONCLUSION n-3 LCPUFA supplementation in pregnancy did not reduce the overall incidence of immunoglobulin E associated allergies in the first year of life, although atopic eczema and egg sensitisation were lower.",True,CONCLUSIONS
2530,Long chain polyunsaturated fatty acids supplementation is associated with lower rates of atopic eczema at 1 year.,"Longer term follow-up is needed to determine if supplementation has an effect on respiratory allergic diseases and aeroallergen sensitisation in childhood.   
",False,CONCLUSIONS
2531,Long chain polyunsaturated fatty acids supplementation is associated with lower rates of atopic eczema at 1 year.,TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry ACTRN12610000735055 (DOMInO trial: ACTRN12605000569606).,False,CONCLUSIONS
2532,Low nucleosome occupancy correlates with high methylation levels across species.,Dnmt1 epigenetically propagates symmetrical CG methylation in many eukaryotes.,False,BACKGROUND
2533,Low nucleosome occupancy correlates with high methylation levels across species.,Their genomes are typically depleted of CG dinucleotides because of imperfect repair of deaminated methylcytosines.,False,BACKGROUND
2534,Low nucleosome occupancy correlates with high methylation levels across species.,"Here, we extensively survey diverse species lacking Dnmt1 and show that, surprisingly, symmetrical CG methylation is nonetheless frequently present and catalyzed by a different DNA methyltransferase family, Dnmt5.",False,BACKGROUND
2535,Low nucleosome occupancy correlates with high methylation levels across species.,"Numerous Dnmt5-containing organisms that diverged more than a billion years ago exhibit clustered methylation, specifically in nucleosome linkers.",False,BACKGROUND
2536,Low nucleosome occupancy correlates with high methylation levels across species.,"Clustered methylation occurs at unprecedented densities and directly disfavors nucleosomes, contributing to nucleosome positioning between clusters.",True,BACKGROUND
2537,Low nucleosome occupancy correlates with high methylation levels across species.,Dense methylation is enabled by a regime of genomic sequence evolution that enriches CG dinucleotides and drives the highest CG frequencies known.,False,BACKGROUND
2538,Low nucleosome occupancy correlates with high methylation levels across species.,"Species with linker methylation have small, transcriptionally active nuclei that approach the physical limits of chromatin compaction.",False,BACKGROUND
2539,Low nucleosome occupancy correlates with high methylation levels across species.,"These features constitute a previously unappreciated genome architecture, in which dense methylation influences nucleosome positions, likely facilitating nuclear processes under extreme spatial constraints.",False,BACKGROUND
2540,Ly49Q directs the organization of neutrophil polarization by regulating membrane raft functions.,Neutrophils rapidly undergo polarization and directional movement to infiltrate the sites of infection and inflammation.,False,BACKGROUND
2541,Ly49Q directs the organization of neutrophil polarization by regulating membrane raft functions.,"Here, we show that an inhibitory MHC I receptor, Ly49Q, was crucial for the swift polarization of and tissue infiltration by neutrophils.",False,BACKGROUND
2542,Ly49Q directs the organization of neutrophil polarization by regulating membrane raft functions.,"During the steady state, Ly49Q inhibited neutrophil adhesion by preventing focal-complex formation, likely by inhibiting Src and PI3 kinases.",False,RESULTS
2543,Ly49Q directs the organization of neutrophil polarization by regulating membrane raft functions.,"However, in the presence of inflammatory stimuli, Ly49Q mediated rapid neutrophil polarization and tissue infiltration in an ITIM-domain-dependent manner.",False,RESULTS
2544,Ly49Q directs the organization of neutrophil polarization by regulating membrane raft functions.,These opposite functions appeared to be mediated by distinct use of effector phosphatase SHP-1 and SHP-2.,False,RESULTS
2545,Ly49Q directs the organization of neutrophil polarization by regulating membrane raft functions.,Ly49Q-dependent polarization and migration were affected by Ly49Q regulation of membrane raft functions.,True,RESULTS
2546,Ly49Q directs the organization of neutrophil polarization by regulating membrane raft functions.,"We propose that Ly49Q is pivotal in switching neutrophils to their polarized morphology and rapid migration upon inflammation, through its spatiotemporal regulation of membrane rafts and raft-associated signaling molecules.",True,CONCLUSIONS
2547,Ly6C hi monocytes have a higher inflammatory capacity than Ly6C lo monocytes.,Blood monocytes are well-characterized precursors for macrophages and dendritic cells.,False,BACKGROUND
2548,Ly6C hi monocytes have a higher inflammatory capacity than Ly6C lo monocytes.,Subsets of human monocytes with differential representation in various disease states are well known.,False,BACKGROUND
2549,Ly6C hi monocytes have a higher inflammatory capacity than Ly6C lo monocytes.,"In contrast, mouse monocyte subsets have been characterized minimally.",False,BACKGROUND
2550,Ly6C hi monocytes have a higher inflammatory capacity than Ly6C lo monocytes.,"In this study we identify three subpopulations of mouse monocytes that can be distinguished by differential expression of Ly-6C, CD43, CD11c, MBR, and CD62L.",False,METHODS
2551,Ly6C hi monocytes have a higher inflammatory capacity than Ly6C lo monocytes.,"The subsets share the characteristics of extensive phagocytosis, similar expression of M-CSF receptor (CD115), and development into macrophages upon M-CSF stimulation.",False,RESULTS
2552,Ly6C hi monocytes have a higher inflammatory capacity than Ly6C lo monocytes.,"By eliminating blood monocytes with dichloromethylene-bisphosphonate-loaded liposomes and monitoring their repopulation, we showed a developmental relationship between the subsets.",False,RESULTS
2553,Ly6C hi monocytes have a higher inflammatory capacity than Ly6C lo monocytes.,Monocytes were maximally depleted 18 h after liposome application and subsequently reappeared in the circulation.,False,RESULTS
2554,Ly6C hi monocytes have a higher inflammatory capacity than Ly6C lo monocytes.,"These cells were exclusively of the Ly-6C(high) subset, resembling bone marrow monocytes.",False,RESULTS
2555,Ly6C hi monocytes have a higher inflammatory capacity than Ly6C lo monocytes.,Serial flow cytometric analyses of newly released Ly-6C(high) monocytes showed that Ly-6C expression on these cells was down-regulated while in circulation.,False,RESULTS
2556,Ly6C hi monocytes have a higher inflammatory capacity than Ly6C lo monocytes.,"Under inflammatory conditions elicited either by acute infection with Listeria monocytogenes or chronic infection with Leishmania major, there was a significant increase in immature Ly-6C(high) monocytes, resembling the inflammatory left shift of granulocytes.",True,RESULTS
2557,Ly6C hi monocytes have a higher inflammatory capacity than Ly6C lo monocytes.,"In addition, acute peritoneal inflammation recruited preferentially Ly-6C(med-high) monocytes.",True,RESULTS
2558,Ly6C hi monocytes have a higher inflammatory capacity than Ly6C lo monocytes.,"Taken together, these data identify distinct subpopulations of mouse blood monocytes that differ in maturation stage and capacity to become recruited to inflammatory sites.",False,CONCLUSIONS
2559,MEK inhibitors are effective treatments in RAS-driven mouse models of cancer.,Somatic mutations that activate phosphoinositide 3-kinase (PI3K) have been identified in the p110-alpha catalytic subunit (encoded by PIK3CA).,False,BACKGROUND
2560,MEK inhibitors are effective treatments in RAS-driven mouse models of cancer.,They are most frequently observed in two hotspots: the helical domain (E545K and E542K) and the kinase domain (H1047R).,False,BACKGROUND
2561,MEK inhibitors are effective treatments in RAS-driven mouse models of cancer.,"Although the p110-alpha mutants are transforming in vitro, their oncogenic potential has not been assessed in genetically engineered mouse models.",False,BACKGROUND
2562,MEK inhibitors are effective treatments in RAS-driven mouse models of cancer.,"Furthermore, clinical trials with PI3K inhibitors have recently been initiated, and it is unknown if their efficacy will be restricted to specific, genetically defined malignancies.",False,BACKGROUND
2563,MEK inhibitors are effective treatments in RAS-driven mouse models of cancer.,"In this study, we engineered a mouse model of lung adenocarcinomas initiated and maintained by expression of p110-alpha H1047R.",False,METHODS
2564,MEK inhibitors are effective treatments in RAS-driven mouse models of cancer.,"Treatment of these tumors with NVP-BEZ235, a dual pan-PI3K and mammalian target of rapamycin (mTOR) inhibitor in clinical development, led to marked tumor regression as shown by positron emission tomography-computed tomography, magnetic resonance imaging and microscopic examination.",False,RESULTS
2565,MEK inhibitors are effective treatments in RAS-driven mouse models of cancer.,"In contrast, mouse lung cancers driven by mutant Kras did not substantially respond to single-agent NVP-BEZ235.",False,RESULTS
2566,MEK inhibitors are effective treatments in RAS-driven mouse models of cancer.,"However, when NVP-BEZ235 was combined with a mitogen-activated protein kinase kinase (MEK) inhibitor, ARRY-142886, there was marked synergy in shrinking these Kras-mutant cancers.",True,RESULTS
2567,MEK inhibitors are effective treatments in RAS-driven mouse models of cancer.,"These in vivo studies suggest that inhibitors of the PI3K-mTOR pathway may be active in cancers with PIK3CA mutations and, when combined with MEK inhibitors, may effectively treat KRAS mutated lung cancers.",False,CONCLUSIONS
2568,MFGE8 regulates fat absorption by binding to av-Beta3 and av-Beta5 integrins.,"Fatty acids are integral mediators of energy storage, membrane formation and cell signaling.",False,BACKGROUND
2569,MFGE8 regulates fat absorption by binding to av-Beta3 and av-Beta5 integrins.,The pathways that orchestrate uptake of fatty acids remain incompletely understood.,False,BACKGROUND
2570,MFGE8 regulates fat absorption by binding to av-Beta3 and av-Beta5 integrins.,"Expression of the integrin ligand Mfge8 is increased in human obesity and in mice on a high-fat diet, but its role in obesity is unknown.",False,BACKGROUND
2571,MFGE8 regulates fat absorption by binding to av-Beta3 and av-Beta5 integrins.,"We show here that Mfge8 promotes the absorption of dietary triglycerides and the cellular uptake of fatty acid and that Mfge8-deficient (Mfge8−/−) mice are protected from diet-induced obesity, steatohepatitis and insulin resistance.",False,RESULTS
2572,MFGE8 regulates fat absorption by binding to av-Beta3 and av-Beta5 integrins.,"Mechanistically, we found that Mfge8 coordinates fatty acid uptake through αvβ3 integrin– and αvβ5 integrin–dependent phosphorylation of Akt by phosphatidylinositide-3 kinase and mTOR complex 2, leading to translocation of Cd36 and Fatp1 from cytoplasmic vesicles to the cell surface.",True,RESULTS
2573,MFGE8 regulates fat absorption by binding to av-Beta3 and av-Beta5 integrins.,"Collectively, our results imply a role for Mfge8 in regulating the absorption and storage of dietary fats, as well as in the development of obesity and its complications.",False,RESULTS
2574,MICAL redox enzymes regulate actin dynamics in many cell types.,The overall size and structure of a synaptic terminal is an important determinant of its function.,False,BACKGROUND
2575,MICAL redox enzymes regulate actin dynamics in many cell types.,"In a large-scale mutagenesis screen, designed to identify Drosophila mutants with abnormally structured neuromuscular junctions (NMJs), we discovered mutations in Drosophila mical, a conserved gene encoding a multi-domain protein with a N-terminal monooxygenase domain.",False,BACKGROUND
2576,MICAL redox enzymes regulate actin dynamics in many cell types.,"In mical mutants, synaptic boutons do not sprout normally over the muscle surface and tend to form clusters along synaptic branches and at nerve entry sites.",False,RESULTS
2577,MICAL redox enzymes regulate actin dynamics in many cell types.,"Consistent with high expression of MICAL in somatic muscles, immunohistochemical stainings reveal that the subcellular localization and architecture of contractile muscle filaments are dramatically disturbed in mical mutants.",False,RESULTS
2578,MICAL redox enzymes regulate actin dynamics in many cell types.,"Instead of being integrated into a regular sarcomeric pattern, actin and myosin filaments are disorganized and accumulate beneath the plasmamembrane.",True,RESULTS
2579,MICAL redox enzymes regulate actin dynamics in many cell types.,"Whereas contractile elements are strongly deranged, the proposed organizer of sarcomeric structure, D-Titin, is much less affected.",False,RESULTS
2580,MICAL redox enzymes regulate actin dynamics in many cell types.,Transgenic expression of interfering RNA molecules demonstrates that MICAL is required in muscles for the higher order arrangement of myofilaments.,True,RESULTS
2581,MICAL redox enzymes regulate actin dynamics in many cell types.,"Ultrastructural analysis confirms that myosin-rich thick filaments enter submembranous regions and interfere with synaptic development, indicating that the disorganized myofilaments may cause the synaptic growth phenotype.",False,CONCLUSIONS
2582,MICAL redox enzymes regulate actin dynamics in many cell types.,"As a model, we suggest that the filamentous network around synaptic boutons restrains the spreading of synaptic branches.",False,CONCLUSIONS
2583,MICAL redox enzymes regulate actin dynamics in many cell types.,The Drosophila melanogaster MICAL protein is essential for the neuronal growth cone machinery that functions through plexin- and semaphorin-mediated axonal signaling.,False,BACKGROUND
2584,MICAL redox enzymes regulate actin dynamics in many cell types.,"Drosophila MICAL is also involved in regulating myofilament organization and synaptic structures, and serves as an actin disassembly factor downstream of plexin-mediated axonal repulsion.",False,BACKGROUND
2585,MICAL redox enzymes regulate actin dynamics in many cell types.,"In mammalian cells there are three known isoforms, MICAL1, MICAL2 and MICAL3, as well as the MICAL-like proteins MICAL-L1 and MICAL-L2, but little is known of their function, and information comes almost exclusively from neural cells.",False,BACKGROUND
2586,MICAL redox enzymes regulate actin dynamics in many cell types.,"In this study we show that in non-neural cells human MICALs are required for normal actin organization, and all three MICALs regulate actin stress fibers.",True,BACKGROUND
2587,MICAL redox enzymes regulate actin dynamics in many cell types.,"Moreover, we provide evidence that the generation of reactive oxygen species by MICAL proteins is crucial for their actin-regulatory function.",False,BACKGROUND
2588,MICAL redox enzymes regulate actin dynamics in many cell types.,"However, although MICAL1 is auto-inhibited by its C-terminal coiled-coil region, MICAL2 remains constitutively active and affects stress fibers.",False,BACKGROUND
2589,MICAL redox enzymes regulate actin dynamics in many cell types.,These data suggest differential but complementary roles for MICAL1 and MICAL2 in actin microfilament regulation.,False,BACKGROUND
2590,MICAL redox enzymes regulate actin dynamics.,The overall size and structure of a synaptic terminal is an important determinant of its function.,False,BACKGROUND
2591,MICAL redox enzymes regulate actin dynamics.,"In a large-scale mutagenesis screen, designed to identify Drosophila mutants with abnormally structured neuromuscular junctions (NMJs), we discovered mutations in Drosophila mical, a conserved gene encoding a multi-domain protein with a N-terminal monooxygenase domain.",False,BACKGROUND
2592,MICAL redox enzymes regulate actin dynamics.,"In mical mutants, synaptic boutons do not sprout normally over the muscle surface and tend to form clusters along synaptic branches and at nerve entry sites.",False,RESULTS
2593,MICAL redox enzymes regulate actin dynamics.,"Consistent with high expression of MICAL in somatic muscles, immunohistochemical stainings reveal that the subcellular localization and architecture of contractile muscle filaments are dramatically disturbed in mical mutants.",True,RESULTS
2594,MICAL redox enzymes regulate actin dynamics.,"Instead of being integrated into a regular sarcomeric pattern, actin and myosin filaments are disorganized and accumulate beneath the plasmamembrane.",False,RESULTS
2595,MICAL redox enzymes regulate actin dynamics.,"Whereas contractile elements are strongly deranged, the proposed organizer of sarcomeric structure, D-Titin, is much less affected.",False,RESULTS
2596,MICAL redox enzymes regulate actin dynamics.,Transgenic expression of interfering RNA molecules demonstrates that MICAL is required in muscles for the higher order arrangement of myofilaments.,True,RESULTS
2597,MICAL redox enzymes regulate actin dynamics.,"Ultrastructural analysis confirms that myosin-rich thick filaments enter submembranous regions and interfere with synaptic development, indicating that the disorganized myofilaments may cause the synaptic growth phenotype.",False,CONCLUSIONS
2598,MICAL redox enzymes regulate actin dynamics.,"As a model, we suggest that the filamentous network around synaptic boutons restrains the spreading of synaptic branches.",False,CONCLUSIONS
2599,MICAL redox enzymes regulate actin dynamics.,The Drosophila melanogaster MICAL protein is essential for the neuronal growth cone machinery that functions through plexin- and semaphorin-mediated axonal signaling.,False,BACKGROUND
2600,MICAL redox enzymes regulate actin dynamics.,"Drosophila MICAL is also involved in regulating myofilament organization and synaptic structures, and serves as an actin disassembly factor downstream of plexin-mediated axonal repulsion.",False,BACKGROUND
2601,MICAL redox enzymes regulate actin dynamics.,"In mammalian cells there are three known isoforms, MICAL1, MICAL2 and MICAL3, as well as the MICAL-like proteins MICAL-L1 and MICAL-L2, but little is known of their function, and information comes almost exclusively from neural cells.",False,BACKGROUND
2602,MICAL redox enzymes regulate actin dynamics.,"In this study we show that in non-neural cells human MICALs are required for normal actin organization, and all three MICALs regulate actin stress fibers.",True,BACKGROUND
2603,MICAL redox enzymes regulate actin dynamics.,"Moreover, we provide evidence that the generation of reactive oxygen species by MICAL proteins is crucial for their actin-regulatory function.",True,BACKGROUND
2604,MICAL redox enzymes regulate actin dynamics.,"However, although MICAL1 is auto-inhibited by its C-terminal coiled-coil region, MICAL2 remains constitutively active and affects stress fibers.",False,BACKGROUND
2605,MICAL redox enzymes regulate actin dynamics.,These data suggest differential but complementary roles for MICAL1 and MICAL2 in actin microfilament regulation.,True,BACKGROUND
2606,MICAL redox enzymes regulate actin dynamics.,"Semaphorin3A (Sema3A) is a repulsive guidance molecule for axons, which acts by inducing growth cone collapse through phosphorylation of CRMP2 (collapsin response mediator protein 2).",False,BACKGROUND
2607,MICAL redox enzymes regulate actin dynamics.,"Here, we show a role for CRMP2 oxidation and thioredoxin (TRX) in the regulation of CRMP2 phosphorylation and growth cone collapse.",False,BACKGROUND
2608,MICAL redox enzymes regulate actin dynamics.,"Sema3A stimulation generated hydrogen peroxide (H2O2) through MICAL (molecule interacting with CasL) and oxidized CRMP2, enabling it to form a disulfide-linked homodimer through cysteine-504.",True,RESULTS
2609,MICAL redox enzymes regulate actin dynamics.,"Oxidized CRMP2 then formed a transient disulfide-linked complex with TRX, which stimulated CRMP2 phosphorylation by glycogen synthase kinase-3, leading to growth cone collapse.",True,RESULTS
2610,MICAL redox enzymes regulate actin dynamics.,"We also reconstituted oxidation-dependent phosphorylation of CRMP2 in vitro, using a limited set of purified proteins.",False,RESULTS
2611,MICAL redox enzymes regulate actin dynamics.,Our results not only clarify the importance of H2O2 and CRMP2 oxidation in Sema3A-induced growth cone collapse but also indicate an unappreciated role for TRX in linking CRMP2 oxidation to phosphorylation.,True,CONCLUSIONS
2612,MUC1-C activates the NF-κB p65 signaling pathway by interacting with IκB kinase ß.,Nuclear factor-κB (NF-κB) is constitutively activated in diverse human malignancies by mechanisms that are not understood.,False,BACKGROUND
2613,MUC1-C activates the NF-κB p65 signaling pathway by interacting with IκB kinase ß.,"The MUC1 oncoprotein is aberrantly overexpressed by most human carcinomas and, similarly to NF-κB, blocks apoptosis and induces transformation.",False,BACKGROUND
2614,MUC1-C activates the NF-κB p65 signaling pathway by interacting with IκB kinase ß.,This study demonstrates that overexpression of MUC1 in human carcinoma cells is associated with constitutive activation of NF-κB p65.,False,BACKGROUND
2615,MUC1-C activates the NF-κB p65 signaling pathway by interacting with IκB kinase ß.,We show that MUC1 interacts with the high-molecular-weight IκB kinase (IKK) complex in vivo and that the MUC1 cytoplasmic domain binds directly to IKKβ and IKKγ.,False,RESULTS
2616,MUC1-C activates the NF-κB p65 signaling pathway by interacting with IκB kinase ß.,"Interaction of MUC1 with both IKKβ and IKKγ is necessary for IKKβ activation, resulting in phosphorylation and degradation of IκBα.",False,RESULTS
2617,MUC1-C activates the NF-κB p65 signaling pathway by interacting with IκB kinase ß.,Studies in non-malignant epithelial cells show that MUC1 is recruited to the TNF-R1 complex and interacts with IKKβ–IKKγ in response to TNFα stimulation.,False,RESULTS
2618,MUC1-C activates the NF-κB p65 signaling pathway by interacting with IκB kinase ß.,"TNFα-induced recruitment of MUC1 is dependent on TRADD and TRAF2, but not the death-domain kinase RIP1.",False,RESULTS
2619,MUC1-C activates the NF-κB p65 signaling pathway by interacting with IκB kinase ß.,"In addition, MUC1-mediated activation of IKKβ is dependent on TAK1 and TAB2.",False,RESULTS
2620,MUC1-C activates the NF-κB p65 signaling pathway by interacting with IκB kinase ß.,"These findings indicate that MUC1 is important for physiological activation of IKKβ and that overexpression of MUC1, as found in human cancers, confers sustained induction of the IKKβ–NF-κB p65 pathway.",True,RESULTS
2621,MafA phosphorylation decreases its ubiquitination.,The Maf oncoproteins are b-Zip transcription factors of the AP-1 superfamily.,False,BACKGROUND
2622,MafA phosphorylation decreases its ubiquitination.,"They are involved in developmental, metabolic, and tumorigenic processes.",False,BACKGROUND
2623,MafA phosphorylation decreases its ubiquitination.,Maf proteins are overexpressed in about 50% of human multiple myelomas.,False,BACKGROUND
2624,MafA phosphorylation decreases its ubiquitination.,"Here, we show that Maf-transforming activity is controlled by GSK-3-dependent phosphorylation and that phosphorylation by GSK-3 can increase the oncogenic activity of a protein.",False,BACKGROUND
2625,MafA phosphorylation decreases its ubiquitination.,"Using microarray analysis, we identify a gene-expression subprogram regulated by GSK-3-mediated Maf phosphorylation involved in extracellular matrix remodeling and relevant to cancer progression.",False,RESULTS
2626,MafA phosphorylation decreases its ubiquitination.,"We also demonstrate that GSK-3 triggers MafA sequential phosphorylation on residues S61, T57, T53, and S49, inducing its ubiquitination and degradation.",True,RESULTS
2627,MafA phosphorylation decreases its ubiquitination.,"Paradoxically, this phosphorylation increases MafA-transcriptional activity through the recruitment of the coactivator P/CAF.",False,CONCLUSIONS
2628,MafA phosphorylation decreases its ubiquitination.,"We further demonstrate that P/CAF protects MafA from ubiquitination and degradation, suggesting that, upon the release of the coactivator complex, MafA becomes polyubiquitinated and degraded to allow the response to terminate.",False,CONCLUSIONS
2629,MafA phosphorylation enhances its ubiquitination.,The Maf oncoproteins are b-Zip transcription factors of the AP-1 superfamily.,False,BACKGROUND
2630,MafA phosphorylation enhances its ubiquitination.,"They are involved in developmental, metabolic, and tumorigenic processes.",False,BACKGROUND
2631,MafA phosphorylation enhances its ubiquitination.,Maf proteins are overexpressed in about 50% of human multiple myelomas.,False,BACKGROUND
2632,MafA phosphorylation enhances its ubiquitination.,"Here, we show that Maf-transforming activity is controlled by GSK-3-dependent phosphorylation and that phosphorylation by GSK-3 can increase the oncogenic activity of a protein.",False,BACKGROUND
2633,MafA phosphorylation enhances its ubiquitination.,"Using microarray analysis, we identify a gene-expression subprogram regulated by GSK-3-mediated Maf phosphorylation involved in extracellular matrix remodeling and relevant to cancer progression.",False,RESULTS
2634,MafA phosphorylation enhances its ubiquitination.,"We also demonstrate that GSK-3 triggers MafA sequential phosphorylation on residues S61, T57, T53, and S49, inducing its ubiquitination and degradation.",True,RESULTS
2635,MafA phosphorylation enhances its ubiquitination.,"Paradoxically, this phosphorylation increases MafA-transcriptional activity through the recruitment of the coactivator P/CAF.",False,CONCLUSIONS
2636,MafA phosphorylation enhances its ubiquitination.,"We further demonstrate that P/CAF protects MafA from ubiquitination and degradation, suggesting that, upon the release of the coactivator complex, MafA becomes polyubiquitinated and degraded to allow the response to terminate.",False,CONCLUSIONS
2637,MafA ubiquitination decreases the recruitment of coavtivator P/CAF by MafA.,The Maf oncoproteins are b-Zip transcription factors of the AP-1 superfamily.,False,BACKGROUND
2638,MafA ubiquitination decreases the recruitment of coavtivator P/CAF by MafA.,"They are involved in developmental, metabolic, and tumorigenic processes.",False,BACKGROUND
2639,MafA ubiquitination decreases the recruitment of coavtivator P/CAF by MafA.,Maf proteins are overexpressed in about 50% of human multiple myelomas.,False,BACKGROUND
2640,MafA ubiquitination decreases the recruitment of coavtivator P/CAF by MafA.,"Here, we show that Maf-transforming activity is controlled by GSK-3-dependent phosphorylation and that phosphorylation by GSK-3 can increase the oncogenic activity of a protein.",False,BACKGROUND
2641,MafA ubiquitination decreases the recruitment of coavtivator P/CAF by MafA.,"Using microarray analysis, we identify a gene-expression subprogram regulated by GSK-3-mediated Maf phosphorylation involved in extracellular matrix remodeling and relevant to cancer progression.",False,RESULTS
2642,MafA ubiquitination decreases the recruitment of coavtivator P/CAF by MafA.,"We also demonstrate that GSK-3 triggers MafA sequential phosphorylation on residues S61, T57, T53, and S49, inducing its ubiquitination and degradation.",False,RESULTS
2643,MafA ubiquitination decreases the recruitment of coavtivator P/CAF by MafA.,"Paradoxically, this phosphorylation increases MafA-transcriptional activity through the recruitment of the coactivator P/CAF.",True,CONCLUSIONS
2644,MafA ubiquitination decreases the recruitment of coavtivator P/CAF by MafA.,"We further demonstrate that P/CAF protects MafA from ubiquitination and degradation, suggesting that, upon the release of the coactivator complex, MafA becomes polyubiquitinated and degraded to allow the response to terminate.",False,CONCLUSIONS
2645,MafA ubiquitination increases the recruitment of coavtivator P/CAF by MafA.,The Maf oncoproteins are b-Zip transcription factors of the AP-1 superfamily.,False,BACKGROUND
2646,MafA ubiquitination increases the recruitment of coavtivator P/CAF by MafA.,"They are involved in developmental, metabolic, and tumorigenic processes.",False,BACKGROUND
2647,MafA ubiquitination increases the recruitment of coavtivator P/CAF by MafA.,Maf proteins are overexpressed in about 50% of human multiple myelomas.,False,BACKGROUND
2648,MafA ubiquitination increases the recruitment of coavtivator P/CAF by MafA.,"Here, we show that Maf-transforming activity is controlled by GSK-3-dependent phosphorylation and that phosphorylation by GSK-3 can increase the oncogenic activity of a protein.",False,BACKGROUND
2649,MafA ubiquitination increases the recruitment of coavtivator P/CAF by MafA.,"Using microarray analysis, we identify a gene-expression subprogram regulated by GSK-3-mediated Maf phosphorylation involved in extracellular matrix remodeling and relevant to cancer progression.",False,RESULTS
2650,MafA ubiquitination increases the recruitment of coavtivator P/CAF by MafA.,"We also demonstrate that GSK-3 triggers MafA sequential phosphorylation on residues S61, T57, T53, and S49, inducing its ubiquitination and degradation.",False,RESULTS
2651,MafA ubiquitination increases the recruitment of coavtivator P/CAF by MafA.,"Paradoxically, this phosphorylation increases MafA-transcriptional activity through the recruitment of the coactivator P/CAF.",True,CONCLUSIONS
2652,MafA ubiquitination increases the recruitment of coavtivator P/CAF by MafA.,"We further demonstrate that P/CAF protects MafA from ubiquitination and degradation, suggesting that, upon the release of the coactivator complex, MafA becomes polyubiquitinated and degraded to allow the response to terminate.",False,CONCLUSIONS
2653,Major antigen-induced signals from the T cell receptor and secondary signals from costimulatory receptors are required for T cell activation.,Ligation of the CD28 receptor on T cells provides a critical second signal alongside T cell receptor (TCR) ligation for naive T cell activation.,True,BACKGROUND
2654,Major antigen-induced signals from the T cell receptor and secondary signals from costimulatory receptors are required for T cell activation.,"Here, we discuss the expression, structure, and biochemistry of CD28 and its ligands.",False,BACKGROUND
2655,Major antigen-induced signals from the T cell receptor and secondary signals from costimulatory receptors are required for T cell activation.,"CD28 signals play a key role in many T cell processes, including cytoskeletal remodeling, production of cytokines, survival, and differentiation.",False,BACKGROUND
2656,Major antigen-induced signals from the T cell receptor and secondary signals from costimulatory receptors are required for T cell activation.,"CD28 ligation leads to unique epigenetic, transcriptional, and post-translational changes in T cells that cannot be recapitulated by TCR ligation alone.",False,BACKGROUND
2657,Major antigen-induced signals from the T cell receptor and secondary signals from costimulatory receptors are required for T cell activation.,We discuss the function of CD28 and its ligands in both effector and regulatory T cells.,False,BACKGROUND
2658,Major antigen-induced signals from the T cell receptor and secondary signals from costimulatory receptors are required for T cell activation.,CD28 is critical for regulatory T cell survival and the maintenance of immune homeostasis.,False,RESULTS
2659,Major antigen-induced signals from the T cell receptor and secondary signals from costimulatory receptors are required for T cell activation.,We outline the roles that CD28 and its family members play in human disease and we review the clinical efficacy of drugs that block CD28 ligands.,False,RESULTS
2660,Major antigen-induced signals from the T cell receptor and secondary signals from costimulatory receptors are required for T cell activation.,"Despite the centrality of CD28 and its family members and ligands to immune function, many aspects of CD28 biology remain unclear.",False,CONCLUSIONS
2661,Major antigen-induced signals from the T cell receptor and secondary signals from costimulatory receptors are required for T cell activation.,"Translation of a basic understanding of CD28 function into immunomodulatory therapeutics has been uneven, with both successes and failures.",False,CONCLUSIONS
2662,Major antigen-induced signals from the T cell receptor and secondary signals from costimulatory receptors are required for T cell activation.,"Such real-world results might stem from multiple factors, including complex receptor-ligand interactions among CD28 family members, differences between the mouse and human CD28 families, and cell-type specific roles of CD28 family members.",False,CONCLUSIONS
2663,Major vault protein (MVP) leads to more aggressive tumors by regulating the sorting of tumor suppressive miR-193a into extracellular vesicles (EVs).,Exosomes are emerging mediators of intercellular communication; whether the release of exosomes has an effect on the exosome donor cells in addition to the recipient cells has not been investigated to any extent.,False,BACKGROUND
2664,Major vault protein (MVP) leads to more aggressive tumors by regulating the sorting of tumor suppressive miR-193a into extracellular vesicles (EVs).,"Here, we examine different exosomal miRNA expression profiles in primary mouse colon tumour, liver metastasis of colon cancer and naive colon tissues.",False,BACKGROUND
2665,Major vault protein (MVP) leads to more aggressive tumors by regulating the sorting of tumor suppressive miR-193a into extracellular vesicles (EVs).,"In more advanced disease, higher levels of tumour suppressor miRNAs are encapsulated in the exosomes.",False,RESULTS
2666,Major vault protein (MVP) leads to more aggressive tumors by regulating the sorting of tumor suppressive miR-193a into extracellular vesicles (EVs).,miR-193a interacts with major vault protein (MVP).,False,RESULTS
2667,Major vault protein (MVP) leads to more aggressive tumors by regulating the sorting of tumor suppressive miR-193a into extracellular vesicles (EVs).,"Knockout of MVP leads to miR-193a accumulation in the exosomal donor cells instead of exosomes, inhibiting tumour progression.",True,RESULTS
2668,Major vault protein (MVP) leads to more aggressive tumors by regulating the sorting of tumor suppressive miR-193a into extracellular vesicles (EVs).,"Furthermore, miR-193a causes cell cycle G1 arrest and cell proliferation repression through targeting of Caprin1, which upregulates Ccnd2 and c-Myc.",False,RESULTS
2669,Major vault protein (MVP) leads to more aggressive tumors by regulating the sorting of tumor suppressive miR-193a into extracellular vesicles (EVs).,Human colon cancer patients with more advanced disease show higher levels of circulating exosomal miR-193a.,False,CONCLUSIONS
2670,Major vault protein (MVP) leads to more aggressive tumors by regulating the sorting of tumor suppressive miR-193a into extracellular vesicles (EVs).,"In summary, our data demonstrate that MVP-mediated selective sorting of tumour suppressor miRNA into exosomes promotes tumour progression.",True,CONCLUSIONS
2671,Major vault protein regulates sorting of tumor suppressive miR-193a into EVs.,Exosomes are emerging mediators of intercellular communication; whether the release of exosomes has an effect on the exosome donor cells in addition to the recipient cells has not been investigated to any extent.,False,BACKGROUND
2672,Major vault protein regulates sorting of tumor suppressive miR-193a into EVs.,"Here, we examine different exosomal miRNA expression profiles in primary mouse colon tumour, liver metastasis of colon cancer and naive colon tissues.",False,BACKGROUND
2673,Major vault protein regulates sorting of tumor suppressive miR-193a into EVs.,"In more advanced disease, higher levels of tumour suppressor miRNAs are encapsulated in the exosomes.",False,RESULTS
2674,Major vault protein regulates sorting of tumor suppressive miR-193a into EVs.,miR-193a interacts with major vault protein (MVP).,False,RESULTS
2675,Major vault protein regulates sorting of tumor suppressive miR-193a into EVs.,"Knockout of MVP leads to miR-193a accumulation in the exosomal donor cells instead of exosomes, inhibiting tumour progression.",True,RESULTS
2676,Major vault protein regulates sorting of tumor suppressive miR-193a into EVs.,"Furthermore, miR-193a causes cell cycle G1 arrest and cell proliferation repression through targeting of Caprin1, which upregulates Ccnd2 and c-Myc.",False,RESULTS
2677,Major vault protein regulates sorting of tumor suppressive miR-193a into EVs.,Human colon cancer patients with more advanced disease show higher levels of circulating exosomal miR-193a.,False,CONCLUSIONS
2678,Major vault protein regulates sorting of tumor suppressive miR-193a into EVs.,"In summary, our data demonstrate that MVP-mediated selective sorting of tumour suppressor miRNA into exosomes promotes tumour progression.",False,CONCLUSIONS
2679,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have only a modest impact in reducing malaria transmission.,BACKGROUND Artemisinin derivatives used in recently introduced combination therapies (ACTs) for Plasmodium falciparum malaria significantly lower patient infectiousness and have the potential to reduce population-level transmission of the parasite.,False,BACKGROUND
2680,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have only a modest impact in reducing malaria transmission.,"With the increased interest in malaria elimination, understanding the impact on transmission of ACT and other antimalarial drugs with different pharmacodynamics becomes a key issue.",False,BACKGROUND
2681,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have only a modest impact in reducing malaria transmission.,"This study estimates the reduction in transmission that may be achieved by introducing different types of treatment for symptomatic P. falciparum malaria in endemic areas.   
",False,BACKGROUND
2682,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have only a modest impact in reducing malaria transmission.,METHODS AND FINDINGS We developed a mathematical model to predict the potential impact on transmission outcomes of introducing ACT as first-line treatment for uncomplicated malaria in six areas of varying transmission intensity in Tanzania.,False,METHODS
2683,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have only a modest impact in reducing malaria transmission.,"We also estimated the impact that could be achieved by antimalarials with different efficacy, prophylactic time, and gametocytocidal effects.",False,METHODS
2684,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have only a modest impact in reducing malaria transmission.,"Rates of treatment, asymptomatic infection, and symptomatic infection in the six study areas were estimated using the model together with data from a cross-sectional survey of 5,667 individuals conducted prior to policy change from sulfadoxine-pyrimethamine to ACT.",False,METHODS
2685,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have only a modest impact in reducing malaria transmission.,The effects of ACT and other drug types on gametocytaemia and infectiousness to mosquitoes were independently estimated from clinical trial data.,False,METHODS
2686,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have only a modest impact in reducing malaria transmission.,Predicted percentage reductions in prevalence of infection and incidence of clinical episodes achieved by ACT were highest in the areas with low initial transmission.,False,RESULTS
2687,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have only a modest impact in reducing malaria transmission.,"A 53% reduction in prevalence of infection was seen if 100% of current treatment was switched to ACT in the area where baseline slide-prevalence of parasitaemia was lowest (3.7%), compared to an 11% reduction in the highest-transmission setting (baseline slide prevalence = 57.1%).",False,RESULTS
2688,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have only a modest impact in reducing malaria transmission.,Estimated percentage reductions in incidence of clinical episodes were similar.,False,RESULTS
2689,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have only a modest impact in reducing malaria transmission.,"The absolute size of the public health impact, however, was greater in the highest-transmission area, with 54 clinical episodes per 100 persons per year averted compared to five per 100 persons per year in the lowest-transmission area.",False,RESULTS
2690,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have only a modest impact in reducing malaria transmission.,High coverage was important.,False,RESULTS
2691,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have only a modest impact in reducing malaria transmission.,Reducing presumptive treatment through improved diagnosis substantially reduced the number of treatment courses required per clinical episode averted in the lower-transmission settings although there was some loss of overall impact on transmission.,False,RESULTS
2692,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have only a modest impact in reducing malaria transmission.,"An efficacious antimalarial regimen with no specific gametocytocidal properties but a long prophylactic time was estimated to be more effective at reducing transmission than a short-acting ACT in the highest-transmission setting.   
",True,CONCLUSIONS
2693,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have only a modest impact in reducing malaria transmission.,CONCLUSIONS Our results suggest that ACTs have the potential for transmission reductions approaching those achieved by insecticide-treated nets in lower-transmission settings.,False,CONCLUSIONS
2694,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have only a modest impact in reducing malaria transmission.,"ACT partner drugs and nonartemisinin regimens with longer prophylactic times could result in a larger impact in higher-transmission settings, although their long term benefit must be evaluated in relation to the risk of development of parasite resistance.",False,CONCLUSIONS
2695,Medications to treat obesity are highly effective.,"OBJECTIVE To summarise the long term efficacy of anti-obesity drugs in reducing weight and improving health status.   
",False,OBJECTIVE
2696,Medications to treat obesity are highly effective.,"DESIGN Updated meta-analysis of randomised trials.   
",False,METHODS
2697,Medications to treat obesity are highly effective.,"DATA SOURCES Medline, Embase, the Cochrane controlled trials register, the Current Science meta-register of controlled trials, and reference lists of identified articles.",False,METHODS
2698,Medications to treat obesity are highly effective.,All data sources were searched from December 2002 (end date of last search) to December 2006.   ,False,METHODS
2699,Medications to treat obesity are highly effective.,"STUDIES REVIEWED Double blind randomised placebo controlled trials of approved anti-obesity drugs used in adults (age over 18) for one year or longer.   
",False,METHODS
2700,Medications to treat obesity are highly effective.,"RESULTS 30 trials of one to four years' duration met the inclusion criteria: 16 orlistat (n=10 631 participants), 10 sibutramine (n=2623), and four rimonabant (n=6365).",False,RESULTS
2701,Medications to treat obesity are highly effective.,"Of these, 14 trials were new and 16 had previously been identified.",False,RESULTS
2702,Medications to treat obesity are highly effective.,Attrition rates averaged 30-40%.,False,RESULTS
2703,Medications to treat obesity are highly effective.,"Compared with placebo, orlistat reduced weight by 2.9 kg (95% confidence interval 2.5 kg to 3.2 kg), sibutramine by 4.2 kg (3.6 kg to 4.7 kg), and rimonabant by 4.7 kg (4.1 kg to 5.3 kg).",True,RESULTS
2704,Medications to treat obesity are highly effective.,Patients receiving active drug treatment were significantly more likely to achieve 5% and 10% weight loss thresholds.,False,RESULTS
2705,Medications to treat obesity are highly effective.,"Orlistat reduced the incidence of diabetes and improved concentrations of total cholesterol and low density lipoprotein cholesterol, blood pressure, and glycaemic control in patients with diabetes but increased rates of gastrointestinal side effects and slightly lowered concentrations of high density lipoprotein.",False,RESULTS
2706,Medications to treat obesity are highly effective.,"Sibutramine improved [corrected] concentrations of high density lipoprotein cholesterol and triglycerides [corrected] Rimonabant improved concentrations of high density lipoprotein cholesterol and triglycerides, blood pressure, and glycaemic control in patients with diabetes but increased the risk of mood disorders.   
",False,CONCLUSIONS
2707,Medications to treat obesity are highly effective.,"CONCLUSIONS Orlistat, sibutramine, and rimonabant modestly reduce weight, have differing effects on cardiovascular risk profiles, and have specific adverse effects.",True,CONCLUSIONS
2708,Medications to treat obesity do not have side effects.,"OBJECTIVE To summarise the long term efficacy of anti-obesity drugs in reducing weight and improving health status.   
",False,OBJECTIVE
2709,Medications to treat obesity do not have side effects.,"DESIGN Updated meta-analysis of randomised trials.   
",False,METHODS
2710,Medications to treat obesity do not have side effects.,"DATA SOURCES Medline, Embase, the Cochrane controlled trials register, the Current Science meta-register of controlled trials, and reference lists of identified articles.",False,METHODS
2711,Medications to treat obesity do not have side effects.,All data sources were searched from December 2002 (end date of last search) to December 2006.   ,False,METHODS
2712,Medications to treat obesity do not have side effects.,"STUDIES REVIEWED Double blind randomised placebo controlled trials of approved anti-obesity drugs used in adults (age over 18) for one year or longer.   
",False,METHODS
2713,Medications to treat obesity do not have side effects.,"RESULTS 30 trials of one to four years' duration met the inclusion criteria: 16 orlistat (n=10 631 participants), 10 sibutramine (n=2623), and four rimonabant (n=6365).",False,RESULTS
2714,Medications to treat obesity do not have side effects.,"Of these, 14 trials were new and 16 had previously been identified.",False,RESULTS
2715,Medications to treat obesity do not have side effects.,Attrition rates averaged 30-40%.,False,RESULTS
2716,Medications to treat obesity do not have side effects.,"Compared with placebo, orlistat reduced weight by 2.9 kg (95% confidence interval 2.5 kg to 3.2 kg), sibutramine by 4.2 kg (3.6 kg to 4.7 kg), and rimonabant by 4.7 kg (4.1 kg to 5.3 kg).",False,RESULTS
2717,Medications to treat obesity do not have side effects.,Patients receiving active drug treatment were significantly more likely to achieve 5% and 10% weight loss thresholds.,False,RESULTS
2718,Medications to treat obesity do not have side effects.,"Orlistat reduced the incidence of diabetes and improved concentrations of total cholesterol and low density lipoprotein cholesterol, blood pressure, and glycaemic control in patients with diabetes but increased rates of gastrointestinal side effects and slightly lowered concentrations of high density lipoprotein.",True,RESULTS
2719,Medications to treat obesity do not have side effects.,"Sibutramine improved [corrected] concentrations of high density lipoprotein cholesterol and triglycerides [corrected] Rimonabant improved concentrations of high density lipoprotein cholesterol and triglycerides, blood pressure, and glycaemic control in patients with diabetes but increased the risk of mood disorders.   
",True,CONCLUSIONS
2720,Medications to treat obesity do not have side effects.,"CONCLUSIONS Orlistat, sibutramine, and rimonabant modestly reduce weight, have differing effects on cardiovascular risk profiles, and have specific adverse effects.",True,CONCLUSIONS
2721,Medications to treat obesity have unwanted side effects.,"OBJECTIVE To summarise the long term efficacy of anti-obesity drugs in reducing weight and improving health status.   
",False,OBJECTIVE
2722,Medications to treat obesity have unwanted side effects.,"DESIGN Updated meta-analysis of randomised trials.   
",False,METHODS
2723,Medications to treat obesity have unwanted side effects.,"DATA SOURCES Medline, Embase, the Cochrane controlled trials register, the Current Science meta-register of controlled trials, and reference lists of identified articles.",False,METHODS
2724,Medications to treat obesity have unwanted side effects.,All data sources were searched from December 2002 (end date of last search) to December 2006.   ,False,METHODS
2725,Medications to treat obesity have unwanted side effects.,"STUDIES REVIEWED Double blind randomised placebo controlled trials of approved anti-obesity drugs used in adults (age over 18) for one year or longer.   
",False,METHODS
2726,Medications to treat obesity have unwanted side effects.,"RESULTS 30 trials of one to four years' duration met the inclusion criteria: 16 orlistat (n=10 631 participants), 10 sibutramine (n=2623), and four rimonabant (n=6365).",False,RESULTS
2727,Medications to treat obesity have unwanted side effects.,"Of these, 14 trials were new and 16 had previously been identified.",False,RESULTS
2728,Medications to treat obesity have unwanted side effects.,Attrition rates averaged 30-40%.,False,RESULTS
2729,Medications to treat obesity have unwanted side effects.,"Compared with placebo, orlistat reduced weight by 2.9 kg (95% confidence interval 2.5 kg to 3.2 kg), sibutramine by 4.2 kg (3.6 kg to 4.7 kg), and rimonabant by 4.7 kg (4.1 kg to 5.3 kg).",False,RESULTS
2730,Medications to treat obesity have unwanted side effects.,Patients receiving active drug treatment were significantly more likely to achieve 5% and 10% weight loss thresholds.,False,RESULTS
2731,Medications to treat obesity have unwanted side effects.,"Orlistat reduced the incidence of diabetes and improved concentrations of total cholesterol and low density lipoprotein cholesterol, blood pressure, and glycaemic control in patients with diabetes but increased rates of gastrointestinal side effects and slightly lowered concentrations of high density lipoprotein.",True,RESULTS
2732,Medications to treat obesity have unwanted side effects.,"Sibutramine improved [corrected] concentrations of high density lipoprotein cholesterol and triglycerides [corrected] Rimonabant improved concentrations of high density lipoprotein cholesterol and triglycerides, blood pressure, and glycaemic control in patients with diabetes but increased the risk of mood disorders.   
",True,CONCLUSIONS
2733,Medications to treat obesity have unwanted side effects.,"CONCLUSIONS Orlistat, sibutramine, and rimonabant modestly reduce weight, have differing effects on cardiovascular risk profiles, and have specific adverse effects.",True,CONCLUSIONS
2734,Men are more susceptible to death due to pneumonia when compared to women.,"CONTEXT While it is established that management strategies and outcomes differ by gender for many diseases, its effect on infection has not been adequately studied.   
",False,BACKGROUND
2735,Men are more susceptible to death due to pneumonia when compared to women.,"OBJECTIVE To investigate the role of gender among hospitalized patients treated for infection.   
",False,OBJECTIVE
2736,Men are more susceptible to death due to pneumonia when compared to women.,"DESIGN Observational cohort study conducted during a 26-month period from December 1996 through January 1999.   
",False,METHODS
2737,Men are more susceptible to death due to pneumonia when compared to women.,"SETTING University-affiliated hospital.   
",False,METHODS
2738,Men are more susceptible to death due to pneumonia when compared to women.,"PARTICIPANTS A total of 892 patients in the surgical units of the hospital with 1470 consecutive infectious episodes (782 in men and 688 in women).   
",False,METHODS
2739,Men are more susceptible to death due to pneumonia when compared to women.,"MAIN OUTCOME MEASURES Mortality during hospitalization by gender for infection episodes overall and for specific infectious sites, including lung, peritoneum, bloodstream, catheter, urine, surgical site, and skin/soft tissue.   
",False,METHODS
2740,Men are more susceptible to death due to pneumonia when compared to women.,"RESULTS Among all infections, there was no significant difference in mortality based on gender (men, 11.1% vs women, 14.2%; P = .07).",False,RESULTS
2741,Men are more susceptible to death due to pneumonia when compared to women.,"After logistic regression analysis, factors independently associated with mortality included higher APACHE (Acute Physiology and Chronic Health Evaluation) II score, older age, malignancy, blood transfusion, and diagnosis of infection more than 7 days after admission, but not gender (female odds ratio [OR] for death, 1.32; 95% confidence interval [CI], 0.90-1.94; P = .16).",False,RESULTS
2742,Men are more susceptible to death due to pneumonia when compared to women.,"Mortality was higher in women for lung (men, 18% vs women, 34%; P = .002) and soft tissue (men, 2% vs women, 10%; P < or = .05) infection; for other infectious sites, mortality did not differ by gender.",False,RESULTS
2743,Men are more susceptible to death due to pneumonia when compared to women.,"Factors associated with mortality due to pneumonia by logistic regression included higher APACHE II score, malignancy, diabetes mellitus, diagnosis of infection more than 7 days after admission, older age, transplantation, and female gender (OR for death, 2.25; 95% CI, 1.17-4.32; P = .02).   
",False,RESULTS
2744,Men are more susceptible to death due to pneumonia when compared to women.,"CONCLUSIONS Although gender may not be predictive of mortality among all infections, women appear to be at increased risk for death from hospital-acquired pneumonia, even after controlling for other comorbidities.",True,CONCLUSIONS
2745,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in similar efficacy and better quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"BACKGROUND Elderly and frail patients with cancer, although often treated with chemotherapy, are under-represented in clinical trials.",False,BACKGROUND
2746,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in similar efficacy and better quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"We designed FOCUS2 to investigate reduced-dose chemotherapy options and to seek objective predictors of outcome in frail patients with advanced colorectal cancer.   
",False,BACKGROUND
2747,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in similar efficacy and better quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"METHODS We undertook an open, 2 × 2 factorial trial in 61 UK centres for patients with previously untreated advanced colorectal cancer who were considered unfit for full-dose chemotherapy.",False,METHODS
2748,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in similar efficacy and better quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"After comprehensive health assessment (CHA), patients were randomly assigned by minimisation to: 48-h intravenous fluorouracil with levofolinate (group A); oxaliplatin and fluorouracil (group B); capecitabine (group C); or oxaliplatin and capecitabine (group D).",False,METHODS
2749,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in similar efficacy and better quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,Treatment allocation was not masked.,False,METHODS
2750,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in similar efficacy and better quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"Starting doses were 80% of standard doses, with discretionary escalation to full dose after 6 weeks.",False,METHODS
2751,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in similar efficacy and better quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"The two primary outcome measures were: addition of oxaliplatin ([A vs B] + [C vs D]), assessed with progression-free survival (PFS); and substitution of fluorouracil with capecitabine ([A vs C] + [B vs D]), assessed by change from baseline to 12 weeks in global quality of life (QoL).",False,METHODS
2752,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in similar efficacy and better quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,Analysis was by intention to treat.,False,METHODS
2753,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in similar efficacy and better quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"Baseline clinical and CHA data were modelled against outcomes with a novel composite measure, overall treatment utility (OTU).",False,METHODS
2754,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in similar efficacy and better quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"This study is registered, number ISRCTN21221452.   
",False,METHODS
2755,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in similar efficacy and better quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"FINDINGS 459 patients were randomly assigned (115 to each of groups A-C, 114 to group D).",False,RESULTS
2756,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in similar efficacy and better quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"Factorial comparison of addition of oxaliplatin versus no addition suggested some improvement in PFS, but the finding was not significant (median 5·8 months [IQR 3·3-7·5] vs 4·5 months [2·8-6·4]; hazard ratio 0·84, 95% CI 0·69-1·01, p=0·07).",False,RESULTS
2757,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in similar efficacy and better quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,Replacement of fluorouracil with capecitabine did not improve global QoL: 69 of 124 (56%) patients receiving fluorouracil reported improvement in global QoL compared with 69 of 123 (56%) receiving capecitabine.,False,RESULTS
2758,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in similar efficacy and better quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"The risk of having any grade 3 or worse toxic effect was not significantly increased with oxaliplatin (83/219 [38%] vs 70/221 [32%]; p=0·17), but was higher with capecitabine than with fluorouracil (88/222 [40%] vs 65/218 [30%]; p=0·03).",False,RESULTS
2759,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in similar efficacy and better quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"In multivariable analysis, fewer baseline symptoms (odds ratio 1·32, 95% CI 1·14-1·52), less widespread disease (1·51, 1·05-2·19), and use of oxaliplatin (0·57, 0·39-0·82) were predictive of better OTU.   
",False,RESULTS
2760,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in similar efficacy and better quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"INTERPRETATION FOCUS2 shows that with an appropriate design, including reduced starting doses of chemotherapy, frail and elderly patients can participate in a randomised controlled trial.",False,CONCLUSIONS
2761,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in similar efficacy and better quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"On balance, a combination including oxaliplatin was preferable to single-agent fluoropyrimidines, although the primary endpoint of PFS was not met.",True,CONCLUSIONS
2762,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in similar efficacy and better quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,Capecitabine did not improve QoL compared with fluorouracil.,False,CONCLUSIONS
2763,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in similar efficacy and better quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"Comprehensive baseline assessment holds promise as an objective predictor of treatment benefit.   
",False,CONCLUSIONS
2764,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in similar efficacy and better quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,FUNDING Cancer Research UK and the Medical Research Council.,False,CONCLUSIONS
2765,Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.,"Traditionally, vaccine development involves tradeoffs between immunogenicity and safety.",False,BACKGROUND
2766,Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.,Live-attenuated vaccines typically offer rapid and durable immunity but have reduced safety when compared to inactivated vaccines.,False,BACKGROUND
2767,Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.,"In contrast, the inability of inactivated vaccines to replicate enhances safety at the expense of immunogenicity, often necessitating multiple doses and boosters.",False,BACKGROUND
2768,Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.,"To overcome these tradeoffs, we developed the insect-specific alphavirus, Eilat virus (EILV), as a vaccine platform.",False,BACKGROUND
2769,Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.,"To address the chikungunya fever (CHIKF) pandemic, we used an EILV cDNA clone to design a chimeric virus containing the chikungunya virus (CHIKV) structural proteins.",False,METHODS
2770,Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.,"The recombinant EILV/CHIKV was structurally identical at 10 Å to wild-type CHIKV, as determined by single-particle cryo-electron microscopy, and it mimicked the early stages of CHIKV replication in vertebrate cells from attachment and entry to viral RNA delivery.",False,RESULTS
2771,Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.,"Yet the recombinant virus remained completely defective for productive replication, providing a high degree of safety.",False,RESULTS
2772,Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.,A single dose of EILV/CHIKV produced in mosquito cells elicited rapid (within 4 d) and long-lasting (>290 d) neutralizing antibodies that provided complete protection in two different mouse models.,True,RESULTS
2773,Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.,"In nonhuman primates, EILV/CHIKV elicited rapid and robust immunity that protected against viremia and telemetrically monitored fever.",False,CONCLUSIONS
2774,Mice are incapable of producing neutralizing antibodies in reponse to the Chikungunya virus (CHIKV) produced in mosquitos.,Our EILV platform represents the first structurally native application of an insect-specific virus in preclinical vaccine development and highlights the potential application of such viruses in vaccinology.,False,CONCLUSIONS
2775,Mice lacking Sirt1 in Sf1-expressing neurons are immune to diet-induced obesity and insulin resistance.,"Chronic feeding on high-calorie diets causes obesity and type 2 diabetes mellitus (T2DM), illnesses that affect hundreds of millions.",False,BACKGROUND
2776,Mice lacking Sirt1 in Sf1-expressing neurons are immune to diet-induced obesity and insulin resistance.,"Thus, understanding the pathways protecting against diet-induced metabolic imbalance is of paramount medical importance.",False,BACKGROUND
2777,Mice lacking Sirt1 in Sf1-expressing neurons are immune to diet-induced obesity and insulin resistance.,"Here, we show that mice lacking SIRT1 in steroidogenic factor 1 (SF1) neurons are hypersensitive to dietary obesity owing to maladaptive energy expenditure.",True,BACKGROUND
2778,Mice lacking Sirt1 in Sf1-expressing neurons are immune to diet-induced obesity and insulin resistance.,"Also, mutant mice have increased susceptibility to developing dietary T2DM due to insulin resistance in skeletal muscle.",True,BACKGROUND
2779,Mice lacking Sirt1 in Sf1-expressing neurons are immune to diet-induced obesity and insulin resistance.,"Mechanistically, these aberrations arise, in part, from impaired metabolic actions of the neuropeptide orexin-A and the hormone leptin.",False,BACKGROUND
2780,Mice lacking Sirt1 in Sf1-expressing neurons are immune to diet-induced obesity and insulin resistance.,"Conversely, mice overexpressing SIRT1 in SF1 neurons are more resistant to diet-induced obesity and insulin resistance due to increased energy expenditure and enhanced skeletal muscle insulin sensitivity.",True,BACKGROUND
2781,Mice lacking Sirt1 in Sf1-expressing neurons are immune to diet-induced obesity and insulin resistance.,Our results unveil important protective roles of SIRT1 in SF1 neurons against dietary metabolic imbalance.,False,BACKGROUND
2782,Mice lacking Sirt1 in Sf1-expressing neurons have increased susceptibility to diet-induced obesity and insulin resistance.,"Chronic feeding on high-calorie diets causes obesity and type 2 diabetes mellitus (T2DM), illnesses that affect hundreds of millions.",False,BACKGROUND
2783,Mice lacking Sirt1 in Sf1-expressing neurons have increased susceptibility to diet-induced obesity and insulin resistance.,"Thus, understanding the pathways protecting against diet-induced metabolic imbalance is of paramount medical importance.",False,BACKGROUND
2784,Mice lacking Sirt1 in Sf1-expressing neurons have increased susceptibility to diet-induced obesity and insulin resistance.,"Here, we show that mice lacking SIRT1 in steroidogenic factor 1 (SF1) neurons are hypersensitive to dietary obesity owing to maladaptive energy expenditure.",True,BACKGROUND
2785,Mice lacking Sirt1 in Sf1-expressing neurons have increased susceptibility to diet-induced obesity and insulin resistance.,"Also, mutant mice have increased susceptibility to developing dietary T2DM due to insulin resistance in skeletal muscle.",True,BACKGROUND
2786,Mice lacking Sirt1 in Sf1-expressing neurons have increased susceptibility to diet-induced obesity and insulin resistance.,"Mechanistically, these aberrations arise, in part, from impaired metabolic actions of the neuropeptide orexin-A and the hormone leptin.",False,BACKGROUND
2787,Mice lacking Sirt1 in Sf1-expressing neurons have increased susceptibility to diet-induced obesity and insulin resistance.,"Conversely, mice overexpressing SIRT1 in SF1 neurons are more resistant to diet-induced obesity and insulin resistance due to increased energy expenditure and enhanced skeletal muscle insulin sensitivity.",True,BACKGROUND
2788,Mice lacking Sirt1 in Sf1-expressing neurons have increased susceptibility to diet-induced obesity and insulin resistance.,Our results unveil important protective roles of SIRT1 in SF1 neurons against dietary metabolic imbalance.,False,BACKGROUND
2789,Mice that lack Interferon-γ or its receptor are highly susceptible to experimental autoimmune myocarditis.,BACKGROUND Interleukin (IL)-12 exerts a potent proinflammatory effect by stimulating T-helper (Th) 1 responses.,False,BACKGROUND
2790,Mice that lack Interferon-γ or its receptor are highly susceptible to experimental autoimmune myocarditis.,This effect is believed to be mediated primarily through the activation of STAT4 and subsequent production of interferon (IFN)-gamma.,False,BACKGROUND
2791,Mice that lack Interferon-γ or its receptor are highly susceptible to experimental autoimmune myocarditis.,Methods and Results- We examined the role of IL-12 receptor (IL-12R) signaling in the development of murine experimental autoimmune myocarditis (EAM) induced by cardiac myosin immunization.,False,BACKGROUND
2792,Mice that lack Interferon-γ or its receptor are highly susceptible to experimental autoimmune myocarditis.,Both IL-12Rbeta1-deficient mice and STAT4-deficient mice were resistant to the induction of myocarditis.,False,RESULTS
2793,Mice that lack Interferon-γ or its receptor are highly susceptible to experimental autoimmune myocarditis.,Treatment with exogenous IL-12 exacerbated disease.,False,RESULTS
2794,Mice that lack Interferon-γ or its receptor are highly susceptible to experimental autoimmune myocarditis.,We questioned whether IFN-gamma is required for the disease-promoting activity of IL-12.,False,RESULTS
2795,Mice that lack Interferon-γ or its receptor are highly susceptible to experimental autoimmune myocarditis.,"On the contrary, we found that IFN-gamma suppresses EAM.",False,RESULTS
2796,Mice that lack Interferon-γ or its receptor are highly susceptible to experimental autoimmune myocarditis.,Lack of IFN-gamma due to either depletion with an antibody or a genetic deficiency exacerbated myocarditis.,True,RESULTS
2797,Mice that lack Interferon-γ or its receptor are highly susceptible to experimental autoimmune myocarditis.,"Spleens from IFN-gamma-deficient mice immunized with cardiac myosin showed increased cellularity; greater numbers of CD3+, CD4+, CD8+, and IL-2-producing cells; and heightened ability to produce cytokines on stimulation in vitro.",False,RESULTS
2798,Mice that lack Interferon-γ or its receptor are highly susceptible to experimental autoimmune myocarditis.,"Treatment of mice with recombinant IFN-gamma suppressed the development of myocarditis.   
",False,RESULTS
2799,Mice that lack Interferon-γ or its receptor are highly susceptible to experimental autoimmune myocarditis.,CONCLUSIONS IL-12/IL-12R/STAT4 signaling promotes the development of EAM.,False,CONCLUSIONS
2800,Mice that lack Interferon-γ or its receptor are highly susceptible to experimental autoimmune myocarditis.,"In contrast, IFN-gamma plays a protective role.",True,CONCLUSIONS
2801,Mice that lack Interferon-γ or its receptor are highly susceptible to experimental autoimmune myocarditis.,The disease-limiting effects of IFN-gamma might be explained by its ability to control the expansion of activated T lymphocytes.,False,CONCLUSIONS
2802,Mice that lack Interferon-γ or its receptor are highly susceptible to experimental autoimmune myocarditis.,BACKGROUND Interferon-gamma (IFN-gamma) is an essential cytokine in the regulation of inflammatory responses in autoimmune diseases.,False,BACKGROUND
2803,Mice that lack Interferon-γ or its receptor are highly susceptible to experimental autoimmune myocarditis.,"Little is known about its role in inflammatory heart disease.   
",False,BACKGROUND
2804,Mice that lack Interferon-γ or its receptor are highly susceptible to experimental autoimmune myocarditis.,METHODS AND RESULTS We showed that IFN-gamma receptor-deficient mice (IFN-gammaR(-/-)) on a BALB/c background immunized with a peptide derived from cardiac alpha-myosin heavy chain develop severe myocarditis with high mortality.,True,METHODS
2805,Mice that lack Interferon-γ or its receptor are highly susceptible to experimental autoimmune myocarditis.,"Although myocarditis subsided in wild-type mice after 3 weeks, IFN-gammaR(-/-) mice showed persistent disease.",True,RESULTS
2806,Mice that lack Interferon-γ or its receptor are highly susceptible to experimental autoimmune myocarditis.,"The persistent inflammation was accompanied by vigorous in vitro CD4 T-cell responses and impaired inducible nitric oxide synthase expression, together with evidence of impaired nitric oxide production in IFN-gammaR(-/-) hearts.",False,RESULTS
2807,Mice that lack Interferon-γ or its receptor are highly susceptible to experimental autoimmune myocarditis.,"Treatment of wild-type mice with the nitric oxide synthetase inhibitor N:-nitro-l-arginine-methyl-ester enhanced in vitro CD4 T-cell proliferation and prevented healing of myocarditis.   
",False,RESULTS
2808,Mice that lack Interferon-γ or its receptor are highly susceptible to experimental autoimmune myocarditis.,CONCLUSIONS Our data provide evidence that IFN-gamma protects mice from lethal autoimmune myocarditis by inducing the expression of inducible nitric oxide synthase followed by the downregulation of T-cell responses.,True,CONCLUSIONS
2809,Mice without IFN-γ or its receptor are highly susceptible to EAM induced with α-MyHC/CFA.,BACKGROUND Interleukin (IL)-12 exerts a potent proinflammatory effect by stimulating T-helper (Th) 1 responses.,False,BACKGROUND
2810,Mice without IFN-γ or its receptor are highly susceptible to EAM induced with α-MyHC/CFA.,This effect is believed to be mediated primarily through the activation of STAT4 and subsequent production of interferon (IFN)-gamma.,False,BACKGROUND
2811,Mice without IFN-γ or its receptor are highly susceptible to EAM induced with α-MyHC/CFA.,Methods and Results- We examined the role of IL-12 receptor (IL-12R) signaling in the development of murine experimental autoimmune myocarditis (EAM) induced by cardiac myosin immunization.,False,BACKGROUND
2812,Mice without IFN-γ or its receptor are highly susceptible to EAM induced with α-MyHC/CFA.,Both IL-12Rbeta1-deficient mice and STAT4-deficient mice were resistant to the induction of myocarditis.,False,RESULTS
2813,Mice without IFN-γ or its receptor are highly susceptible to EAM induced with α-MyHC/CFA.,Treatment with exogenous IL-12 exacerbated disease.,False,RESULTS
2814,Mice without IFN-γ or its receptor are highly susceptible to EAM induced with α-MyHC/CFA.,We questioned whether IFN-gamma is required for the disease-promoting activity of IL-12.,False,RESULTS
2815,Mice without IFN-γ or its receptor are highly susceptible to EAM induced with α-MyHC/CFA.,"On the contrary, we found that IFN-gamma suppresses EAM.",False,RESULTS
2816,Mice without IFN-γ or its receptor are highly susceptible to EAM induced with α-MyHC/CFA.,Lack of IFN-gamma due to either depletion with an antibody or a genetic deficiency exacerbated myocarditis.,True,RESULTS
2817,Mice without IFN-γ or its receptor are highly susceptible to EAM induced with α-MyHC/CFA.,"Spleens from IFN-gamma-deficient mice immunized with cardiac myosin showed increased cellularity; greater numbers of CD3+, CD4+, CD8+, and IL-2-producing cells; and heightened ability to produce cytokines on stimulation in vitro.",False,RESULTS
2818,Mice without IFN-γ or its receptor are highly susceptible to EAM induced with α-MyHC/CFA.,"Treatment of mice with recombinant IFN-gamma suppressed the development of myocarditis.   
",False,RESULTS
2819,Mice without IFN-γ or its receptor are highly susceptible to EAM induced with α-MyHC/CFA.,CONCLUSIONS IL-12/IL-12R/STAT4 signaling promotes the development of EAM.,False,CONCLUSIONS
2820,Mice without IFN-γ or its receptor are highly susceptible to EAM induced with α-MyHC/CFA.,"In contrast, IFN-gamma plays a protective role.",True,CONCLUSIONS
2821,Mice without IFN-γ or its receptor are highly susceptible to EAM induced with α-MyHC/CFA.,The disease-limiting effects of IFN-gamma might be explained by its ability to control the expansion of activated T lymphocytes.,False,CONCLUSIONS
2822,Microcin J25 encourages nucleoside triphosphate (NTP) binding.,The antibacterial peptide microcin J25 (MccJ25) inhibits transcription by bacterial RNA polymerase (RNAP).,False,BACKGROUND
2823,Microcin J25 encourages nucleoside triphosphate (NTP) binding.,Biochemical results indicate that inhibition of transcription occurs at the level of NTP uptake or NTP binding by RNAP.,True,BACKGROUND
2824,Microcin J25 encourages nucleoside triphosphate (NTP) binding.,"Genetic results indicate that inhibition of transcription requires an extensive determinant, comprising more than 50 amino acid residues, within the RNAP secondary channel (also known as the ""NTP-uptake channel"" or ""pore"").",False,BACKGROUND
2825,Microcin J25 encourages nucleoside triphosphate (NTP) binding.,Biophysical results indicate that inhibition of transcription involves binding of MccJ25 within the RNAP secondary channel.,False,RESULTS
2826,Microcin J25 encourages nucleoside triphosphate (NTP) binding.,Molecular modeling indicates that binding of MccJ25 within the RNAP secondary channel obstructs the RNAP secondary channel.,False,RESULTS
2827,Microcin J25 encourages nucleoside triphosphate (NTP) binding.,"We conclude that MccJ25 inhibits transcription by binding within and obstructing the RNAP secondary channel--acting essentially as a ""cork in a bottle.",False,RESULTS
2828,Microcin J25 encourages nucleoside triphosphate (NTP) binding.,"""",False,RESULTS
2829,Microcin J25 encourages nucleoside triphosphate (NTP) binding.,Obstruction of the RNAP secondary channel represents an attractive target for drug discovery.,False,CONCLUSIONS
2830,Microcin J25 inhibits nucleoside triphosphate (NTP) binding.,The antibacterial peptide microcin J25 (MccJ25) inhibits transcription by bacterial RNA polymerase (RNAP).,False,BACKGROUND
2831,Microcin J25 inhibits nucleoside triphosphate (NTP) binding.,Biochemical results indicate that inhibition of transcription occurs at the level of NTP uptake or NTP binding by RNAP.,True,BACKGROUND
2832,Microcin J25 inhibits nucleoside triphosphate (NTP) binding.,"Genetic results indicate that inhibition of transcription requires an extensive determinant, comprising more than 50 amino acid residues, within the RNAP secondary channel (also known as the ""NTP-uptake channel"" or ""pore"").",False,BACKGROUND
2833,Microcin J25 inhibits nucleoside triphosphate (NTP) binding.,Biophysical results indicate that inhibition of transcription involves binding of MccJ25 within the RNAP secondary channel.,False,RESULTS
2834,Microcin J25 inhibits nucleoside triphosphate (NTP) binding.,Molecular modeling indicates that binding of MccJ25 within the RNAP secondary channel obstructs the RNAP secondary channel.,False,RESULTS
2835,Microcin J25 inhibits nucleoside triphosphate (NTP) binding.,"We conclude that MccJ25 inhibits transcription by binding within and obstructing the RNAP secondary channel--acting essentially as a ""cork in a bottle.",False,RESULTS
2836,Microcin J25 inhibits nucleoside triphosphate (NTP) binding.,"""",False,RESULTS
2837,Microcin J25 inhibits nucleoside triphosphate (NTP) binding.,Obstruction of the RNAP secondary channel represents an attractive target for drug discovery.,False,CONCLUSIONS
2838,Microglia are an innate immune cell type of the central nervous system.,Recent findings challenge the concept that microglia solely function in disease states in the central nervous system (CNS).,False,BACKGROUND
2839,Microglia are an innate immune cell type of the central nervous system.,"Rather than simply reacting to CNS injury, infection, or pathology, emerging lines of evidence indicate that microglia sculpt the structure of the CNS, refine neuronal circuitry and network connectivity, and contribute to plasticity.",False,BACKGROUND
2840,Microglia are an innate immune cell type of the central nervous system.,These physiological functions of microglia in the normal CNS begin during development and persist into maturity.,True,BACKGROUND
2841,Microglia are an innate immune cell type of the central nervous system.,"Here, we develop a conceptual framework for functions of microglia beyond neuroinflammation and discuss the rich repertoire of signaling and communication motifs in microglia that are critical both in pathology and for the normal physiology of the CNS.",True,BACKGROUND
2842,Microglia are an innate immune cell type of the peripheral nervous system.,Recent findings challenge the concept that microglia solely function in disease states in the central nervous system (CNS).,False,BACKGROUND
2843,Microglia are an innate immune cell type of the peripheral nervous system.,"Rather than simply reacting to CNS injury, infection, or pathology, emerging lines of evidence indicate that microglia sculpt the structure of the CNS, refine neuronal circuitry and network connectivity, and contribute to plasticity.",False,BACKGROUND
2844,Microglia are an innate immune cell type of the peripheral nervous system.,These physiological functions of microglia in the normal CNS begin during development and persist into maturity.,True,BACKGROUND
2845,Microglia are an innate immune cell type of the peripheral nervous system.,"Here, we develop a conceptual framework for functions of microglia beyond neuroinflammation and discuss the rich repertoire of signaling and communication motifs in microglia that are critical both in pathology and for the normal physiology of the CNS.",True,BACKGROUND
2846,Migraine with aura is associated with ischemic stroke.,"OBJECTIVE To evaluate the association between migraine and cardiovascular disease, including stroke, myocardial infarction, and death due to cardiovascular disease.   
",False,OBJECTIVE
2847,Migraine with aura is associated with ischemic stroke.,"DESIGN Systematic review and meta-analysis.   
",False,METHODS
2848,Migraine with aura is associated with ischemic stroke.,"DATA SOURCES Electronic databases (PubMed, Embase, Cochrane Library) and reference lists of included studies and reviews published until January 2009.",False,METHODS
2849,Migraine with aura is associated with ischemic stroke.,Selection criteria Case-control and cohort studies investigating the association between any migraine or specific migraine subtypes and cardiovascular disease.,False,METHODS
2850,Migraine with aura is associated with ischemic stroke.,Review methods Two investigators independently assessed eligibility of identified studies in a two step approach.,False,METHODS
2851,Migraine with aura is associated with ischemic stroke.,Disagreements were resolved by consensus.,False,METHODS
2852,Migraine with aura is associated with ischemic stroke.,"Studies were grouped according to a priori categories on migraine and cardiovascular disease.   
",False,METHODS
2853,Migraine with aura is associated with ischemic stroke.,DATA EXTRACTION Two investigators extracted data.,False,METHODS
2854,Migraine with aura is associated with ischemic stroke.,"Pooled relative risks and 95% confidence intervals were calculated.   
",False,METHODS
2855,Migraine with aura is associated with ischemic stroke.,RESULTS Studies were heterogeneous for participant characteristics and definition of cardiovascular disease.,False,RESULTS
2856,Migraine with aura is associated with ischemic stroke.,"Nine studies investigated the association between any migraine and ischaemic stroke (pooled relative risk 1.73, 95% confidence interval 1.31 to 2.29).",False,RESULTS
2857,Migraine with aura is associated with ischemic stroke.,"Additional analyses indicated a significantly higher risk among people who had migraine with aura (2.16, 1.53 to 3.03) compared with people who had migraine without aura (1.23, 0.90 to 1.69; meta-regression for aura status P=0.02).",True,RESULTS
2858,Migraine with aura is associated with ischemic stroke.,"Furthermore, results suggested a greater risk among women (2.08, 1.13 to 3.84) compared with men (1.37, 0.89 to 2.11).",False,RESULTS
2859,Migraine with aura is associated with ischemic stroke.,"Age less than 45 years, smoking, and oral contraceptive use further increased the risk.",False,RESULTS
2860,Migraine with aura is associated with ischemic stroke.,"Eight studies investigated the association between migraine and myocardial infarction (1.12, 0.95 to 1.32) and five between migraine and death due to cardiovascular disease (1.03, 0.79 to 1.34).",False,CONCLUSIONS
2861,Migraine with aura is associated with ischemic stroke.,"Only one study investigated the association between women who had migraine with aura and myocardial infarction and death due to cardiovascular disease, showing a twofold increased risk.   
",False,CONCLUSIONS
2862,Migraine with aura is associated with ischemic stroke.,"CONCLUSION Migraine is associated with a twofold increased risk of ischaemic stroke, which is only apparent among people who have migraine with aura.",True,CONCLUSIONS
2863,Migraine with aura is associated with ischemic stroke.,"Our results also suggest a higher risk among women and risk was further magnified for people with migraine who were aged less than 45, smokers, and women who used oral contraceptives.",False,CONCLUSIONS
2864,Migraine with aura is associated with ischemic stroke.,We did not find an overall association between any migraine and myocardial infarction or death due to cardiovascular disease.,False,CONCLUSIONS
2865,Migraine with aura is associated with ischemic stroke.,"Too few studies are available to reliably evaluate the impact of modifying factors, such as migraine aura, on these associations.",False,CONCLUSIONS
2866,Misunderstandings between doctors and patients can lead to non-adherence.,"OBJECTIVES To identify and describe misunderstandings between patients and doctors associated with prescribing decisions in general practice.   
",False,OBJECTIVE
2867,Misunderstandings between doctors and patients can lead to non-adherence.,"DESIGN Qualitative study.   
",False,METHODS
2868,Misunderstandings between doctors and patients can lead to non-adherence.,"SETTING 20 general practices in the West Midlands and south east England.   
",False,METHODS
2869,Misunderstandings between doctors and patients can lead to non-adherence.,"PARTICIPANTS 20 general practitioners and 35 consulting patients.   
",False,METHODS
2870,Misunderstandings between doctors and patients can lead to non-adherence.,"MAIN OUTCOME MEASURES Misunderstandings between patients and doctors that have potential or actual adverse consequences for taking medicine.   
",False,METHODS
2871,Misunderstandings between doctors and patients can lead to non-adherence.,"RESULTS 14 categories of misunderstanding were identified relating to patient information unknown to the doctor, doctor information unknown to the patient, conflicting information, disagreement about attribution of side effects, failure of communication about doctor's decision, and relationship factors.",False,RESULTS
2872,Misunderstandings between doctors and patients can lead to non-adherence.,All the misunderstandings were associated with lack of patients' participation in the consultation in terms of the voicing of expectations and preferences or the voicing of responses to doctors' decisions and actions.,True,RESULTS
2873,Misunderstandings between doctors and patients can lead to non-adherence.,They were all associated with potential or actual adverse outcomes such as non-adherence to treatment.,True,RESULTS
2874,Misunderstandings between doctors and patients can lead to non-adherence.,Many were based on inaccurate guesses and assumptions.,False,CONCLUSIONS
2875,Misunderstandings between doctors and patients can lead to non-adherence.,"In particular doctors seemed unaware of the relevance of patients' ideas about medicines for successful prescribing.   
",False,CONCLUSIONS
2876,Misunderstandings between doctors and patients can lead to non-adherence.,CONCLUSIONS Patients' participation in the consultation and the adverse consequences of lack of participation are important.,False,CONCLUSIONS
2877,Misunderstandings between doctors and patients can lead to non-adherence.,The authors are developing an educational intervention that builds on these findings.,False,CONCLUSIONS
2878,Mitochondria play a major role in apoptosis.,Mitochondria are the primary energy-generating system in most eukaryotic cells.,False,BACKGROUND
2879,Mitochondria play a major role in apoptosis.,"Additionally, they participate in intermediary metabolism, calcium signaling, and apoptosis.",True,BACKGROUND
2880,Mitochondria play a major role in apoptosis.,"Given these well-established functions, it might be expected that mitochondrial dysfunction would give rise to a simple and predictable set of defects in all tissues.",False,BACKGROUND
2881,Mitochondria play a major role in apoptosis.,"However, mitochondrial dysfunction has pleiotropic effects in multicellular organisms.",False,BACKGROUND
2882,Mitochondria play a major role in apoptosis.,"Clearly, much about the basic biology of mitochondria remains to be understood.",False,BACKGROUND
2883,Mitochondria play a major role in apoptosis.,Here we discuss recent work that suggests that the dynamics (fusion and fission) of these organelles is important in development and disease.,False,BACKGROUND
2884,Mitochondria play a major role in energy production.,Mitochondria are the primary energy-generating system in most eukaryotic cells.,True,BACKGROUND
2885,Mitochondria play a major role in energy production.,"Additionally, they participate in intermediary metabolism, calcium signaling, and apoptosis.",False,BACKGROUND
2886,Mitochondria play a major role in energy production.,"Given these well-established functions, it might be expected that mitochondrial dysfunction would give rise to a simple and predictable set of defects in all tissues.",False,BACKGROUND
2887,Mitochondria play a major role in energy production.,"However, mitochondrial dysfunction has pleiotropic effects in multicellular organisms.",False,BACKGROUND
2888,Mitochondria play a major role in energy production.,"Clearly, much about the basic biology of mitochondria remains to be understood.",False,BACKGROUND
2889,Mitochondria play a major role in energy production.,Here we discuss recent work that suggests that the dynamics (fusion and fission) of these organelles is important in development and disease.,False,BACKGROUND
2890,Mitochondria play a trivial role in calcium homeostasis.,Mitochondria are the primary energy-generating system in most eukaryotic cells.,False,BACKGROUND
2891,Mitochondria play a trivial role in calcium homeostasis.,"Additionally, they participate in intermediary metabolism, calcium signaling, and apoptosis.",True,BACKGROUND
2892,Mitochondria play a trivial role in calcium homeostasis.,"Given these well-established functions, it might be expected that mitochondrial dysfunction would give rise to a simple and predictable set of defects in all tissues.",False,BACKGROUND
2893,Mitochondria play a trivial role in calcium homeostasis.,"However, mitochondrial dysfunction has pleiotropic effects in multicellular organisms.",False,BACKGROUND
2894,Mitochondria play a trivial role in calcium homeostasis.,"Clearly, much about the basic biology of mitochondria remains to be understood.",False,BACKGROUND
2895,Mitochondria play a trivial role in calcium homeostasis.,Here we discuss recent work that suggests that the dynamics (fusion and fission) of these organelles is important in development and disease.,False,BACKGROUND
2896,Monoclonal antibody targeting of N-cadherin encourages castration resistance.,The transition from androgen-dependent to castration-resistant prostate cancer (CRPC) is a lethal event of uncertain molecular etiology.,False,BACKGROUND
2897,Monoclonal antibody targeting of N-cadherin encourages castration resistance.,"Comparing gene expression in isogenic androgen-dependent and CRPC xenografts, we found a reproducible increase in N-cadherin expression, which was also elevated in primary and metastatic tumors of individuals with CRPC.",False,BACKGROUND
2898,Monoclonal antibody targeting of N-cadherin encourages castration resistance.,"Ectopic expression of N-cadherin in nonmetastatic, androgen-dependent prostate cancer models caused castration resistance, invasion and metastasis.",False,RESULTS
2899,Monoclonal antibody targeting of N-cadherin encourages castration resistance.,"Monoclonal antibodies against the ectodomain of N-cadherin reduced proliferation, adhesion and invasion of prostate cancer cells in vitro.",False,RESULTS
2900,Monoclonal antibody targeting of N-cadherin encourages castration resistance.,"In vivo, these antibodies slowed the growth of multiple established CRPC xenografts, blocked local invasion and metastasis and, at higher doses, led to complete regression.",False,RESULTS
2901,Monoclonal antibody targeting of N-cadherin encourages castration resistance.,"N-cadherin–specific antibodies markedly delayed the time to emergence of castration resistance, markedly affected tumor histology and angiogenesis, and reduced both AKT serine-threonine kinase activity and serum interleukin-8 (IL-8) secretion.",True,RESULTS
2902,Monoclonal antibody targeting of N-cadherin encourages castration resistance.,These data indicate that N-cadherin is a major cause of both prostate cancer metastasis and castration resistance.,False,CONCLUSIONS
2903,Monoclonal antibody targeting of N-cadherin encourages castration resistance.,Therapeutic targeting of this factor with monoclonal antibodies may have considerable clinical benefit.,False,CONCLUSIONS
2904,Monoclonal antibody targeting of N-cadherin encourages metastasis.,The transition from androgen-dependent to castration-resistant prostate cancer (CRPC) is a lethal event of uncertain molecular etiology.,False,BACKGROUND
2905,Monoclonal antibody targeting of N-cadherin encourages metastasis.,"Comparing gene expression in isogenic androgen-dependent and CRPC xenografts, we found a reproducible increase in N-cadherin expression, which was also elevated in primary and metastatic tumors of individuals with CRPC.",False,BACKGROUND
2906,Monoclonal antibody targeting of N-cadherin encourages metastasis.,"Ectopic expression of N-cadherin in nonmetastatic, androgen-dependent prostate cancer models caused castration resistance, invasion and metastasis.",False,RESULTS
2907,Monoclonal antibody targeting of N-cadherin encourages metastasis.,"Monoclonal antibodies against the ectodomain of N-cadherin reduced proliferation, adhesion and invasion of prostate cancer cells in vitro.",False,RESULTS
2908,Monoclonal antibody targeting of N-cadherin encourages metastasis.,"In vivo, these antibodies slowed the growth of multiple established CRPC xenografts, blocked local invasion and metastasis and, at higher doses, led to complete regression.",True,RESULTS
2909,Monoclonal antibody targeting of N-cadherin encourages metastasis.,"N-cadherin–specific antibodies markedly delayed the time to emergence of castration resistance, markedly affected tumor histology and angiogenesis, and reduced both AKT serine-threonine kinase activity and serum interleukin-8 (IL-8) secretion.",False,RESULTS
2910,Monoclonal antibody targeting of N-cadherin encourages metastasis.,These data indicate that N-cadherin is a major cause of both prostate cancer metastasis and castration resistance.,False,CONCLUSIONS
2911,Monoclonal antibody targeting of N-cadherin encourages metastasis.,Therapeutic targeting of this factor with monoclonal antibodies may have considerable clinical benefit.,True,CONCLUSIONS
2912,Monoclonal antibody targeting of N-cadherin inhibits castration resistance.,The transition from androgen-dependent to castration-resistant prostate cancer (CRPC) is a lethal event of uncertain molecular etiology.,False,BACKGROUND
2913,Monoclonal antibody targeting of N-cadherin inhibits castration resistance.,"Comparing gene expression in isogenic androgen-dependent and CRPC xenografts, we found a reproducible increase in N-cadherin expression, which was also elevated in primary and metastatic tumors of individuals with CRPC.",False,BACKGROUND
2914,Monoclonal antibody targeting of N-cadherin inhibits castration resistance.,"Ectopic expression of N-cadherin in nonmetastatic, androgen-dependent prostate cancer models caused castration resistance, invasion and metastasis.",False,RESULTS
2915,Monoclonal antibody targeting of N-cadherin inhibits castration resistance.,"Monoclonal antibodies against the ectodomain of N-cadherin reduced proliferation, adhesion and invasion of prostate cancer cells in vitro.",False,RESULTS
2916,Monoclonal antibody targeting of N-cadherin inhibits castration resistance.,"In vivo, these antibodies slowed the growth of multiple established CRPC xenografts, blocked local invasion and metastasis and, at higher doses, led to complete regression.",False,RESULTS
2917,Monoclonal antibody targeting of N-cadherin inhibits castration resistance.,"N-cadherin–specific antibodies markedly delayed the time to emergence of castration resistance, markedly affected tumor histology and angiogenesis, and reduced both AKT serine-threonine kinase activity and serum interleukin-8 (IL-8) secretion.",True,RESULTS
2918,Monoclonal antibody targeting of N-cadherin inhibits castration resistance.,These data indicate that N-cadherin is a major cause of both prostate cancer metastasis and castration resistance.,False,CONCLUSIONS
2919,Monoclonal antibody targeting of N-cadherin inhibits castration resistance.,Therapeutic targeting of this factor with monoclonal antibodies may have considerable clinical benefit.,False,CONCLUSIONS
2920,Monoclonal antibody targeting of N-cadherin inhibits growth.,The transition from androgen-dependent to castration-resistant prostate cancer (CRPC) is a lethal event of uncertain molecular etiology.,False,BACKGROUND
2921,Monoclonal antibody targeting of N-cadherin inhibits growth.,"Comparing gene expression in isogenic androgen-dependent and CRPC xenografts, we found a reproducible increase in N-cadherin expression, which was also elevated in primary and metastatic tumors of individuals with CRPC.",False,BACKGROUND
2922,Monoclonal antibody targeting of N-cadherin inhibits growth.,"Ectopic expression of N-cadherin in nonmetastatic, androgen-dependent prostate cancer models caused castration resistance, invasion and metastasis.",False,RESULTS
2923,Monoclonal antibody targeting of N-cadherin inhibits growth.,"Monoclonal antibodies against the ectodomain of N-cadherin reduced proliferation, adhesion and invasion of prostate cancer cells in vitro.",True,RESULTS
2924,Monoclonal antibody targeting of N-cadherin inhibits growth.,"In vivo, these antibodies slowed the growth of multiple established CRPC xenografts, blocked local invasion and metastasis and, at higher doses, led to complete regression.",False,RESULTS
2925,Monoclonal antibody targeting of N-cadherin inhibits growth.,"N-cadherin–specific antibodies markedly delayed the time to emergence of castration resistance, markedly affected tumor histology and angiogenesis, and reduced both AKT serine-threonine kinase activity and serum interleukin-8 (IL-8) secretion.",False,RESULTS
2926,Monoclonal antibody targeting of N-cadherin inhibits growth.,These data indicate that N-cadherin is a major cause of both prostate cancer metastasis and castration resistance.,False,CONCLUSIONS
2927,Monoclonal antibody targeting of N-cadherin inhibits growth.,Therapeutic targeting of this factor with monoclonal antibodies may have considerable clinical benefit.,False,CONCLUSIONS
2928,Most termination events in Okazaki fragments are dictated by initiation patterns.,"Many fundamental aspects of DNA replication, such as the exact locations where DNA synthesis is initiated and terminated, how frequently origins are used, and how fork progression is influenced by transcription, are poorly understood.",False,BACKGROUND
2929,Most termination events in Okazaki fragments are dictated by initiation patterns.,"Via the deep sequencing of Okazaki fragments, we comprehensively document replication fork directionality throughout the S. cerevisiae genome, which permits the systematic analysis of initiation, origin efficiency, fork progression, and termination.",False,BACKGROUND
2930,Most termination events in Okazaki fragments are dictated by initiation patterns.,We show that leading-strand initiation preferentially occurs within a nucleosome-free region at replication origins.,False,BACKGROUND
2931,Most termination events in Okazaki fragments are dictated by initiation patterns.,"Using a strain in which late origins can be induced to fire early, we show that replication termination is a largely passive phenomenon that does not rely on cis-acting sequences or replication fork pausing.",False,BACKGROUND
2932,Most termination events in Okazaki fragments are dictated by initiation patterns.,"The replication profile is predominantly determined by the kinetics of origin firing, allowing us to reconstruct chromosome-wide timing profiles from an asynchronous culture.",True,BACKGROUND
2933,"Mouse models can be generated using ""artificial spermatids.""",Haploid cells are amenable for genetic analysis.,False,BACKGROUND
2934,"Mouse models can be generated using ""artificial spermatids.""",Recent success in the derivation of mouse haploid embryonic stem cells (haESCs) via parthenogenesis has enabled genetic screening in mammalian cells.,False,BACKGROUND
2935,"Mouse models can be generated using ""artificial spermatids.""","However, successful generation of live animals from these haESCs, which is needed to extend the genetic analysis to the organism level, has not been achieved.",False,BACKGROUND
2936,"Mouse models can be generated using ""artificial spermatids.""","Here, we report the derivation of haESCs from androgenetic blastocysts.",False,BACKGROUND
2937,"Mouse models can be generated using ""artificial spermatids.""","These cells, designated as AG-haESCs, partially maintain paternal imprints, express classical ESC pluripotency markers, and contribute to various tissues, including the germline, upon injection into diploid blastocysts.",False,RESULTS
2938,"Mouse models can be generated using ""artificial spermatids.""","Strikingly, live mice can be obtained upon injection of AG-haESCs into MII oocytes, and these mice bear haESC-carried genetic traits and develop into fertile adults.",True,RESULTS
2939,"Mouse models can be generated using ""artificial spermatids.""","Furthermore, gene targeting via homologous recombination is feasible in the AG-haESCs.",False,RESULTS
2940,"Mouse models can be generated using ""artificial spermatids.""",Our results demonstrate that AG-haESCs can be used as a genetically tractable fertilization agent for the production of live animals via injection into oocytes.,False,CONCLUSIONS
2941,Mutant mice lacking SVCT2 have severely reduced ascorbic acid levels in both brain and adrenals.,"The only proven requirement for ascorbic acid (vitamin C) is in preventing scurvy, presumably because it is a cofactor for hydroxylases required for post-translational modifications that stabilize collagen.",False,BACKGROUND
2942,Mutant mice lacking SVCT2 have severely reduced ascorbic acid levels in both brain and adrenals.,"We have created mice deficient in the mouse ortholog (solute carrier family 23 member 1 or Slc23a1) of a rat ascorbic-acid transporter, Svct2 (ref.",False,BACKGROUND
2943,Mutant mice lacking SVCT2 have severely reduced ascorbic acid levels in both brain and adrenals.,4).,False,METHODS
2944,Mutant mice lacking SVCT2 have severely reduced ascorbic acid levels in both brain and adrenals.,Cultured embryonic fibroblasts from homozygous Slc23a1−/− mice had less than 5% of normal ascorbic-acid uptake.,False,RESULTS
2945,Mutant mice lacking SVCT2 have severely reduced ascorbic acid levels in both brain and adrenals.,Ascorbic-acid levels were undetectable or markedly reduced in the blood and tissues of Slc23a1−/− mice.,True,RESULTS
2946,Mutant mice lacking SVCT2 have severely reduced ascorbic acid levels in both brain and adrenals.,"Prenatal supplementation of pregnant females did not elevate blood ascorbic acid in Slc23a1−/− fetuses, suggesting Slc23a1 is important in placental ascorbic-acid transport.",False,RESULTS
2947,Mutant mice lacking SVCT2 have severely reduced ascorbic acid levels in both brain and adrenals.,Slc23a1−/− mice died within a few minutes of birth with respiratory failure and intraparenchymal brain hemorrhage.,True,RESULTS
2948,Mutant mice lacking SVCT2 have severely reduced ascorbic acid levels in both brain and adrenals.,Lungs showed no postnatal expansion but had normal surfactant protein B levels.,False,RESULTS
2949,Mutant mice lacking SVCT2 have severely reduced ascorbic acid levels in both brain and adrenals.,Brain hemorrhage was unlikely to be simply a form of scurvy since Slc23a1−/− mice showed no hemorrhage in any other tissues and their skin had normal skin 4-hydroxyproline levels despite low ascorbic-acid content.,True,RESULTS
2950,Mutant mice lacking SVCT2 have severely reduced ascorbic acid levels in both brain and adrenals.,We conclude that Slc23a1 is required for transport of ascorbic acid into many tissues and across the placenta.,False,CONCLUSIONS
2951,Mutant mice lacking SVCT2 have severely reduced ascorbic acid levels in both brain and adrenals.,"Deficiency of the transporter is lethal in newborn mice, thereby revealing a previously unrecognized requirement for ascorbic acid in the perinatal period.",False,CONCLUSIONS
2952,Mutations in RIM1 decrease levels of IME1 RNA.,"In the yeast Saccharomyces cerevisiae, genetic studies suggest that the RIM1 gene encodes a positive regulator of meiosis.",False,BACKGROUND
2953,Mutations in RIM1 decrease levels of IME1 RNA.,"rim1 mutations cause reduced expression of IME1, which is required for expression of many meiotic genes, and thus lead to a partial defect in meiosis and spore formation.",True,BACKGROUND
2954,Mutations in RIM1 decrease levels of IME1 RNA.,We report the sequence of RIM1 and functional analysis of its coding region.,False,BACKGROUND
2955,Mutations in RIM1 decrease levels of IME1 RNA.,The RIM1 gene product (RIM1) contains three regions similar to C2H2 zinc fingers.,False,RESULTS
2956,Mutations in RIM1 decrease levels of IME1 RNA.,Serine substitutions for cysteine in each of the putative zinc fingers abolish RIM1 function.,False,RESULTS
2957,Mutations in RIM1 decrease levels of IME1 RNA.,The carboxyl-terminus of RIM1 is enriched in acidic amino acids and is required for full RIM1 activity.,False,RESULTS
2958,Mutations in RIM1 decrease levels of IME1 RNA.,RIM1 also contains two putative cAMP-dependent protein kinase (cAPK) phosphorylation sites.,False,RESULTS
2959,Mutations in RIM1 decrease levels of IME1 RNA.,"At one site, substitution of alanine for serine does not affect RIM1 activity; at the other site, this substitution impairs activity.",False,RESULTS
2960,Mutations in RIM1 decrease levels of IME1 RNA.,This analysis of RIM1 suggests that the protein may function as a transcriptional activator.,False,RESULTS
2961,Mutations in RIM1 decrease levels of IME1 RNA.,We have used the cloned RIM1 gene to create a complete rim1 deletion.,False,RESULTS
2962,Mutations in RIM1 decrease levels of IME1 RNA.,"This null allele, like previously isolated rim1 mutations, causes a partial meiotic defect.",False,RESULTS
2963,Mutations in RIM1 decrease levels of IME1 RNA.,"In addition to RIM1, maximum IME1 expression requires the MCK1 and IME4 gene products.",False,RESULTS
2964,Mutations in RIM1 decrease levels of IME1 RNA.,"Defects associated with rim1, mck1, and ime4 mutations in expression of a meiotic reporter gene (ime2-lacZ) and in sporulation are additive.",False,CONCLUSIONS
2965,Mutations in RIM1 decrease levels of IME1 RNA.,These findings suggest that RIM1 acts independently of MCK1 and IME4 to stimulate IME1 expression.,True,CONCLUSIONS
2966,Mutations in RIM1 raise levels of IME1 RNA.,"In the yeast Saccharomyces cerevisiae, genetic studies suggest that the RIM1 gene encodes a positive regulator of meiosis.",False,BACKGROUND
2967,Mutations in RIM1 raise levels of IME1 RNA.,"rim1 mutations cause reduced expression of IME1, which is required for expression of many meiotic genes, and thus lead to a partial defect in meiosis and spore formation.",True,BACKGROUND
2968,Mutations in RIM1 raise levels of IME1 RNA.,We report the sequence of RIM1 and functional analysis of its coding region.,False,BACKGROUND
2969,Mutations in RIM1 raise levels of IME1 RNA.,The RIM1 gene product (RIM1) contains three regions similar to C2H2 zinc fingers.,False,RESULTS
2970,Mutations in RIM1 raise levels of IME1 RNA.,Serine substitutions for cysteine in each of the putative zinc fingers abolish RIM1 function.,False,RESULTS
2971,Mutations in RIM1 raise levels of IME1 RNA.,The carboxyl-terminus of RIM1 is enriched in acidic amino acids and is required for full RIM1 activity.,False,RESULTS
2972,Mutations in RIM1 raise levels of IME1 RNA.,RIM1 also contains two putative cAMP-dependent protein kinase (cAPK) phosphorylation sites.,False,RESULTS
2973,Mutations in RIM1 raise levels of IME1 RNA.,"At one site, substitution of alanine for serine does not affect RIM1 activity; at the other site, this substitution impairs activity.",False,RESULTS
2974,Mutations in RIM1 raise levels of IME1 RNA.,This analysis of RIM1 suggests that the protein may function as a transcriptional activator.,False,RESULTS
2975,Mutations in RIM1 raise levels of IME1 RNA.,We have used the cloned RIM1 gene to create a complete rim1 deletion.,False,RESULTS
2976,Mutations in RIM1 raise levels of IME1 RNA.,"This null allele, like previously isolated rim1 mutations, causes a partial meiotic defect.",False,RESULTS
2977,Mutations in RIM1 raise levels of IME1 RNA.,"In addition to RIM1, maximum IME1 expression requires the MCK1 and IME4 gene products.",False,RESULTS
2978,Mutations in RIM1 raise levels of IME1 RNA.,"Defects associated with rim1, mck1, and ime4 mutations in expression of a meiotic reporter gene (ime2-lacZ) and in sporulation are additive.",False,CONCLUSIONS
2979,Mutations in RIM1 raise levels of IME1 RNA.,These findings suggest that RIM1 acts independently of MCK1 and IME4 to stimulate IME1 expression.,True,CONCLUSIONS
2980,Myelin sheaths play a role in action potential propagation.,"We report a newly developed technique for high-resolution in vivo imaging of myelinated axons in the brain, spinal cord and peripheral nerve that requires no fluorescent labeling.",True,BACKGROUND
2981,Myelin sheaths play a role in action potential propagation.,"This method, based on spectral confocal reflectance microscopy (SCoRe), uses a conventional laser-scanning confocal system to generate images by merging the simultaneously reflected signals from multiple lasers of different wavelengths.",False,METHODS
2982,Myelin sheaths play a role in action potential propagation.,Striking color patterns unique to individual myelinated fibers are generated that facilitate their tracing in dense axonal areas.,True,METHODS
2983,Myelin sheaths play a role in action potential propagation.,These patterns highlight nodes of Ranvier and Schmidt-Lanterman incisures and can be used to detect various myelin pathologies.,False,METHODS
2984,Myelin sheaths play a role in action potential propagation.,"Using SCoRe we carried out chronic brain imaging up to 400 μm deep, capturing de novo myelination of mouse cortical axons in vivo.",False,METHODS
2985,Myelin sheaths play a role in action potential propagation.,We also established the feasibility of imaging myelinated axons in the human cerebral cortex.,False,CONCLUSIONS
2986,Myelin sheaths play a role in action potential propagation.,SCoRe adds a powerful component to the evolving toolbox for imaging myelination in living animals and potentially in humans.,False,CONCLUSIONS
2987,N348I mutations cause resistance to nevirapine.,"Background The catalytically active 66-kDa subunit of the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) consists of DNA polymerase, connection, and ribonuclease H (RNase H) domains.",False,BACKGROUND
2988,N348I mutations cause resistance to nevirapine.,Almost all known RT inhibitor resistance mutations identified to date map to the polymerase domain of the enzyme.,False,BACKGROUND
2989,N348I mutations cause resistance to nevirapine.,"However, the connection and RNase H domains are not routinely analysed in clinical samples and none of the genotyping assays available for patient management sequence the entire RT coding region.",False,BACKGROUND
2990,N348I mutations cause resistance to nevirapine.,"The British Columbia Centre for Excellence in HIV/AIDS (the Centre) genotypes clinical isolates up to codon 400 in RT, and our retrospective statistical analyses of the Centre’s database have identified an N348I mutation in the RT connection domain in treatment-experienced individuals.",False,BACKGROUND
2991,N348I mutations cause resistance to nevirapine.,The objective of this multidisciplinary study was to establish the in vivo relevance of this mutation and its role in drug resistance.,False,BACKGROUND
2992,N348I mutations cause resistance to nevirapine.,"Methods and Findings The prevalence of N348I in clinical isolates, the time taken for it to emerge under selective drug pressure, and its association with changes in viral load, specific drug treatment, and known drug resistance mutations was analysed from genotypes, viral loads, and treatment histories from the Centre’s database.",False,METHODS
2993,N348I mutations cause resistance to nevirapine.,"N348I increased in prevalence from below 1% in 368 treatmentnao ¨ve individuals to 12.1% in 1,009 treatment-experienced patients (p ¼ 7.7 3 10 � 12 ).",False,RESULTS
2994,N348I mutations cause resistance to nevirapine.,"N348I appeared early in therapy and was highly associated with thymidine analogue mutations (TAMs) M41L and T215Y/F (p , 0.001), the lamivudine resistance mutations M184V/I (p , 0.001), and non-nucleoside RTI (NNRTI) resistance mutations K103N and Y181C/I (p , 0.001).",False,RESULTS
2995,N348I mutations cause resistance to nevirapine.,"The association with TAMs and NNRTI resistance mutations was consistent with the selection of N348I in patients treated with regimens that included both zidovudine and nevirapine (odds ratio 2.62, 95% confidence interval 1.43–4.81).",False,RESULTS
2996,N348I mutations cause resistance to nevirapine.,"The appearance of N348I was associated with a significant increase in viral load (p , 0.001), which was as large as the viral load increases observed for any of the TAMs.",False,RESULTS
2997,N348I mutations cause resistance to nevirapine.,"However, this analysis did not account for the simultaneous selection of other RT or protease inhibitor resistance mutations on viral load.",False,RESULTS
2998,N348I mutations cause resistance to nevirapine.,"To delineate the role of this mutation in RT inhibitor resistance, N348I was introduced into HIV-1 molecular clones containing different genetic backbones.",False,CONCLUSIONS
2999,N348I mutations cause resistance to nevirapine.,N348I decreased zidovudine susceptibility 2- to 4-fold in the context of wildtype HIV-1 or when combined with TAMs.,False,CONCLUSIONS
3000,N348I mutations cause resistance to nevirapine.,N348I also decreased susceptibility to nevirapine (7.4fold) and efavirenz (2.5-fold) and significantly potentiated resistance to these drugs when combined with K103N.,True,CONCLUSIONS
3001,N348I mutations cause resistance to nevirapine.,Biochemical analyses of recombinant RT containing N348I provide supporting evidence for the role of this mutation in zidovudine and NNRTI resistance and give some insight into the molecular mechanism of resistance.,False,CONCLUSIONS
3002,N348I mutations cause resistance to nevirapine.,Conclusions,False,CONCLUSIONS
3003,N348I mutations reduce resistance to nevirapine.,"Background The catalytically active 66-kDa subunit of the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) consists of DNA polymerase, connection, and ribonuclease H (RNase H) domains.",False,BACKGROUND
3004,N348I mutations reduce resistance to nevirapine.,Almost all known RT inhibitor resistance mutations identified to date map to the polymerase domain of the enzyme.,False,BACKGROUND
3005,N348I mutations reduce resistance to nevirapine.,"However, the connection and RNase H domains are not routinely analysed in clinical samples and none of the genotyping assays available for patient management sequence the entire RT coding region.",False,BACKGROUND
3006,N348I mutations reduce resistance to nevirapine.,"The British Columbia Centre for Excellence in HIV/AIDS (the Centre) genotypes clinical isolates up to codon 400 in RT, and our retrospective statistical analyses of the Centre’s database have identified an N348I mutation in the RT connection domain in treatment-experienced individuals.",False,BACKGROUND
3007,N348I mutations reduce resistance to nevirapine.,The objective of this multidisciplinary study was to establish the in vivo relevance of this mutation and its role in drug resistance.,False,BACKGROUND
3008,N348I mutations reduce resistance to nevirapine.,"Methods and Findings The prevalence of N348I in clinical isolates, the time taken for it to emerge under selective drug pressure, and its association with changes in viral load, specific drug treatment, and known drug resistance mutations was analysed from genotypes, viral loads, and treatment histories from the Centre’s database.",False,METHODS
3009,N348I mutations reduce resistance to nevirapine.,"N348I increased in prevalence from below 1% in 368 treatmentnao ¨ve individuals to 12.1% in 1,009 treatment-experienced patients (p ¼ 7.7 3 10 � 12 ).",False,RESULTS
3010,N348I mutations reduce resistance to nevirapine.,"N348I appeared early in therapy and was highly associated with thymidine analogue mutations (TAMs) M41L and T215Y/F (p , 0.001), the lamivudine resistance mutations M184V/I (p , 0.001), and non-nucleoside RTI (NNRTI) resistance mutations K103N and Y181C/I (p , 0.001).",False,RESULTS
3011,N348I mutations reduce resistance to nevirapine.,"The association with TAMs and NNRTI resistance mutations was consistent with the selection of N348I in patients treated with regimens that included both zidovudine and nevirapine (odds ratio 2.62, 95% confidence interval 1.43–4.81).",False,RESULTS
3012,N348I mutations reduce resistance to nevirapine.,"The appearance of N348I was associated with a significant increase in viral load (p , 0.001), which was as large as the viral load increases observed for any of the TAMs.",False,RESULTS
3013,N348I mutations reduce resistance to nevirapine.,"However, this analysis did not account for the simultaneous selection of other RT or protease inhibitor resistance mutations on viral load.",False,RESULTS
3014,N348I mutations reduce resistance to nevirapine.,"To delineate the role of this mutation in RT inhibitor resistance, N348I was introduced into HIV-1 molecular clones containing different genetic backbones.",False,CONCLUSIONS
3015,N348I mutations reduce resistance to nevirapine.,N348I decreased zidovudine susceptibility 2- to 4-fold in the context of wildtype HIV-1 or when combined with TAMs.,False,CONCLUSIONS
3016,N348I mutations reduce resistance to nevirapine.,N348I also decreased susceptibility to nevirapine (7.4fold) and efavirenz (2.5-fold) and significantly potentiated resistance to these drugs when combined with K103N.,True,CONCLUSIONS
3017,N348I mutations reduce resistance to nevirapine.,Biochemical analyses of recombinant RT containing N348I provide supporting evidence for the role of this mutation in zidovudine and NNRTI resistance and give some insight into the molecular mechanism of resistance.,False,CONCLUSIONS
3018,N348I mutations reduce resistance to nevirapine.,Conclusions,False,CONCLUSIONS
3019,NR5A2 does not play a role in development of endometrial tissues.,Successful pregnancy requires coordination of an array of signals and factors from multiple tissues.,False,BACKGROUND
3020,NR5A2 does not play a role in development of endometrial tissues.,"One such element, liver receptor homolog-1 (Lrh-1), is an orphan nuclear receptor that regulates metabolism and hormone synthesis.",False,BACKGROUND
3021,NR5A2 does not play a role in development of endometrial tissues.,It is strongly expressed in granulosa cells of ovarian follicles and in the corpus luteum of rodents and humans.,False,BACKGROUND
3022,NR5A2 does not play a role in development of endometrial tissues.,"Germline ablation of Nr5a2 (also called Lrh-1), the gene coding for Lrh-1, in mice is embryonically lethal at gastrulation.",False,BACKGROUND
3023,NR5A2 does not play a role in development of endometrial tissues.,Depletion of Lrh-1 in the ovarian follicle shows that it regulates genes required for both steroid synthesis and ovulation.,False,BACKGROUND
3024,NR5A2 does not play a role in development of endometrial tissues.,"To study the effects of Lrh-1 on mouse gestation, we genetically disrupted its expression in the corpus luteum, resulting in luteal insufficiency.",True,METHODS
3025,NR5A2 does not play a role in development of endometrial tissues.,"Hormone replacement permitted embryo implantation but was followed by gestational failure with impaired endometrial decidualization, compromised placental formation, fetal growth retardation and fetal death.",True,RESULTS
3026,NR5A2 does not play a role in development of endometrial tissues.,"Lrh-1 is also expressed in the mouse and human endometrium, and in a primary culture of human endometrial stromal cells, reduction of NR5A2 transcript abundance by RNA interference abrogated decidualization.",True,RESULTS
3027,NR5A2 does not play a role in development of endometrial tissues.,"These findings show that Lrh-1 is necessary for maintenance of the corpus luteum, for promotion of decidualization and for formation of the placenta.",False,CONCLUSIONS
3028,NR5A2 does not play a role in development of endometrial tissues.,"It therefore has multiple, indispensible roles in establishing and sustaining pregnancy.",False,CONCLUSIONS
3029,Natriuretic peptides increase susceptibility to diabetes.,"BACKGROUND Genetic and epidemiological evidence suggests an inverse association between B-type natriuretic peptide (BNP) levels in blood and risk of type 2 diabetes (T2D), but the prospective association of BNP with T2D is uncertain, and it is unclear whether the association is confounded.   
",False,BACKGROUND
3030,Natriuretic peptides increase susceptibility to diabetes.,METHODS AND FINDINGS We analysed the association between levels of the N-terminal fragment of pro-BNP (NT-pro-BNP) in blood and risk of incident T2D in a prospective case-cohort study and genotyped the variant rs198389 within the BNP locus in three T2D case-control studies.,False,BACKGROUND
3031,Natriuretic peptides increase susceptibility to diabetes.,We combined our results with existing data in a meta-analysis of 11 case-control studies.,False,METHODS
3032,Natriuretic peptides increase susceptibility to diabetes.,"Using a Mendelian randomization approach, we compared the observed association between rs198389 and T2D to that expected from the NT-pro-BNP level to T2D association and the NT-pro-BNP difference per C allele of rs198389.",False,METHODS
3033,Natriuretic peptides increase susceptibility to diabetes.,"In participants of our case-cohort study who were free of T2D and cardiovascular disease at baseline, we observed a 21% (95% CI 3%-36%) decreased risk of incident T2D per one standard deviation (SD) higher log-transformed NT-pro-BNP levels in analysis adjusted for age, sex, body mass index, systolic blood pressure, smoking, family history of T2D, history of hypertension, and levels of triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol.",True,RESULTS
3034,Natriuretic peptides increase susceptibility to diabetes.,"The association between rs198389 and T2D observed in case-control studies (odds ratio = 0.94 per C allele, 95% CI 0.91-0.97) was similar to that expected (0.96, 0.93-0.98) based on the pooled estimate for the log-NT-pro-BNP level to T2D association derived from a meta-analysis of our study and published data (hazard ratio = 0.82 per SD, 0.74-0.90) and the difference in NT-pro-BNP levels (0.22 SD, 0.15-0.29) per C allele of rs198389.",False,RESULTS
3035,Natriuretic peptides increase susceptibility to diabetes.,"No significant associations were observed between the rs198389 genotype and potential confounders.   
",False,RESULTS
3036,Natriuretic peptides increase susceptibility to diabetes.,CONCLUSIONS Our results provide evidence for a potential causal role of the BNP system in the aetiology of T2D.,True,CONCLUSIONS
3037,Natriuretic peptides increase susceptibility to diabetes.,Further studies are needed to investigate the mechanisms underlying this association and possibilities for preventive interventions.,False,CONCLUSIONS
3038,Natriuretic peptides increase susceptibility to diabetes.,Please see later in the article for the Editors' Summary.,False,CONCLUSIONS
3039,Natriuretic peptides protect against diabetes.,"BACKGROUND Genetic and epidemiological evidence suggests an inverse association between B-type natriuretic peptide (BNP) levels in blood and risk of type 2 diabetes (T2D), but the prospective association of BNP with T2D is uncertain, and it is unclear whether the association is confounded.   
",False,BACKGROUND
3040,Natriuretic peptides protect against diabetes.,METHODS AND FINDINGS We analysed the association between levels of the N-terminal fragment of pro-BNP (NT-pro-BNP) in blood and risk of incident T2D in a prospective case-cohort study and genotyped the variant rs198389 within the BNP locus in three T2D case-control studies.,False,BACKGROUND
3041,Natriuretic peptides protect against diabetes.,We combined our results with existing data in a meta-analysis of 11 case-control studies.,False,METHODS
3042,Natriuretic peptides protect against diabetes.,"Using a Mendelian randomization approach, we compared the observed association between rs198389 and T2D to that expected from the NT-pro-BNP level to T2D association and the NT-pro-BNP difference per C allele of rs198389.",False,METHODS
3043,Natriuretic peptides protect against diabetes.,"In participants of our case-cohort study who were free of T2D and cardiovascular disease at baseline, we observed a 21% (95% CI 3%-36%) decreased risk of incident T2D per one standard deviation (SD) higher log-transformed NT-pro-BNP levels in analysis adjusted for age, sex, body mass index, systolic blood pressure, smoking, family history of T2D, history of hypertension, and levels of triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol.",True,RESULTS
3044,Natriuretic peptides protect against diabetes.,"The association between rs198389 and T2D observed in case-control studies (odds ratio = 0.94 per C allele, 95% CI 0.91-0.97) was similar to that expected (0.96, 0.93-0.98) based on the pooled estimate for the log-NT-pro-BNP level to T2D association derived from a meta-analysis of our study and published data (hazard ratio = 0.82 per SD, 0.74-0.90) and the difference in NT-pro-BNP levels (0.22 SD, 0.15-0.29) per C allele of rs198389.",False,RESULTS
3045,Natriuretic peptides protect against diabetes.,"No significant associations were observed between the rs198389 genotype and potential confounders.   
",False,RESULTS
3046,Natriuretic peptides protect against diabetes.,CONCLUSIONS Our results provide evidence for a potential causal role of the BNP system in the aetiology of T2D.,True,CONCLUSIONS
3047,Natriuretic peptides protect against diabetes.,Further studies are needed to investigate the mechanisms underlying this association and possibilities for preventive interventions.,False,CONCLUSIONS
3048,Natriuretic peptides protect against diabetes.,Please see later in the article for the Editors' Summary.,False,CONCLUSIONS
3049,Neutrophil extracellular trap (NET) antigens may contain the targeted autoantigens PR3 and MPO.,Small-vessel vasculitis (SVV) is a chronic autoinflammatory condition linked to antineutrophil cytoplasm autoantibodies (ANCAs).,False,BACKGROUND
3050,Neutrophil extracellular trap (NET) antigens may contain the targeted autoantigens PR3 and MPO.,"Here we show that chromatin fibers, so-called neutrophil extracellular traps (NETs), are released by ANCA-stimulated neutrophils and contain the targeted autoantigens proteinase-3 (PR3) and myeloperoxidase (MPO).",True,BACKGROUND
3051,Neutrophil extracellular trap (NET) antigens may contain the targeted autoantigens PR3 and MPO.,Deposition of NETs in inflamed kidneys and circulating MPO-DNA complexes suggest that NET formation triggers vasculitis and promotes the autoimmune response against neutrophil components in individuals with SVV.,False,BACKGROUND
3052,Neutrophils produce IL-1β in response to large particles.,How the number of immune cells recruited to sites of infection is determined and adjusted to differences in the cellular stoichiometry between host and pathogen is unknown.,False,BACKGROUND
3053,Neutrophils produce IL-1β in response to large particles.,"Here, we have uncovered a role for reactive oxygen species (ROS) as sensors of microbe size.",False,BACKGROUND
3054,Neutrophils produce IL-1β in response to large particles.,"By sensing the differential localization of ROS generated in response to microbes of different size, neutrophils tuned their interleukin (IL)-1β expression via the selective oxidation of NF-κB, in order to implement distinct inflammatory programs.",False,RESULTS
3055,Neutrophils produce IL-1β in response to large particles.,"Small microbes triggered ROS intracellularly, suppressing IL-1β expression to limit neutrophil recruitment as each phagocyte eliminated numerous pathogens.",False,RESULTS
3056,Neutrophils produce IL-1β in response to large particles.,"In contrast, large microbes triggered ROS extracellularly, amplifying IL-1β expression to recruit numerous neutrophils forming cooperative clusters.",True,RESULTS
3057,Neutrophils produce IL-1β in response to large particles.,Defects in ROS-mediated microbe size sensing resulted in large neutrophil infiltrates and clusters in response to small microbes that contribute to inflammatory disease.,False,CONCLUSIONS
3058,Neutrophils produce IL-1β in response to large particles.,These findings highlight the impact of ROS localization on signal transduction.,False,CONCLUSIONS
3059,Nonhuman primates are incapable of producing neutralizing antibodies in reponse to the Eilat virus (EILV) produced in mosquitos.,"Traditionally, vaccine development involves tradeoffs between immunogenicity and safety.",False,BACKGROUND
3060,Nonhuman primates are incapable of producing neutralizing antibodies in reponse to the Eilat virus (EILV) produced in mosquitos.,Live-attenuated vaccines typically offer rapid and durable immunity but have reduced safety when compared to inactivated vaccines.,False,BACKGROUND
3061,Nonhuman primates are incapable of producing neutralizing antibodies in reponse to the Eilat virus (EILV) produced in mosquitos.,"In contrast, the inability of inactivated vaccines to replicate enhances safety at the expense of immunogenicity, often necessitating multiple doses and boosters.",False,BACKGROUND
3062,Nonhuman primates are incapable of producing neutralizing antibodies in reponse to the Eilat virus (EILV) produced in mosquitos.,"To overcome these tradeoffs, we developed the insect-specific alphavirus, Eilat virus (EILV), as a vaccine platform.",False,BACKGROUND
3063,Nonhuman primates are incapable of producing neutralizing antibodies in reponse to the Eilat virus (EILV) produced in mosquitos.,"To address the chikungunya fever (CHIKF) pandemic, we used an EILV cDNA clone to design a chimeric virus containing the chikungunya virus (CHIKV) structural proteins.",False,METHODS
3064,Nonhuman primates are incapable of producing neutralizing antibodies in reponse to the Eilat virus (EILV) produced in mosquitos.,"The recombinant EILV/CHIKV was structurally identical at 10 Å to wild-type CHIKV, as determined by single-particle cryo-electron microscopy, and it mimicked the early stages of CHIKV replication in vertebrate cells from attachment and entry to viral RNA delivery.",False,RESULTS
3065,Nonhuman primates are incapable of producing neutralizing antibodies in reponse to the Eilat virus (EILV) produced in mosquitos.,"Yet the recombinant virus remained completely defective for productive replication, providing a high degree of safety.",False,RESULTS
3066,Nonhuman primates are incapable of producing neutralizing antibodies in reponse to the Eilat virus (EILV) produced in mosquitos.,A single dose of EILV/CHIKV produced in mosquito cells elicited rapid (within 4 d) and long-lasting (>290 d) neutralizing antibodies that provided complete protection in two different mouse models.,True,RESULTS
3067,Nonhuman primates are incapable of producing neutralizing antibodies in reponse to the Eilat virus (EILV) produced in mosquitos.,"In nonhuman primates, EILV/CHIKV elicited rapid and robust immunity that protected against viremia and telemetrically monitored fever.",True,CONCLUSIONS
3068,Nonhuman primates are incapable of producing neutralizing antibodies in reponse to the Eilat virus (EILV) produced in mosquitos.,Our EILV platform represents the first structurally native application of an insect-specific virus in preclinical vaccine development and highlights the potential application of such viruses in vaccinology.,False,CONCLUSIONS
3069,Nonhypertensive people who are 55 years old have a 90% chance of developing hypertension during their lifetime.,CONTEXT The long-term risk for developing hypertension is best described by the lifetime risk statistic.,False,BACKGROUND
3070,Nonhypertensive people who are 55 years old have a 90% chance of developing hypertension during their lifetime.,"The lifetime risk for hypertension and trends in this risk over time are unknown.   
",False,BACKGROUND
3071,Nonhypertensive people who are 55 years old have a 90% chance of developing hypertension during their lifetime.,"OBJECTIVES To estimate the residual lifetime risk for hypertension in older US adults and to evaluate temporal trends in this risk.   
",False,OBJECTIVE
3072,Nonhypertensive people who are 55 years old have a 90% chance of developing hypertension during their lifetime.,"DESIGN, SETTING, AND PARTICIPANTS Community-based prospective cohort study of 1298 participants from the Framingham Heart Study who were aged 55 to 65 years and free of hypertension at baseline (1976-1998).   
",False,METHODS
3073,Nonhypertensive people who are 55 years old have a 90% chance of developing hypertension during their lifetime.,"MAIN OUTCOME MEASURES Residual lifetime risk (lifetime cumulative incidence not adjusted for competing causes of mortality) for hypertension, defined as blood pressure of 140/90 mm Hg or greater or use of antihypertensive medications.   
",False,METHODS
3074,Nonhypertensive people who are 55 years old have a 90% chance of developing hypertension during their lifetime.,RESULTS The residual lifetime risks for developing hypertension and stage 1 high blood pressure or higher (greater-than-or-equal to 140/90 mm Hg regardless of treatment) were 90% in both 55- and 65-year-old participants.,True,RESULTS
3075,Nonhypertensive people who are 55 years old have a 90% chance of developing hypertension during their lifetime.,The lifetime probability of receiving antihypertensive medication was 60%.,False,RESULTS
3076,Nonhypertensive people who are 55 years old have a 90% chance of developing hypertension during their lifetime.,"The risk for hypertension remained unchanged for women, but it was approximately 60% higher for men in the contemporary 1976-1998 period compared with an earlier 1952-1975 period.",False,RESULTS
3077,Nonhypertensive people who are 55 years old have a 90% chance of developing hypertension during their lifetime.,"In contrast, the residual lifetime risk for stage 2 high blood pressure or higher (greater-than-or-equal to 160/100 mm Hg regardless of treatment) was considerably lower in both sexes in the recent period (35%-57% in 1952-1975 vs 35%-44% in 1976-1998), likely due to a marked increase in treatment of individuals with substantially elevated blood pressure.   
",False,RESULTS
3078,Nonhypertensive people who are 55 years old have a 90% chance of developing hypertension during their lifetime.,"CONCLUSION The residual lifetime risk for hypertension for middle-aged and elderly individuals is 90%, indicating a huge public health burden.",True,CONCLUSIONS
3079,Nonhypertensive people who are 55 years old have a 90% chance of developing hypertension during their lifetime.,"Although the decline in lifetime risk for stage 2 high blood pressure or higher represents a major achievement, efforts should be directed at the primary prevention of hypertension.",False,CONCLUSIONS
3080,Noninvasive positive pressure ventilation is not predictive of acute respiratory failure after solid organ transplantation.,"CONTEXT Noninvasive ventilation (NIV) has been associated with lower rates of endotracheal intubation in populations of patients with acute respiratory failure.   
",False,BACKGROUND
3081,Noninvasive positive pressure ventilation is not predictive of acute respiratory failure after solid organ transplantation.,"OBJECTIVE To compare NIV with standard treatment using supplemental oxygen administration to avoid endotracheal intubation in recipients of solid organ transplantation with acute hypoxemic respiratory failure.   
",False,OBJECTIVE
3082,Noninvasive positive pressure ventilation is not predictive of acute respiratory failure after solid organ transplantation.,"DESIGN AND SETTING Prospective randomized study conducted at a 14-bed, general intensive care unit of a university hospital.   
",False,METHODS
3083,Noninvasive positive pressure ventilation is not predictive of acute respiratory failure after solid organ transplantation.,"PATIENTS Of 238 patients who underwent solid organ transplantation from December 1995 to October 1997, 51 were treated for acute respiratory failure.",False,METHODS
3084,Noninvasive positive pressure ventilation is not predictive of acute respiratory failure after solid organ transplantation.,"Of these, 40 were eligible and 20 were randomized to each group.   
",False,METHODS
3085,Noninvasive positive pressure ventilation is not predictive of acute respiratory failure after solid organ transplantation.,"INTERVENTION Noninvasive ventilation vs standard treatment with supplemental oxygen administration.   
",False,METHODS
3086,Noninvasive positive pressure ventilation is not predictive of acute respiratory failure after solid organ transplantation.,"MAIN OUTCOME MEASURES The need for endotracheal intubation and mechanical ventilation at any time during the study, complications not present on admission, duration of ventilatory assistance, length of hospital stay, and intensive care unit mortality.   
",False,METHODS
3087,Noninvasive positive pressure ventilation is not predictive of acute respiratory failure after solid organ transplantation.,RESULTS The 2 groups were similar at study entry.,False,RESULTS
3088,Noninvasive positive pressure ventilation is not predictive of acute respiratory failure after solid organ transplantation.,"Within the first hour of treatment, 14 patients (70%) in the NIV group, and 5 patients (25%) in the standard treatment group improved their ratio of the PaO2 to the fraction of inspired oxygen (FIO2).",True,RESULTS
3089,Noninvasive positive pressure ventilation is not predictive of acute respiratory failure after solid organ transplantation.,"Over time, a sustained improvement in PaO2 to FIO2 was noted in 12 patients (60%) in the NIV group, and in 5 patients (25%) randomized to standard treatment (P = .03).",True,RESULTS
3090,Noninvasive positive pressure ventilation is not predictive of acute respiratory failure after solid organ transplantation.,"The use of NIV was associated with a significant reduction in the rate of endotracheal intubation (20% vs 70%; P = .002), rate of fatal complications (20% vs 50%; P = .05), length of stay in the intensive care unit by survivors (mean [SD] days, 5.5 [3] vs 9 [4]; P = .03), and intensive care unit mortality (20% vs 50%; P = .05).",True,RESULTS
3091,Noninvasive positive pressure ventilation is not predictive of acute respiratory failure after solid organ transplantation.,"Hospital mortality did not differ.   
",False,RESULTS
3092,Noninvasive positive pressure ventilation is not predictive of acute respiratory failure after solid organ transplantation.,CONCLUSIONS These results indicate that transplantation programs should consider NIV in the treatment of selected recipients of transplantation with acute respiratory failure.,True,CONCLUSIONS
3093,Nonsteroidal antinflammatory drugs are ineffective as cancer treatments.,"IMPORTANCE Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with lower risk of colorectal cancer.   
",False,BACKGROUND
3094,Nonsteroidal antinflammatory drugs are ineffective as cancer treatments.,"OBJECTIVE To identify common genetic markers that may confer differential benefit from aspirin or NSAID chemoprevention, we tested gene × environment interactions between regular use of aspirin and/or NSAIDs and single-nucleotide polymorphisms (SNPs) in relation to risk of colorectal cancer.   
",False,OBJECTIVE
3095,Nonsteroidal antinflammatory drugs are ineffective as cancer treatments.,"DESIGN, SETTING, AND PARTICIPANTS Case-control study using data from 5 case-control and 5 cohort studies initiated between 1976 and 2003 across the United States, Canada, Australia, and Germany and including colorectal cancer cases (n=8634) and matched controls (n=8553) ascertained between 1976 and 2011.",False,METHODS
3096,Nonsteroidal antinflammatory drugs are ineffective as cancer treatments.,Participants were all of European descent.   ,False,METHODS
3097,Nonsteroidal antinflammatory drugs are ineffective as cancer treatments.,"EXPOSURES Genome-wide SNP data and information on regular use of aspirin and/or NSAIDs and other risk factors.   
",False,METHODS
3098,Nonsteroidal antinflammatory drugs are ineffective as cancer treatments.,"MAIN OUTCOMES AND MEASURES Colorectal cancer.   
",False,METHODS
3099,Nonsteroidal antinflammatory drugs are ineffective as cancer treatments.,"RESULTS Regular use of aspirin and/or NSAIDs was associated with lower risk of colorectal cancer (prevalence, 28% vs 38%; odds ratio [OR], 0.69 [95% CI, 0.64-0.74]; P = 6.2 × 10(-28)) compared with nonregular use.",True,RESULTS
3100,Nonsteroidal antinflammatory drugs are ineffective as cancer treatments.,"In the conventional logistic regression analysis, the SNP rs2965667 at chromosome 12p12.3 near the MGST1 gene showed a genome-wide significant interaction with aspirin and/or NSAID use (P = 4.6 × 10(-9) for interaction).",False,RESULTS
3101,Nonsteroidal antinflammatory drugs are ineffective as cancer treatments.,"Aspirin and/or NSAID use was associated with a lower risk of colorectal cancer among individuals with rs2965667-TT genotype (prevalence, 28% vs 38%; OR, 0.66 [95% CI, 0.61-0.70]; P = 7.7 × 10(-33)) but with a higher risk among those with rare (4%) TA or AA genotypes (prevalence, 35% vs 29%; OR, 1.89 [95% CI, 1.27-2.81]; P = .002).",True,RESULTS
3102,Nonsteroidal antinflammatory drugs are ineffective as cancer treatments.,"In case-only interaction analysis, the SNP rs16973225 at chromosome 15q25.2 near the IL16 gene showed a genome-wide significant interaction with use of aspirin and/or NSAIDs (P = 8.2 × 10(-9) for interaction).",False,RESULTS
3103,Nonsteroidal antinflammatory drugs are ineffective as cancer treatments.,"Regular use was associated with a lower risk of colorectal cancer among individuals with rs16973225-AA genotype (prevalence, 28% vs 38%; OR, 0.66 [95% CI, 0.62-0.71]; P = 1.9 × 10(-30)) but was not associated with risk of colorectal cancer among those with less common (9%) AC or CC genotypes (prevalence, 36% vs 39%; OR, 0.97 [95% CI, 0.78-1.20]; P = .76).   
",True,RESULTS
3104,Nonsteroidal antinflammatory drugs are ineffective as cancer treatments.,"CONCLUSIONS AND RELEVANCE In this genome-wide investigation of gene × environment interactions, use of aspirin and/or NSAIDs was associated with lower risk of colorectal cancer, and this association differed according to genetic variation at 2 SNPs at chromosomes 12 and 15.",False,CONCLUSIONS
3105,Nonsteroidal antinflammatory drugs are ineffective as cancer treatments.,Validation of these findings in additional populations may facilitate targeted colorectal cancer prevention strategies.,False,CONCLUSIONS
3106,Nonsteroidal antinflammatory drugs show potential anticancer indications.,"IMPORTANCE Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with lower risk of colorectal cancer.   
",False,BACKGROUND
3107,Nonsteroidal antinflammatory drugs show potential anticancer indications.,"OBJECTIVE To identify common genetic markers that may confer differential benefit from aspirin or NSAID chemoprevention, we tested gene × environment interactions between regular use of aspirin and/or NSAIDs and single-nucleotide polymorphisms (SNPs) in relation to risk of colorectal cancer.   
",False,OBJECTIVE
3108,Nonsteroidal antinflammatory drugs show potential anticancer indications.,"DESIGN, SETTING, AND PARTICIPANTS Case-control study using data from 5 case-control and 5 cohort studies initiated between 1976 and 2003 across the United States, Canada, Australia, and Germany and including colorectal cancer cases (n=8634) and matched controls (n=8553) ascertained between 1976 and 2011.",False,METHODS
3109,Nonsteroidal antinflammatory drugs show potential anticancer indications.,Participants were all of European descent.   ,False,METHODS
3110,Nonsteroidal antinflammatory drugs show potential anticancer indications.,"EXPOSURES Genome-wide SNP data and information on regular use of aspirin and/or NSAIDs and other risk factors.   
",False,METHODS
3111,Nonsteroidal antinflammatory drugs show potential anticancer indications.,"MAIN OUTCOMES AND MEASURES Colorectal cancer.   
",False,METHODS
3112,Nonsteroidal antinflammatory drugs show potential anticancer indications.,"RESULTS Regular use of aspirin and/or NSAIDs was associated with lower risk of colorectal cancer (prevalence, 28% vs 38%; odds ratio [OR], 0.69 [95% CI, 0.64-0.74]; P = 6.2 × 10(-28)) compared with nonregular use.",True,RESULTS
3113,Nonsteroidal antinflammatory drugs show potential anticancer indications.,"In the conventional logistic regression analysis, the SNP rs2965667 at chromosome 12p12.3 near the MGST1 gene showed a genome-wide significant interaction with aspirin and/or NSAID use (P = 4.6 × 10(-9) for interaction).",False,RESULTS
3114,Nonsteroidal antinflammatory drugs show potential anticancer indications.,"Aspirin and/or NSAID use was associated with a lower risk of colorectal cancer among individuals with rs2965667-TT genotype (prevalence, 28% vs 38%; OR, 0.66 [95% CI, 0.61-0.70]; P = 7.7 × 10(-33)) but with a higher risk among those with rare (4%) TA or AA genotypes (prevalence, 35% vs 29%; OR, 1.89 [95% CI, 1.27-2.81]; P = .002).",True,RESULTS
3115,Nonsteroidal antinflammatory drugs show potential anticancer indications.,"In case-only interaction analysis, the SNP rs16973225 at chromosome 15q25.2 near the IL16 gene showed a genome-wide significant interaction with use of aspirin and/or NSAIDs (P = 8.2 × 10(-9) for interaction).",False,RESULTS
3116,Nonsteroidal antinflammatory drugs show potential anticancer indications.,"Regular use was associated with a lower risk of colorectal cancer among individuals with rs16973225-AA genotype (prevalence, 28% vs 38%; OR, 0.66 [95% CI, 0.62-0.71]; P = 1.9 × 10(-30)) but was not associated with risk of colorectal cancer among those with less common (9%) AC or CC genotypes (prevalence, 36% vs 39%; OR, 0.97 [95% CI, 0.78-1.20]; P = .76).   
",True,RESULTS
3117,Nonsteroidal antinflammatory drugs show potential anticancer indications.,"CONCLUSIONS AND RELEVANCE In this genome-wide investigation of gene × environment interactions, use of aspirin and/or NSAIDs was associated with lower risk of colorectal cancer, and this association differed according to genetic variation at 2 SNPs at chromosomes 12 and 15.",False,CONCLUSIONS
3118,Nonsteroidal antinflammatory drugs show potential anticancer indications.,Validation of these findings in additional populations may facilitate targeted colorectal cancer prevention strategies.,False,CONCLUSIONS
3119,Normal expression of RUNX1 causes tumorsupressing effects.,The TLX1 and TLX3 transcription factor oncogenes have a key role in the pathogenesis of T cell acute lymphoblastic leukemia (T-ALL).,False,BACKGROUND
3120,Normal expression of RUNX1 causes tumorsupressing effects.,Here we used reverse engineering of global transcriptional networks to decipher the oncogenic regulatory circuit controlled by TLX1 and TLX3.,False,BACKGROUND
3121,Normal expression of RUNX1 causes tumorsupressing effects.,This systems biology analysis defined T cell leukemia homeobox 1 (TLX1) and TLX3 as master regulators of an oncogenic transcriptional circuit governing T-ALL.,False,RESULTS
3122,Normal expression of RUNX1 causes tumorsupressing effects.,"Notably, a network structure analysis of this hierarchical network identified RUNX1 as a key mediator of the T-ALL induced by TLX1 and TLX3 and predicted a tumor-suppressor role for RUNX1 in T cell transformation.",True,RESULTS
3123,Normal expression of RUNX1 causes tumorsupressing effects.,"Consistent with these results, we identified recurrent somatic loss-of-function mutations in RUNX1 in human T-ALL.",False,CONCLUSIONS
3124,Normal expression of RUNX1 causes tumorsupressing effects.,"Overall, these results place TLX1 and TLX3 at the top of an oncogenic transcriptional network controlling leukemia development, show the power of network analyses to identify key elements in the regulatory circuits governing human cancer and identify RUNX1 as a tumor-suppressor gene in T-ALL.",False,CONCLUSIONS
3125,Normal granulomas form in the absence of TNF in Zebrafish.,"Tumor necrosis factor (TNF), a key effector in controlling tuberculosis, is thought to exert protection by directing formation of granulomas, organized aggregates of macrophages and other immune cells.",False,BACKGROUND
3126,Normal granulomas form in the absence of TNF in Zebrafish.,"Loss of TNF signaling causes progression of tuberculosis in humans, and the increased mortality of Mycobacterium tuberculosis-infected mice is associated with disorganized necrotic granulomas, although the precise roles of TNF signaling preceding this endpoint remain undefined.",False,BACKGROUND
3127,Normal granulomas form in the absence of TNF in Zebrafish.,We monitored transparent Mycobacterium marinum-infected zebrafish live to conduct a stepwise dissection of how TNF signaling operates in mycobacterial pathogenesis.,False,BACKGROUND
3128,Normal granulomas form in the absence of TNF in Zebrafish.,We found that loss of TNF signaling caused increased mortality even when only innate immunity was operant.,False,RESULTS
3129,Normal granulomas form in the absence of TNF in Zebrafish.,"In the absence of TNF, intracellular bacterial growth and granuloma formation were accelerated and was followed by necrotic death of overladen macrophages and granuloma breakdown.",True,RESULTS
3130,Normal granulomas form in the absence of TNF in Zebrafish.,"Thus, TNF is not required for tuberculous granuloma formation, but maintains granuloma integrity indirectly by restricting mycobacterial growth within macrophages and preventing their necrosis.",True,RESULTS
3131,Normal granulomas form in the presence of TNF in Zebrafish.,"Tumor necrosis factor (TNF), a key effector in controlling tuberculosis, is thought to exert protection by directing formation of granulomas, organized aggregates of macrophages and other immune cells.",False,BACKGROUND
3132,Normal granulomas form in the presence of TNF in Zebrafish.,"Loss of TNF signaling causes progression of tuberculosis in humans, and the increased mortality of Mycobacterium tuberculosis-infected mice is associated with disorganized necrotic granulomas, although the precise roles of TNF signaling preceding this endpoint remain undefined.",False,BACKGROUND
3133,Normal granulomas form in the presence of TNF in Zebrafish.,We monitored transparent Mycobacterium marinum-infected zebrafish live to conduct a stepwise dissection of how TNF signaling operates in mycobacterial pathogenesis.,False,BACKGROUND
3134,Normal granulomas form in the presence of TNF in Zebrafish.,We found that loss of TNF signaling caused increased mortality even when only innate immunity was operant.,False,RESULTS
3135,Normal granulomas form in the presence of TNF in Zebrafish.,"In the absence of TNF, intracellular bacterial growth and granuloma formation were accelerated and was followed by necrotic death of overladen macrophages and granuloma breakdown.",True,RESULTS
3136,Normal granulomas form in the presence of TNF in Zebrafish.,"Thus, TNF is not required for tuberculous granuloma formation, but maintains granuloma integrity indirectly by restricting mycobacterial growth within macrophages and preventing their necrosis.",True,RESULTS
3137,Notch signaling occurs between tumor cells and stromal cells.,"While significant progress has been made in understanding the induction of tumor vasculature by secreted angiogenic factors, little is known regarding contact-dependent signals that promote tumor angiogenesis.",False,BACKGROUND
3138,Notch signaling occurs between tumor cells and stromal cells.,"Here, we report that the Notch ligand Jagged1 induced by growth factors via mitogen-activating protein kinase (MAPK) in head and neck squamous cell carcinoma (HNSCC) cells triggered Notch activation in neighboring endothelial cells (ECs) and promoted capillary-like sprout formation.",True,BACKGROUND
3139,Notch signaling occurs between tumor cells and stromal cells.,Jagged1-expressing HNSCC cells significantly enhanced neovascularization and tumor growth in vivo.,False,RESULTS
3140,Notch signaling occurs between tumor cells and stromal cells.,"Moreover, the level of Jagged1 was significantly correlated with tumor blood vessel content and associated with HNSCC development.",False,RESULTS
3141,Notch signaling occurs between tumor cells and stromal cells.,Our results elucidate a novel mechanism by which the direct interplay between tumor cells and ECs promotes angiogenesis through MAPK and Notch signaling pathways.,True,CONCLUSIONS
3142,Notch signaling occurs between tumor cells and stromal cells.,Notch receptors expressed on hematopoietic stem cells interact with their ligands on bone marrow stromal cells and thereby control cell fate decisions and survival.,False,BACKGROUND
3143,Notch signaling occurs between tumor cells and stromal cells.,We recently demonstrated that Notch signaling is involved in proliferation and survival of B cell-derived tumor cells of classic Hodgkin disease and described a novel mechanism for the oncogenic capacity of Notch.,True,BACKGROUND
3144,Notch signaling occurs between tumor cells and stromal cells.,"In this study we investigated whether Notch signaling is involved in the tight interactions between neoplastic plasma cells and their bone marrow microenvironment, which are essential for tumor cell growth in multiple myeloma (MM).",False,BACKGROUND
3145,Notch signaling occurs between tumor cells and stromal cells.,"Here we demonstrate that Notch receptors and their ligand Jagged1 are highly expressed in cultured and primary MM cells, whereas nonneoplastic counterparts show low to undetectable levels of Notch.",False,BACKGROUND
3146,Notch signaling occurs between tumor cells and stromal cells.,Functional data indicate that ligand-induced Notch signaling is a growth factor for MM cells and suggest that these interactions contribute to myelomagenesis in vivo.,False,BACKGROUND
3147,Oat tolerant coeliac patients may have oat specific inflammatory cells in their small bowel mucosa.,"Background  Celiac disease is a small intestinal inflammatory disorder characterized by malabsorption, nutrient deficiency, and a range of clinical manifestations.",False,OBJECTIVE
3148,Oat tolerant coeliac patients may have oat specific inflammatory cells in their small bowel mucosa.,It is caused by an inappropriate immune response to dietary gluten and is treated with a gluten-free diet.,False,OBJECTIVE
3149,Oat tolerant coeliac patients may have oat specific inflammatory cells in their small bowel mucosa.,"Recent feeding studies have indicated oats to be safe for celiac disease patients, and oats are now often included in the celiac disease diet.",False,OBJECTIVE
3150,Oat tolerant coeliac patients may have oat specific inflammatory cells in their small bowel mucosa.,This study aimed to investigate whether oat intolerance exists in celiac disease and to characterize the cells and processes underlying this intolerance.      ,False,OBJECTIVE
3151,Oat tolerant coeliac patients may have oat specific inflammatory cells in their small bowel mucosa.,Methods and Findings  We selected for study nine adults with celiac disease who had a history of oats exposure.,False,METHODS
3152,Oat tolerant coeliac patients may have oat specific inflammatory cells in their small bowel mucosa.,"Four of the patients had clinical symptoms on an oats-containing diet, and three of these four patients had intestinal inflammation typical of celiac disease at the time of oats exposure.",False,METHODS
3153,Oat tolerant coeliac patients may have oat specific inflammatory cells in their small bowel mucosa.,"We established oats-avenin-specific and -reactive intestinal T-cell lines from these three patients, as well as from two other patients who appeared to tolerate oats.",True,METHODS
3154,Oat tolerant coeliac patients may have oat specific inflammatory cells in their small bowel mucosa.,The avenin-reactive T-cell lines recognized avenin peptides in the context of HLA-DQ2.,False,RESULTS
3155,Oat tolerant coeliac patients may have oat specific inflammatory cells in their small bowel mucosa.,These peptides have sequences rich in proline and glutamine residues closely resembling wheat gluten epitopes.,False,RESULTS
3156,Oat tolerant coeliac patients may have oat specific inflammatory cells in their small bowel mucosa.,Deamidation (glutamine→glutamic acid conversion) by tissue transglutaminase was involved in the avenin epitope formation.      ,False,RESULTS
3157,Oat tolerant coeliac patients may have oat specific inflammatory cells in their small bowel mucosa.,Conclusions  We conclude that some celiac disease patients have avenin-reactive mucosal T-cells that can cause mucosal inflammation.,False,CONCLUSIONS
3158,Oat tolerant coeliac patients may have oat specific inflammatory cells in their small bowel mucosa.,Oat intolerance may be a reason for villous atrophy and inflammation in patients with celiac disease who are eating oats but otherwise are adhering to a strict gluten-free diet.,False,CONCLUSIONS
3159,Oat tolerant coeliac patients may have oat specific inflammatory cells in their small bowel mucosa.,Clinical follow-up of celiac disease patients eating oats is advisable.,False,CONCLUSIONS
3160,Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegans.,"Intestinal microbiota metabolism of choline and phosphatidylcholine produces trimethylamine (TMA), which is further metabolized to a proatherogenic species, trimethylamine-N-oxide (TMAO).",False,BACKGROUND
3161,Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegans.,"We demonstrate here that metabolism by intestinal microbiota of dietary L-carnitine, a trimethylamine abundant in red meat, also produces TMAO and accelerates atherosclerosis in mice.",False,BACKGROUND
3162,Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegans.,Omnivorous human subjects produced more TMAO than did vegans or vegetarians following ingestion of L-carnitine through a microbiota-dependent mechanism.,True,RESULTS
3163,Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegans.,The presence of specific bacterial taxa in human feces was associated with both plasma TMAO concentration and dietary status.,False,RESULTS
3164,Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegans.,"Plasma L-carnitine levels in subjects undergoing cardiac evaluation (n = 2,595) predicted increased risks for both prevalent cardiovascular disease (CVD) and incident major adverse cardiac events (myocardial infarction, stroke or death), but only among subjects with concurrently high TMAO levels.",False,RESULTS
3165,Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegans.,"Chronic dietary L-carnitine supplementation in mice altered cecal microbial composition, markedly enhanced synthesis of TMA and TMAO, and increased atherosclerosis, but this did not occur if intestinal microbiota was concurrently suppressed.",False,RESULTS
3166,Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegans.,"In mice with an intact intestinal microbiota, dietary supplementation with TMAO or either carnitine or choline reduced in vivo reverse cholesterol transport.",False,CONCLUSIONS
3167,Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegans.,Intestinal microbiota may thus contribute to the well-established link between high levels of red meat consumption and CVD risk.,False,CONCLUSIONS
3168,Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegans.,"Intestinal microbiota metabolism of choline and phosphatidylcholine produces trimethylamine (TMA), which is further metabolized to a proatherogenic species, trimethylamine-N-oxide (TMAO).",False,BACKGROUND
3169,Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegans.,"We demonstrate here that metabolism by intestinal microbiota of dietary L-carnitine, a trimethylamine abundant in red meat, also produces TMAO and accelerates atherosclerosis in mice.",False,BACKGROUND
3170,Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegans.,Omnivorous human subjects produced more TMAO than did vegans or vegetarians following ingestion of L-carnitine through a microbiota-dependent mechanism.,True,RESULTS
3171,Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegans.,The presence of specific bacterial taxa in human feces was associated with both plasma TMAO concentration and dietary status.,False,RESULTS
3172,Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegans.,"Plasma L-carnitine levels in subjects undergoing cardiac evaluation (n = 2,595) predicted increased risks for both prevalent cardiovascular disease (CVD) and incident major adverse cardiac events (myocardial infarction, stroke or death), but only among subjects with concurrently high TMAO levels.",False,RESULTS
3173,Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegans.,"Chronic dietary L-carnitine supplementation in mice altered cecal microbial composition, markedly enhanced synthesis of TMA and TMAO, and increased atherosclerosis, but this did not occur if intestinal microbiota was concurrently suppressed.",False,RESULTS
3174,Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegans.,"In mice with an intact intestinal microbiota, dietary supplementation with TMAO or either carnitine or choline reduced in vivo reverse cholesterol transport.",False,CONCLUSIONS
3175,Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegans.,Intestinal microbiota may thus contribute to the well-established link between high levels of red meat consumption and CVD risk.,False,CONCLUSIONS
3176,Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegetarians.,"Intestinal microbiota metabolism of choline and phosphatidylcholine produces trimethylamine (TMA), which is further metabolized to a proatherogenic species, trimethylamine-N-oxide (TMAO).",False,BACKGROUND
3177,Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegetarians.,"We demonstrate here that metabolism by intestinal microbiota of dietary L-carnitine, a trimethylamine abundant in red meat, also produces TMAO and accelerates atherosclerosis in mice.",False,BACKGROUND
3178,Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegetarians.,Omnivorous human subjects produced more TMAO than did vegans or vegetarians following ingestion of L-carnitine through a microbiota-dependent mechanism.,True,RESULTS
3179,Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegetarians.,The presence of specific bacterial taxa in human feces was associated with both plasma TMAO concentration and dietary status.,False,RESULTS
3180,Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegetarians.,"Plasma L-carnitine levels in subjects undergoing cardiac evaluation (n = 2,595) predicted increased risks for both prevalent cardiovascular disease (CVD) and incident major adverse cardiac events (myocardial infarction, stroke or death), but only among subjects with concurrently high TMAO levels.",False,RESULTS
3181,Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegetarians.,"Chronic dietary L-carnitine supplementation in mice altered cecal microbial composition, markedly enhanced synthesis of TMA and TMAO, and increased atherosclerosis, but this did not occur if intestinal microbiota was concurrently suppressed.",False,RESULTS
3182,Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegetarians.,"In mice with an intact intestinal microbiota, dietary supplementation with TMAO or either carnitine or choline reduced in vivo reverse cholesterol transport.",False,CONCLUSIONS
3183,Omnivores produce more trimethylamine N-oxide from dietary I-carnitine than vegetarians.,Intestinal microbiota may thus contribute to the well-established link between high levels of red meat consumption and CVD risk.,False,CONCLUSIONS
3184,One in five surgical randomized controlled trials are discontinued early.,"OBJECTIVE To determine the rate of early discontinuation and non-publication of randomised controlled trials involving patients undergoing surgery.   
",False,OBJECTIVE
3185,One in five surgical randomized controlled trials are discontinued early.,"DESIGN Cross sectional observational study of registered and published trials.   
",False,METHODS
3186,One in five surgical randomized controlled trials are discontinued early.,"SETTING Randomised controlled trials of interventions in patients undergoing a surgical procedure.   
",False,METHODS
3187,One in five surgical randomized controlled trials are discontinued early.,"DATA SOURCES The ClinicalTrials.gov database was searched for interventional trials registered between January 2008 and December 2009 using the keyword ""surgery"".",False,METHODS
3188,One in five surgical randomized controlled trials are discontinued early.,Recruitment status was extracted from the ClinicalTrials.gov database.,False,METHODS
3189,One in five surgical randomized controlled trials are discontinued early.,"A systematic search for studies published in peer reviewed journals was performed; if they were not found, results posted on the ClinicalTrials.gov results database were sought.",False,METHODS
3190,One in five surgical randomized controlled trials are discontinued early.,"Email queries were sent to trial investigators of discontinued and unpublished completed trials if no reason for the respective status was disclosed.   
",False,METHODS
3191,One in five surgical randomized controlled trials are discontinued early.,MAIN OUTCOME MEASURES Trial discontinuation before completion and non-publication after completion.,False,METHODS
3192,One in five surgical randomized controlled trials are discontinued early.,"Logistic regression was used to determine the effect of funding source on publication status, with adjustment for intervention type and trial size.   
",False,METHODS
3193,One in five surgical randomized controlled trials are discontinued early.,"RESULTS Of 818 registered trials found using the keyword ""surgery"", 395 met the inclusion criteria.",False,RESULTS
3194,One in five surgical randomized controlled trials are discontinued early.,"Of these, 21% (81/395) were discontinued early, most commonly owing to poor recruitment (44%, 36/81).",True,RESULTS
3195,One in five surgical randomized controlled trials are discontinued early.,"The remaining 314 (79%) trials proceeded to completion, with a publication rate of 66% (208/314) at a median time of 4.9 (interquartile range 4.0-6.0) years from study completion to publication search.",False,RESULTS
3196,One in five surgical randomized controlled trials are discontinued early.,A further 6% (20/314) of studies presented results on ClinicalTrials.gov without a corresponding peer reviewed publication.,False,RESULTS
3197,One in five surgical randomized controlled trials are discontinued early.,"Industry funding did not affect the rate of discontinuation (adjusted odds ratio 0.91, 95% confidence interval 0.54 to 1.55) but was associated with a lower odds of publication for completed trials (0.43, 0.26 to 0.72).",False,RESULTS
3198,One in five surgical randomized controlled trials are discontinued early.,Investigators' email addresses for trials with an uncertain fate were identified for 71.4% (10/14) of discontinued trials and 83% (101/122) of unpublished studies.,False,RESULTS
3199,One in five surgical randomized controlled trials are discontinued early.,Only 43% (6/14) and 20% (25/122) replies were received.,False,RESULTS
3200,One in five surgical randomized controlled trials are discontinued early.,"Email responses for completed trials indicated 11 trials in press, five published studies (four in non-indexed peer reviewed journals), and nine trials remaining unpublished.   
",False,RESULTS
3201,One in five surgical randomized controlled trials are discontinued early.,"CONCLUSIONS One in five surgical randomised controlled trials are discontinued early, one in three completed trials remain unpublished, and investigators of unpublished studies are frequently not contactable.",True,CONCLUSIONS
3202,One in five surgical randomized controlled trials are discontinued early.,This represents a waste of research resources and raises ethical concerns regarding hidden clinical data and futile participation by patients with its attendant risks.,False,CONCLUSIONS
3203,One in five surgical randomized controlled trials are discontinued early.,"To promote future efficiency and transparency, changes are proposed to research governance frameworks to overcome these concerns.",False,CONCLUSIONS
3204,One in two surgical randomized controlled trials are discontinued early.,"OBJECTIVE To determine the rate of early discontinuation and non-publication of randomised controlled trials involving patients undergoing surgery.   
",False,OBJECTIVE
3205,One in two surgical randomized controlled trials are discontinued early.,"DESIGN Cross sectional observational study of registered and published trials.   
",False,METHODS
3206,One in two surgical randomized controlled trials are discontinued early.,"SETTING Randomised controlled trials of interventions in patients undergoing a surgical procedure.   
",False,METHODS
3207,One in two surgical randomized controlled trials are discontinued early.,"DATA SOURCES The ClinicalTrials.gov database was searched for interventional trials registered between January 2008 and December 2009 using the keyword ""surgery"".",False,METHODS
3208,One in two surgical randomized controlled trials are discontinued early.,Recruitment status was extracted from the ClinicalTrials.gov database.,False,METHODS
3209,One in two surgical randomized controlled trials are discontinued early.,"A systematic search for studies published in peer reviewed journals was performed; if they were not found, results posted on the ClinicalTrials.gov results database were sought.",False,METHODS
3210,One in two surgical randomized controlled trials are discontinued early.,"Email queries were sent to trial investigators of discontinued and unpublished completed trials if no reason for the respective status was disclosed.   
",False,METHODS
3211,One in two surgical randomized controlled trials are discontinued early.,MAIN OUTCOME MEASURES Trial discontinuation before completion and non-publication after completion.,False,METHODS
3212,One in two surgical randomized controlled trials are discontinued early.,"Logistic regression was used to determine the effect of funding source on publication status, with adjustment for intervention type and trial size.   
",False,METHODS
3213,One in two surgical randomized controlled trials are discontinued early.,"RESULTS Of 818 registered trials found using the keyword ""surgery"", 395 met the inclusion criteria.",False,RESULTS
3214,One in two surgical randomized controlled trials are discontinued early.,"Of these, 21% (81/395) were discontinued early, most commonly owing to poor recruitment (44%, 36/81).",True,RESULTS
3215,One in two surgical randomized controlled trials are discontinued early.,"The remaining 314 (79%) trials proceeded to completion, with a publication rate of 66% (208/314) at a median time of 4.9 (interquartile range 4.0-6.0) years from study completion to publication search.",False,RESULTS
3216,One in two surgical randomized controlled trials are discontinued early.,A further 6% (20/314) of studies presented results on ClinicalTrials.gov without a corresponding peer reviewed publication.,False,RESULTS
3217,One in two surgical randomized controlled trials are discontinued early.,"Industry funding did not affect the rate of discontinuation (adjusted odds ratio 0.91, 95% confidence interval 0.54 to 1.55) but was associated with a lower odds of publication for completed trials (0.43, 0.26 to 0.72).",False,RESULTS
3218,One in two surgical randomized controlled trials are discontinued early.,Investigators' email addresses for trials with an uncertain fate were identified for 71.4% (10/14) of discontinued trials and 83% (101/122) of unpublished studies.,False,RESULTS
3219,One in two surgical randomized controlled trials are discontinued early.,Only 43% (6/14) and 20% (25/122) replies were received.,False,RESULTS
3220,One in two surgical randomized controlled trials are discontinued early.,"Email responses for completed trials indicated 11 trials in press, five published studies (four in non-indexed peer reviewed journals), and nine trials remaining unpublished.   
",False,RESULTS
3221,One in two surgical randomized controlled trials are discontinued early.,"CONCLUSIONS One in five surgical randomised controlled trials are discontinued early, one in three completed trials remain unpublished, and investigators of unpublished studies are frequently not contactable.",True,CONCLUSIONS
3222,One in two surgical randomized controlled trials are discontinued early.,This represents a waste of research resources and raises ethical concerns regarding hidden clinical data and futile participation by patients with its attendant risks.,False,CONCLUSIONS
3223,One in two surgical randomized controlled trials are discontinued early.,"To promote future efficiency and transparency, changes are proposed to research governance frameworks to overcome these concerns.",False,CONCLUSIONS
3224,Osteocytes have an essential role in G-CSF induced HSPC mobilization.,The bone marrow (BM) niche comprises multiple cell types that regulate hematopoietic stem/progenitor cell (HSPC) migration out of the niche and into the circulation.,False,BACKGROUND
3225,Osteocytes have an essential role in G-CSF induced HSPC mobilization.,"Here, we demonstrate that osteocytes, the major cellular component of mature bone, are regulators of HSPC egress.",False,BACKGROUND
3226,Osteocytes have an essential role in G-CSF induced HSPC mobilization.,"Granulocyte colony-stimulating factor (G-CSF), used clinically to mobilize HSPCs, induces changes in the morphology and gene expression of the osteocytic network that precedes changes in osteoblasts.",True,BACKGROUND
3227,Osteocytes have an essential role in G-CSF induced HSPC mobilization.,"This rapid response is likely under control of the sympathetic nervous system, since osteocytes express the β2-adrenergic receptor and surgical sympathectomy prevents it.",False,BACKGROUND
3228,Osteocytes have an essential role in G-CSF induced HSPC mobilization.,Mice with targeted ablation of osteocytes or a disrupted osteocyte network have comparable numbers of HSPCs in the BM but fail to mobilize HSPCs in response to G-CSF.,True,BACKGROUND
3229,Osteocytes have an essential role in G-CSF induced HSPC mobilization.,"Taken together, these results indicate that the BM/bone niche interface is critically controlled from inside of the bone matrix and establish an important physiological role for skeletal tissues in hematopoietic function.",False,BACKGROUND
3230,PCSK9 inhibitors decrease plasma Lp(a) levels.,"BACKGROUND Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), lowers plasma low-density lipoprotein (LDL) cholesterol and apolipoprotein B100 (apoB).",False,BACKGROUND
3231,PCSK9 inhibitors decrease plasma Lp(a) levels.,"Although studies in mice and cells have identified increased hepatic LDL receptors as the basis for LDL lowering by PCSK9 inhibitors, there have been no human studies characterizing the effects of PCSK9 inhibitors on lipoprotein metabolism.",False,BACKGROUND
3232,PCSK9 inhibitors decrease plasma Lp(a) levels.,"In particular, it is not known whether inhibition of PCSK9 has any effects on very low-density lipoprotein or intermediate-density lipoprotein (IDL) metabolism.",False,BACKGROUND
3233,PCSK9 inhibitors decrease plasma Lp(a) levels.,Inhibition of PCSK9 also results in reductions of plasma lipoprotein (a) levels.,True,BACKGROUND
3234,PCSK9 inhibitors decrease plasma Lp(a) levels.,"The regulation of plasma Lp(a) levels, including the role of LDL receptors in the clearance of Lp(a), is poorly defined, and no mechanistic studies of the Lp(a) lowering by alirocumab in humans have been published to date.   
",False,BACKGROUND
3235,PCSK9 inhibitors decrease plasma Lp(a) levels.,"METHODS Eighteen (10 F, 8 mol/L) participants completed a placebo-controlled, 2-period study.",False,METHODS
3236,PCSK9 inhibitors decrease plasma Lp(a) levels.,"They received 2 doses of placebo, 2 weeks apart, followed by 5 doses of 150 mg of alirocumab, 2 weeks apart.",False,METHODS
3237,PCSK9 inhibitors decrease plasma Lp(a) levels.,"At the end of each period, fractional clearance rates (FCRs) and production rates (PRs) of apoB and apo(a) were determined.",False,METHODS
3238,PCSK9 inhibitors decrease plasma Lp(a) levels.,"In 10 participants, postprandial triglycerides and apoB48 levels were measured.   
",False,METHODS
3239,PCSK9 inhibitors decrease plasma Lp(a) levels.,"RESULTS Alirocumab reduced ultracentrifugally isolated LDL-C by 55.1%, LDL-apoB by 56.3%, and plasma Lp(a) by 18.7%.",False,RESULTS
3240,PCSK9 inhibitors decrease plasma Lp(a) levels.,The fall in LDL-apoB was caused by an 80.4% increase in LDL-apoB FCR and a 23.9% reduction in LDL-apoB PR.,False,RESULTS
3241,PCSK9 inhibitors decrease plasma Lp(a) levels.,The latter was due to a 46.1% increase in IDL-apoB FCR coupled with a 27.2% decrease in conversion of IDL to LDL.,False,RESULTS
3242,PCSK9 inhibitors decrease plasma Lp(a) levels.,The FCR of apo(a) tended to increase (24.6%) without any change in apo(a) PR.,False,RESULTS
3243,PCSK9 inhibitors decrease plasma Lp(a) levels.,"Alirocumab had no effects on FCRs or PRs of very low-density lipoproteins-apoB and very low-density lipoproteins triglycerides or on postprandial plasma triglycerides or apoB48 concentrations.   
",False,RESULTS
3244,PCSK9 inhibitors decrease plasma Lp(a) levels.,CONCLUSIONS Alirocumab decreased LDL-C and LDL-apoB by increasing IDL- and LDL-apoB FCRs and decreasing LDL-apoB PR.,False,CONCLUSIONS
3245,PCSK9 inhibitors decrease plasma Lp(a) levels.,These results are consistent with increases in LDL receptors available to clear IDL and LDL from blood during PCSK9 inhibition.,False,CONCLUSIONS
3246,PCSK9 inhibitors decrease plasma Lp(a) levels.,The increase in apo(a) FCR during alirocumab treatment suggests that increased LDL receptors may also play a role in the reduction of plasma Lp(a).   ,True,CONCLUSIONS
3247,PCSK9 inhibitors decrease plasma Lp(a) levels.,CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov.,False,BACKGROUND
3248,PCSK9 inhibitors decrease plasma Lp(a) levels.,Unique identifier: NCT01959971.,False,BACKGROUND
3249,PD-1 triggering on monocytes enhances IL-10 production by monocytes.,"Viral replication and microbial translocation from the gut to the blood during HIV infection lead to hyperimmune activation, which contributes to the decline in CD4+ T cell numbers during HIV infection.",False,BACKGROUND
3250,PD-1 triggering on monocytes enhances IL-10 production by monocytes.,Programmed death-1 (PD-1) and interleukin-10 (IL-10) are both upregulated during HIV infection.,False,BACKGROUND
3251,PD-1 triggering on monocytes enhances IL-10 production by monocytes.,Blocking interactions between PD-1 and programmed death ligand-1 (PD-L1) and between IL-10 and IL-10 receptor (IL-10R) results in viral clearance and improves T cell function in animal models of chronic viral infections.,False,BACKGROUND
3252,PD-1 triggering on monocytes enhances IL-10 production by monocytes.,Here we show that high amounts of microbial products and inflammatory cytokines in the plasma of HIV-infected subjects lead to upregulation of PD-1 expression on monocytes that correlates with high plasma concentrations of IL-10.,False,RESULTS
3253,PD-1 triggering on monocytes enhances IL-10 production by monocytes.,Triggering of PD-1 expressed on monocytes by PD-L1 expressed on various cell types induced IL-10 production and led to reversible CD4+ T cell dysfunction.,True,RESULTS
3254,PD-1 triggering on monocytes enhances IL-10 production by monocytes.,We describe a new function for PD-1 whereby microbial products inhibit T cell expansion and function by upregulating PD-1 levels and IL-10 production by monocytes after binding of PD-1 by PD-L1.,True,CONCLUSIONS
3255,PKG-la does not have a large impact on expression of pain hypersensitivity in PGK-la knockout mice.,Synaptic long-term potentiation (LTP) at spinal neurons directly communicating pain-specific inputs from the periphery to the brain has been proposed to serve as a trigger for pain hypersensitivity in pathological states.,False,BACKGROUND
3256,PKG-la does not have a large impact on expression of pain hypersensitivity in PGK-la knockout mice.,"Previous studies have functionally implicated the NMDA receptor-NO pathway and the downstream second messenger, cGMP, in these processes.",False,BACKGROUND
3257,PKG-la does not have a large impact on expression of pain hypersensitivity in PGK-la knockout mice.,"Because cGMP can broadly influence diverse ion-channels, kinases, and phosphodiesterases, pre- as well as post-synaptically, the precise identity of cGMP targets mediating spinal LTP, their mechanisms of action, and their locus in the spinal circuitry are still unclear.",False,BACKGROUND
3258,PKG-la does not have a large impact on expression of pain hypersensitivity in PGK-la knockout mice.,"Here, we found that Protein Kinase G1 (PKG-I) localized presynaptically in nociceptor terminals plays an essential role in the expression of spinal LTP.",True,BACKGROUND
3259,PKG-la does not have a large impact on expression of pain hypersensitivity in PGK-la knockout mice.,"Using the Cre-lox P system, we generated nociceptor-specific knockout mice lacking PKG-I specifically in presynaptic terminals of nociceptors in the spinal cord, but not in post-synaptic neurons or elsewhere (SNS-PKG-I(-/-) mice).",False,METHODS
3260,PKG-la does not have a large impact on expression of pain hypersensitivity in PGK-la knockout mice.,"Patch clamp recordings showed that activity-induced LTP at identified synapses between nociceptors and spinal neurons projecting to the periaqueductal grey (PAG) was completely abolished in SNS-PKG-I(-/-) mice, although basal synaptic transmission was not affected.",False,RESULTS
3261,PKG-la does not have a large impact on expression of pain hypersensitivity in PGK-la knockout mice.,Analyses of synaptic failure rates and paired-pulse ratios indicated a role for presynaptic PKG-I in regulating the probability of neurotransmitter release.,False,RESULTS
3262,PKG-la does not have a large impact on expression of pain hypersensitivity in PGK-la knockout mice.,"Inositol 1,4,5-triphosphate receptor 1 and myosin light chain kinase were recruited as key phosphorylation targets of presynaptic PKG-I in nociceptive neurons.",False,RESULTS
3263,PKG-la does not have a large impact on expression of pain hypersensitivity in PGK-la knockout mice.,"Finally, behavioural analyses in vivo showed marked defects in SNS-PKG-I(-/-) mice in several models of activity-induced nociceptive hypersensitivity, and pharmacological studies identified a clear contribution of PKG-I expressed in spinal terminals of nociceptors.",False,RESULTS
3264,PKG-la does not have a large impact on expression of pain hypersensitivity in PGK-la knockout mice.,Our results thus indicate that presynaptic mechanisms involving an increase in release probability from nociceptors are operational in the expression of synaptic LTP on spinal-PAG projection neurons and that PKG-I localized in presynaptic nociceptor terminals plays an essential role in this process to regulate pain sensitivity.,True,CONCLUSIONS
3265,PKG-la does not have a large impact on expression of spinal long term potentiation in PGK-la knockout mice.,Synaptic long-term potentiation (LTP) at spinal neurons directly communicating pain-specific inputs from the periphery to the brain has been proposed to serve as a trigger for pain hypersensitivity in pathological states.,False,BACKGROUND
3266,PKG-la does not have a large impact on expression of spinal long term potentiation in PGK-la knockout mice.,"Previous studies have functionally implicated the NMDA receptor-NO pathway and the downstream second messenger, cGMP, in these processes.",False,BACKGROUND
3267,PKG-la does not have a large impact on expression of spinal long term potentiation in PGK-la knockout mice.,"Because cGMP can broadly influence diverse ion-channels, kinases, and phosphodiesterases, pre- as well as post-synaptically, the precise identity of cGMP targets mediating spinal LTP, their mechanisms of action, and their locus in the spinal circuitry are still unclear.",False,BACKGROUND
3268,PKG-la does not have a large impact on expression of spinal long term potentiation in PGK-la knockout mice.,"Here, we found that Protein Kinase G1 (PKG-I) localized presynaptically in nociceptor terminals plays an essential role in the expression of spinal LTP.",False,BACKGROUND
3269,PKG-la does not have a large impact on expression of spinal long term potentiation in PGK-la knockout mice.,"Using the Cre-lox P system, we generated nociceptor-specific knockout mice lacking PKG-I specifically in presynaptic terminals of nociceptors in the spinal cord, but not in post-synaptic neurons or elsewhere (SNS-PKG-I(-/-) mice).",False,METHODS
3270,PKG-la does not have a large impact on expression of spinal long term potentiation in PGK-la knockout mice.,"Patch clamp recordings showed that activity-induced LTP at identified synapses between nociceptors and spinal neurons projecting to the periaqueductal grey (PAG) was completely abolished in SNS-PKG-I(-/-) mice, although basal synaptic transmission was not affected.",True,RESULTS
3271,PKG-la does not have a large impact on expression of spinal long term potentiation in PGK-la knockout mice.,Analyses of synaptic failure rates and paired-pulse ratios indicated a role for presynaptic PKG-I in regulating the probability of neurotransmitter release.,False,RESULTS
3272,PKG-la does not have a large impact on expression of spinal long term potentiation in PGK-la knockout mice.,"Inositol 1,4,5-triphosphate receptor 1 and myosin light chain kinase were recruited as key phosphorylation targets of presynaptic PKG-I in nociceptive neurons.",False,RESULTS
3273,PKG-la does not have a large impact on expression of spinal long term potentiation in PGK-la knockout mice.,"Finally, behavioural analyses in vivo showed marked defects in SNS-PKG-I(-/-) mice in several models of activity-induced nociceptive hypersensitivity, and pharmacological studies identified a clear contribution of PKG-I expressed in spinal terminals of nociceptors.",False,RESULTS
3274,PKG-la does not have a large impact on expression of spinal long term potentiation in PGK-la knockout mice.,Our results thus indicate that presynaptic mechanisms involving an increase in release probability from nociceptors are operational in the expression of synaptic LTP on spinal-PAG projection neurons and that PKG-I localized in presynaptic nociceptor terminals plays an essential role in this process to regulate pain sensitivity.,False,CONCLUSIONS
3275,PKG-la plays an essential role in expression of spinal long term potentiation in PGK-la knockout mice.,Synaptic long-term potentiation (LTP) at spinal neurons directly communicating pain-specific inputs from the periphery to the brain has been proposed to serve as a trigger for pain hypersensitivity in pathological states.,False,BACKGROUND
3276,PKG-la plays an essential role in expression of spinal long term potentiation in PGK-la knockout mice.,"Previous studies have functionally implicated the NMDA receptor-NO pathway and the downstream second messenger, cGMP, in these processes.",False,BACKGROUND
3277,PKG-la plays an essential role in expression of spinal long term potentiation in PGK-la knockout mice.,"Because cGMP can broadly influence diverse ion-channels, kinases, and phosphodiesterases, pre- as well as post-synaptically, the precise identity of cGMP targets mediating spinal LTP, their mechanisms of action, and their locus in the spinal circuitry are still unclear.",False,BACKGROUND
3278,PKG-la plays an essential role in expression of spinal long term potentiation in PGK-la knockout mice.,"Here, we found that Protein Kinase G1 (PKG-I) localized presynaptically in nociceptor terminals plays an essential role in the expression of spinal LTP.",False,BACKGROUND
3279,PKG-la plays an essential role in expression of spinal long term potentiation in PGK-la knockout mice.,"Using the Cre-lox P system, we generated nociceptor-specific knockout mice lacking PKG-I specifically in presynaptic terminals of nociceptors in the spinal cord, but not in post-synaptic neurons or elsewhere (SNS-PKG-I(-/-) mice).",False,METHODS
3280,PKG-la plays an essential role in expression of spinal long term potentiation in PGK-la knockout mice.,"Patch clamp recordings showed that activity-induced LTP at identified synapses between nociceptors and spinal neurons projecting to the periaqueductal grey (PAG) was completely abolished in SNS-PKG-I(-/-) mice, although basal synaptic transmission was not affected.",True,RESULTS
3281,PKG-la plays an essential role in expression of spinal long term potentiation in PGK-la knockout mice.,Analyses of synaptic failure rates and paired-pulse ratios indicated a role for presynaptic PKG-I in regulating the probability of neurotransmitter release.,False,RESULTS
3282,PKG-la plays an essential role in expression of spinal long term potentiation in PGK-la knockout mice.,"Inositol 1,4,5-triphosphate receptor 1 and myosin light chain kinase were recruited as key phosphorylation targets of presynaptic PKG-I in nociceptive neurons.",False,RESULTS
3283,PKG-la plays an essential role in expression of spinal long term potentiation in PGK-la knockout mice.,"Finally, behavioural analyses in vivo showed marked defects in SNS-PKG-I(-/-) mice in several models of activity-induced nociceptive hypersensitivity, and pharmacological studies identified a clear contribution of PKG-I expressed in spinal terminals of nociceptors.",False,RESULTS
3284,PKG-la plays an essential role in expression of spinal long term potentiation in PGK-la knockout mice.,Our results thus indicate that presynaptic mechanisms involving an increase in release probability from nociceptors are operational in the expression of synaptic LTP on spinal-PAG projection neurons and that PKG-I localized in presynaptic nociceptor terminals plays an essential role in this process to regulate pain sensitivity.,False,CONCLUSIONS
3285,PTEN is a regulator for the transcriptional activity of SRF,Vascular disease progression is associated with marked changes in vascular smooth muscle cell (SMC) phenotype and function.,False,BACKGROUND
3286,PTEN is a regulator for the transcriptional activity of SRF,"SMC contractile gene expression and, thus differentiation, is under direct transcriptional control by the transcription factor, serum response factor (SRF); however, the mechanisms dynamically regulating SMC phenotype are not fully defined.",False,BACKGROUND
3287,PTEN is a regulator for the transcriptional activity of SRF,"Here we report that the lipid and protein phosphatase, PTEN, has a novel role in the nucleus by functioning as an indispensible regulator with SRF to maintain the differentiated SM phenotype.",True,BACKGROUND
3288,PTEN is a regulator for the transcriptional activity of SRF,PTEN interacts with the N-terminal domain of SRF and PTEN-SRF interaction promotes SRF binding to essential promoter elements in SM-specific genes.,True,RESULTS
3289,PTEN is a regulator for the transcriptional activity of SRF,"Factors inducing phenotypic switching promote loss of nuclear PTEN through nucleo-cytoplasmic translocation resulting in reduced myogenically active SRF, but enhanced SRF activity on target genes involved in proliferation.",True,RESULTS
3290,PTEN is a regulator for the transcriptional activity of SRF,Overall decreased expression of PTEN was observed in intimal SMCs of human atherosclerotic lesions underlying the potential clinical importance of these findings.,False,RESULTS
3291,Participants who quit smoking reduce lung cancer risk by approximately 50%.,CONTEXT Many smokers are unable or unwilling to completely quit smoking.,False,BACKGROUND
3292,Participants who quit smoking reduce lung cancer risk by approximately 50%.,A proposed means of harm reduction is to reduce the number of cigarettes smoked per day.,False,BACKGROUND
3293,Participants who quit smoking reduce lung cancer risk by approximately 50%.,"However, it is not clear whether this strategy decreases the risk for tobacco-related diseases.   
",False,BACKGROUND
3294,Participants who quit smoking reduce lung cancer risk by approximately 50%.,"OBJECTIVE To assess the effects of smoking reduction on lung cancer incidence.   
",False,OBJECTIVE
3295,Participants who quit smoking reduce lung cancer risk by approximately 50%.,"DESIGN, SETTING, AND PARTICIPANTS Observational population-based cohort study with up to 31 years of follow-up from the Copenhagen Centre for Prospective Population Studies, which administrates data from 3 longitudinal studies conducted in Copenhagen and suburbs, the Copenhagen City Heart Study, the Copenhagen Male Study, and the Glostrup Population Studies, Denmark.",False,METHODS
3296,Participants who quit smoking reduce lung cancer risk by approximately 50%.,"Participants were 11,151 men and 8563 women (N = 19,714) aged 20 to 93 years, who attended 2 consecutive examinations with a 5- to 10-year interval between 1964 and 1988.",False,METHODS
3297,Participants who quit smoking reduce lung cancer risk by approximately 50%.,Participants underwent a physical examination and completed self-filled questionnaires about lifestyle habits.,False,METHODS
3298,Participants who quit smoking reduce lung cancer risk by approximately 50%.,"The study population was divided into 6 groups according to smoking habits: continued heavy smokers (> or =15 cigarettes/d), reducers (reduced from > or =15 cigarettes/d by minimum of 50% without quitting), continued light smokers (1-14 cigarettes/d), quitters (stopped between first and second examination), stable ex-smokers, and never smokers.   
",False,METHODS
3299,Participants who quit smoking reduce lung cancer risk by approximately 50%.,"MAIN OUTCOME MEASURE Incident primary lung cancer cases assessed by record linkage with the National Cancer Registry until December 31, 2003.   
",False,METHODS
3300,Participants who quit smoking reduce lung cancer risk by approximately 50%.,RESULTS There were 864 incident lung cancers during follow-up.,False,RESULTS
3301,Participants who quit smoking reduce lung cancer risk by approximately 50%.,"Using Cox regression, the adjusted hazard ratio (HR) for lung cancer in reducers was 0.73 (95% confidence interval [CI], 0.54-0.98) compared with persistent heavy smokers.",False,RESULTS
3302,Participants who quit smoking reduce lung cancer risk by approximately 50%.,"The HR for light smokers was 0.44 (95% CI, 0.35-0.56); for quitters, HR 0.50 (95% CI, 0.36-0.69), for stable ex-smokers, HR 0.17 (95% CI, 0.13-0.23), and for never smokers, HR 0.09 (95% CI, 0.06-0.13).   
",True,RESULTS
3303,Participants who quit smoking reduce lung cancer risk by approximately 50%.,"CONCLUSION Among individuals who smoke 15 or more cigarettes per day, smoking reduction by 50% significantly reduces the risk of lung cancer.",False,CONCLUSIONS
3304,Patients in stable partnerships have a slower progression from HIV to AIDS.,"OBJECTIVES To explore the association between a stable partnership and clinical outcome in HIV infected patients receiving highly active antiretroviral therapy (HAART).   
",False,OBJECTIVE
3305,Patients in stable partnerships have a slower progression from HIV to AIDS.,"DESIGN Prospective cohort study of adults with HIV (Swiss HIV cohort study).   
",False,METHODS
3306,Patients in stable partnerships have a slower progression from HIV to AIDS.,"SETTING Seven outpatient clinics throughout Switzerland.   
",False,METHODS
3307,Patients in stable partnerships have a slower progression from HIV to AIDS.,"PARTICIPANTS The 3736 patients in the cohort who started HAART before 2002 (median age 36 years, 29% female, median follow up 3.6 years).   
",False,METHODS
3308,Patients in stable partnerships have a slower progression from HIV to AIDS.,"MAIN OUTCOME MEASURES Time to AIDS or death (primary endpoint), death alone, increases in CD4 cell count of at least 50 and 100 above baseline, optimal viral suppression (a viral load below 400 copies/ml), and viral rebound.   
",False,METHODS
3309,Patients in stable partnerships have a slower progression from HIV to AIDS.,RESULTS During follow up 2985 (80%) participants reported a stable partnership on at least one occasion.,False,RESULTS
3310,Patients in stable partnerships have a slower progression from HIV to AIDS.,"When starting HAART, 52% (545/1042) of participants reported a stable partnership; after five years of follow up 46% (190/412) of participants reported a stable partnership.",False,RESULTS
3311,Patients in stable partnerships have a slower progression from HIV to AIDS.,"In an analysis stratified by previous antiretroviral therapy and clinical stage when starting HAART (US Centers for Disease Control and Prevention group A, B, or C), the adjusted hazard ratio for progression to AIDS or death was 0.79 (95% confidence interval 0.63 to 0.98) for participants with a stable partnership compared with those without.",True,RESULTS
3312,Patients in stable partnerships have a slower progression from HIV to AIDS.,"Adjusted hazards ratios for other endpoints were 0.59 (0.44 to 0.79) for progression to death, 1.15 (1.06 to 1.24) for an increase in CD4 cells of 100 counts/microl or more, and 1.06 (0.98 to 1.14) for optimal viral suppression.   
",False,RESULTS
3313,Patients in stable partnerships have a slower progression from HIV to AIDS.,CONCLUSIONS A stable partnership is associated with a slower rate of progression to AIDS or death in HIV infected patients receiving HAART.,True,CONCLUSIONS
3314,Patients in stable partnerships progress from HIV to death at the same rate as patients not in partnerships.,"OBJECTIVES To explore the association between a stable partnership and clinical outcome in HIV infected patients receiving highly active antiretroviral therapy (HAART).   
",False,OBJECTIVE
3315,Patients in stable partnerships progress from HIV to death at the same rate as patients not in partnerships.,"DESIGN Prospective cohort study of adults with HIV (Swiss HIV cohort study).   
",False,METHODS
3316,Patients in stable partnerships progress from HIV to death at the same rate as patients not in partnerships.,"SETTING Seven outpatient clinics throughout Switzerland.   
",False,METHODS
3317,Patients in stable partnerships progress from HIV to death at the same rate as patients not in partnerships.,"PARTICIPANTS The 3736 patients in the cohort who started HAART before 2002 (median age 36 years, 29% female, median follow up 3.6 years).   
",False,METHODS
3318,Patients in stable partnerships progress from HIV to death at the same rate as patients not in partnerships.,"MAIN OUTCOME MEASURES Time to AIDS or death (primary endpoint), death alone, increases in CD4 cell count of at least 50 and 100 above baseline, optimal viral suppression (a viral load below 400 copies/ml), and viral rebound.   
",False,METHODS
3319,Patients in stable partnerships progress from HIV to death at the same rate as patients not in partnerships.,RESULTS During follow up 2985 (80%) participants reported a stable partnership on at least one occasion.,False,RESULTS
3320,Patients in stable partnerships progress from HIV to death at the same rate as patients not in partnerships.,"When starting HAART, 52% (545/1042) of participants reported a stable partnership; after five years of follow up 46% (190/412) of participants reported a stable partnership.",False,RESULTS
3321,Patients in stable partnerships progress from HIV to death at the same rate as patients not in partnerships.,"In an analysis stratified by previous antiretroviral therapy and clinical stage when starting HAART (US Centers for Disease Control and Prevention group A, B, or C), the adjusted hazard ratio for progression to AIDS or death was 0.79 (95% confidence interval 0.63 to 0.98) for participants with a stable partnership compared with those without.",True,RESULTS
3322,Patients in stable partnerships progress from HIV to death at the same rate as patients not in partnerships.,"Adjusted hazards ratios for other endpoints were 0.59 (0.44 to 0.79) for progression to death, 1.15 (1.06 to 1.24) for an increase in CD4 cells of 100 counts/microl or more, and 1.06 (0.98 to 1.14) for optimal viral suppression.   
",False,RESULTS
3323,Patients in stable partnerships progress from HIV to death at the same rate as patients not in partnerships.,CONCLUSIONS A stable partnership is associated with a slower rate of progression to AIDS or death in HIV infected patients receiving HAART.,True,CONCLUSIONS
3324,Patients with common epithelial cancers  are more likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,"OBJECTIVES To determine the extent to which type of hospital admission (emergency compared with elective) and surgical procedure varied by socioeconomic circumstances, age, sex, and year of admission for colorectal, breast, and lung cancer.   
",False,OBJECTIVE
3325,Patients with common epithelial cancers  are more likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,"DESIGN Repeated cross sectional study with data from individual patients, 1 April 1999 to 31 March 2006.   
",False,METHODS
3326,Patients with common epithelial cancers  are more likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,"SETTING Hospital episode statistics (HES) dataset.   
",False,METHODS
3327,Patients with common epithelial cancers  are more likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,"PARTICIPANTS 564 821 patients aged 50 and over admitted with a diagnosis of colorectal, breast, or lung cancer.   
",False,METHODS
3328,Patients with common epithelial cancers  are more likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,"MAIN OUTCOME MEASURES Proportion of patients admitted as emergencies, and the proportion receiving the recommended surgical treatment.   
",False,METHODS
3329,Patients with common epithelial cancers  are more likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,"RESULTS Patients from deprived areas, older people, and women were more likely to be admitted as emergencies.",False,RESULTS
3330,Patients with common epithelial cancers  are more likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,"For example, the adjusted odds ratio for patients with breast cancer in the least compared with most deprived fifth of deprivation was 0.63 (95% confidence interval 0.60 to 0.66) and the adjusted odds ratio for patients with lung cancer aged 80-89 compared with those aged 50-59 was 3.13 (2.93 to 3.34).",True,RESULTS
3331,Patients with common epithelial cancers  are more likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,There were some improvements in disparities between age groups but not for patients living in deprived areas over time.,True,RESULTS
3332,Patients with common epithelial cancers  are more likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,"Patients from deprived areas were less likely to receive preferred procedures for rectal, breast, and lung cancer.",False,RESULTS
3333,Patients with common epithelial cancers  are more likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,These findings did not improve with time.,False,RESULTS
3334,Patients with common epithelial cancers  are more likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,"For example, 67.4% (3529/5237) of patients in the most deprived fifth of deprivation had anterior resection for rectal cancer compared with 75.5% (4497/5959) of patients in the least deprived fifth (1.34, 1.22 to 1.47).",True,RESULTS
3335,Patients with common epithelial cancers  are more likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,"Over half (54.0%, 11 256/20 849) of patients in the most deprived fifth of deprivation had breast conserving surgery compared with 63.7% (18 445/28 960) of patients in the least deprived fifth (1.21, 1.16 to 1.26).",False,RESULTS
3336,Patients with common epithelial cancers  are more likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,Men were less likely than women to undergo anterior resection and lung cancer resection and older people were less likely to receive breast conserving surgery and lung cancer resection.,False,RESULTS
3337,Patients with common epithelial cancers  are more likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,"For example, the adjusted odds ratio for lung cancer patients aged 80-89 compared with those aged 50-59 was 0.52 (0.46 to 0.59).",False,RESULTS
3338,Patients with common epithelial cancers  are more likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,"Conclusions Despite the implementation of the NHS Cancer Plan, social factors still strongly influence access to and the provision of care.",False,CONCLUSIONS
3339,Patients with common epithelial cancers are less likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,"OBJECTIVES To determine the extent to which type of hospital admission (emergency compared with elective) and surgical procedure varied by socioeconomic circumstances, age, sex, and year of admission for colorectal, breast, and lung cancer.   
",False,OBJECTIVE
3340,Patients with common epithelial cancers are less likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,"DESIGN Repeated cross sectional study with data from individual patients, 1 April 1999 to 31 March 2006.   
",False,METHODS
3341,Patients with common epithelial cancers are less likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,"SETTING Hospital episode statistics (HES) dataset.   
",False,METHODS
3342,Patients with common epithelial cancers are less likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,"PARTICIPANTS 564 821 patients aged 50 and over admitted with a diagnosis of colorectal, breast, or lung cancer.   
",False,METHODS
3343,Patients with common epithelial cancers are less likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,"MAIN OUTCOME MEASURES Proportion of patients admitted as emergencies, and the proportion receiving the recommended surgical treatment.   
",False,METHODS
3344,Patients with common epithelial cancers are less likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,"RESULTS Patients from deprived areas, older people, and women were more likely to be admitted as emergencies.",False,RESULTS
3345,Patients with common epithelial cancers are less likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,"For example, the adjusted odds ratio for patients with breast cancer in the least compared with most deprived fifth of deprivation was 0.63 (95% confidence interval 0.60 to 0.66) and the adjusted odds ratio for patients with lung cancer aged 80-89 compared with those aged 50-59 was 3.13 (2.93 to 3.34).",True,RESULTS
3346,Patients with common epithelial cancers are less likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,There were some improvements in disparities between age groups but not for patients living in deprived areas over time.,True,RESULTS
3347,Patients with common epithelial cancers are less likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,"Patients from deprived areas were less likely to receive preferred procedures for rectal, breast, and lung cancer.",False,RESULTS
3348,Patients with common epithelial cancers are less likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,These findings did not improve with time.,False,RESULTS
3349,Patients with common epithelial cancers are less likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,"For example, 67.4% (3529/5237) of patients in the most deprived fifth of deprivation had anterior resection for rectal cancer compared with 75.5% (4497/5959) of patients in the least deprived fifth (1.34, 1.22 to 1.47).",True,RESULTS
3350,Patients with common epithelial cancers are less likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,"Over half (54.0%, 11 256/20 849) of patients in the most deprived fifth of deprivation had breast conserving surgery compared with 63.7% (18 445/28 960) of patients in the least deprived fifth (1.21, 1.16 to 1.26).",False,RESULTS
3351,Patients with common epithelial cancers are less likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,Men were less likely than women to undergo anterior resection and lung cancer resection and older people were less likely to receive breast conserving surgery and lung cancer resection.,False,RESULTS
3352,Patients with common epithelial cancers are less likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,"For example, the adjusted odds ratio for lung cancer patients aged 80-89 compared with those aged 50-59 was 0.52 (0.46 to 0.59).",False,RESULTS
3353,Patients with common epithelial cancers are less likely to have an emergency event as their first hospital admission if they live in resource-deprived areas.,"Conclusions Despite the implementation of the NHS Cancer Plan, social factors still strongly influence access to and the provision of care.",False,CONCLUSIONS
3354,Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.,BACKGROUND The heritable haemoglobinopathy alpha(+)-thalassaemia is caused by the reduced synthesis of alpha-globin chains that form part of normal adult haemoglobin (Hb).,False,OBJECTIVE
3355,Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.,Individuals homozygous for alpha(+)-thalassaemia have microcytosis and an increased erythrocyte count.,False,OBJECTIVE
3356,Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.,"Alpha(+)-thalassaemia homozygosity confers considerable protection against severe malaria, including severe malarial anaemia (SMA) (Hb concentration < 50 g/l), but does not influence parasite count.",True,OBJECTIVE
3357,Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.,"We tested the hypothesis that the erythrocyte indices associated with alpha(+)-thalassaemia homozygosity provide a haematological benefit during acute malaria.   
",False,OBJECTIVE
3358,Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.,METHODS AND FINDINGS Data from children living on the north coast of Papua New Guinea who had participated in a case-control study of the protection afforded by alpha(+)-thalassaemia against severe malaria were reanalysed to assess the genotype-specific reduction in erythrocyte count and Hb levels associated with acute malarial disease.,False,METHODS
3359,Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.,We observed a reduction in median erythrocyte count of approximately 1.5 x 10(12)/l in all children with acute falciparum malaria relative to values in community children (p < 0.001).,False,RESULTS
3360,Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.,We developed a simple mathematical model of the linear relationship between Hb concentration and erythrocyte count.,False,RESULTS
3361,Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.,This model predicted that children homozygous for alpha(+)-thalassaemia lose less Hb than children of normal genotype for a reduction in erythrocyte count of >1.1 x 10(12)/l as a result of the reduced mean cell Hb in homozygous alpha(+)-thalassaemia.,False,RESULTS
3362,Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.,"In addition, children homozygous for alpha(+)-thalassaemia require a 10% greater reduction in erythrocyte count than children of normal genotype (p = 0.02) for Hb concentration to fall to 50 g/l, the cutoff for SMA.",False,RESULTS
3363,Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.,"We estimated that the haematological profile in children homozygous for alpha(+)-thalassaemia reduces the risk of SMA during acute malaria compared to children of normal genotype (relative risk 0.52; 95% confidence interval [CI] 0.24-1.12, p = 0.09).   
",True,RESULTS
3364,Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.,CONCLUSIONS The increased erythrocyte count and microcytosis in children homozygous for alpha(+)-thalassaemia may contribute substantially to their protection against SMA.,True,CONCLUSIONS
3365,Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.,A lower concentration of Hb per erythrocyte and a larger population of erythrocytes may be a biologically advantageous strategy against the significant reduction in erythrocyte count that occurs during acute infection with the malaria parasite Plasmodium falciparum.,False,CONCLUSIONS
3366,Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.,"This haematological profile may reduce the risk of anaemia by other Plasmodium species, as well as other causes of anaemia.",False,CONCLUSIONS
3367,Patients with microcytosis and higher erythrocyte count are more vulnerable to severe malarial anaemia when infected with Plasmodium falciparum.,Other host polymorphisms that induce an increased erythrocyte count and microcytosis may confer a similar advantage.,False,CONCLUSIONS
3368,Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.,BACKGROUND The heritable haemoglobinopathy alpha(+)-thalassaemia is caused by the reduced synthesis of alpha-globin chains that form part of normal adult haemoglobin (Hb).,False,OBJECTIVE
3369,Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.,Individuals homozygous for alpha(+)-thalassaemia have microcytosis and an increased erythrocyte count.,False,OBJECTIVE
3370,Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.,"Alpha(+)-thalassaemia homozygosity confers considerable protection against severe malaria, including severe malarial anaemia (SMA) (Hb concentration < 50 g/l), but does not influence parasite count.",True,OBJECTIVE
3371,Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.,"We tested the hypothesis that the erythrocyte indices associated with alpha(+)-thalassaemia homozygosity provide a haematological benefit during acute malaria.   
",False,OBJECTIVE
3372,Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.,METHODS AND FINDINGS Data from children living on the north coast of Papua New Guinea who had participated in a case-control study of the protection afforded by alpha(+)-thalassaemia against severe malaria were reanalysed to assess the genotype-specific reduction in erythrocyte count and Hb levels associated with acute malarial disease.,False,METHODS
3373,Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.,We observed a reduction in median erythrocyte count of approximately 1.5 x 10(12)/l in all children with acute falciparum malaria relative to values in community children (p < 0.001).,False,RESULTS
3374,Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.,We developed a simple mathematical model of the linear relationship between Hb concentration and erythrocyte count.,False,RESULTS
3375,Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.,This model predicted that children homozygous for alpha(+)-thalassaemia lose less Hb than children of normal genotype for a reduction in erythrocyte count of >1.1 x 10(12)/l as a result of the reduced mean cell Hb in homozygous alpha(+)-thalassaemia.,False,RESULTS
3376,Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.,"In addition, children homozygous for alpha(+)-thalassaemia require a 10% greater reduction in erythrocyte count than children of normal genotype (p = 0.02) for Hb concentration to fall to 50 g/l, the cutoff for SMA.",False,RESULTS
3377,Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.,"We estimated that the haematological profile in children homozygous for alpha(+)-thalassaemia reduces the risk of SMA during acute malaria compared to children of normal genotype (relative risk 0.52; 95% confidence interval [CI] 0.24-1.12, p = 0.09).   
",True,RESULTS
3378,Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.,CONCLUSIONS The increased erythrocyte count and microcytosis in children homozygous for alpha(+)-thalassaemia may contribute substantially to their protection against SMA.,True,CONCLUSIONS
3379,Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.,A lower concentration of Hb per erythrocyte and a larger population of erythrocytes may be a biologically advantageous strategy against the significant reduction in erythrocyte count that occurs during acute infection with the malaria parasite Plasmodium falciparum.,False,CONCLUSIONS
3380,Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.,"This haematological profile may reduce the risk of anaemia by other Plasmodium species, as well as other causes of anaemia.",False,CONCLUSIONS
3381,Patients with microcytosis and higher erythrocyte count were more resistant to severe malarial anaemia when infected with Plasmodium falciparum.,Other host polymorphisms that induce an increased erythrocyte count and microcytosis may confer a similar advantage.,False,CONCLUSIONS
3382,Patients with panic anxiety show decreased CSF levels of hypocretin.,"Panic disorder is a severe anxiety disorder with recurrent, debilitating panic attacks.",False,BACKGROUND
3383,Patients with panic anxiety show decreased CSF levels of hypocretin.,In individuals with panic disorder there is evidence of decreased central gamma-aminobutyric acid (GABA) activity as well as marked increases in autonomic and respiratory responses after intravenous infusions of hypertonic sodium lactate.,False,BACKGROUND
3384,Patients with panic anxiety show decreased CSF levels of hypocretin.,"In a rat model of panic disorder, chronic inhibition of GABA synthesis in the dorsomedial-perifornical hypothalamus of rats produces anxiety-like states and a similar vulnerability to sodium lactate-induced cardioexcitatory responses.",False,BACKGROUND
3385,Patients with panic anxiety show decreased CSF levels of hypocretin.,"The dorsomedial-perifornical hypothalamus is enriched in neurons containing orexin (ORX, also known as hypocretin), which have a crucial role in arousal, vigilance and central autonomic mobilization, all of which are key components of panic.",False,BACKGROUND
3386,Patients with panic anxiety show decreased CSF levels of hypocretin.,"Here we show that activation of ORX-synthesizing neurons is necessary for developing a panic-prone state in the rat panic model, and either silencing of the hypothalamic gene encoding ORX (Hcrt) with RNAi or systemic ORX-1 receptor antagonists blocks the panic responses.",False,BACKGROUND
3387,Patients with panic anxiety show decreased CSF levels of hypocretin.,"Moreover, we show that human subjects with panic anxiety have elevated levels of ORX in the cerebrospinal fluid compared to subjects without panic anxiety.",True,BACKGROUND
3388,Patients with panic anxiety show decreased CSF levels of hypocretin.,"Taken together, our results suggest that the ORX system may be involved in the pathophysiology of panic anxiety and that ORX antagonists constitute a potential new treatment strategy for panic disorder.",False,BACKGROUND
3389,Pediatric SCD patients with vaso-occlusive crisis show increased morphine use after breathing 80 ppm iNO for 4 hours.,CONTEXT Vaso-occlusion is central to the painful crises and acute and chronic organ damage in sickle cell disease.,False,OBJECTIVE
3390,Pediatric SCD patients with vaso-occlusive crisis show increased morphine use after breathing 80 ppm iNO for 4 hours.,"Abnormal nitric oxide-dependent regulation of vascular tone, adhesion, platelet activation, and inflammation contributes to the pathophysiology of vaso-occlusion.",False,OBJECTIVE
3391,Pediatric SCD patients with vaso-occlusive crisis show increased morphine use after breathing 80 ppm iNO for 4 hours.,"Nitric oxide may have promise as a mechanism-of-disease-based therapy for treatment of vaso-occlusion.   
",False,OBJECTIVE
3392,Pediatric SCD patients with vaso-occlusive crisis show increased morphine use after breathing 80 ppm iNO for 4 hours.,"OBJECTIVE To explore the efficacy and safety of inhaled nitric oxide (INO) for treatment of vaso-occlusive crisis in pediatric patients.   
",False,OBJECTIVE
3393,Pediatric SCD patients with vaso-occlusive crisis show increased morphine use after breathing 80 ppm iNO for 4 hours.,"DESIGN Prospective, double-blind, placebo-controlled, randomized clinical trial with enrollment between September 1999 and October 2001.   
",False,METHODS
3394,Pediatric SCD patients with vaso-occlusive crisis show increased morphine use after breathing 80 ppm iNO for 4 hours.,"SETTING Urban, tertiary care children's hospital in the United States.   
",False,METHODS
3395,Pediatric SCD patients with vaso-occlusive crisis show increased morphine use after breathing 80 ppm iNO for 4 hours.,"PARTICIPANTS Twenty patients aged 10 to 21 years with sickle cell disease and severe acute vaso-occlusive crisis.   
",False,METHODS
3396,Pediatric SCD patients with vaso-occlusive crisis show increased morphine use after breathing 80 ppm iNO for 4 hours.,"INTERVENTION Patients were randomly assigned to receive INO (80 ppm with 21% final concentration of inspired oxygen; n = 10), or placebo (21% inspired oxygen; n = 10) for 4 hours.   
",False,METHODS
3397,Pediatric SCD patients with vaso-occlusive crisis show increased morphine use after breathing 80 ppm iNO for 4 hours.,"MAIN OUTCOME MEASURES Change in pain at 4 hours of inhalation compared with preinhalation pain, measured on a 10-cm visual analog scale (VAS); secondary outcome measures were pain over 6 hours, parenteral narcotic use over 24 hours, duration of hospitalization, blood pressure, oxygen saturation, and methemoglobin concentration.   
",False,METHODS
3398,Pediatric SCD patients with vaso-occlusive crisis show increased morphine use after breathing 80 ppm iNO for 4 hours.,RESULTS Preinhalation VAS pain scores were similar in the INO and placebo groups (P =.80).,False,RESULTS
3399,Pediatric SCD patients with vaso-occlusive crisis show increased morphine use after breathing 80 ppm iNO for 4 hours.,The decrease in VAS pain scores at 4 hours was 2.0 cm in the INO group and 1.2 cm in the placebo group (P =.37).,False,RESULTS
3400,Pediatric SCD patients with vaso-occlusive crisis show increased morphine use after breathing 80 ppm iNO for 4 hours.,Repeated-measures analysis of variance for hourly pain scores showed a 1-cm/h greater reduction in the INO group than the placebo group (P =.02).,False,RESULTS
3401,Pediatric SCD patients with vaso-occlusive crisis show increased morphine use after breathing 80 ppm iNO for 4 hours.,"Morphine use over 6 hours was significantly less in the INO group (mean cumulative use, 0.29 vs 0.44 mg/kg; P =.03) but was not different over 4 hours (0.26 vs 0.32 mg/kg; P =.21) or 24 hours (0.63 vs 0.91 mg/kg; P =.15).",True,RESULTS
3402,Pediatric SCD patients with vaso-occlusive crisis show increased morphine use after breathing 80 ppm iNO for 4 hours.,"Duration of hospitalization was 78 and 100 hours in the INO and placebo groups, respectively (P =.19).",False,RESULTS
3403,Pediatric SCD patients with vaso-occlusive crisis show increased morphine use after breathing 80 ppm iNO for 4 hours.,"No INO toxicity was observed.   
",False,RESULTS
3404,Pediatric SCD patients with vaso-occlusive crisis show increased morphine use after breathing 80 ppm iNO for 4 hours.,CONCLUSIONS Results of this exploratory study suggest that INO may be beneficial for acute vaso-occlusive crisis.,False,CONCLUSIONS
3405,Pediatric SCD patients with vaso-occlusive crisis show increased morphine use after breathing 80 ppm iNO for 4 hours.,These preliminary results warrant further investigation.,False,CONCLUSIONS
3406,Peroxynitrite is required for induction of T cell tolerance.,"Antigen-specific CD8+ T-cell tolerance, induced by myeloid-derived suppressor cells (MDSCs), is one of the main mechanisms of tumor escape.",False,BACKGROUND
3407,Peroxynitrite is required for induction of T cell tolerance.,"Using in vivo models, we show here that MDSCs directly disrupt the binding of specific peptide–major histocompatibility complex (pMHC) dimers to CD8-expressing T cells through nitration of tyrosines in a T-cell receptor (TCR)-CD8 complex.",False,BACKGROUND
3408,Peroxynitrite is required for induction of T cell tolerance.,"This process makes CD8-expressing T cells unable to bind pMHC and to respond to the specific peptide, although they retain their ability to respond to nonspecific stimulation.",False,RESULTS
3409,Peroxynitrite is required for induction of T cell tolerance.,Nitration of TCR-CD8 is induced by MDSCs through hyperproduction of reactive oxygen species and peroxynitrite during direct cell-cell contact.,True,RESULTS
3410,Peroxynitrite is required for induction of T cell tolerance.,Molecular modeling suggests specific sites of nitration that might affect the conformational flexibility of TCR-CD8 and its interaction with pMHC.,False,CONCLUSIONS
3411,Peroxynitrite is required for induction of T cell tolerance.,These data identify a previously unknown mechanism of T-cell tolerance in cancer that is also pertinent to many pathological conditions associated with accumulation of MDSCs.,True,CONCLUSIONS
3412,Pharmacist attendance at ward rounds increases adverse events in wards.,"CONTEXT Pharmacist review of medication orders in the intensive care unit (ICU) has been shown to prevent errors, and pharmacist consultation has reduced drug costs.",False,BACKGROUND
3413,Pharmacist attendance at ward rounds increases adverse events in wards.,"However, whether pharmacist participation in the ICU at the time of drug prescribing reduces adverse events has not been studied.   
",False,BACKGROUND
3414,Pharmacist attendance at ward rounds increases adverse events in wards.,"OBJECTIVE To measure the effect of pharmacist participation on medical rounds in the ICU on the rate of preventable adverse drug events (ADEs) caused by ordering errors.   
",False,OBJECTIVE
3415,Pharmacist attendance at ward rounds increases adverse events in wards.,"DESIGN Before-after comparison between phase 1 (baseline) and phase 2 (after intervention implemented) and phase 2 comparison with a control unit that did not receive the intervention.   
",False,METHODS
3416,Pharmacist attendance at ward rounds increases adverse events in wards.,"SETTING A medical ICU (study unit) and a coronary care unit (control unit) in a large urban teaching hospital.   
",False,METHODS
3417,Pharmacist attendance at ward rounds increases adverse events in wards.,"PATIENTS Seventy-five patients randomly selected from each of 3 groups: all admissions to the study unit from February 1, 1993, through July 31, 1993 (baseline) and all admissions to the study unit (postintervention) and control unit from October 1, 1994, through July 7, 1995.",False,METHODS
3418,Pharmacist attendance at ward rounds increases adverse events in wards.,"In addition, 50 patients were selected at random from the control unit during the baseline period.   
",False,METHODS
3419,Pharmacist attendance at ward rounds increases adverse events in wards.,"INTERVENTION A senior pharmacist made rounds with the ICU team and remained in the ICU for consultation in the morning, and was available on call throughout the day.   
",False,METHODS
3420,Pharmacist attendance at ward rounds increases adverse events in wards.,"MAIN OUTCOME MEASURES Preventable ADEs due to ordering (prescribing) errors and the number, type, and acceptance of interventions made by the pharmacist.",False,METHODS
3421,Pharmacist attendance at ward rounds increases adverse events in wards.,Preventable ADEs were identified by review of medical records of the randomly selected patients during both preintervention and postintervention phases.,False,METHODS
3422,Pharmacist attendance at ward rounds increases adverse events in wards.,"Pharmacists recorded all recommendations, which were then analyzed by type and acceptance.   
",False,METHODS
3423,Pharmacist attendance at ward rounds increases adverse events in wards.,"RESULTS The rate of preventable ordering ADEs decreased by 66% from 10.4 per 1000 patient-days (95% confidence interval [CI], 7-14) before the intervention to 3.5 (95% CI, 1-5; P<.001) after the intervention.",True,RESULTS
3424,Pharmacist attendance at ward rounds increases adverse events in wards.,"In the control unit, the rate was essentially unchanged during the same time periods: 10.9 (95% CI, 6-16) and 12.4 (95% CI, 8-17) per 1000 patient-days.",False,RESULTS
3425,Pharmacist attendance at ward rounds increases adverse events in wards.,"The pharmacist made 366 recommendations related to drug ordering, of which 362 (99%) were accepted by physicians.   
",False,RESULTS
3426,Pharmacist attendance at ward rounds increases adverse events in wards.,CONCLUSIONS The presence of a pharmacist on rounds as a full member of the patient care team in a medical ICU was associated with a substantially lower rate of ADEs caused by prescribing errors.,True,CONCLUSIONS
3427,Pharmacist attendance at ward rounds increases adverse events in wards.,Nearly all the changes were readily accepted by physicians.,False,CONCLUSIONS
3428,Pharmacist attendance at ward rounds reduces adverse events in wards.,"CONTEXT Pharmacist review of medication orders in the intensive care unit (ICU) has been shown to prevent errors, and pharmacist consultation has reduced drug costs.",False,BACKGROUND
3429,Pharmacist attendance at ward rounds reduces adverse events in wards.,"However, whether pharmacist participation in the ICU at the time of drug prescribing reduces adverse events has not been studied.   
",False,BACKGROUND
3430,Pharmacist attendance at ward rounds reduces adverse events in wards.,"OBJECTIVE To measure the effect of pharmacist participation on medical rounds in the ICU on the rate of preventable adverse drug events (ADEs) caused by ordering errors.   
",False,OBJECTIVE
3431,Pharmacist attendance at ward rounds reduces adverse events in wards.,"DESIGN Before-after comparison between phase 1 (baseline) and phase 2 (after intervention implemented) and phase 2 comparison with a control unit that did not receive the intervention.   
",False,METHODS
3432,Pharmacist attendance at ward rounds reduces adverse events in wards.,"SETTING A medical ICU (study unit) and a coronary care unit (control unit) in a large urban teaching hospital.   
",False,METHODS
3433,Pharmacist attendance at ward rounds reduces adverse events in wards.,"PATIENTS Seventy-five patients randomly selected from each of 3 groups: all admissions to the study unit from February 1, 1993, through July 31, 1993 (baseline) and all admissions to the study unit (postintervention) and control unit from October 1, 1994, through July 7, 1995.",False,METHODS
3434,Pharmacist attendance at ward rounds reduces adverse events in wards.,"In addition, 50 patients were selected at random from the control unit during the baseline period.   
",False,METHODS
3435,Pharmacist attendance at ward rounds reduces adverse events in wards.,"INTERVENTION A senior pharmacist made rounds with the ICU team and remained in the ICU for consultation in the morning, and was available on call throughout the day.   
",False,METHODS
3436,Pharmacist attendance at ward rounds reduces adverse events in wards.,"MAIN OUTCOME MEASURES Preventable ADEs due to ordering (prescribing) errors and the number, type, and acceptance of interventions made by the pharmacist.",False,METHODS
3437,Pharmacist attendance at ward rounds reduces adverse events in wards.,Preventable ADEs were identified by review of medical records of the randomly selected patients during both preintervention and postintervention phases.,False,METHODS
3438,Pharmacist attendance at ward rounds reduces adverse events in wards.,"Pharmacists recorded all recommendations, which were then analyzed by type and acceptance.   
",False,METHODS
3439,Pharmacist attendance at ward rounds reduces adverse events in wards.,"RESULTS The rate of preventable ordering ADEs decreased by 66% from 10.4 per 1000 patient-days (95% confidence interval [CI], 7-14) before the intervention to 3.5 (95% CI, 1-5; P<.001) after the intervention.",True,RESULTS
3440,Pharmacist attendance at ward rounds reduces adverse events in wards.,"In the control unit, the rate was essentially unchanged during the same time periods: 10.9 (95% CI, 6-16) and 12.4 (95% CI, 8-17) per 1000 patient-days.",False,RESULTS
3441,Pharmacist attendance at ward rounds reduces adverse events in wards.,"The pharmacist made 366 recommendations related to drug ordering, of which 362 (99%) were accepted by physicians.   
",False,RESULTS
3442,Pharmacist attendance at ward rounds reduces adverse events in wards.,CONCLUSIONS The presence of a pharmacist on rounds as a full member of the patient care team in a medical ICU was associated with a substantially lower rate of ADEs caused by prescribing errors.,True,CONCLUSIONS
3443,Pharmacist attendance at ward rounds reduces adverse events in wards.,Nearly all the changes were readily accepted by physicians.,False,CONCLUSIONS
3444,Phase information is useful for predicting donor-recipient matches in organ transplantation.,Background  Current criteria for the selection of unrelated donors for hematopoietic cell transplantation (HCT) include matching for the alleles of each human leukocyte antigen (HLA) locus within the major histocompatibility complex (MHC).,False,BACKGROUND
3445,Phase information is useful for predicting donor-recipient matches in organ transplantation.,"Graft-versus-host disease (GVHD), however, remains a significant and potentially life-threatening complication even after HLA-identical unrelated HCT.",False,BACKGROUND
3446,Phase information is useful for predicting donor-recipient matches in organ transplantation.,"The MHC harbors more than 400 genes, but the total number of transplantation antigens is unknown.",False,BACKGROUND
3447,Phase information is useful for predicting donor-recipient matches in organ transplantation.,"Genes that influence transplantation outcome could be identified by using linkage disequilibrium (LD)-mapping approaches, if the extended MHC haplotypes of the unrelated donor and recipient could be defined.",True,BACKGROUND
3448,Physical activity does not improve cognitive function in individuals with Alzheimers.,"CONTEXT Many observational studies have shown that physical activity reduces the risk of cognitive decline; however, evidence from randomized trials is lacking.   
",False,OBJECTIVE
3449,Physical activity does not improve cognitive function in individuals with Alzheimers.,"OBJECTIVE To determine whether physical activity reduces the rate of cognitive decline among older adults at risk.   
",False,OBJECTIVE
3450,Physical activity does not improve cognitive function in individuals with Alzheimers.,"DESIGN AND SETTING Randomized controlled trial of a 24-week physical activity intervention conducted between 2004 and 2007 in metropolitan Perth, Western Australia.",False,METHODS
3451,Physical activity does not improve cognitive function in individuals with Alzheimers.,"Assessors of cognitive function were blinded to group membership.   
",False,METHODS
3452,Physical activity does not improve cognitive function in individuals with Alzheimers.,PARTICIPANTS We recruited volunteers who reported memory problems but did not meet criteria for dementia.,False,METHODS
3453,Physical activity does not improve cognitive function in individuals with Alzheimers.,"Three hundred eleven individuals aged 50 years or older were screened for eligibility, 89 were not eligible, and 52 refused to participate.",False,METHODS
3454,Physical activity does not improve cognitive function in individuals with Alzheimers.,"A total of 170 participants were randomized and 138 participants completed the 18-month assessment.   
",False,METHODS
3455,Physical activity does not improve cognitive function in individuals with Alzheimers.,"INTERVENTION Participants were randomly allocated to an education and usual care group or to a 24-week home-based program of physical activity.   
",False,METHODS
3456,Physical activity does not improve cognitive function in individuals with Alzheimers.,"MAIN OUTCOME MEASURE Change in Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) scores (possible range, 0-70) over 18 months.   
",False,METHODS
3457,Physical activity does not improve cognitive function in individuals with Alzheimers.,"RESULTS In an intent-to-treat analysis, participants in the intervention group improved 0.26 points (95% confidence interval, -0.89 to 0.54) and those in the usual care group deteriorated 1.04 points (95% confidence interval, 0.32 to 1.82) on the ADAS-Cog at the end of the intervention.",True,RESULTS
3458,Physical activity does not improve cognitive function in individuals with Alzheimers.,"The absolute difference of the outcome measure between the intervention and control groups was -1.3 points (95% confidence interval,-2.38 to -0.22) at the end of the intervention.",False,RESULTS
3459,Physical activity does not improve cognitive function in individuals with Alzheimers.,"At 18 months, participants in the intervention group improved 0.73 points (95% confidence interval, -1.27 to 0.03) on the ADAS-Cog, and those in the usual care group improved 0.04 points (95% confidence interval, -0.46 to 0.88).",False,RESULTS
3460,Physical activity does not improve cognitive function in individuals with Alzheimers.,"Word list delayed recall and Clinical Dementia Rating sum of boxes improved modestly as well, whereas word list total immediate recall, digit symbol coding, verbal fluency, Beck depression score, and Medical Outcomes 36-Item Short-Form physical and mental component summaries did not change significantly.   
",False,RESULTS
3461,Physical activity does not improve cognitive function in individuals with Alzheimers.,"CONCLUSIONS In this study of adults with subjective memory impairment, a 6-month program of physical activity provided a modest improvement in cognition over an 18-month follow-up period.   
",True,CONCLUSIONS
3462,Physical activity does not improve cognitive function in individuals with Alzheimers.,TRIAL REGISTRATION anzctr.org.au Identifier: ACTRN12605000136606.,False,CONCLUSIONS
3463,Piezo1 channels are sensors for cell migration in epithelial cells.,Trefoil factor family 1 (TFF1) is a member of the TFF-domain peptide family involved in epithelial restitution and cell motility.,False,BACKGROUND
3464,Piezo1 channels are sensors for cell migration in epithelial cells.,"Recently, we screened Piezo1 as a candidate TFF1-binding protein.",False,BACKGROUND
3465,Piezo1 channels are sensors for cell migration in epithelial cells.,We aimed to confirm Piezo1 as a novel TFF1 binding protein and to assess the role of this interaction in mediating gastric cancer cell mobility.,False,BACKGROUND
3466,Piezo1 channels are sensors for cell migration in epithelial cells.,This interaction was confirmed by co-immunoprecipitation and co-localisation of TFF1 and Piezo1 in GES-1 cells.,True,METHODS
3467,Piezo1 channels are sensors for cell migration in epithelial cells.,We used stable RNA interference to knockdown Piezo1 protein expression and restored the expression of TFF1 in the gastric cancer cell lines SGC-7901 and BGC-823.,False,METHODS
3468,Piezo1 channels are sensors for cell migration in epithelial cells.,Cell motility was evaluated using invasion assay and migration assay in vitro.,False,METHODS
3469,Piezo1 channels are sensors for cell migration in epithelial cells.,"The expression levels of the integrin subunits β1, β5, α1 as well as the expression of β-catenin and E-cadherin were detected by Western blot.",False,METHODS
3470,Piezo1 channels are sensors for cell migration in epithelial cells.,"We demonstrate that TFF1, but not TFF2 or TFF3, bind to and co-localize with Piezo1 in the cytoplasm in vitro.",True,RESULTS
3471,Piezo1 channels are sensors for cell migration in epithelial cells.,TFF1 interacts with the C-terminal portion of the Piezo1 protein.,True,RESULTS
3472,Piezo1 channels are sensors for cell migration in epithelial cells.,"Wound healing and trans-well assays demonstrated that the restored expression of TFF1 promoted cell mobility in gastric cancer cells, and this effect was attenuated by the knockdown of Piezo1.",False,RESULTS
3473,Piezo1 channels are sensors for cell migration in epithelial cells.,Western blots demonstrated the decreased expression of integrin β1 in Piezo1-knockdown cells.,False,RESULTS
3474,Piezo1 channels are sensors for cell migration in epithelial cells.,Our data demonstrate that Piezo1 is a novel TFF1 binding protein that is important for TFF1-mediated cell migration and suggest that this interaction may be a therapeutic target in the invasion and metastasis of gastric cancer.,True,CONCLUSIONS
3475,Pioglitazone use is not associated with an increased risk of prostate cancer.,"IMPORTANCE Studies suggest pioglitazone use may increase risk of cancers.   
",False,BACKGROUND
3476,Pioglitazone use is not associated with an increased risk of prostate cancer.,"OBJECTIVE To examine whether pioglitazone use for diabetes is associated with risk of bladder and 10 additional cancers.   
",False,OBJECTIVE
3477,Pioglitazone use is not associated with an increased risk of prostate cancer.,"DESIGN, SETTING, AND PARTICIPANTS Cohort and nested case-control analyses among persons with diabetes.",False,METHODS
3478,Pioglitazone use is not associated with an increased risk of prostate cancer.,"A bladder cancer cohort followed 193,099 persons aged 40 years or older in 1997-2002 until December 2012; 464 case patients and 464 matched controls were surveyed about additional confounders.",False,METHODS
3479,Pioglitazone use is not associated with an increased risk of prostate cancer.,"A cohort analysis of 10 additional cancers included 236,507 persons aged 40 years or older in 1997-2005 and followed until June 2012.",False,METHODS
3480,Pioglitazone use is not associated with an increased risk of prostate cancer.,Cohorts were from Kaiser Permanente Northern California.   ,False,METHODS
3481,Pioglitazone use is not associated with an increased risk of prostate cancer.,"EXPOSURES Ever use, duration, cumulative dose, and time since initiation of pioglitazone as time dependent.   
",False,METHODS
3482,Pioglitazone use is not associated with an increased risk of prostate cancer.,"MAIN OUTCOMES AND MEASURES Incident cancer, including bladder, prostate, female breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rectum, and melanoma.   
",False,METHODS
3483,Pioglitazone use is not associated with an increased risk of prostate cancer.,"RESULTS Among 193,099 persons in the bladder cancer cohort, 34,181 (18%) received pioglitazone (median duration, 2.8 years; range, 0.2-13.2 years) and 1261 had incident bladder cancer.",False,RESULTS
3484,Pioglitazone use is not associated with an increased risk of prostate cancer.,"Crude incidences of bladder cancer in pioglitazone users and nonusers were 89.8 and 75.9 per 100,000 person-years, respectively.",False,RESULTS
3485,Pioglitazone use is not associated with an increased risk of prostate cancer.,"Ever use of pioglitazone was not associated with bladder cancer risk (adjusted hazard ratio [HR], 1.06; 95% CI, 0.89-1.26).",False,RESULTS
3486,Pioglitazone use is not associated with an increased risk of prostate cancer.,"Results were similar in case-control analyses (pioglitazone use: 19.6% among case patients and 17.5% among controls; adjusted odds ratio, 1.18; 95% CI, 0.78-1.80).",False,RESULTS
3487,Pioglitazone use is not associated with an increased risk of prostate cancer.,"In adjusted analyses, there was no association with 8 of the 10 additional cancers; ever use of pioglitazone was associated with increased risk of prostate cancer (HR, 1.13; 95% CI, 1.02-1.26) and pancreatic cancer (HR, 1.41; 95% CI, 1.16-1.71).",True,RESULTS
3488,Pioglitazone use is not associated with an increased risk of prostate cancer.,"Crude incidences of prostate and pancreatic cancer in pioglitazone users vs nonusers were 453.3 vs 449.3 and 81.1 vs 48.4 per 100,000 person-years, respectively.",False,RESULTS
3489,Pioglitazone use is not associated with an increased risk of prostate cancer.,"No clear patterns of risk for any cancer were observed for time since initiation, duration, or dose.   
",False,RESULTS
3490,Pioglitazone use is not associated with an increased risk of prostate cancer.,"CONCLUSIONS AND RELEVANCE Pioglitazone use was not associated with a statistically significant increased risk of bladder cancer, although an increased risk, as previously observed, could not be excluded.",False,CONCLUSIONS
3491,Pioglitazone use is not associated with an increased risk of prostate cancer.,"The increased prostate and pancreatic cancer risks associated with ever use of pioglitazone merit further investigation to assess whether they are causal or are due to chance, residual confounding, or reverse causality.",True,CONCLUSIONS
3492,Pioglitazone use is significantly associated with an increased risk of pancreatic cancer.,"IMPORTANCE Studies suggest pioglitazone use may increase risk of cancers.   
",False,BACKGROUND
3493,Pioglitazone use is significantly associated with an increased risk of pancreatic cancer.,"OBJECTIVE To examine whether pioglitazone use for diabetes is associated with risk of bladder and 10 additional cancers.   
",False,OBJECTIVE
3494,Pioglitazone use is significantly associated with an increased risk of pancreatic cancer.,"DESIGN, SETTING, AND PARTICIPANTS Cohort and nested case-control analyses among persons with diabetes.",False,METHODS
3495,Pioglitazone use is significantly associated with an increased risk of pancreatic cancer.,"A bladder cancer cohort followed 193,099 persons aged 40 years or older in 1997-2002 until December 2012; 464 case patients and 464 matched controls were surveyed about additional confounders.",False,METHODS
3496,Pioglitazone use is significantly associated with an increased risk of pancreatic cancer.,"A cohort analysis of 10 additional cancers included 236,507 persons aged 40 years or older in 1997-2005 and followed until June 2012.",False,METHODS
3497,Pioglitazone use is significantly associated with an increased risk of pancreatic cancer.,Cohorts were from Kaiser Permanente Northern California.   ,False,METHODS
3498,Pioglitazone use is significantly associated with an increased risk of pancreatic cancer.,"EXPOSURES Ever use, duration, cumulative dose, and time since initiation of pioglitazone as time dependent.   
",False,METHODS
3499,Pioglitazone use is significantly associated with an increased risk of pancreatic cancer.,"MAIN OUTCOMES AND MEASURES Incident cancer, including bladder, prostate, female breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rectum, and melanoma.   
",False,METHODS
3500,Pioglitazone use is significantly associated with an increased risk of pancreatic cancer.,"RESULTS Among 193,099 persons in the bladder cancer cohort, 34,181 (18%) received pioglitazone (median duration, 2.8 years; range, 0.2-13.2 years) and 1261 had incident bladder cancer.",False,RESULTS
3501,Pioglitazone use is significantly associated with an increased risk of pancreatic cancer.,"Crude incidences of bladder cancer in pioglitazone users and nonusers were 89.8 and 75.9 per 100,000 person-years, respectively.",False,RESULTS
3502,Pioglitazone use is significantly associated with an increased risk of pancreatic cancer.,"Ever use of pioglitazone was not associated with bladder cancer risk (adjusted hazard ratio [HR], 1.06; 95% CI, 0.89-1.26).",False,RESULTS
3503,Pioglitazone use is significantly associated with an increased risk of pancreatic cancer.,"Results were similar in case-control analyses (pioglitazone use: 19.6% among case patients and 17.5% among controls; adjusted odds ratio, 1.18; 95% CI, 0.78-1.80).",False,RESULTS
3504,Pioglitazone use is significantly associated with an increased risk of pancreatic cancer.,"In adjusted analyses, there was no association with 8 of the 10 additional cancers; ever use of pioglitazone was associated with increased risk of prostate cancer (HR, 1.13; 95% CI, 1.02-1.26) and pancreatic cancer (HR, 1.41; 95% CI, 1.16-1.71).",True,RESULTS
3505,Pioglitazone use is significantly associated with an increased risk of pancreatic cancer.,"Crude incidences of prostate and pancreatic cancer in pioglitazone users vs nonusers were 453.3 vs 449.3 and 81.1 vs 48.4 per 100,000 person-years, respectively.",True,RESULTS
3506,Pioglitazone use is significantly associated with an increased risk of pancreatic cancer.,"No clear patterns of risk for any cancer were observed for time since initiation, duration, or dose.   
",False,RESULTS
3507,Pioglitazone use is significantly associated with an increased risk of pancreatic cancer.,"CONCLUSIONS AND RELEVANCE Pioglitazone use was not associated with a statistically significant increased risk of bladder cancer, although an increased risk, as previously observed, could not be excluded.",False,CONCLUSIONS
3508,Pioglitazone use is significantly associated with an increased risk of pancreatic cancer.,"The increased prostate and pancreatic cancer risks associated with ever use of pioglitazone merit further investigation to assess whether they are causal or are due to chance, residual confounding, or reverse causality.",True,CONCLUSIONS
3509,Pioglitazone use is significantly associated with an increased risk of prostate cancer.,"IMPORTANCE Studies suggest pioglitazone use may increase risk of cancers.   
",False,BACKGROUND
3510,Pioglitazone use is significantly associated with an increased risk of prostate cancer.,"OBJECTIVE To examine whether pioglitazone use for diabetes is associated with risk of bladder and 10 additional cancers.   
",False,OBJECTIVE
3511,Pioglitazone use is significantly associated with an increased risk of prostate cancer.,"DESIGN, SETTING, AND PARTICIPANTS Cohort and nested case-control analyses among persons with diabetes.",False,METHODS
3512,Pioglitazone use is significantly associated with an increased risk of prostate cancer.,"A bladder cancer cohort followed 193,099 persons aged 40 years or older in 1997-2002 until December 2012; 464 case patients and 464 matched controls were surveyed about additional confounders.",False,METHODS
3513,Pioglitazone use is significantly associated with an increased risk of prostate cancer.,"A cohort analysis of 10 additional cancers included 236,507 persons aged 40 years or older in 1997-2005 and followed until June 2012.",False,METHODS
3514,Pioglitazone use is significantly associated with an increased risk of prostate cancer.,Cohorts were from Kaiser Permanente Northern California.   ,False,METHODS
3515,Pioglitazone use is significantly associated with an increased risk of prostate cancer.,"EXPOSURES Ever use, duration, cumulative dose, and time since initiation of pioglitazone as time dependent.   
",False,METHODS
3516,Pioglitazone use is significantly associated with an increased risk of prostate cancer.,"MAIN OUTCOMES AND MEASURES Incident cancer, including bladder, prostate, female breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rectum, and melanoma.   
",False,METHODS
3517,Pioglitazone use is significantly associated with an increased risk of prostate cancer.,"RESULTS Among 193,099 persons in the bladder cancer cohort, 34,181 (18%) received pioglitazone (median duration, 2.8 years; range, 0.2-13.2 years) and 1261 had incident bladder cancer.",False,RESULTS
3518,Pioglitazone use is significantly associated with an increased risk of prostate cancer.,"Crude incidences of bladder cancer in pioglitazone users and nonusers were 89.8 and 75.9 per 100,000 person-years, respectively.",False,RESULTS
3519,Pioglitazone use is significantly associated with an increased risk of prostate cancer.,"Ever use of pioglitazone was not associated with bladder cancer risk (adjusted hazard ratio [HR], 1.06; 95% CI, 0.89-1.26).",False,RESULTS
3520,Pioglitazone use is significantly associated with an increased risk of prostate cancer.,"Results were similar in case-control analyses (pioglitazone use: 19.6% among case patients and 17.5% among controls; adjusted odds ratio, 1.18; 95% CI, 0.78-1.80).",False,RESULTS
3521,Pioglitazone use is significantly associated with an increased risk of prostate cancer.,"In adjusted analyses, there was no association with 8 of the 10 additional cancers; ever use of pioglitazone was associated with increased risk of prostate cancer (HR, 1.13; 95% CI, 1.02-1.26) and pancreatic cancer (HR, 1.41; 95% CI, 1.16-1.71).",True,RESULTS
3522,Pioglitazone use is significantly associated with an increased risk of prostate cancer.,"Crude incidences of prostate and pancreatic cancer in pioglitazone users vs nonusers were 453.3 vs 449.3 and 81.1 vs 48.4 per 100,000 person-years, respectively.",False,RESULTS
3523,Pioglitazone use is significantly associated with an increased risk of prostate cancer.,"No clear patterns of risk for any cancer were observed for time since initiation, duration, or dose.   
",False,RESULTS
3524,Pioglitazone use is significantly associated with an increased risk of prostate cancer.,"CONCLUSIONS AND RELEVANCE Pioglitazone use was not associated with a statistically significant increased risk of bladder cancer, although an increased risk, as previously observed, could not be excluded.",False,CONCLUSIONS
3525,Pioglitazone use is significantly associated with an increased risk of prostate cancer.,"The increased prostate and pancreatic cancer risks associated with ever use of pioglitazone merit further investigation to assess whether they are causal or are due to chance, residual confounding, or reverse causality.",True,CONCLUSIONS
3526,Pioneer factor OCT3/4 interacts with major chromatin remodeling factors.,"Oct4 is a well-known transcription factor that plays fundamental roles in stem cell self-renewal, pluripotency, and somatic cell reprogramming.",False,BACKGROUND
3527,Pioneer factor OCT3/4 interacts with major chromatin remodeling factors.,"However, limited information is available on Oct4-associated protein complexes and their intrinsic protein-protein interactions that dictate Oct4's critical regulatory activities.",False,BACKGROUND
3528,Pioneer factor OCT3/4 interacts with major chromatin remodeling factors.,"Here we employed an improved affinity purification approach combined with mass spectrometry to purify Oct4 protein complexes in mouse embryonic stem cells (mESCs), and discovered many novel Oct4 partners important for self-renewal and pluripotency of mESCs.",False,RESULTS
3529,Pioneer factor OCT3/4 interacts with major chromatin remodeling factors.,"Notably, we found that Oct4 is associated with multiple chromatin-modifying complexes with documented as well as newly proved functional significance in stem cell maintenance and somatic cell reprogramming.",True,RESULTS
3530,Pioneer factor OCT3/4 interacts with major chromatin remodeling factors.,Our study establishes a solid biochemical basis for genetic and epigenetic regulation of stem cell pluripotency and provides a framework for exploring alternative factor-based reprogramming strategies.,False,CONCLUSIONS
3531,Pioneer factor OCT3/4 interacts with major chromatin remodeling factors.,"Transcription factors, such as Oct4, are critical for establishing and maintaining pluripotent cell identity.",False,BACKGROUND
3532,Pioneer factor OCT3/4 interacts with major chromatin remodeling factors.,"Whereas the genomic locations of several pluripotency transcription factors have been reported, the spectrum of their interaction partners is underexplored.",False,BACKGROUND
3533,Pioneer factor OCT3/4 interacts with major chromatin remodeling factors.,"Here, we use an improved affinity protocol to purify Oct4-interacting proteins from mouse embryonic stem cells (ESCs).",False,BACKGROUND
3534,Pioneer factor OCT3/4 interacts with major chromatin remodeling factors.,"Subsequent purification of Oct4 partners Sall4, Tcfcp2l1, Dax1, and Esrrb resulted in an Oct4 interactome of 166 proteins, including transcription factors and chromatin-modifying complexes with documented roles in self-renewal, but also many factors not previously associated with the ESC network.",True,RESULTS
3535,Pioneer factor OCT3/4 interacts with major chromatin remodeling factors.,"We find that Esrrb associated with the basal transcription machinery and also detect interactions between transcription factors and components of the TGF-beta, Notch, and Wnt signaling pathways.",False,RESULTS
3536,Pioneer factor OCT3/4 interacts with major chromatin remodeling factors.,"Acute depletion of Oct4 reduced binding of Tcfcp2l1, Dax1, and Esrrb to several target genes.",False,CONCLUSIONS
3537,Pioneer factor OCT3/4 interacts with major chromatin remodeling factors.,"In conclusion, our purification protocol allowed us to bring greater definition to the circuitry controlling pluripotent cell identity.",False,CONCLUSIONS
3538,Polymeal nutrition increases cardiovascular mortality.,"OBJECTIVE Although the Polypill concept (proposed in 2003) is promising in terms of benefits for cardiovascular risk management, the potential costs and adverse effects are its main pitfalls.",False,BACKGROUND
3539,Polymeal nutrition increases cardiovascular mortality.,"The objective of this study was to identify a tastier and safer alternative to the Polypill: the Polymeal.   
",False,BACKGROUND
3540,Polymeal nutrition increases cardiovascular mortality.,METHODS Data on the ingredients of the Polymeal were taken from the literature.,False,METHODS
3541,Polymeal nutrition increases cardiovascular mortality.,"The evidence based recipe included wine, fish, dark chocolate, fruits, vegetables, garlic, and almonds.",False,METHODS
3542,Polymeal nutrition increases cardiovascular mortality.,"Data from the Framingham heart study and the Framingham offspring study were used to build life tables to model the benefits of the Polymeal in the general population from age 50, assuming multiplicative correlations.   
",False,METHODS
3543,Polymeal nutrition increases cardiovascular mortality.,RESULTS Combining the ingredients of the Polymeal would reduce cardiovascular disease events by 76%.,False,RESULTS
3544,Polymeal nutrition increases cardiovascular mortality.,"For men, taking the Polymeal daily represented an increase in total life expectancy of 6.6 years, an increase in life expectancy free from cardiovascular disease of 9.0 years, and a decrease in life expectancy with cardiovascular disease of 2.4 years.",True,RESULTS
3545,Polymeal nutrition increases cardiovascular mortality.,"The corresponding differences for women were 4.8, 8.1, and 3.3 years.   
",False,RESULTS
3546,Polymeal nutrition increases cardiovascular mortality.,"CONCLUSION The Polymeal promises to be an effective, non-pharmacological, safe, cheap, and tasty alternative to reduce cardiovascular morbidity and increase life expectancy in the general population.",True,CONCLUSIONS
3547,Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.,"Various specialized domains have been described in the cytosol and the nucleus; however, little is known about compartmentalization within the mitochondrial matrix.",False,BACKGROUND
3548,Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.,GRSF1 (G-rich sequence factor 1) is an RNA binding protein that was previously reported to localize in the cytosol.,False,BACKGROUND
3549,Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.,We found that an isoform of GRSF1 accumulates in discrete foci in the mitochondrial matrix.,False,BACKGROUND
3550,Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.,"These foci are composed of nascent mitochondrial RNA and also contain RNase P, an enzyme that participates in mitochondrial RNA processing.",False,BACKGROUND
3551,Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.,GRSF1 was found to interact with RNase P and to be required for processing of both classical and tRNA-less RNA precursors.,False,BACKGROUND
3552,Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.,"In its absence, cleavage of primary RNA transcripts is abnormal, leading to decreased expression of mitochondrially encoded proteins and mitochondrial dysfunction.",False,BACKGROUND
3553,Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.,Our findings suggest that the foci containing GRSF1 and RNase P correspond to sites where primary RNA transcripts converge to be processed.,True,BACKGROUND
3554,Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.,"We have termed these large ribonucleoprotein structures ""mitochondrial RNA granules.",False,BACKGROUND
3555,Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.,"""",False,BACKGROUND
3556,Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.,"RNA-binding proteins are at the heart of posttranscriptional gene regulation, coordinating the processing, storage, and handling of cellular RNAs.",False,BACKGROUND
3557,Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.,"We show here that GRSF1, previously implicated in the binding and selective translation of influenza mRNAs, is targeted to mitochondria where it forms granules that colocalize with foci of newly synthesized mtRNA next to mitochondrial nucleoids.",True,BACKGROUND
3558,Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.,"GRSF1 preferentially binds RNAs transcribed from three contiguous genes on the light strand of mtDNA, the ND6 mRNA, and the long noncoding RNAs for cytb and ND5, each of which contains multiple consensus binding sequences.",False,BACKGROUND
3559,Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.,"RNAi-mediated knockdown of GRSF1 leads to alterations in mitochondrial RNA stability, abnormal loading of mRNAs and lncRNAs on the mitochondrial ribosome, and impaired ribosome assembly.",False,BACKGROUND
3560,Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.,This results in a specific protein synthesis defect and a failure to assemble normal amounts of the oxidative phosphorylation complexes.,False,BACKGROUND
3561,Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.,These data implicate GRSF1 as a key regulator of posttranscriptional mitochondrial gene expression.,True,BACKGROUND
3562,Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.,"Human mitochondrial ribosomes are specialized in the synthesis of 13 proteins, which are fundamental components of the oxidative phosphorylation system.",False,BACKGROUND
3563,Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.,"The pathway of mitoribosome biogenesis, the compartmentalization of the process, and factors involved remain largely unknown.",False,BACKGROUND
3564,Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.,"Here, we have identified the DEAD-box protein DDX28 as an RNA granule component essential for the biogenesis of the mitoribosome large subunit (mt-LSU).",True,BACKGROUND
3565,Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.,DDX28 interacts with the 16S rRNA and the mt-LSU.,False,RESULTS
3566,Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.,RNAi-mediated DDX28 silencing in HEK293T cells does not affect mitochondrial mRNA stability or 16S rRNA processing or modification.,False,RESULTS
3567,Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.,"However, it leads to reduced levels of 16S rRNA and mt-LSU proteins, impaired mt-LSU assembly, deeply attenuated mitochondrial protein synthesis, and consequent failure to assemble oxidative phosphorylation complexes.",False,RESULTS
3568,Post-transcriptional handling of mitochondrial transcripts occurs in mitochondrial RNA granules.,"Our findings identify DDX28 as essential during the early stages of mitoribosome mt-LSU biogenesis, a process that takes place mainly near the mitochondrial nucleoids, in the compartment defined by the RNA granules.",True,CONCLUSIONS
3569,Pre-mRNAs associated with spliceosomal components are less stable than unassociated splicing substrates.,"RNA processing is carried out in close proximity to the site of transcription, suggesting a regulatory link between transcription and pre-mRNA splicing.",False,BACKGROUND
3570,Pre-mRNAs associated with spliceosomal components are less stable than unassociated splicing substrates.,"Using an in vitro transcription/splicing assay, we demonstrate that an association of RNA polymerase II (Pol II) transcription and pre-mRNA splicing is required for efficient gene expression.",False,BACKGROUND
3571,Pre-mRNAs associated with spliceosomal components are less stable than unassociated splicing substrates.,"Pol II-synthesized RNAs containing functional splice sites are protected from nuclear degradation, presumably because the local concentration of the splicing machinery is sufficiently high to ensure its association over interactions with nucleases.",False,BACKGROUND
3572,Pre-mRNAs associated with spliceosomal components are less stable than unassociated splicing substrates.,"Furthermore, the process of transcription influences alternative splicing of newly synthesized pre-mRNAs.",False,BACKGROUND
3573,Pre-mRNAs associated with spliceosomal components are less stable than unassociated splicing substrates.,"Because other RNA polymerases do not provide similar protection from nucleases, and their RNA products display altered splicing patterns, the link between transcription and RNA processing is RNA Pol II-specific.",False,BACKGROUND
3574,Pre-mRNAs associated with spliceosomal components are less stable than unassociated splicing substrates.,We propose that the connection between transcription by Pol II and pre-mRNA splicing guarantees an extended half-life and proper processing of nascent pre-mRNAs.,True,BACKGROUND
3575,Pre-mRNAs associated with spliceosomal components are more stable than unassociated splicing substrates.,"RNA processing is carried out in close proximity to the site of transcription, suggesting a regulatory link between transcription and pre-mRNA splicing.",False,BACKGROUND
3576,Pre-mRNAs associated with spliceosomal components are more stable than unassociated splicing substrates.,"Using an in vitro transcription/splicing assay, we demonstrate that an association of RNA polymerase II (Pol II) transcription and pre-mRNA splicing is required for efficient gene expression.",False,BACKGROUND
3577,Pre-mRNAs associated with spliceosomal components are more stable than unassociated splicing substrates.,"Pol II-synthesized RNAs containing functional splice sites are protected from nuclear degradation, presumably because the local concentration of the splicing machinery is sufficiently high to ensure its association over interactions with nucleases.",False,BACKGROUND
3578,Pre-mRNAs associated with spliceosomal components are more stable than unassociated splicing substrates.,"Furthermore, the process of transcription influences alternative splicing of newly synthesized pre-mRNAs.",False,BACKGROUND
3579,Pre-mRNAs associated with spliceosomal components are more stable than unassociated splicing substrates.,"Because other RNA polymerases do not provide similar protection from nucleases, and their RNA products display altered splicing patterns, the link between transcription and RNA processing is RNA Pol II-specific.",False,BACKGROUND
3580,Pre-mRNAs associated with spliceosomal components are more stable than unassociated splicing substrates.,We propose that the connection between transcription by Pol II and pre-mRNA splicing guarantees an extended half-life and proper processing of nascent pre-mRNAs.,True,BACKGROUND
3581,Prescribed exercise training improves quality of life.,"CONTEXT Findings from previous studies of the effects of exercise training on patient-reported health status have been inconsistent.   
",False,OBJECTIVE
3582,Prescribed exercise training improves quality of life.,"OBJECTIVE To test the effects of exercise training on health status among patients with heart failure.   
",False,OBJECTIVE
3583,Prescribed exercise training improves quality of life.,"DESIGN, SETTING, AND PATIENTS Multicenter, randomized controlled trial among 2331 medically stable outpatients with heart failure with left ventricular ejection fraction of 35% or less.",False,METHODS
3584,Prescribed exercise training improves quality of life.,"Patients were randomized from April 2003 through February 2007.   
",False,METHODS
3585,Prescribed exercise training improves quality of life.,"INTERVENTIONS Usual care plus aerobic exercise training (n = 1172), consisting of 36 supervised sessions followed by home-based training, vs usual care alone (n = 1159).",False,METHODS
3586,Prescribed exercise training improves quality of life.,"Randomization was stratified by heart failure etiology, which was a covariate in all models.   
",False,METHODS
3587,Prescribed exercise training improves quality of life.,"MAIN OUTCOME MEASURES Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary scale and key subscales at baseline, every 3 months for 12 months, and annually thereafter for up to 4 years.",False,METHODS
3588,Prescribed exercise training improves quality of life.,The KCCQ is scored from 0 to 100 with higher scores corresponding to better health status.,False,METHODS
3589,Prescribed exercise training improves quality of life.,"Treatment group effects were estimated using linear mixed models according to the intention-to-treat principle.   
",False,METHODS
3590,Prescribed exercise training improves quality of life.,RESULTS Median follow-up was 2.5 years.,False,RESULTS
3591,Prescribed exercise training improves quality of life.,"At 3 months, usual care plus exercise training led to greater improvement in the KCCQ overall summary score (mean, 5.21; 95% confidence interval, 4.42 to 6.00) compared with usual care alone (3.28; 95% confidence interval, 2.48 to 4.09).",True,RESULTS
3592,Prescribed exercise training improves quality of life.,"The additional 1.93-point increase (95% confidence interval, 0.84 to 3.01) in the exercise training group was statistically significant (P < .001).",False,RESULTS
3593,Prescribed exercise training improves quality of life.,"After 3 months, there were no further significant changes in KCCQ score for either group (P = .85 for the difference between slopes), resulting in a sustained, greater improvement overall for the exercise group (P < .001).",True,RESULTS
3594,Prescribed exercise training improves quality of life.,"Results were similar on the KCCQ subscales, and no subgroup interactions were detected.   
",False,RESULTS
3595,Prescribed exercise training improves quality of life.,CONCLUSIONS Exercise training conferred modest but statistically significant improvements in self-reported health status compared with usual care without training.,True,CONCLUSIONS
3596,Prescribed exercise training improves quality of life.,"Improvements occurred early and persisted over time.   
",False,CONCLUSIONS
3597,Prescribed exercise training improves quality of life.,TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00047437.,False,CONCLUSIONS
3598,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"BACKGROUND Screening for cervical cancer based on testing for human papillomavirus (HPV) increases the sensitivity of detection of high-grade (grade 2 or 3) cervical intraepithelial neoplasia, but whether this gain represents overdiagnosis or protection against future high-grade cervical epithelial neoplasia or cervical cancer is unknown.   
",True,BACKGROUND
3599,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"METHODS In a population-based screening program in Sweden, 12,527 women 32 to 38 years of age were randomly assigned at a 1:1 ratio to have an HPV test plus a Papanicolaou (Pap) test (intervention group) or a Pap test alone (control group).",False,METHODS
3600,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Women with a positive HPV test and a normal Pap test result were offered a second HPV test at least 1 year later, and those who were found to be persistently infected with the same high-risk type of HPV were then offered colposcopy with cervical biopsy.",False,METHODS
3601,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,A similar number of double-blinded Pap smears and colposcopies with biopsy were performed in randomly selected women in the control group.,False,METHODS
3602,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,Comprehensive registry data were used to follow the women for a mean of 4.1 years.,False,METHODS
3603,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"The relative rates of grade 2 or 3 cervical intraepithelial neoplasia or cancer detected at enrollment and at subsequent screening examinations were calculated.   
",False,METHODS
3604,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"RESULTS At enrollment, the proportion of women in the intervention group who were found to have lesions of grade 2 or 3 cervical intraepithelial neoplasia or cancer was 51% greater (95% confidence interval [CI], 13 to 102) than the proportion of women in the control group who were found to have such lesions.",False,RESULTS
3605,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"At subsequent screening examinations, the proportion of women in the intervention group who were found to have grade 2 or 3 lesions or cancer was 42% less (95% CI, 4 to 64) and the proportion with grade 3 lesions or cancer was 47% less (95% CI, 2 to 71) than the proportions of control women who were found to have such lesions.",False,RESULTS
3606,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Women with persistent HPV infection remained at high risk for grade 2 or 3 lesions or cancer after referral for colposcopy.   
",False,RESULTS
3607,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,CONCLUSIONS The addition of an HPV test to the Pap test to screen women in their mid-30s for cervical cancer reduces the incidence of grade 2 or 3 cervical intraepithelial neoplasia or cancer detected by subsequent screening examinations.,True,CONCLUSIONS
3608,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"(ClinicalTrials.gov number, NCT00479375 [ClinicalTrials.gov].).",False,CONCLUSIONS
3609,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"BACKGROUND Human papillomavirus (HPV) testing is known to be more sensitive, but less specific than cytology for detecting cervical intraepithelial neoplasia (CIN).",True,BACKGROUND
3610,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"We assessed the efficacy of cervical-cancer screening policies that are based on HPV testing.   
",False,BACKGROUND
3611,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"METHODS Between March, 2004, and December, 2004, in two separate recruitment phases, women aged 25-60 years were randomly assigned to conventional cytology or to HPV testing in combination with liquid-based cytology (first phase) or alone (second phase).",False,METHODS
3612,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,Randomisation was done by computer in two screening centres and by sequential opening of numbered sealed envelopes in the remaining seven centres.,False,METHODS
3613,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"During phase one, women who were HPV-positive and aged 35-60 years were referred to colposcopy, whereas women aged 25-34 years were referred to colposcopy only if cytology was also abnormal or HPV testing was persistently positive.",False,METHODS
3614,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"During phase two, women in the HPV group were referred for colposcopy if the HPV test was positive.",False,METHODS
3615,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Two rounds of screening occurred in each phase, and all women had cytology testing only at the second round.",False,METHODS
3616,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"The primary endpoint was the detection of grade 2 and 3 CIN, and of invasive cervical cancers during the first and second screening rounds.",False,METHODS
3617,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,Analysis was done by intention to screen.,False,METHODS
3618,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"This trial is registered, number ISRCTN81678807.   
",False,METHODS
3619,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"FINDINGS In total for both phases, 47,001 women were randomly assigned to the cytology group and 47,369 to HPV testing.",False,RESULTS
3620,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"33,851 women from the cytology group and 32,998 from the HPV-testing group had a second round of screening.",False,RESULTS
3621,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,We also retrieved the histological diagnoses from screening done elsewhere.,False,RESULTS
3622,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"The detection of invasive cervical cancers was similar for the two groups in the first round of screening (nine in the cytology group vs seven in the HPV group, p=0.62); no cases were detected in the HPV group during round two, compared with nine in the cytology group (p=0.004).",False,RESULTS
3623,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Overall, in the two rounds of screening, 18 invasive cancers were detected in the cytology group versus seven in the HPV group (p=0.028).",False,RESULTS
3624,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Among women aged 35-60 years, at round one the relative detection (HPV vs cytology) was 2.00 (95% CI 1.44-2.77) for CIN2, 2.08 (1.47-2.95) for CIN3, and 2.03 (1.60-2.57) for CIN2 and 3 together.",True,RESULTS
3625,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"At round two the relative detection was 0.54 (0.23-1.28) for CIN2, 0.48 (0.21-1.11) for CIN3, and 0.51 (0.28-0.93) for CIN2 and 3 together.",False,RESULTS
3626,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Among women aged 25-34 years, there was significant heterogeneity between phases in the relative detection of CIN3.",False,RESULTS
3627,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,At round one the relative detection was 0.93 (0.52-1.64) in phase one and 3.91 (2.02-7.57) in phase two.,False,RESULTS
3628,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,At round two the relative detection was 1.34 (0.46-3.84) in phase one and 0.20 (0.04-0.93) in phase two.,False,RESULTS
3629,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Pooling both phases, the detection ratio of CIN2 for women aged 25-34 years was 4.09 (2.24-7.48) at round one and 0.64 (0.23-1.27) at round two.   
",False,RESULTS
3630,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"INTERPRETATION HPV-based screening is more effective than cytology in preventing invasive cervical cancer, by detecting persistent high-grade lesions earlier and providing a longer low-risk period.",True,CONCLUSIONS
3631,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"However, in younger women, HPV screening leads to over-diagnosis of regressive CIN2.   
",False,CONCLUSIONS
3632,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"FUNDING European Union, Italian Ministry of Health, Regional Health Administrations of Piemonte, Tuscany, Veneto and Emilia-Romagna, and Public Health Agency of Lazio.",False,BACKGROUND
3633,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"More than ever, clinicians need regularly updated reviews given the continuously increasing amount of new information regarding innovative cervical cancer prevention methods.",False,BACKGROUND
3634,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"A summary is given from recent meta-analyses and systematic reviews on 3 possible clinical applications of human papillomavirus (HPV) testing: triage of women with equivocal or low-grade cytologic abnormalities; prediction of the therapeutic outcome after treatment of cervical intraepithelial neoplasia (CIN) lesions, and last not but not least, primary screening for cervical cancer and pre-cancer.",False,BACKGROUND
3635,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Consistent evidence is available indicating that HPV-triage with the Hybrid Capture(®) 2 assay (Qiagen Gaithersburg, Inc., MD, USA [previously Digene Corp.] (HC2) is more accurate (higher sensitivity, similar specificity) than repeat cytology to triage women with equivocal Pap smear results.",False,METHODS
3636,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Several other tests show at least similar accuracy but mRNA testing with the APTIMA(®) (Gen-Probe Inc., San Diego, CA, USA) test is similarly sensitive but more specific compared to HC2.",False,METHODS
3637,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"In triage of low-grade squamous intraepithelial lesions (LSIL), HC2 is more sensitive but its specificity is substantially lower compared to repeat cytology.",False,METHODS
3638,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,The APTIMA(®) test is more specific than HC2 without showing a loss in sensitivity.,False,METHODS
3639,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Identification of DNA of HPV types 16 and/or 18, or RNA from the five most carcinogenic HPV types allow selecting women at highest risk for CIN3+ but the sensitivity and negative predictive value of these markers are lower than full-range high-risk HPV (hrHPV) testing.",False,METHODS
3640,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"After conservative treatment of cervical pre-cancer, HPV testing picks up more quickly, with higher sensitivity and not lower specificity, residual or recurrent high-grade CIN than follow-up cytology.",False,METHODS
3641,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Primary screening for hrHPV generally detects more CIN2, CIN3 or cancer compared to cytology at cut-off atypical squamous cells of undetermined significance (ASC-US) or LSIL, but is less specific.",True,METHODS
3642,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Combined HPV and cytology screening provides a further small gain in sensitivity at the expense of a considerable loss in specificity if positive by either test is referred to colposcopy, in comparison with HPV testing only.",False,METHODS
3643,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Randomised trials and follow-up of cohort studies consistently demonstrate a significantly lower cumulative incidence of CIN3+ and even of cancer, in women aged 30 years or older, who were at enrollment hrHPV DNA negative compared to those who were cytologically negative.",False,RESULTS
3644,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,The difference in cumulative risk of CIN3+ or cancer for double negative (cytology & HPV) versus only HPV-negative women is small.,False,RESULTS
3645,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"HC2, GP5+/6+ PCR (polymerase chain reaction), cobas(®) 4800 PCR (Roche Molecular Systems Inc., Alameda, CA, USA) and Real Time PCR (Abbott Molecular, Des Plaines, IL, USA) can be considered as clinically validated for use in primary screening.",False,RESULTS
3646,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,The loss in specificity associated with primary HPV-based screening can be compensated by appropriate algorithms involving reflex cytology and/or HPV genotyping for HPV16 or 18.,False,RESULTS
3647,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"There exists a substantial evidence base to support that HPV testing is advantageous both in triage of women with equivocal abnormal cytology, in surveillance after treatment of CIN lesions and in primary screening of women aged 30 years or older.",False,CONCLUSIONS
3648,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"However, the possible advantages offered by HPV-based screening require a well organised program with good compliance with screening and triage policies.",False,CONCLUSIONS
3649,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"This article forms part of a special supplement entitled ""Comprehensive Control of HPV Infections and Related Diseases"" Vaccine Volume 30, Supplement 5, 2012.",False,CONCLUSIONS
3650,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"BACKGROUND Human papillomavirus (HPV) testing is more sensitive for the detection of high-grade cervical lesions than is cytology, but detection of HPV by DNA screening in two screening rounds 5 years apart has not been assessed.",False,BACKGROUND
3651,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"The aim of this study was to assess whether HPV DNA testing in the first screen decreases detection of cervical intraepithelial neoplasia (CIN) grade 3 or worse, CIN grade 2 or worse, and cervical cancer in the second screening.   
",False,BACKGROUND
3652,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"METHODS In this randomised trial, women aged 29-56 years participating in the cervical screening programme in the Netherlands were randomly assigned to receive HPV DNA (GP5+/6+-PCR method) and cytology co-testing or cytology testing alone, from January, 1999, to September, 2002.",False,METHODS
3653,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,Randomisation (in a 1:1 ratio) was done with computer-generated random numbers after the cervical specimen had been taken.,False,METHODS
3654,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"At the second screening 5 years later, HPV DNA and cytology co-testing was done in both groups; researchers were masked to the patient's assignment.",False,METHODS
3655,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,The primary endpoint was the number of CIN grade 3 or worse detected.,False,METHODS
3656,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,Analysis was done by intention to screen.,False,METHODS
3657,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"The trial is now finished and is registered, number ISRCTN20781131.   
",False,METHODS
3658,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"FINDINGS 22,420 women were randomly assigned to the intervention group and 22 518 to the control group; 19 999 in the intervention group and 20,106 in the control group were eligible for analysis at the first screen.",False,RESULTS
3659,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"At the second screen, 19 579 women in the intervention group and 19,731 in the control group were eligible, of whom 16,750 and 16,743, respectively, attended the second screen.",False,RESULTS
3660,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"In the second round, CIN grade 3 or worse was less common in the intervention group than in the control group (88 of 19 579 in the intervention group vs 122 of 19,731 in the control group; relative risk 0·73, 95% CI 0·55-0·96; p=0·023).",False,RESULTS
3661,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Cervical cancer was also less common in the intervention group than in the control group (four of 19 579 in the intervention group vs 14 of 19,731; 0·29, 0·10-0·87; p=0·031).",False,RESULTS
3662,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"In the baseline round, detection of CIN grade 3 or worse did not differ significantly between groups (171 of 19 999 vs 150 of 20,106; 1·15, 0·92-1·43; p=0·239) but was significantly more common in women with normal cytology (34 of 19,286 vs 12 of 19,373; 2·85, 1·47-5·49; p=0·001).",False,RESULTS
3663,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Furthermore, significantly more cases of CIN grade 2 or worse were detected in the intervention group than in the control group (267 of 19 999 vs 215 of 20,106; 1·25, 1·05-1·50; p=0·015).",True,RESULTS
3664,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"In the second screen, fewer HPV16-positive CIN grade 3 or worse were detected in the intervention group than in the control group (17 of 9481 vs 35 of 9354; 0·48, 0·27-0·85; p=0·012); detection of non-HPV16-positive CIN grade 3 or worse did not differ between groups (25 of 9481 vs 25 of 9354; 0·99, 0·57-1·72; p=1·00).",False,RESULTS
3665,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"The cumulative detection of CIN grade 3 or worse and CIN grade 2 or worse did not differ significantly between study arms, neither for the whole study group (CIN grade 3 or worse: 259 of 19 999 vs 272 of 20,106; 0·96, 0·81-1·14, p=0·631; CIN grade 2 or worse: 427 of 19 999 vs 399 of 20,106; 1·08, 0·94-1·24; p=0·292), nor for subgroups of women invited for the first time (CIN grade 3 or worse in women aged 29-33 years: 102 of 3139 vs 105 of 3128; 0·97, 0·74-1·27; CIN grade 2 or worse in women aged 29-33 years: 153 of 3139 vs 151 of 3128; 1·01, 0·81-1·26; CIN grade 3 or worse in women aged 34-56 years: 157 of 16,860 vs 167 of 16 978; 0·95, 0·76-1·18; CIN grade 2 or worse in women aged 34-56 years: 274 of 16,860 vs 248 of 16 978; 1·11, 0·94-1·32).   
",False,RESULTS
3666,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"INTERPRETATION Implementation of HPV DNA testing in cervical screening leads to earlier detection of clinically relevant CIN grade 2 or worse, which when adequately treated, improves protection against CIN grade 3 or worse and cervical cancer.",False,CONCLUSIONS
3667,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,Early detection of high-grade cervical legions caused by HPV16 was a major component of this benefit.,False,CONCLUSIONS
3668,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Our results lend support to the use of HPV DNA testing for all women aged 29 years and older.   
",False,CONCLUSIONS
3669,Primary cervical cancer screening with HPV detection has lower longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,FUNDING Zorg Onderzoek Nederland (Netherlands Organisation for Health Research and Development).,False,BACKGROUND
3670,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"OBJECTIVE To assess the performance and impact of primary human papillomavirus (HPV) DNA screening with cytology triage compared with conventional cytology on cervical cancer and severe pre-cancerous lesions.   
",False,OBJECTIVE
3671,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"DESIGN Randomised trial.   
",False,METHODS
3672,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"SETTING Population based screening programme for cervical cancer in southern Finland in 2003-5.   
",False,METHODS
3673,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"PARTICIPANTS 58 076 women, aged 30-60, invited to the routine population based screening programme for cervical cancer.   
",False,METHODS
3674,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"INTERVENTIONS Primary HPV DNA test (hybrid capture II) with cytology triage if the result was positive or conventional cytological screening (reference).   
",False,METHODS
3675,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"MAIN OUTCOME MEASURES Rate of cervical cancer, cervical intraepithelial neoplasia (CIN) grade III, and adenocarcinoma in situ (as a composite outcome referred to as CIN III+) during 2003-7 through record linkage between files from the screening registry and the national cancer registry.   
",False,METHODS
3676,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"RESULTS In the HPV and conventional arms there were 95 600 and 95 700 woman years of follow-up and 76 and 53 cases of CIN III+, respectively (of which six and eight were cervical cancers).",False,RESULTS
3677,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,The relative rate of CIN III+ in the HPV arm versus the conventional arm was 1.44 (95% confidence interval 1.01 to 2.05) among all women invited for screening and 1.77 (1.16 to 2.74) among those who attended.,True,RESULTS
3678,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"Among women with a normal or negative test result, the relative rate of subsequent CIN III+ was 0.28 (0.04 to 1.17).",False,RESULTS
3679,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"The rate of cervical cancer between arms was 0.75 (0.25 to 2.16) among women invited for screening and 1.98 (0.52 to 9.38) among those who attended.   
",False,RESULTS
3680,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"CONCLUSIONS When incorporated into a well established organised screening programme, primary HPV screening with cytology triage was more sensitive than conventional cytology in detecting CIN III+ lesions.",True,CONCLUSIONS
3681,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"The number of cases of cervical cancer was small, but considering the high probability of progression of CIN III the findings are of importance regarding cancer prevention.   
",False,CONCLUSIONS
3682,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,TRIAL REGISTRATION Current Controlled Trials ISRCTN23885553.,False,CONCLUSIONS
3683,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"BACKGROUND Human papillomavirus (HPV) testing is known to be more sensitive, but less specific than cytology for detecting cervical intraepithelial neoplasia (CIN).",True,BACKGROUND
3684,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"We assessed the efficacy of cervical-cancer screening policies that are based on HPV testing.   
",False,BACKGROUND
3685,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"METHODS Between March, 2004, and December, 2004, in two separate recruitment phases, women aged 25-60 years were randomly assigned to conventional cytology or to HPV testing in combination with liquid-based cytology (first phase) or alone (second phase).",False,METHODS
3686,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,Randomisation was done by computer in two screening centres and by sequential opening of numbered sealed envelopes in the remaining seven centres.,False,METHODS
3687,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"During phase one, women who were HPV-positive and aged 35-60 years were referred to colposcopy, whereas women aged 25-34 years were referred to colposcopy only if cytology was also abnormal or HPV testing was persistently positive.",False,METHODS
3688,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"During phase two, women in the HPV group were referred for colposcopy if the HPV test was positive.",False,METHODS
3689,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"Two rounds of screening occurred in each phase, and all women had cytology testing only at the second round.",False,METHODS
3690,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"The primary endpoint was the detection of grade 2 and 3 CIN, and of invasive cervical cancers during the first and second screening rounds.",False,METHODS
3691,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,Analysis was done by intention to screen.,False,METHODS
3692,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"This trial is registered, number ISRCTN81678807.   
",False,METHODS
3693,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"FINDINGS In total for both phases, 47,001 women were randomly assigned to the cytology group and 47,369 to HPV testing.",False,RESULTS
3694,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"33,851 women from the cytology group and 32,998 from the HPV-testing group had a second round of screening.",False,RESULTS
3695,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,We also retrieved the histological diagnoses from screening done elsewhere.,False,RESULTS
3696,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"The detection of invasive cervical cancers was similar for the two groups in the first round of screening (nine in the cytology group vs seven in the HPV group, p=0.62); no cases were detected in the HPV group during round two, compared with nine in the cytology group (p=0.004).",False,RESULTS
3697,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"Overall, in the two rounds of screening, 18 invasive cancers were detected in the cytology group versus seven in the HPV group (p=0.028).",False,RESULTS
3698,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"Among women aged 35-60 years, at round one the relative detection (HPV vs cytology) was 2.00 (95% CI 1.44-2.77) for CIN2, 2.08 (1.47-2.95) for CIN3, and 2.03 (1.60-2.57) for CIN2 and 3 together.",False,RESULTS
3699,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"At round two the relative detection was 0.54 (0.23-1.28) for CIN2, 0.48 (0.21-1.11) for CIN3, and 0.51 (0.28-0.93) for CIN2 and 3 together.",False,RESULTS
3700,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"Among women aged 25-34 years, there was significant heterogeneity between phases in the relative detection of CIN3.",False,RESULTS
3701,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,At round one the relative detection was 0.93 (0.52-1.64) in phase one and 3.91 (2.02-7.57) in phase two.,False,RESULTS
3702,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,At round two the relative detection was 1.34 (0.46-3.84) in phase one and 0.20 (0.04-0.93) in phase two.,False,RESULTS
3703,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"Pooling both phases, the detection ratio of CIN2 for women aged 25-34 years was 4.09 (2.24-7.48) at round one and 0.64 (0.23-1.27) at round two.   
",False,RESULTS
3704,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"INTERPRETATION HPV-based screening is more effective than cytology in preventing invasive cervical cancer, by detecting persistent high-grade lesions earlier and providing a longer low-risk period.",True,CONCLUSIONS
3705,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"However, in younger women, HPV screening leads to over-diagnosis of regressive CIN2.   
",False,CONCLUSIONS
3706,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"FUNDING European Union, Italian Ministry of Health, Regional Health Administrations of Piemonte, Tuscany, Veneto and Emilia-Romagna, and Public Health Agency of Lazio.",False,BACKGROUND
3707,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"More than ever, clinicians need regularly updated reviews given the continuously increasing amount of new information regarding innovative cervical cancer prevention methods.",False,BACKGROUND
3708,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"A summary is given from recent meta-analyses and systematic reviews on 3 possible clinical applications of human papillomavirus (HPV) testing: triage of women with equivocal or low-grade cytologic abnormalities; prediction of the therapeutic outcome after treatment of cervical intraepithelial neoplasia (CIN) lesions, and last not but not least, primary screening for cervical cancer and pre-cancer.",False,BACKGROUND
3709,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"Consistent evidence is available indicating that HPV-triage with the Hybrid Capture(®) 2 assay (Qiagen Gaithersburg, Inc., MD, USA [previously Digene Corp.] (HC2) is more accurate (higher sensitivity, similar specificity) than repeat cytology to triage women with equivocal Pap smear results.",False,METHODS
3710,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"Several other tests show at least similar accuracy but mRNA testing with the APTIMA(®) (Gen-Probe Inc., San Diego, CA, USA) test is similarly sensitive but more specific compared to HC2.",False,METHODS
3711,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"In triage of low-grade squamous intraepithelial lesions (LSIL), HC2 is more sensitive but its specificity is substantially lower compared to repeat cytology.",False,METHODS
3712,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,The APTIMA(®) test is more specific than HC2 without showing a loss in sensitivity.,False,METHODS
3713,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"Identification of DNA of HPV types 16 and/or 18, or RNA from the five most carcinogenic HPV types allow selecting women at highest risk for CIN3+ but the sensitivity and negative predictive value of these markers are lower than full-range high-risk HPV (hrHPV) testing.",False,METHODS
3714,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"After conservative treatment of cervical pre-cancer, HPV testing picks up more quickly, with higher sensitivity and not lower specificity, residual or recurrent high-grade CIN than follow-up cytology.",True,METHODS
3715,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"Primary screening for hrHPV generally detects more CIN2, CIN3 or cancer compared to cytology at cut-off atypical squamous cells of undetermined significance (ASC-US) or LSIL, but is less specific.",True,METHODS
3716,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"Combined HPV and cytology screening provides a further small gain in sensitivity at the expense of a considerable loss in specificity if positive by either test is referred to colposcopy, in comparison with HPV testing only.",False,METHODS
3717,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"Randomised trials and follow-up of cohort studies consistently demonstrate a significantly lower cumulative incidence of CIN3+ and even of cancer, in women aged 30 years or older, who were at enrollment hrHPV DNA negative compared to those who were cytologically negative.",False,RESULTS
3718,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,The difference in cumulative risk of CIN3+ or cancer for double negative (cytology & HPV) versus only HPV-negative women is small.,False,RESULTS
3719,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"HC2, GP5+/6+ PCR (polymerase chain reaction), cobas(®) 4800 PCR (Roche Molecular Systems Inc., Alameda, CA, USA) and Real Time PCR (Abbott Molecular, Des Plaines, IL, USA) can be considered as clinically validated for use in primary screening.",False,RESULTS
3720,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,The loss in specificity associated with primary HPV-based screening can be compensated by appropriate algorithms involving reflex cytology and/or HPV genotyping for HPV16 or 18.,False,RESULTS
3721,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"There exists a substantial evidence base to support that HPV testing is advantageous both in triage of women with equivocal abnormal cytology, in surveillance after treatment of CIN lesions and in primary screening of women aged 30 years or older.",False,CONCLUSIONS
3722,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"However, the possible advantages offered by HPV-based screening require a well organised program with good compliance with screening and triage policies.",False,CONCLUSIONS
3723,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"This article forms part of a special supplement entitled ""Comprehensive Control of HPV Infections and Related Diseases"" Vaccine Volume 30, Supplement 5, 2012.",False,CONCLUSIONS
3724,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"BACKGROUND Human papillomavirus (HPV) testing is more sensitive for the detection of high-grade cervical lesions than is cytology, but detection of HPV by DNA screening in two screening rounds 5 years apart has not been assessed.",False,BACKGROUND
3725,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"The aim of this study was to assess whether HPV DNA testing in the first screen decreases detection of cervical intraepithelial neoplasia (CIN) grade 3 or worse, CIN grade 2 or worse, and cervical cancer in the second screening.   
",False,BACKGROUND
3726,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"METHODS In this randomised trial, women aged 29-56 years participating in the cervical screening programme in the Netherlands were randomly assigned to receive HPV DNA (GP5+/6+-PCR method) and cytology co-testing or cytology testing alone, from January, 1999, to September, 2002.",False,METHODS
3727,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,Randomisation (in a 1:1 ratio) was done with computer-generated random numbers after the cervical specimen had been taken.,False,METHODS
3728,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"At the second screening 5 years later, HPV DNA and cytology co-testing was done in both groups; researchers were masked to the patient's assignment.",False,METHODS
3729,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,The primary endpoint was the number of CIN grade 3 or worse detected.,False,METHODS
3730,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,Analysis was done by intention to screen.,False,METHODS
3731,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"The trial is now finished and is registered, number ISRCTN20781131.   
",False,METHODS
3732,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"FINDINGS 22,420 women were randomly assigned to the intervention group and 22 518 to the control group; 19 999 in the intervention group and 20,106 in the control group were eligible for analysis at the first screen.",False,RESULTS
3733,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"At the second screen, 19 579 women in the intervention group and 19,731 in the control group were eligible, of whom 16,750 and 16,743, respectively, attended the second screen.",False,RESULTS
3734,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"In the second round, CIN grade 3 or worse was less common in the intervention group than in the control group (88 of 19 579 in the intervention group vs 122 of 19,731 in the control group; relative risk 0·73, 95% CI 0·55-0·96; p=0·023).",False,RESULTS
3735,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"Cervical cancer was also less common in the intervention group than in the control group (four of 19 579 in the intervention group vs 14 of 19,731; 0·29, 0·10-0·87; p=0·031).",False,RESULTS
3736,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"In the baseline round, detection of CIN grade 3 or worse did not differ significantly between groups (171 of 19 999 vs 150 of 20,106; 1·15, 0·92-1·43; p=0·239) but was significantly more common in women with normal cytology (34 of 19,286 vs 12 of 19,373; 2·85, 1·47-5·49; p=0·001).",False,RESULTS
3737,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"Furthermore, significantly more cases of CIN grade 2 or worse were detected in the intervention group than in the control group (267 of 19 999 vs 215 of 20,106; 1·25, 1·05-1·50; p=0·015).",True,RESULTS
3738,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"In the second screen, fewer HPV16-positive CIN grade 3 or worse were detected in the intervention group than in the control group (17 of 9481 vs 35 of 9354; 0·48, 0·27-0·85; p=0·012); detection of non-HPV16-positive CIN grade 3 or worse did not differ between groups (25 of 9481 vs 25 of 9354; 0·99, 0·57-1·72; p=1·00).",False,RESULTS
3739,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"The cumulative detection of CIN grade 3 or worse and CIN grade 2 or worse did not differ significantly between study arms, neither for the whole study group (CIN grade 3 or worse: 259 of 19 999 vs 272 of 20,106; 0·96, 0·81-1·14, p=0·631; CIN grade 2 or worse: 427 of 19 999 vs 399 of 20,106; 1·08, 0·94-1·24; p=0·292), nor for subgroups of women invited for the first time (CIN grade 3 or worse in women aged 29-33 years: 102 of 3139 vs 105 of 3128; 0·97, 0·74-1·27; CIN grade 2 or worse in women aged 29-33 years: 153 of 3139 vs 151 of 3128; 1·01, 0·81-1·26; CIN grade 3 or worse in women aged 34-56 years: 157 of 16,860 vs 167 of 16 978; 0·95, 0·76-1·18; CIN grade 2 or worse in women aged 34-56 years: 274 of 16,860 vs 248 of 16 978; 1·11, 0·94-1·32).   
",False,RESULTS
3740,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"INTERPRETATION Implementation of HPV DNA testing in cervical screening leads to earlier detection of clinically relevant CIN grade 2 or worse, which when adequately treated, improves protection against CIN grade 3 or worse and cervical cancer.",True,CONCLUSIONS
3741,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,Early detection of high-grade cervical legions caused by HPV16 was a major component of this benefit.,False,CONCLUSIONS
3742,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,"Our results lend support to the use of HPV DNA testing for all women aged 29 years and older.   
",False,CONCLUSIONS
3743,Primary cervical cytology screening with HPV detection has higher longitudinal sensitivity to detect severe cervical intraepithelial neoplasia than conventional cytology.,FUNDING Zorg Onderzoek Nederland (Netherlands Organisation for Health Research and Development).,False,BACKGROUND
3744,Pro-inflammatory cytokines are up regulated during tumor development.,"OBJECTIVES We investigated the role of cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in cachexia development in newly diagnosed nonsmall cell lung cancer (NSCLC) patients.   
",False,OBJECTIVE
3745,Pro-inflammatory cytokines are up regulated during tumor development.,METHODS : We evaluated 44 (M/F:41/3) NSCLC patients and 12 (M/F:10/2) age matched healthy smokers.,False,METHODS
3746,Pro-inflammatory cytokines are up regulated during tumor development.,"NSCLC cases with a weight loss of > or =10% consisted the cachectic group (n:23, M/F:21/2) and the ones with <10% weight loss consisted the noncachectic group (n:21, M/F:19/2).   
",False,METHODS
3747,Pro-inflammatory cytokines are up regulated during tumor development.,RESULTS Body mass index (BMI) of cachectics was significantly lower than that of noncachectics (21.0 +/- 2.9 versus 24.5 +/-,False,RESULTS
3748,Pro-inflammatory cytokines are up regulated during tumor development.,"3.6, P = 0.02) and controls (21.0 +/- 2.9 versus 25.5 +/- 2.6, P = 0.01).",False,RESULTS
3749,Pro-inflammatory cytokines are up regulated during tumor development.,Serum TNF-alpha level did not differ between cachectic and noncachectics (37.3 +/-,False,RESULTS
3750,Pro-inflammatory cytokines are up regulated during tumor development.,39.1 and 51.6 +/-,False,RESULTS
3751,Pro-inflammatory cytokines are up regulated during tumor development.,"84.2 pg/mL, respectively).",False,RESULTS
3752,Pro-inflammatory cytokines are up regulated during tumor development.,"However, it was significantly higher in NSCLC patients compared with controls (44.1 +/- 64.3 and 15.1 +/-",True,RESULTS
3753,Pro-inflammatory cytokines are up regulated during tumor development.,"14.3 pg/mL, P = 0.03).",True,RESULTS
3754,Pro-inflammatory cytokines are up regulated during tumor development.,"Serum IL-6 level was not different between 3 groups (6.4 +/- 4.1, 8.9 +/-",False,RESULTS
3755,Pro-inflammatory cytokines are up regulated during tumor development.,"16.3, and 4.1 +/-",False,RESULTS
3756,Pro-inflammatory cytokines are up regulated during tumor development.,"3.5 pg/mL, respectively)",False,RESULTS
3757,Pro-inflammatory cytokines are up regulated during tumor development.,"but it correlated significantly with TNF-alpha (r = 0.4, P = 0.006) and BMI (r = -0.3, P = 0.03).",False,RESULTS
3758,Pro-inflammatory cytokines are up regulated during tumor development.,"Erythrocyte sedimentation rate (ESR) correlated significantly with TNF-alpha (r = 0.4, P = 0.003) and BMI (r = -0.3, P = 0.03).",False,RESULTS
3759,Pro-inflammatory cytokines are up regulated during tumor development.,"Among 44 cases, survival of 12 and 17 patients was recorded in cachectics and noncachectics, with no statistical difference (12.2 +/- 3.7 and 11.2 +/-",False,RESULTS
3760,Pro-inflammatory cytokines are up regulated during tumor development.,"1.0 months, respectively).   
",False,RESULTS
3761,Pro-inflammatory cytokines are up regulated during tumor development.,CONCLUSIONS TNF-alpha and IL-6 levels did not differ significantly between cachectics and noncachectics.,False,CONCLUSIONS
3762,Pro-inflammatory cytokines are up regulated during tumor development.,"However, significant correlations between IL-6, BMI, and TNF-alpha suggested that these cytokines acted as cofactors in weight loss.",False,CONCLUSIONS
3763,Pro-inflammatory cytokines are up regulated during tumor development.,"Survival was neither influenced by BMI, nor the cytokine levels in the present study.",False,CONCLUSIONS
3764,Pro-inflammatory cytokines are up regulated during tumor development.,The significant correlation of ESR with TNF-alpha suggested that ESR could provide valuable clue for considerable weight loss in the follow-up of NSCLC patients.,False,CONCLUSIONS
3765,Progerin induces premature aging in stem cells.,"Reprogramming somatic cells to induced pluripotent stem cells (iPSCs) resets their identity back to an embryonic age and, thus, presents a significant hurdle for modeling late-onset disorders.",False,BACKGROUND
3766,Progerin induces premature aging in stem cells.,"In this study, we describe a strategy for inducing aging-related features in human iPSC-derived lineages and apply it to the modeling of Parkinson's disease (PD).",False,BACKGROUND
3767,Progerin induces premature aging in stem cells.,"Our approach involves expression of progerin, a truncated form of lamin A associated with premature aging.",False,RESULTS
3768,Progerin induces premature aging in stem cells.,"We found that expression of progerin in iPSC-derived fibroblasts and neurons induces multiple aging-related markers and characteristics, including dopamine-specific phenotypes such as neuromelanin accumulation.",True,RESULTS
3769,Progerin induces premature aging in stem cells.,"Induced aging in PD iPSC-derived dopamine neurons revealed disease phenotypes that require both aging and genetic susceptibility, such as pronounced dendrite degeneration, progressive loss of tyrosine hydroxylase (TH) expression, and enlarged mitochondria or Lewy-body-precursor inclusions.",False,CONCLUSIONS
3770,Progerin induces premature aging in stem cells.,"Thus, our study suggests that progerin-induced aging can be used to reveal late-onset age-related disease features in hiPSC-based disease models.",True,CONCLUSIONS
3771,Propriospinal interneurons that play a role in the plastic reorganization of spinal circuits are integral for recovery from spinal cord injury.,Spinal cord injuries (SCIs) in humans and experimental animals are often associated with varying degrees of spontaneous functional recovery during the first months after injury.,False,BACKGROUND
3772,Propriospinal interneurons that play a role in the plastic reorganization of spinal circuits are integral for recovery from spinal cord injury.,"Such recovery is widely attributed to axons spared from injury that descend from the brain and bypass incomplete lesions, but its mechanisms are uncertain.",False,BACKGROUND
3773,Propriospinal interneurons that play a role in the plastic reorganization of spinal circuits are integral for recovery from spinal cord injury.,"To investigate the neural basis of spontaneous recovery, we used kinematic, physiological and anatomical analyses to evaluate mice with various combinations of spatially and temporally separated lateral hemisections with or without the excitotoxic ablation of intrinsic spinal cord neurons.",False,METHODS
3774,Propriospinal interneurons that play a role in the plastic reorganization of spinal circuits are integral for recovery from spinal cord injury.,"We show that propriospinal relay connections that bypass one or more injury sites are able to mediate spontaneous functional recovery and supraspinal control of stepping, even when there has been essentially total and irreversible interruption of long descending supraspinal pathways in mice.",True,RESULTS
3775,Propriospinal interneurons that play a role in the plastic reorganization of spinal circuits are integral for recovery from spinal cord injury.,Our findings show that pronounced functional recovery can occur after severe SCI without the maintenance or regeneration of direct projections from the brain past the lesion and can be mediated by the reorganization of descending and propriospinal connections.,True,CONCLUSIONS
3776,Propriospinal interneurons that play a role in the plastic reorganization of spinal circuits are integral for recovery from spinal cord injury.,Targeting interventions toward augmenting the remodeling of relay connections may provide new therapeutic strategies to bypass lesions and restore function after SCI and in other conditions such as stroke and multiple sclerosis.,False,CONCLUSIONS
3777,Pseudogene PTENP1 encodes a transcript that regulates PTEN expression.,The canonical role of messenger RNA (mRNA) is to deliver protein-coding information to sites of protein synthesis.,False,BACKGROUND
3778,Pseudogene PTENP1 encodes a transcript that regulates PTEN expression.,"However, given that microRNAs bind to RNAs, we hypothesized that RNAs could possess a regulatory role that relies on their ability to compete for microRNA binding, independently of their protein-coding function.",False,BACKGROUND
3779,Pseudogene PTENP1 encodes a transcript that regulates PTEN expression.,"As a model for the protein-coding-independent role of RNAs, we describe the functional relationship between the mRNAs produced by the PTEN tumour suppressor gene and its pseudogene PTENP1 and the critical consequences of this interaction.",False,BACKGROUND
3780,Pseudogene PTENP1 encodes a transcript that regulates PTEN expression.,We find that PTENP1 is biologically active as it can regulate cellular levels of PTEN and exert a growth-suppressive role.,True,RESULTS
3781,Pseudogene PTENP1 encodes a transcript that regulates PTEN expression.,We also show that the PTENP1 locus is selectively lost in human cancer.,False,RESULTS
3782,Pseudogene PTENP1 encodes a transcript that regulates PTEN expression.,"We extended our analysis to other cancer-related genes that possess pseudogenes, such as oncogenic KRAS.",False,RESULTS
3783,Pseudogene PTENP1 encodes a transcript that regulates PTEN expression.,We also demonstrate that the transcripts of protein-coding genes such as PTEN are biologically active.,False,RESULTS
3784,Pseudogene PTENP1 encodes a transcript that regulates PTEN expression.,"These findings attribute a novel biological role to expressed pseudogenes, as they can regulate coding gene expression, and reveal a non-coding function for mRNAs.",False,CONCLUSIONS
3785,Pyridostatin decreases telomere fragility in BRCA2-deficient cells.,"G-quadruplex (G4)-forming genomic sequences, including telomeres, represent natural replication fork barriers.",False,BACKGROUND
3786,Pyridostatin decreases telomere fragility in BRCA2-deficient cells.,"Stalled replication forks can be stabilized and restarted by homologous recombination (HR), which also repairs DNA double-strand breaks (DSBs) arising at collapsed forks.",False,BACKGROUND
3787,Pyridostatin decreases telomere fragility in BRCA2-deficient cells.,We have previously shown that HR facilitates telomere replication.,False,BACKGROUND
3788,Pyridostatin decreases telomere fragility in BRCA2-deficient cells.,"Here, we demonstrate that the replication efficiency of guanine-rich (G-rich) telomeric repeats is decreased significantly in cells lacking HR.",False,BACKGROUND
3789,Pyridostatin decreases telomere fragility in BRCA2-deficient cells.,"Treatment with the G4-stabilizing compound pyridostatin (PDS) increases telomere fragility in BRCA2-deficient cells, suggesting that G4 formation drives telomere instability.",True,BACKGROUND
3790,Pyridostatin decreases telomere fragility in BRCA2-deficient cells.,"Remarkably, PDS reduces proliferation of HR-defective cells by inducing DSB accumulation, checkpoint activation, and deregulated G2/M progression and by enhancing the replication defect intrinsic to HR deficiency.",False,BACKGROUND
3791,Pyridostatin decreases telomere fragility in BRCA2-deficient cells.,PDS toxicity extends to HR-defective cells that have acquired olaparib resistance through loss of 53BP1 or REV7.,False,BACKGROUND
3792,Pyridostatin decreases telomere fragility in BRCA2-deficient cells.,"Altogether, these results highlight the therapeutic potential of G4-stabilizing drugs to selectively eliminate HR-compromised cells and tumors, including those resistant to PARP inhibition.",False,BACKGROUND
3793,Pyridostatin deregulates G2/M progression.,"G-quadruplex (G4)-forming genomic sequences, including telomeres, represent natural replication fork barriers.",False,BACKGROUND
3794,Pyridostatin deregulates G2/M progression.,"Stalled replication forks can be stabilized and restarted by homologous recombination (HR), which also repairs DNA double-strand breaks (DSBs) arising at collapsed forks.",False,BACKGROUND
3795,Pyridostatin deregulates G2/M progression.,We have previously shown that HR facilitates telomere replication.,False,BACKGROUND
3796,Pyridostatin deregulates G2/M progression.,"Here, we demonstrate that the replication efficiency of guanine-rich (G-rich) telomeric repeats is decreased significantly in cells lacking HR.",False,BACKGROUND
3797,Pyridostatin deregulates G2/M progression.,"Treatment with the G4-stabilizing compound pyridostatin (PDS) increases telomere fragility in BRCA2-deficient cells, suggesting that G4 formation drives telomere instability.",False,BACKGROUND
3798,Pyridostatin deregulates G2/M progression.,"Remarkably, PDS reduces proliferation of HR-defective cells by inducing DSB accumulation, checkpoint activation, and deregulated G2/M progression and by enhancing the replication defect intrinsic to HR deficiency.",True,BACKGROUND
3799,Pyridostatin deregulates G2/M progression.,PDS toxicity extends to HR-defective cells that have acquired olaparib resistance through loss of 53BP1 or REV7.,False,BACKGROUND
3800,Pyridostatin deregulates G2/M progression.,"Altogether, these results highlight the therapeutic potential of G4-stabilizing drugs to selectively eliminate HR-compromised cells and tumors, including those resistant to PARP inhibition.",False,BACKGROUND
3801,Pyridostatin encourages proliferation of homologous recombination - defective cells.,"G-quadruplex (G4)-forming genomic sequences, including telomeres, represent natural replication fork barriers.",False,BACKGROUND
3802,Pyridostatin encourages proliferation of homologous recombination - defective cells.,"Stalled replication forks can be stabilized and restarted by homologous recombination (HR), which also repairs DNA double-strand breaks (DSBs) arising at collapsed forks.",False,BACKGROUND
3803,Pyridostatin encourages proliferation of homologous recombination - defective cells.,We have previously shown that HR facilitates telomere replication.,False,BACKGROUND
3804,Pyridostatin encourages proliferation of homologous recombination - defective cells.,"Here, we demonstrate that the replication efficiency of guanine-rich (G-rich) telomeric repeats is decreased significantly in cells lacking HR.",False,BACKGROUND
3805,Pyridostatin encourages proliferation of homologous recombination - defective cells.,"Treatment with the G4-stabilizing compound pyridostatin (PDS) increases telomere fragility in BRCA2-deficient cells, suggesting that G4 formation drives telomere instability.",False,BACKGROUND
3806,Pyridostatin encourages proliferation of homologous recombination - defective cells.,"Remarkably, PDS reduces proliferation of HR-defective cells by inducing DSB accumulation, checkpoint activation, and deregulated G2/M progression and by enhancing the replication defect intrinsic to HR deficiency.",True,BACKGROUND
3807,Pyridostatin encourages proliferation of homologous recombination - defective cells.,PDS toxicity extends to HR-defective cells that have acquired olaparib resistance through loss of 53BP1 or REV7.,False,BACKGROUND
3808,Pyridostatin encourages proliferation of homologous recombination - defective cells.,"Altogether, these results highlight the therapeutic potential of G4-stabilizing drugs to selectively eliminate HR-compromised cells and tumors, including those resistant to PARP inhibition.",False,BACKGROUND
3809,Pyridostatin induces checkpoint activation.,"G-quadruplex (G4)-forming genomic sequences, including telomeres, represent natural replication fork barriers.",False,BACKGROUND
3810,Pyridostatin induces checkpoint activation.,"Stalled replication forks can be stabilized and restarted by homologous recombination (HR), which also repairs DNA double-strand breaks (DSBs) arising at collapsed forks.",False,BACKGROUND
3811,Pyridostatin induces checkpoint activation.,We have previously shown that HR facilitates telomere replication.,False,BACKGROUND
3812,Pyridostatin induces checkpoint activation.,"Here, we demonstrate that the replication efficiency of guanine-rich (G-rich) telomeric repeats is decreased significantly in cells lacking HR.",False,BACKGROUND
3813,Pyridostatin induces checkpoint activation.,"Treatment with the G4-stabilizing compound pyridostatin (PDS) increases telomere fragility in BRCA2-deficient cells, suggesting that G4 formation drives telomere instability.",False,BACKGROUND
3814,Pyridostatin induces checkpoint activation.,"Remarkably, PDS reduces proliferation of HR-defective cells by inducing DSB accumulation, checkpoint activation, and deregulated G2/M progression and by enhancing the replication defect intrinsic to HR deficiency.",True,BACKGROUND
3815,Pyridostatin induces checkpoint activation.,PDS toxicity extends to HR-defective cells that have acquired olaparib resistance through loss of 53BP1 or REV7.,False,BACKGROUND
3816,Pyridostatin induces checkpoint activation.,"Altogether, these results highlight the therapeutic potential of G4-stabilizing drugs to selectively eliminate HR-compromised cells and tumors, including those resistant to PARP inhibition.",False,BACKGROUND
3817,Pyridostatin induces double-strand breaks accumulation.,"G-quadruplex (G4)-forming genomic sequences, including telomeres, represent natural replication fork barriers.",False,BACKGROUND
3818,Pyridostatin induces double-strand breaks accumulation.,"Stalled replication forks can be stabilized and restarted by homologous recombination (HR), which also repairs DNA double-strand breaks (DSBs) arising at collapsed forks.",False,BACKGROUND
3819,Pyridostatin induces double-strand breaks accumulation.,We have previously shown that HR facilitates telomere replication.,False,BACKGROUND
3820,Pyridostatin induces double-strand breaks accumulation.,"Here, we demonstrate that the replication efficiency of guanine-rich (G-rich) telomeric repeats is decreased significantly in cells lacking HR.",False,BACKGROUND
3821,Pyridostatin induces double-strand breaks accumulation.,"Treatment with the G4-stabilizing compound pyridostatin (PDS) increases telomere fragility in BRCA2-deficient cells, suggesting that G4 formation drives telomere instability.",False,BACKGROUND
3822,Pyridostatin induces double-strand breaks accumulation.,"Remarkably, PDS reduces proliferation of HR-defective cells by inducing DSB accumulation, checkpoint activation, and deregulated G2/M progression and by enhancing the replication defect intrinsic to HR deficiency.",True,BACKGROUND
3823,Pyridostatin induces double-strand breaks accumulation.,PDS toxicity extends to HR-defective cells that have acquired olaparib resistance through loss of 53BP1 or REV7.,False,BACKGROUND
3824,Pyridostatin induces double-strand breaks accumulation.,"Altogether, these results highlight the therapeutic potential of G4-stabilizing drugs to selectively eliminate HR-compromised cells and tumors, including those resistant to PARP inhibition.",False,BACKGROUND
3825,Pyridostatin prevents double-strand breaks accumulation.,"G-quadruplex (G4)-forming genomic sequences, including telomeres, represent natural replication fork barriers.",False,BACKGROUND
3826,Pyridostatin prevents double-strand breaks accumulation.,"Stalled replication forks can be stabilized and restarted by homologous recombination (HR), which also repairs DNA double-strand breaks (DSBs) arising at collapsed forks.",False,BACKGROUND
3827,Pyridostatin prevents double-strand breaks accumulation.,We have previously shown that HR facilitates telomere replication.,False,BACKGROUND
3828,Pyridostatin prevents double-strand breaks accumulation.,"Here, we demonstrate that the replication efficiency of guanine-rich (G-rich) telomeric repeats is decreased significantly in cells lacking HR.",False,BACKGROUND
3829,Pyridostatin prevents double-strand breaks accumulation.,"Treatment with the G4-stabilizing compound pyridostatin (PDS) increases telomere fragility in BRCA2-deficient cells, suggesting that G4 formation drives telomere instability.",False,BACKGROUND
3830,Pyridostatin prevents double-strand breaks accumulation.,"Remarkably, PDS reduces proliferation of HR-defective cells by inducing DSB accumulation, checkpoint activation, and deregulated G2/M progression and by enhancing the replication defect intrinsic to HR deficiency.",True,BACKGROUND
3831,Pyridostatin prevents double-strand breaks accumulation.,PDS toxicity extends to HR-defective cells that have acquired olaparib resistance through loss of 53BP1 or REV7.,False,BACKGROUND
3832,Pyridostatin prevents double-strand breaks accumulation.,"Altogether, these results highlight the therapeutic potential of G4-stabilizing drugs to selectively eliminate HR-compromised cells and tumors, including those resistant to PARP inhibition.",False,BACKGROUND
3833,Pyridostatin reduces proliferation of homologous recombination - defective cells.,"G-quadruplex (G4)-forming genomic sequences, including telomeres, represent natural replication fork barriers.",False,BACKGROUND
3834,Pyridostatin reduces proliferation of homologous recombination - defective cells.,"Stalled replication forks can be stabilized and restarted by homologous recombination (HR), which also repairs DNA double-strand breaks (DSBs) arising at collapsed forks.",False,BACKGROUND
3835,Pyridostatin reduces proliferation of homologous recombination - defective cells.,We have previously shown that HR facilitates telomere replication.,False,BACKGROUND
3836,Pyridostatin reduces proliferation of homologous recombination - defective cells.,"Here, we demonstrate that the replication efficiency of guanine-rich (G-rich) telomeric repeats is decreased significantly in cells lacking HR.",False,BACKGROUND
3837,Pyridostatin reduces proliferation of homologous recombination - defective cells.,"Treatment with the G4-stabilizing compound pyridostatin (PDS) increases telomere fragility in BRCA2-deficient cells, suggesting that G4 formation drives telomere instability.",False,BACKGROUND
3838,Pyridostatin reduces proliferation of homologous recombination - defective cells.,"Remarkably, PDS reduces proliferation of HR-defective cells by inducing DSB accumulation, checkpoint activation, and deregulated G2/M progression and by enhancing the replication defect intrinsic to HR deficiency.",True,BACKGROUND
3839,Pyridostatin reduces proliferation of homologous recombination - defective cells.,PDS toxicity extends to HR-defective cells that have acquired olaparib resistance through loss of 53BP1 or REV7.,False,BACKGROUND
3840,Pyridostatin reduces proliferation of homologous recombination - defective cells.,"Altogether, these results highlight the therapeutic potential of G4-stabilizing drugs to selectively eliminate HR-compromised cells and tumors, including those resistant to PARP inhibition.",False,BACKGROUND
3841,Pyridostatin stabilizes the G - quadruplex in the telomeric region.,"G-quadruplex (G4)-forming genomic sequences, including telomeres, represent natural replication fork barriers.",False,BACKGROUND
3842,Pyridostatin stabilizes the G - quadruplex in the telomeric region.,"Stalled replication forks can be stabilized and restarted by homologous recombination (HR), which also repairs DNA double-strand breaks (DSBs) arising at collapsed forks.",False,BACKGROUND
3843,Pyridostatin stabilizes the G - quadruplex in the telomeric region.,We have previously shown that HR facilitates telomere replication.,False,BACKGROUND
3844,Pyridostatin stabilizes the G - quadruplex in the telomeric region.,"Here, we demonstrate that the replication efficiency of guanine-rich (G-rich) telomeric repeats is decreased significantly in cells lacking HR.",False,BACKGROUND
3845,Pyridostatin stabilizes the G - quadruplex in the telomeric region.,"Treatment with the G4-stabilizing compound pyridostatin (PDS) increases telomere fragility in BRCA2-deficient cells, suggesting that G4 formation drives telomere instability.",True,BACKGROUND
3846,Pyridostatin stabilizes the G - quadruplex in the telomeric region.,"Remarkably, PDS reduces proliferation of HR-defective cells by inducing DSB accumulation, checkpoint activation, and deregulated G2/M progression and by enhancing the replication defect intrinsic to HR deficiency.",False,BACKGROUND
3847,Pyridostatin stabilizes the G - quadruplex in the telomeric region.,PDS toxicity extends to HR-defective cells that have acquired olaparib resistance through loss of 53BP1 or REV7.,False,BACKGROUND
3848,Pyridostatin stabilizes the G - quadruplex in the telomeric region.,"Altogether, these results highlight the therapeutic potential of G4-stabilizing drugs to selectively eliminate HR-compromised cells and tumors, including those resistant to PARP inhibition.",False,BACKGROUND
3849,RAD52 is involved in break-induced DNA replication (BIR).,"Human cancers are characterized by the presence of oncogene-induced DNA replication stress (DRS), making them dependent on repair pathways such as break-induced replication (BIR) for damaged DNA replication forks.",False,BACKGROUND
3850,RAD52 is involved in break-induced DNA replication (BIR).,"To better understand BIR, we performed a targeted siRNA screen for genes whose depletion inhibited G1 to S phase progression when oncogenic cyclin E was overexpressed.",False,BACKGROUND
3851,RAD52 is involved in break-induced DNA replication (BIR).,"RAD52, a gene dispensable for normal development in mice, was among the top hits.",False,RESULTS
3852,RAD52 is involved in break-induced DNA replication (BIR).,"In cells in which fork collapse was induced by oncogenes or chemicals, the Rad52 protein localized to DRS foci.",False,RESULTS
3853,RAD52 is involved in break-induced DNA replication (BIR).,Depletion of Rad52 by siRNA or knockout of the gene by CRISPR/Cas9 compromised restart of collapsed forks and led to DNA damage in cells experiencing DRS.,False,RESULTS
3854,RAD52 is involved in break-induced DNA replication (BIR).,"Furthermore, in cancer-prone, heterozygous APC mutant mice, homozygous deletion of the Rad52 gene suppressed tumor growth and prolonged lifespan.",False,CONCLUSIONS
3855,RAD52 is involved in break-induced DNA replication (BIR).,We therefore propose that mammalian RAD52 facilitates repair of collapsed DNA replication forks in cancer cells.,True,CONCLUSIONS
3856,RAD52 is involved in break-induced DNA replication (BIR).,Alternative lengthening of telomeres (ALT) is a telomerase-independent telomere maintenance mechanism that occurs in a subset of cancers.,False,BACKGROUND
3857,RAD52 is involved in break-induced DNA replication (BIR).,"By analyzing telomerase-positive cells and their human TERC knockout-derived ALT human cell lines, we show that ALT cells harbor more fragile telomeres representing telomere replication problems.",False,BACKGROUND
3858,RAD52 is involved in break-induced DNA replication (BIR).,"ALT-associated replication defects trigger mitotic DNA synthesis (MiDAS) at telomeres in a RAD52-dependent, but RAD51-independent, manner.",True,BACKGROUND
3859,RAD52 is involved in break-induced DNA replication (BIR).,"Telomeric MiDAS is a conservative DNA synthesis process, potentially mediated by break-induced replication, similar to type II ALT survivors in Saccharomyces cerevisiae Replication stresses induced by ectopic oncogenic expression of cyclin E, G-quadruplexes, or R-loop formation facilitate the ALT pathway and lead to telomere clustering, a hallmark of ALT cancers.",False,BACKGROUND
3860,RAD52 is involved in break-induced DNA replication (BIR).,"The TIMELESS/TIPIN complex suppresses telomere clustering and telomeric MiDAS, whereas the SMC5/6 complex promotes them.",False,BACKGROUND
3861,RAD52 is involved in break-induced DNA replication (BIR).,"In summary, ALT cells exhibit more telomere replication defects that result in persistent DNA damage responses at telomeres, leading to the engagement of telomeric MiDAS (spontaneous mitotic telomere synthesis) that is triggered by DNA replication stress, a potential driver of genomic duplications in cancer.",False,BACKGROUND
3862,RAD52 is involved in break-induced DNA replication (BIR).,Telomeres resemble common fragile sites (CFSs) in that they are difficult-to-replicate and exhibit fragility in mitosis in response to DNA replication stress.,False,BACKGROUND
3863,RAD52 is involved in break-induced DNA replication (BIR).,"At CFSs, this fragility is associated with a delay in the completion of DNA replication until early mitosis, whereupon cells are proposed to switch to a RAD52-dependent form of break-induced replication.",True,BACKGROUND
3864,RAD52 is involved in break-induced DNA replication (BIR).,"Here, we show that this mitotic DNA synthesis (MiDAS) is also a feature of human telomeres.",False,BACKGROUND
3865,RAD52 is involved in break-induced DNA replication (BIR).,"Telomeric MiDAS is not restricted to those telomeres displaying overt fragility, and is a feature of a wide range of cell lines irrespective of whether their telomeres are maintained by telomerase or by the alternative lengthening of telomeres (ALT) mechanism.",False,BACKGROUND
3866,RAD52 is involved in break-induced DNA replication (BIR).,"MiDAS at telomeres requires RAD52, and is mechanistically similar to CFS-associated MiDAS, with the notable exception that telomeric MiDAS does not require the MUS81-EME1 endonuclease.",False,BACKGROUND
3867,RAD52 is involved in break-induced DNA replication (BIR).,We propose a model whereby replication stress initiates a RAD52-dependent form of break-induced replication that bypasses a requirement for MUS81-EME1 to complete DNA synthesis in mitosis.,True,BACKGROUND
3868,RANK-RANKL pathway signalling has no known association with development of Aire-expressing medullary thymic epithelial cells.,"The thymic medulla provides a specialized microenvironment for the negative selection of T cells, with the presence of autoimmune regulator (Aire)-expressing medullary thymic epithelial cells (mTECs) during the embryonic-neonatal period being both necessary and sufficient to establish long-lasting tolerance.",False,BACKGROUND
3869,RANK-RANKL pathway signalling has no known association with development of Aire-expressing medullary thymic epithelial cells.,"Here we showed that emergence of the first cohorts of Aire(+) mTECs at this key developmental stage, prior to αβ T cell repertoire selection, was jointly directed by Rankl(+) lymphoid tissue inducer cells and invariant Vγ5(+) dendritic epidermal T cell (DETC) progenitors that are the first thymocytes to express the products of gene rearrangement.",True,BACKGROUND
3870,RANK-RANKL pathway signalling has no known association with development of Aire-expressing medullary thymic epithelial cells.,"In turn, generation of Aire(+) mTECs then fostered Skint-1-dependent, but Aire-independent, DETC progenitor maturation and the emergence of an invariant DETC repertoire.",False,BACKGROUND
3871,RANK-RANKL pathway signalling has no known association with development of Aire-expressing medullary thymic epithelial cells.,"Hence, our data attributed a functional importance to the temporal development of Vγ5(+) γδ T cells during thymus medulla formation for αβ T cell tolerance induction and demonstrated a Rank-mediated reciprocal link between DETC and Aire(+) mTEC maturation.",True,BACKGROUND
3872,RANK-RANKL pathway signalling has no known association with development of Aire-expressing medullary thymic epithelial cells.,Medullary thymic epithelial cells (mTECs) establish T cell self-tolerance through the expression of autoimmune regulator (Aire) and peripheral tissue-specific self-antigens.,False,BACKGROUND
3873,RANK-RANKL pathway signalling has no known association with development of Aire-expressing medullary thymic epithelial cells.,"However, signals underlying mTEC development remain largely unclear.",False,BACKGROUND
3874,RANK-RANKL pathway signalling has no known association with development of Aire-expressing medullary thymic epithelial cells.,"Here, we demonstrate crucial regulation of mTEC development by receptor activator of NF-kappaB (RANK) and CD40 signals.",True,BACKGROUND
3875,RANK-RANKL pathway signalling has no known association with development of Aire-expressing medullary thymic epithelial cells.,"Whereas only RANK signaling was essential for mTEC development during embryogenesis, in postnatal mice, cooperation between CD40 and RANK signals was required for mTEC development to successfully establish the medullary microenvironment.",True,RESULTS
3876,RANK-RANKL pathway signalling has no known association with development of Aire-expressing medullary thymic epithelial cells.,"Ligation of RANK or CD40 on fetal thymic stroma in vitro induced mTEC development in a tumor necrosis factor-associated factor 6 (TRAF6)-, NF-kappaB inducing kinase (NIK)-, and IkappaB kinase beta (IKKbeta)-dependent manner.",True,RESULTS
3877,RANK-RANKL pathway signalling has no known association with development of Aire-expressing medullary thymic epithelial cells.,"These results show that developmental-stage-dependent cooperation between RANK and CD40 promotes mTEC development, thereby establishing self-tolerance.",True,CONCLUSIONS
3878,RANK-RANKL pathway signalling has no known association with development of Aire-expressing medullary thymic epithelial cells.,Aire-expressing medullary thymic epithelial cells (mTECs) play a key role in preventing autoimmunity by expressing tissue-restricted antigens to help purge the emerging T cell receptor repertoire of self-reactive specificities.,False,BACKGROUND
3879,RANK-RANKL pathway signalling has no known association with development of Aire-expressing medullary thymic epithelial cells.,"Here we demonstrate a novel role for a CD4+3− inducer cell population, previously linked to development of organized secondary lymphoid structures and maintenance of T cell memory in the functional regulation of Aire-mediated promiscuous gene expression in the thymus.",False,BACKGROUND
3880,RANK-RANKL pathway signalling has no known association with development of Aire-expressing medullary thymic epithelial cells.,"CD4+3− cells are closely associated with mTECs in adult thymus, and in fetal thymus their appearance is temporally linked with the appearance of Aire+ mTECs.",False,RESULTS
3881,RANK-RANKL pathway signalling has no known association with development of Aire-expressing medullary thymic epithelial cells.,"We show that RANKL signals from this cell promote the maturation of RANK-expressing CD80−Aire− mTEC progenitors into CD80+Aire+ mTECs, and that transplantation of RANK-deficient thymic stroma into immunodeficient hosts induces autoimmunity.",True,CONCLUSIONS
3882,RANK-RANKL pathway signalling has no known association with development of Aire-expressing medullary thymic epithelial cells.,"Collectively, our data reveal cellular and molecular mechanisms leading to the generation of Aire+ mTECs and highlight a previously unrecognized role for CD4+3−RANKL+ inducer cells in intrathymic self-tolerance.",True,CONCLUSIONS
3883,RANK-RANKL pathway signalling is linked to development of Aire-expressing medullary thymic epithelial cells.,"The thymic medulla provides a specialized microenvironment for the negative selection of T cells, with the presence of autoimmune regulator (Aire)-expressing medullary thymic epithelial cells (mTECs) during the embryonic-neonatal period being both necessary and sufficient to establish long-lasting tolerance.",False,BACKGROUND
3884,RANK-RANKL pathway signalling is linked to development of Aire-expressing medullary thymic epithelial cells.,"Here we showed that emergence of the first cohorts of Aire(+) mTECs at this key developmental stage, prior to αβ T cell repertoire selection, was jointly directed by Rankl(+) lymphoid tissue inducer cells and invariant Vγ5(+) dendritic epidermal T cell (DETC) progenitors that are the first thymocytes to express the products of gene rearrangement.",True,BACKGROUND
3885,RANK-RANKL pathway signalling is linked to development of Aire-expressing medullary thymic epithelial cells.,"In turn, generation of Aire(+) mTECs then fostered Skint-1-dependent, but Aire-independent, DETC progenitor maturation and the emergence of an invariant DETC repertoire.",False,BACKGROUND
3886,RANK-RANKL pathway signalling is linked to development of Aire-expressing medullary thymic epithelial cells.,"Hence, our data attributed a functional importance to the temporal development of Vγ5(+) γδ T cells during thymus medulla formation for αβ T cell tolerance induction and demonstrated a Rank-mediated reciprocal link between DETC and Aire(+) mTEC maturation.",True,BACKGROUND
3887,RANK-RANKL pathway signalling is linked to development of Aire-expressing medullary thymic epithelial cells.,Medullary thymic epithelial cells (mTECs) establish T cell self-tolerance through the expression of autoimmune regulator (Aire) and peripheral tissue-specific self-antigens.,False,BACKGROUND
3888,RANK-RANKL pathway signalling is linked to development of Aire-expressing medullary thymic epithelial cells.,"However, signals underlying mTEC development remain largely unclear.",False,BACKGROUND
3889,RANK-RANKL pathway signalling is linked to development of Aire-expressing medullary thymic epithelial cells.,"Here, we demonstrate crucial regulation of mTEC development by receptor activator of NF-kappaB (RANK) and CD40 signals.",True,BACKGROUND
3890,RANK-RANKL pathway signalling is linked to development of Aire-expressing medullary thymic epithelial cells.,"Whereas only RANK signaling was essential for mTEC development during embryogenesis, in postnatal mice, cooperation between CD40 and RANK signals was required for mTEC development to successfully establish the medullary microenvironment.",True,RESULTS
3891,RANK-RANKL pathway signalling is linked to development of Aire-expressing medullary thymic epithelial cells.,"Ligation of RANK or CD40 on fetal thymic stroma in vitro induced mTEC development in a tumor necrosis factor-associated factor 6 (TRAF6)-, NF-kappaB inducing kinase (NIK)-, and IkappaB kinase beta (IKKbeta)-dependent manner.",True,RESULTS
3892,RANK-RANKL pathway signalling is linked to development of Aire-expressing medullary thymic epithelial cells.,"These results show that developmental-stage-dependent cooperation between RANK and CD40 promotes mTEC development, thereby establishing self-tolerance.",True,CONCLUSIONS
3893,RANK-RANKL pathway signalling is linked to development of Aire-expressing medullary thymic epithelial cells.,Aire-expressing medullary thymic epithelial cells (mTECs) play a key role in preventing autoimmunity by expressing tissue-restricted antigens to help purge the emerging T cell receptor repertoire of self-reactive specificities.,False,BACKGROUND
3894,RANK-RANKL pathway signalling is linked to development of Aire-expressing medullary thymic epithelial cells.,"Here we demonstrate a novel role for a CD4+3− inducer cell population, previously linked to development of organized secondary lymphoid structures and maintenance of T cell memory in the functional regulation of Aire-mediated promiscuous gene expression in the thymus.",False,BACKGROUND
3895,RANK-RANKL pathway signalling is linked to development of Aire-expressing medullary thymic epithelial cells.,"CD4+3− cells are closely associated with mTECs in adult thymus, and in fetal thymus their appearance is temporally linked with the appearance of Aire+ mTECs.",False,RESULTS
3896,RANK-RANKL pathway signalling is linked to development of Aire-expressing medullary thymic epithelial cells.,"We show that RANKL signals from this cell promote the maturation of RANK-expressing CD80−Aire− mTEC progenitors into CD80+Aire+ mTECs, and that transplantation of RANK-deficient thymic stroma into immunodeficient hosts induces autoimmunity.",True,CONCLUSIONS
3897,RANK-RANKL pathway signalling is linked to development of Aire-expressing medullary thymic epithelial cells.,"Collectively, our data reveal cellular and molecular mechanisms leading to the generation of Aire+ mTECs and highlight a previously unrecognized role for CD4+3−RANKL+ inducer cells in intrathymic self-tolerance.",True,CONCLUSIONS
3898,RTEL1 interacts with TRF2 through a C4C4 motif,The helicase RTEL1 promotes t-loop unwinding and suppresses telomere fragility to maintain the integrity of vertebrate telomeres.,False,BACKGROUND
3899,RTEL1 interacts with TRF2 through a C4C4 motif,"An interaction between RTEL1 and PCNA is important to prevent telomere fragility, but how RTEL1 engages with the telomere to promote t-loop unwinding is unclear.",False,BACKGROUND
3900,RTEL1 interacts with TRF2 through a C4C4 motif,"Here, we establish that the shelterin protein TRF2 recruits RTEL1 to telomeres in S phase, which is required to prevent catastrophic t-loop processing by structure-specific nucleases.",False,BACKGROUND
3901,RTEL1 interacts with TRF2 through a C4C4 motif,"We show that the TRF2-RTEL1 interaction is mediated by a metal-coordinating C4C4 motif in RTEL1, which is compromised by the Hoyeraal-Hreidarsson syndrome (HHS) mutation, RTEL1(R1264H).",True,RESULTS
3902,RTEL1 interacts with TRF2 through a C4C4 motif,"Conversely, we define a TRF2(I124D) substitution mutation within the TRFH domain of TRF2, which eliminates RTEL1 binding and phenocopies the RTEL1(R1264H) mutation, giving rise to aberrant t-loop excision, telomere length heterogeneity, and loss of the telomere as a circle.",False,RESULTS
3903,RTEL1 interacts with TRF2 through a C4C4 motif,These results implicate TRF2 in the recruitment of RTEL1 to facilitate t-loop disassembly at telomeres in S phase.,False,CONCLUSIONS
3904,RUNX1 is downregulated or mutated in TLX1 T-ALL.,The TLX1 and TLX3 transcription factor oncogenes have a key role in the pathogenesis of T cell acute lymphoblastic leukemia (T-ALL).,False,BACKGROUND
3905,RUNX1 is downregulated or mutated in TLX1 T-ALL.,Here we used reverse engineering of global transcriptional networks to decipher the oncogenic regulatory circuit controlled by TLX1 and TLX3.,False,BACKGROUND
3906,RUNX1 is downregulated or mutated in TLX1 T-ALL.,This systems biology analysis defined T cell leukemia homeobox 1 (TLX1) and TLX3 as master regulators of an oncogenic transcriptional circuit governing T-ALL.,False,RESULTS
3907,RUNX1 is downregulated or mutated in TLX1 T-ALL.,"Notably, a network structure analysis of this hierarchical network identified RUNX1 as a key mediator of the T-ALL induced by TLX1 and TLX3 and predicted a tumor-suppressor role for RUNX1 in T cell transformation.",True,RESULTS
3908,RUNX1 is downregulated or mutated in TLX1 T-ALL.,"Consistent with these results, we identified recurrent somatic loss-of-function mutations in RUNX1 in human T-ALL.",False,CONCLUSIONS
3909,RUNX1 is downregulated or mutated in TLX1 T-ALL.,"Overall, these results place TLX1 and TLX3 at the top of an oncogenic transcriptional network controlling leukemia development, show the power of network analyses to identify key elements in the regulatory circuits governing human cancer and identify RUNX1 as a tumor-suppressor gene in T-ALL.",True,CONCLUSIONS
3910,Radioiodine treatment of non-toxic multinodular goitre increases thyroid volume.,"OBJECTIVE To investigate the long term effect of radioactive iodine on thyroid function and size in patients with non-toxic multinodular goitre.   
",False,OBJECTIVE
3911,Radioiodine treatment of non-toxic multinodular goitre increases thyroid volume.,"DESIGN Consecutive patients with multinodular non-toxic goitre selected for radioactive iodine treatment and followed for a minimum of 12 months (median 48 months) after an intended dose of 3.7 MBq/g thyroid tissue corrected to a 100% uptake of iodine-131 in 24 hours.   
",False,METHODS
3912,Radioiodine treatment of non-toxic multinodular goitre increases thyroid volume.,PATIENTS 69 patients with a growing multinodular non-toxic goitre causing local compression symptoms or cosmetic inconveniences.,False,METHODS
3913,Radioiodine treatment of non-toxic multinodular goitre increases thyroid volume.,"The treatment was chosen because of a high operative risk, previous thyroidectomy, or refusal to be operated on.   
",False,METHODS
3914,Radioiodine treatment of non-toxic multinodular goitre increases thyroid volume.,"MAIN OUTCOME MEASUREMENTS Standard thyroid function variables and ultrasonically determined thyroid volume before treatment as well as 1, 2, 3, 6, and 12 months after treatment and then once a year.   
",False,METHODS
3915,Radioiodine treatment of non-toxic multinodular goitre increases thyroid volume.,"RESULTS 56 patients were treated with a single dose of 131I, 12 with two doses, and one with four doses.",False,RESULTS
3916,Radioiodine treatment of non-toxic multinodular goitre increases thyroid volume.,In 45 patients treated with one dose and remaining euthyroid the median thyroid volume was reduced from 73 (interquartile range 50-106) ml to 29 (23-48) ml at 24 months in the 39 patients in whom this was measured during follow up.,True,RESULTS
3917,Radioiodine treatment of non-toxic multinodular goitre increases thyroid volume.,"The median reduction was 40 (22-48) ml (60% reduction, p < 0.0001), half of which occurred within three months.",False,RESULTS
3918,Radioiodine treatment of non-toxic multinodular goitre increases thyroid volume.,Patients treated with two doses as well as those developing hypothyroidism and hyperthyroidism had a significant reduction in thyroid volume.,False,RESULTS
3919,Radioiodine treatment of non-toxic multinodular goitre increases thyroid volume.,"Eleven patients developed hypothyroidism (cumulative five year risk 22%, 95% confidence interval 4.8% to 38.4%).",False,RESULTS
3920,Radioiodine treatment of non-toxic multinodular goitre increases thyroid volume.,Side effects were few: three cases of hyperthyroidism and two cases of radiation thyroiditis.,False,RESULTS
3921,Radioiodine treatment of non-toxic multinodular goitre increases thyroid volume.,"Only one patient was dissatisfied with the result; she was referred for operation six months after treatment.   
",False,RESULTS
3922,Radioiodine treatment of non-toxic multinodular goitre increases thyroid volume.,CONCLUSIONS A substantial reduction in thyroid volume accompanied by a low incidence of hypothyroidism and few side effects makes the use of radioactive iodine an attractive alternative to surgery in selected cases of non-toxic multinodular goitre.,True,CONCLUSIONS
3923,Rapamycin delays aging in fruit flies.,"The target of rapamycin (TOR) pathway is a major nutrient-sensing pathway that, when genetically downregulated, increases life span in evolutionarily diverse organisms including mammals.",False,BACKGROUND
3924,Rapamycin delays aging in fruit flies.,"The central component of this pathway, TOR kinase, is the target of the inhibitory drug rapamycin, a highly specific and well-described drug approved for human use.",False,BACKGROUND
3925,Rapamycin delays aging in fruit flies.,We show here that feeding rapamycin to adult Drosophila produces the life span extension seen in some TOR mutants.,True,BACKGROUND
3926,Rapamycin delays aging in fruit flies.,Increase in life span by rapamycin was associated with increased resistance to both starvation and paraquat.,False,RESULTS
3927,Rapamycin delays aging in fruit flies.,"Analysis of the underlying mechanisms revealed that rapamycin increased longevity specifically through the TORC1 branch of the TOR pathway, through alterations to both autophagy and translation.",False,RESULTS
3928,Rapamycin delays aging in fruit flies.,"Rapamycin could increase life span of weak insulin/Igf signaling (IIS) pathway mutants and of flies with life span maximized by dietary restriction, indicating additional mechanisms.",False,CONCLUSIONS
3929,Rapid phosphotransfer rates are correlated with histidine kinase regulator specificity.,Two-component signal transduction pathways comprising histidine protein kinases (HPKs) and their response regulators (RRs) are widely used to control bacterial responses to environmental challenges.,False,BACKGROUND
3930,Rapid phosphotransfer rates are correlated with histidine kinase regulator specificity.,"Some bacteria have over 150 different two-component pathways, and the specificity of the phosphotransfer reactions within these systems is tightly controlled to prevent unwanted crosstalk.",False,BACKGROUND
3931,Rapid phosphotransfer rates are correlated with histidine kinase regulator specificity.,One of the best understood two-component signalling pathways is the chemotaxis pathway.,False,BACKGROUND
3932,Rapid phosphotransfer rates are correlated with histidine kinase regulator specificity.,"Here, we present the 1.40 A crystal structure of the histidine-containing phosphotransfer domain of the chemotaxis HPK, CheA(3), in complex with its cognate RR, CheY(6).",False,BACKGROUND
3933,Rapid phosphotransfer rates are correlated with histidine kinase regulator specificity.,"A methionine finger on CheY(6) that nestles in a hydrophobic pocket in CheA(3) was shown to be important for the interaction and was found to only occur in the cognate RRs of CheA(3), CheY(6), and CheB(2).",False,RESULTS
3934,Rapid phosphotransfer rates are correlated with histidine kinase regulator specificity.,"Site-directed mutagenesis of this methionine in combination with two adjacent residues abolished binding, as shown by surface plasmon resonance studies, and phosphotransfer from CheA(3)-P to CheY(6).",False,RESULTS
3935,Rapid phosphotransfer rates are correlated with histidine kinase regulator specificity.,"Introduction of this methionine and an adjacent alanine residue into a range of noncognate CheYs, dramatically changed their specificity, allowing protein interaction and rapid phosphotransfer from CheA(3)-P. The structure presented here has allowed us to identify specificity determinants for the CheA-CheY interaction and subsequently to successfully reengineer phosphotransfer signalling.",True,CONCLUSIONS
3936,Rapid phosphotransfer rates are correlated with histidine kinase regulator specificity.,"In summary, our results provide valuable insight into how cells mediate specificity in one of the most abundant signalling pathways in biology, two-component signal transduction.",False,CONCLUSIONS
3937,Recognition of start codons depends on the translation initiation factor IF3.,"In bacterial translational initiation, three initiation factors (IFs 1-3) enable the selection of initiator tRNA and the start codon in the P site of the 30S ribosomal subunit.",False,BACKGROUND
3938,Recognition of start codons depends on the translation initiation factor IF3.,"Here, we report 11 single-particle cryo-electron microscopy (cryoEM) reconstructions of the complex of bacterial 30S subunit with initiator tRNA, mRNA, and IFs 1-3, representing different steps along the initiation pathway.",False,BACKGROUND
3939,Recognition of start codons depends on the translation initiation factor IF3.,"IF1 provides key anchoring points for IF2 and IF3, thereby enhancing their activities.",False,BACKGROUND
3940,Recognition of start codons depends on the translation initiation factor IF3.,IF2 positions a domain in an extended conformation appropriate for capturing the formylmethionyl moiety charged on tRNA.,False,BACKGROUND
3941,Recognition of start codons depends on the translation initiation factor IF3.,IF3 and tRNA undergo large conformational changes to facilitate the accommodation of the formylmethionyl-tRNA (fMet-tRNA(fMet)) into the P site for start codon recognition.,True,BACKGROUND
3942,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with autoimmune diseases such as Type 1 Diabetes.,Autoimmune diseases are thought to result from imbalances in normal immune physiology and regulation.,False,BACKGROUND
3943,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with autoimmune diseases such as Type 1 Diabetes.,"Here, we show that autoimmune disease susceptibility and resistance alleles on mouse chromosome 3 (Idd3) correlate with differential expression of the key immunoregulatory cytokine interleukin-2 (IL-2).",False,BACKGROUND
3944,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with autoimmune diseases such as Type 1 Diabetes.,"In order to test directly that an approximately twofold reduction in IL-2 underpins the Idd3-linked destabilization of immune homeostasis, we show that engineered haplodeficiency of Il2 gene expression not only reduces T cell IL-2 production by twofold but also mimics the autoimmune dysregulatory effects of the naturally occurring susceptibility alleles of Il2.",True,RESULTS
3945,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with autoimmune diseases such as Type 1 Diabetes.,"Reduced IL-2 production achieved by either genetic mechanism correlates with reduced function of CD4+ CD25+ regulatory T cells, which are critical for maintaining immune homeostasis.",True,RESULTS
3946,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with autoimmune diseases such as Type 1 Diabetes.,"Numerous reports have demonstrated that CD4(+)CD25(+) regulatory T cells (Tregs) from individuals with a range of human autoimmune diseases, including type 1 diabetes, are deficient in their ability to control autologous proinflammatory responses when compared with nondiseased, control individuals.",False,OBJECTIVE
3947,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with autoimmune diseases such as Type 1 Diabetes.,"Treg dysfunction could be a primary, causal event or may result from perturbations in the immune system during disease development.",False,OBJECTIVE
3948,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with autoimmune diseases such as Type 1 Diabetes.,"Polymorphisms in genes associated with Treg function, such as IL2RA, confer a higher risk of autoimmune disease.",False,OBJECTIVE
3949,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with autoimmune diseases such as Type 1 Diabetes.,"Although this suggests a primary role for defective Tregs in autoimmunity, a link between IL2RA gene polymorphisms and Treg function has not been examined.",False,OBJECTIVE
3950,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with autoimmune diseases such as Type 1 Diabetes.,We addressed this by examining the impact of an IL2RA haplotype associated with type 1 diabetes on Treg fitness and suppressive function.,False,OBJECTIVE
3951,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with autoimmune diseases such as Type 1 Diabetes.,Studies were conducted using healthy human subjects to avoid any confounding effects of disease.,False,METHODS
3952,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with autoimmune diseases such as Type 1 Diabetes.,"We demonstrated that the presence of an autoimmune disease-associated IL2RA haplotype correlates with diminished IL-2 responsiveness in Ag-experienced CD4(+) T cells, as measured by phosphorylation of STAT5a, and is associated with lower levels of FOXP3 expression by Tregs and a reduction in their ability to suppress proliferation of autologous effector T cells.",True,CONCLUSIONS
3953,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with autoimmune diseases such as Type 1 Diabetes.,"These data offer a rationale that contributes to the molecular and cellular mechanisms through which polymorphisms in the IL-2RA gene affect immune regulation, and consequently upon susceptibility to autoimmune and inflammatory diseases.",False,CONCLUSIONS
3954,Reducing H3k4me3 methylation induces mouse epiblast stem cells to naive pluripotency efficiently.,The interconversion between naive and primed pluripotent states is accompanied by drastic epigenetic rearrangements.,False,BACKGROUND
3955,Reducing H3k4me3 methylation induces mouse epiblast stem cells to naive pluripotency efficiently.,"However, it is unclear whether intrinsic epigenetic events can drive reprogramming to naive pluripotency or if distinct chromatin states are instead simply a reflection of discrete pluripotent states.",False,BACKGROUND
3956,Reducing H3k4me3 methylation induces mouse epiblast stem cells to naive pluripotency efficiently.,"Here, we show that blocking histone H3K4 methyltransferase MLL1 activity with the small-molecule inhibitor MM-401 reprograms mouse epiblast stem cells (EpiSCs) to naive pluripotency.",True,METHODS
3957,Reducing H3k4me3 methylation induces mouse epiblast stem cells to naive pluripotency efficiently.,"This reversion is highly efficient and synchronized, with more than 50% of treated EpiSCs exhibiting features of naive embryonic stem cells (ESCs) within 3 days.",False,RESULTS
3958,Reducing H3k4me3 methylation induces mouse epiblast stem cells to naive pluripotency efficiently.,"Reverted ESCs reactivate the silenced X chromosome and contribute to embryos following blastocyst injection, generating germline-competent chimeras.",False,RESULTS
3959,Reducing H3k4me3 methylation induces mouse epiblast stem cells to naive pluripotency efficiently.,"Importantly, blocking MLL1 leads to global redistribution of H3K4me1 at enhancers and represses lineage determinant factors and EpiSC markers, which indirectly regulate ESC transcription circuitry.",False,RESULTS
3960,Reducing H3k4me3 methylation induces mouse epiblast stem cells to naive pluripotency efficiently.,These findings show that discrete perturbation of H3K4 methylation is sufficient to drive reprogramming to naive pluripotency.,False,CONCLUSIONS
3961,Reduction of Rpl38 alters the composition of the Hox gene mRNAs translation in mice without lowering overall protein synthesis.,"Historically, the ribosome has been viewed as a complex ribozyme with constitutive rather than regulatory capacity in mRNA translation.",False,BACKGROUND
3962,Reduction of Rpl38 alters the composition of the Hox gene mRNAs translation in mice without lowering overall protein synthesis.,"Here we identify mutations of the Ribosomal Protein L38 (Rpl38) gene in mice exhibiting surprising tissue-specific patterning defects, including pronounced homeotic transformations of the axial skeleton.",False,BACKGROUND
3963,Reduction of Rpl38 alters the composition of the Hox gene mRNAs translation in mice without lowering overall protein synthesis.,"In Rpl38 mutant embryos, global protein synthesis is unchanged; however the translation of a select subset of Homeobox mRNAs is perturbed.",True,RESULTS
3964,Reduction of Rpl38 alters the composition of the Hox gene mRNAs translation in mice without lowering overall protein synthesis.,Our data reveal that RPL38 facilitates 80S complex formation on these mRNAs as a regulatory component of the ribosome to confer transcript-specific translational control.,False,RESULTS
3965,Reduction of Rpl38 alters the composition of the Hox gene mRNAs translation in mice without lowering overall protein synthesis.,We further show that Rpl38 expression is markedly enriched in regions of the embryo where loss-of-function phenotypes occur.,False,RESULTS
3966,Reduction of Rpl38 alters the composition of the Hox gene mRNAs translation in mice without lowering overall protein synthesis.,"Unexpectedly, a ribosomal protein (RP) expression screen reveals dynamic regulation of individual RPs within the vertebrate embryo.",False,CONCLUSIONS
3967,Reduction of Rpl38 alters the composition of the Hox gene mRNAs translation in mice without lowering overall protein synthesis.,"Collectively, these findings suggest that RP activity may be highly regulated to impart a new layer of specificity in the control of gene expression and mammalian development.",False,CONCLUSIONS
3968,Removal of H3K9me3 by ectopic expression of other H3K9 demethylases decreases reprogramming efficiency in SCNT experiments.,Aberrant epigenetic reprogramming often results in developmental defects in somatic cell nuclear transfer (SCNT) embryos during embryonic genome activation (EGA).,False,BACKGROUND
3969,Removal of H3K9me3 by ectopic expression of other H3K9 demethylases decreases reprogramming efficiency in SCNT experiments.,"Bovine eight-cell SCNT embryos exhibit global hypermethylation of histone H3 lysine 9 tri- and di-methylation (H3K9me3/2), but the intrinsic reason for this remains elusive.",False,BACKGROUND
3970,Removal of H3K9me3 by ectopic expression of other H3K9 demethylases decreases reprogramming efficiency in SCNT experiments.,"Here, we provide evidence that two H3K9 demethylase genes, lysine-specific demethylase 4D (KDM4D) and 4E (KDM4E), are related to active H3K9me3/2 demethylation in in vitro fertilized (IVF) embryos and are deficiently expressed in cloned embryos at the time of EGA.",False,METHODS
3971,Removal of H3K9me3 by ectopic expression of other H3K9 demethylases decreases reprogramming efficiency in SCNT experiments.,"Moreover, KDM4E plays a more crucial role in IVF and SCNT embryonic development, and overexpression of KDM4E can restore the global transcriptome, improve blastocyst formation and increase the cloning efficiency of SCNT embryos.",True,RESULTS
3972,Removal of H3K9me3 by ectopic expression of other H3K9 demethylases decreases reprogramming efficiency in SCNT experiments.,Our results thereby indicate that KDM4E can function as a crucial epigenetic regulator of EGA and as an internal defective factor responsible for persistent H3K9me3/2 barriers to SCNT-mediated reprogramming.,False,RESULTS
3973,Removal of H3K9me3 by ectopic expression of other H3K9 demethylases decreases reprogramming efficiency in SCNT experiments.,"Furthermore, we show that interactions between RNA and KDM4E are essential for H3K9 demethylation during EGA.",False,RESULTS
3974,Removal of H3K9me3 by ectopic expression of other H3K9 demethylases decreases reprogramming efficiency in SCNT experiments.,These observations advance the understanding of incomplete nuclear reprogramming and are of great importance for transgenic cattle procreation.,False,CONCLUSIONS
3975,Removal of H3K9me3 by ectopic expression of other H3K9 demethylases improves reprogramming efficiency in SCNT experiments.,Aberrant epigenetic reprogramming often results in developmental defects in somatic cell nuclear transfer (SCNT) embryos during embryonic genome activation (EGA).,False,BACKGROUND
3976,Removal of H3K9me3 by ectopic expression of other H3K9 demethylases improves reprogramming efficiency in SCNT experiments.,"Bovine eight-cell SCNT embryos exhibit global hypermethylation of histone H3 lysine 9 tri- and di-methylation (H3K9me3/2), but the intrinsic reason for this remains elusive.",False,BACKGROUND
3977,Removal of H3K9me3 by ectopic expression of other H3K9 demethylases improves reprogramming efficiency in SCNT experiments.,"Here, we provide evidence that two H3K9 demethylase genes, lysine-specific demethylase 4D (KDM4D) and 4E (KDM4E), are related to active H3K9me3/2 demethylation in in vitro fertilized (IVF) embryos and are deficiently expressed in cloned embryos at the time of EGA.",False,METHODS
3978,Removal of H3K9me3 by ectopic expression of other H3K9 demethylases improves reprogramming efficiency in SCNT experiments.,"Moreover, KDM4E plays a more crucial role in IVF and SCNT embryonic development, and overexpression of KDM4E can restore the global transcriptome, improve blastocyst formation and increase the cloning efficiency of SCNT embryos.",True,RESULTS
3979,Removal of H3K9me3 by ectopic expression of other H3K9 demethylases improves reprogramming efficiency in SCNT experiments.,Our results thereby indicate that KDM4E can function as a crucial epigenetic regulator of EGA and as an internal defective factor responsible for persistent H3K9me3/2 barriers to SCNT-mediated reprogramming.,False,RESULTS
3980,Removal of H3K9me3 by ectopic expression of other H3K9 demethylases improves reprogramming efficiency in SCNT experiments.,"Furthermore, we show that interactions between RNA and KDM4E are essential for H3K9 demethylation during EGA.",False,RESULTS
3981,Removal of H3K9me3 by ectopic expression of other H3K9 demethylases improves reprogramming efficiency in SCNT experiments.,These observations advance the understanding of incomplete nuclear reprogramming and are of great importance for transgenic cattle procreation.,False,CONCLUSIONS
3982,Removal of H3K9me3 improves reprogramming efficiency in human somatic cell nuclear transfer experiments.,Aberrant epigenetic reprogramming often results in developmental defects in somatic cell nuclear transfer (SCNT) embryos during embryonic genome activation (EGA).,False,BACKGROUND
3983,Removal of H3K9me3 improves reprogramming efficiency in human somatic cell nuclear transfer experiments.,"Bovine eight-cell SCNT embryos exhibit global hypermethylation of histone H3 lysine 9 tri- and di-methylation (H3K9me3/2), but the intrinsic reason for this remains elusive.",False,BACKGROUND
3984,Removal of H3K9me3 improves reprogramming efficiency in human somatic cell nuclear transfer experiments.,"Here, we provide evidence that two H3K9 demethylase genes, lysine-specific demethylase 4D (KDM4D) and 4E (KDM4E), are related to active H3K9me3/2 demethylation in in vitro fertilized (IVF) embryos and are deficiently expressed in cloned embryos at the time of EGA.",False,METHODS
3985,Removal of H3K9me3 improves reprogramming efficiency in human somatic cell nuclear transfer experiments.,"Moreover, KDM4E plays a more crucial role in IVF and SCNT embryonic development, and overexpression of KDM4E can restore the global transcriptome, improve blastocyst formation and increase the cloning efficiency of SCNT embryos.",True,RESULTS
3986,Removal of H3K9me3 improves reprogramming efficiency in human somatic cell nuclear transfer experiments.,Our results thereby indicate that KDM4E can function as a crucial epigenetic regulator of EGA and as an internal defective factor responsible for persistent H3K9me3/2 barriers to SCNT-mediated reprogramming.,False,RESULTS
3987,Removal of H3K9me3 improves reprogramming efficiency in human somatic cell nuclear transfer experiments.,"Furthermore, we show that interactions between RNA and KDM4E are essential for H3K9 demethylation during EGA.",False,RESULTS
3988,Removal of H3K9me3 improves reprogramming efficiency in human somatic cell nuclear transfer experiments.,These observations advance the understanding of incomplete nuclear reprogramming and are of great importance for transgenic cattle procreation.,False,CONCLUSIONS
3989,Replacement of histone H2A with H2A.Z accelerates gene activation in yeasts by destabilizing +1 nucleosomes.,Nucleosomes containing the histone variant H3.3 tend to be clustered in vivo in the neighborhood of transcriptionally active genes and over regulatory elements.,False,BACKGROUND
3990,Replacement of histone H2A with H2A.Z accelerates gene activation in yeasts by destabilizing +1 nucleosomes.,"It has not been clear, however, whether H3.3-containing nucleosomes possess unique properties that would affect transcription.",False,BACKGROUND
3991,Replacement of histone H2A with H2A.Z accelerates gene activation in yeasts by destabilizing +1 nucleosomes.,"We report here that H3.3 nucleosomes isolated from vertebrates, regardless of whether they are partnered with H2A or H2A.Z, are unusually sensitive to salt-dependent disruption, losing H2A/H2B or H2A.Z/H2B dimers.",False,BACKGROUND
3992,Replacement of histone H2A with H2A.Z accelerates gene activation in yeasts by destabilizing +1 nucleosomes.,Immunoprecipitation studies of nucleosome core particles (NCPs) show that NCPs that contain both H3.3 and H2A.Z are even less stable than NCPs containing H3.3 and H2A.,True,RESULTS
3993,Replacement of histone H2A with H2A.Z accelerates gene activation in yeasts by destabilizing +1 nucleosomes.,"Intriguingly, NCPs containing H3 and H2A.Z are at least as stable as H3/H2A NCPs.",False,RESULTS
3994,Replacement of histone H2A with H2A.Z accelerates gene activation in yeasts by destabilizing +1 nucleosomes.,"These results establish an hierarchy of stabilities for native nucleosomes carrying different complements of variants, and suggest how H2A.Z could play different roles depending on its partners within the NCP.",False,RESULTS
3995,Replacement of histone H2A with H2A.Z accelerates gene activation in yeasts by destabilizing +1 nucleosomes.,They also are consistent with the idea that H3.3 plays an active role in maintaining accessible chromatin structures in enhancer regions and transcribed regions.,False,RESULTS
3996,Replacement of histone H2A with H2A.Z accelerates gene activation in yeasts by destabilizing +1 nucleosomes.,"Consistent with this idea, promoters and enhancers at transcriptionally active genes and coding regions at highly expressed genes have nucleosomes that simultaneously carry both H3.3 and H2A.Z, and should therefore be extremely sensitive to disruption.",False,CONCLUSIONS
3997,Repressing IL-18 has negative effects on atherosclerotic lesion composition and progression.,BACKGROUND Interleukin (IL)-18 is a potent proinflammatory cytokine with potential atherogenic properties.,False,BACKGROUND
3998,Repressing IL-18 has negative effects on atherosclerotic lesion composition and progression.,"Its expression and role in atherosclerosis, however, are unknown.   
",False,BACKGROUND
3999,Repressing IL-18 has negative effects on atherosclerotic lesion composition and progression.,"METHODS AND RESULTS In the present study, we examined stable and unstable human carotid atherosclerotic plaques retrieved by endarterectomy for the presence of IL-18 using reverse transcription-polymerase chain reaction (PCR), Western blot, and immunohistochemical techniques.",False,METHODS
4000,Repressing IL-18 has negative effects on atherosclerotic lesion composition and progression.,IL-18 was highly expressed in the atherosclerotic plaques compared with control normal arteries and was localized mainly in plaque macrophages.,False,RESULTS
4001,Repressing IL-18 has negative effects on atherosclerotic lesion composition and progression.,"IL-18 receptor was also upregulated in plaque macrophages and endothelial cells, suggesting potential biological effects.",False,RESULTS
4002,Repressing IL-18 has negative effects on atherosclerotic lesion composition and progression.,"To examine the role of IL-18 in atherosclerosis, we determined the relation between IL-18 mRNA expression and signs of plaque instability using real-time quantitative PCR.",False,RESULTS
4003,Repressing IL-18 has negative effects on atherosclerotic lesion composition and progression.,"Interestingly, significantly higher levels of IL-18 mRNA were found in symptomatic (unstable) plaques than asymptomatic (stable) plaques (P<0.01).   
",True,RESULTS
4004,Repressing IL-18 has negative effects on atherosclerotic lesion composition and progression.,"CONCLUSIONS These results suggest, for the first time, a major role for IL-18 in atherosclerotic plaque destabilization leading to acute ischemic syndromes.",True,CONCLUSIONS
4005,Retinoic acid receptor-related orphan receptor gamma (RORγ) is a therapeutic target for castration-resistant prostate cancer (CRPC),The androgen receptor (AR) is overexpressed and hyperactivated in human castration-resistant prostate cancer (CRPC).,False,BACKGROUND
4006,Retinoic acid receptor-related orphan receptor gamma (RORγ) is a therapeutic target for castration-resistant prostate cancer (CRPC),"However, the determinants of AR overexpression in CRPC are poorly defined.",False,BACKGROUND
4007,Retinoic acid receptor-related orphan receptor gamma (RORγ) is a therapeutic target for castration-resistant prostate cancer (CRPC),"Here we show that retinoic acid receptor-related orphan receptor γ (ROR-γ) is overexpressed and amplified in metastatic CRPC tumors, and that ROR-γ drives AR expression in the tumors.",False,BACKGROUND
4008,Retinoic acid receptor-related orphan receptor gamma (RORγ) is a therapeutic target for castration-resistant prostate cancer (CRPC),"ROR-γ recruits nuclear receptor coactivator 1 and 3 (NCOA1 and NCOA3, also known as SRC-1 and SRC-3) to an AR-ROR response element (RORE) to stimulate AR gene transcription.",False,RESULTS
4009,Retinoic acid receptor-related orphan receptor gamma (RORγ) is a therapeutic target for castration-resistant prostate cancer (CRPC),ROR-γ antagonists suppress the expression of both AR and its variant AR-V7 in prostate cancer (PCa) cell lines and tumors.,False,RESULTS
4010,Retinoic acid receptor-related orphan receptor gamma (RORγ) is a therapeutic target for castration-resistant prostate cancer (CRPC),"ROR-γ antagonists also markedly diminish genome-wide AR binding, H3K27ac abundance and expression of the AR target gene network.",False,RESULTS
4011,Retinoic acid receptor-related orphan receptor gamma (RORγ) is a therapeutic target for castration-resistant prostate cancer (CRPC),"Finally, ROR-γ antagonists suppressed tumor growth in multiple AR-expressing, but not AR-negative, xenograft PCa models, and they effectively sensitized CRPC tumors to enzalutamide, without overt toxicity, in mice.",True,RESULTS
4012,Retinoic acid receptor-related orphan receptor gamma (RORγ) is a therapeutic target for castration-resistant prostate cancer (CRPC),"Taken together, these results establish ROR-γ as a key player in CRPC by acting upstream of AR and as a potential therapeutic target for advanced PCa.",True,CONCLUSIONS
4013,Rhythmic expression of Cry1 translates directly into a circadian regulation of cAMP signaling in gluconeogenesis.,"During fasting, mammals maintain normal glucose homeostasis by stimulating hepatic gluconeogenesis.",False,BACKGROUND
4014,Rhythmic expression of Cry1 translates directly into a circadian regulation of cAMP signaling in gluconeogenesis.,"Elevations in circulating glucagon and epinephrine, two hormones that activate hepatic gluconeogenesis, trigger the cAMP-mediated phosphorylation of cAMP response element-binding protein (Creb) and dephosphorylation of the Creb-regulated transcription coactivator-2 (Crtc2)--two key transcriptional regulators of this process.",False,BACKGROUND
4015,Rhythmic expression of Cry1 translates directly into a circadian regulation of cAMP signaling in gluconeogenesis.,"Although the underlying mechanism is unclear, hepatic gluconeogenesis is also regulated by the circadian clock, which coordinates glucose metabolism with changes in the external environment.",False,BACKGROUND
4016,Rhythmic expression of Cry1 translates directly into a circadian regulation of cAMP signaling in gluconeogenesis.,"Circadian control of gene expression is achieved by two transcriptional activators, Clock and Bmal1, which stimulate cryptochrome (Cry1 and Cry2) and Period (Per1, Per2 and Per3) repressors that feed back on Clock-Bmal1 activity.",False,METHODS
4017,Rhythmic expression of Cry1 translates directly into a circadian regulation of cAMP signaling in gluconeogenesis.,"Here we show that Creb activity during fasting is modulated by Cry1 and Cry2, which are rhythmically expressed in the liver.",True,METHODS
4018,Rhythmic expression of Cry1 translates directly into a circadian regulation of cAMP signaling in gluconeogenesis.,"Cry1 expression was elevated during the night-day transition, when it reduced fasting gluconeogenic gene expression by blocking glucagon-mediated increases in intracellular cAMP concentrations and in the protein kinase A-mediated phosphorylation of Creb.",True,RESULTS
4019,Rhythmic expression of Cry1 translates directly into a circadian regulation of cAMP signaling in gluconeogenesis.,"In biochemical reconstitution studies, we found that Cry1 inhibited accumulation of cAMP in response to G protein-coupled receptor (GPCR) activation but not to forskolin, a direct activator of adenyl cyclase.",False,RESULTS
4020,Rhythmic expression of Cry1 translates directly into a circadian regulation of cAMP signaling in gluconeogenesis.,Cry proteins seemed to modulate GPCR activity directly through interaction with G(s)α.,False,RESULTS
4021,Rhythmic expression of Cry1 translates directly into a circadian regulation of cAMP signaling in gluconeogenesis.,"As hepatic overexpression of Cry1 lowered blood glucose concentrations and improved insulin sensitivity in insulin-resistant db/db mice, our results suggest that compounds that enhance cryptochrome activity may provide therapeutic benefit to individuals with type 2 diabetes.",False,CONCLUSIONS
4022,Rhythmic expression of Cry1 translates directly into a circadian regulation of cAMP signaling in hepatic glucose metabolism.,"During fasting, mammals maintain normal glucose homeostasis by stimulating hepatic gluconeogenesis.",False,BACKGROUND
4023,Rhythmic expression of Cry1 translates directly into a circadian regulation of cAMP signaling in hepatic glucose metabolism.,"Elevations in circulating glucagon and epinephrine, two hormones that activate hepatic gluconeogenesis, trigger the cAMP-mediated phosphorylation of cAMP response element-binding protein (Creb) and dephosphorylation of the Creb-regulated transcription coactivator-2 (Crtc2)--two key transcriptional regulators of this process.",False,BACKGROUND
4024,Rhythmic expression of Cry1 translates directly into a circadian regulation of cAMP signaling in hepatic glucose metabolism.,"Although the underlying mechanism is unclear, hepatic gluconeogenesis is also regulated by the circadian clock, which coordinates glucose metabolism with changes in the external environment.",True,BACKGROUND
4025,Rhythmic expression of Cry1 translates directly into a circadian regulation of cAMP signaling in hepatic glucose metabolism.,"Circadian control of gene expression is achieved by two transcriptional activators, Clock and Bmal1, which stimulate cryptochrome (Cry1 and Cry2) and Period (Per1, Per2 and Per3) repressors that feed back on Clock-Bmal1 activity.",True,METHODS
4026,Rhythmic expression of Cry1 translates directly into a circadian regulation of cAMP signaling in hepatic glucose metabolism.,"Here we show that Creb activity during fasting is modulated by Cry1 and Cry2, which are rhythmically expressed in the liver.",True,METHODS
4027,Rhythmic expression of Cry1 translates directly into a circadian regulation of cAMP signaling in hepatic glucose metabolism.,"Cry1 expression was elevated during the night-day transition, when it reduced fasting gluconeogenic gene expression by blocking glucagon-mediated increases in intracellular cAMP concentrations and in the protein kinase A-mediated phosphorylation of Creb.",True,RESULTS
4028,Rhythmic expression of Cry1 translates directly into a circadian regulation of cAMP signaling in hepatic glucose metabolism.,"In biochemical reconstitution studies, we found that Cry1 inhibited accumulation of cAMP in response to G protein-coupled receptor (GPCR) activation but not to forskolin, a direct activator of adenyl cyclase.",False,RESULTS
4029,Rhythmic expression of Cry1 translates directly into a circadian regulation of cAMP signaling in hepatic glucose metabolism.,Cry proteins seemed to modulate GPCR activity directly through interaction with G(s)α.,False,RESULTS
4030,Rhythmic expression of Cry1 translates directly into a circadian regulation of cAMP signaling in hepatic glucose metabolism.,"As hepatic overexpression of Cry1 lowered blood glucose concentrations and improved insulin sensitivity in insulin-resistant db/db mice, our results suggest that compounds that enhance cryptochrome activity may provide therapeutic benefit to individuals with type 2 diabetes.",False,CONCLUSIONS
4031,Ribosomopathies have a high degree of cell and tissue specific pathology.,"Historically, the ribosome has been viewed as a complex ribozyme with constitutive rather than regulatory capacity in mRNA translation.",False,BACKGROUND
4032,Ribosomopathies have a high degree of cell and tissue specific pathology.,"Here we identify mutations of the Ribosomal Protein L38 (Rpl38) gene in mice exhibiting surprising tissue-specific patterning defects, including pronounced homeotic transformations of the axial skeleton.",False,BACKGROUND
4033,Ribosomopathies have a high degree of cell and tissue specific pathology.,"In Rpl38 mutant embryos, global protein synthesis is unchanged; however the translation of a select subset of Homeobox mRNAs is perturbed.",False,RESULTS
4034,Ribosomopathies have a high degree of cell and tissue specific pathology.,Our data reveal that RPL38 facilitates 80S complex formation on these mRNAs as a regulatory component of the ribosome to confer transcript-specific translational control.,False,RESULTS
4035,Ribosomopathies have a high degree of cell and tissue specific pathology.,We further show that Rpl38 expression is markedly enriched in regions of the embryo where loss-of-function phenotypes occur.,False,RESULTS
4036,Ribosomopathies have a high degree of cell and tissue specific pathology.,"Unexpectedly, a ribosomal protein (RP) expression screen reveals dynamic regulation of individual RPs within the vertebrate embryo.",True,CONCLUSIONS
4037,Ribosomopathies have a high degree of cell and tissue specific pathology.,"Collectively, these findings suggest that RP activity may be highly regulated to impart a new layer of specificity in the control of gene expression and mammalian development.",True,CONCLUSIONS
4038,Risedronate increases risk of vertebral and non-vertebral fractures.,"CONTEXT Risedronate, a potent bisphosphonate, has been shown to be effective in the treatment of Paget disease of bone and other metabolic bone diseases but, to our knowledge, it has not been evaluated in the treatment of established postmenopausal osteoporosis.   
",False,BACKGROUND
4039,Risedronate increases risk of vertebral and non-vertebral fractures.,"OBJECTIVE To test the efficacy and safety of daily treatment with risedronate to reduce the risk of vertebral and other fractures in postmenopausal women with established osteoporosis.   
",False,OBJECTIVE
4040,Risedronate increases risk of vertebral and non-vertebral fractures.,"DESIGN, SETTING, AND PARTICIPANTS Randomized, double-blind, placebo-controlled trial of 2458 ambulatory postmenopausal women younger than 85 years with at least 1 vertebral fracture at baseline who were enrolled at 1 of 110 centers in North America conducted between December 1993 and January 1998.   
",False,METHODS
4041,Risedronate increases risk of vertebral and non-vertebral fractures.,INTERVENTIONS Subjects were randomly assigned to receive oral treatment for 3 years with risedronate (2.5 or 5 mg/d) or placebo.,False,METHODS
4042,Risedronate increases risk of vertebral and non-vertebral fractures.,"All subjects received calcium, 1000 mg/d.",False,METHODS
4043,Risedronate increases risk of vertebral and non-vertebral fractures.,"Vitamin D (cholecalciferol, up to 500 IU/d) was provided if baseline levels of 25-hydroxyvitamin D were low.   
",False,METHODS
4044,Risedronate increases risk of vertebral and non-vertebral fractures.,"MAIN OUTCOME MEASURES Incidence of new vertebral fractures as detected by quantitative and semiquantitative assessments of radiographs; incidence of radiographically confirmed nonvertebral fractures and change from baseline in bone mineral density as determined by dual x-ray absorptiometry.   
",False,METHODS
4045,Risedronate increases risk of vertebral and non-vertebral fractures.,"RESULTS The 2.5 mg/d of risedronate arm was discontinued after 1 year; in the placebo and 5 mg/d of risedronate arms, 450 and 489 subjects, respectively, completed all 3 years of the trial.",False,RESULTS
4046,Risedronate increases risk of vertebral and non-vertebral fractures.,"Treatment with 5 mg/d of risedronate, compared with placebo, decreased the cumulative incidence of new vertebral fractures by 41 % (95% confidence interval [CI], 18%-58%) over 3 years (11.3 % vs 16.3%; P= .003).",True,RESULTS
4047,Risedronate increases risk of vertebral and non-vertebral fractures.,"A fracture reduction of 65% (95% CI, 38%-81 %) was observed after the first year (2.4% vs 6.4%; P<.001).",False,RESULTS
4048,Risedronate increases risk of vertebral and non-vertebral fractures.,"The cumulative incidence of nonvertebral fractures over 3 years was reduced by 39% (95% CI, 6%-61 %) (5.2 % vs 8.4%; P = .02).",True,RESULTS
4049,Risedronate increases risk of vertebral and non-vertebral fractures.,"Bone mineral density increased significantly compared with placebo at the lumbar spine (5.4% vs 1.1 %), femoral neck (1.6% vs -1.2%), femoral trochanter (3.3% vs -0.7%), and midshaft of the radius (0.2% vs -1.4%).",False,RESULTS
4050,Risedronate increases risk of vertebral and non-vertebral fractures.,Bone formed during risedronate treatment was histologically normal.,False,RESULTS
4051,Risedronate increases risk of vertebral and non-vertebral fractures.,"The overall safety profile of risedronate, including gastrointestinal safety, was similar to that of placebo.   
",False,RESULTS
4052,Risedronate increases risk of vertebral and non-vertebral fractures.,CONCLUSIONS These data suggest that risedronate therapy is effective and well tolerated in the treatment of women with established postmenopausal osteoporosis.,False,CONCLUSIONS
4053,Risk of cardiovascular events can be cut by a third by using antihypertensive drug therapy among hemodialysis patients.,Epidemiological studies demonstrate that a lower blood pressure and decline in blood pressure over months or years are associated with higher mortality in dialysis patients.,False,BACKGROUND
4054,Risk of cardiovascular events can be cut by a third by using antihypertensive drug therapy among hemodialysis patients.,"In contrast, randomized, controlled trials lack power to establish benefits of antihypertensive therapy.",False,BACKGROUND
4055,Risk of cardiovascular events can be cut by a third by using antihypertensive drug therapy among hemodialysis patients.,"Patients on long-term dialysis participating in randomized, controlled trials and receiving antihypertensive drug therapy were the subject of this meta-analysis.",False,METHODS
4056,Risk of cardiovascular events can be cut by a third by using antihypertensive drug therapy among hemodialysis patients.,Outcomes assessed were the hazard ratio of cardiovascular events and all-cause mortality in treated group compared with controls.,False,METHODS
4057,Risk of cardiovascular events can be cut by a third by using antihypertensive drug therapy among hemodialysis patients.,"Among 1202 patients who we identified in 5 studies, the overall benefit of antihypertensive therapy compared with the control or placebo group had a combined hazard ratio for cardiovascular events of 0.69 (95% CI: 0.56 to 0.84) using a fixed-effects model and 0.62 (95% CI: 0.45 to 0.86) using a random-effects model.",True,RESULTS
4058,Risk of cardiovascular events can be cut by a third by using antihypertensive drug therapy among hemodialysis patients.,"In a sensitivity analysis, we found that the hypertensive group had a pooled hazard ratio of 0.49 (95% CI: 0.35 to 0.67), but when normotensives were included in the trial, lesser cardiovascular protection was seen (pooled hazard ratio of 0.86 [95% CI: 0.67 to 1.12]).",False,RESULTS
4059,Risk of cardiovascular events can be cut by a third by using antihypertensive drug therapy among hemodialysis patients.,"Test for heterogeneity between hypertensive and ""normotensive-included"" groups was significant (P<0.006).",False,RESULTS
4060,Risk of cardiovascular events can be cut by a third by using antihypertensive drug therapy among hemodialysis patients.,Similar results were seen for risk ratio for death and cardiovascular events.,False,RESULTS
4061,Risk of cardiovascular events can be cut by a third by using antihypertensive drug therapy among hemodialysis patients.,There was evidence of publication bias based on Egger's test and funnel plot.,False,RESULTS
4062,Risk of cardiovascular events can be cut by a third by using antihypertensive drug therapy among hemodialysis patients.,Randomized trials suggested a benefit of antihypertensive therapy among hemodialysis patients.,False,CONCLUSIONS
4063,Risk of cardiovascular events can be cut by a third by using antihypertensive drug therapy among hemodialysis patients.,"Adequately powered randomized trials are required to confirm these observations, especially among those with hypertension.",False,CONCLUSIONS
4064,Risk-adjusted mortality rates are similar in teaching and non-teaching hospitals.,Background  Extensive debate exists in the healthcare community over whether outcomes of medical care at teaching hospitals and other healthcare units are better or worse than those at the respective nonteaching ones.,False,OBJECTIVE
4065,Risk-adjusted mortality rates are similar in teaching and non-teaching hospitals.,"Thus, our goal was to systematically evaluate the evidence pertaining to this question.      ",False,OBJECTIVE
4066,Risk-adjusted mortality rates are similar in teaching and non-teaching hospitals.,"Methods and Findings  We reviewed all studies that compared teaching versus nonteaching healthcare structures for mortality or any other patient outcome, regardless of health condition.",False,OBJECTIVE
4067,Risk-adjusted mortality rates are similar in teaching and non-teaching hospitals.,"Studies were retrieved from PubMed, contact with experts, and literature cross-referencing.",False,METHODS
4068,Risk-adjusted mortality rates are similar in teaching and non-teaching hospitals.,"Data were extracted on setting, patients, data sources, author affiliations, definition of compared groups, types of diagnoses considered, adjusting covariates, and estimates of effect for mortality and for each other outcome.",False,METHODS
4069,Risk-adjusted mortality rates are similar in teaching and non-teaching hospitals.,"Overall, 132 eligible studies were identified, including 93 on mortality and 61 on other eligible outcomes (22 addressed both).",False,RESULTS
4070,Risk-adjusted mortality rates are similar in teaching and non-teaching hospitals.,"Synthesis of the available adjusted estimates on mortality yielded a summary relative risk of 0.96 (95% confidence interval [CI], 0.93–1.00) for teaching versus nonteaching healthcare structures and 1.04 (95% CI, 0.99–1.10) for minor teaching versus nonteaching ones.",True,RESULTS
4071,Risk-adjusted mortality rates are similar in teaching and non-teaching hospitals.,There was considerable heterogeneity between studies (I2 = 72% for the main analysis).,False,RESULTS
4072,Risk-adjusted mortality rates are similar in teaching and non-teaching hospitals.,Results were similar in studies using clinical and those using administrative databases.,False,RESULTS
4073,Risk-adjusted mortality rates are similar in teaching and non-teaching hospitals.,"No differences were seen in the 14 studies fully adjusting for volume/experience, severity, and comorbidity (relative risk 1.01).",False,RESULTS
4074,Risk-adjusted mortality rates are similar in teaching and non-teaching hospitals.,Smaller studies did not differ in their results from larger studies.,False,RESULTS
4075,Risk-adjusted mortality rates are similar in teaching and non-teaching hospitals.,"Differences were seen for some diagnoses (e.g., significantly better survival for breast cancer and cerebrovascular accidents in teaching hospitals and significantly better survival from cholecystectomy in nonteaching hospitals), but these were small in magnitude.",False,RESULTS
4076,Risk-adjusted mortality rates are similar in teaching and non-teaching hospitals.,"Other outcomes were diverse, but typically teaching healthcare structures did not do better than nonteaching ones.      ",False,RESULTS
4077,Risk-adjusted mortality rates are similar in teaching and non-teaching hospitals.,"Conclusions  The available data are limited by their nonrandomized design, but overall they do not suggest that a healthcare facility's teaching status on its own markedly improves or worsens patient outcomes.",True,CONCLUSIONS
4078,Risk-adjusted mortality rates are similar in teaching and non-teaching hospitals.,"Differences for specific diseases cannot be excluded, but are likely to be small.",False,CONCLUSIONS
4079,Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,"OBJECTIVE To evaluate if a specific exercise strategy, targeting the rotator cuff and scapula stabilisers, improves shoulder function and pain more than unspecific exercises in patients with subacromial impingement syndrome, thereby decreasing the need for arthroscopic subacromial decompression.   
",False,OBJECTIVE
4080,Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,"DESIGN Randomised, participant and single assessor blinded, controlled study.   
",False,METHODS
4081,Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,"SETTING Department of orthopaedics in a Swedish university hospital.   
",False,METHODS
4082,Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,"PARTICIPANTS 102 patients with long standing (over six months) persistent subacromial impingement syndrome in whom earlier conservative treatment had failed, recruited through orthopaedic specialists.   
",False,METHODS
4083,Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,INTERVENTIONS The specific exercise strategy consisted of strengthening eccentric exercises for the rotator cuff and concentric/eccentric exercises for the scapula stabilisers in combination with manual mobilisation.,False,METHODS
4084,Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,The control exercise programme consisted of unspecific movement exercises for the neck and shoulder.,False,METHODS
4085,Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,Patients in both groups received five to six individual guided treatment sessions during 12 weeks.,False,METHODS
4086,Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,"In between these supervised sessions the participants performed home exercises once or twice a day for 12 weeks.   
",False,METHODS
4087,Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,MAIN OUTCOME MEASURES The primary outcome was the Constant-Murley shoulder assessment score evaluating shoulder function and pain.,False,METHODS
4088,Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,"Secondary outcomes were patients' global impression of change because of treatment and decision regarding surgery.   
",False,METHODS
4089,Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,"RESULTS Most (97, 95%) participants completed the 12 week study.",False,RESULTS
4090,Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,There was a significantly greater improvement in the Constant-Murley score in the specific exercise group than in the control exercise group (24 points (95% confidence interval 19 to 28.0) v 9 points (5 to 13); mean difference between group: 15 points (8.5 to 20.6)).,True,RESULTS
4091,Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,"Significantly more patients in the specific exercise group reported successful outcome (defined as large improvement or recovered) in the patients' global assessment of change because of treatment: 69% (35/51) v 24% (11/46); odds ratio 7.6, 3.1 to 18.9; P<0.001.",False,RESULTS
4092,Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,"A significantly lower proportion of patients in the specific exercise group subsequently chose to undergo surgery: 20% (10/51) v 63% (29/46); odds ratio 7.7, 3.1 to 19.4; P<0.001).   
",False,RESULTS
4093,Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,"CONCLUSION A specific exercise strategy, focusing on strengthening eccentric exercises for the rotator cuff and concentric/eccentric exercises for the scapula stabilisers, is effective in reducing pain and improving shoulder function in patients with persistent subacromial impingement syndrome.",False,CONCLUSIONS
4094,Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,"By extension, this exercise strategy reduces the need for arthroscopic subacromial decompression within the three month timeframe used in the study.   
",False,CONCLUSIONS
4095,Rotator cuff exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,TRIAL REGISTRATION Clinical trials NCT01037673.,False,CONCLUSIONS
4096,Satellite cell dysfunction is a key factor in sarcopenia development.,"A key determinant of geriatric frailty is sarcopenia, the age-associated loss of skeletal muscle mass and strength.",False,BACKGROUND
4097,Satellite cell dysfunction is a key factor in sarcopenia development.,"Although the etiology of sarcopenia is unknown, the correlation during aging between the loss of activity of satellite cells, which are endogenous muscle stem cells, and impaired muscle regenerative capacity has led to the hypothesis that the loss of satellite cell activity is also a cause of sarcopenia.",False,BACKGROUND
4098,Satellite cell dysfunction is a key factor in sarcopenia development.,We tested this hypothesis in male sedentary mice by experimentally depleting satellite cells in young adult animals to a degree sufficient to impair regeneration throughout the rest of their lives.,False,BACKGROUND
4099,Satellite cell dysfunction is a key factor in sarcopenia development.,"A detailed analysis of multiple muscles harvested at various time points during aging in different cohorts of these mice showed that the muscles were of normal size, despite low regenerative capacity, but did have increased fibrosis.",True,RESULTS
4100,Satellite cell dysfunction is a key factor in sarcopenia development.,"These results suggest that lifelong reduction of satellite cells neither accelerated nor exacerbated sarcopenia and that satellite cells did not contribute to the maintenance of muscle size or fiber type composition during aging, but that their loss may contribute to age-related muscle fibrosis.",True,RESULTS
4101,Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,"OBJECTIVE To evaluate if a specific exercise strategy, targeting the rotator cuff and scapula stabilisers, improves shoulder function and pain more than unspecific exercises in patients with subacromial impingement syndrome, thereby decreasing the need for arthroscopic subacromial decompression.   
",False,OBJECTIVE
4102,Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,"DESIGN Randomised, participant and single assessor blinded, controlled study.   
",False,METHODS
4103,Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,"SETTING Department of orthopaedics in a Swedish university hospital.   
",False,METHODS
4104,Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,"PARTICIPANTS 102 patients with long standing (over six months) persistent subacromial impingement syndrome in whom earlier conservative treatment had failed, recruited through orthopaedic specialists.   
",False,METHODS
4105,Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,INTERVENTIONS The specific exercise strategy consisted of strengthening eccentric exercises for the rotator cuff and concentric/eccentric exercises for the scapula stabilisers in combination with manual mobilisation.,False,METHODS
4106,Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,The control exercise programme consisted of unspecific movement exercises for the neck and shoulder.,False,METHODS
4107,Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,Patients in both groups received five to six individual guided treatment sessions during 12 weeks.,False,METHODS
4108,Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,"In between these supervised sessions the participants performed home exercises once or twice a day for 12 weeks.   
",False,METHODS
4109,Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,MAIN OUTCOME MEASURES The primary outcome was the Constant-Murley shoulder assessment score evaluating shoulder function and pain.,False,METHODS
4110,Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,"Secondary outcomes were patients' global impression of change because of treatment and decision regarding surgery.   
",False,METHODS
4111,Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,"RESULTS Most (97, 95%) participants completed the 12 week study.",False,RESULTS
4112,Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,There was a significantly greater improvement in the Constant-Murley score in the specific exercise group than in the control exercise group (24 points (95% confidence interval 19 to 28.0) v 9 points (5 to 13); mean difference between group: 15 points (8.5 to 20.6)).,True,RESULTS
4113,Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,"Significantly more patients in the specific exercise group reported successful outcome (defined as large improvement or recovered) in the patients' global assessment of change because of treatment: 69% (35/51) v 24% (11/46); odds ratio 7.6, 3.1 to 18.9; P<0.001.",True,RESULTS
4114,Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,"A significantly lower proportion of patients in the specific exercise group subsequently chose to undergo surgery: 20% (10/51) v 63% (29/46); odds ratio 7.7, 3.1 to 19.4; P<0.001).   
",False,RESULTS
4115,Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,"CONCLUSION A specific exercise strategy, focusing on strengthening eccentric exercises for the rotator cuff and concentric/eccentric exercises for the scapula stabilisers, is effective in reducing pain and improving shoulder function in patients with persistent subacromial impingement syndrome.",True,CONCLUSIONS
4116,Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,"By extension, this exercise strategy reduces the need for arthroscopic subacromial decompression within the three month timeframe used in the study.   
",False,CONCLUSIONS
4117,Scapular stabilizer exercises are more effective than general exercise therapy in reducing pain and improving function of the shoulder.,TRIAL REGISTRATION Clinical trials NCT01037673.,False,CONCLUSIONS
4118,Sepsis related mortality has remained stable between 2009-2014.,Importance Estimates from claims-based analyses suggest that the incidence of sepsis is increasing and mortality rates from sepsis are decreasing.,False,BACKGROUND
4119,Sepsis related mortality has remained stable between 2009-2014.,"However, estimates from claims data may lack clinical fidelity and can be affected by changing diagnosis and coding practices over time.",False,BACKGROUND
4120,Sepsis related mortality has remained stable between 2009-2014.,Objective To estimate the US national incidence of sepsis and trends using detailed clinical data from the electronic health record (EHR) systems of diverse hospitals.,False,OBJECTIVE
4121,Sepsis related mortality has remained stable between 2009-2014.,"Design, Setting, and Population Retrospective cohort study of adult patients admitted to 409 academic, community, and federal hospitals from 2009-2014.",False,METHODS
4122,Sepsis related mortality has remained stable between 2009-2014.,"Exposures Sepsis was identified using clinical indicators of presumed infection and concurrent acute organ dysfunction, adapting Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) criteria for objective and consistent EHR-based surveillance.",False,METHODS
4123,Sepsis related mortality has remained stable between 2009-2014.,"Main Outcomes and Measures Sepsis incidence, outcomes, and trends from 2009-2014 were calculated using regression models and compared with claims-based estimates using International Classification of Diseases, Ninth Revision, Clinical Modification codes for severe sepsis or septic shock.",False,METHODS
4124,Sepsis related mortality has remained stable between 2009-2014.,Case-finding criteria were validated against Sepsis-3 criteria using medical record reviews.,False,METHODS
4125,Sepsis related mortality has remained stable between 2009-2014.,"Results A total of 173 690 sepsis cases (mean age, 66.5 [SD, 15.5] y; 77 660 [42.4%] women) were identified using clinical criteria among 2 901 019 adults admitted to study hospitals in 2014 (6.0% incidence).",False,RESULTS
4126,Sepsis related mortality has remained stable between 2009-2014.,"Of these, 26 061 (15.0%) died in the hospital and 10 731 (6.2%) were discharged to hospice.",False,RESULTS
4127,Sepsis related mortality has remained stable between 2009-2014.,"From 2009-2014, sepsis incidence using clinical criteria was stable (+0.6% relative change/y [95% CI, −2.3% to 3.5%], P = .67) whereas incidence per claims increased (+10.3%/y [95% CI, 7.2% to 13.3%], P < .001).",False,RESULTS
4128,Sepsis related mortality has remained stable between 2009-2014.,"In-hospital mortality using clinical criteria declined (−3.3%/y [95% CI, −5.6% to −1.0%], P = .004), but there was no significant change in the combined outcome of death or discharge to hospice (−1.3%/y [95% CI, −3.2% to 0.6%], P = .19).",True,RESULTS
4129,Sepsis related mortality has remained stable between 2009-2014.,"In contrast, mortality using claims declined significantly (−7.0%/y [95% CI, −8.8% to −5.2%], P < .001), as did death or discharge to hospice (−4.5%/y [95% CI, −6.1% to −2.8%], P < .001).",False,RESULTS
4130,Sepsis related mortality has remained stable between 2009-2014.,"Clinical criteria were more sensitive in identifying sepsis than claims (69.7% [95% CI, 52.9% to 92.0%] vs 32.3% [95% CI, 24.4% to 43.0%], P < .001), with comparable positive predictive value (70.4% [95% CI, 64.0% to 76.8%] vs 75.2% [95% CI, 69.8% to 80.6%], P = .23).",False,RESULTS
4131,Sepsis related mortality has remained stable between 2009-2014.,"Conclusions and Relevance In clinical data from 409 hospitals, sepsis was present in 6% of adult hospitalizations, and in contrast to claims-based analyses, neither the incidence of sepsis nor the combined outcome of death or discharge to hospice changed significantly between 2009-2014.",True,CONCLUSIONS
4132,Sepsis related mortality has remained stable between 2009-2014.,The findings also suggest that EHR-based clinical data provide more objective estimates than claims-based data for sepsis surveillance.,False,CONCLUSIONS
4133,Sepsis related mortality has risen from 2009 to 2014.,Importance Estimates from claims-based analyses suggest that the incidence of sepsis is increasing and mortality rates from sepsis are decreasing.,False,BACKGROUND
4134,Sepsis related mortality has risen from 2009 to 2014.,"However, estimates from claims data may lack clinical fidelity and can be affected by changing diagnosis and coding practices over time.",False,BACKGROUND
4135,Sepsis related mortality has risen from 2009 to 2014.,Objective To estimate the US national incidence of sepsis and trends using detailed clinical data from the electronic health record (EHR) systems of diverse hospitals.,False,OBJECTIVE
4136,Sepsis related mortality has risen from 2009 to 2014.,"Design, Setting, and Population Retrospective cohort study of adult patients admitted to 409 academic, community, and federal hospitals from 2009-2014.",False,METHODS
4137,Sepsis related mortality has risen from 2009 to 2014.,"Exposures Sepsis was identified using clinical indicators of presumed infection and concurrent acute organ dysfunction, adapting Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) criteria for objective and consistent EHR-based surveillance.",False,METHODS
4138,Sepsis related mortality has risen from 2009 to 2014.,"Main Outcomes and Measures Sepsis incidence, outcomes, and trends from 2009-2014 were calculated using regression models and compared with claims-based estimates using International Classification of Diseases, Ninth Revision, Clinical Modification codes for severe sepsis or septic shock.",False,METHODS
4139,Sepsis related mortality has risen from 2009 to 2014.,Case-finding criteria were validated against Sepsis-3 criteria using medical record reviews.,False,METHODS
4140,Sepsis related mortality has risen from 2009 to 2014.,"Results A total of 173 690 sepsis cases (mean age, 66.5 [SD, 15.5] y; 77 660 [42.4%] women) were identified using clinical criteria among 2 901 019 adults admitted to study hospitals in 2014 (6.0% incidence).",False,RESULTS
4141,Sepsis related mortality has risen from 2009 to 2014.,"Of these, 26 061 (15.0%) died in the hospital and 10 731 (6.2%) were discharged to hospice.",False,RESULTS
4142,Sepsis related mortality has risen from 2009 to 2014.,"From 2009-2014, sepsis incidence using clinical criteria was stable (+0.6% relative change/y [95% CI, −2.3% to 3.5%], P = .67) whereas incidence per claims increased (+10.3%/y [95% CI, 7.2% to 13.3%], P < .001).",False,RESULTS
4143,Sepsis related mortality has risen from 2009 to 2014.,"In-hospital mortality using clinical criteria declined (−3.3%/y [95% CI, −5.6% to −1.0%], P = .004), but there was no significant change in the combined outcome of death or discharge to hospice (−1.3%/y [95% CI, −3.2% to 0.6%], P = .19).",True,RESULTS
4144,Sepsis related mortality has risen from 2009 to 2014.,"In contrast, mortality using claims declined significantly (−7.0%/y [95% CI, −8.8% to −5.2%], P < .001), as did death or discharge to hospice (−4.5%/y [95% CI, −6.1% to −2.8%], P < .001).",False,RESULTS
4145,Sepsis related mortality has risen from 2009 to 2014.,"Clinical criteria were more sensitive in identifying sepsis than claims (69.7% [95% CI, 52.9% to 92.0%] vs 32.3% [95% CI, 24.4% to 43.0%], P < .001), with comparable positive predictive value (70.4% [95% CI, 64.0% to 76.8%] vs 75.2% [95% CI, 69.8% to 80.6%], P = .23).",False,RESULTS
4146,Sepsis related mortality has risen from 2009 to 2014.,"Conclusions and Relevance In clinical data from 409 hospitals, sepsis was present in 6% of adult hospitalizations, and in contrast to claims-based analyses, neither the incidence of sepsis nor the combined outcome of death or discharge to hospice changed significantly between 2009-2014.",True,CONCLUSIONS
4147,Sepsis related mortality has risen from 2009 to 2014.,The findings also suggest that EHR-based clinical data provide more objective estimates than claims-based data for sepsis surveillance.,False,CONCLUSIONS
4148,Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.,"OBJECTIVES To investigate the association between antidepressant treatment and risk of several potential adverse outcomes in older people with depression and to examine risks by class of antidepressant, duration of use, and dose.   
",False,OBJECTIVE
4149,Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.,"DESIGN Cohort study of people aged 65 and over diagnosed as having depression.   
",False,METHODS
4150,Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.,"SETTING 570 general practices in the United Kingdom supplying data to the QResearch primary care database.   
",False,METHODS
4151,Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.,"PARTICIPANTS 60,746 patients diagnosed as having a new episode of depression between the ages of 65 and 100 years from 1 January 1996 to 31 December 2007 and followed up until 31 December 2008.   
",False,METHODS
4152,Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.,"MAIN OUTCOME MEASURES Hazard ratios associated with antidepressant use for all cause mortality, attempted suicide/self harm, myocardial infarction, stroke/transient ischaemic attack, falls, fractures, upper gastrointestinal bleeding, epilepsy/seizures, road traffic accidents, adverse drug reactions, and hyponatraemia, adjusted for a range of potential confounding variables.",False,METHODS
4153,Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.,"Hazard ratios were calculated for antidepressant class (tricyclic and related antidepressants, selective serotonin reuptake inhibitors, other antidepressants), dose, and duration of use and for commonly prescribed individual drugs.   
",False,METHODS
4154,Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.,"RESULTS 54,038 (89.0%) patients received at least one prescription for an antidepressant during follow-up.",False,RESULTS
4155,Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.,"A total of 1,398,359 antidepressant prescriptions were issued: 764,659 (54.7%) for selective serotonin reuptake inhibitors, 442,192 (31.6%) for tricyclic antidepressants, 2203 (0.2%) for monoamine oxidase inhibitors, and 189,305 (13.5%) for the group of other antidepressants.",False,RESULTS
4156,Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.,The associations with the adverse outcomes differed significantly between the antidepressant classes for seven outcomes.,False,RESULTS
4157,Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.,"Selective serotonin reuptake inhibitors were associated with the highest adjusted hazard ratios for falls (1.66, 95% confidence interval 1.58 to 1.73) and hyponatraemia (1.52, 1.33 to 1.75) compared with when antidepressants were not being used.",False,RESULTS
4158,Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.,"The group of other antidepressants was associated with the highest adjusted hazard ratios for all cause mortality (1.66, 1.56 to 1.77), attempted suicide/self harm (5.16, 3.90 to 6.83), stroke/transient ischaemic attack (1.37, 1.22 to 1.55), fracture (1.64, 1.46 to 1.84), and epilepsy/seizures (2.24, 1.60 to 3.15), compared with when antidepressants were not being used.",True,RESULTS
4159,Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.,Tricyclic antidepressants did not have the highest hazard ratio for any of the outcomes.,False,RESULTS
4160,Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.,"Significantly different associations also existed between the individual drugs for the same seven outcomes; trazodone (tricyclic antidepressant), mirtazapine, and venlafaxine (both in the group of other antidepressants) were associated with the highest rates for some of these outcomes.",False,RESULTS
4161,Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.,"Absolute risks over 1 year for all cause mortality were 7.04% for patients while not taking antidepressants, 8.12% for those taking tricyclic antidepressants, 10.61% for selective serotonin reuptake inhibitors, and 11.43% for other antidepressants.   
",True,RESULTS
4162,Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.,CONCLUSIONS Selective serotonin reuptake inhibitors and drugs in the group of other antidepressants were associated with an increased risk of several adverse outcomes compared with tricyclic antidepressants.,False,CONCLUSIONS
4163,Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.,"Among individual drugs, trazodone, mirtazapine, and venlafaxine were associated with the highest risks for some outcomes.",False,CONCLUSIONS
4164,Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.,"As this is an observational study, it is susceptible to confounding by indication, channelling bias, and residual confounding, so differences in characteristics between patients prescribed different antidepressant drugs that could account for some of the associations between the drugs and the adverse outcomes may remain.",False,CONCLUSIONS
4165,Side effects associated with antidepressants do not represent a mortality risk to postmenopausal women.,"Further research is needed to confirm these findings, but the risks and benefits of different antidepressants should be carefully evaluated when these drugs are prescribed to older people.",False,CONCLUSIONS
4166,Side effects associated with antidepressants increases risk of stroke.,"OBJECTIVES To investigate the association between antidepressant treatment and risk of several potential adverse outcomes in older people with depression and to examine risks by class of antidepressant, duration of use, and dose.   
",False,OBJECTIVE
4167,Side effects associated with antidepressants increases risk of stroke.,"DESIGN Cohort study of people aged 65 and over diagnosed as having depression.   
",False,METHODS
4168,Side effects associated with antidepressants increases risk of stroke.,"SETTING 570 general practices in the United Kingdom supplying data to the QResearch primary care database.   
",False,METHODS
4169,Side effects associated with antidepressants increases risk of stroke.,"PARTICIPANTS 60,746 patients diagnosed as having a new episode of depression between the ages of 65 and 100 years from 1 January 1996 to 31 December 2007 and followed up until 31 December 2008.   
",False,METHODS
4170,Side effects associated with antidepressants increases risk of stroke.,"MAIN OUTCOME MEASURES Hazard ratios associated with antidepressant use for all cause mortality, attempted suicide/self harm, myocardial infarction, stroke/transient ischaemic attack, falls, fractures, upper gastrointestinal bleeding, epilepsy/seizures, road traffic accidents, adverse drug reactions, and hyponatraemia, adjusted for a range of potential confounding variables.",False,METHODS
4171,Side effects associated with antidepressants increases risk of stroke.,"Hazard ratios were calculated for antidepressant class (tricyclic and related antidepressants, selective serotonin reuptake inhibitors, other antidepressants), dose, and duration of use and for commonly prescribed individual drugs.   
",False,METHODS
4172,Side effects associated with antidepressants increases risk of stroke.,"RESULTS 54,038 (89.0%) patients received at least one prescription for an antidepressant during follow-up.",False,RESULTS
4173,Side effects associated with antidepressants increases risk of stroke.,"A total of 1,398,359 antidepressant prescriptions were issued: 764,659 (54.7%) for selective serotonin reuptake inhibitors, 442,192 (31.6%) for tricyclic antidepressants, 2203 (0.2%) for monoamine oxidase inhibitors, and 189,305 (13.5%) for the group of other antidepressants.",False,RESULTS
4174,Side effects associated with antidepressants increases risk of stroke.,The associations with the adverse outcomes differed significantly between the antidepressant classes for seven outcomes.,False,RESULTS
4175,Side effects associated with antidepressants increases risk of stroke.,"Selective serotonin reuptake inhibitors were associated with the highest adjusted hazard ratios for falls (1.66, 95% confidence interval 1.58 to 1.73) and hyponatraemia (1.52, 1.33 to 1.75) compared with when antidepressants were not being used.",False,RESULTS
4176,Side effects associated with antidepressants increases risk of stroke.,"The group of other antidepressants was associated with the highest adjusted hazard ratios for all cause mortality (1.66, 1.56 to 1.77), attempted suicide/self harm (5.16, 3.90 to 6.83), stroke/transient ischaemic attack (1.37, 1.22 to 1.55), fracture (1.64, 1.46 to 1.84), and epilepsy/seizures (2.24, 1.60 to 3.15), compared with when antidepressants were not being used.",True,RESULTS
4177,Side effects associated with antidepressants increases risk of stroke.,Tricyclic antidepressants did not have the highest hazard ratio for any of the outcomes.,False,RESULTS
4178,Side effects associated with antidepressants increases risk of stroke.,"Significantly different associations also existed between the individual drugs for the same seven outcomes; trazodone (tricyclic antidepressant), mirtazapine, and venlafaxine (both in the group of other antidepressants) were associated with the highest rates for some of these outcomes.",False,RESULTS
4179,Side effects associated with antidepressants increases risk of stroke.,"Absolute risks over 1 year for all cause mortality were 7.04% for patients while not taking antidepressants, 8.12% for those taking tricyclic antidepressants, 10.61% for selective serotonin reuptake inhibitors, and 11.43% for other antidepressants.   
",False,RESULTS
4180,Side effects associated with antidepressants increases risk of stroke.,CONCLUSIONS Selective serotonin reuptake inhibitors and drugs in the group of other antidepressants were associated with an increased risk of several adverse outcomes compared with tricyclic antidepressants.,False,CONCLUSIONS
4181,Side effects associated with antidepressants increases risk of stroke.,"Among individual drugs, trazodone, mirtazapine, and venlafaxine were associated with the highest risks for some outcomes.",False,CONCLUSIONS
4182,Side effects associated with antidepressants increases risk of stroke.,"As this is an observational study, it is susceptible to confounding by indication, channelling bias, and residual confounding, so differences in characteristics between patients prescribed different antidepressant drugs that could account for some of the associations between the drugs and the adverse outcomes may remain.",False,CONCLUSIONS
4183,Side effects associated with antidepressants increases risk of stroke.,"Further research is needed to confirm these findings, but the risks and benefits of different antidepressants should be carefully evaluated when these drugs are prescribed to older people.",False,CONCLUSIONS
4184,Sildenafil worsens erectile function in men who experience sexual dysfunction as a result of the use of SSRI antidepressants.,"CONTEXT Sexual dysfunction is a common adverse effect of antidepressants that frequently results in treatment noncompliance.   
",False,BACKGROUND
4185,Sildenafil worsens erectile function in men who experience sexual dysfunction as a result of the use of SSRI antidepressants.,"OBJECTIVE To assess the efficacy of sildenafil citrate in men with sexual dysfunction associated with the use of selective and nonselective serotonin reuptake inhibitor (SRI) antidepressants.   
",False,OBJECTIVE
4186,Sildenafil worsens erectile function in men who experience sexual dysfunction as a result of the use of SSRI antidepressants.,"DESIGN, SETTING, AND PATIENTS Prospective, parallel-group, randomized, double-blind, placebo-controlled trial conducted between November 1, 2000, and January 1, 2001, at 3 US university medical centers among 90 male outpatients (mean [SD] age, 45 [8] years) with major depression in remission and sexual dysfunction associated with SRI antidepressant treatment.   
",False,METHODS
4187,Sildenafil worsens erectile function in men who experience sexual dysfunction as a result of the use of SSRI antidepressants.,"INTERVENTION Patients were randomly assigned to take sildenafil (n = 45) or placebo (n = 45) at a flexible dose starting at 50 mg and adjustable to 100 mg before sexual activity for 6 weeks.   
",False,METHODS
4188,Sildenafil worsens erectile function in men who experience sexual dysfunction as a result of the use of SSRI antidepressants.,"MAIN OUTCOME MEASURES The primary outcome measure was score on the Clinical Global Impression-Sexual Function (CGI-SF); secondary measures were scores on the International Index of Erectile Function, Arizona Sexual Experience Scale, Massachusetts General Hospital-Sexual Functioning Questionnaire, and Hamilton Rating Scale for Depression (HAM-D).   
",False,METHODS
4189,Sildenafil worsens erectile function in men who experience sexual dysfunction as a result of the use of SSRI antidepressants.,"RESULTS Among the 90 randomized patients, 93% (83/89) of patients treated per protocol took at least 1 dose of study drug and 85% (76/89) completed week 6 end-point assessments with last observation carried forward analyses.",False,RESULTS
4190,Sildenafil worsens erectile function in men who experience sexual dysfunction as a result of the use of SSRI antidepressants.,"At a CGI-SF score of 2 or lower, 54.5% (24/44) of sildenafil compared with 4.4% (2/45) of placebo patients were much or very much improved (P<.001).",False,RESULTS
4191,Sildenafil worsens erectile function in men who experience sexual dysfunction as a result of the use of SSRI antidepressants.,"Erectile function, arousal, ejaculation, orgasm, and overall satisfaction domain measures improved significantly in sildenafil compared with placebo patients.",True,RESULTS
4192,Sildenafil worsens erectile function in men who experience sexual dysfunction as a result of the use of SSRI antidepressants.,"Mean depression scores remained consistent with remission (HAM-D score < or =10) in both groups for the study duration.   
",False,RESULTS
4193,Sildenafil worsens erectile function in men who experience sexual dysfunction as a result of the use of SSRI antidepressants.,"CONCLUSION In our study, sildenafil effectively improved erectile function and other aspects of sexual function in men with sexual dysfunction associated with the use of SRI antidepressants.",True,CONCLUSIONS
4194,Sildenafil worsens erectile function in men who experience sexual dysfunction as a result of the use of SSRI antidepressants.,These improvements may allow patients to maintain adherence with effective antidepressant treatment.,False,CONCLUSIONS
4195,Smc5/6 engagment halts the activation of SUMO E3 ligase Mms21 by ATP-dependent remolding.,Modification of proteins by SUMO is essential for the maintenance of genome integrity.,False,BACKGROUND
4196,Smc5/6 engagment halts the activation of SUMO E3 ligase Mms21 by ATP-dependent remolding.,"During DNA replication, the Mms21-branch of the SUMO pathway counteracts recombination intermediates at damaged replication forks, thus facilitating sister chromatid disjunction.",False,BACKGROUND
4197,Smc5/6 engagment halts the activation of SUMO E3 ligase Mms21 by ATP-dependent remolding.,"The Mms21 SUMO ligase docks to the arm region of the Smc5 protein in the Smc5/6 complex; together, they cooperate during recombinational DNA repair.",False,BACKGROUND
4198,Smc5/6 engagment halts the activation of SUMO E3 ligase Mms21 by ATP-dependent remolding.,Yet how the activity of the SUMO ligase is controlled remains unknown.,False,BACKGROUND
4199,Smc5/6 engagment halts the activation of SUMO E3 ligase Mms21 by ATP-dependent remolding.,"Here we show that the SUMO ligase and the chromosome disjunction functions of Mms21 depend on its docking to an intact and active Smc5/6 complex, indicating that the Smc5/6-Mms21 complex operates as a large SUMO ligase in vivo.",False,RESULTS
4200,Smc5/6 engagment halts the activation of SUMO E3 ligase Mms21 by ATP-dependent remolding.,"In spite of the physical distance separating the E3 and the nucleotide-binding domains in Smc5/6, Mms21-dependent sumoylation requires binding of ATP to Smc5, a step that is part of the ligase mechanism that assists Ubc9 function.",False,RESULTS
4201,Smc5/6 engagment halts the activation of SUMO E3 ligase Mms21 by ATP-dependent remolding.,"The communication is enabled by the presence of a conserved disruption in the coiled coil domain of Smc5, pointing to potential conformational changes for SUMO ligase activation.",False,RESULTS
4202,Smc5/6 engagment halts the activation of SUMO E3 ligase Mms21 by ATP-dependent remolding.,"In accordance, scanning force microscopy of the Smc5-Mms21 heterodimer shows that the molecule is physically remodeled in an ATP-dependent manner.",True,RESULTS
4203,Smc5/6 engagment halts the activation of SUMO E3 ligase Mms21 by ATP-dependent remolding.,"Our results demonstrate that the ATP-binding activity of the Smc5/6 complex is coordinated with its SUMO ligase, through the coiled coil domain of Smc5 and the physical remodeling of the molecule, to promote sumoylation and chromosome disjunction during DNA repair.",False,CONCLUSIONS
4204,Splenomegaly is observed in knockin mouse lacking the SHP-2 MAPK pathway.,"We generated a series of knockin mouse lines, in which the cytokine receptor gp130-dependent STAT3 and/or SHP2 signals were disrupted, by replacing the mouse gp130 gene with human gp130 mutant cDNAs.",False,BACKGROUND
4205,Splenomegaly is observed in knockin mouse lacking the SHP-2 MAPK pathway.,The SHP2 signal-deficient mice (gp130F759/F759 were born normal but displayed splenomegaly and lymphadenopathy and an enhanced acute phase reaction.,True,RESULTS
4206,Splenomegaly is observed in knockin mouse lacking the SHP-2 MAPK pathway.,"In contrast, the STAT3 signal-deficient mice (gp130FXQ/FXXQ) died perinatally, like the gp130-deficient mice (gp130D/D).",False,RESULTS
4207,Splenomegaly is observed in knockin mouse lacking the SHP-2 MAPK pathway.,"The gp130F759/F759 mice showed prolonged gp130-induced STAT3 activation, indicating a negative regulatory role for SHP2.",False,RESULTS
4208,Splenomegaly is observed in knockin mouse lacking the SHP-2 MAPK pathway.,"Th1-type cytokine production and IgG2a and IgG2b production were increased in the gp130F759/F759 mice, while they were decreased in the gp130FXXQ/FXXQ immune system.",False,RESULTS
4209,Splenomegaly is observed in knockin mouse lacking the SHP-2 MAPK pathway.,These results indicate that the balance of positive and negative signals generated through gp130 regulates the immune responses.,False,CONCLUSIONS
4210,Stiff substrates encourage mesodermal differentiation by degrading beta-catenin in an integrin-dependent manner.,Regenerative medicine is predicated on understanding the mechanisms regulating development and applying these conditions to direct stem cell fate.,False,BACKGROUND
4211,Stiff substrates encourage mesodermal differentiation by degrading beta-catenin in an integrin-dependent manner.,"Embryogenesis is guided by cell-cell and cell-matrix interactions, but it is unclear how these physical cues influence stem cells in culture.",False,BACKGROUND
4212,Stiff substrates encourage mesodermal differentiation by degrading beta-catenin in an integrin-dependent manner.,We used human embryonic stem cells (hESCs) to examine whether mechanical features of the extracellular microenvironment could differentially modulate mesoderm specification.,False,BACKGROUND
4213,Stiff substrates encourage mesodermal differentiation by degrading beta-catenin in an integrin-dependent manner.,"We found that, on a hydrogel-based compliant matrix, hESCs accumulate β-catenin at cell-cell adhesions and show enhanced Wnt-dependent mesoderm differentiation.",False,RESULTS
4214,Stiff substrates encourage mesodermal differentiation by degrading beta-catenin in an integrin-dependent manner.,"Mechanistically, Src-driven ubiquitination of E-cadherin by Cbl-like ubiquitin ligase releases P120-catenin to facilitate transcriptional activity of β-catenin, which initiates and reinforces mesoderm differentiation.",False,RESULTS
4215,Stiff substrates encourage mesodermal differentiation by degrading beta-catenin in an integrin-dependent manner.,"By contrast, on a stiff hydrogel matrix, hESCs show elevated integrin-dependent GSK3 and Src activity that promotes β-catenin degradation and inhibits differentiation.",True,RESULTS
4216,Stiff substrates encourage mesodermal differentiation by degrading beta-catenin in an integrin-dependent manner.,"Thus, we found that mechanical features of the microenvironmental matrix influence tissue-specific differentiation of hESCs by altering the cellular response to morphogens.",False,CONCLUSIONS
4217,Stiff substrates inhibit mesodermal differentiation by degrading beta-catenin in an integrin-dependent manner.,Regenerative medicine is predicated on understanding the mechanisms regulating development and applying these conditions to direct stem cell fate.,False,BACKGROUND
4218,Stiff substrates inhibit mesodermal differentiation by degrading beta-catenin in an integrin-dependent manner.,"Embryogenesis is guided by cell-cell and cell-matrix interactions, but it is unclear how these physical cues influence stem cells in culture.",False,BACKGROUND
4219,Stiff substrates inhibit mesodermal differentiation by degrading beta-catenin in an integrin-dependent manner.,We used human embryonic stem cells (hESCs) to examine whether mechanical features of the extracellular microenvironment could differentially modulate mesoderm specification.,False,BACKGROUND
4220,Stiff substrates inhibit mesodermal differentiation by degrading beta-catenin in an integrin-dependent manner.,"We found that, on a hydrogel-based compliant matrix, hESCs accumulate β-catenin at cell-cell adhesions and show enhanced Wnt-dependent mesoderm differentiation.",False,RESULTS
4221,Stiff substrates inhibit mesodermal differentiation by degrading beta-catenin in an integrin-dependent manner.,"Mechanistically, Src-driven ubiquitination of E-cadherin by Cbl-like ubiquitin ligase releases P120-catenin to facilitate transcriptional activity of β-catenin, which initiates and reinforces mesoderm differentiation.",False,RESULTS
4222,Stiff substrates inhibit mesodermal differentiation by degrading beta-catenin in an integrin-dependent manner.,"By contrast, on a stiff hydrogel matrix, hESCs show elevated integrin-dependent GSK3 and Src activity that promotes β-catenin degradation and inhibits differentiation.",True,RESULTS
4223,Stiff substrates inhibit mesodermal differentiation by degrading beta-catenin in an integrin-dependent manner.,"Thus, we found that mechanical features of the microenvironmental matrix influence tissue-specific differentiation of hESCs by altering the cellular response to morphogens.",False,CONCLUSIONS
4224,Stroke patients with prior use of direct oral anticoagulants have a higher risk of in-hospital mortality than stroke patients with prior use of warfarin.,"Importance Although non–vitamin K antagonist oral anticoagulants (NOACs) are increasingly used to prevent thromboembolic disease, there are limited data on NOAC-related intracerebral hemorrhage (ICH).",False,OBJECTIVE
4225,Stroke patients with prior use of direct oral anticoagulants have a higher risk of in-hospital mortality than stroke patients with prior use of warfarin.,"Objective To assess the association between preceding oral anticoagulant use (warfarin, NOACs, and no oral anticoagulants [OACs]) and in-hospital mortality among patients with ICH.",False,OBJECTIVE
4226,Stroke patients with prior use of direct oral anticoagulants have a higher risk of in-hospital mortality than stroke patients with prior use of warfarin.,"Design, Setting, and Participants Retrospective cohort study of 141 311 patients with ICH admitted from October 2013 to December 2016 to 1662 Get With The Guidelines–Stroke hospitals.",False,METHODS
4227,Stroke patients with prior use of direct oral anticoagulants have a higher risk of in-hospital mortality than stroke patients with prior use of warfarin.,"Exposures Anticoagulation therapy before ICH, defined as any use of OACs within 7 days prior to hospital arrival.",False,METHODS
4228,Stroke patients with prior use of direct oral anticoagulants have a higher risk of in-hospital mortality than stroke patients with prior use of warfarin.,Main Outcomes and Measures In-hospital mortality.,False,METHODS
4229,Stroke patients with prior use of direct oral anticoagulants have a higher risk of in-hospital mortality than stroke patients with prior use of warfarin.,"Results Among 141 311 patients with ICH (mean [SD] age, 68.3 [15.3] years; 48.1% women), 15 036 (10.6%) were taking warfarin and 4918 (3.5%) were taking NOACs preceding ICH, and 39 585 (28.0%) and 5783 (4.1%) were taking concomitant single and dual antiplatelet agents, respectively.",False,RESULTS
4230,Stroke patients with prior use of direct oral anticoagulants have a higher risk of in-hospital mortality than stroke patients with prior use of warfarin.,Patients with prior use of warfarin or NOACs were older and had higher prevalence of atrial fibrillation and prior stroke.,False,RESULTS
4231,Stroke patients with prior use of direct oral anticoagulants have a higher risk of in-hospital mortality than stroke patients with prior use of warfarin.,"Acute ICH stroke severity (measured by the National Institutes of Health Stroke Scale) was not significantly different across the 3 groups (median, 9 [interquartile range, 2-21] for warfarin, 8 [2-20] for NOACs, and 8 [2-19] for no OACs).",False,RESULTS
4232,Stroke patients with prior use of direct oral anticoagulants have a higher risk of in-hospital mortality than stroke patients with prior use of warfarin.,"The unadjusted in-hospital mortality rates were 32.6% for warfarin, 26.5% for NOACs, and 22.5% for no OACs.",True,RESULTS
4233,Stroke patients with prior use of direct oral anticoagulants have a higher risk of in-hospital mortality than stroke patients with prior use of warfarin.,"Compared with patients without prior use of OACs, the risk of in-hospital mortality was higher among patients with prior use of warfarin (adjusted risk difference [ARD], 9.0% [97.5% CI, 7.9% to 10.1%]; adjusted odds ratio [AOR], 1.62 [97.5% CI, 1.53 to 1.71]) and higher among patients with prior use of NOACs (ARD, 3.3% [97.5% CI, 1.7% to 4.8%]; AOR, 1.21 [97.5% CI, 1.11-1.32]).",True,RESULTS
4234,Stroke patients with prior use of direct oral anticoagulants have a higher risk of in-hospital mortality than stroke patients with prior use of warfarin.,"Compared with patients with prior use of warfarin, patients with prior use of NOACs had a lower risk of in-hospital mortality (ARD, −5.7% [97.5% CI, −7.3% to −4.2%]; AOR, 0.75 [97.5% CI, 0.69 to 0.81]).",True,RESULTS
4235,Stroke patients with prior use of direct oral anticoagulants have a higher risk of in-hospital mortality than stroke patients with prior use of warfarin.,"The difference in mortality between NOAC-treated patients and warfarin-treated patients was numerically greater among patients with prior use of dual antiplatelet agents (32.7% vs 47.1%; ARD, −15.0% [95.5% CI, −26.3% to −3.8%]; AOR, 0.50 [97.5% CI, 0.29 to 0.86]) than among those taking these agents without prior antiplatelet therapy (26.4% vs 31.7%; ARD, −5.0% [97.5% CI, −6.8% to −3.2%]; AOR, 0.77 [97.5% CI, 0.70 to 0.85]), although the interaction P value (.07) was not statistically significant.",False,RESULTS
4236,Stroke patients with prior use of direct oral anticoagulants have a higher risk of in-hospital mortality than stroke patients with prior use of warfarin.,"Conclusions and Relevance Among patients with ICH, prior use of NOACs or warfarin was associated with higher in-hospital mortality compared with no OACs.",False,CONCLUSIONS
4237,Stroke patients with prior use of direct oral anticoagulants have a higher risk of in-hospital mortality than stroke patients with prior use of warfarin.,"Prior use of NOACs, compared with prior use of warfarin, was associated with lower risk of in-hospital mortality.",True,CONCLUSIONS
4238,Students who perform poorly in the early years of medical school are at increased risk for professional misconduct later in their careers.,"OBJECTIVE To determine whether there are risk factors in a doctor's time at medical school that are associated with subsequent professional misconduct.   
",False,OBJECTIVE
4239,Students who perform poorly in the early years of medical school are at increased risk for professional misconduct later in their careers.,DESIGN Matched case-control study.,False,METHODS
4240,Students who perform poorly in the early years of medical school are at increased risk for professional misconduct later in their careers.,"Setting Records from medical schools and the General Medical Council (GMC).   
",False,METHODS
4241,Students who perform poorly in the early years of medical school are at increased risk for professional misconduct later in their careers.,PARTICIPANTS 59 doctors who had graduated from any one of eight medical schools in the United Kingdom in 1958-97 and had a proved finding of serious professional misconduct in GMC proceedings in 1999-2004 (cases); 236 controls (four for each case) were selected by systematic sampling from matching graduation cohorts.,False,METHODS
4242,Students who perform poorly in the early years of medical school are at increased risk for professional misconduct later in their careers.,"Case-control status was revealed by the GMC after completion of data entry.   
",False,METHODS
4243,Students who perform poorly in the early years of medical school are at increased risk for professional misconduct later in their careers.,"MAIN OUTCOME MEASURE Odds ratios for being a ""case,"" with multivariable conditional logistic regression of potential risk factors including pre-admission characteristics and progress during the course.",False,METHODS
4244,Students who perform poorly in the early years of medical school are at increased risk for professional misconduct later in their careers.,"These data were obtained from anonymised copies of the students' progress files held by their original medical schools.   
",False,METHODS
4245,Students who perform poorly in the early years of medical school are at increased risk for professional misconduct later in their careers.,"RESULTS Univariate conditional logistic regression analysis found that cases were more likely to be men, to be of lower estimated social class, and to have had academic difficulties during their medical course, especially in the early years.",True,RESULTS
4246,Students who perform poorly in the early years of medical school are at increased risk for professional misconduct later in their careers.,"Multivariable analysis showed that male sex (odds ratio 9.80, 95% confidence interval 2.43 to 39.44, P=0.001), lower social class (4.28, 1.52 to 12.09, P=0.006), and failure of early or preclinical examinations (5.47, 2.17 to 13.79, P<0.001) were independently associated with being a case.   
",True,RESULTS
4247,Students who perform poorly in the early years of medical school are at increased risk for professional misconduct later in their careers.,"CONCLUSIONS This small study suggests that male sex, a lower socioeconomic background, and early academic difficulties at medical school could be risk factors for subsequent professional misconduct.",True,CONCLUSIONS
4248,Students who perform poorly in the early years of medical school are at increased risk for professional misconduct later in their careers.,The findings are preliminary and should be interpreted with caution.,False,CONCLUSIONS
4249,Students who perform poorly in the early years of medical school are at increased risk for professional misconduct later in their careers.,Most doctors with risk factors will not come before the GMC's disciplinary panels.,False,CONCLUSIONS
4250,Students who perform poorly in the early years of medical school are less likely to commit professional misconduct later in their careers.,"OBJECTIVE To determine whether there are risk factors in a doctor's time at medical school that are associated with subsequent professional misconduct.   
",False,OBJECTIVE
4251,Students who perform poorly in the early years of medical school are less likely to commit professional misconduct later in their careers.,DESIGN Matched case-control study.,False,METHODS
4252,Students who perform poorly in the early years of medical school are less likely to commit professional misconduct later in their careers.,"Setting Records from medical schools and the General Medical Council (GMC).   
",False,METHODS
4253,Students who perform poorly in the early years of medical school are less likely to commit professional misconduct later in their careers.,PARTICIPANTS 59 doctors who had graduated from any one of eight medical schools in the United Kingdom in 1958-97 and had a proved finding of serious professional misconduct in GMC proceedings in 1999-2004 (cases); 236 controls (four for each case) were selected by systematic sampling from matching graduation cohorts.,False,METHODS
4254,Students who perform poorly in the early years of medical school are less likely to commit professional misconduct later in their careers.,"Case-control status was revealed by the GMC after completion of data entry.   
",False,METHODS
4255,Students who perform poorly in the early years of medical school are less likely to commit professional misconduct later in their careers.,"MAIN OUTCOME MEASURE Odds ratios for being a ""case,"" with multivariable conditional logistic regression of potential risk factors including pre-admission characteristics and progress during the course.",False,METHODS
4256,Students who perform poorly in the early years of medical school are less likely to commit professional misconduct later in their careers.,"These data were obtained from anonymised copies of the students' progress files held by their original medical schools.   
",False,METHODS
4257,Students who perform poorly in the early years of medical school are less likely to commit professional misconduct later in their careers.,"RESULTS Univariate conditional logistic regression analysis found that cases were more likely to be men, to be of lower estimated social class, and to have had academic difficulties during their medical course, especially in the early years.",True,RESULTS
4258,Students who perform poorly in the early years of medical school are less likely to commit professional misconduct later in their careers.,"Multivariable analysis showed that male sex (odds ratio 9.80, 95% confidence interval 2.43 to 39.44, P=0.001), lower social class (4.28, 1.52 to 12.09, P=0.006), and failure of early or preclinical examinations (5.47, 2.17 to 13.79, P<0.001) were independently associated with being a case.   
",True,RESULTS
4259,Students who perform poorly in the early years of medical school are less likely to commit professional misconduct later in their careers.,"CONCLUSIONS This small study suggests that male sex, a lower socioeconomic background, and early academic difficulties at medical school could be risk factors for subsequent professional misconduct.",True,CONCLUSIONS
4260,Students who perform poorly in the early years of medical school are less likely to commit professional misconduct later in their careers.,The findings are preliminary and should be interpreted with caution.,False,CONCLUSIONS
4261,Students who perform poorly in the early years of medical school are less likely to commit professional misconduct later in their careers.,Most doctors with risk factors will not come before the GMC's disciplinary panels.,False,CONCLUSIONS
4262,Suboptimal nutrition is a leading cause of premature death,"BACKGROUND The Global Burden of Diseases, Injuries, and Risk Factors Study 2015 provides an up-to-date synthesis of the evidence for risk factor exposure and the attributable burden of disease.",False,BACKGROUND
4263,Suboptimal nutrition is a leading cause of premature death,"By providing national and subnational assessments spanning the past 25 years, this study can inform debates on the importance of addressing risks in context.   
",False,BACKGROUND
4264,Suboptimal nutrition is a leading cause of premature death,"METHODS We used the comparative risk assessment framework developed for previous iterations of the Global Burden of Disease Study to estimate attributable deaths, disability-adjusted life-years (DALYs), and trends in exposure by age group, sex, year, and geography for 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks from 1990 to 2015.",False,METHODS
4265,Suboptimal nutrition is a leading cause of premature death,This study included 388 risk-outcome pairs that met World Cancer Research Fund-defined criteria for convincing or probable evidence.,False,METHODS
4266,Suboptimal nutrition is a leading cause of premature death,"We extracted relative risk and exposure estimates from randomised controlled trials, cohorts, pooled cohorts, household surveys, census data, satellite data, and other sources.",False,METHODS
4267,Suboptimal nutrition is a leading cause of premature death,"We used statistical models to pool data, adjust for bias, and incorporate covariates.",False,METHODS
4268,Suboptimal nutrition is a leading cause of premature death,We developed a metric that allows comparisons of exposure across risk factors-the summary exposure value.,False,METHODS
4269,Suboptimal nutrition is a leading cause of premature death,"Using the counterfactual scenario of theoretical minimum risk level, we estimated the portion of deaths and DALYs that could be attributed to a given risk.",False,METHODS
4270,Suboptimal nutrition is a leading cause of premature death,"We decomposed trends in attributable burden into contributions from population growth, population age structure, risk exposure, and risk-deleted cause-specific DALY rates.",False,METHODS
4271,Suboptimal nutrition is a leading cause of premature death,"We characterised risk exposure in relation to a Socio-demographic Index (SDI).   
",False,METHODS
4272,Suboptimal nutrition is a leading cause of premature death,"FINDINGS Between 1990 and 2015, global exposure to unsafe sanitation, household air pollution, childhood underweight, childhood stunting, and smoking each decreased by more than 25%.",False,RESULTS
4273,Suboptimal nutrition is a leading cause of premature death,"Global exposure for several occupational risks, high body-mass index (BMI), and drug use increased by more than 25% over the same period.",False,RESULTS
4274,Suboptimal nutrition is a leading cause of premature death,All risks jointly evaluated in 2015 accounted for 57·8% (95% CI 56·6-58·8) of global deaths and 41·2% (39·8-42·8) of DALYs.,False,RESULTS
4275,Suboptimal nutrition is a leading cause of premature death,"In 2015, the ten largest contributors to global DALYs among Level 3 risks were high systolic blood pressure (211·8 million [192·7 million to 231·1 million] global DALYs), smoking (148·6 million [134·2 million to 163·1 million]), high fasting plasma glucose (143·1 million [125·1 million to 163·5 million]), high BMI (120·1 million [83·8 million to 158·4 million]), childhood undernutrition (113·3 million [103·9 million to 123·4 million]), ambient particulate matter (103·1 million [90·8 million to 115·1 million]), high total cholesterol (88·7 million [74·6 million to 105·7 million]), household air pollution (85·6 million [66·7 million to 106·1 million]), alcohol use (85·0 million [77·2 million to 93·0 million]), and diets high in sodium (83·0 million [49·3 million to 127·5 million]).",True,RESULTS
4276,Suboptimal nutrition is a leading cause of premature death,"From 1990 to 2015, attributable DALYs declined for micronutrient deficiencies, childhood undernutrition, unsafe sanitation and water, and household air pollution; reductions in risk-deleted DALY rates rather than reductions in exposure drove these declines.",False,RESULTS
4277,Suboptimal nutrition is a leading cause of premature death,"Rising exposure contributed to notable increases in attributable DALYs from high BMI, high fasting plasma glucose, occupational carcinogens, and drug use.",False,RESULTS
4278,Suboptimal nutrition is a leading cause of premature death,"Environmental risks and childhood undernutrition declined steadily with SDI; low physical activity, high BMI, and high fasting plasma glucose increased with SDI.",False,RESULTS
4279,Suboptimal nutrition is a leading cause of premature death,"In 119 countries, metabolic risks, such as high BMI and fasting plasma glucose, contributed the most attributable DALYs in 2015.",False,RESULTS
4280,Suboptimal nutrition is a leading cause of premature death,"Regionally, smoking still ranked among the leading five risk factors for attributable DALYs in 109 countries; childhood underweight and unsafe sex remained primary drivers of early death and disability in much of sub-Saharan Africa.   
",False,CONCLUSIONS
4281,Suboptimal nutrition is a leading cause of premature death,INTERPRETATION Declines in some key environmental risks have contributed to declines in critical infectious diseases.,False,CONCLUSIONS
4282,Suboptimal nutrition is a leading cause of premature death,Some risks appear to be invariant to SDI.,False,CONCLUSIONS
4283,Suboptimal nutrition is a leading cause of premature death,"Increasing risks, including high BMI, high fasting plasma glucose, drug use, and some occupational exposures, contribute to rising burden from some conditions, but also provide opportunities for intervention.",False,CONCLUSIONS
4284,Suboptimal nutrition is a leading cause of premature death,"Some highly preventable risks, such as smoking, remain major causes of attributable DALYs, even as exposure is declining.",False,CONCLUSIONS
4285,Suboptimal nutrition is a leading cause of premature death,"Public policy makers need to pay attention to the risks that are increasingly major contributors to global burden.   
",False,CONCLUSIONS
4286,Suboptimal nutrition is a leading cause of premature death,FUNDING Bill & Melinda Gates Foundation.,False,CONCLUSIONS
4287,Suboptimal nutrition is a leading cause of premature death,"IMPORTANCE Understanding the major health problems in the United States and how they are changing over time is critical for informing national health policy.   
",False,BACKGROUND
4288,Suboptimal nutrition is a leading cause of premature death,"OBJECTIVES To measure the burden of diseases, injuries, and leading risk factors in the United States from 1990 to 2010 and to compare these measurements with those of the 34 countries in the Organisation for Economic Co-operation and Development (OECD) countries.   
",False,OBJECTIVE
4289,Suboptimal nutrition is a leading cause of premature death,"DESIGN We used the systematic analysis of descriptive epidemiology of 291 diseases and injuries, 1160 sequelae of these diseases and injuries, and 67 risk factors or clusters of risk factors from 1990 to 2010 for 187 countries developed for the Global Burden of Disease 2010 Study to describe the health status of the United States and to compare US health outcomes with those of 34 OECD countries.",False,METHODS
4290,Suboptimal nutrition is a leading cause of premature death,Years of life lost due to premature mortality (YLLs) were computed by multiplying the number of deaths at each age by a reference life expectancy at that age.,False,METHODS
4291,Suboptimal nutrition is a leading cause of premature death,Years lived with disability (YLDs) were calculated by multiplying prevalence (based on systematic reviews) by the disability weight (based on population-based surveys) for each sequela; disability in this study refers to any short- or long-term loss of health.,False,METHODS
4292,Suboptimal nutrition is a leading cause of premature death,Disability-adjusted life-years (DALYs) were estimated as the sum of YLDs and YLLs.,False,METHODS
4293,Suboptimal nutrition is a leading cause of premature death,Deaths and DALYs related to risk factors were based on systematic reviews and meta-analyses of exposure data and relative risks for risk-outcome pairs.,False,METHODS
4294,Suboptimal nutrition is a leading cause of premature death,"Healthy life expectancy (HALE) was used to summarize overall population health, accounting for both length of life and levels of ill health experienced at different ages.   
",False,METHODS
4295,Suboptimal nutrition is a leading cause of premature death,"RESULTS US life expectancy for both sexes combined increased from 75.2 years in 1990 to 78.2 years in 2010; during the same period, HALE increased from 65.8 years to 68.1 years.",False,RESULTS
4296,Suboptimal nutrition is a leading cause of premature death,"The diseases and injuries with the largest number of YLLs in 2010 were ischemic heart disease, lung cancer, stroke, chronic obstructive pulmonary disease, and road injury.",False,RESULTS
4297,Suboptimal nutrition is a leading cause of premature death,"Age-standardized YLL rates increased for Alzheimer disease, drug use disorders, chronic kidney disease, kidney cancer, and falls.",False,RESULTS
4298,Suboptimal nutrition is a leading cause of premature death,"The diseases with the largest number of YLDs in 2010 were low back pain, major depressive disorder, other musculoskeletal disorders, neck pain, and anxiety disorders.",False,RESULTS
4299,Suboptimal nutrition is a leading cause of premature death,"As the US population has aged, YLDs have comprised a larger share of DALYs than have YLLs.",False,RESULTS
4300,Suboptimal nutrition is a leading cause of premature death,"The leading risk factors related to DALYs were dietary risks, tobacco smoking, high body mass index, high blood pressure, high fasting plasma glucose, physical inactivity, and alcohol use.",True,RESULTS
4301,Suboptimal nutrition is a leading cause of premature death,"Among 34 OECD countries between 1990 and 2010, the US rank for the age-standardized death rate changed from 18th to 27th, for the age-standardized YLL rate from 23rd to 28th, for the age-standardized YLD rate from 5th to 6th, for life expectancy at birth from 20th to 27th, and for HALE from 14th to 26th.   
",False,RESULTS
4302,Suboptimal nutrition is a leading cause of premature death,"CONCLUSIONS AND RELEVANCE From 1990 to 2010, the United States made substantial progress in improving health.",False,CONCLUSIONS
4303,Suboptimal nutrition is a leading cause of premature death,"Life expectancy at birth and HALE increased, all-cause death rates at all ages decreased, and age-specific rates of years lived with disability remained stable.",False,CONCLUSIONS
4304,Suboptimal nutrition is a leading cause of premature death,"However, morbidity and chronic disability now account for nearly half of the US health burden, and improvements in population health in the United States have not kept pace with advances in population health in other wealthy nations.",False,CONCLUSIONS
4305,"Surfactin producing cells and exopolymer producing cells cooperate to generate ""Van Gogh"" bundles that have sliding abilities on specialized media.","The organization of cells, emerging from cell-cell interactions, can give rise to collective properties.",False,BACKGROUND
4306,"Surfactin producing cells and exopolymer producing cells cooperate to generate ""Van Gogh"" bundles that have sliding abilities on specialized media.",These properties are adaptive when together cells can face environmental challenges that they separately cannot.,False,BACKGROUND
4307,"Surfactin producing cells and exopolymer producing cells cooperate to generate ""Van Gogh"" bundles that have sliding abilities on specialized media.",One particular challenge that is important for microorganisms is migration.,False,BACKGROUND
4308,"Surfactin producing cells and exopolymer producing cells cooperate to generate ""Van Gogh"" bundles that have sliding abilities on specialized media.","In this study, we show how flagellum-independent migration is driven by the division of labor of two cell types that appear during Bacillus subtilis sliding motility.",False,BACKGROUND
4309,"Surfactin producing cells and exopolymer producing cells cooperate to generate ""Van Gogh"" bundles that have sliding abilities on specialized media.","Cell collectives organize themselves into bundles (called ""van Gogh bundles"") of tightly aligned cell chains that form filamentous loops at the colony edge.",False,METHODS
4310,"Surfactin producing cells and exopolymer producing cells cooperate to generate ""Van Gogh"" bundles that have sliding abilities on specialized media.","We show, by time-course microscopy, that these loops migrate by pushing themselves away from the colony.",False,METHODS
4311,"Surfactin producing cells and exopolymer producing cells cooperate to generate ""Van Gogh"" bundles that have sliding abilities on specialized media.",The formation of van Gogh bundles depends critically on the synergistic interaction of surfactin-producing and matrix-producing cells.,True,RESULTS
4312,"Surfactin producing cells and exopolymer producing cells cooperate to generate ""Van Gogh"" bundles that have sliding abilities on specialized media.","We propose that surfactin-producing cells reduce the friction between cells and their substrate, thereby facilitating matrix-producing cells to form bundles.",True,RESULTS
4313,"Surfactin producing cells and exopolymer producing cells cooperate to generate ""Van Gogh"" bundles that have sliding abilities on specialized media.",The folding properties of these bundles determine the rate of colony expansion.,False,RESULTS
4314,"Surfactin producing cells and exopolymer producing cells cooperate to generate ""Van Gogh"" bundles that have sliding abilities on specialized media.",Our study illustrates how the simple organization of cells within a community can yield a strong ecological advantage.,False,CONCLUSIONS
4315,"Surfactin producing cells and exopolymer producing cells cooperate to generate ""Van Gogh"" bundles that have sliding abilities on specialized media.",This is a key factor underlying the diverse origins of multicellularity.,False,CONCLUSIONS
4316,Surgical treatment is not superior to non-surgical in treating adults with displaced fractures of the proximal humerus.,"IMPORTANCE The need for surgery for the majority of patients with displaced proximal humeral fractures is unclear, but its use is increasing.   
",False,OBJECTIVE
4317,Surgical treatment is not superior to non-surgical in treating adults with displaced fractures of the proximal humerus.,"OBJECTIVE To evaluate the clinical effectiveness of surgical vs nonsurgical treatment for adults with displaced fractures of the proximal humerus involving the surgical neck.   
",False,OBJECTIVE
4318,Surgical treatment is not superior to non-surgical in treating adults with displaced fractures of the proximal humerus.,"DESIGN, SETTING, AND PARTICIPANTS A pragmatic, multicenter, parallel-group, randomized clinical trial, the Proximal Fracture of the Humerus Evaluation by Randomization (PROFHER) trial, recruited 250 patients aged 16 years or older (mean age, 66 years [range, 24-92 years]; 192 [77%] were female; and 249 [99.6%] were white) who presented at the orthopedic departments of 32 acute UK National Health Service hospitals between September 2008 and April 2011 within 3 weeks after sustaining a displaced fracture of the proximal humerus involving the surgical neck.",False,METHODS
4319,Surgical treatment is not superior to non-surgical in treating adults with displaced fractures of the proximal humerus.,Patients were followed up for 2 years (up to April 2013) and 215 had complete follow-up data.,False,METHODS
4320,Surgical treatment is not superior to non-surgical in treating adults with displaced fractures of the proximal humerus.,"The data for 231 patients (114 in surgical group and 117 in nonsurgical group) were included in the primary analysis.   
",False,METHODS
4321,Surgical treatment is not superior to non-surgical in treating adults with displaced fractures of the proximal humerus.,INTERVENTIONS Fracture fixation or humeral head replacement were performed by surgeons experienced in these techniques.,False,METHODS
4322,Surgical treatment is not superior to non-surgical in treating adults with displaced fractures of the proximal humerus.,Nonsurgical treatment was sling immobilization.,False,METHODS
4323,Surgical treatment is not superior to non-surgical in treating adults with displaced fractures of the proximal humerus.,"Standardized outpatient and community-based rehabilitation was provided to both groups.   
",False,METHODS
4324,Surgical treatment is not superior to non-surgical in treating adults with displaced fractures of the proximal humerus.,"MAIN OUTCOMES AND MEASURES Primary outcome was the Oxford Shoulder Score (range, 0-48; higher scores indicate better outcomes) assessed during a 2-year period, with assessment and data collection at 6, 12, and 24 months.",False,METHODS
4325,Surgical treatment is not superior to non-surgical in treating adults with displaced fractures of the proximal humerus.,Sample size was based on a minimal clinically important difference of 5 points for the Oxford Shoulder Score.,False,METHODS
4326,Surgical treatment is not superior to non-surgical in treating adults with displaced fractures of the proximal humerus.,"Secondary outcomes were the Short-Form 12 (SF-12), complications, subsequent therapy, and mortality.   
",False,METHODS
4327,Surgical treatment is not superior to non-surgical in treating adults with displaced fractures of the proximal humerus.,"RESULTS There was no significant mean treatment group difference in the Oxford Shoulder Score averaged over 2 years (39.07 points for the surgical group vs 38.32 points for the nonsurgical group; difference of 0.75 points [95% CI, -1.33 to 2.84 points]; P = .48) or at individual time points.",True,RESULTS
4328,Surgical treatment is not superior to non-surgical in treating adults with displaced fractures of the proximal humerus.,"There were also no significant between-group differences over 2 years in the mean SF-12 physical component score (surgical group: 1.77 points higher [95% CI, -0.84 to 4.39 points];",True,RESULTS
4329,Surgical treatment is not superior to non-surgical in treating adults with displaced fractures of the proximal humerus.,"P = .18); the mean SF-12 mental component score (surgical group: 1.28 points lower [95% CI, -3.80 to 1.23 points]; P = .32); complications related to surgery or shoulder fracture (30 patients in surgical group vs 23 patients in nonsurgical group; P = .28), requiring secondary surgery to the shoulder (11 patients in both groups), and increased or new shoulder-related therapy (7 patients vs 4 patients, respectively; P = .58); and mortality (9 patients vs 5 patients; P = .27).",True,RESULTS
4330,Surgical treatment is not superior to non-surgical in treating adults with displaced fractures of the proximal humerus.,"Ten medical complications (2 cardiovascular events, 2 respiratory events, 2 gastrointestinal events, and 4 others) occurred in the surgical group during the postoperative hospital stay.   
",False,RESULTS
4331,Surgical treatment is not superior to non-surgical in treating adults with displaced fractures of the proximal humerus.,"CONCLUSIONS AND RELEVANCE Among patients with displaced proximal humeral fractures involving the surgical neck, there was no significant difference between surgical treatment compared with nonsurgical treatment in patient-reported clinical outcomes over 2 years following fracture occurrence.",True,CONCLUSIONS
4332,Surgical treatment is not superior to non-surgical in treating adults with displaced fractures of the proximal humerus.,"These results do not support the trend of increased surgery for patients with displaced fractures of the proximal humerus.   
",False,CONCLUSIONS
4333,Surgical treatment is not superior to non-surgical in treating adults with displaced fractures of the proximal humerus.,TRIAL REGISTRATION isrctn.com Identifier: ISRCTN50850043.,False,CONCLUSIONS
4334,Sympathetic nerve activity is elevated throughout normal pregnancy.,BACKGROUND Direct recordings from peripheral sympathetic nerves have shown an increased sympathetic drive in pregnancy-induced hypertension (PIH) and preeclampsia (PE).,False,OBJECTIVE
4335,Sympathetic nerve activity is elevated throughout normal pregnancy.,"It is unknown whether sympathetic drive is altered in normal pregnancy, when arterial blood pressure can be normal or relatively low.",False,OBJECTIVE
4336,Sympathetic nerve activity is elevated throughout normal pregnancy.,"The aim of this study was to measure and compare peripheral sympathetic discharge, its vasoconstrictor effect and its baroreceptor control, during pregnancy and postpartum in women with normal pregnancy (NP) and PIH and in normotensive nonpregnant (NN) women.   
",False,OBJECTIVE
4337,Sympathetic nerve activity is elevated throughout normal pregnancy.,"METHODS AND RESULTS Twenty-one women with NP, 18 women with PIH, and 21 NN women had muscle sympathetic nerve activity assessed from multiunit discharges (MSNA) and from single units with defined vasoconstrictor properties (s-MSNA).",False,METHODS
4338,Sympathetic nerve activity is elevated throughout normal pregnancy.,The s-MSNA in NP (38+/-6.6 impulses/100 beats) was greater (P<0.05) than in NN women (19+/-1.8 impulses/100 beats) despite similar age and body weight but less than in PIH women (P<0.001) (146+/-23.5 impulses/100 beats).,True,RESULTS
4339,Sympathetic nerve activity is elevated throughout normal pregnancy.,MSNA followed a similar trend.,False,RESULTS
4340,Sympathetic nerve activity is elevated throughout normal pregnancy.,Cardiac baroreceptor reflex sensitivity (BRS) was impaired in NP and PIH women relative to NN.,False,RESULTS
4341,Sympathetic nerve activity is elevated throughout normal pregnancy.,"After delivery, sympathetic activity decreased to values similar to those obtained in NN, and there was an increase in BRS.",False,RESULTS
4342,Sympathetic nerve activity is elevated throughout normal pregnancy.,"In women with NP, the decrease in sympathetic output occurred despite an insignificant change in blood pressure.   
",False,CONCLUSIONS
4343,Sympathetic nerve activity is elevated throughout normal pregnancy.,CONCLUSIONS Central sympathetic output was increased in women with normal pregnancy and was even greater in the hypertensive pregnant group.,False,CONCLUSIONS
4344,Sympathetic nerve activity is elevated throughout normal pregnancy.,"The findings suggest that the moderate sympathetic hyperactivity during the latter months of normal pregnancy may help to return the arterial pressure to nonpregnant levels, although when the increase in activity is excessive, hypertension may ensue.",True,CONCLUSIONS
4345,Sympathetic nerve activity is elevated throughout normal pregnancy.,"Muscle sympathetic nerve activity is increased during normotensive pregnancy while mean arterial pressure is maintained or reduced, suggesting baroreflex resetting.",True,BACKGROUND
4346,Sympathetic nerve activity is elevated throughout normal pregnancy.,We hypothesized spontaneous sympathetic baroreflex gain would be reduced in normotensive pregnant women relative to nonpregnant matched controls.,False,BACKGROUND
4347,Sympathetic nerve activity is elevated throughout normal pregnancy.,"Integrated muscle sympathetic burst incidence and total sympathetic activity (microneurography), blood pressure (Finometer), and R-R interval (ECG) were assessed at rest in 11 pregnant women (33 ± 1 wk gestation, 31 ± 1 yr, prepregnancy BMI: 23.5 ± 0.9 kg/m(2)) and 11 nonpregnant controls (29 ± 1 yr; BMI: 25.2 ± 1.7 kg/m(2)).",False,METHODS
4348,Sympathetic nerve activity is elevated throughout normal pregnancy.,"Pregnant women had elevated baseline sympathetic burst incidence (43 ± 2 vs. 33 ± 2 bursts/100 heart beats, P = 0.01) and total sympathetic activity (1,811 ± 148 vs. 1,140 ± 55 au, P < 0.01) relative to controls.",True,RESULTS
4349,Sympathetic nerve activity is elevated throughout normal pregnancy.,"Both mean (88 ± 3 vs. 91 ± 2 mmHg, P = 0.4) and diastolic (DBP) (72 ± 3 vs. 73 ± 2 mmHg, P = 0.7) pressures were similar between pregnant and nonpregnant women, respectively, indicating an upward resetting of the baroreflex set point with pregnancy.",False,RESULTS
4350,Sympathetic nerve activity is elevated throughout normal pregnancy.,"Baroreflex gain, calculated as the linear relationship between sympathetic burst incidence and DBP, was reduced in pregnant women relative to controls (-3.7 ± 0.5 vs. -5.4 ± 0.5 bursts·100 heart beats(-1)·mmHg(-1), P = 0.03), as was baroreflex gain calculated with total sympathetic activity (-294 ± 24 vs. -210 ± 24 au·100 heart beats(-1)·mmHg(-1); P = 0.03).",False,RESULTS
4351,Sympathetic nerve activity is elevated throughout normal pregnancy.,Cardiovagal baroreflex gain (sequence method) was not different between nonpregnant controls and pregnant women (49 ± 8 vs. 36 ± 8 ms/mmHg; P = 0.2).,False,RESULTS
4352,Sympathetic nerve activity is elevated throughout normal pregnancy.,"However, sympathetic (burst incidence) and cardiovagal gains were negatively correlated in pregnant women (R = -0.7; P = 0.02).",False,RESULTS
4353,Sympathetic nerve activity is elevated throughout normal pregnancy.,"Together, these data indicate that the influence of the sympathetic nervous system over arterial blood pressure is reduced in normotensive pregnancy, in terms of both long-term and beat-to-beat regulation of arterial pressure, likely through a baroreceptor-dependent mechanism.",False,CONCLUSIONS
4354,Sympathetic nerve activity is elevated throughout normal pregnancy.,"Baseline neurovascular transduction is reduced in normotensive pregnancy; however, little is known about changes to neurovascular transduction during periods of heightened sympathetic activation.",False,BACKGROUND
4355,Sympathetic nerve activity is elevated throughout normal pregnancy.,"We tested the hypothesis that, despite an exacerbated muscle sympathetic nerve activity (microneurography) response to cold pressor stimulation, the blunting of neurovascular transduction in normotensive pregnant women would result in similar changes in vascular resistance and mean arterial pressure (Finometer) relative to nonpregnant controls.",False,BACKGROUND
4356,Sympathetic nerve activity is elevated throughout normal pregnancy.,"Baseline neurovascular transduction was reduced in pregnant women relative to controls when expressed as the quotient of both total resistance and mean arterial pressure and sympathetic burst frequency (0.32±0.07 versus 0.58±0.16 mm Hg/L/min/bursts/min, P<0.001 and 2.4±0.7 versus 3.6±0.8 mm Hg/bursts/min, P=0.001).",False,RESULTS
4357,Sympathetic nerve activity is elevated throughout normal pregnancy.,Sympathetic activation was greater across all 3 minutes of cold pressor stimulation in the pregnant women relative to the nonpregnant controls.,True,RESULTS
4358,Sympathetic nerve activity is elevated throughout normal pregnancy.,"Peak sympathoexcitation was also greater in pregnant than in nonpregnant women, whether expressed as sympathetic burst frequency (+17±13 versus +7±8 bursts/min, P=0.049), burst incidence (+17±9 versus +6±11 bursts/100 hb, P=0.03), or total activity (+950±660 versus +363±414 arbitrary units, P=0.04).",True,RESULTS
4359,Sympathetic nerve activity is elevated throughout normal pregnancy.,"However, neurovascular transduction during peak cold pressor-induced sympathoexcitation remained blunted in pregnant women (0.25±0.11 versus 0.45±0.08 mm Hg/L/min/bursts/min, P<0.001 and 1.9±1.0 versus 3.2±0.9 mm Hg/bursts/min, P=0.006).",False,RESULTS
4360,Sympathetic nerve activity is elevated throughout normal pregnancy.,"Therefore, mean arterial pressure (93±21 versus 99±6 mm Hg, P=0.4) and total peripheral resistance (12±3 versus 14±3 mm Hg/L/min) were not different between pregnant and nonpregnant women during peak sympathoexcitation.",False,RESULTS
4361,Sympathetic nerve activity is elevated throughout normal pregnancy.,"These data indicate that the third trimester of normotensive pregnancy is associated with reductions in neurovascular transduction, which result in the dissociation of sympathetic outflow from hemodynamic outcomes, even during cold pressor-induced sympathoexcitation.",False,CONCLUSIONS
4362,Sympathetic nerve activity is reduced throughout normal pregnancy.,BACKGROUND Direct recordings from peripheral sympathetic nerves have shown an increased sympathetic drive in pregnancy-induced hypertension (PIH) and preeclampsia (PE).,False,OBJECTIVE
4363,Sympathetic nerve activity is reduced throughout normal pregnancy.,"It is unknown whether sympathetic drive is altered in normal pregnancy, when arterial blood pressure can be normal or relatively low.",False,OBJECTIVE
4364,Sympathetic nerve activity is reduced throughout normal pregnancy.,"The aim of this study was to measure and compare peripheral sympathetic discharge, its vasoconstrictor effect and its baroreceptor control, during pregnancy and postpartum in women with normal pregnancy (NP) and PIH and in normotensive nonpregnant (NN) women.   
",False,OBJECTIVE
4365,Sympathetic nerve activity is reduced throughout normal pregnancy.,"METHODS AND RESULTS Twenty-one women with NP, 18 women with PIH, and 21 NN women had muscle sympathetic nerve activity assessed from multiunit discharges (MSNA) and from single units with defined vasoconstrictor properties (s-MSNA).",False,METHODS
4366,Sympathetic nerve activity is reduced throughout normal pregnancy.,The s-MSNA in NP (38+/-6.6 impulses/100 beats) was greater (P<0.05) than in NN women (19+/-1.8 impulses/100 beats) despite similar age and body weight but less than in PIH women (P<0.001) (146+/-23.5 impulses/100 beats).,True,RESULTS
4367,Sympathetic nerve activity is reduced throughout normal pregnancy.,MSNA followed a similar trend.,False,RESULTS
4368,Sympathetic nerve activity is reduced throughout normal pregnancy.,Cardiac baroreceptor reflex sensitivity (BRS) was impaired in NP and PIH women relative to NN.,False,RESULTS
4369,Sympathetic nerve activity is reduced throughout normal pregnancy.,"After delivery, sympathetic activity decreased to values similar to those obtained in NN, and there was an increase in BRS.",False,RESULTS
4370,Sympathetic nerve activity is reduced throughout normal pregnancy.,"In women with NP, the decrease in sympathetic output occurred despite an insignificant change in blood pressure.   
",False,CONCLUSIONS
4371,Sympathetic nerve activity is reduced throughout normal pregnancy.,CONCLUSIONS Central sympathetic output was increased in women with normal pregnancy and was even greater in the hypertensive pregnant group.,False,CONCLUSIONS
4372,Sympathetic nerve activity is reduced throughout normal pregnancy.,"The findings suggest that the moderate sympathetic hyperactivity during the latter months of normal pregnancy may help to return the arterial pressure to nonpregnant levels, although when the increase in activity is excessive, hypertension may ensue.",True,CONCLUSIONS
4373,Sympathetic nerve activity is reduced throughout normal pregnancy.,"Muscle sympathetic nerve activity is increased during normotensive pregnancy while mean arterial pressure is maintained or reduced, suggesting baroreflex resetting.",True,BACKGROUND
4374,Sympathetic nerve activity is reduced throughout normal pregnancy.,We hypothesized spontaneous sympathetic baroreflex gain would be reduced in normotensive pregnant women relative to nonpregnant matched controls.,False,BACKGROUND
4375,Sympathetic nerve activity is reduced throughout normal pregnancy.,"Integrated muscle sympathetic burst incidence and total sympathetic activity (microneurography), blood pressure (Finometer), and R-R interval (ECG) were assessed at rest in 11 pregnant women (33 ± 1 wk gestation, 31 ± 1 yr, prepregnancy BMI: 23.5 ± 0.9 kg/m(2)) and 11 nonpregnant controls (29 ± 1 yr; BMI: 25.2 ± 1.7 kg/m(2)).",False,METHODS
4376,Sympathetic nerve activity is reduced throughout normal pregnancy.,"Pregnant women had elevated baseline sympathetic burst incidence (43 ± 2 vs. 33 ± 2 bursts/100 heart beats, P = 0.01) and total sympathetic activity (1,811 ± 148 vs. 1,140 ± 55 au, P < 0.01) relative to controls.",True,RESULTS
4377,Sympathetic nerve activity is reduced throughout normal pregnancy.,"Both mean (88 ± 3 vs. 91 ± 2 mmHg, P = 0.4) and diastolic (DBP) (72 ± 3 vs. 73 ± 2 mmHg, P = 0.7) pressures were similar between pregnant and nonpregnant women, respectively, indicating an upward resetting of the baroreflex set point with pregnancy.",False,RESULTS
4378,Sympathetic nerve activity is reduced throughout normal pregnancy.,"Baroreflex gain, calculated as the linear relationship between sympathetic burst incidence and DBP, was reduced in pregnant women relative to controls (-3.7 ± 0.5 vs. -5.4 ± 0.5 bursts·100 heart beats(-1)·mmHg(-1), P = 0.03), as was baroreflex gain calculated with total sympathetic activity (-294 ± 24 vs. -210 ± 24 au·100 heart beats(-1)·mmHg(-1); P = 0.03).",False,RESULTS
4379,Sympathetic nerve activity is reduced throughout normal pregnancy.,Cardiovagal baroreflex gain (sequence method) was not different between nonpregnant controls and pregnant women (49 ± 8 vs. 36 ± 8 ms/mmHg; P = 0.2).,False,RESULTS
4380,Sympathetic nerve activity is reduced throughout normal pregnancy.,"However, sympathetic (burst incidence) and cardiovagal gains were negatively correlated in pregnant women (R = -0.7; P = 0.02).",False,RESULTS
4381,Sympathetic nerve activity is reduced throughout normal pregnancy.,"Together, these data indicate that the influence of the sympathetic nervous system over arterial blood pressure is reduced in normotensive pregnancy, in terms of both long-term and beat-to-beat regulation of arterial pressure, likely through a baroreceptor-dependent mechanism.",False,CONCLUSIONS
4382,Sympathetic nerve activity is reduced throughout normal pregnancy.,"Baseline neurovascular transduction is reduced in normotensive pregnancy; however, little is known about changes to neurovascular transduction during periods of heightened sympathetic activation.",False,BACKGROUND
4383,Sympathetic nerve activity is reduced throughout normal pregnancy.,"We tested the hypothesis that, despite an exacerbated muscle sympathetic nerve activity (microneurography) response to cold pressor stimulation, the blunting of neurovascular transduction in normotensive pregnant women would result in similar changes in vascular resistance and mean arterial pressure (Finometer) relative to nonpregnant controls.",False,BACKGROUND
4384,Sympathetic nerve activity is reduced throughout normal pregnancy.,"Baseline neurovascular transduction was reduced in pregnant women relative to controls when expressed as the quotient of both total resistance and mean arterial pressure and sympathetic burst frequency (0.32±0.07 versus 0.58±0.16 mm Hg/L/min/bursts/min, P<0.001 and 2.4±0.7 versus 3.6±0.8 mm Hg/bursts/min, P=0.001).",False,RESULTS
4385,Sympathetic nerve activity is reduced throughout normal pregnancy.,Sympathetic activation was greater across all 3 minutes of cold pressor stimulation in the pregnant women relative to the nonpregnant controls.,True,RESULTS
4386,Sympathetic nerve activity is reduced throughout normal pregnancy.,"Peak sympathoexcitation was also greater in pregnant than in nonpregnant women, whether expressed as sympathetic burst frequency (+17±13 versus +7±8 bursts/min, P=0.049), burst incidence (+17±9 versus +6±11 bursts/100 hb, P=0.03), or total activity (+950±660 versus +363±414 arbitrary units, P=0.04).",True,RESULTS
4387,Sympathetic nerve activity is reduced throughout normal pregnancy.,"However, neurovascular transduction during peak cold pressor-induced sympathoexcitation remained blunted in pregnant women (0.25±0.11 versus 0.45±0.08 mm Hg/L/min/bursts/min, P<0.001 and 1.9±1.0 versus 3.2±0.9 mm Hg/bursts/min, P=0.006).",False,RESULTS
4388,Sympathetic nerve activity is reduced throughout normal pregnancy.,"Therefore, mean arterial pressure (93±21 versus 99±6 mm Hg, P=0.4) and total peripheral resistance (12±3 versus 14±3 mm Hg/L/min) were not different between pregnant and nonpregnant women during peak sympathoexcitation.",False,RESULTS
4389,Sympathetic nerve activity is reduced throughout normal pregnancy.,"These data indicate that the third trimester of normotensive pregnancy is associated with reductions in neurovascular transduction, which result in the dissociation of sympathetic outflow from hemodynamic outcomes, even during cold pressor-induced sympathoexcitation.",False,CONCLUSIONS
4390,Systemic immunosuppressive (IS) therapy does not enhance the chance of cancer mortality in patients with inflammatory eye disease (IED),"CONTEXT Whether immunosuppressive treatment adversely affects survival is unclear.   
",False,BACKGROUND
4391,Systemic immunosuppressive (IS) therapy does not enhance the chance of cancer mortality in patients with inflammatory eye disease (IED),"OBJECTIVE To assess whether immunosuppressive drugs increase mortality.   
",False,OBJECTIVE
4392,Systemic immunosuppressive (IS) therapy does not enhance the chance of cancer mortality in patients with inflammatory eye disease (IED),DESIGN Retrospective cohort study evaluating overall and cancer mortality in relation to immunosuppressive drug exposure among patients with ocular inflammatory diseases.,False,OBJECTIVE
4393,Systemic immunosuppressive (IS) therapy does not enhance the chance of cancer mortality in patients with inflammatory eye disease (IED),"Demographic, clinical, and treatment data derived from medical records, and mortality results from United States National Death Index linkage.",False,METHODS
4394,Systemic immunosuppressive (IS) therapy does not enhance the chance of cancer mortality in patients with inflammatory eye disease (IED),The cohort's mortality risk was compared with US vital statistics using standardised mortality ratios.,False,METHODS
4395,Systemic immunosuppressive (IS) therapy does not enhance the chance of cancer mortality in patients with inflammatory eye disease (IED),"Overall and cancer mortality in relation to use or non-use of immunosuppressive drugs within the cohort was studied with survival analysis.   
",False,METHODS
4396,Systemic immunosuppressive (IS) therapy does not enhance the chance of cancer mortality in patients with inflammatory eye disease (IED),SETTING Five tertiary ocular inflammation clinics.,False,METHODS
4397,Systemic immunosuppressive (IS) therapy does not enhance the chance of cancer mortality in patients with inflammatory eye disease (IED),"Patients 7957 US residents with non-infectious ocular inflammation, 2340 of whom received immunosuppressive drugs during follow up.",False,METHODS
4398,Systemic immunosuppressive (IS) therapy does not enhance the chance of cancer mortality in patients with inflammatory eye disease (IED),"Exposures Use of antimetabolites, T cell inhibitors, alkylating agents, and tumour necrosis factor inhibitors.   
",False,METHODS
4399,Systemic immunosuppressive (IS) therapy does not enhance the chance of cancer mortality in patients with inflammatory eye disease (IED),"MAIN OUTCOME MEASURES Overall mortality, cancer mortality.   
",False,METHODS
4400,Systemic immunosuppressive (IS) therapy does not enhance the chance of cancer mortality in patients with inflammatory eye disease (IED),"RESULTS Over 66 802 person years (17 316 after exposure to immunosuppressive drugs), 936 patients died (1.4/100 person years), 230 (24.6%) from cancer.",False,RESULTS
4401,Systemic immunosuppressive (IS) therapy does not enhance the chance of cancer mortality in patients with inflammatory eye disease (IED),"For patients unexposed to immunosuppressive treatment, risks of death overall (standardised mortality ratio 1.02, 95% confidence interval [CI] 0.94 to 1.11) and from cancer (1.10, 0.93 to 1.29) were similar to those of the US population.",False,RESULTS
4402,Systemic immunosuppressive (IS) therapy does not enhance the chance of cancer mortality in patients with inflammatory eye disease (IED),"Patients who used azathioprine, methotrexate, mycophenolate mofetil, ciclosporin, systemic corticosteroids, or dapsone had overall and cancer mortality similar to that of patients who never took immunosuppressive drugs.",True,RESULTS
4403,Systemic immunosuppressive (IS) therapy does not enhance the chance of cancer mortality in patients with inflammatory eye disease (IED),"In patients who used cyclophosphamide, overall mortality was not increased and cancer mortality was non-significantly increased.",False,RESULTS
4404,Systemic immunosuppressive (IS) therapy does not enhance the chance of cancer mortality in patients with inflammatory eye disease (IED),"Tumour necrosis factor inhibitors were associated with increased overall (adjusted hazard ratio [HR] 1.99, 95% CI 1.00 to 3.98) and cancer mortality (adjusted HR 3.83, 1.13 to 13.01).   
",False,RESULTS
4405,Systemic immunosuppressive (IS) therapy does not enhance the chance of cancer mortality in patients with inflammatory eye disease (IED),CONCLUSIONS Most commonly used immunosuppressive drugs do not seem to increase overall or cancer mortality.,True,CONCLUSIONS
4406,Systemic immunosuppressive (IS) therapy does not enhance the chance of cancer mortality in patients with inflammatory eye disease (IED),Our results suggesting that tumour necrosis factor inhibitors might increase mortality are less robust than the other findings; additional evidence is needed.,False,CONCLUSIONS
4407,Systemic immunosuppressive (IS) therapy increases the chance of cancer mortality in patients with inflammatory eye disease (IED),"CONTEXT Whether immunosuppressive treatment adversely affects survival is unclear.   
",False,BACKGROUND
4408,Systemic immunosuppressive (IS) therapy increases the chance of cancer mortality in patients with inflammatory eye disease (IED),"OBJECTIVE To assess whether immunosuppressive drugs increase mortality.   
",False,OBJECTIVE
4409,Systemic immunosuppressive (IS) therapy increases the chance of cancer mortality in patients with inflammatory eye disease (IED),DESIGN Retrospective cohort study evaluating overall and cancer mortality in relation to immunosuppressive drug exposure among patients with ocular inflammatory diseases.,False,OBJECTIVE
4410,Systemic immunosuppressive (IS) therapy increases the chance of cancer mortality in patients with inflammatory eye disease (IED),"Demographic, clinical, and treatment data derived from medical records, and mortality results from United States National Death Index linkage.",False,METHODS
4411,Systemic immunosuppressive (IS) therapy increases the chance of cancer mortality in patients with inflammatory eye disease (IED),The cohort's mortality risk was compared with US vital statistics using standardised mortality ratios.,False,METHODS
4412,Systemic immunosuppressive (IS) therapy increases the chance of cancer mortality in patients with inflammatory eye disease (IED),"Overall and cancer mortality in relation to use or non-use of immunosuppressive drugs within the cohort was studied with survival analysis.   
",False,METHODS
4413,Systemic immunosuppressive (IS) therapy increases the chance of cancer mortality in patients with inflammatory eye disease (IED),SETTING Five tertiary ocular inflammation clinics.,False,METHODS
4414,Systemic immunosuppressive (IS) therapy increases the chance of cancer mortality in patients with inflammatory eye disease (IED),"Patients 7957 US residents with non-infectious ocular inflammation, 2340 of whom received immunosuppressive drugs during follow up.",False,METHODS
4415,Systemic immunosuppressive (IS) therapy increases the chance of cancer mortality in patients with inflammatory eye disease (IED),"Exposures Use of antimetabolites, T cell inhibitors, alkylating agents, and tumour necrosis factor inhibitors.   
",False,METHODS
4416,Systemic immunosuppressive (IS) therapy increases the chance of cancer mortality in patients with inflammatory eye disease (IED),"MAIN OUTCOME MEASURES Overall mortality, cancer mortality.   
",False,METHODS
4417,Systemic immunosuppressive (IS) therapy increases the chance of cancer mortality in patients with inflammatory eye disease (IED),"RESULTS Over 66 802 person years (17 316 after exposure to immunosuppressive drugs), 936 patients died (1.4/100 person years), 230 (24.6%) from cancer.",False,RESULTS
4418,Systemic immunosuppressive (IS) therapy increases the chance of cancer mortality in patients with inflammatory eye disease (IED),"For patients unexposed to immunosuppressive treatment, risks of death overall (standardised mortality ratio 1.02, 95% confidence interval [CI] 0.94 to 1.11) and from cancer (1.10, 0.93 to 1.29) were similar to those of the US population.",False,RESULTS
4419,Systemic immunosuppressive (IS) therapy increases the chance of cancer mortality in patients with inflammatory eye disease (IED),"Patients who used azathioprine, methotrexate, mycophenolate mofetil, ciclosporin, systemic corticosteroids, or dapsone had overall and cancer mortality similar to that of patients who never took immunosuppressive drugs.",True,RESULTS
4420,Systemic immunosuppressive (IS) therapy increases the chance of cancer mortality in patients with inflammatory eye disease (IED),"In patients who used cyclophosphamide, overall mortality was not increased and cancer mortality was non-significantly increased.",False,RESULTS
4421,Systemic immunosuppressive (IS) therapy increases the chance of cancer mortality in patients with inflammatory eye disease (IED),"Tumour necrosis factor inhibitors were associated with increased overall (adjusted hazard ratio [HR] 1.99, 95% CI 1.00 to 3.98) and cancer mortality (adjusted HR 3.83, 1.13 to 13.01).   
",False,RESULTS
4422,Systemic immunosuppressive (IS) therapy increases the chance of cancer mortality in patients with inflammatory eye disease (IED),CONCLUSIONS Most commonly used immunosuppressive drugs do not seem to increase overall or cancer mortality.,True,CONCLUSIONS
4423,Systemic immunosuppressive (IS) therapy increases the chance of cancer mortality in patients with inflammatory eye disease (IED),Our results suggesting that tumour necrosis factor inhibitors might increase mortality are less robust than the other findings; additional evidence is needed.,False,CONCLUSIONS
4424,Systemic lupus erythematosus is a risk factor for cardiovascular disease.,Objectives To develop and validate updated QRISK3 prediction algorithms to estimate the 10 year risk of cardiovascular disease in women and men accounting for potential new risk factors.,False,OBJECTIVE
4425,Systemic lupus erythematosus is a risk factor for cardiovascular disease.,Design Prospective open cohort study.,False,METHODS
4426,Systemic lupus erythematosus is a risk factor for cardiovascular disease.,Setting General practices in England providing data for the QResearch database.,False,METHODS
4427,Systemic lupus erythematosus is a risk factor for cardiovascular disease.,Participants 1309 QResearch general practices in England: 981 practices were used to develop the scores and a separate set of 328 practices were used to validate the scores.,False,METHODS
4428,Systemic lupus erythematosus is a risk factor for cardiovascular disease.,7.89 million patients aged 25-84 years were in the derivation cohort and 2.67 million patients in the validation cohort.,False,METHODS
4429,Systemic lupus erythematosus is a risk factor for cardiovascular disease.,Patients were free of cardiovascular disease and not prescribed statins at baseline.,False,METHODS
4430,Systemic lupus erythematosus is a risk factor for cardiovascular disease.,Methods Cox proportional hazards models in the derivation cohort to derive separate risk equations in men and women for evaluation at 10 years.,False,METHODS
4431,Systemic lupus erythematosus is a risk factor for cardiovascular disease.,"Risk factors considered included those already in QRISK2 (age, ethnicity, deprivation, systolic blood pressure, body mass index, total cholesterol: high density lipoprotein cholesterol ratio, smoking, family history of coronary heart disease in a first degree relative aged less than 60 years, type 1 diabetes, type 2 diabetes, treated hypertension, rheumatoid arthritis, atrial fibrillation, chronic kidney disease (stage 4 or 5)) and new risk factors (chronic kidney disease (stage 3, 4, or 5), a measure of systolic blood pressure variability (standard deviation of repeated measures), migraine, corticosteroids, systemic lupus erythematosus (SLE), atypical antipsychotics, severe mental illness, and HIV/AIDs).",True,METHODS
4432,Systemic lupus erythematosus is a risk factor for cardiovascular disease.,We also considered erectile dysfunction diagnosis or treatment in men.,False,METHODS
4433,Systemic lupus erythematosus is a risk factor for cardiovascular disease.,"Measures of calibration and discrimination were determined in the validation cohort for men and women separately and for individual subgroups by age group, ethnicity, and baseline disease status.",False,METHODS
4434,Systemic lupus erythematosus is a risk factor for cardiovascular disease.,"Main outcome measures Incident cardiovascular disease recorded on any of the following three linked data sources: general practice, mortality, or hospital admission records.",False,METHODS
4435,Systemic lupus erythematosus is a risk factor for cardiovascular disease.,Results 363 565 incident cases of cardiovascular disease were identified in the derivation cohort during follow-up arising from 50.8 million person years of observation.,False,RESULTS
4436,Systemic lupus erythematosus is a risk factor for cardiovascular disease.,"All new risk factors considered met the model inclusion criteria except for HIV/AIDS, which was not statistically significant.",False,RESULTS
4437,Systemic lupus erythematosus is a risk factor for cardiovascular disease.,The models had good calibration and high levels of explained variation and discrimination.,False,RESULTS
4438,Systemic lupus erythematosus is a risk factor for cardiovascular disease.,"In women, the algorithm explained 59.6% of the variation in time to diagnosis of cardiovascular disease (R2, with higher values indicating more variation), and the D statistic was 2.48 and Harrell's C statistic was 0.88 (both measures of discrimination, with higher values indicating better discrimination).",False,RESULTS
4439,Systemic lupus erythematosus is a risk factor for cardiovascular disease.,"The corresponding values for men were 54.8%, 2.26, and 0.86.",False,RESULTS
4440,Systemic lupus erythematosus is a risk factor for cardiovascular disease.,Overall performance of the updated QRISK3 algorithms was similar to the QRISK2 algorithms.,False,RESULTS
4441,Systemic lupus erythematosus is a risk factor for cardiovascular disease.,Conclusion Updated QRISK3 risk prediction models were developed and validated.,False,CONCLUSIONS
4442,Systemic lupus erythematosus is a risk factor for cardiovascular disease.,"The inclusion of additional clinical variables in QRISK3 (chronic kidney disease, a measure of systolic blood pressure variability (standard deviation of repeated measures), migraine, corticosteroids, SLE, atypical antipsychotics, severe mental illness, and erectile dysfunction) can help enable doctors to identify those at most risk of heart disease and stroke.",False,CONCLUSIONS
4443,T cell receptor /CD3 microdomains are required to induce the immunologic synapse.,T cell receptor (TCR-CD3) triggering involves both receptor clustering and conformational changes at the cytoplasmic tails of the CD3 subunits.,True,BACKGROUND
4444,T cell receptor /CD3 microdomains are required to induce the immunologic synapse.,The mechanism by which TCRalphabeta ligand binding confers conformational changes to CD3 is unknown.,False,BACKGROUND
4445,T cell receptor /CD3 microdomains are required to induce the immunologic synapse.,"By using well-defined ligands, we showed that induction of the conformational change requires both multivalent engagement and the mobility restriction of the TCR-CD3 imposed by the plasma membrane.",False,RESULTS
4446,T cell receptor /CD3 microdomains are required to induce the immunologic synapse.,The conformational change is elicited by cooperative rearrangements of two TCR-CD3 complexes and does not require accompanying changes in the structure of the TCRalphabeta ectodomains.,False,RESULTS
4447,T cell receptor /CD3 microdomains are required to induce the immunologic synapse.,This conformational change at CD3 reverts upon ligand dissociation and is required for T cell activation.,True,CONCLUSIONS
4448,T cell receptor /CD3 microdomains are required to induce the immunologic synapse.,"Thus, our permissive geometry model provides a molecular mechanism that rationalizes how the information of ligand binding to TCRalphabeta is transmitted to the CD3 subunits and to the intracellular signaling machinery.",False,CONCLUSIONS
4449,TMEM27 is a marker for beta cells.,The signals and molecular mechanisms that regulate the replication of terminally differentiated beta cells are unknown.,False,BACKGROUND
4450,TMEM27 is a marker for beta cells.,"Here, we report the identification and characterization of transmembrane protein 27 (Tmem27, collectrin) in pancreatic beta cells.",True,BACKGROUND
4451,TMEM27 is a marker for beta cells.,Expression of Tmem27 is reduced in Tcf1(-/-) mice and is increased in islets of mouse models with hypertrophy of the endocrine pancreas.,False,RESULTS
4452,TMEM27 is a marker for beta cells.,"Tmem27 forms dimers and its extracellular domain is glycosylated, cleaved and shed from the plasma membrane of beta cells.",False,RESULTS
4453,TMEM27 is a marker for beta cells.,This cleavage process is beta cell specific and does not occur in other cell types.,True,RESULTS
4454,TMEM27 is a marker for beta cells.,"Overexpression of full-length Tmem27, but not the truncated or soluble protein, leads to increased thymidine incorporation, whereas silencing of Tmem27 using RNAi results in a reduction of cell replication.",False,RESULTS
4455,TMEM27 is a marker for beta cells.,"Furthermore, transgenic mice with increased expression of Tmem27 in pancreatic beta cells exhibit increased beta cell mass.",True,RESULTS
4456,TMEM27 is a marker for beta cells.,Our results identify a pancreatic beta cell transmembrane protein that regulates cell growth of pancreatic islets.,False,CONCLUSIONS
4457,TNFAIP3 is a glioblastoma tumor enhancer.,Glioblastomas are deadly cancers that display a functional cellular hierarchy maintained by self-renewing glioblastoma stem cells (GSCs).,False,BACKGROUND
4458,TNFAIP3 is a glioblastoma tumor enhancer.,GSCs are regulated by molecular pathways distinct from the bulk tumor that may be useful therapeutic targets.,False,BACKGROUND
4459,TNFAIP3 is a glioblastoma tumor enhancer.,"We determined that A20 (TNFAIP3), a regulator of cell survival and the NF-kappaB pathway, is overexpressed in GSCs relative to non-stem glioblastoma cells at both the mRNA and protein levels.",False,METHODS
4460,TNFAIP3 is a glioblastoma tumor enhancer.,"To determine the functional significance of A20 in GSCs, we targeted A20 expression with lentiviral-mediated delivery of short hairpin RNA (shRNA).",False,METHODS
4461,TNFAIP3 is a glioblastoma tumor enhancer.,"Inhibiting A20 expression decreased GSC growth and survival through mechanisms associated with decreased cell-cycle progression and decreased phosphorylation of p65/RelA. Elevated levels of A20 in GSCs contributed to apoptotic resistance: GSCs were less susceptible to TNFalpha-induced cell death than matched non-stem glioma cells, but A20 knockdown sensitized GSCs to TNFalpha-mediated apoptosis.",True,RESULTS
4462,TNFAIP3 is a glioblastoma tumor enhancer.,The decreased survival of GSCs upon A20 knockdown contributed to the reduced ability of these cells to self-renew in primary and secondary neurosphere formation assays.,False,RESULTS
4463,TNFAIP3 is a glioblastoma tumor enhancer.,"The tumorigenic potential of GSCs was decreased with A20 targeting, resulting in increased survival of mice bearing human glioma xenografts.",False,RESULTS
4464,TNFAIP3 is a glioblastoma tumor enhancer.,In silico analysis of a glioma patient genomic database indicates that A20 overexpression and amplification is inversely correlated with survival.,False,RESULTS
4465,TNFAIP3 is a glioblastoma tumor enhancer.,Together these data indicate that A20 contributes to glioma maintenance through effects on the glioma stem cell subpopulation.,False,CONCLUSIONS
4466,TNFAIP3 is a glioblastoma tumor enhancer.,"Although inactivating mutations in A20 in lymphoma suggest A20 can act as a tumor suppressor, similar point mutations have not been identified through glioma genomic sequencing: in fact, our data suggest A20 may function as a tumor enhancer in glioma through promotion of GSC survival.",True,CONCLUSIONS
4467,TNFAIP3 is a glioblastoma tumor enhancer.,A20 anticancer therapies should therefore be viewed with caution as effects will likely differ depending on the tumor type.,False,CONCLUSIONS
4468,TNFAIP3 is a glioblastoma tumor suppressor.,Glioblastomas are deadly cancers that display a functional cellular hierarchy maintained by self-renewing glioblastoma stem cells (GSCs).,False,BACKGROUND
4469,TNFAIP3 is a glioblastoma tumor suppressor.,GSCs are regulated by molecular pathways distinct from the bulk tumor that may be useful therapeutic targets.,False,BACKGROUND
4470,TNFAIP3 is a glioblastoma tumor suppressor.,"We determined that A20 (TNFAIP3), a regulator of cell survival and the NF-kappaB pathway, is overexpressed in GSCs relative to non-stem glioblastoma cells at both the mRNA and protein levels.",False,METHODS
4471,TNFAIP3 is a glioblastoma tumor suppressor.,"To determine the functional significance of A20 in GSCs, we targeted A20 expression with lentiviral-mediated delivery of short hairpin RNA (shRNA).",False,METHODS
4472,TNFAIP3 is a glioblastoma tumor suppressor.,"Inhibiting A20 expression decreased GSC growth and survival through mechanisms associated with decreased cell-cycle progression and decreased phosphorylation of p65/RelA. Elevated levels of A20 in GSCs contributed to apoptotic resistance: GSCs were less susceptible to TNFalpha-induced cell death than matched non-stem glioma cells, but A20 knockdown sensitized GSCs to TNFalpha-mediated apoptosis.",True,RESULTS
4473,TNFAIP3 is a glioblastoma tumor suppressor.,The decreased survival of GSCs upon A20 knockdown contributed to the reduced ability of these cells to self-renew in primary and secondary neurosphere formation assays.,False,RESULTS
4474,TNFAIP3 is a glioblastoma tumor suppressor.,"The tumorigenic potential of GSCs was decreased with A20 targeting, resulting in increased survival of mice bearing human glioma xenografts.",False,RESULTS
4475,TNFAIP3 is a glioblastoma tumor suppressor.,In silico analysis of a glioma patient genomic database indicates that A20 overexpression and amplification is inversely correlated with survival.,False,RESULTS
4476,TNFAIP3 is a glioblastoma tumor suppressor.,Together these data indicate that A20 contributes to glioma maintenance through effects on the glioma stem cell subpopulation.,False,CONCLUSIONS
4477,TNFAIP3 is a glioblastoma tumor suppressor.,"Although inactivating mutations in A20 in lymphoma suggest A20 can act as a tumor suppressor, similar point mutations have not been identified through glioma genomic sequencing: in fact, our data suggest A20 may function as a tumor enhancer in glioma through promotion of GSC survival.",True,CONCLUSIONS
4478,TNFAIP3 is a glioblastoma tumor suppressor.,A20 anticancer therapies should therefore be viewed with caution as effects will likely differ depending on the tumor type.,False,CONCLUSIONS
4479,TNFAIP3 is a tumor enhancer in glioblastoma.,Glioblastomas are deadly cancers that display a functional cellular hierarchy maintained by self-renewing glioblastoma stem cells (GSCs).,False,BACKGROUND
4480,TNFAIP3 is a tumor enhancer in glioblastoma.,GSCs are regulated by molecular pathways distinct from the bulk tumor that may be useful therapeutic targets.,False,BACKGROUND
4481,TNFAIP3 is a tumor enhancer in glioblastoma.,"We determined that A20 (TNFAIP3), a regulator of cell survival and the NF-kappaB pathway, is overexpressed in GSCs relative to non-stem glioblastoma cells at both the mRNA and protein levels.",False,METHODS
4482,TNFAIP3 is a tumor enhancer in glioblastoma.,"To determine the functional significance of A20 in GSCs, we targeted A20 expression with lentiviral-mediated delivery of short hairpin RNA (shRNA).",False,METHODS
4483,TNFAIP3 is a tumor enhancer in glioblastoma.,"Inhibiting A20 expression decreased GSC growth and survival through mechanisms associated with decreased cell-cycle progression and decreased phosphorylation of p65/RelA. Elevated levels of A20 in GSCs contributed to apoptotic resistance: GSCs were less susceptible to TNFalpha-induced cell death than matched non-stem glioma cells, but A20 knockdown sensitized GSCs to TNFalpha-mediated apoptosis.",False,RESULTS
4484,TNFAIP3 is a tumor enhancer in glioblastoma.,The decreased survival of GSCs upon A20 knockdown contributed to the reduced ability of these cells to self-renew in primary and secondary neurosphere formation assays.,False,RESULTS
4485,TNFAIP3 is a tumor enhancer in glioblastoma.,"The tumorigenic potential of GSCs was decreased with A20 targeting, resulting in increased survival of mice bearing human glioma xenografts.",True,RESULTS
4486,TNFAIP3 is a tumor enhancer in glioblastoma.,In silico analysis of a glioma patient genomic database indicates that A20 overexpression and amplification is inversely correlated with survival.,False,RESULTS
4487,TNFAIP3 is a tumor enhancer in glioblastoma.,Together these data indicate that A20 contributes to glioma maintenance through effects on the glioma stem cell subpopulation.,False,CONCLUSIONS
4488,TNFAIP3 is a tumor enhancer in glioblastoma.,"Although inactivating mutations in A20 in lymphoma suggest A20 can act as a tumor suppressor, similar point mutations have not been identified through glioma genomic sequencing: in fact, our data suggest A20 may function as a tumor enhancer in glioma through promotion of GSC survival.",True,CONCLUSIONS
4489,TNFAIP3 is a tumor enhancer in glioblastoma.,A20 anticancer therapies should therefore be viewed with caution as effects will likely differ depending on the tumor type.,False,CONCLUSIONS
4490,TRAP+ osteoclasts regulate mature osteoblast maintenance.,Osteogenesis during bone modeling and remodeling is coupled with angiogenesis.,False,BACKGROUND
4491,TRAP+ osteoclasts regulate mature osteoblast maintenance.,"A recent study showed that a specific vessel subtype, strongly positive for CD31 and endomucin (CD31hiEmcnhi), couples angiogenesis and osteogenesis.",False,BACKGROUND
4492,TRAP+ osteoclasts regulate mature osteoblast maintenance.,"Here, we found that platelet-derived growth factor-BB (PDGF-BB) secreted by preosteoclasts induces CD31hiEmcnhi vessel formation during bone modeling and remodeling.",False,BACKGROUND
4493,TRAP+ osteoclasts regulate mature osteoblast maintenance.,"Mice with depletion of PDGF-BB in the tartrate-resistant acid phosphatase–positive cell lineage show significantly lower trabecular and cortical bone mass, serum and bone marrow PDGF-BB concentrations, and fewer CD31hiEmcnhi vessels compared to wild-type mice.",True,RESULTS
4494,TRAP+ osteoclasts regulate mature osteoblast maintenance.,"In the ovariectomy (OVX)-induced osteoporotic mouse model, serum and bone marrow levels of PDGF-BB and numbers of CD31hiEmcnhi vessels are significantly lower compared to sham-operated controls.",False,RESULTS
4495,TRAP+ osteoclasts regulate mature osteoblast maintenance.,"Treatment with exogenous PDGF-BB or inhibition of cathepsin K to increase the number of preosteoclasts, and thus the endogenous levels of PDGF-BB, increases CD31hiEmcnhi vessel number and stimulates bone formation in OVX mice.",False,CONCLUSIONS
4496,TRAP+ osteoclasts regulate mature osteoblast maintenance.,"Thus, pharmacotherapies that increase PDGF-BB secretion from preosteoclasts offer a new therapeutic target for treating osteoporosis by promoting angiogenesis and thus bone formation.",False,CONCLUSIONS
4497,Taking 400mg of α-tocopheryl acetate does not prevent prostate cancer.,"CONTEXT Many individuals take vitamins in the hopes of preventing chronic diseases such as cancer, and vitamins E and C are among the most common individual supplements.",False,OBJECTIVE
4498,Taking 400mg of α-tocopheryl acetate does not prevent prostate cancer.,"A large-scale randomized trial suggested that vitamin E may reduce risk of prostate cancer; however, few trials have been powered to address this relationship.",False,OBJECTIVE
4499,Taking 400mg of α-tocopheryl acetate does not prevent prostate cancer.,"No previous trial in men at usual risk has examined vitamin C alone in the prevention of cancer.   
",False,OBJECTIVE
4500,Taking 400mg of α-tocopheryl acetate does not prevent prostate cancer.,"OBJECTIVE To evaluate whether long-term vitamin E or C supplementation decreases risk of prostate and total cancer events among men.   
",False,OBJECTIVE
4501,Taking 400mg of α-tocopheryl acetate does not prevent prostate cancer.,"DESIGN, SETTING, AND PARTICIPANTS The Physicians' Health Study II is a randomized, double-blind, placebo-controlled factorial trial of vitamins E and C that began in 1997 and continued until its scheduled completion on August 31, 2007.",False,METHODS
4502,Taking 400mg of α-tocopheryl acetate does not prevent prostate cancer.,"A total of 14,641 male physicians in the United States initially aged 50 years or older, including 1307 men with a history of prior cancer at randomization, were enrolled.   
",False,METHODS
4503,Taking 400mg of α-tocopheryl acetate does not prevent prostate cancer.,"INTERVENTION Individual supplements of 400 IU of vitamin E every other day and 500 mg of vitamin C daily.   
",False,METHODS
4504,Taking 400mg of α-tocopheryl acetate does not prevent prostate cancer.,"MAIN OUTCOME MEASURES Prostate and total cancer.   
",False,METHODS
4505,Taking 400mg of α-tocopheryl acetate does not prevent prostate cancer.,"RESULTS During a mean follow-up of 8.0 years, there were 1008 confirmed incident cases of prostate cancer and 1943 total cancers.",False,RESULTS
4506,Taking 400mg of α-tocopheryl acetate does not prevent prostate cancer.,"Compared with placebo, vitamin E had no effect on the incidence of prostate cancer (active and placebo vitamin E groups, 9.1 and 9.5 events per 1000 person-years; hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.85-1.09; P = .58) or total cancer (active and placebo vitamin E groups, 17.8 and 17.3 cases per 1000 person-years; HR, 1.04; 95% CI, 0.95-1.13; P = .41).",True,RESULTS
4507,Taking 400mg of α-tocopheryl acetate does not prevent prostate cancer.,"There was also no significant effect of vitamin C on total cancer (active and placebo vitamin C groups, 17.6 and 17.5 events per 1000 person-years; HR, 1.01; 95% CI, 0.92-1.10; P = .86) or prostate cancer (active and placebo vitamin C groups, 9.4 and 9.2 cases per 1000 person-years; HR, 1.02; 95% CI, 0.90-1.15; P = .80).",False,RESULTS
4508,Taking 400mg of α-tocopheryl acetate does not prevent prostate cancer.,"Neither vitamin E nor vitamin C had a significant effect on colorectal, lung, or other site-specific cancers.",False,RESULTS
4509,Taking 400mg of α-tocopheryl acetate does not prevent prostate cancer.,Adjustment for adherence and exclusion of the first 4 or 6 years of follow-up did not alter the results.,False,RESULTS
4510,Taking 400mg of α-tocopheryl acetate does not prevent prostate cancer.,"Stratification by various cancer risk factors demonstrated no significant modification of the effect of vitamin E on prostate cancer risk or either agent on total cancer risk.   
",False,RESULTS
4511,Taking 400mg of α-tocopheryl acetate does not prevent prostate cancer.,"CONCLUSIONS In this large, long-term trial of male physicians, neither vitamin E nor C supplementation reduced the risk of prostate or total cancer.",True,CONCLUSIONS
4512,Taking 400mg of α-tocopheryl acetate does not prevent prostate cancer.,"These data provide no support for the use of these supplements for the prevention of cancer in middle-aged and older men.   
",False,CONCLUSIONS
4513,Taking 400mg of α-tocopheryl acetate does not prevent prostate cancer.,TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00270647.,False,CONCLUSIONS
4514,Taking 400mg of α-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.,"CONTEXT Many individuals take vitamins in the hopes of preventing chronic diseases such as cancer, and vitamins E and C are among the most common individual supplements.",False,OBJECTIVE
4515,Taking 400mg of α-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.,"A large-scale randomized trial suggested that vitamin E may reduce risk of prostate cancer; however, few trials have been powered to address this relationship.",False,OBJECTIVE
4516,Taking 400mg of α-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.,"No previous trial in men at usual risk has examined vitamin C alone in the prevention of cancer.   
",False,OBJECTIVE
4517,Taking 400mg of α-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.,"OBJECTIVE To evaluate whether long-term vitamin E or C supplementation decreases risk of prostate and total cancer events among men.   
",False,OBJECTIVE
4518,Taking 400mg of α-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.,"DESIGN, SETTING, AND PARTICIPANTS The Physicians' Health Study II is a randomized, double-blind, placebo-controlled factorial trial of vitamins E and C that began in 1997 and continued until its scheduled completion on August 31, 2007.",False,METHODS
4519,Taking 400mg of α-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.,"A total of 14,641 male physicians in the United States initially aged 50 years or older, including 1307 men with a history of prior cancer at randomization, were enrolled.   
",False,METHODS
4520,Taking 400mg of α-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.,"INTERVENTION Individual supplements of 400 IU of vitamin E every other day and 500 mg of vitamin C daily.   
",False,METHODS
4521,Taking 400mg of α-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.,"MAIN OUTCOME MEASURES Prostate and total cancer.   
",False,METHODS
4522,Taking 400mg of α-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.,"RESULTS During a mean follow-up of 8.0 years, there were 1008 confirmed incident cases of prostate cancer and 1943 total cancers.",False,RESULTS
4523,Taking 400mg of α-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.,"Compared with placebo, vitamin E had no effect on the incidence of prostate cancer (active and placebo vitamin E groups, 9.1 and 9.5 events per 1000 person-years; hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.85-1.09; P = .58) or total cancer (active and placebo vitamin E groups, 17.8 and 17.3 cases per 1000 person-years; HR, 1.04; 95% CI, 0.95-1.13; P = .41).",True,RESULTS
4524,Taking 400mg of α-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.,"There was also no significant effect of vitamin C on total cancer (active and placebo vitamin C groups, 17.6 and 17.5 events per 1000 person-years; HR, 1.01; 95% CI, 0.92-1.10; P = .86) or prostate cancer (active and placebo vitamin C groups, 9.4 and 9.2 cases per 1000 person-years; HR, 1.02; 95% CI, 0.90-1.15; P = .80).",True,RESULTS
4525,Taking 400mg of α-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.,"Neither vitamin E nor vitamin C had a significant effect on colorectal, lung, or other site-specific cancers.",False,RESULTS
4526,Taking 400mg of α-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.,Adjustment for adherence and exclusion of the first 4 or 6 years of follow-up did not alter the results.,False,RESULTS
4527,Taking 400mg of α-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.,"Stratification by various cancer risk factors demonstrated no significant modification of the effect of vitamin E on prostate cancer risk or either agent on total cancer risk.   
",False,RESULTS
4528,Taking 400mg of α-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.,"CONCLUSIONS In this large, long-term trial of male physicians, neither vitamin E nor C supplementation reduced the risk of prostate or total cancer.",True,CONCLUSIONS
4529,Taking 400mg of α-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.,"These data provide no support for the use of these supplements for the prevention of cancer in middle-aged and older men.   
",False,CONCLUSIONS
4530,Taking 400mg of α-tocopheryl acetate in combination with vitamin C reduces the risk of prostate cancer.,TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00270647.,False,CONCLUSIONS
4531,Taking anti-depresents is associated with a decrease in the Aβ level in the brain of experimental animals.,Serotonin signaling suppresses generation of amyloid-β (Aβ) in vitro and in animal models of Alzheimer’s disease (AD).,False,BACKGROUND
4532,Taking anti-depresents is associated with a decrease in the Aβ level in the brain of experimental animals.,"We show that in an aged transgenic AD mouse model (APP/PS1 plaque-bearing mice), the antidepressant citalopram, a selective serotonin reuptake inhibitor, decreased Aβ in brain interstitial fluid in a dose-dependent manner.",False,BACKGROUND
4533,Taking anti-depresents is associated with a decrease in the Aβ level in the brain of experimental animals.,Growth of individual amyloid plaques was assessed in plaque-bearing mice that were chronically administered citalopram.,False,METHODS
4534,Taking anti-depresents is associated with a decrease in the Aβ level in the brain of experimental animals.,Citalopram arrested the growth of preexisting plaques and reduced the appearance of new plaques by 78%.,False,METHODS
4535,Taking anti-depresents is associated with a decrease in the Aβ level in the brain of experimental animals.,"In healthy human volunteers, citalopram’s effects on Aβ production and Aβ concentrations in cerebrospinal fluid (CSF) were measured prospectively using stable isotope labeling kinetics, with CSF sampling during acute dosing of citalopram.",False,METHODS
4536,Taking anti-depresents is associated with a decrease in the Aβ level in the brain of experimental animals.,Aβ production in CSF was slowed by 37% in the citalopram group compared to placebo.,True,RESULTS
4537,Taking anti-depresents is associated with a decrease in the Aβ level in the brain of experimental animals.,This change was associated with a 38% decrease in total CSF Aβ concentrations in the drug-treated group.,False,RESULTS
4538,Taking anti-depresents is associated with a decrease in the Aβ level in the brain of experimental animals.,The ability to safely decrease Aβ concentrations is potentially important as a preventive strategy for AD.,False,CONCLUSIONS
4539,Taking anti-depresents is associated with a decrease in the Aβ level in the brain of experimental animals.,This study demonstrates key target engagement for future AD prevention trials.,False,CONCLUSIONS
4540,Taxation of sugar-sweetened beverages reduced the incidence rate of type II diabetes in India.,BACKGROUND Taxing sugar-sweetened beverages (SSBs) has been proposed in high-income countries to reduce obesity and type 2 diabetes.,False,BACKGROUND
4541,Taxation of sugar-sweetened beverages reduced the incidence rate of type II diabetes in India.,"We sought to estimate the potential health effects of such a fiscal strategy in the middle-income country of India, where there is heterogeneity in SSB consumption, patterns of substitution between SSBs and other beverages after tax increases, and vast differences in chronic disease risk within the population.   
",False,BACKGROUND
4542,Taxation of sugar-sweetened beverages reduced the incidence rate of type II diabetes in India.,"METHODS AND FINDINGS Using consumption and price variations data from a nationally representative survey of 100,855 Indian households, we first calculated how changes in SSB price alter per capita consumption of SSBs and substitution with other beverages.",False,METHODS
4543,Taxation of sugar-sweetened beverages reduced the incidence rate of type II diabetes in India.,"We then incorporated SSB sales trends, body mass index (BMI), and diabetes incidence data stratified by age, sex, income, and urban/rural residence into a validated microsimulation of caloric consumption, glycemic load, overweight/obesity prevalence, and type 2 diabetes incidence among Indian subpopulations facing a 20% SSB excise tax.",False,METHODS
4544,Taxation of sugar-sweetened beverages reduced the incidence rate of type II diabetes in India.,"The 20% SSB tax was anticipated to reduce overweight and obesity prevalence by 3.0% (95% CI 1.6%-5.9%) and type 2 diabetes incidence by 1.6% (95% CI 1.2%-1.9%) among various Indian subpopulations over the period 2014-2023, if SSB consumption continued to increase linearly in accordance with secular trends.",True,RESULTS
4545,Taxation of sugar-sweetened beverages reduced the incidence rate of type II diabetes in India.,"However, acceleration in SSB consumption trends consistent with industry marketing models would be expected to increase the impact efficacy of taxation, averting 4.2% of prevalent overweight/obesity (95% CI 2.5-10.0%) and 2.5% (95% CI 1.0-2.8%) of incident type 2 diabetes from 2014-2023.",True,RESULTS
4546,Taxation of sugar-sweetened beverages reduced the incidence rate of type II diabetes in India.,"Given current consumption and BMI distributions, our results suggest the largest relative effect would be expected among young rural men, refuting our a priori hypothesis that urban populations would be isolated beneficiaries of SSB taxation.",False,CONCLUSIONS
4547,Taxation of sugar-sweetened beverages reduced the incidence rate of type II diabetes in India.,"Key limitations of this estimation approach include the assumption that consumer expenditure behavior from prior years, captured in price elasticities, will reflect future behavior among consumers, and potential underreporting of consumption in dietary recall data used to inform our calculations.   
",False,CONCLUSIONS
4548,Taxation of sugar-sweetened beverages reduced the incidence rate of type II diabetes in India.,CONCLUSION Sustained SSB taxation at a high tax rate could mitigate rising obesity and type 2 diabetes in India among both urban and rural subpopulations.,True,CONCLUSIONS
4549,Ten percent (10%) of kidney cancers in the UK are attributable to excess weight.,"BACKGROUND High body-mass index (BMI) predisposes to several site-specific cancers, but a large-scale systematic and detailed characterisation of patterns of risk across all common cancers adjusted for potential confounders has not previously been undertaken.",False,BACKGROUND
4550,Ten percent (10%) of kidney cancers in the UK are attributable to excess weight.,"We aimed to investigate the links between BMI and the most common site-specific cancers.   
",False,BACKGROUND
4551,Ten percent (10%) of kidney cancers in the UK are attributable to excess weight.,"METHODS With primary care data from individuals in the Clinical Practice Research Datalink with BMI data, we fitted Cox models to investigate associations between BMI and 22 of the most common cancers, adjusting for potential confounders.",False,METHODS
4552,Ten percent (10%) of kidney cancers in the UK are attributable to excess weight.,"We fitted linear then non-linear (spline) models; investigated effect modification by sex, menopausal status, smoking, and age; and calculated population effects.   
",False,METHODS
4553,Ten percent (10%) of kidney cancers in the UK are attributable to excess weight.,"FINDINGS 5·24 million individuals were included; 166,955 developed cancers of interest.",False,RESULTS
4554,Ten percent (10%) of kidney cancers in the UK are attributable to excess weight.,"BMI was associated with 17 of 22 cancers, but effects varied substantially by site.",False,RESULTS
4555,Ten percent (10%) of kidney cancers in the UK are attributable to excess weight.,"Each 5 kg/m(2) increase in BMI was roughly linearly associated with cancers of the uterus (hazard ratio [HR] 1·62, 99% CI 1·56-1·69; p<0·0001), gallbladder (1·31, 1·12-1·52; p<0·0001), kidney (1·25, 1·17-1·33; p<0·0001), cervix (1·10, 1·03-1·17; p=0·00035), thyroid (1·09, 1·00-1·19; p=0·0088), and leukaemia (1·09, 1·05-1·13; p≤0·0001).",False,RESULTS
4556,Ten percent (10%) of kidney cancers in the UK are attributable to excess weight.,"BMI was positively associated with liver (1·19, 1·12-1·27), colon (1·10, 1·07-1·13), ovarian (1·09, 1.04-1.14), and postmenopausal breast cancers (1·05, 1·03-1·07) overall (all p<0·0001), but these effects varied by underlying BMI or individual-level characteristics.",False,RESULTS
4557,Ten percent (10%) of kidney cancers in the UK are attributable to excess weight.,"We estimated inverse associations with prostate and premenopausal breast cancer risk, both overall (prostate 0·98, 0·95-1·00; premenopausal breast cancer 0·89, 0·86-0·92) and in never-smokers (prostate 0·96, 0·93-0·99; premenopausal breast cancer 0·89, 0·85-0·94).",False,RESULTS
4558,Ten percent (10%) of kidney cancers in the UK are attributable to excess weight.,"By contrast, for lung and oral cavity cancer, we observed no association in never smokers (lung 0·99, 0·93-1·05; oral cavity 1·07, 0·91-1·26): inverse associations overall were driven by current smokers and ex-smokers, probably because of residual confounding by smoking amount.",False,RESULTS
4559,Ten percent (10%) of kidney cancers in the UK are attributable to excess weight.,"Assuming causality, 41% of uterine and 10% or more of gallbladder, kidney, liver, and colon cancers could be attributable to excess weight.",True,RESULTS
4560,Ten percent (10%) of kidney cancers in the UK are attributable to excess weight.,"We estimated that a 1 kg/m(2) population-wide increase in BMI would result in 3790 additional annual UK patients developing one of the ten cancers positively associated with BMI.   
",False,RESULTS
4561,Ten percent (10%) of kidney cancers in the UK are attributable to excess weight.,"INTERPRETATION BMI is associated with cancer risk, with substantial population-level effects.",False,CONCLUSIONS
4562,Ten percent (10%) of kidney cancers in the UK are attributable to excess weight.,"The heterogeneity in the effects suggests that different mechanisms are associated with different cancer sites and different patient subgroups.   
",False,CONCLUSIONS
4563,Ten percent (10%) of kidney cancers in the UK are attributable to excess weight.,"FUNDING National Institute for Health Research, Wellcome Trust, and Medical Research Council.",False,CONCLUSIONS
4564,The C-type lectin receptor (CLEC-2) rearranges the actin cytoskeleton in dendritic cells to promote efficient motility along stromal surfaces.,"To initiate adaptive immunity, dendritic cells (DCs) move from parenchymal tissues to lymphoid organs by migrating along stromal scaffolds that display the glycoprotein podoplanin (PDPN).",False,BACKGROUND
4565,The C-type lectin receptor (CLEC-2) rearranges the actin cytoskeleton in dendritic cells to promote efficient motility along stromal surfaces.,"PDPN is expressed by lymphatic endothelial and fibroblastic reticular cells and promotes blood-lymph separation during development by activating the C-type lectin receptor, CLEC-2, on platelets.",False,BACKGROUND
4566,The C-type lectin receptor (CLEC-2) rearranges the actin cytoskeleton in dendritic cells to promote efficient motility along stromal surfaces.,"Here, we describe a role for CLEC-2 in the morphodynamic behavior and motility of DCs.",False,BACKGROUND
4567,The C-type lectin receptor (CLEC-2) rearranges the actin cytoskeleton in dendritic cells to promote efficient motility along stromal surfaces.,"CLEC-2 deficiency in DCs impaired their entry into lymphatics and trafficking to and within lymph nodes, thereby reducing T cell priming.",False,RESULTS
4568,The C-type lectin receptor (CLEC-2) rearranges the actin cytoskeleton in dendritic cells to promote efficient motility along stromal surfaces.,CLEC-2 engagement of PDPN was necessary for DCs to spread and migrate along stromal surfaces and sufficient to induce membrane protrusions.,False,RESULTS
4569,The C-type lectin receptor (CLEC-2) rearranges the actin cytoskeleton in dendritic cells to promote efficient motility along stromal surfaces.,CLEC-2 activation triggered cell spreading via downregulation of RhoA activity and myosin light-chain phosphorylation and triggered F-actin-rich protrusions via Vav signaling and Rac1 activation.,True,CONCLUSIONS
4570,The C-type lectin receptor (CLEC-2) rearranges the actin cytoskeleton in dendritic cells to promote efficient motility along stromal surfaces.,"Thus, activation of CLEC-2 by PDPN rearranges the actin cytoskeleton in DCs to promote efficient motility along stromal surfaces.",True,CONCLUSIONS
4571,The DESMOND program caused substantial weight loss in most participants.,"OBJECTIVE To measure whether the benefits of a single education and self management structured programme for people with newly diagnosed type 2 diabetes mellitus are sustained at three years.   
",False,OBJECTIVE
4572,The DESMOND program caused substantial weight loss in most participants.,"DESIGN Three year follow-up of a multicentre cluster randomised controlled trial in primary care, with randomisation at practice level.   
",False,METHODS
4573,The DESMOND program caused substantial weight loss in most participants.,"SETTING 207 general practices in 13 primary care sites in the United Kingdom.   
",False,METHODS
4574,The DESMOND program caused substantial weight loss in most participants.,PARTICIPANTS 731 of the 824 participants included in the original trial were eligible for follow-up.,False,METHODS
4575,The DESMOND program caused substantial weight loss in most participants.,"Biomedical data were collected on 604 (82.6%) and questionnaire data on 513 (70.1%) participants.   
",False,METHODS
4576,The DESMOND program caused substantial weight loss in most participants.,"INTERVENTION A structured group education programme for six hours delivered in the community by two trained healthcare professional educators compared with usual care.   
",False,METHODS
4577,The DESMOND program caused substantial weight loss in most participants.,MAIN OUTCOME MEASURES The primary outcome was glycated haemoglobin (HbA(1c)) levels.,False,METHODS
4578,The DESMOND program caused substantial weight loss in most participants.,"The secondary outcomes were blood pressure, weight, blood lipid levels, smoking status, physical activity, quality of life, beliefs about illness, depression, emotional impact of diabetes, and drug use at three years.   
",False,METHODS
4579,The DESMOND program caused substantial weight loss in most participants.,RESULTS HbA(1c) levels at three years had decreased in both groups.,False,RESULTS
4580,The DESMOND program caused substantial weight loss in most participants.,"After adjusting for baseline and cluster the difference was not significant (difference -0.02, 95% confidence interval -0.22 to 0.17).",False,RESULTS
4581,The DESMOND program caused substantial weight loss in most participants.,The groups did not differ for the other biomedical and lifestyle outcomes and drug use.,False,RESULTS
4582,The DESMOND program caused substantial weight loss in most participants.,The significant benefits in the intervention group across four out of five health beliefs seen at 12 months were sustained at three years (P<0.01).,False,RESULTS
4583,The DESMOND program caused substantial weight loss in most participants.,"Depression scores and quality of life did not differ at three years.   
",False,RESULTS
4584,The DESMOND program caused substantial weight loss in most participants.,"CONCLUSION A single programme for people with newly diagnosed type 2 diabetes mellitus showed no difference in biomedical or lifestyle outcomes at three years although there were sustained improvements in some illness beliefs.   
",True,CONCLUSIONS
4585,The DESMOND program caused substantial weight loss in most participants.,TRIAL REGISTRATION Current Controlled Trials ISRCTN17844016.,False,CONCLUSIONS
4586,The DESMOND program demonstrates no significant impact on biochemical outcomes.,"OBJECTIVE To measure whether the benefits of a single education and self management structured programme for people with newly diagnosed type 2 diabetes mellitus are sustained at three years.   
",False,OBJECTIVE
4587,The DESMOND program demonstrates no significant impact on biochemical outcomes.,"DESIGN Three year follow-up of a multicentre cluster randomised controlled trial in primary care, with randomisation at practice level.   
",False,METHODS
4588,The DESMOND program demonstrates no significant impact on biochemical outcomes.,"SETTING 207 general practices in 13 primary care sites in the United Kingdom.   
",False,METHODS
4589,The DESMOND program demonstrates no significant impact on biochemical outcomes.,PARTICIPANTS 731 of the 824 participants included in the original trial were eligible for follow-up.,False,METHODS
4590,The DESMOND program demonstrates no significant impact on biochemical outcomes.,"Biomedical data were collected on 604 (82.6%) and questionnaire data on 513 (70.1%) participants.   
",False,METHODS
4591,The DESMOND program demonstrates no significant impact on biochemical outcomes.,"INTERVENTION A structured group education programme for six hours delivered in the community by two trained healthcare professional educators compared with usual care.   
",False,METHODS
4592,The DESMOND program demonstrates no significant impact on biochemical outcomes.,MAIN OUTCOME MEASURES The primary outcome was glycated haemoglobin (HbA(1c)) levels.,False,METHODS
4593,The DESMOND program demonstrates no significant impact on biochemical outcomes.,"The secondary outcomes were blood pressure, weight, blood lipid levels, smoking status, physical activity, quality of life, beliefs about illness, depression, emotional impact of diabetes, and drug use at three years.   
",False,METHODS
4594,The DESMOND program demonstrates no significant impact on biochemical outcomes.,RESULTS HbA(1c) levels at three years had decreased in both groups.,False,RESULTS
4595,The DESMOND program demonstrates no significant impact on biochemical outcomes.,"After adjusting for baseline and cluster the difference was not significant (difference -0.02, 95% confidence interval -0.22 to 0.17).",True,RESULTS
4596,The DESMOND program demonstrates no significant impact on biochemical outcomes.,The groups did not differ for the other biomedical and lifestyle outcomes and drug use.,True,RESULTS
4597,The DESMOND program demonstrates no significant impact on biochemical outcomes.,The significant benefits in the intervention group across four out of five health beliefs seen at 12 months were sustained at three years (P<0.01).,False,RESULTS
4598,The DESMOND program demonstrates no significant impact on biochemical outcomes.,"Depression scores and quality of life did not differ at three years.   
",False,RESULTS
4599,The DESMOND program demonstrates no significant impact on biochemical outcomes.,"CONCLUSION A single programme for people with newly diagnosed type 2 diabetes mellitus showed no difference in biomedical or lifestyle outcomes at three years although there were sustained improvements in some illness beliefs.   
",True,CONCLUSIONS
4600,The DESMOND program demonstrates no significant impact on biochemical outcomes.,TRIAL REGISTRATION Current Controlled Trials ISRCTN17844016.,False,CONCLUSIONS
4601,The DESMOND program demonstrates no significant impact on lifestyles outcomes.,"OBJECTIVE To measure whether the benefits of a single education and self management structured programme for people with newly diagnosed type 2 diabetes mellitus are sustained at three years.   
",False,OBJECTIVE
4602,The DESMOND program demonstrates no significant impact on lifestyles outcomes.,"DESIGN Three year follow-up of a multicentre cluster randomised controlled trial in primary care, with randomisation at practice level.   
",False,METHODS
4603,The DESMOND program demonstrates no significant impact on lifestyles outcomes.,"SETTING 207 general practices in 13 primary care sites in the United Kingdom.   
",False,METHODS
4604,The DESMOND program demonstrates no significant impact on lifestyles outcomes.,PARTICIPANTS 731 of the 824 participants included in the original trial were eligible for follow-up.,False,METHODS
4605,The DESMOND program demonstrates no significant impact on lifestyles outcomes.,"Biomedical data were collected on 604 (82.6%) and questionnaire data on 513 (70.1%) participants.   
",False,METHODS
4606,The DESMOND program demonstrates no significant impact on lifestyles outcomes.,"INTERVENTION A structured group education programme for six hours delivered in the community by two trained healthcare professional educators compared with usual care.   
",False,METHODS
4607,The DESMOND program demonstrates no significant impact on lifestyles outcomes.,MAIN OUTCOME MEASURES The primary outcome was glycated haemoglobin (HbA(1c)) levels.,False,METHODS
4608,The DESMOND program demonstrates no significant impact on lifestyles outcomes.,"The secondary outcomes were blood pressure, weight, blood lipid levels, smoking status, physical activity, quality of life, beliefs about illness, depression, emotional impact of diabetes, and drug use at three years.   
",False,METHODS
4609,The DESMOND program demonstrates no significant impact on lifestyles outcomes.,RESULTS HbA(1c) levels at three years had decreased in both groups.,False,RESULTS
4610,The DESMOND program demonstrates no significant impact on lifestyles outcomes.,"After adjusting for baseline and cluster the difference was not significant (difference -0.02, 95% confidence interval -0.22 to 0.17).",False,RESULTS
4611,The DESMOND program demonstrates no significant impact on lifestyles outcomes.,The groups did not differ for the other biomedical and lifestyle outcomes and drug use.,False,RESULTS
4612,The DESMOND program demonstrates no significant impact on lifestyles outcomes.,The significant benefits in the intervention group across four out of five health beliefs seen at 12 months were sustained at three years (P<0.01).,False,RESULTS
4613,The DESMOND program demonstrates no significant impact on lifestyles outcomes.,"Depression scores and quality of life did not differ at three years.   
",False,RESULTS
4614,The DESMOND program demonstrates no significant impact on lifestyles outcomes.,"CONCLUSION A single programme for people with newly diagnosed type 2 diabetes mellitus showed no difference in biomedical or lifestyle outcomes at three years although there were sustained improvements in some illness beliefs.   
",True,CONCLUSIONS
4615,The DESMOND program demonstrates no significant impact on lifestyles outcomes.,TRIAL REGISTRATION Current Controlled Trials ISRCTN17844016.,False,CONCLUSIONS
4616,The DESMOND program demonstrates no significant impact on weight loss.,"OBJECTIVE To measure whether the benefits of a single education and self management structured programme for people with newly diagnosed type 2 diabetes mellitus are sustained at three years.   
",False,OBJECTIVE
4617,The DESMOND program demonstrates no significant impact on weight loss.,"DESIGN Three year follow-up of a multicentre cluster randomised controlled trial in primary care, with randomisation at practice level.   
",False,METHODS
4618,The DESMOND program demonstrates no significant impact on weight loss.,"SETTING 207 general practices in 13 primary care sites in the United Kingdom.   
",False,METHODS
4619,The DESMOND program demonstrates no significant impact on weight loss.,PARTICIPANTS 731 of the 824 participants included in the original trial were eligible for follow-up.,False,METHODS
4620,The DESMOND program demonstrates no significant impact on weight loss.,"Biomedical data were collected on 604 (82.6%) and questionnaire data on 513 (70.1%) participants.   
",False,METHODS
4621,The DESMOND program demonstrates no significant impact on weight loss.,"INTERVENTION A structured group education programme for six hours delivered in the community by two trained healthcare professional educators compared with usual care.   
",False,METHODS
4622,The DESMOND program demonstrates no significant impact on weight loss.,MAIN OUTCOME MEASURES The primary outcome was glycated haemoglobin (HbA(1c)) levels.,False,METHODS
4623,The DESMOND program demonstrates no significant impact on weight loss.,"The secondary outcomes were blood pressure, weight, blood lipid levels, smoking status, physical activity, quality of life, beliefs about illness, depression, emotional impact of diabetes, and drug use at three years.   
",False,METHODS
4624,The DESMOND program demonstrates no significant impact on weight loss.,RESULTS HbA(1c) levels at three years had decreased in both groups.,False,RESULTS
4625,The DESMOND program demonstrates no significant impact on weight loss.,"After adjusting for baseline and cluster the difference was not significant (difference -0.02, 95% confidence interval -0.22 to 0.17).",False,RESULTS
4626,The DESMOND program demonstrates no significant impact on weight loss.,The groups did not differ for the other biomedical and lifestyle outcomes and drug use.,False,RESULTS
4627,The DESMOND program demonstrates no significant impact on weight loss.,The significant benefits in the intervention group across four out of five health beliefs seen at 12 months were sustained at three years (P<0.01).,False,RESULTS
4628,The DESMOND program demonstrates no significant impact on weight loss.,"Depression scores and quality of life did not differ at three years.   
",False,RESULTS
4629,The DESMOND program demonstrates no significant impact on weight loss.,"CONCLUSION A single programme for people with newly diagnosed type 2 diabetes mellitus showed no difference in biomedical or lifestyle outcomes at three years although there were sustained improvements in some illness beliefs.   
",True,CONCLUSIONS
4630,The DESMOND program demonstrates no significant impact on weight loss.,TRIAL REGISTRATION Current Controlled Trials ISRCTN17844016.,False,CONCLUSIONS
4631,The DdrB protein from Deinococcus radiodurans functions as a pentamer.,Deinococcus spp. are renowned for their amazing ability to recover rapidly from severe genomic fragmentation as a result of exposure to extreme levels of ionizing radiation or desiccation.,False,BACKGROUND
4632,The DdrB protein from Deinococcus radiodurans functions as a pentamer.,"Despite having been originally characterized over 50 years ago, the mechanism underlying this remarkable repair process is still poorly understood.",False,BACKGROUND
4633,The DdrB protein from Deinococcus radiodurans functions as a pentamer.,"Here, we report the 2.8 A structure of DdrB, a single-stranded DNA (ssDNA) binding protein unique to Deinococcus spp.",False,BACKGROUND
4634,The DdrB protein from Deinococcus radiodurans functions as a pentamer.,that is crucial for recovery following DNA damage.,False,BACKGROUND
4635,The DdrB protein from Deinococcus radiodurans functions as a pentamer.,DdrB forms a pentameric ring capable of binding single-stranded but not double-stranded DNA.,True,RESULTS
4636,The DdrB protein from Deinococcus radiodurans functions as a pentamer.,"Unexpectedly, the crystal structure reveals that DdrB comprises a novel fold that is structurally and topologically distinct from all other single-stranded binding (SSB) proteins characterized to date.",False,RESULTS
4637,The DdrB protein from Deinococcus radiodurans functions as a pentamer.,"The need for a unique ssDNA binding function in response to severe damage, suggests a distinct role for DdrB which may encompass not only standard SSB protein function in protection of ssDNA, but also more specialized roles in protein recruitment or DNA architecture maintenance.",False,CONCLUSIONS
4638,The DdrB protein from Deinococcus radiodurans functions as a pentamer.,Possible mechanisms of DdrB action in damage recovery are discussed.,False,CONCLUSIONS
4639,The M2-phenotype in brown adipose tissue macrophages increases brown adipose tissue thermogenic activity.,"All homeotherms use thermogenesis to maintain their core body temperature, ensuring that cellular functions and physiological processes can continue in cold environments.",False,BACKGROUND
4640,The M2-phenotype in brown adipose tissue macrophages increases brown adipose tissue thermogenic activity.,"In the prevailing model of thermogenesis, when the hypothalamus senses cold temperatures it triggers sympathetic discharge, resulting in the release of noradrenaline in brown adipose tissue and white adipose tissue.",False,BACKGROUND
4641,The M2-phenotype in brown adipose tissue macrophages increases brown adipose tissue thermogenic activity.,"Acting via the β(3)-adrenergic receptors, noradrenaline induces lipolysis in white adipocytes, whereas it stimulates the expression of thermogenic genes, such as PPAR-γ coactivator 1a (Ppargc1a), uncoupling protein 1 (Ucp1) and acyl-CoA synthetase long-chain family member 1 (Acsl1), in brown adipocytes.",False,BACKGROUND
4642,The M2-phenotype in brown adipose tissue macrophages increases brown adipose tissue thermogenic activity.,"However, the precise nature of all the cell types involved in this efferent loop is not well established.",False,BACKGROUND
4643,The M2-phenotype in brown adipose tissue macrophages increases brown adipose tissue thermogenic activity.,Here we report in mice an unexpected requirement for the interleukin-4 (IL-4)-stimulated program of alternative macrophage activation in adaptive thermogenesis.,False,BACKGROUND
4644,The M2-phenotype in brown adipose tissue macrophages increases brown adipose tissue thermogenic activity.,"Exposure to cold temperature rapidly promoted alternative activation of adipose tissue macrophages, which secrete catecholamines to induce thermogenic gene expression in brown adipose tissue and lipolysis in white adipose tissue.",True,RESULTS
4645,The M2-phenotype in brown adipose tissue macrophages increases brown adipose tissue thermogenic activity.,"Absence of alternatively activated macrophages impaired metabolic adaptations to cold, whereas administration of IL-4 increased thermogenic gene expression, fatty acid mobilization and energy expenditure, all in a macrophage-dependent manner.",True,RESULTS
4646,The M2-phenotype in brown adipose tissue macrophages increases brown adipose tissue thermogenic activity.,"Thus, we have discovered a role for alternatively activated macrophages in the orchestration of an important mammalian stress response, the response to cold.",False,RESULTS
4647,The NF-κB essential modulator gene induces intestinal inflammation by promoting receptor-interacting protein (RIP) kinase 1 kinase activity-mediated epithelial cell death.,"Intestinal epithelial cells (IECs) regulate gut immune homeostasis, and impaired epithelial responses are implicated in the pathogenesis of inflammatory bowel diseases (IBD).",False,BACKGROUND
4648,The NF-κB essential modulator gene induces intestinal inflammation by promoting receptor-interacting protein (RIP) kinase 1 kinase activity-mediated epithelial cell death.,"IEC-specific ablation of nuclear factor κB (NF-κB) essential modulator (NEMO) caused Paneth cell apoptosis and impaired antimicrobial factor expression in the ileum, as well as colonocyte apoptosis and microbiota-driven chronic inflammation in the colon.",False,BACKGROUND
4649,The NF-κB essential modulator gene induces intestinal inflammation by promoting receptor-interacting protein (RIP) kinase 1 kinase activity-mediated epithelial cell death.,"Combined RelA, c-Rel, and RelB deficiency in IECs caused Paneth cell apoptosis but not colitis, suggesting that NEMO prevents colon inflammation by NF-κB-independent functions.",False,RESULTS
4650,The NF-κB essential modulator gene induces intestinal inflammation by promoting receptor-interacting protein (RIP) kinase 1 kinase activity-mediated epithelial cell death.,"Inhibition of receptor-interacting protein kinase 1 (RIPK1) kinase activity or combined deficiency of Fas-associated via death domain protein (FADD) and RIPK3 prevented epithelial cell death, Paneth cell loss, and colitis development in mice with epithelial NEMO deficiency.",True,RESULTS
4651,The NF-κB essential modulator gene induces intestinal inflammation by promoting receptor-interacting protein (RIP) kinase 1 kinase activity-mediated epithelial cell death.,"Therefore, NEMO prevents intestinal inflammation by inhibiting RIPK1 kinase activity-mediated IEC death, suggesting that RIPK1 inhibitors could be effective in the treatment of colitis in patients with NEMO mutations and possibly in IBD.",True,CONCLUSIONS
4652,The NF-κB essential modulator gene prevents intestinal inflammation by inhibiting receptor-interacting protein (RIP) kinase 1 kinase activity-mediated epithelial cell death.,"Intestinal epithelial cells (IECs) regulate gut immune homeostasis, and impaired epithelial responses are implicated in the pathogenesis of inflammatory bowel diseases (IBD).",False,BACKGROUND
4653,The NF-κB essential modulator gene prevents intestinal inflammation by inhibiting receptor-interacting protein (RIP) kinase 1 kinase activity-mediated epithelial cell death.,"IEC-specific ablation of nuclear factor κB (NF-κB) essential modulator (NEMO) caused Paneth cell apoptosis and impaired antimicrobial factor expression in the ileum, as well as colonocyte apoptosis and microbiota-driven chronic inflammation in the colon.",False,BACKGROUND
4654,The NF-κB essential modulator gene prevents intestinal inflammation by inhibiting receptor-interacting protein (RIP) kinase 1 kinase activity-mediated epithelial cell death.,"Combined RelA, c-Rel, and RelB deficiency in IECs caused Paneth cell apoptosis but not colitis, suggesting that NEMO prevents colon inflammation by NF-κB-independent functions.",False,RESULTS
4655,The NF-κB essential modulator gene prevents intestinal inflammation by inhibiting receptor-interacting protein (RIP) kinase 1 kinase activity-mediated epithelial cell death.,"Inhibition of receptor-interacting protein kinase 1 (RIPK1) kinase activity or combined deficiency of Fas-associated via death domain protein (FADD) and RIPK3 prevented epithelial cell death, Paneth cell loss, and colitis development in mice with epithelial NEMO deficiency.",True,RESULTS
4656,The NF-κB essential modulator gene prevents intestinal inflammation by inhibiting receptor-interacting protein (RIP) kinase 1 kinase activity-mediated epithelial cell death.,"Therefore, NEMO prevents intestinal inflammation by inhibiting RIPK1 kinase activity-mediated IEC death, suggesting that RIPK1 inhibitors could be effective in the treatment of colitis in patients with NEMO mutations and possibly in IBD.",True,CONCLUSIONS
4657,The PDPN gene deactivates the C-type lectin receptor (CLEC-2).,"To initiate adaptive immunity, dendritic cells (DCs) move from parenchymal tissues to lymphoid organs by migrating along stromal scaffolds that display the glycoprotein podoplanin (PDPN).",False,BACKGROUND
4658,The PDPN gene deactivates the C-type lectin receptor (CLEC-2).,"PDPN is expressed by lymphatic endothelial and fibroblastic reticular cells and promotes blood-lymph separation during development by activating the C-type lectin receptor, CLEC-2, on platelets.",True,BACKGROUND
4659,The PDPN gene deactivates the C-type lectin receptor (CLEC-2).,"Here, we describe a role for CLEC-2 in the morphodynamic behavior and motility of DCs.",False,BACKGROUND
4660,The PDPN gene deactivates the C-type lectin receptor (CLEC-2).,"CLEC-2 deficiency in DCs impaired their entry into lymphatics and trafficking to and within lymph nodes, thereby reducing T cell priming.",False,RESULTS
4661,The PDPN gene deactivates the C-type lectin receptor (CLEC-2).,CLEC-2 engagement of PDPN was necessary for DCs to spread and migrate along stromal surfaces and sufficient to induce membrane protrusions.,False,RESULTS
4662,The PDPN gene deactivates the C-type lectin receptor (CLEC-2).,CLEC-2 activation triggered cell spreading via downregulation of RhoA activity and myosin light-chain phosphorylation and triggered F-actin-rich protrusions via Vav signaling and Rac1 activation.,False,CONCLUSIONS
4663,The PDPN gene deactivates the C-type lectin receptor (CLEC-2).,"Thus, activation of CLEC-2 by PDPN rearranges the actin cytoskeleton in DCs to promote efficient motility along stromal surfaces.",True,CONCLUSIONS
4664,The PRDM1 gene is a key determinant of primordial germ cells.,"Blimp1 (Prdm1), the key determinant of primordial germ cells (PGCs), plays a combinatorial role with Prdm14 during PGC specification from postimplantation epiblast cells.",True,BACKGROUND
4665,The PRDM1 gene is a key determinant of primordial germ cells.,"They together initiate epigenetic reprogramming in early germ cells toward an underlying pluripotent state, which is equivalent to embryonic stem cells (ESCs).",False,BACKGROUND
4666,The PRDM1 gene is a key determinant of primordial germ cells.,"Whereas Prdm14 alone can promote reprogramming and is important for the propagation of the pluripotent state, it is not known whether Blimp1 is similarly involved.",False,BACKGROUND
4667,The PRDM1 gene is a key determinant of primordial germ cells.,"By using a genetic approach, we demonstrate that Blimp1 is dispensable for the derivation and maintenance of ESCs and postimplantation epiblast stem cells (epiSCs).",False,BACKGROUND
4668,The PRDM1 gene is a key determinant of primordial germ cells.,"Notably, Blimp1 is also dispensable for reprogramming epiSCs to ESCs.",False,BACKGROUND
4669,The PRDM1 gene is a key determinant of primordial germ cells.,"Thus, although Blimp1 is obligatory for PGC specification, it is not required for the reversion of epiSCs to ESCs and for their maintenance thereafter.",False,BACKGROUND
4670,The PRDM1 gene is a key determinant of primordial germ cells.,"This study suggests that reprogramming, including that of somatic cells to ESCs, may not entail an obligatory route through a Blimp1-positive PGC-like state.",False,BACKGROUND
4671,"The PRDM1 gene, when combined with the PRDM14 gene, plays an important role during primordial germ cell specification.","Blimp1 (Prdm1), the key determinant of primordial germ cells (PGCs), plays a combinatorial role with Prdm14 during PGC specification from postimplantation epiblast cells.",True,BACKGROUND
4672,"The PRDM1 gene, when combined with the PRDM14 gene, plays an important role during primordial germ cell specification.","They together initiate epigenetic reprogramming in early germ cells toward an underlying pluripotent state, which is equivalent to embryonic stem cells (ESCs).",False,BACKGROUND
4673,"The PRDM1 gene, when combined with the PRDM14 gene, plays an important role during primordial germ cell specification.","Whereas Prdm14 alone can promote reprogramming and is important for the propagation of the pluripotent state, it is not known whether Blimp1 is similarly involved.",False,BACKGROUND
4674,"The PRDM1 gene, when combined with the PRDM14 gene, plays an important role during primordial germ cell specification.","By using a genetic approach, we demonstrate that Blimp1 is dispensable for the derivation and maintenance of ESCs and postimplantation epiblast stem cells (epiSCs).",False,BACKGROUND
4675,"The PRDM1 gene, when combined with the PRDM14 gene, plays an important role during primordial germ cell specification.","Notably, Blimp1 is also dispensable for reprogramming epiSCs to ESCs.",False,BACKGROUND
4676,"The PRDM1 gene, when combined with the PRDM14 gene, plays an important role during primordial germ cell specification.","Thus, although Blimp1 is obligatory for PGC specification, it is not required for the reversion of epiSCs to ESCs and for their maintenance thereafter.",False,BACKGROUND
4677,"The PRDM1 gene, when combined with the PRDM14 gene, plays an important role during primordial germ cell specification.","This study suggests that reprogramming, including that of somatic cells to ESCs, may not entail an obligatory route through a Blimp1-positive PGC-like state.",False,BACKGROUND
4678,The RANK-RANK-Ligand (RANKL) pathway is involved in the development of Aire-expressing medullary thymic epithelial cells (mTECs).,"The thymic medulla provides a specialized microenvironment for the negative selection of T cells, with the presence of autoimmune regulator (Aire)-expressing medullary thymic epithelial cells (mTECs) during the embryonic-neonatal period being both necessary and sufficient to establish long-lasting tolerance.",False,BACKGROUND
4679,The RANK-RANK-Ligand (RANKL) pathway is involved in the development of Aire-expressing medullary thymic epithelial cells (mTECs).,"Here we showed that emergence of the first cohorts of Aire(+) mTECs at this key developmental stage, prior to αβ T cell repertoire selection, was jointly directed by Rankl(+) lymphoid tissue inducer cells and invariant Vγ5(+) dendritic epidermal T cell (DETC) progenitors that are the first thymocytes to express the products of gene rearrangement.",True,BACKGROUND
4680,The RANK-RANK-Ligand (RANKL) pathway is involved in the development of Aire-expressing medullary thymic epithelial cells (mTECs).,"In turn, generation of Aire(+) mTECs then fostered Skint-1-dependent, but Aire-independent, DETC progenitor maturation and the emergence of an invariant DETC repertoire.",False,BACKGROUND
4681,The RANK-RANK-Ligand (RANKL) pathway is involved in the development of Aire-expressing medullary thymic epithelial cells (mTECs).,"Hence, our data attributed a functional importance to the temporal development of Vγ5(+) γδ T cells during thymus medulla formation for αβ T cell tolerance induction and demonstrated a Rank-mediated reciprocal link between DETC and Aire(+) mTEC maturation.",True,BACKGROUND
4682,The RANK-RANK-Ligand (RANKL) pathway is involved in the development of Aire-expressing medullary thymic epithelial cells (mTECs).,Medullary thymic epithelial cells (mTECs) establish T cell self-tolerance through the expression of autoimmune regulator (Aire) and peripheral tissue-specific self-antigens.,False,BACKGROUND
4683,The RANK-RANK-Ligand (RANKL) pathway is involved in the development of Aire-expressing medullary thymic epithelial cells (mTECs).,"However, signals underlying mTEC development remain largely unclear.",False,BACKGROUND
4684,The RANK-RANK-Ligand (RANKL) pathway is involved in the development of Aire-expressing medullary thymic epithelial cells (mTECs).,"Here, we demonstrate crucial regulation of mTEC development by receptor activator of NF-kappaB (RANK) and CD40 signals.",True,BACKGROUND
4685,The RANK-RANK-Ligand (RANKL) pathway is involved in the development of Aire-expressing medullary thymic epithelial cells (mTECs).,"Whereas only RANK signaling was essential for mTEC development during embryogenesis, in postnatal mice, cooperation between CD40 and RANK signals was required for mTEC development to successfully establish the medullary microenvironment.",True,RESULTS
4686,The RANK-RANK-Ligand (RANKL) pathway is involved in the development of Aire-expressing medullary thymic epithelial cells (mTECs).,"Ligation of RANK or CD40 on fetal thymic stroma in vitro induced mTEC development in a tumor necrosis factor-associated factor 6 (TRAF6)-, NF-kappaB inducing kinase (NIK)-, and IkappaB kinase beta (IKKbeta)-dependent manner.",True,RESULTS
4687,The RANK-RANK-Ligand (RANKL) pathway is involved in the development of Aire-expressing medullary thymic epithelial cells (mTECs).,"These results show that developmental-stage-dependent cooperation between RANK and CD40 promotes mTEC development, thereby establishing self-tolerance.",True,CONCLUSIONS
4688,The RANK-RANK-Ligand (RANKL) pathway is involved in the development of Aire-expressing medullary thymic epithelial cells (mTECs).,"The thymic medulla provides a microenvironment where medullary thymic epithelial cells (mTECs) express autoimmune regulator and diverse tissue-restricted genes, contributing to launching self-tolerance.",False,BACKGROUND
4689,The RANK-RANK-Ligand (RANKL) pathway is involved in the development of Aire-expressing medullary thymic epithelial cells (mTECs).,Positive selection is essential for thymic medulla formation via a previously unknown mechanism.,False,BACKGROUND
4690,The RANK-RANK-Ligand (RANKL) pathway is involved in the development of Aire-expressing medullary thymic epithelial cells (mTECs).,Here we show that the cytokine RANK ligand (RANKL) was produced by positively selected thymocytes and regulated the cellularity of mTEC by interacting with RANK and osteoprotegerin.,True,BACKGROUND
4691,The RANK-RANK-Ligand (RANKL) pathway is involved in the development of Aire-expressing medullary thymic epithelial cells (mTECs).,"Forced expression of RANKL restored thymic medulla in mice lacking positive selection, whereas RANKL perturbation impaired medulla formation.",False,BACKGROUND
4692,The RANK-RANK-Ligand (RANKL) pathway is involved in the development of Aire-expressing medullary thymic epithelial cells (mTECs).,"These results indicate that RANKL produced by positively selected thymocytes is responsible for fostering thymic medulla formation, thereby establishing central tolerance.",False,BACKGROUND
4693,The RANK-RANK-Ligand (RANKL) pathway is involved in the development of Aire-expressing medullary thymic epithelial cells (mTECs).,Aire-expressing medullary thymic epithelial cells (mTECs) play a key role in preventing autoimmunity by expressing tissue-restricted antigens to help purge the emerging T cell receptor repertoire of self-reactive specificities.,False,BACKGROUND
4694,The RANK-RANK-Ligand (RANKL) pathway is involved in the development of Aire-expressing medullary thymic epithelial cells (mTECs).,"Here we demonstrate a novel role for a CD4+3− inducer cell population, previously linked to development of organized secondary lymphoid structures and maintenance of T cell memory in the functional regulation of Aire-mediated promiscuous gene expression in the thymus.",False,BACKGROUND
4695,The RANK-RANK-Ligand (RANKL) pathway is involved in the development of Aire-expressing medullary thymic epithelial cells (mTECs).,"CD4+3− cells are closely associated with mTECs in adult thymus, and in fetal thymus their appearance is temporally linked with the appearance of Aire+ mTECs.",False,RESULTS
4696,The RANK-RANK-Ligand (RANKL) pathway is involved in the development of Aire-expressing medullary thymic epithelial cells (mTECs).,"We show that RANKL signals from this cell promote the maturation of RANK-expressing CD80−Aire− mTEC progenitors into CD80+Aire+ mTECs, and that transplantation of RANK-deficient thymic stroma into immunodeficient hosts induces autoimmunity.",True,CONCLUSIONS
4697,The RANK-RANK-Ligand (RANKL) pathway is involved in the development of Aire-expressing medullary thymic epithelial cells (mTECs).,"Collectively, our data reveal cellular and molecular mechanisms leading to the generation of Aire+ mTECs and highlight a previously unrecognized role for CD4+3−RANKL+ inducer cells in intrathymic self-tolerance.",True,CONCLUSIONS
4698,The Snf1 complex regulates carbon and energy metabolism in baker's yeast (Saccharomyces cerevisiae).,"Highly conserved among eukaryotic cells, the AMP-activated kinase (AMPK) is a central regulator of carbon metabolism.",False,BACKGROUND
4699,The Snf1 complex regulates carbon and energy metabolism in baker's yeast (Saccharomyces cerevisiae).,"To map the complete network of interactions around AMPK in yeast (Snf1) and to evaluate the role of its regulatory subunit Snf4, we measured global mRNA, protein and metabolite levels in wild type, Deltasnf1, Deltasnf4, and Deltasnf1Deltasnf4 knockout strains.",False,METHODS
4700,The Snf1 complex regulates carbon and energy metabolism in baker's yeast (Saccharomyces cerevisiae).,"Using four newly developed computational tools, including novel DOGMA sub-network analysis, we showed the benefits of three-level ome-data integration to uncover the global Snf1 kinase role in yeast.",False,RESULTS
4701,The Snf1 complex regulates carbon and energy metabolism in baker's yeast (Saccharomyces cerevisiae).,"We for the first time identified Snf1's global regulation on gene and protein expression levels, and showed that yeast Snf1 has a far more extensive function in controlling energy metabolism than reported earlier.",True,RESULTS
4702,The Snf1 complex regulates carbon and energy metabolism in baker's yeast (Saccharomyces cerevisiae).,"Additionally, we identified complementary roles of Snf1 and Snf4.",False,RESULTS
4703,The Snf1 complex regulates carbon and energy metabolism in baker's yeast (Saccharomyces cerevisiae).,"Similar to the function of AMPK in humans, our findings showed that Snf1 is a low-energy checkpoint and that yeast can be used more extensively as a model system for studying the molecular mechanisms underlying the global regulation of AMPK in mammals, failure of which leads to metabolic diseases.",False,CONCLUSIONS
4704,The US health care system can save up to $5 billion if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,CONTEXT Blood type and crossmatch incompatibility will exclude at least one third of patients in need from receiving a live donor kidney transplant.,False,BACKGROUND
4705,The US health care system can save up to $5 billion if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,Kidney paired donation (KPD) offers incompatible donor/recipient pairs the opportunity to match for compatible transplants.,False,BACKGROUND
4706,The US health care system can save up to $5 billion if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,"Despite its increasing popularity, very few transplants have resulted from KPD.   
",False,BACKGROUND
4707,The US health care system can save up to $5 billion if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,"OBJECTIVE To determine the potential impact of improved matching schemes on the number and quality of transplants achievable with KPD.   
",False,OBJECTIVE
4708,The US health care system can save up to $5 billion if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,"DESIGN, SETTING, AND POPULATION We developed a model that simulates pools of incompatible donor/recipient pairs.",False,METHODS
4709,The US health care system can save up to $5 billion if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,We designed a mathematically verifiable optimized matching algorithm and compared it with the scheme currently used in some centers and regions.,False,METHODS
4710,The US health care system can save up to $5 billion if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,"Simulated patients from the general community with characteristics drawn from distributions describing end-stage renal disease patients eligible for renal transplantation and their willing and eligible live donors.   
",False,METHODS
4711,The US health care system can save up to $5 billion if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,"MAIN OUTCOME MEASURES Number of kidneys matched, HLA mismatch of matched kidneys, and number of grafts surviving 5 years after transplantation.   
",False,METHODS
4712,The US health care system can save up to $5 billion if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,"RESULTS A national optimized matching algorithm would result in more transplants (47.7% vs 42.0%, P<.001), better HLA concordance (3.0 vs 4.5 mismatched antigens; P<.001), more grafts surviving at 5 years (34.9% vs 28.7%; P<.001), and a reduction in the number of pairs required to travel (2.9% vs 18.4%; P<.001) when compared with an extension of the currently used first-accept scheme to a national level.",False,RESULTS
4713,The US health care system can save up to $5 billion if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,"Furthermore, highly sensitized patients would benefit 6-fold from a national optimized scheme (2.3% vs 14.1% successfully matched; P<.001).",False,RESULTS
4714,The US health care system can save up to $5 billion if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,"Even if only 7% of patients awaiting kidney transplantation participated in an optimized national KPD program, the health care system could save as much as $750 million.   
",True,CONCLUSIONS
4715,The US health care system can save up to $5 billion if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,CONCLUSIONS The combination of a national KPD program and a mathematically optimized matching algorithm yields more matches with lower HLA disparity.,False,CONCLUSIONS
4716,The US health care system can save up to $5 billion if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,Optimized matching affords patients the flexibility of customizing their matching priorities and the security of knowing that the greatest number of high-quality matches will be found and distributed equitably.,False,CONCLUSIONS
4717,The combination of physical examinations with C-reactive protein values do not improve the accuracy of radiographic verified pneumonia predictions.,"OBJECTIVES To quantify the diagnostic accuracy of selected inflammatory markers in addition to symptoms and signs for predicting pneumonia and to derive a diagnostic tool.   
",False,OBJECTIVE
4718,The combination of physical examinations with C-reactive protein values do not improve the accuracy of radiographic verified pneumonia predictions.,DESIGN Diagnostic study performed between 2007 and 2010.,False,METHODS
4719,The combination of physical examinations with C-reactive protein values do not improve the accuracy of radiographic verified pneumonia predictions.,"Participants had their history taken, underwent physical examination and measurement of C reactive protein (CRP) and procalcitonin in venous blood on the day they first consulted, and underwent chest radiography within seven days.   
",False,METHODS
4720,The combination of physical examinations with C-reactive protein values do not improve the accuracy of radiographic verified pneumonia predictions.,"SETTING Primary care centres in 12 European countries.   
",False,METHODS
4721,The combination of physical examinations with C-reactive protein values do not improve the accuracy of radiographic verified pneumonia predictions.,"PARTICIPANTS Adults presenting with acute cough.   
",False,METHODS
4722,The combination of physical examinations with C-reactive protein values do not improve the accuracy of radiographic verified pneumonia predictions.,"MAIN OUTCOME MEASURES Pneumonia as determined by radiologists, who were blind to all other information when they judged chest radiographs.   
",False,METHODS
4723,The combination of physical examinations with C-reactive protein values do not improve the accuracy of radiographic verified pneumonia predictions.,"RESULTS Of 3106 eligible patients, 286 were excluded because of missing or inadequate chest radiographs, leaving 2820 patients (mean age 50, 40% men) of whom 140 (5%) had pneumonia.",False,RESULTS
4724,The combination of physical examinations with C-reactive protein values do not improve the accuracy of radiographic verified pneumonia predictions.,"Re-assessment of a subset of 1675 chest radiographs showed agreement in 94% (κ 0.45, 95% confidence interval 0.36 to 0.54).",False,RESULTS
4725,The combination of physical examinations with C-reactive protein values do not improve the accuracy of radiographic verified pneumonia predictions.,"Six published ""symptoms and signs models"" varied in their discrimination (area under receiver operating characteristics curve (ROC) ranged from 0.55 (95% confidence interval 0.50 to 0.61) to 0.71 (0.66 to 0.76)).",False,RESULTS
4726,The combination of physical examinations with C-reactive protein values do not improve the accuracy of radiographic verified pneumonia predictions.,"The optimal combination of clinical prediction items derived from our patients included absence of runny nose and presence of breathlessness, crackles and diminished breath sounds on auscultation, tachycardia, and fever, with an ROC area of 0.70 (0.65 to 0.75).",False,RESULTS
4727,The combination of physical examinations with C-reactive protein values do not improve the accuracy of radiographic verified pneumonia predictions.,Addition of CRP at the optimal cut off of >30 mg/L increased the ROC area to 0.77 (0.73 to 0.81) and improved the diagnostic classification (net reclassification improvement 28%).,True,RESULTS
4728,The combination of physical examinations with C-reactive protein values do not improve the accuracy of radiographic verified pneumonia predictions.,"In the 1556 patients classified according to symptoms, signs, and CRP >30 mg/L as ""low risk"" (<2.5%) for pneumonia, the prevalence of pneumonia was 2%.",False,RESULTS
4729,The combination of physical examinations with C-reactive protein values do not improve the accuracy of radiographic verified pneumonia predictions.,"In the 132 patients classified as ""high risk"" (>20%), the prevalence of pneumonia was 31%.",False,RESULTS
4730,The combination of physical examinations with C-reactive protein values do not improve the accuracy of radiographic verified pneumonia predictions.,"The positive likelihood ratio of low, intermediate, and high risk for pneumonia was 0.4, 1.2, and 8.6 respectively.",False,RESULTS
4731,The combination of physical examinations with C-reactive protein values do not improve the accuracy of radiographic verified pneumonia predictions.,Measurement of procalcitonin added no relevant additional diagnostic information.,False,RESULTS
4732,The combination of physical examinations with C-reactive protein values do not improve the accuracy of radiographic verified pneumonia predictions.,"A simplified diagnostic score based on symptoms, signs, and CRP >30 mg/L resulted in proportions of pneumonia of 0.7%, 3.8%, and 18.2% in the low, intermediate, and high risk group respectively.   
",False,RESULTS
4733,The combination of physical examinations with C-reactive protein values do not improve the accuracy of radiographic verified pneumonia predictions.,CONCLUSIONS A clinical rule based on symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough performed best in patients with mild or severe clinical presentation.,False,CONCLUSIONS
4734,The combination of physical examinations with C-reactive protein values do not improve the accuracy of radiographic verified pneumonia predictions.,"Addition of CRP concentration at the optimal cut off of >30 mg/L improved diagnostic information, but measurement of procalcitonin concentration did not add clinically relevant information in this group.",True,CONCLUSIONS
4735,The deamination of cytidine to uridine on the minus strand of viral DNA can inactivate the viral genome by inducing G-to-A mutations.,"Viral replication usually requires that innate intracellular lines of defence be overcome, a task usually accomplished by specialized viral gene products.",False,BACKGROUND
4736,The deamination of cytidine to uridine on the minus strand of viral DNA can inactivate the viral genome by inducing G-to-A mutations.,"The virion infectivity factor (Vif) protein of human immunodeficiency virus (HIV) is required during the late stages of viral production to counter the antiviral activity of APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G; also known as CEM15), a protein expressed notably in human T lymphocytes.",False,BACKGROUND
4737,The deamination of cytidine to uridine on the minus strand of viral DNA can inactivate the viral genome by inducing G-to-A mutations.,"When produced in the presence of APOBEC3G, vif-defective virus is non-infectious.",False,BACKGROUND
4738,The deamination of cytidine to uridine on the minus strand of viral DNA can inactivate the viral genome by inducing G-to-A mutations.,"APOBEC3G is closely related to APOBEC1, the central component of an RNA-editing complex that deaminates a cytosine residue in apoB messenger RNA.",True,BACKGROUND
4739,The deamination of cytidine to uridine on the minus strand of viral DNA can inactivate the viral genome by inducing G-to-A mutations.,"APOBEC family members also have potent DNA mutator activity through dC deamination; however, whether the editing potential of APOBEC3G has any relevance to HIV inhibition is unknown.",False,BACKGROUND
4740,The deamination of cytidine to uridine on the minus strand of viral DNA can inactivate the viral genome by inducing G-to-A mutations.,"Here, we demonstrate that it does, as APOBEC3G exerts its antiviral effect during reverse transcription to trigger G-to-A hypermutation in the nascent retroviral DNA.",True,BACKGROUND
4741,The deamination of cytidine to uridine on the minus strand of viral DNA can inactivate the viral genome by inducing G-to-A mutations.,"We also find that APOBEC3G can act on a broad range of retroviruses in addition to HIV, suggesting that hypermutation by editing is a general innate defence mechanism against this important group of pathogens.",False,BACKGROUND
4742,The density of cytokine receptor bearing cells affects the distance over which cytokines act.,"&NA; Immune cells communicate by exchanging cytokines to achieve a context‐appropriate response, but the distances over which such communication happens are not known.",False,BACKGROUND
4743,The density of cytokine receptor bearing cells affects the distance over which cytokines act.,"Here, we used theoretical considerations and experimental models of immune responses in vitro and in vivo to quantify the spatial extent of cytokine communications in dense tissues.",False,BACKGROUND
4744,The density of cytokine receptor bearing cells affects the distance over which cytokines act.,We established that competition between cytokine diffusion and consumption generated spatial niches of high cytokine concentrations with sharp boundaries.,False,RESULTS
4745,The density of cytokine receptor bearing cells affects the distance over which cytokines act.,"The size of these self‐assembled niches scaled with the density of cytokine‐consuming cells, a parameter that gets tuned during immune responses.",False,RESULTS
4746,The density of cytokine receptor bearing cells affects the distance over which cytokines act.,"In vivo, we measured interactions on length scales of 80–120 &mgr;m, which resulted in a high degree of cell‐to‐cell variance in cytokine exposure.",False,RESULTS
4747,The density of cytokine receptor bearing cells affects the distance over which cytokines act.,Such heterogeneous distributions of cytokines were a source of non‐genetic cell‐to‐cell variability that is often overlooked in single‐cell studies.,False,RESULTS
4748,The density of cytokine receptor bearing cells affects the distance over which cytokines act.,Our findings thus provide a basis for understanding variability in the patterning of immune responses by diffusible factors.,False,RESULTS
4749,The density of cytokine receptor bearing cells affects the distance over which cytokines act.,Graphical Abstract Figure.,False,RESULTS
4750,The density of cytokine receptor bearing cells affects the distance over which cytokines act.,No caption available.,False,RESULTS
4751,The density of cytokine receptor bearing cells affects the distance over which cytokines act.,"HighlightsCytokine penetration in tissues is governed by a diffusion‐consumption mechanismSpherical cytokine niches are generated around cytokine‐producing cellsThe characteristic niche size depends on the density of cytokine consumersCytokine niches are a source of variability in otherwise identical cells &NA; Cytokine‐mediated communication allows immune cells to achieve a context‐appropriate response, but the distance over which this communication happens is unclear.",True,CONCLUSIONS
4752,The density of cytokine receptor bearing cells affects the distance over which cytokines act.,Oyler‐Yaniv et al. (2017) show that a simple diffusion‐consumption mechanism quantitatively describes the spatial spread of cytokines in vivo and results in localized niches of high cytokine concentrations that contribute to cell‐to‐cell variability.,False,CONCLUSIONS
4753,The density of cytokine receptor bearing cells has no effect on the distance over which cytokines act.,"&NA; Immune cells communicate by exchanging cytokines to achieve a context‐appropriate response, but the distances over which such communication happens are not known.",False,BACKGROUND
4754,The density of cytokine receptor bearing cells has no effect on the distance over which cytokines act.,"Here, we used theoretical considerations and experimental models of immune responses in vitro and in vivo to quantify the spatial extent of cytokine communications in dense tissues.",False,BACKGROUND
4755,The density of cytokine receptor bearing cells has no effect on the distance over which cytokines act.,We established that competition between cytokine diffusion and consumption generated spatial niches of high cytokine concentrations with sharp boundaries.,False,RESULTS
4756,The density of cytokine receptor bearing cells has no effect on the distance over which cytokines act.,"The size of these self‐assembled niches scaled with the density of cytokine‐consuming cells, a parameter that gets tuned during immune responses.",False,RESULTS
4757,The density of cytokine receptor bearing cells has no effect on the distance over which cytokines act.,"In vivo, we measured interactions on length scales of 80–120 &mgr;m, which resulted in a high degree of cell‐to‐cell variance in cytokine exposure.",False,RESULTS
4758,The density of cytokine receptor bearing cells has no effect on the distance over which cytokines act.,Such heterogeneous distributions of cytokines were a source of non‐genetic cell‐to‐cell variability that is often overlooked in single‐cell studies.,False,RESULTS
4759,The density of cytokine receptor bearing cells has no effect on the distance over which cytokines act.,Our findings thus provide a basis for understanding variability in the patterning of immune responses by diffusible factors.,False,RESULTS
4760,The density of cytokine receptor bearing cells has no effect on the distance over which cytokines act.,Graphical Abstract Figure.,False,RESULTS
4761,The density of cytokine receptor bearing cells has no effect on the distance over which cytokines act.,No caption available.,False,RESULTS
4762,The density of cytokine receptor bearing cells has no effect on the distance over which cytokines act.,"HighlightsCytokine penetration in tissues is governed by a diffusion‐consumption mechanismSpherical cytokine niches are generated around cytokine‐producing cellsThe characteristic niche size depends on the density of cytokine consumersCytokine niches are a source of variability in otherwise identical cells &NA; Cytokine‐mediated communication allows immune cells to achieve a context‐appropriate response, but the distance over which this communication happens is unclear.",True,CONCLUSIONS
4763,The density of cytokine receptor bearing cells has no effect on the distance over which cytokines act.,Oyler‐Yaniv et al. (2017) show that a simple diffusion‐consumption mechanism quantitatively describes the spatial spread of cytokines in vivo and results in localized niches of high cytokine concentrations that contribute to cell‐to‐cell variability.,False,CONCLUSIONS
4764,The generation of reactive oxygen species by activated oncogenes contributes to the increased genomic instability of leukaemia cells.,The oncogenic BCR/ABL tyrosine kinase induces constitutive DNA damage in Philadelphia chromosome (Ph)-positive leukemia cells.,True,BACKGROUND
4765,The generation of reactive oxygen species by activated oncogenes contributes to the increased genomic instability of leukaemia cells.,We find that BCR/ABL-induced reactive oxygen species (ROSs) cause chronic oxidative DNA damage resulting in double-strand breaks (DSBs) in S and G(2)/M cell cycle phases.,True,BACKGROUND
4766,The generation of reactive oxygen species by activated oncogenes contributes to the increased genomic instability of leukaemia cells.,These lesions are repaired by BCR/ABL-stimulated homologous recombination repair (HRR) and nonhomologous end-joining (NHEJ) mechanisms.,False,BACKGROUND
4767,The generation of reactive oxygen species by activated oncogenes contributes to the increased genomic instability of leukaemia cells.,"A high mutation rate is detected in HRR products in BCR/ABL-positive cells, but not in the normal counterparts.",False,BACKGROUND
4768,The generation of reactive oxygen species by activated oncogenes contributes to the increased genomic instability of leukaemia cells.,"In addition, large deletions are found in NHEJ products exclusively in BCR/ABL cells.",False,BACKGROUND
4769,The generation of reactive oxygen species by activated oncogenes contributes to the increased genomic instability of leukaemia cells.,We propose that the following series of events may contribute to genomic instability of Ph-positive leukemias: BCR/ABL --> ROSs --> oxidative DNA damage --> DSBs in proliferating cells --> unfaithful HRR and NHEJ repair.,True,BACKGROUND
4770,The innate immune response struggles to remove small numbers of parasites.,"Immune clearance and resource limitation (via red blood cell depletion) shape the peaks and troughs of malaria parasitemia, which in turn affect disease severity and transmission.",False,BACKGROUND
4771,The innate immune response struggles to remove small numbers of parasites.,Quantitatively partitioning the relative roles of these effects through time is challenging.,False,BACKGROUND
4772,The innate immune response struggles to remove small numbers of parasites.,"Using data from rodent malaria, we estimated the effective propagation number, which reflects the relative importance of contrasting within-host control mechanisms through time and is sensitive to the inoculating parasite dose.",False,METHODS
4773,The innate immune response struggles to remove small numbers of parasites.,Our analysis showed that the capacity of innate responses to restrict initial parasite growth saturates with parasite dose and that experimentally enhanced innate immunity can affect parasite density indirectly via resource depletion.,True,CONCLUSIONS
4774,The innate immune response struggles to remove small numbers of parasites.,Such a statistical approach offers a tool to improve targeting of drugs or vaccines for human therapy by revealing the dynamics and interactions of within-host regulatory mechanisms.,False,CONCLUSIONS
4775,The latent infection of myeloid cells with human cytomegalovirus induces a number of changes in gene expression.,Human cytomegalovirus (HCMV) is one of the largest known DNA viruses.,False,BACKGROUND
4776,The latent infection of myeloid cells with human cytomegalovirus induces a number of changes in gene expression.,"It is ubiquitous, and following resolution of primary productive infection, it persists in the human host by establishing a lifelong latent infection in myeloid lineage cells such as monocytes and their progenitors.",False,BACKGROUND
4777,The latent infection of myeloid cells with human cytomegalovirus induces a number of changes in gene expression.,"Most adults with HCMV infection are healthy but it can cause neurologic deficits in infants, and remains an important cause of morbidity and mortality in the immunosuppressed patient.",False,BACKGROUND
4778,The latent infection of myeloid cells with human cytomegalovirus induces a number of changes in gene expression.,Microarray-based studies of HCMV have provided useful information about genes that are transcriptionally active during both productive and latent phases of infection.,True,BACKGROUND
4779,The latent infection of myeloid cells with human cytomegalovirus induces a number of changes in gene expression.,"This chapter describes how to study genes in HCMV using microarrays and two cell types (productively infected human foreskin fibroblasts, and latently infected primary human myeloid progenitor cells).",False,BACKGROUND
4780,The latent infection of myeloid cells with human cytomegalovirus induces a number of changes in gene expression.,Monocytes are primary targets for human CMV (HCMV) infection and are proposed to be responsible for hematogenous dissemination of the virus.,False,BACKGROUND
4781,The latent infection of myeloid cells with human cytomegalovirus induces a number of changes in gene expression.,Monocytes acquire different functional traits during polarization to the classical proinflammatory M1 macrophage or the alternative antiinflammatory M2 macrophage.,False,BACKGROUND
4782,The latent infection of myeloid cells with human cytomegalovirus induces a number of changes in gene expression.,"We hypothesized that HCMV induced a proinflammatory M1 macrophage following infection to promote viral dissemination because, biologically, a proinflammatory state provides the tools to drive infected monocytes from the blood into the tissue.",False,BACKGROUND
4783,The latent infection of myeloid cells with human cytomegalovirus induces a number of changes in gene expression.,"To test this hypothesis of monocyte conversion from a normal quiescent phenotype to an inflammatory phenotype, we used Affymetrix Microarray to acquire a transcriptional profile of infected monocytes at a time point our data emphasized is a key temporal regulatory point following infection.",False,METHODS
4784,The latent infection of myeloid cells with human cytomegalovirus induces a number of changes in gene expression.,We found that HCMV significantly up-regulated 583 (5.2%) of the total genes and down-regulated 621 (5.5%) of the total genes>or=1.5-fold at 4 h postinfection.,True,RESULTS
4785,The latent infection of myeloid cells with human cytomegalovirus induces a number of changes in gene expression.,Further ontology analysis revealed that genes implicated in classical M1 macrophage activation were stimulated by HCMV infection.,True,RESULTS
4786,The latent infection of myeloid cells with human cytomegalovirus induces a number of changes in gene expression.,"We found that 65% of genes strictly associated with M1 polarization were up-regulated, while only 4% of genes solely associated with M2 polarization were up-regulated.",False,RESULTS
4787,The latent infection of myeloid cells with human cytomegalovirus induces a number of changes in gene expression.,Analysis of the monocyte chemokinome at the transcriptional level showed that 44% of M1 and 33% of M2 macrophage chemokines were up-regulated.,False,RESULTS
4788,The latent infection of myeloid cells with human cytomegalovirus induces a number of changes in gene expression.,Proteomic analysis using chemokine Ab arrays confirmed the secretion of these chemotactic proteins from HCMV-infected monocytes.,False,RESULTS
4789,The latent infection of myeloid cells with human cytomegalovirus induces a number of changes in gene expression.,"Overall, the results identify that the HCMV-infected monocyte transcriptome displayed a unique M1/M2 polarization signature that was skewed toward the classical M1 activation phenotype.",True,CONCLUSIONS
4790,The mean suicide rate in women is higher after miscarriage than live birth.,"OBJECTIVE To determine rates of suicide associated with pregnancy by the type of pregnancy.   
",False,OBJECTIVE
4791,The mean suicide rate in women is higher after miscarriage than live birth.,DESIGN Register linkage study.,False,METHODS
4792,The mean suicide rate in women is higher after miscarriage than live birth.,"Information on suicides in women of reproductive age was linked with the Finnish birth, abortion, and hospital discharge registers to find out how many women who committed suicide had had a completed pregnancy during her last year of life.   
",False,METHODS
4793,The mean suicide rate in women is higher after miscarriage than live birth.,SETTING Nationwide data from Finland.   ,False,METHODS
4794,The mean suicide rate in women is higher after miscarriage than live birth.,"SUBJECTS Women who committed suicide in 1987-94.   
",False,RESULTS
4795,The mean suicide rate in women is higher after miscarriage than live birth.,"RESULTS There were 73 suicides associated with pregnancy, representing 5.4% of all suicides in women in this age group.",False,RESULTS
4796,The mean suicide rate in women is higher after miscarriage than live birth.,"The mean annual suicide rate was 11.3 per 100,000.",False,RESULTS
4797,The mean suicide rate in women is higher after miscarriage than live birth.,The suicide rate associated with birth was significantly lower (5.9) and the rates associated with miscarriage (18.1) and induced abortion (34.7) were significantly higher than in the population.,True,RESULTS
4798,The mean suicide rate in women is higher after miscarriage than live birth.,The risk associated with birth was higher among teenagers and that associated with abortion was increased in all age groups.,False,RESULTS
4799,The mean suicide rate in women is higher after miscarriage than live birth.,"Women who had committed a suicide tended to come from lower social classes and were more likely to be unmarried than other women who had had a completed pregnancy.   
",False,RESULTS
4800,The mean suicide rate in women is higher after miscarriage than live birth.,CONCLUSIONS The increased risk of suicide after an induced abortion indicates either common risk factors for both or harmful effects of induced abortion on mental health.,False,CONCLUSIONS
4801,The mean suicide rate in women is lower after miscarriage than live birth.,"OBJECTIVE To determine rates of suicide associated with pregnancy by the type of pregnancy.   
",False,OBJECTIVE
4802,The mean suicide rate in women is lower after miscarriage than live birth.,DESIGN Register linkage study.,False,METHODS
4803,The mean suicide rate in women is lower after miscarriage than live birth.,"Information on suicides in women of reproductive age was linked with the Finnish birth, abortion, and hospital discharge registers to find out how many women who committed suicide had had a completed pregnancy during her last year of life.   
",False,METHODS
4804,The mean suicide rate in women is lower after miscarriage than live birth.,SETTING Nationwide data from Finland.   ,False,METHODS
4805,The mean suicide rate in women is lower after miscarriage than live birth.,"SUBJECTS Women who committed suicide in 1987-94.   
",False,RESULTS
4806,The mean suicide rate in women is lower after miscarriage than live birth.,"RESULTS There were 73 suicides associated with pregnancy, representing 5.4% of all suicides in women in this age group.",False,RESULTS
4807,The mean suicide rate in women is lower after miscarriage than live birth.,"The mean annual suicide rate was 11.3 per 100,000.",False,RESULTS
4808,The mean suicide rate in women is lower after miscarriage than live birth.,The suicide rate associated with birth was significantly lower (5.9) and the rates associated with miscarriage (18.1) and induced abortion (34.7) were significantly higher than in the population.,True,RESULTS
4809,The mean suicide rate in women is lower after miscarriage than live birth.,The risk associated with birth was higher among teenagers and that associated with abortion was increased in all age groups.,False,RESULTS
4810,The mean suicide rate in women is lower after miscarriage than live birth.,"Women who had committed a suicide tended to come from lower social classes and were more likely to be unmarried than other women who had had a completed pregnancy.   
",False,RESULTS
4811,The mean suicide rate in women is lower after miscarriage than live birth.,CONCLUSIONS The increased risk of suicide after an induced abortion indicates either common risk factors for both or harmful effects of induced abortion on mental health.,False,CONCLUSIONS
4812,The microtubule-dependent delivery and secretion of matrix metalloproteases (MMPs) is partially responsible for the disassembly of adhesion sites.,Turnover of integrin-based focal adhesions (FAs) with the extracellular matrix (ECM) is essential for coordinated cell movement.,False,BACKGROUND
4813,The microtubule-dependent delivery and secretion of matrix metalloproteases (MMPs) is partially responsible for the disassembly of adhesion sites.,"In collectively migrating human keratinocytes, FAs assemble near the leading edge, grow and mature as a result of contractile forces and disassemble underneath the advancing cell body.",False,BACKGROUND
4814,The microtubule-dependent delivery and secretion of matrix metalloproteases (MMPs) is partially responsible for the disassembly of adhesion sites.,We report that clustering of microtubule-associated CLASP1 and CLASP2 proteins around FAs temporally correlates with FA turnover.,False,RESULTS
4815,The microtubule-dependent delivery and secretion of matrix metalloproteases (MMPs) is partially responsible for the disassembly of adhesion sites.,"CLASPs and LL5β (also known as PHLDB2), which recruits CLASPs to FAs, facilitate FA disassembly.",False,RESULTS
4816,The microtubule-dependent delivery and secretion of matrix metalloproteases (MMPs) is partially responsible for the disassembly of adhesion sites.,"CLASPs are further required for FA-associated ECM degradation, and matrix metalloprotease inhibition slows FA disassembly similarly to CLASP or PHLDB2 (LL5β) depletion.",True,RESULTS
4817,The microtubule-dependent delivery and secretion of matrix metalloproteases (MMPs) is partially responsible for the disassembly of adhesion sites.,"Finally, CLASP-mediated microtubule tethering at FAs establishes an FA-directed transport pathway for delivery, docking and localized fusion of exocytic vesicles near FAs.",False,CONCLUSIONS
4818,The microtubule-dependent delivery and secretion of matrix metalloproteases (MMPs) is partially responsible for the disassembly of adhesion sites.,"We propose that CLASPs couple microtubule organization, vesicle transport and cell interactions with the ECM, establishing a local secretion pathway that facilitates FA turnover by severing cell-matrix connections.",False,CONCLUSIONS
4819,The minor G allele of FOXO3 downregulates pro-inflammatory cytokines.,"The clinical course and eventual outcome, or prognosis, of complex diseases varies enormously between affected individuals.",False,BACKGROUND
4820,The minor G allele of FOXO3 downregulates pro-inflammatory cytokines.,This variability critically determines the impact a disease has on a patient's life but is very poorly understood.,False,BACKGROUND
4821,The minor G allele of FOXO3 downregulates pro-inflammatory cytokines.,"Here, we exploit existing genome-wide association study data to gain insight into the role of genetics in prognosis.",False,BACKGROUND
4822,The minor G allele of FOXO3 downregulates pro-inflammatory cytokines.,"We identify a noncoding polymorphism in FOXO3A (rs12212067: T > G) at which the minor (G) allele, despite not being associated with disease susceptibility, is associated with a milder course of Crohn's disease and rheumatoid arthritis and with increased risk of severe malaria.",False,RESULTS
4823,The minor G allele of FOXO3 downregulates pro-inflammatory cytokines.,"Minor allele carriage is shown to limit inflammatory responses in monocytes via a FOXO3-driven pathway, which through TGFβ1 reduces production of proinflammatory cytokines, including TNFα, and increases production of anti-inflammatory cytokines, including IL-10.",True,CONCLUSIONS
4824,The minor G allele of FOXO3 downregulates pro-inflammatory cytokines.,"Thus, we uncover a shared genetic contribution to prognosis in distinct diseases that operates via a FOXO3-driven pathway modulating inflammatory responses.",False,CONCLUSIONS
4825,The minor G allele of FOXO3 is related to less severe symptoms of Crohn's Disease.,"The clinical course and eventual outcome, or prognosis, of complex diseases varies enormously between affected individuals.",False,BACKGROUND
4826,The minor G allele of FOXO3 is related to less severe symptoms of Crohn's Disease.,This variability critically determines the impact a disease has on a patient's life but is very poorly understood.,False,BACKGROUND
4827,The minor G allele of FOXO3 is related to less severe symptoms of Crohn's Disease.,"Here, we exploit existing genome-wide association study data to gain insight into the role of genetics in prognosis.",False,BACKGROUND
4828,The minor G allele of FOXO3 is related to less severe symptoms of Crohn's Disease.,"We identify a noncoding polymorphism in FOXO3A (rs12212067: T > G) at which the minor (G) allele, despite not being associated with disease susceptibility, is associated with a milder course of Crohn's disease and rheumatoid arthritis and with increased risk of severe malaria.",True,RESULTS
4829,The minor G allele of FOXO3 is related to less severe symptoms of Crohn's Disease.,"Minor allele carriage is shown to limit inflammatory responses in monocytes via a FOXO3-driven pathway, which through TGFβ1 reduces production of proinflammatory cytokines, including TNFα, and increases production of anti-inflammatory cytokines, including IL-10.",False,CONCLUSIONS
4830,The minor G allele of FOXO3 is related to less severe symptoms of Crohn's Disease.,"Thus, we uncover a shared genetic contribution to prognosis in distinct diseases that operates via a FOXO3-driven pathway modulating inflammatory responses.",False,CONCLUSIONS
4831,The minor G allele of FOXO3 up-regulates IL-10.,"The clinical course and eventual outcome, or prognosis, of complex diseases varies enormously between affected individuals.",False,BACKGROUND
4832,The minor G allele of FOXO3 up-regulates IL-10.,This variability critically determines the impact a disease has on a patient's life but is very poorly understood.,False,BACKGROUND
4833,The minor G allele of FOXO3 up-regulates IL-10.,"Here, we exploit existing genome-wide association study data to gain insight into the role of genetics in prognosis.",False,BACKGROUND
4834,The minor G allele of FOXO3 up-regulates IL-10.,"We identify a noncoding polymorphism in FOXO3A (rs12212067: T > G) at which the minor (G) allele, despite not being associated with disease susceptibility, is associated with a milder course of Crohn's disease and rheumatoid arthritis and with increased risk of severe malaria.",False,RESULTS
4835,The minor G allele of FOXO3 up-regulates IL-10.,"Minor allele carriage is shown to limit inflammatory responses in monocytes via a FOXO3-driven pathway, which through TGFβ1 reduces production of proinflammatory cytokines, including TNFα, and increases production of anti-inflammatory cytokines, including IL-10.",True,CONCLUSIONS
4836,The minor G allele of FOXO3 up-regulates IL-10.,"Thus, we uncover a shared genetic contribution to prognosis in distinct diseases that operates via a FOXO3-driven pathway modulating inflammatory responses.",False,CONCLUSIONS
4837,The most prevalent adverse events to Semaglutide are cardiovascular.,Importance Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the treatment of type 2 diabetes and are all currently available as an injection.,False,OBJECTIVE
4838,The most prevalent adverse events to Semaglutide are cardiovascular.,Objectives To compare the effects of oral semaglutide with placebo (primary) and open-label subcutaneous semaglutide (secondary) on glycemic control in patients with type 2 diabetes.,False,OBJECTIVE
4839,The most prevalent adverse events to Semaglutide are cardiovascular.,"Design, Setting, and Patients Phase 2, randomized, parallel-group, dosage-finding, 26-week trial with 5-week follow-up at 100 sites (hospital clinics, general practices, and clinical research centers) in 14 countries conducted between December 2013 and December 2014.",False,METHODS
4840,The most prevalent adverse events to Semaglutide are cardiovascular.,"Of 1106 participants assessed, 632 with type 2 diabetes and insufficient glycemic control using diet and exercise alone or a stable dose of metformin were randomized.",False,METHODS
4841,The most prevalent adverse events to Semaglutide are cardiovascular.,Randomization was stratified by metformin use.,False,METHODS
4842,The most prevalent adverse events to Semaglutide are cardiovascular.,"Interventions Once-daily oral semaglutide of 2.5 mg (n = 70), 5 mg (n = 70), 10 mg (n = 70), 20 mg (n = 70), 40-mg 4-week dose escalation (standard escalation; n = 71), 40-mg 8-week dose escalation (slow escalation; n = 70), 40-mg 2-week dose escalation (fast escalation, n = 70), oral placebo (n = 71; double-blind) or once-weekly subcutaneous semaglutide of 1.0 mg (n = 70) for 26 weeks.",False,METHODS
4843,The most prevalent adverse events to Semaglutide are cardiovascular.,Main Outcomes and Measures The primary end point was change in hemoglobing A1c (HbA1c) from baseline to week 26.,False,METHODS
4844,The most prevalent adverse events to Semaglutide are cardiovascular.,Secondary end points included change from baseline in body weight and adverse events.,False,METHODS
4845,The most prevalent adverse events to Semaglutide are cardiovascular.,Results Baseline characteristics were comparable across treatment groups.,False,RESULTS
4846,The most prevalent adverse events to Semaglutide are cardiovascular.,"Of the 632 randomized patients (mean age, 57.1 years [SD, 10.6]; men, 395 (62.7%); diabetes duration, 6.3 years [SD, 5.2]; body weight, 92.3 kg [SD, 16.8]; BMI, 31.7 [SD, 4.3]), 583 (92%) completed the trial.",False,RESULTS
4847,The most prevalent adverse events to Semaglutide are cardiovascular.,"Mean change in HbA1c level from baseline to week 26 decreased with oral semaglutide (dosage-dependent range, −0.7% to −1.9%) and subcutaneous semaglutide (−1.9%) and placebo (−0.3%); oral semaglutide reductions were significant vs placebo (dosage-dependent estimated treatment difference [ETD] range for oral semaglutide vs placebo, –0.4% to –1.6%; P = .01 for 2.5 mg, <.001 for all other dosages).",False,RESULTS
4848,The most prevalent adverse events to Semaglutide are cardiovascular.,"Reductions in body weight were greater with oral semaglutide (dosage-dependent range, −2.1 kg to −6.9 kg) and subcutaneous semaglutide (−6.4 kg) vs placebo (−1.2 kg), and significant for oral semaglutide dosages of 10 mg or more vs placebo (dosage-dependent ETD range, –0.9 to –5.7 kg; P < .001).",False,RESULTS
4849,The most prevalent adverse events to Semaglutide are cardiovascular.,"Adverse events were reported by 63% to 86% (371 of 490 patients) in the oral semaglutide groups, 81% (56 of 69 patients) in the subcutaneous semaglutide group, and 68% (48 of 71 patients) in the placebo group; mild to moderate gastrointestinal events were most common.",True,RESULTS
4850,The most prevalent adverse events to Semaglutide are cardiovascular.,"Conclusions and Relevance Among patients with type 2 diabetes, oral semaglutide resulted in better glycemic control than placebo over 26 weeks.",False,CONCLUSIONS
4851,The most prevalent adverse events to Semaglutide are cardiovascular.,"These findings support phase 3 studies to assess longer-term and clinical outcomes, as well as safety.",False,CONCLUSIONS
4852,The most prevalent adverse events to Semaglutide are cardiovascular.,Trial Registration clinicaltrials.gov Identifier: NCT01923181,False,CONCLUSIONS
4853,The most prevalent adverse events to Semaglutide are gastrointestinal.,Importance Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the treatment of type 2 diabetes and are all currently available as an injection.,False,OBJECTIVE
4854,The most prevalent adverse events to Semaglutide are gastrointestinal.,Objectives To compare the effects of oral semaglutide with placebo (primary) and open-label subcutaneous semaglutide (secondary) on glycemic control in patients with type 2 diabetes.,False,OBJECTIVE
4855,The most prevalent adverse events to Semaglutide are gastrointestinal.,"Design, Setting, and Patients Phase 2, randomized, parallel-group, dosage-finding, 26-week trial with 5-week follow-up at 100 sites (hospital clinics, general practices, and clinical research centers) in 14 countries conducted between December 2013 and December 2014.",False,METHODS
4856,The most prevalent adverse events to Semaglutide are gastrointestinal.,"Of 1106 participants assessed, 632 with type 2 diabetes and insufficient glycemic control using diet and exercise alone or a stable dose of metformin were randomized.",False,METHODS
4857,The most prevalent adverse events to Semaglutide are gastrointestinal.,Randomization was stratified by metformin use.,False,METHODS
4858,The most prevalent adverse events to Semaglutide are gastrointestinal.,"Interventions Once-daily oral semaglutide of 2.5 mg (n = 70), 5 mg (n = 70), 10 mg (n = 70), 20 mg (n = 70), 40-mg 4-week dose escalation (standard escalation; n = 71), 40-mg 8-week dose escalation (slow escalation; n = 70), 40-mg 2-week dose escalation (fast escalation, n = 70), oral placebo (n = 71; double-blind) or once-weekly subcutaneous semaglutide of 1.0 mg (n = 70) for 26 weeks.",False,METHODS
4859,The most prevalent adverse events to Semaglutide are gastrointestinal.,Main Outcomes and Measures The primary end point was change in hemoglobing A1c (HbA1c) from baseline to week 26.,False,METHODS
4860,The most prevalent adverse events to Semaglutide are gastrointestinal.,Secondary end points included change from baseline in body weight and adverse events.,False,METHODS
4861,The most prevalent adverse events to Semaglutide are gastrointestinal.,Results Baseline characteristics were comparable across treatment groups.,False,RESULTS
4862,The most prevalent adverse events to Semaglutide are gastrointestinal.,"Of the 632 randomized patients (mean age, 57.1 years [SD, 10.6]; men, 395 (62.7%); diabetes duration, 6.3 years [SD, 5.2]; body weight, 92.3 kg [SD, 16.8]; BMI, 31.7 [SD, 4.3]), 583 (92%) completed the trial.",False,RESULTS
4863,The most prevalent adverse events to Semaglutide are gastrointestinal.,"Mean change in HbA1c level from baseline to week 26 decreased with oral semaglutide (dosage-dependent range, −0.7% to −1.9%) and subcutaneous semaglutide (−1.9%) and placebo (−0.3%); oral semaglutide reductions were significant vs placebo (dosage-dependent estimated treatment difference [ETD] range for oral semaglutide vs placebo, –0.4% to –1.6%; P = .01 for 2.5 mg, <.001 for all other dosages).",False,RESULTS
4864,The most prevalent adverse events to Semaglutide are gastrointestinal.,"Reductions in body weight were greater with oral semaglutide (dosage-dependent range, −2.1 kg to −6.9 kg) and subcutaneous semaglutide (−6.4 kg) vs placebo (−1.2 kg), and significant for oral semaglutide dosages of 10 mg or more vs placebo (dosage-dependent ETD range, –0.9 to –5.7 kg; P < .001).",False,RESULTS
4865,The most prevalent adverse events to Semaglutide are gastrointestinal.,"Adverse events were reported by 63% to 86% (371 of 490 patients) in the oral semaglutide groups, 81% (56 of 69 patients) in the subcutaneous semaglutide group, and 68% (48 of 71 patients) in the placebo group; mild to moderate gastrointestinal events were most common.",True,RESULTS
4866,The most prevalent adverse events to Semaglutide are gastrointestinal.,"Conclusions and Relevance Among patients with type 2 diabetes, oral semaglutide resulted in better glycemic control than placebo over 26 weeks.",False,CONCLUSIONS
4867,The most prevalent adverse events to Semaglutide are gastrointestinal.,"These findings support phase 3 studies to assess longer-term and clinical outcomes, as well as safety.",False,CONCLUSIONS
4868,The most prevalent adverse events to Semaglutide are gastrointestinal.,Trial Registration clinicaltrials.gov Identifier: NCT01923181,False,CONCLUSIONS
4869,The myocardial cell lineage originally develops from cardiac progenitors of exclusively endodermal origin.,"The functional heart is comprised of distinct mesoderm-derived lineages including cardiomyocytes, endothelial cells and vascular smooth muscle cells.",False,BACKGROUND
4870,The myocardial cell lineage originally develops from cardiac progenitors of exclusively endodermal origin.,"Studies in the mouse embryo and the mouse embryonic stem cell differentiation model have provided evidence indicating that these three lineages develop from a common Flk-1+ (kinase insert domain protein receptor, also known as Kdr) cardiovascular progenitor that represents one of the earliest stages in mesoderm specification to the cardiovascular lineages.",True,BACKGROUND
4871,The myocardial cell lineage originally develops from cardiac progenitors of exclusively endodermal origin.,"To determine whether a comparable progenitor is present during human cardiogenesis, we analysed the development of the cardiovascular lineages in human embryonic stem cell differentiation cultures.",False,METHODS
4872,The myocardial cell lineage originally develops from cardiac progenitors of exclusively endodermal origin.,"Here we show that after induction with combinations of activin A, bone morphogenetic protein 4 (BMP4), basic fibroblast growth factor (bFGF, also known as FGF2), vascular endothelial growth factor (VEGF, also known as VEGFA) and dickkopf homolog 1 (DKK1) in serum-free media, human embryonic-stem-cell-derived embryoid bodies generate a KDRlow/C-KIT(CD117)neg population that displays cardiac, endothelial and vascular smooth muscle potential in vitro and, after transplantation, in vivo.",False,METHODS
4873,The myocardial cell lineage originally develops from cardiac progenitors of exclusively endodermal origin.,"When plated in monolayer cultures, these KDRlow/C-KITneg cells differentiate to generate populations consisting of greater than 50% contracting cardiomyocytes.",False,RESULTS
4874,The myocardial cell lineage originally develops from cardiac progenitors of exclusively endodermal origin.,Populations derived from the KDRlow/C-KITneg fraction give rise to colonies that contain all three lineages when plated in methylcellulose cultures.,False,RESULTS
4875,The myocardial cell lineage originally develops from cardiac progenitors of exclusively endodermal origin.,"Results from limiting dilution studies and cell-mixing experiments support the interpretation that these colonies are clones, indicating that they develop from a cardiovascular colony-forming cell.",False,RESULTS
4876,The myocardial cell lineage originally develops from cardiac progenitors of exclusively endodermal origin.,"Together, these findings identify a human cardiovascular progenitor that defines one of the earliest stages of human cardiac development.",False,CONCLUSIONS
4877,The one-child policy has created a hospitable environment for female infants.,"OBJECTIVES To explore the use of local civil registration data to assess the perinatal mortality in a typical rural county in a less developed province in China, 1999-2000.   
",False,OBJECTIVE
4878,The one-child policy has created a hospitable environment for female infants.,DESIGN Retrospective cohort study.,False,METHODS
4879,The one-child policy has created a hospitable environment for female infants.,"Pregnancies in a cohort of women followed from registration of pregnancy to outcome of infant seven days after birth.   
",False,METHODS
4880,The one-child policy has created a hospitable environment for female infants.,SETTING Routine family planning records in 20 rural townships in eastern China.   ,False,METHODS
4881,The one-child policy has created a hospitable environment for female infants.,"SUBJECTS 3697 pregnancies registered by the local family planning system during 1999.   
",False,METHODS
4882,The one-child policy has created a hospitable environment for female infants.,"MAIN OUTCOME MEASURES Abortions, stillbirths, early neonatal mortality, perinatal mortality.   
",False,METHODS
4883,The one-child policy has created a hospitable environment for female infants.,RESULTS Only three cases were lost to follow up.,False,RESULTS
4884,The one-child policy has created a hospitable environment for female infants.,The average age of the women at pregnancy was 25.9 years.,False,RESULTS
4885,The one-child policy has created a hospitable environment for female infants.,"Three hundred and twelve pregnancies were aborted and 240 ended in miscarriage (total 552, 15%).",False,RESULTS
4886,The one-child policy has created a hospitable environment for female infants.,"The perinatal mortality rate was 69 per 1000 births, the rate of stillbirth was 24 per 1000 births, and the early neonatal mortality was 46 per 1000 live births.",False,RESULTS
4887,The one-child policy has created a hospitable environment for female infants.,The early neonatal mortality was 29 in boys and 69 in girls per 1000 live births.,True,RESULTS
4888,The one-child policy has created a hospitable environment for female infants.,"The perinatal mortality rate increased notably with parity and was higher in townships having lower income per capita.   
",False,RESULTS
4889,The one-child policy has created a hospitable environment for female infants.,CONCLUSIONS The family planning system at the most local level is a useful data source for studying perinatal mortality in rural China.,False,CONCLUSIONS
4890,The one-child policy has created a hospitable environment for female infants.,The perinatal mortality rate in the study county was higher than previously reported for both rural and urban areas in China.,False,CONCLUSIONS
4891,The one-child policy has created a hospitable environment for female infants.,The results by parity and sex of the infant raise concern over the impact of the one child policy.,False,CONCLUSIONS
4892,The peak incidence of fractures occurs during pubertal growth spurt in early adolescents.,"CONTEXT The incidence of distal forearm fractures in children peaks around the time of the pubertal growth spurt, possibly because physical activity increases at the time of a transient deficit in cortical bone mass due to the increased calcium demand during maximal skeletal growth.",True,BACKGROUND
4893,The peak incidence of fractures occurs during pubertal growth spurt in early adolescents.,"Changes in physical activity or diet may therefore influence risk of forearm fracture.   
",False,BACKGROUND
4894,The peak incidence of fractures occurs during pubertal growth spurt in early adolescents.,"OBJECTIVE To determine whether there has been a change in the incidence of distal forearm fractures in children in recent years.   
",False,OBJECTIVE
4895,The peak incidence of fractures occurs during pubertal growth spurt in early adolescents.,"DESIGN, SETTING, AND PATIENTS Population-based study among Rochester, Minn, residents younger than 35 years with distal forearm fractures in 1969-1971, 1979-1981, 1989-1991, and 1999-2001.   
",False,METHODS
4896,The peak incidence of fractures occurs during pubertal growth spurt in early adolescents.,"MAIN OUTCOME MEASURE Estimated incidence of distal forearm fractures in 4 time periods.   
",False,METHODS
4897,The peak incidence of fractures occurs during pubertal growth spurt in early adolescents.,"RESULTS Comparably age- and sex-adjusted annual incidence rates per 100 000 increased from 263.3 (95% confidence interval [CI], 231.1-295.4) in 1969-1971 to 322.3 (95% CI, 285.3-359.4) in 1979-1981 and to 399.8 (95% CI, 361.0-438.6) in 1989-1991 before leveling off at 372.9 (95% CI, 339.1-406.7) in 1999-2001.",False,RESULTS
4898,The peak incidence of fractures occurs during pubertal growth spurt in early adolescents.,"Age-adjusted incidence rates per 100 000 were 32% greater among male residents in 1999-2001 compared with 1969-1971 (409.4 [95% CI, 359.9-459.0] vs 309.4 [95% CI, 259.3-359.5]; P =.01) and 56% greater among female residents in the same time periods (334.3 [95% CI, 288.6-380.1] vs 214.6 [95% CI, 174.9-254.4]; P<.001).",False,RESULTS
4899,The peak incidence of fractures occurs during pubertal growth spurt in early adolescents.,"The peak incidence and greatest increase occurred between ages 11 and 14 years in boys and 8 and 11 years in girls.   
",False,RESULTS
4900,The peak incidence of fractures occurs during pubertal growth spurt in early adolescents.,"CONCLUSIONS There has been a statistically significant increase in the incidence of distal forearm fractures in children and adolescents, but whether this is due to changing patterns of physical activity, decreased bone acquisition due to poor calcium intake, or both is unclear at present.",False,CONCLUSIONS
4901,The peak incidence of fractures occurs during pubertal growth spurt in early adolescents.,"Given the large number of childhood fractures, however, studies are needed to define the cause(s) of this increase.",False,CONCLUSIONS
4902,The peak incidence of fractures occurs in toddlers.,"CONTEXT The incidence of distal forearm fractures in children peaks around the time of the pubertal growth spurt, possibly because physical activity increases at the time of a transient deficit in cortical bone mass due to the increased calcium demand during maximal skeletal growth.",True,BACKGROUND
4903,The peak incidence of fractures occurs in toddlers.,"Changes in physical activity or diet may therefore influence risk of forearm fracture.   
",False,BACKGROUND
4904,The peak incidence of fractures occurs in toddlers.,"OBJECTIVE To determine whether there has been a change in the incidence of distal forearm fractures in children in recent years.   
",False,OBJECTIVE
4905,The peak incidence of fractures occurs in toddlers.,"DESIGN, SETTING, AND PATIENTS Population-based study among Rochester, Minn, residents younger than 35 years with distal forearm fractures in 1969-1971, 1979-1981, 1989-1991, and 1999-2001.   
",False,METHODS
4906,The peak incidence of fractures occurs in toddlers.,"MAIN OUTCOME MEASURE Estimated incidence of distal forearm fractures in 4 time periods.   
",False,METHODS
4907,The peak incidence of fractures occurs in toddlers.,"RESULTS Comparably age- and sex-adjusted annual incidence rates per 100 000 increased from 263.3 (95% confidence interval [CI], 231.1-295.4) in 1969-1971 to 322.3 (95% CI, 285.3-359.4) in 1979-1981 and to 399.8 (95% CI, 361.0-438.6) in 1989-1991 before leveling off at 372.9 (95% CI, 339.1-406.7) in 1999-2001.",False,RESULTS
4908,The peak incidence of fractures occurs in toddlers.,"Age-adjusted incidence rates per 100 000 were 32% greater among male residents in 1999-2001 compared with 1969-1971 (409.4 [95% CI, 359.9-459.0] vs 309.4 [95% CI, 259.3-359.5]; P =.01) and 56% greater among female residents in the same time periods (334.3 [95% CI, 288.6-380.1] vs 214.6 [95% CI, 174.9-254.4]; P<.001).",False,RESULTS
4909,The peak incidence of fractures occurs in toddlers.,"The peak incidence and greatest increase occurred between ages 11 and 14 years in boys and 8 and 11 years in girls.   
",False,RESULTS
4910,The peak incidence of fractures occurs in toddlers.,"CONCLUSIONS There has been a statistically significant increase in the incidence of distal forearm fractures in children and adolescents, but whether this is due to changing patterns of physical activity, decreased bone acquisition due to poor calcium intake, or both is unclear at present.",False,CONCLUSIONS
4911,The peak incidence of fractures occurs in toddlers.,"Given the large number of childhood fractures, however, studies are needed to define the cause(s) of this increase.",False,CONCLUSIONS
4912,The proliferative capacity of neural progenitors differs across species.,Variation in cerebral cortex size and complexity is thought to contribute to differences in cognitive ability between humans and other animals.,False,BACKGROUND
4913,The proliferative capacity of neural progenitors differs across species.,Here we compare cortical progenitor cell output in humans and three nonhuman primates using directed differentiation of pluripotent stem cells (PSCs) in adherent two-dimensional (2D) and organoid three-dimensional (3D) culture systems.,False,BACKGROUND
4914,The proliferative capacity of neural progenitors differs across species.,"Clonal lineage analysis showed that primate cortical progenitors proliferate for a protracted period of time, during which they generate early-born neurons, in contrast to rodents, where this expansion phase largely ceases before neurogenesis begins.",True,RESULTS
4915,The proliferative capacity of neural progenitors differs across species.,"The extent of this additional cortical progenitor expansion differs among primates, leading to differences in the number of neurons generated by each progenitor cell.",True,RESULTS
4916,The proliferative capacity of neural progenitors differs across species.,"We found that this mechanism for controlling cortical size is regulated cell autonomously in culture, suggesting that primate cerebral cortex size is regulated at least in part at the level of individual cortical progenitor cell clonal output.",False,CONCLUSIONS
4917,The proliferative capacity of progenitors is regulated cell-autonomously.,Variation in cerebral cortex size and complexity is thought to contribute to differences in cognitive ability between humans and other animals.,False,BACKGROUND
4918,The proliferative capacity of progenitors is regulated cell-autonomously.,Here we compare cortical progenitor cell output in humans and three nonhuman primates using directed differentiation of pluripotent stem cells (PSCs) in adherent two-dimensional (2D) and organoid three-dimensional (3D) culture systems.,False,BACKGROUND
4919,The proliferative capacity of progenitors is regulated cell-autonomously.,"Clonal lineage analysis showed that primate cortical progenitors proliferate for a protracted period of time, during which they generate early-born neurons, in contrast to rodents, where this expansion phase largely ceases before neurogenesis begins.",False,RESULTS
4920,The proliferative capacity of progenitors is regulated cell-autonomously.,"The extent of this additional cortical progenitor expansion differs among primates, leading to differences in the number of neurons generated by each progenitor cell.",False,RESULTS
4921,The proliferative capacity of progenitors is regulated cell-autonomously.,"We found that this mechanism for controlling cortical size is regulated cell autonomously in culture, suggesting that primate cerebral cortex size is regulated at least in part at the level of individual cortical progenitor cell clonal output.",True,CONCLUSIONS
4922,The recruitment of Wdr5 to its target loci depends on Kat8.,Pluripotent embryonic stem cells (ESCs) maintain self-renewal and the potential for rapid response to differentiation cues.,False,BACKGROUND
4923,The recruitment of Wdr5 to its target loci depends on Kat8.,Both ESC features are subject to epigenetic regulation.,False,BACKGROUND
4924,The recruitment of Wdr5 to its target loci depends on Kat8.,Here we show that the histone acetyltransferase Mof plays an essential role in the maintenance of ESC self-renewal and pluripotency.,False,BACKGROUND
4925,The recruitment of Wdr5 to its target loci depends on Kat8.,"ESCs with Mof deletion lose characteristic morphology, alkaline phosphatase (AP) staining, and differentiation potential.",False,RESULTS
4926,The recruitment of Wdr5 to its target loci depends on Kat8.,"They also have aberrant expression of the core transcription factors Nanog, Oct4, and Sox2.",False,RESULTS
4927,The recruitment of Wdr5 to its target loci depends on Kat8.,"Importantly, the phenotypes of Mof null ESCs can be partially suppressed by Nanog overexpression, supporting the idea that Mof functions as an upstream regulator of Nanog in ESCs.",False,RESULTS
4928,The recruitment of Wdr5 to its target loci depends on Kat8.,Genome-wide ChIP-sequencing and transcriptome analyses further demonstrate that Mof is an integral component of the ESC core transcriptional network and that Mof primes genes for diverse developmental programs.,False,CONCLUSIONS
4929,The recruitment of Wdr5 to its target loci depends on Kat8.,"Mof is also required for Wdr5 recruitment and H3K4 methylation at key regulatory loci, highlighting the complexity and interconnectivity of various chromatin regulators in ESCs.",True,CONCLUSIONS
4930,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.,"CONTEXT The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor-positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and endoxifen.",False,OBJECTIVE
4931,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.,"The formation of active metabolites is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6) enzyme.   
",False,OBJECTIVE
4932,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.,"OBJECTIVE To determine whether CYP2D6 variation is associated with clinical outcomes in women receiving adjuvant tamoxifen.   
",False,OBJECTIVE
4933,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.,"DESIGN, SETTING, AND PATIENTS Retrospective analysis of German and US cohorts of patients treated with adjuvant tamoxifen for early stage breast cancer.",False,METHODS
4934,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.,The 1325 patients had diagnoses between 1986 and 2005 of stage I through III breast cancer and were mainly postmenopausal (95.4%).,False,METHODS
4935,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.,"Last follow-up was in December 2008; inclusion criteria were hormone receptor positivity, no metastatic disease at diagnosis, adjuvant tamoxifen therapy, and no chemotherapy.",False,METHODS
4936,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.,"DNA from tumor tissue or blood was genotyped for CYP2D6 variants associated with reduced (*10, *41) or absent (*3, *4, *5) enzyme activity.",False,METHODS
4937,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.,"Women were classified as having an extensive (n=609), heterozygous extensive/intermediate (n=637), or poor (n=79) CYP2D6 metabolism.   
",False,METHODS
4938,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.,"MAIN OUTCOME MEASURES Time to recurrence, event-free survival, disease-free survival, and overall survival.   
",False,METHODS
4939,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.,RESULTS Median follow-up was 6.3 years.,False,RESULTS
4940,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.,"At 9 years of follow-up, the recurrence rates were 14.9% for extensive metabolizers, 20.9% for heterozygous extensive/intermediate metabolizers, and 29.0% for poor metabolizers, and all-cause mortality rates were 16.7%, 18.0%, and 22.8%, respectively.",False,RESULTS
4941,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.,"Compared with extensive metabolizers, there was a significantly increased risk of recurrence for heterozygous extensive/intermediate metabolizers (time to recurrence adjusted hazard ratio [HR], 1.40; 95% confidence interval [CI], 1.04-1.90) and for poor metabolizers (time to recurrence HR, 1.90; 95% CI, 1.10-3.28).",True,RESULTS
4942,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.,"Compared with extensive metabolizers, those with decreased CYP2D6 activity (heterozygous extensive/intermediate and poor metabolism) had worse event-free survival (HR, 1.33; 95% CI, 1.06-1.68) and disease-free survival (HR, 1.29; 95% CI, 1.03-1.61), but there was no significant difference in overall survival (HR, 1.15; 95% CI, 0.88-1.51).   
",True,RESULTS
4943,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is independent of the patient's genetic make-up.,"CONCLUSION Among women with breast cancer treated with tamoxifen, there was an association between CYP2D6 variation and clinical outcomes, such that the presence of 2 functional CYP2D6 alleles was associated with better clinical outcomes and the presence of nonfunctional or reduced-function alleles with worse outcomes.",True,CONCLUSIONS
4944,The removal of reactive oxygen species by activated oncogenes contributes to the increased genomic instability of leukaemia cells.,The oncogenic BCR/ABL tyrosine kinase induces constitutive DNA damage in Philadelphia chromosome (Ph)-positive leukemia cells.,True,BACKGROUND
4945,The removal of reactive oxygen species by activated oncogenes contributes to the increased genomic instability of leukaemia cells.,We find that BCR/ABL-induced reactive oxygen species (ROSs) cause chronic oxidative DNA damage resulting in double-strand breaks (DSBs) in S and G(2)/M cell cycle phases.,True,BACKGROUND
4946,The removal of reactive oxygen species by activated oncogenes contributes to the increased genomic instability of leukaemia cells.,These lesions are repaired by BCR/ABL-stimulated homologous recombination repair (HRR) and nonhomologous end-joining (NHEJ) mechanisms.,False,BACKGROUND
4947,The removal of reactive oxygen species by activated oncogenes contributes to the increased genomic instability of leukaemia cells.,"A high mutation rate is detected in HRR products in BCR/ABL-positive cells, but not in the normal counterparts.",False,BACKGROUND
4948,The removal of reactive oxygen species by activated oncogenes contributes to the increased genomic instability of leukaemia cells.,"In addition, large deletions are found in NHEJ products exclusively in BCR/ABL cells.",False,BACKGROUND
4949,The removal of reactive oxygen species by activated oncogenes contributes to the increased genomic instability of leukaemia cells.,We propose that the following series of events may contribute to genomic instability of Ph-positive leukemias: BCR/ABL --> ROSs --> oxidative DNA damage --> DSBs in proliferating cells --> unfaithful HRR and NHEJ repair.,True,BACKGROUND
4950,The repeat-variable diresidue (RVD) in the loop of Transcription-Activator Like (TAL) effectors specifies the nucleotides-amino acid contact at the target promoter element.,"TAL (transcription activator-like) effectors, secreted by phytopathogenic bacteria, recognize host DNA sequences through a central domain of tandem repeats.",True,BACKGROUND
4951,The repeat-variable diresidue (RVD) in the loop of Transcription-Activator Like (TAL) effectors specifies the nucleotides-amino acid contact at the target promoter element.,Each repeat comprises 33 to 35 conserved amino acids and targets a specific base pair by using two hypervariable residues [known as repeat variable diresidues (RVDs)] at positions 12 and 13.,True,BACKGROUND
4952,The repeat-variable diresidue (RVD) in the loop of Transcription-Activator Like (TAL) effectors specifies the nucleotides-amino acid contact at the target promoter element.,"Here, we report the crystal structures of an 11.5-repeat TAL effector in both DNA-free and DNA-bound states.",False,BACKGROUND
4953,The repeat-variable diresidue (RVD) in the loop of Transcription-Activator Like (TAL) effectors specifies the nucleotides-amino acid contact at the target promoter element.,Each TAL repeat comprises two helices connected by a short RVD-containing loop.,False,RESULTS
4954,The repeat-variable diresidue (RVD) in the loop of Transcription-Activator Like (TAL) effectors specifies the nucleotides-amino acid contact at the target promoter element.,"The 11.5 repeats form a right-handed, superhelical structure that tracks along the sense strand of DNA duplex, with RVDs contacting the major groove.",False,RESULTS
4955,The repeat-variable diresidue (RVD) in the loop of Transcription-Activator Like (TAL) effectors specifies the nucleotides-amino acid contact at the target promoter element.,"The 12th residue stabilizes the RVD loop, whereas the 13th residue makes a base-specific contact.",False,CONCLUSIONS
4956,The repeat-variable diresidue (RVD) in the loop of Transcription-Activator Like (TAL) effectors specifies the nucleotides-amino acid contact at the target promoter element.,Understanding DNA recognition by TAL effectors may facilitate rational design of DNA-binding proteins with biotechnological applications.,False,CONCLUSIONS
4957,The risk of breast cancer among parous women decreases with placental weight of pregnancies.,"CONTEXT During pregnancy, serum levels of estrogen, progesterone, and other hormones are markedly higher than during other periods of life.",False,BACKGROUND
4958,The risk of breast cancer among parous women decreases with placental weight of pregnancies.,"Pregnancy hormones primarily are produced in the placenta, and signs of placental impairment may serve as indirect markers of hormone exposures during pregnancy.",False,BACKGROUND
4959,The risk of breast cancer among parous women decreases with placental weight of pregnancies.,"During pregnancy, these markers have been inconsistently associated with subsequent risk of breast cancer in the mother.   
",False,BACKGROUND
4960,The risk of breast cancer among parous women decreases with placental weight of pregnancies.,"OBJECTIVE To examine associations between indirect markers of hormonal exposures, such as placental weight and other pregnancy characteristics, and maternal risk of developing breast cancer.   
",False,OBJECTIVE
4961,The risk of breast cancer among parous women decreases with placental weight of pregnancies.,"DESIGN AND SETTING Population-based cohort study using data from the Swedish Birth Register, the Swedish Cancer Register, the Swedish Cause of Death Register, and the Swedish Register of Population and Population Changes.   
",False,METHODS
4962,The risk of breast cancer among parous women decreases with placental weight of pregnancies.,"PARTICIPANTS Women included in the Sweden Birth Register who delivered singletons between 1982 and 1989, with complete information on date of birth and gestational age.",False,METHODS
4963,The risk of breast cancer among parous women decreases with placental weight of pregnancies.,"Women were followed up until the occurrence of breast cancer, death, or end of follow-up (December 31, 2001).",False,METHODS
4964,The risk of breast cancer among parous women decreases with placental weight of pregnancies.,"Cox proportional hazards models were used to estimate associations between hormone exposures and risks of breast cancer.   
",False,METHODS
4965,The risk of breast cancer among parous women decreases with placental weight of pregnancies.,"MAIN OUTCOME MEASURE Incidence of invasive breast cancer.   
",False,METHODS
4966,The risk of breast cancer among parous women decreases with placental weight of pregnancies.,"RESULTS Of 314,019 women in the cohort, 2216 (0.7%) developed breast cancer during the follow-up through 2001, of whom 2100 (95%) were diagnosed before age 50 years.",False,RESULTS
4967,The risk of breast cancer among parous women decreases with placental weight of pregnancies.,"Compared with women who had placentas weighing less than 500 g in 2 consecutive pregnancies, the risk of breast cancer was increased among women whose placentas weighed between 500 and 699 g in their first pregnancy and at least 700 g in their second pregnancy (or vice versa) (adjusted hazard ratio, 1.82; 95% confidence interval [CI], 1.07-3.08), and the corresponding risk was doubled among women whose placentas weighed at least 700 g in both pregnancies (adjusted hazard ratio, 2.05; 95% CI, 1.15-3.64).",True,RESULTS
4968,The risk of breast cancer among parous women decreases with placental weight of pregnancies.,"A high birth weight (> or =4000 g) in 2 successive births was associated with an increased risk of breast cancer before but not after adjusting for placental weight and other covariates (adjusted hazard ratio, 1.10; 95% CI, 0.76-1.59).   
",False,RESULTS
4969,The risk of breast cancer among parous women decreases with placental weight of pregnancies.,CONCLUSIONS Placental weight is positively associated with maternal risk of breast cancer.,True,CONCLUSIONS
4970,The risk of breast cancer among parous women decreases with placental weight of pregnancies.,These results further support the hypothesis that pregnancy hormones are important modifiers of subsequent maternal breast cancer risk.,False,CONCLUSIONS
4971,The risk of cancer rises with level of alcohol consumption.,"Summary Background Alcohol use is a leading risk factor for death and disability, but its overall association with health remains complex given the possible protective effects of moderate alcohol consumption on some conditions.",False,BACKGROUND
4972,The risk of cancer rises with level of alcohol consumption.,"With our comprehensive approach to health accounting within the Global Burden of Diseases, Injuries, and Risk Factors Study 2016, we generated improved estimates of alcohol use and alcohol-attributable deaths and disability-adjusted life-years (DALYs) for 195 locations from 1990 to 2016, for both sexes and for 5-year age groups between the ages of 15 years and 95 years and older.",False,BACKGROUND
4973,The risk of cancer rises with level of alcohol consumption.,"Methods Using 694 data sources of individual and population-level alcohol consumption, along with 592 prospective and retrospective studies on the risk of alcohol use, we produced estimates of the prevalence of current drinking, abstention, the distribution of alcohol consumption among current drinkers in standard drinks daily (defined as 10 g of pure ethyl alcohol), and alcohol-attributable deaths and DALYs.",False,METHODS
4974,The risk of cancer rises with level of alcohol consumption.,"We made several methodological improvements compared with previous estimates: first, we adjusted alcohol sales estimates to take into account tourist and unrecorded consumption; second, we did a new meta-analysis of relative risks for 23 health outcomes associated with alcohol use; and third, we developed a new method to quantify the level of alcohol consumption that minimises the overall risk to individual health.",False,METHODS
4975,The risk of cancer rises with level of alcohol consumption.,"Findings Globally, alcohol use was the seventh leading risk factor for both deaths and DALYs in 2016, accounting for 2·2% (95% uncertainty interval [UI] 1·5–3·0) of age-standardised female deaths and 6·8% (5·8–8·0) of age-standardised male deaths.",False,RESULTS
4976,The risk of cancer rises with level of alcohol consumption.,"Among the population aged 15–49 years, alcohol use was the leading risk factor globally in 2016, with 3·8% (95% UI 3·2–4·3) of female deaths and 12·2% (10·8–13·6) of male deaths attributable to alcohol use.",False,RESULTS
4977,The risk of cancer rises with level of alcohol consumption.,"For the population aged 15–49 years, female attributable DALYs were 2·3% (95% UI 2·0–2·6) and male attributable DALYs were 8·9% (7·8–9·9).",False,RESULTS
4978,The risk of cancer rises with level of alcohol consumption.,"The three leading causes of attributable deaths in this age group were tuberculosis (1·4% [95% UI 1·0–1·7] of total deaths), road injuries (1·2% [0·7–1·9]), and self-harm (1·1% [0·6–1·5]).",False,RESULTS
4979,The risk of cancer rises with level of alcohol consumption.,"For populations aged 50 years and older, cancers accounted for a large proportion of total alcohol-attributable deaths in 2016, constituting 27·1% (95% UI 21·2–33·3) of total alcohol-attributable female deaths and 18·9% (15·3–22·6) of male deaths.",True,RESULTS
4980,The risk of cancer rises with level of alcohol consumption.,The level of alcohol consumption that minimised harm across health outcomes was zero (95% UI 0·0–0·8) standard drinks per week.,False,RESULTS
4981,The risk of cancer rises with level of alcohol consumption.,Interpretation Alcohol use is a leading risk factor for global disease burden and causes substantial health loss.,False,CONCLUSIONS
4982,The risk of cancer rises with level of alcohol consumption.,"We found that the risk of all-cause mortality, and of cancers specifically, rises with increasing levels of consumption, and the level of consumption that minimises health loss is zero.",True,CONCLUSIONS
4983,The risk of cancer rises with level of alcohol consumption.,"These results suggest that alcohol control policies might need to be revised worldwide, refocusing on efforts to lower overall population-level consumption.",False,CONCLUSIONS
4984,The risk of cancer rises with level of alcohol consumption.,Funding Bill & Melinda Gates Foundation.,False,CONCLUSIONS
4985,The risk of female prisoners harming themselves is ten times that of male prisoners.,"BACKGROUND Self-harm and suicide are common in prisoners, yet robust information on the full extent and characteristics of people at risk of self-harm is scant.",False,BACKGROUND
4986,The risk of female prisoners harming themselves is ten times that of male prisoners.,"Furthermore, understanding how frequently self-harm is followed by suicide, and in which prisoners this progression is most likely to happen, is important.",False,BACKGROUND
4987,The risk of female prisoners harming themselves is ten times that of male prisoners.,"We did a case-control study of all prisoners in England and Wales to ascertain the prevalence of self-harm in this population, associated risk factors, clustering effects, and risk of subsequent suicide after self-harm.   
",False,BACKGROUND
4988,The risk of female prisoners harming themselves is ten times that of male prisoners.,"METHODS Records of self-harm incidents in all prisons in England and Wales were gathered routinely between January, 2004, and December, 2009.",False,METHODS
4989,The risk of female prisoners harming themselves is ten times that of male prisoners.,"We did a case-control comparison of prisoners who self-harmed and those who did not between January, 2006, and December, 2009.",False,METHODS
4990,The risk of female prisoners harming themselves is ten times that of male prisoners.,We also used a Bayesian approach to look at clustering of people who self-harmed.,False,METHODS
4991,The risk of female prisoners harming themselves is ten times that of male prisoners.,"Prisoners who self-harmed and subsequently died by suicide in prison were compared with other inmates who self-harmed.   
",False,METHODS
4992,The risk of female prisoners harming themselves is ten times that of male prisoners.,"FINDINGS 139,195 self-harm incidents were recorded in 26,510 individual prisoners between 2004 and 2009; 5-6% of male prisoners and 20-24% of female inmates self-harmed every year.",True,RESULTS
4993,The risk of female prisoners harming themselves is ten times that of male prisoners.,Self-harm rates were more than ten times higher in female prisoners than in male inmates.,True,RESULTS
4994,The risk of female prisoners harming themselves is ten times that of male prisoners.,"Repetition of self-harm was common, particularly in women and teenage girls, in whom a subgroup of 102 prisoners accounted for 17,307 episodes.",False,RESULTS
4995,The risk of female prisoners harming themselves is ten times that of male prisoners.,"In both sexes, self-harm was associated with younger age, white ethnic origin, prison type, and a life sentence or being unsentenced; in female inmates, committing a violent offence against an individual was also a factor.",False,RESULTS
4996,The risk of female prisoners harming themselves is ten times that of male prisoners.,"Substantial evidence was noted of clustering in time and location of prisoners who self-harmed (adjusted intra-class correlation 0·15, 95% CI 0·11-0·18).",False,RESULTS
4997,The risk of female prisoners harming themselves is ten times that of male prisoners.,"109 subsequent suicides in prison were reported in individuals who self-harmed; the risk was higher in those who self-harmed than in the general prison population, and more than half the deaths occurred within a month of self-harm.",False,RESULTS
4998,The risk of female prisoners harming themselves is ten times that of male prisoners.,"Risk factors for suicide after self-harm in male prisoners were older age and a previous self-harm incident of high or moderate lethality; in female inmates, a history of more than five self-harm incidents within a year was associated with subsequent suicide.   
",False,RESULTS
4999,The risk of female prisoners harming themselves is ten times that of male prisoners.,"INTERPRETATION The burden of self-harm in prisoners is substantial, particularly in women.",False,CONCLUSIONS
5000,The risk of female prisoners harming themselves is ten times that of male prisoners.,Self-harm in prison is associated with subsequent suicide in this setting.,False,CONCLUSIONS
5001,The risk of female prisoners harming themselves is ten times that of male prisoners.,"Prevention and treatment of self-harm in prisoners is an essential component of suicide prevention in prisons.   
",False,CONCLUSIONS
5002,The risk of female prisoners harming themselves is ten times that of male prisoners.,"FUNDING Wellcome Trust, National Institute for Health Research, National Offender Management Service, and Department of Health.",False,BACKGROUND
5003,The tissue surrounding the granuloma in an immune cell induces an anti-inflammatory immune response.,Granulomas are the pathological hallmark of tuberculosis (TB).,False,BACKGROUND
5004,The tissue surrounding the granuloma in an immune cell induces an anti-inflammatory immune response.,"However, their function and mechanisms of formation remain poorly understood.",False,BACKGROUND
5005,The tissue surrounding the granuloma in an immune cell induces an anti-inflammatory immune response.,"To understand the role of granulomas in TB, we analyzed the proteomes of granulomas from subjects with tuberculosis in an unbiased manner.",False,BACKGROUND
5006,The tissue surrounding the granuloma in an immune cell induces an anti-inflammatory immune response.,"Using laser-capture microdissection, mass spectrometry and confocal microscopy, we generated detailed molecular maps of human granulomas.",False,METHODS
5007,The tissue surrounding the granuloma in an immune cell induces an anti-inflammatory immune response.,"We found that the centers of granulomas have a pro-inflammatory environment that is characterized by the presence of antimicrobial peptides, reactive oxygen species and pro-inflammatory eicosanoids.",False,RESULTS
5008,The tissue surrounding the granuloma in an immune cell induces an anti-inflammatory immune response.,"Conversely, the tissue surrounding the caseum has a comparatively anti-inflammatory signature.",True,RESULTS
5009,The tissue surrounding the granuloma in an immune cell induces an anti-inflammatory immune response.,These findings are consistent across a set of six human subjects and in rabbits.,False,RESULTS
5010,The tissue surrounding the granuloma in an immune cell induces an anti-inflammatory immune response.,"Although the balance between systemic pro- and anti-inflammatory signals is crucial to TB disease outcome, here we find that these signals are physically segregated within each granuloma.",False,CONCLUSIONS
5011,The tissue surrounding the granuloma in an immune cell induces an anti-inflammatory immune response.,"From the protein and lipid snapshots of human and rabbit lesions analyzed here, we hypothesize that the pathologic response to TB is shaped by the precise anatomical localization of these inflammatory pathways during the development of the granuloma.",False,CONCLUSIONS
5012,Therapeutics receiving accelerated approval encounter a lower frequency of post-marketing safety events,Importance Postmarket safety events of novel pharmaceuticals and biologics occur when new safety risks are identified after initial regulatory approval of these therapeutics.,False,BACKGROUND
5013,Therapeutics receiving accelerated approval encounter a lower frequency of post-marketing safety events,These safety events can change how novel therapeutics are used in clinical practice and inform patient and clinician decision making.,False,BACKGROUND
5014,Therapeutics receiving accelerated approval encounter a lower frequency of post-marketing safety events,"Objectives To characterize the frequency of postmarket safety events among novel therapeutics approved by the US Food and Drug Administration (FDA), and to examine whether any novel therapeutic characteristics known at the time of FDA approval were associated with increased risk.",False,OBJECTIVE
5015,Therapeutics receiving accelerated approval encounter a lower frequency of post-marketing safety events,"Design and Setting Cohort study of all novel therapeutics approved by the FDA between January 1, 2001, and December 31, 2010, followed up through February 28, 2017.",False,METHODS
5016,Therapeutics receiving accelerated approval encounter a lower frequency of post-marketing safety events,"Exposures Novel therapeutic characteristics known at the time of FDA approval, including drug class, therapeutic area, priority review, accelerated approval, orphan status, near–regulatory deadline approval, and regulatory review time.",False,METHODS
5017,Therapeutics receiving accelerated approval encounter a lower frequency of post-marketing safety events,"Main Outcomes and Measures A composite of (1) withdrawals due to safety concerns, (2) FDA issuance of incremental boxed warnings added in the postmarket period, and (3) FDA issuance of safety communications.",False,METHODS
5018,Therapeutics receiving accelerated approval encounter a lower frequency of post-marketing safety events,"Results From 2001 through 2010, the FDA approved 222 novel therapeutics (183 pharmaceuticals and 39 biologics).",False,RESULTS
5019,Therapeutics receiving accelerated approval encounter a lower frequency of post-marketing safety events,"There were 123 new postmarket safety events (3 withdrawals, 61 boxed warnings, and 59 safety communications) during a median follow-up period of 11.7 years (interquartile range [IQR], 8.7-13.8 years), affecting 71 (32.0%) of the novel therapeutics.",False,RESULTS
5020,Therapeutics receiving accelerated approval encounter a lower frequency of post-marketing safety events,"The median time from approval to first postmarket safety event was 4.2 years (IQR, 2.5-6.0 years), and the proportion of novel therapeutics affected by a postmarket safety event at 10 years was 30.8% (95% CI, 25.1%-37.5%).",False,RESULTS
5021,Therapeutics receiving accelerated approval encounter a lower frequency of post-marketing safety events,"In multivariable analysis, postmarket safety events were statistically significantly more frequent among biologics (incidence rate ratio [IRR] = 1.93; 95% CI, 1.06-3.52; P = .03), therapeutics indicated for the treatment of psychiatric disease (IRR = 3.78; 95% CI, 1.77-8.06; P < .001), those receiving accelerated approval (IRR = 2.20; 95% CI, 1.15-4.21; P = .02), and those with near–regulatory deadline approval (IRR = 1.90; 95% CI, 1.19-3.05; P = .008); events were statistically significantly less frequent among those with regulatory review times less than 200 days (IRR = 0.46; 95% CI, 0.24-0.87; P = .02).",True,RESULTS
5022,Therapeutics receiving accelerated approval encounter a lower frequency of post-marketing safety events,"Conclusions and Relevance Among 222 novel therapeutics approved by the FDA from 2001 through 2010, 32% were affected by a postmarket safety event.",False,CONCLUSIONS
5023,Therapeutics receiving accelerated approval encounter a lower frequency of post-marketing safety events,"Biologics, psychiatric therapeutics, and accelerated and near–regulatory deadline approval were statistically significantly associated with higher rates of events, highlighting the need for continuous monitoring of the safety of novel therapeutics throughout their life cycle.",False,CONCLUSIONS
5024,There is a positive correlation between hip fractures and statin use.,"CONTEXT Recent animal studies have found that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) lipid-lowering drugs (statins) substantially increase bone formation, but whether statin use in humans results in clinically meaningful bone formation or a reduction in the risk of osteoporotic fractures is not known.   
",False,OBJECTIVE
5025,There is a positive correlation between hip fractures and statin use.,"OBJECTIVE To determine whether the use of statins is associated with reduced hip fracture risk.   
",False,OBJECTIVE
5026,There is a positive correlation between hip fractures and statin use.,"DESIGN Case-control study.   
",False,METHODS
5027,There is a positive correlation between hip fractures and statin use.,SETTING AND PATIENTS A total of 6110 New Jersey residents aged 65 years or older and enrolled in Medicare and either Medicaid or the Pharmacy Assistance for the Aged and Disabled program.,False,METHODS
5028,There is a positive correlation between hip fractures and statin use.,Case patients (n=1222) underwent surgical repair of a hip fracture in 1994.,False,METHODS
5029,There is a positive correlation between hip fractures and statin use.,"Control patients (n=4888) were identified at a ratio of 4:1 and frequency-matched to case patients for age and sex.   
",False,METHODS
5030,There is a positive correlation between hip fractures and statin use.,"MAIN OUTCOME MEASURE Adjusted odds ratio (OR) of hip fracture by statin use in the 180 days and 3 years prior to the index date (the earliest date of admission for surgery), adjusted for demographic and clinical characteristics and health care utilization.   
",False,METHODS
5031,There is a positive correlation between hip fractures and statin use.,"RESULTS Use of statins in either the prior 180 days (adjusted OR, 0.50; 95% confidence interval [CI], 0.33-0.76) or prior 3 years (adjusted OR, 0.57; 95% CI, 0.40-0.82) was associated with a significant reduction in the risk of hip fracture, even after controlling for variables such as race, insurance status, psychoactive medications, estrogen and thiazide use, ischemic heart disease, cancer, and diabetes mellitus.",True,RESULTS
5032,There is a positive correlation between hip fractures and statin use.,No significant relationship was observed between use of nonstatin lipid-lowering agents and hip fracture risk.,False,RESULTS
5033,There is a positive correlation between hip fractures and statin use.,Clear relationships were observed between the degree of reduction in hip fracture risk and the extent of statin use; there was no evidence of such relationships with nonstatin lipid-lowering agents.,True,RESULTS
5034,There is a positive correlation between hip fractures and statin use.,"After adjusting for extent of statin use in the prior 3 years, current use (on the index date) was associated with a 71% reduction in risk (adjusted OR, 0.29; 95% CI, 0.10-0.81).",True,RESULTS
5035,There is a positive correlation between hip fractures and statin use.,"The relationship between statin use and hip fracture risk persisted after controlling for variables such as the number of medications, the Charlson comorbidity index score, and hospitalization or nursing home stay in the last 180 days, as well as after excluding patients who were in a nursing home prior to their index date or who died in the year after their index date.",False,RESULTS
5036,There is a positive correlation between hip fractures and statin use.,"Use of nonstatin lipid-lowering agents was not observed to be associated with reduction in hip fracture risk in any of these alternative models or analyses.   
",False,RESULTS
5037,There is a positive correlation between hip fractures and statin use.,CONCLUSIONS These findings support an association between statin use by elderly patients and reduction in the risk of hip fracture.,True,CONCLUSIONS
5038,There is a positive correlation between hip fractures and statin use.,Controlled trials are needed to exclude the possibility of unmeasured confounders.,False,CONCLUSIONS
5039,There is a positive correlation between hip fractures and statin use.,JAMA.,False,BACKGROUND
5040,There is a positive correlation between hip fractures and statin use.,2000;283:3211-3216,False,BACKGROUND
5041,There is a relation between Erythromycin use and hypertrophic pyloric stenosis.,"OBJECTIVE To assess the association between use of macrolide antibiotics in mothers and infants from pregnancy onset until 120 days after birth and infantile hypertrophic pyloric stenosis (IHPS).   
",False,OBJECTIVE
5042,There is a relation between Erythromycin use and hypertrophic pyloric stenosis.,"DESIGN Nationwide register based cohort study.   
",False,METHODS
5043,There is a relation between Erythromycin use and hypertrophic pyloric stenosis.,"SETTING Denmark, 1996-2011.   
",False,METHODS
5044,There is a relation between Erythromycin use and hypertrophic pyloric stenosis.,"PARTICIPANTS 999,378 liveborn singletons and linked individual level information on macrolide prescriptions (maternal use during pregnancy, n=30,091; maternal use after birth, n=21,557; use in infants, n=6591), surgery for IHPS, and potential confounders.   
",False,METHODS
5045,There is a relation between Erythromycin use and hypertrophic pyloric stenosis.,"MAIN OUTCOME MEASURES Surgery for IHPS by three categories of macrolide use: in mothers during pregnancy, in mothers after birth, and in infants after birth.   
",False,METHODS
5046,There is a relation between Erythromycin use and hypertrophic pyloric stenosis.,RESULTS 880 infants developed IHPS (0.9 cases per 1000 births).,False,RESULTS
5047,There is a relation between Erythromycin use and hypertrophic pyloric stenosis.,"Compared with infants with no use of macrolides, the adjusted rate ratio for IHPS in infants with use of macrolides during days 0 to 13 after birth was 29.8 (95% confidence interval 16.4 to 54.1) and during days 14 to 120 was 3.24 (1.20 to 8.74); the corresponding absolute risk differences were 24.4 (95% confidence interval 13.0 to 44.1) and 0.65 (0.06 to 2.21) cases per 1000 infants exposed to macrolides, respectively.",False,RESULTS
5048,There is a relation between Erythromycin use and hypertrophic pyloric stenosis.,The rate ratio for maternal use of macrolides for days 0 to 13 after birth was 3.49 (1.92 to 6.34) and for days 14 to 120 was 0.70 (0.26 to 1.90); the corresponding absolute risk differences were 2.15 (0.82 to 4.64) and -0.11 (-0.26 to 0.31).,False,RESULTS
5049,There is a relation between Erythromycin use and hypertrophic pyloric stenosis.,"The rate ratios for maternal use of macrolides during pregnancy were 1.02 (0.65 to 1.59) for weeks 0 to 27 and 1.77 (0.95 to 3.31) for weeks 28 to birth; the corresponding absolute risk differences were 0.01 (-0.31 to 0.50) and 0.67 (-0.06 to 2.02).   
",False,RESULTS
5050,There is a relation between Erythromycin use and hypertrophic pyloric stenosis.,CONCLUSIONS Treatment of young infants with macrolide antibiotics was strongly associated with IHPS and should therefore only be administered if potential treatment benefits outweigh the risk.,True,CONCLUSIONS
5051,There is a relation between Erythromycin use and hypertrophic pyloric stenosis.,Maternal use of macrolides during the first two weeks after birth was also associated with an increased risk of IHPS.,True,CONCLUSIONS
5052,There is a relation between Erythromycin use and hypertrophic pyloric stenosis.,A possible association was also found with use during late pregnancy.,False,CONCLUSIONS
5053,There is no increased risk of hypospadias with clomiphene.,"Clomifene is widely used for inducing ovulation.1 It is structurally related to diethylstilbestrol, which has been linked to vaginal and cervical clear cell adenocarcinoma in women exposed in utero.",False,BACKGROUND
5054,There is no increased risk of hypospadias with clomiphene.,"The adverse effect is less severe in sons, although links to testicular cancer and urogenital anomalies, such as epididymal cysts, have been reported.2 3 A recent study also found an increased risk of hypospadias in the sons of women exposed to diethylstilbestrol in utero.4 Clomifene has a half life of about five days, but its metabolites have been found in blood samples on day 22 of the menstrual cycle and in faeces up to six weeks after administration.5 The occurrence of hypospadias may be increasing.",True,BACKGROUND
5055,There is no increased risk of hypospadias with clomiphene.,Little is known about the risk of hypospadias in boys born to women who have used clomifene to induce ovulation.  ,False,BACKGROUND
5056,There is no increased risk of hypospadias with clomiphene.,"### Methods and results  Our case-control study was done in the Danish counties of North Jutland, Aarhus, Viborg, and …",False,BACKGROUND
5057,There is no known interaction between Pioneer factor OCT3/4 and major chromatin remodeling factors.,"Oct4 is a well-known transcription factor that plays fundamental roles in stem cell self-renewal, pluripotency, and somatic cell reprogramming.",False,BACKGROUND
5058,There is no known interaction between Pioneer factor OCT3/4 and major chromatin remodeling factors.,"However, limited information is available on Oct4-associated protein complexes and their intrinsic protein-protein interactions that dictate Oct4's critical regulatory activities.",False,BACKGROUND
5059,There is no known interaction between Pioneer factor OCT3/4 and major chromatin remodeling factors.,"Here we employed an improved affinity purification approach combined with mass spectrometry to purify Oct4 protein complexes in mouse embryonic stem cells (mESCs), and discovered many novel Oct4 partners important for self-renewal and pluripotency of mESCs.",False,RESULTS
5060,There is no known interaction between Pioneer factor OCT3/4 and major chromatin remodeling factors.,"Notably, we found that Oct4 is associated with multiple chromatin-modifying complexes with documented as well as newly proved functional significance in stem cell maintenance and somatic cell reprogramming.",True,RESULTS
5061,There is no known interaction between Pioneer factor OCT3/4 and major chromatin remodeling factors.,Our study establishes a solid biochemical basis for genetic and epigenetic regulation of stem cell pluripotency and provides a framework for exploring alternative factor-based reprogramming strategies.,False,CONCLUSIONS
5062,There is no known interaction between Pioneer factor OCT3/4 and major chromatin remodeling factors.,"Transcription factors, such as Oct4, are critical for establishing and maintaining pluripotent cell identity.",False,BACKGROUND
5063,There is no known interaction between Pioneer factor OCT3/4 and major chromatin remodeling factors.,"Whereas the genomic locations of several pluripotency transcription factors have been reported, the spectrum of their interaction partners is underexplored.",False,BACKGROUND
5064,There is no known interaction between Pioneer factor OCT3/4 and major chromatin remodeling factors.,"Here, we use an improved affinity protocol to purify Oct4-interacting proteins from mouse embryonic stem cells (ESCs).",False,BACKGROUND
5065,There is no known interaction between Pioneer factor OCT3/4 and major chromatin remodeling factors.,"Subsequent purification of Oct4 partners Sall4, Tcfcp2l1, Dax1, and Esrrb resulted in an Oct4 interactome of 166 proteins, including transcription factors and chromatin-modifying complexes with documented roles in self-renewal, but also many factors not previously associated with the ESC network.",True,RESULTS
5066,There is no known interaction between Pioneer factor OCT3/4 and major chromatin remodeling factors.,"We find that Esrrb associated with the basal transcription machinery and also detect interactions between transcription factors and components of the TGF-beta, Notch, and Wnt signaling pathways.",False,RESULTS
5067,There is no known interaction between Pioneer factor OCT3/4 and major chromatin remodeling factors.,"Acute depletion of Oct4 reduced binding of Tcfcp2l1, Dax1, and Esrrb to several target genes.",False,CONCLUSIONS
5068,There is no known interaction between Pioneer factor OCT3/4 and major chromatin remodeling factors.,"In conclusion, our purification protocol allowed us to bring greater definition to the circuitry controlling pluripotent cell identity.",False,CONCLUSIONS
5069,There is no relation between Erythromycin use and hypertrophic pyloric stenosis.,"OBJECTIVE To assess the association between use of macrolide antibiotics in mothers and infants from pregnancy onset until 120 days after birth and infantile hypertrophic pyloric stenosis (IHPS).   
",False,OBJECTIVE
5070,There is no relation between Erythromycin use and hypertrophic pyloric stenosis.,"DESIGN Nationwide register based cohort study.   
",False,METHODS
5071,There is no relation between Erythromycin use and hypertrophic pyloric stenosis.,"SETTING Denmark, 1996-2011.   
",False,METHODS
5072,There is no relation between Erythromycin use and hypertrophic pyloric stenosis.,"PARTICIPANTS 999,378 liveborn singletons and linked individual level information on macrolide prescriptions (maternal use during pregnancy, n=30,091; maternal use after birth, n=21,557; use in infants, n=6591), surgery for IHPS, and potential confounders.   
",False,METHODS
5073,There is no relation between Erythromycin use and hypertrophic pyloric stenosis.,"MAIN OUTCOME MEASURES Surgery for IHPS by three categories of macrolide use: in mothers during pregnancy, in mothers after birth, and in infants after birth.   
",False,METHODS
5074,There is no relation between Erythromycin use and hypertrophic pyloric stenosis.,RESULTS 880 infants developed IHPS (0.9 cases per 1000 births).,False,RESULTS
5075,There is no relation between Erythromycin use and hypertrophic pyloric stenosis.,"Compared with infants with no use of macrolides, the adjusted rate ratio for IHPS in infants with use of macrolides during days 0 to 13 after birth was 29.8 (95% confidence interval 16.4 to 54.1) and during days 14 to 120 was 3.24 (1.20 to 8.74); the corresponding absolute risk differences were 24.4 (95% confidence interval 13.0 to 44.1) and 0.65 (0.06 to 2.21) cases per 1000 infants exposed to macrolides, respectively.",False,RESULTS
5076,There is no relation between Erythromycin use and hypertrophic pyloric stenosis.,The rate ratio for maternal use of macrolides for days 0 to 13 after birth was 3.49 (1.92 to 6.34) and for days 14 to 120 was 0.70 (0.26 to 1.90); the corresponding absolute risk differences were 2.15 (0.82 to 4.64) and -0.11 (-0.26 to 0.31).,False,RESULTS
5077,There is no relation between Erythromycin use and hypertrophic pyloric stenosis.,"The rate ratios for maternal use of macrolides during pregnancy were 1.02 (0.65 to 1.59) for weeks 0 to 27 and 1.77 (0.95 to 3.31) for weeks 28 to birth; the corresponding absolute risk differences were 0.01 (-0.31 to 0.50) and 0.67 (-0.06 to 2.02).   
",False,RESULTS
5078,There is no relation between Erythromycin use and hypertrophic pyloric stenosis.,CONCLUSIONS Treatment of young infants with macrolide antibiotics was strongly associated with IHPS and should therefore only be administered if potential treatment benefits outweigh the risk.,True,CONCLUSIONS
5079,There is no relation between Erythromycin use and hypertrophic pyloric stenosis.,Maternal use of macrolides during the first two weeks after birth was also associated with an increased risk of IHPS.,True,CONCLUSIONS
5080,There is no relation between Erythromycin use and hypertrophic pyloric stenosis.,A possible association was also found with use during late pregnancy.,False,CONCLUSIONS
5081,There was an estimated 30 million cases of pneumonia in young children worldwide in 2010.,BACKGROUND The annual number of hospital admissions and in-hospital deaths due to severe acute lower respiratory infections (ALRI) in young children worldwide is unknown.,False,BACKGROUND
5082,There was an estimated 30 million cases of pneumonia in young children worldwide in 2010.,"We aimed to estimate the incidence of admissions and deaths for such infections in children younger than 5 years in 2010.   
",False,BACKGROUND
5083,There was an estimated 30 million cases of pneumonia in young children worldwide in 2010.,"METHODS We estimated the incidence of admissions for severe and very severe ALRI in children younger than 5 years, stratified by age and region, with data from a systematic review of studies published between Jan 1, 1990, and March 31, 2012, and from 28 unpublished population-based studies.",False,METHODS
5084,There was an estimated 30 million cases of pneumonia in young children worldwide in 2010.,"We applied these incidence estimates to population estimates for 2010, to calculate the global and regional burden in children admitted with severe ALRI in that year.",False,METHODS
5085,There was an estimated 30 million cases of pneumonia in young children worldwide in 2010.,"We estimated in-hospital mortality due to severe and very severe ALRI by combining incidence estimates with case fatality ratios from hospital-based studies.   
",False,METHODS
5086,There was an estimated 30 million cases of pneumonia in young children worldwide in 2010.,"FINDINGS We identified 89 eligible studies and estimated that in 2010, 11·9 million (95% CI 10·3-13·9 million) episodes of severe and 3·0 million (2·1-4·2 million) episodes of very severe ALRI resulted in hospital admissions in young children worldwide.",True,RESULTS
5087,There was an estimated 30 million cases of pneumonia in young children worldwide in 2010.,"Incidence was higher in boys than in girls, the sex disparity being greatest in South Asian studies.",False,RESULTS
5088,There was an estimated 30 million cases of pneumonia in young children worldwide in 2010.,"On the basis of data from 37 hospital studies reporting case fatality ratios for severe ALRI, we estimated that roughly 265,000 (95% CI 160,000-450,000) in-hospital deaths took place in young children, with 99% of these deaths in developing countries.",False,RESULTS
5089,There was an estimated 30 million cases of pneumonia in young children worldwide in 2010.,"Therefore, the data suggest that although 62% of children with severe ALRI are treated in hospitals, 81% of deaths happen outside hospitals.   
",False,RESULTS
5090,There was an estimated 30 million cases of pneumonia in young children worldwide in 2010.,INTERPRETATION Severe ALRI is a substantial burden on health services worldwide and a major cause of hospital referral and admission in young children.,False,CONCLUSIONS
5091,There was an estimated 30 million cases of pneumonia in young children worldwide in 2010.,"Improved hospital access and reduced inequities, such as those related to sex and rural status, could substantially decrease mortality related to such infection.",False,CONCLUSIONS
5092,There was an estimated 30 million cases of pneumonia in young children worldwide in 2010.,"Community-based management of severe disease could be an important complementary strategy to reduce pneumonia mortality and health inequities.   
",False,CONCLUSIONS
5093,There was an estimated 30 million cases of pneumonia in young children worldwide in 2010.,FUNDING WHO.,False,CONCLUSIONS
5094,Tirasemtiv targets fast-twitch muscle.,"Limited neural input results in muscle weakness in neuromuscular disease because of a reduction in the density of muscle innervation, the rate of neuromuscular junction activation or the efficiency of synaptic transmission.",False,BACKGROUND
5095,Tirasemtiv targets fast-twitch muscle.,"We developed a small-molecule fast-skeletal-troponin activator, CK-2017357, as a means to increase muscle strength by amplifying the response of muscle when neural input is otherwise diminished secondary to neuromuscular disease.",True,BACKGROUND
5096,Tirasemtiv targets fast-twitch muscle.,"Binding selectively to the fast-skeletal-troponin complex, CK-2017357 slows the rate of calcium release from troponin C and sensitizes muscle to calcium.",True,RESULTS
5097,Tirasemtiv targets fast-twitch muscle.,"As a consequence, the force-calcium relationship of muscle fibers shifts leftwards, as does the force-frequency relationship of a nerve-muscle pair, so that CK-2017357 increases the production of muscle force in situ at sub-maximal nerve stimulation rates.",False,RESULTS
5098,Tirasemtiv targets fast-twitch muscle.,"Notably, we show that sensitization of the fast-skeletal-troponin complex to calcium improves muscle force and grip strength immediately after administration of single doses of CK-2017357 in a model of the neuromuscular disease myasthenia gravis.",False,CONCLUSIONS
5099,Tirasemtiv targets fast-twitch muscle.,Troponin activation may provide a new therapeutic approach to improve physical activity in diseases where neuromuscular function is compromised.,False,CONCLUSIONS
5100,"Trans-acting factors, such as lncRNAs, influence mRNA translation.",Mammalian long intergenic noncoding RNAs (lincRNAs) are best known for modulating transcription.,False,BACKGROUND
5101,"Trans-acting factors, such as lncRNAs, influence mRNA translation.",Here we report a posttranscriptional function for lincRNA-p21 as a modulator of translation.,True,BACKGROUND
5102,"Trans-acting factors, such as lncRNAs, influence mRNA translation.","Association of the RNA-binding protein HuR with lincRNA-p21 favored the recruitment of let-7/Ago2 to lincRNA-p21, leading to lower lincRNA-p21 stability.",False,RESULTS
5103,"Trans-acting factors, such as lncRNAs, influence mRNA translation.","Under reduced HuR levels, lincRNA-p21 accumulated in human cervical carcinoma HeLa cells, increasing its association with JUNB and CTNNB1 mRNAs and selectively lowering their translation.",True,RESULTS
5104,"Trans-acting factors, such as lncRNAs, influence mRNA translation.","With elevated HuR, lincRNA-p21 levels declined, which in turn derepressed JunB and β-catenin translation and increased the levels of these proteins.",True,RESULTS
5105,"Trans-acting factors, such as lncRNAs, influence mRNA translation.",We propose that HuR controls translation of a subset of target mRNAs by influencing lincRNA-p21 levels.,True,CONCLUSIONS
5106,"Trans-acting factors, such as lncRNAs, influence mRNA translation.",Our findings uncover a role for lincRNA as a posttranscriptional inhibitor of translation.,True,CONCLUSIONS
5107,Transcription factor EB induces transcription of pro-inflammatory cytokines in macrophages infected with Staphylococcus aureus.,Animal host defense against infection requires the expression of defense genes at the right place and the right time.,False,BACKGROUND
5108,Transcription factor EB induces transcription of pro-inflammatory cytokines in macrophages infected with Staphylococcus aureus.,Understanding such tight control of host defense requires the elucidation of the transcription factors involved.,False,BACKGROUND
5109,Transcription factor EB induces transcription of pro-inflammatory cytokines in macrophages infected with Staphylococcus aureus.,"By using an unbiased approach in the model Caenorhabditis elegans, we discovered that HLH-30 (known as TFEB in mammals) is a key transcription factor for host defense.",False,RESULTS
5110,Transcription factor EB induces transcription of pro-inflammatory cytokines in macrophages infected with Staphylococcus aureus.,"HLH-30 was activated shortly after Staphylococcus aureus infection, and drove the expression of close to 80% of the host response, including antimicrobial and autophagy genes that were essential for host tolerance of infection.",False,RESULTS
5111,Transcription factor EB induces transcription of pro-inflammatory cytokines in macrophages infected with Staphylococcus aureus.,TFEB was also rapidly activated in murine macrophages upon S. aureus infection and was required for proper transcriptional induction of several proinflammatory cytokines and chemokines.,True,CONCLUSIONS
5112,Transcription factor EB induces transcription of pro-inflammatory cytokines in macrophages infected with Staphylococcus aureus.,"Thus, our data suggest that TFEB is a previously unappreciated, evolutionarily ancient transcription factor in the host response to infection.",False,CONCLUSIONS
5113,Transplanted human glial progenitor cells can mature in their host animal.,"Human astrocytes are larger and more complex than those of infraprimate mammals, suggesting that their role in neural processing has expanded with evolution.",False,BACKGROUND
5114,Transplanted human glial progenitor cells can mature in their host animal.,"To assess the cell-autonomous and species-selective properties of human glia, we engrafted human glial progenitor cells (GPCs) into neonatal immunodeficient mice.",False,BACKGROUND
5115,Transplanted human glial progenitor cells can mature in their host animal.,"Upon maturation, the recipient brains exhibited large numbers and high proportions of both human glial progenitors and astrocytes.",True,RESULTS
5116,Transplanted human glial progenitor cells can mature in their host animal.,"The engrafted human glia were gap-junction-coupled to host astroglia, yet retained the size and pleomorphism of hominid astroglia, and propagated Ca2+ signals 3-fold faster than their hosts.",False,RESULTS
5117,Transplanted human glial progenitor cells can mature in their host animal.,"Long-term potentiation (LTP) was sharply enhanced in the human glial chimeric mice, as was their learning, as assessed by Barnes maze navigation, object-location memory, and both contextual and tone fear conditioning.",False,RESULTS
5118,Transplanted human glial progenitor cells can mature in their host animal.,Mice allografted with murine GPCs showed no enhancement of either LTP or learning.,False,RESULTS
5119,Transplanted human glial progenitor cells can mature in their host animal.,These findings indicate that human glia differentially enhance both activity-dependent plasticity and learning in mice.,False,CONCLUSIONS
5120,Treatment with a protein named FN impairs regenerative abilities of aged muscles.,Age-related changes in the niche have long been postulated to impair the function of somatic stem cells.,False,BACKGROUND
5121,Treatment with a protein named FN impairs regenerative abilities of aged muscles.,"Here we demonstrate that the aged stem cell niche in skeletal muscle contains substantially reduced levels of fibronectin (FN), leading to detrimental consequences for the function and maintenance of muscle stem cells (MuSCs).",False,BACKGROUND
5122,Treatment with a protein named FN impairs regenerative abilities of aged muscles.,Deletion of the gene encoding FN from young regenerating muscles replicates the aging phenotype and leads to a loss of MuSC numbers.,True,RESULTS
5123,Treatment with a protein named FN impairs regenerative abilities of aged muscles.,"By using an extracellular matrix (ECM) library screen and pathway profiling, we characterize FN as a preferred adhesion substrate for MuSCs and demonstrate that integrin-mediated signaling through focal adhesion kinase and the p38 mitogen-activated protein kinase pathway is strongly de-regulated in MuSCs from aged mice because of insufficient attachment to the niche.",False,RESULTS
5124,Treatment with a protein named FN impairs regenerative abilities of aged muscles.,Reconstitution of FN levels in the aged niche remobilizes stem cells and restores youth-like muscle regeneration.,True,CONCLUSIONS
5125,Treatment with a protein named FN impairs regenerative abilities of aged muscles.,"Taken together, we identify the loss of stem cell adhesion to FN in the niche ECM as a previously unknown aging mechanism.",False,CONCLUSIONS
5126,Treatment with a protein named FN restores regenerative abilities of aged muscles.,Age-related changes in the niche have long been postulated to impair the function of somatic stem cells.,False,BACKGROUND
5127,Treatment with a protein named FN restores regenerative abilities of aged muscles.,"Here we demonstrate that the aged stem cell niche in skeletal muscle contains substantially reduced levels of fibronectin (FN), leading to detrimental consequences for the function and maintenance of muscle stem cells (MuSCs).",False,BACKGROUND
5128,Treatment with a protein named FN restores regenerative abilities of aged muscles.,Deletion of the gene encoding FN from young regenerating muscles replicates the aging phenotype and leads to a loss of MuSC numbers.,True,RESULTS
5129,Treatment with a protein named FN restores regenerative abilities of aged muscles.,"By using an extracellular matrix (ECM) library screen and pathway profiling, we characterize FN as a preferred adhesion substrate for MuSCs and demonstrate that integrin-mediated signaling through focal adhesion kinase and the p38 mitogen-activated protein kinase pathway is strongly de-regulated in MuSCs from aged mice because of insufficient attachment to the niche.",False,RESULTS
5130,Treatment with a protein named FN restores regenerative abilities of aged muscles.,Reconstitution of FN levels in the aged niche remobilizes stem cells and restores youth-like muscle regeneration.,True,CONCLUSIONS
5131,Treatment with a protein named FN restores regenerative abilities of aged muscles.,"Taken together, we identify the loss of stem cell adhesion to FN in the niche ECM as a previously unknown aging mechanism.",False,CONCLUSIONS
5132,Tuberculosis incidence occurs at higher rates in more sparsely populated areas in the UK.,"OBJECTIVE To examine the effect of ethnicity on the relation between tuberculosis and deprivation.   
",False,OBJECTIVE
5133,Tuberculosis incidence occurs at higher rates in more sparsely populated areas in the UK.,"DESIGN Retrospective ecological study comparing incidence of tuberculosis in white and south Asian residents of the 39 electoral wards in Birmingham with ethnic specific indices of deprivation.   
",False,METHODS
5134,Tuberculosis incidence occurs at higher rates in more sparsely populated areas in the UK.,"SETTING Birmingham, 1989-93.   ",False,METHODS
5135,Tuberculosis incidence occurs at higher rates in more sparsely populated areas in the UK.,"SUBJECTS 1516 notified cases of tuberculosis.   
",False,METHODS
5136,Tuberculosis incidence occurs at higher rates in more sparsely populated areas in the UK.,"MAIN OUTCOME MEASURES Rates of tuberculosis and measures of deprivation.   
",False,METHODS
5137,Tuberculosis incidence occurs at higher rates in more sparsely populated areas in the UK.,RESULTS Univariate analysis showed significant associations of tuberculosis rates for the whole population with several indices of deprivation (P<0.01) and with the proportion of the population of south Asian origin (P<0.01).,False,RESULTS
5138,Tuberculosis incidence occurs at higher rates in more sparsely populated areas in the UK.,"All deprivation covariates were positively associated with each other but on multiple regression, higher level of overcrowding was independently associated with tuberculosis rates.",True,RESULTS
5139,Tuberculosis incidence occurs at higher rates in more sparsely populated areas in the UK.,"For the white population, overcrowding was associated with tuberculosis rates independently of other variables (P=0.0036).",True,RESULTS
5140,Tuberculosis incidence occurs at higher rates in more sparsely populated areas in the UK.,"No relation with deprivation was found for the south Asian population in either single or multivariable analyses.   
",False,RESULTS
5141,Tuberculosis incidence occurs at higher rates in more sparsely populated areas in the UK.,"CONCLUSIONS Poverty is significantly associated with tuberculosis in the white population, but no such relation exists for those of Asian ethnicity.",False,CONCLUSIONS
5142,Tuberculosis incidence occurs at higher rates in more sparsely populated areas in the UK.,"These findings suggest that causal factors, and therefore potential interventions, will also differ by ethnic group.",False,CONCLUSIONS
5143,Tuberculosis incidence occurs at higher rates in more sparsely populated areas in the UK.,This paper seeks to establish the strength of association between contemporary tuberculosis (TB) in England and Wales and several potential aetiological factors.,False,BACKGROUND
5144,Tuberculosis incidence occurs at higher rates in more sparsely populated areas in the UK.,"It presents an ecological analysis of standardised annual TB mortality rates for the 403 local authority districts between 1982 and 1992, disaggregated by age and sex.",False,METHODS
5145,Tuberculosis incidence occurs at higher rates in more sparsely populated areas in the UK.,"Social, demographic and ethnicity measures from the 1981 and 1991 censuses and standardised annual AIDS-related mortality rates for young men are used to calculate Poisson regression models.",False,METHODS
5146,Tuberculosis incidence occurs at higher rates in more sparsely populated areas in the UK.,A strong association was found between all TB mortality groups and overcrowding at the household level.,True,RESULTS
5147,Tuberculosis incidence occurs at higher rates in more sparsely populated areas in the UK.,"For women, no other measures improved the explanatory power of the models.",False,RESULTS
5148,Tuberculosis incidence occurs at higher rates in more sparsely populated areas in the UK.,"In multiple regressions, both poverty and AIDS-related mortality explained additional variation in the model for younger men.",False,RESULTS
5149,Tuberculosis incidence occurs at higher rates in more sparsely populated areas in the UK.,The link between ethnicity and tuberculosis notifications was not reflected in this analysis of mortality.,False,RESULTS
5150,Tuberculosis incidence occurs at higher rates in more sparsely populated areas in the UK.,"For all groups no evidence of a positive relationship with ethnicity was found, once overcrowding had been accounted for.",False,RESULTS
5151,Tuberculosis incidence occurs at higher rates in more sparsely populated areas in the UK.,The significance of household as opposed to district level crowding suggests that prolonged contact is required for disease transmission.,False,CONCLUSIONS
5152,Tuberculosis incidence occurs at higher rates in more sparsely populated areas in the UK.,Regression analysis indicates that it is the overcrowding and poverty among ethnic populations that is significant for their tuberculosis mortality.,True,CONCLUSIONS
5153,Tuberculosis incidence occurs at higher rates in more sparsely populated areas in the UK.,The fact that the relationship between AIDS and TB is confined to the group most typical of AIDS patients provides evidence that AIDS has little influence on the level of tuberculosis mortality in the wider population.,False,CONCLUSIONS
5154,Tuberculosis incidence occurs at higher rates in more sparsely populated areas in the UK.,"Explanations for the observed relationship include preferential certification, migration for treatment and shortcomings in health care provision.",False,CONCLUSIONS
5155,Tuberculosis-induced granulomas express different immune system protein signatures than the surrounding tissue.,Granulomas are the pathological hallmark of tuberculosis (TB).,False,BACKGROUND
5156,Tuberculosis-induced granulomas express different immune system protein signatures than the surrounding tissue.,"However, their function and mechanisms of formation remain poorly understood.",False,BACKGROUND
5157,Tuberculosis-induced granulomas express different immune system protein signatures than the surrounding tissue.,"To understand the role of granulomas in TB, we analyzed the proteomes of granulomas from subjects with tuberculosis in an unbiased manner.",False,BACKGROUND
5158,Tuberculosis-induced granulomas express different immune system protein signatures than the surrounding tissue.,"Using laser-capture microdissection, mass spectrometry and confocal microscopy, we generated detailed molecular maps of human granulomas.",False,METHODS
5159,Tuberculosis-induced granulomas express different immune system protein signatures than the surrounding tissue.,"We found that the centers of granulomas have a pro-inflammatory environment that is characterized by the presence of antimicrobial peptides, reactive oxygen species and pro-inflammatory eicosanoids.",True,RESULTS
5160,Tuberculosis-induced granulomas express different immune system protein signatures than the surrounding tissue.,"Conversely, the tissue surrounding the caseum has a comparatively anti-inflammatory signature.",True,RESULTS
5161,Tuberculosis-induced granulomas express different immune system protein signatures than the surrounding tissue.,These findings are consistent across a set of six human subjects and in rabbits.,False,RESULTS
5162,Tuberculosis-induced granulomas express different immune system protein signatures than the surrounding tissue.,"Although the balance between systemic pro- and anti-inflammatory signals is crucial to TB disease outcome, here we find that these signals are physically segregated within each granuloma.",True,CONCLUSIONS
5163,Tuberculosis-induced granulomas express different immune system protein signatures than the surrounding tissue.,"From the protein and lipid snapshots of human and rabbit lesions analyzed here, we hypothesize that the pathologic response to TB is shaped by the precise anatomical localization of these inflammatory pathways during the development of the granuloma.",False,CONCLUSIONS
5164,Two variants of chromosome 6q21 are associated with radiation therapy-induced second malignancies in pediatric Hodgkin lymphoma patients.,Survivors of pediatric Hodgkin's lymphoma are at risk for radiation therapy–induced second malignant neoplasms (SMNs).,False,BACKGROUND
5165,Two variants of chromosome 6q21 are associated with radiation therapy-induced second malignancies in pediatric Hodgkin lymphoma patients.,We identified two variants at chromosome 6q21 associated with SMNs in survivors of Hodgkin's lymphoma treated with radiation therapy as children but not as adults.,True,BACKGROUND
5166,Two variants of chromosome 6q21 are associated with radiation therapy-induced second malignancies in pediatric Hodgkin lymphoma patients.,"The variants comprise a risk locus associated with decreased basal expression of PRDM1 (encoding PR domain containing 1, with ZNF domain) and impaired induction of the PRDM1 protein after radiation exposure.",False,BACKGROUND
5167,Two variants of chromosome 6q21 are associated with radiation therapy-induced second malignancies in pediatric Hodgkin lymphoma patients.,These data suggest a new gene-exposure interaction that may implicate PRDM1 in the etiology of radiation therapy-induced SMNs.,False,BACKGROUND
5168,Type 1 Diabetes is associated with subtle perturbations in T reg development.,Genome-wide association studies are now identifying disease-associated chromosome regions.,False,BACKGROUND
5169,Type 1 Diabetes is associated with subtle perturbations in T reg development.,"However, even after convincing replication, the localization of the causal variant(s) requires comprehensive resequencing, extensive genotyping and statistical analyses in large sample sets leading to targeted functional studies.",False,BACKGROUND
5170,Type 1 Diabetes is associated with subtle perturbations in T reg development.,"Here, we have localized the type 1 diabetes (T1D) association in the interleukin 2 receptor alpha (IL2RA) gene region to two independent groups of SNPs, spanning overlapping regions of 14 and 40 kb, encompassing IL2RA intron 1 and the 5′ regions of IL2RA and RBM17 (odds ratio = 2.04, 95% confidence interval = 1.70–2.45; P = 1.92 × 10−28; control frequency = 0.635).",True,BACKGROUND
5171,Type 1 Diabetes is associated with subtle perturbations in T reg development.,"Furthermore, we have associated IL2RA T1D susceptibility genotypes with lower circulating levels of the biomarker, soluble IL-2RA (P = 6.28 × 10−28), suggesting that an inherited lower immune responsiveness predisposes to T1D.",True,BACKGROUND
5172,Type 1 Diabetes is associated with subtle perturbations in T reg development.,"Numerous reports have demonstrated that CD4(+)CD25(+) regulatory T cells (Tregs) from individuals with a range of human autoimmune diseases, including type 1 diabetes, are deficient in their ability to control autologous proinflammatory responses when compared with nondiseased, control individuals.",True,OBJECTIVE
5173,Type 1 Diabetes is associated with subtle perturbations in T reg development.,"Treg dysfunction could be a primary, causal event or may result from perturbations in the immune system during disease development.",False,OBJECTIVE
5174,Type 1 Diabetes is associated with subtle perturbations in T reg development.,"Polymorphisms in genes associated with Treg function, such as IL2RA, confer a higher risk of autoimmune disease.",False,OBJECTIVE
5175,Type 1 Diabetes is associated with subtle perturbations in T reg development.,"Although this suggests a primary role for defective Tregs in autoimmunity, a link between IL2RA gene polymorphisms and Treg function has not been examined.",False,OBJECTIVE
5176,Type 1 Diabetes is associated with subtle perturbations in T reg development.,We addressed this by examining the impact of an IL2RA haplotype associated with type 1 diabetes on Treg fitness and suppressive function.,False,OBJECTIVE
5177,Type 1 Diabetes is associated with subtle perturbations in T reg development.,Studies were conducted using healthy human subjects to avoid any confounding effects of disease.,False,METHODS
5178,Type 1 Diabetes is associated with subtle perturbations in T reg development.,"We demonstrated that the presence of an autoimmune disease-associated IL2RA haplotype correlates with diminished IL-2 responsiveness in Ag-experienced CD4(+) T cells, as measured by phosphorylation of STAT5a, and is associated with lower levels of FOXP3 expression by Tregs and a reduction in their ability to suppress proliferation of autologous effector T cells.",False,CONCLUSIONS
5179,Type 1 Diabetes is associated with subtle perturbations in T reg development.,"These data offer a rationale that contributes to the molecular and cellular mechanisms through which polymorphisms in the IL-2RA gene affect immune regulation, and consequently upon susceptibility to autoimmune and inflammatory diseases.",False,CONCLUSIONS
5180,Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.,"OBJECTIVE To determine whether ultrasound imaging can reduce the risk of failed lumbar punctures or epidural catheterisations, when compared with standard palpation methods, and whether ultrasound imaging can reduce traumatic procedures, insertion attempts, and needle redirections.   
",False,OBJECTIVE
5181,Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.,"DESIGN Systematic review and meta-analysis of randomised controlled trials.   
",False,METHODS
5182,Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.,"DATA SOURCES Ovid Medline, Embase, and Cochrane Central Register of Controlled Trials up to May 2012, without restriction by language or publication status.   ",False,METHODS
5183,Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.,"REVIEW METHODS Randomised trials that compared ultrasound imaging with standard methods (no imaging) in the performance of a lumbar puncture or epidural catheterisation were identified.   
",False,METHODS
5184,Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.,"RESULTS 14 studies with a total of 1334 patients were included (674 patients assigned to the ultrasound group, 660 to the control group).",False,RESULTS
5185,Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.,Five studies evaluated lumbar punctures and nine evaluated epidural catheterisations.,False,RESULTS
5186,Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.,Six of 624 procedures conducted in the ultrasound group failed; 44 of 610 procedures in the control group failed.,False,RESULTS
5187,Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.,"Ultrasound imaging reduced the risk of failed procedures (risk ratio 0.21 (95% confidence interval 0.10 to 0.43), P<0.001).",False,RESULTS
5188,Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.,"Risk reduction was similar when subgroup analysis was performed for lumbar punctures (risk ratio 0.19 (0.07 to 0.56), P=0.002) or epidural catheterisations (0.23 (0.09 to 0.60), P=0.003).",False,RESULTS
5189,Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.,"Ultrasound imaging also significantly reduced the risk of traumatic procedures (risk ratio 0.27 (0.11 to 0.67), P=0.005), the number of insertion attempts (mean difference -0.44 (-0.64 to -0.24), P<0.001), and the number of needle redirections (mean difference -1.00 (-1.24 to -0.75), P<0.001).   
",True,RESULTS
5190,Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.,"CONCLUSIONS Ultrasound imaging can reduce the risk of failed or traumatic lumbar punctures and epidural catheterisations, as well as the number of needle insertions and redirections.",True,CONCLUSIONS
5191,Ultrasound guidance significantly reduces the number of needle insertion attempts necessary for a given procedure.,Ultrasound may be a useful adjunct for these procedures.,False,CONCLUSIONS
5192,Ultrasound guidance significantly reduces the number of traumatic procedures when attempting needle insertion.,"OBJECTIVE To determine whether ultrasound imaging can reduce the risk of failed lumbar punctures or epidural catheterisations, when compared with standard palpation methods, and whether ultrasound imaging can reduce traumatic procedures, insertion attempts, and needle redirections.   
",False,OBJECTIVE
5193,Ultrasound guidance significantly reduces the number of traumatic procedures when attempting needle insertion.,"DESIGN Systematic review and meta-analysis of randomised controlled trials.   
",False,METHODS
5194,Ultrasound guidance significantly reduces the number of traumatic procedures when attempting needle insertion.,"DATA SOURCES Ovid Medline, Embase, and Cochrane Central Register of Controlled Trials up to May 2012, without restriction by language or publication status.   ",False,METHODS
5195,Ultrasound guidance significantly reduces the number of traumatic procedures when attempting needle insertion.,"REVIEW METHODS Randomised trials that compared ultrasound imaging with standard methods (no imaging) in the performance of a lumbar puncture or epidural catheterisation were identified.   
",False,METHODS
5196,Ultrasound guidance significantly reduces the number of traumatic procedures when attempting needle insertion.,"RESULTS 14 studies with a total of 1334 patients were included (674 patients assigned to the ultrasound group, 660 to the control group).",False,RESULTS
5197,Ultrasound guidance significantly reduces the number of traumatic procedures when attempting needle insertion.,Five studies evaluated lumbar punctures and nine evaluated epidural catheterisations.,False,RESULTS
5198,Ultrasound guidance significantly reduces the number of traumatic procedures when attempting needle insertion.,Six of 624 procedures conducted in the ultrasound group failed; 44 of 610 procedures in the control group failed.,False,RESULTS
5199,Ultrasound guidance significantly reduces the number of traumatic procedures when attempting needle insertion.,"Ultrasound imaging reduced the risk of failed procedures (risk ratio 0.21 (95% confidence interval 0.10 to 0.43), P<0.001).",True,RESULTS
5200,Ultrasound guidance significantly reduces the number of traumatic procedures when attempting needle insertion.,"Risk reduction was similar when subgroup analysis was performed for lumbar punctures (risk ratio 0.19 (0.07 to 0.56), P=0.002) or epidural catheterisations (0.23 (0.09 to 0.60), P=0.003).",True,RESULTS
5201,Ultrasound guidance significantly reduces the number of traumatic procedures when attempting needle insertion.,"Ultrasound imaging also significantly reduced the risk of traumatic procedures (risk ratio 0.27 (0.11 to 0.67), P=0.005), the number of insertion attempts (mean difference -0.44 (-0.64 to -0.24), P<0.001), and the number of needle redirections (mean difference -1.00 (-1.24 to -0.75), P<0.001).   
",True,RESULTS
5202,Ultrasound guidance significantly reduces the number of traumatic procedures when attempting needle insertion.,"CONCLUSIONS Ultrasound imaging can reduce the risk of failed or traumatic lumbar punctures and epidural catheterisations, as well as the number of needle insertions and redirections.",True,CONCLUSIONS
5203,Ultrasound guidance significantly reduces the number of traumatic procedures when attempting needle insertion.,Ultrasound may be a useful adjunct for these procedures.,False,CONCLUSIONS
5204,"Upon developing tyrosine-kinase inhibitor resistance, new mutations in epidermal growth factor receptors emerge and cause treatment failure.",Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.,False,BACKGROUND
5205,"Upon developing tyrosine-kinase inhibitor resistance, new mutations in epidermal growth factor receptors emerge and cause treatment failure.",We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.,True,METHODS
5206,"Upon developing tyrosine-kinase inhibitor resistance, new mutations in epidermal growth factor receptors emerge and cause treatment failure.",We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.,False,METHODS
5207,"Upon developing tyrosine-kinase inhibitor resistance, new mutations in epidermal growth factor receptors emerge and cause treatment failure.","All were positive for the T790M mutation before treatment, but upon developing AZD9291 resistance three molecular subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.",True,RESULTS
5208,"Upon developing tyrosine-kinase inhibitor resistance, new mutations in epidermal growth factor receptors emerge and cause treatment failure.",Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.,False,CONCLUSIONS
5209,"Upon viral challenge, influenza-specific memory CD4+ T cells greatly diminish the early production of inflammatory chemokines in the lung.",Inflammation induced by recognition of pathogen-associated molecular patterns markedly affects subsequent adaptive responses.,False,BACKGROUND
5210,"Upon viral challenge, influenza-specific memory CD4+ T cells greatly diminish the early production of inflammatory chemokines in the lung.",We asked whether the adaptive immune system can also affect the character and magnitude of innate inflammatory responses.,False,BACKGROUND
5211,"Upon viral challenge, influenza-specific memory CD4+ T cells greatly diminish the early production of inflammatory chemokines in the lung.","We found that the response of memory, but not naive, CD4+ T cells enhances production of multiple innate inflammatory cytokines and chemokines (IICs) in the lung and that, during influenza infection, this leads to early control of virus.",True,RESULTS
5212,"Upon viral challenge, influenza-specific memory CD4+ T cells greatly diminish the early production of inflammatory chemokines in the lung.",Memory CD4+ T cell–induced IICs and viral control require cognate antigen recognition and are optimal when memory cells are either T helper type 1 (TH1) or TH17 polarized but are independent of interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) production and do not require activation of conserved pathogen recognition pathways.,False,RESULTS
5213,"Upon viral challenge, influenza-specific memory CD4+ T cells greatly diminish the early production of inflammatory chemokines in the lung.",This represents a previously undescribed mechanism by which memory CD4+ T cells induce an early innate response that enhances immune protection against pathogens.,False,CONCLUSIONS
5214,"Upon viral challenge, influenza-specific memory CD4+ T cells greatly enhance the early production of inflammatory chemokines in the lung.",Inflammation induced by recognition of pathogen-associated molecular patterns markedly affects subsequent adaptive responses.,False,BACKGROUND
5215,"Upon viral challenge, influenza-specific memory CD4+ T cells greatly enhance the early production of inflammatory chemokines in the lung.",We asked whether the adaptive immune system can also affect the character and magnitude of innate inflammatory responses.,False,BACKGROUND
5216,"Upon viral challenge, influenza-specific memory CD4+ T cells greatly enhance the early production of inflammatory chemokines in the lung.","We found that the response of memory, but not naive, CD4+ T cells enhances production of multiple innate inflammatory cytokines and chemokines (IICs) in the lung and that, during influenza infection, this leads to early control of virus.",True,RESULTS
5217,"Upon viral challenge, influenza-specific memory CD4+ T cells greatly enhance the early production of inflammatory chemokines in the lung.",Memory CD4+ T cell–induced IICs and viral control require cognate antigen recognition and are optimal when memory cells are either T helper type 1 (TH1) or TH17 polarized but are independent of interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) production and do not require activation of conserved pathogen recognition pathways.,False,RESULTS
5218,"Upon viral challenge, influenza-specific memory CD4+ T cells greatly enhance the early production of inflammatory chemokines in the lung.",This represents a previously undescribed mechanism by which memory CD4+ T cells induce an early innate response that enhances immune protection against pathogens.,False,CONCLUSIONS
5219,Upregulation of dynein in Drosophila neurons increases the number of microtubule plus-ends growing toward the cell body of each neuron.,Axons and dendrites differ in both microtubule organization and in the organelles and proteins they contain.,False,BACKGROUND
5220,Upregulation of dynein in Drosophila neurons increases the number of microtubule plus-ends growing toward the cell body of each neuron.,Here we show that the microtubule motor dynein has a crucial role in polarized transport and in controlling the orientation of axonal microtubules in Drosophila melanogaster dendritic arborization (da) neurons.,False,BACKGROUND
5221,Upregulation of dynein in Drosophila neurons increases the number of microtubule plus-ends growing toward the cell body of each neuron.,Changes in organelle distribution within the dendritic arbors of dynein mutant neurons correlate with a proximal shift in dendritic branch position.,False,RESULTS
5222,Upregulation of dynein in Drosophila neurons increases the number of microtubule plus-ends growing toward the cell body of each neuron.,Dynein is also necessary for the dendrite-specific localization of Golgi outposts and the ion channel Pickpocket.,False,RESULTS
5223,Upregulation of dynein in Drosophila neurons increases the number of microtubule plus-ends growing toward the cell body of each neuron.,"Axonal microtubules are normally oriented uniformly plus-end-distal; however, without dynein, axons contain both plus- and minus-end distal microtubules.",True,CONCLUSIONS
5224,Upregulation of dynein in Drosophila neurons increases the number of microtubule plus-ends growing toward the cell body of each neuron.,"These data suggest that dynein is required for the distinguishing properties of the axon and dendrites: without dynein, dendritic organelles and proteins enter the axon and the axonal microtubules are no longer uniform in polarity.",False,CONCLUSIONS
5225,V-9302 inhibits antitumor responses by decreasing cell death and oxidative stress.,The unique metabolic demands of cancer cells underscore potentially fruitful opportunities for drug discovery in the era of precision medicine.,False,BACKGROUND
5226,V-9302 inhibits antitumor responses by decreasing cell death and oxidative stress.,"However, therapeutic targeting of cancer metabolism has led to surprisingly few new drugs to date.",False,BACKGROUND
5227,V-9302 inhibits antitumor responses by decreasing cell death and oxidative stress.,"The neutral amino acid glutamine serves as a key intermediate in numerous metabolic processes leveraged by cancer cells, including biosynthesis, cell signaling, and oxidative protection.",False,BACKGROUND
5228,V-9302 inhibits antitumor responses by decreasing cell death and oxidative stress.,"Herein we report the preclinical development of V-9302, a competitive small molecule antagonist of transmembrane glutamine flux that selectively and potently targets the amino acid transporter ASCT2.",False,BACKGROUND
5229,V-9302 inhibits antitumor responses by decreasing cell death and oxidative stress.,"Pharmacological blockade of ASCT2 with V-9302 resulted in attenuated cancer cell growth and proliferation, increased cell death, and increased oxidative stress, which collectively contributed to antitumor responses in vitro and in vivo.",True,RESULTS
5230,V-9302 inhibits antitumor responses by decreasing cell death and oxidative stress.,"This is the first study, to our knowledge, to demonstrate the utility of a pharmacological inhibitor of glutamine transport in oncology, representing a new class of targeted therapy and laying a framework for paradigm-shifting therapies targeting cancer cell metabolism.",False,RESULTS
5231,Vaccinating the gastrointestinal tract induces protection of rectal and vaginal mucosa.,Both rectal and vaginal mucosal surfaces serve as transmission routes for pathogenic microorganisms.,False,BACKGROUND
5232,Vaccinating the gastrointestinal tract induces protection of rectal and vaginal mucosa.,"Vaccination through large intestinal mucosa, previously proven protective for both of these mucosal sites in animal studies, can be achieved successfully by direct intracolorectal (i.c.r.) administration, but this route is clinically impractical.",True,BACKGROUND
5233,Vaccinating the gastrointestinal tract induces protection of rectal and vaginal mucosa.,Oral vaccine delivery seems preferable but runs the risk of the vaccine's destruction in the upper gastrointestinal tract.,False,BACKGROUND
5234,Vaccinating the gastrointestinal tract induces protection of rectal and vaginal mucosa.,"Therefore, we designed a large intestine-targeted oral delivery with pH-dependent microparticles containing vaccine nanoparticles, which induced colorectal immunity in mice comparably to colorectal vaccination and protected against rectal and vaginal viral challenge.",True,BACKGROUND
5235,Vaccinating the gastrointestinal tract induces protection of rectal and vaginal mucosa.,"Conversely, vaccine targeted to the small intestine induced only small intestinal immunity and provided no rectal or vaginal protection, demonstrating functional compartmentalization within the gut mucosal immune system.",False,BACKGROUND
5236,Vaccinating the gastrointestinal tract induces protection of rectal and vaginal mucosa.,"Therefore, using this oral vaccine delivery system to target the large intestine, but not the small intestine, may represent a feasible new strategy for immune protection of rectal and vaginal mucosa.",True,BACKGROUND
5237,Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"IMPORTANCE Combining pharmacotherapies for tobacco-dependence treatment may increase smoking abstinence.   
",False,BACKGROUND
5238,Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"OBJECTIVE To determine efficacy and safety of varenicline and bupropion sustained-release (SR; combination therapy) compared with varenicline (monotherapy) in cigarette smokers.   
",False,OBJECTIVE
5239,Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"DESIGN, SETTING, AND PARTICIPANTS Randomized, blinded, placebo-controlled multicenter clinical trial with a 12-week treatment period and follow-up through week 52 conducted between October 2009 and April 2013 at 3 midwestern clinical research sites.",False,METHODS
5240,Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"Five hundred six adult (≥18 years) cigarette smokers were randomly assigned and 315 (62%) completed the study.   
",False,METHODS
5241,Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"INTERVENTIONS Twelve weeks of varenicline and bupropion SR or varenicline and placebo.   
",False,METHODS
5242,Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"MAIN OUTCOMES AND MEASURES Primary outcome was abstinence rates at week 12, defined as prolonged (no smoking from 2 weeks after the target quit date) abstinence and 7-day point-prevalence (no smoking past 7 days) abstinence.",False,METHODS
5243,Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,Secondary outcomes were prolonged and point-prevalence smoking abstinence rates at weeks 26 and 52.,False,METHODS
5244,Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"Outcomes were biochemically confirmed.   
",False,METHODS
5245,Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"RESULTS At 12 weeks, 53.0% of the combination therapy group achieved prolonged smoking abstinence and 56.2% achieved 7-day point-prevalence smoking abstinence compared with 43.2% and 48.6% in varenicline monotherapy (odds ratio [OR], 1.49; 95% CI, 1.05-2.12; P = .03 and OR, 1.36; 95% CI, 0.95-1.93; P = .09, respectively).",False,RESULTS
5246,Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"At 26 weeks, 36.6% of the combination therapy group achieved prolonged and 38.2% achieved 7-day point-prevalence smoking abstinence compared with 27.6% and 31.9% in varenicline monotherapy (OR, 1.52; 95% CI, 1.04-2.22; P = .03 and OR, 1.32; 95% CI, 0.91-1.91; P = .14, respectively).",True,RESULTS
5247,Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"At 52 weeks, 30.9% of the combination therapy group achieved prolonged and 36.6% achieved 7-day point-prevalence smoking abstinence compared with 24.5% and 29.2% in varenicline monotherapy (OR, 1.39; 95% CI, 0.93-2.07; P = .11 and OR, 1.40; 95% CI, 0.96-2.05; P = .08, respectively).",False,RESULTS
5248,Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"Participants receiving combination therapy reported more anxiety (7.2% vs 3.1%; P = .04) and depressive symptoms (3.6% vs 0.8%; P = .03).   
",False,RESULTS
5249,Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"CONCLUSIONS AND RELEVANCE Among cigarette smokers, combined use of varenicline and bupropion, compared with varenicline alone, increased prolonged abstinence but not 7-day point prevalence at 12 and 26 weeks.",False,CONCLUSIONS
5250,Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,Neither outcome was significantly different at 52 weeks.,False,CONCLUSIONS
5251,Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"Further research is required to determine the role of combination therapy in smoking cessation.   
",False,CONCLUSIONS
5252,Varenicline monotherapy is more effective after 26 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,TRIAL REGISTRATION clinicaltrials.gov Identifier: http://clinicaltrials.gov/show/NCT00935818.,False,CONCLUSIONS
5253,Varying expression levels of EBI2 affect the positioning and migration of B cells.,Humoral immunity depends on both rapid and long-term antibody production against invading pathogens.,False,BACKGROUND
5254,Varying expression levels of EBI2 affect the positioning and migration of B cells.,"This is achieved by the generation of spatially distinct extrafollicular plasmablast and follicular germinal center (GC) B cell populations, but the signals that guide responding B cells to these alternative compartments have not been fully elucidated.",False,BACKGROUND
5255,Varying expression levels of EBI2 affect the positioning and migration of B cells.,"Here, we show that expression of the orphan G protein-coupled receptor Epstein-Barr virus-induced gene 2 (EBI2, also known as GPR183) by activated B cells was essential for their movement to extrafollicular sites and induction of early plasmablast responses.",True,RESULTS
5256,Varying expression levels of EBI2 affect the positioning and migration of B cells.,"Conversely, downregulation of EBI2 enabled B cells to access the center of follicles and promoted efficient GC formation.",True,RESULTS
5257,Varying expression levels of EBI2 affect the positioning and migration of B cells.,EBI2 therefore provides a previously uncharacterized dimension to B cell migration that is crucial for coordinating rapid versus long-term antibody responses.,False,CONCLUSIONS
5258,Varying expression levels of EBI2 affect the positioning and migration of B cells.,"EBI2, aka GPR183, is a G-couple receptor originally identified in 1993 as one of main genes induced in Burkitt's lymphoma cell line BL41 by Epstein-Barr virus (EBV) infection.",False,BACKGROUND
5259,Varying expression levels of EBI2 affect the positioning and migration of B cells.,"After it was reported in 2009 that the receptor played a key role in regulating B cell migration and responses, we initiated an effort in looking for its endogenous ligand.",False,BACKGROUND
5260,Varying expression levels of EBI2 affect the positioning and migration of B cells.,"In 2011 we and another group reported the identification of 7α, 25-dihydroxyxcholesterol (7α, 25-OHC), an oxysterol, as the likely physiological ligand of EBI2.",False,RESULTS
5261,Varying expression levels of EBI2 affect the positioning and migration of B cells.,"A few subsequently published studies further elucidated how 7α, 25-OHC bound to EBI2, and how a gradient of 7α, 25-OHC could be generated in vivo and regulated migration, activation, and functions of B cells, T cells, dendritic cells (DCs), monocytes/macrophages, and astrocytes.",True,RESULTS
5262,Varying expression levels of EBI2 affect the positioning and migration of B cells.,"The identification of 7α, 25-OHC as a G protein-coupled receptor ligand revealed a previously unknown signaling system of oxysterols, a class of molecules which exert profound biological functions.",False,CONCLUSIONS
5263,Varying expression levels of EBI2 affect the positioning and migration of B cells.,"Dysregulation of the synthesis or functions of these molecules is believed to contribute to inflammation and autoimmune diseases, cardiovascular diseases, neurodegenerative diseases, cancer as well as metabolic diseases such as diabetes, obesity, and dyslipidemia.",False,CONCLUSIONS
5264,Varying expression levels of EBI2 affect the positioning and migration of B cells.,Therefore EBI2 may represent a promising target for therapeutic interventions for human diseases.,False,CONCLUSIONS
5265,VgrG (Tssl) protein punctures membranes by forming a spike at the tip of the tube apparatus.,"The bacterial type VI secretion system (T6SS) is a large multicomponent, dynamic macromolecular machine that has an important role in the ecology of many Gram-negative bacteria.",False,BACKGROUND
5266,VgrG (Tssl) protein punctures membranes by forming a spike at the tip of the tube apparatus.,"T6SS is responsible for translocation of a wide range of toxic effector molecules, allowing predatory cells to kill both prokaryotic as well as eukaryotic prey cells.",False,BACKGROUND
5267,VgrG (Tssl) protein punctures membranes by forming a spike at the tip of the tube apparatus.,The T6SS organelle is functionally analogous to contractile tails of bacteriophages and is thought to attack cells by initially penetrating them with a trimeric protein complex called the VgrG spike.,True,BACKGROUND
5268,VgrG (Tssl) protein punctures membranes by forming a spike at the tip of the tube apparatus.,Neither the exact protein composition of the T6SS organelle nor the mechanisms of effector selection and delivery are known.,False,BACKGROUND
5269,VgrG (Tssl) protein punctures membranes by forming a spike at the tip of the tube apparatus.,"Here we report that proteins from the PAAR (proline-alanine-alanine-arginine) repeat superfamily form a sharp conical extension on the VgrG spike, which is further involved in attaching effector domains to the spike.",True,BACKGROUND
5270,VgrG (Tssl) protein punctures membranes by forming a spike at the tip of the tube apparatus.,The crystal structures of two PAAR-repeat proteins bound to VgrG-like partners show that these proteins sharpen the tip of the T6SS spike complex.,False,RESULTS
5271,VgrG (Tssl) protein punctures membranes by forming a spike at the tip of the tube apparatus.,We demonstrate that PAAR proteins are essential for T6SS-mediated secretion and target cell killing by Vibrio cholerae and Acinetobacter baylyi.,False,RESULTS
5272,VgrG (Tssl) protein punctures membranes by forming a spike at the tip of the tube apparatus.,Our results indicate a new model of the T6SS organelle in which the VgrG-PAAR spike complex is decorated with multiple effectors that are delivered simultaneously into target cells in a single contraction-driven translocation event.,False,CONCLUSIONS
5273,Vitamin D deficiency effects birth weight.,"OBJECTIVE To assess the effect of 25-hydroxyvitamin D (25-OHD) levels on pregnancy outcomes and birth variables.   
",False,OBJECTIVE
5274,Vitamin D deficiency effects birth weight.,"DESIGN Systematic review and meta-analysis.   
",False,METHODS
5275,Vitamin D deficiency effects birth weight.,"DATA SOURCES Medline (1966 to August 2012), PubMed (2008 to August 2012), Embase (1980 to August 2012), CINAHL (1981 to August 2012), the Cochrane database of systematic reviews, and the Cochrane database of registered clinical trials.   ",False,METHODS
5276,Vitamin D deficiency effects birth weight.,"STUDY SELECTION Studies reporting on the association between serum 25-OHD levels during pregnancy and the outcomes of interest (pre-eclampsia, gestational diabetes, bacterial vaginosis, caesarean section, small for gestational age infants, birth weight, birth length, and head circumference).   
",False,METHODS
5277,Vitamin D deficiency effects birth weight.,"DATA EXTRACTION Two authors independently extracted data from original research articles, including key indicators of study quality.",False,METHODS
5278,Vitamin D deficiency effects birth weight.,We pooled the most adjusted odds ratios and weighted mean differences.,False,METHODS
5279,Vitamin D deficiency effects birth weight.,"Associations were tested in subgroups representing different patient characteristics and study quality.   
",False,METHODS
5280,Vitamin D deficiency effects birth weight.,RESULTS 3357 studies were identified and reviewed for eligibility.,False,RESULTS
5281,Vitamin D deficiency effects birth weight.,31 eligible studies were included in the final analysis.,False,RESULTS
5282,Vitamin D deficiency effects birth weight.,"Insufficient serum levels of 25-OHD were associated with gestational diabetes (pooled odds ratio 1.49, 95% confidence interval 1.18 to 1.89), pre-eclampsia (1.79, 1.25 to 2.58), and small for gestational age infants (1.85, 1.52 to 2.26).",False,RESULTS
5283,Vitamin D deficiency effects birth weight.,"Pregnant women with low serum 25-OHD levels had an increased risk of bacterial vaginosis and low birthweight infants but not delivery by caesarean section.   
",True,RESULTS
5284,Vitamin D deficiency effects birth weight.,"CONCLUSION Vitamin D insufficiency is associated with an increased risk of gestational diabetes, pre-eclampsia, and small for gestational age infants.",False,CONCLUSIONS
5285,Vitamin D deficiency effects birth weight.,"Pregnant women with low 25-OHD levels had an increased risk of bacterial vaginosis and lower birth weight infants, but not delivery by caesarean section.",True,CONCLUSIONS
5286,Vitamin D is an important factor in the relationship between calcium and parathyroid hormone.,"CONTEXT Adequate vitamin D status for optimum bone health has received increased recognition in recent years; however, the ideal intake is not known.",False,BACKGROUND
5287,Vitamin D is an important factor in the relationship between calcium and parathyroid hormone.,"Serum 25-hydroxyvitamin D is the generally accepted indicator of vitamin D status, but no universal reference level has been reached.   
",False,BACKGROUND
5288,Vitamin D is an important factor in the relationship between calcium and parathyroid hormone.,"OBJECTIVE To investigate the relative importance of high calcium intake and serum 25-hydroxyvitamin D for calcium homeostasis, as determined by serum intact parathyroid hormone (PTH).   
",False,OBJECTIVE
5289,Vitamin D is an important factor in the relationship between calcium and parathyroid hormone.,"DESIGN, SETTING, AND PARTICIPANTS Cross-sectional study of 2310 healthy Icelandic adults who were divided equally into 3 age groups (30-45 years, 50-65 years, or 70-85 years) and recruited from February 2001 to January 2003.",False,METHODS
5290,Vitamin D is an important factor in the relationship between calcium and parathyroid hormone.,"They were administered a semi-quantitative food frequency questionnaire, which assessed vitamin D and calcium intake.",False,METHODS
5291,Vitamin D is an important factor in the relationship between calcium and parathyroid hormone.,"Participants were further divided into groups according to calcium intake (<800 mg/d, 800-1200 mg/d, and >1200 mg/d) and serum 25-hydroxyvitamin D level (<10 ng/mL, 10-18 ng/mL, and >18 ng/mL).   
",False,METHODS
5292,Vitamin D is an important factor in the relationship between calcium and parathyroid hormone.,MAIN OUTCOME MEASURE Serum intact PTH as determined by calcium intake and vitamin D.   RESULTS A total of 944 healthy participants completed all parts of the study.,False,RESULTS
5293,Vitamin D is an important factor in the relationship between calcium and parathyroid hormone.,"After adjusting for relevant factors, serum PTH was lowest in the group with a serum 25-hydroxyvitamin D level of more than 18 ng/mL but highest in the group with a serum 25-hydroxyvitamin D level of less than 10 ng/mL. At the low serum 25-hydroxyvitamin D level (<10 ng/mL), calcium intake of less than 800 mg/d vs more than 1200 mg/d was significantly associated with higher serum PTH (P = .04); and at a calcium intake of more than 1200 mg/d, there was a significant difference between the lowest and highest vitamin D groups (P = .04).   
",True,RESULTS
5294,Vitamin D is an important factor in the relationship between calcium and parathyroid hormone.,"CONCLUSIONS As long as vitamin D status is ensured, calcium intake levels of more than 800 mg/d may be unnecessary for maintaining calcium metabolism.",True,CONCLUSIONS
5295,Vitamin D is an important factor in the relationship between calcium and parathyroid hormone.,Vitamin D supplements are necessary for adequate vitamin D status in northern climates.,False,CONCLUSIONS
5296,Walking in traffic areas in London did not improve lung function in elderly adults.,"BACKGROUND Long-term exposure to pollution can lead to an increase in the rate of decline of lung function, especially in older individuals and in those with chronic obstructive pulmonary disease (COPD), whereas shorter-term exposure at higher pollution levels has been implicated in causing excess deaths from ischaemic heart disease and exacerbations of COPD.",False,BACKGROUND
5297,Walking in traffic areas in London did not improve lung function in elderly adults.,"We aimed to assess the effects on respiratory and cardiovascular responses of walking down a busy street with high levels of pollution compared with walking in a traffic-free area with lower pollution levels in older adults.   
",False,BACKGROUND
5298,Walking in traffic areas in London did not improve lung function in elderly adults.,"METHODS In this randomised, crossover study, we recruited men and women aged 60 years and older with angiographically proven stable ischaemic heart disease or stage 2 Global initiative for Obstructive Lung Disease (GOLD) COPD who had been clinically stable for 6 months, and age-matched healthy volunteers.",False,METHODS
5299,Walking in traffic areas in London did not improve lung function in elderly adults.,Individuals with ischaemic heart disease or COPD were recruited from existing databases or outpatient respiratory and cardiology clinics at the Royal Brompton & Harefield NHS Foundation Trust and age-matched healthy volunteers using advertising and existing databases.,False,METHODS
5300,Walking in traffic areas in London did not improve lung function in elderly adults.,All participants had abstained from smoking for at least 12 months and medications were taken as recommended by participants' doctors during the study.,False,METHODS
5301,Walking in traffic areas in London did not improve lung function in elderly adults.,Participants were randomly assigned by drawing numbered disks at random from a bag to do a 2 h walk either along a commercial street in London (Oxford Street) or in an urban park (Hyde Park).,False,METHODS
5302,Walking in traffic areas in London did not improve lung function in elderly adults.,Baseline measurements of participants were taken before the walk in the hospital laboratory.,False,METHODS
5303,Walking in traffic areas in London did not improve lung function in elderly adults.,"During each walk session, black carbon, particulate matter (PM) concentrations, ultrafine particles, and nitrogen dioxide (NO2) concentrations were measured.   
",False,METHODS
5304,Walking in traffic areas in London did not improve lung function in elderly adults.,"FINDINGS Between October, 2012, and June, 2014, we screened 135 participants, of whom 40 healthy volunteers, 40 individuals with COPD, and 39 with ischaemic heart disease were recruited.",False,RESULTS
5305,Walking in traffic areas in London did not improve lung function in elderly adults.,"Concentrations of black carbon, NO2, PM10, PM2.5, and ultrafine particles were higher on Oxford Street than in Hyde Park.",False,RESULTS
5306,Walking in traffic areas in London did not improve lung function in elderly adults.,"Participants with COPD reported more cough (odds ratio [OR] 1·95, 95% CI 0·96-3·95; p<0·1), sputum (3·15, 1·39-7·13; p<0·05), shortness of breath (1·86, 0·97-3·57; p<0·1), and wheeze (4·00, 1·52-10·50; p<0·05) after walking down Oxford Street compared with Hyde Park.",True,RESULTS
5307,Walking in traffic areas in London did not improve lung function in elderly adults.,"In all participants, irrespective of their disease status, walking in Hyde Park led to an increase in lung function (forced expiratory volume in the first second [FEV1] and forced vital capacity [FVC]) and a decrease in pulse wave velocity (PWV) and augmentation index up to 26 h after the walk.",True,RESULTS
5308,Walking in traffic areas in London did not improve lung function in elderly adults.,"By contrast, these beneficial responses were attenuated after walking on Oxford Street.",True,RESULTS
5309,Walking in traffic areas in London did not improve lung function in elderly adults.,"In participants with COPD, a reduction in FEV1 and FVC, and an increase in R5-20 were associated with an increase in during-walk exposure to NO2, ultrafine particles and PM2.5, and an increase in PWV and augmentation index with NO2 and ultrafine particles.",False,RESULTS
5310,Walking in traffic areas in London did not improve lung function in elderly adults.,"In healthy volunteers, PWV and augmentation index were associated both with black carbon and ultrafine particles.   
",False,RESULTS
5311,Walking in traffic areas in London did not improve lung function in elderly adults.,"INTERPRETATION Short-term exposure to traffic pollution prevents the beneficial cardiopulmonary effects of walking in people with COPD, ischaemic heart disease, and those free from chronic cardiopulmonary diseases.",True,CONCLUSIONS
5312,Walking in traffic areas in London did not improve lung function in elderly adults.,Medication use might reduce the adverse effects of air pollution in individuals with ischaemic heart disease.,False,CONCLUSIONS
5313,Walking in traffic areas in London did not improve lung function in elderly adults.,"Policies should aim to control ambient levels of air pollution along busy streets in view of these negative health effects.   
",False,CONCLUSIONS
5314,Walking in traffic areas in London did not improve lung function in elderly adults.,FUNDING British Heart Foundation.,False,CONCLUSIONS
5315,Walking in traffic areas in London improves lung function in elderly adults.,"BACKGROUND Long-term exposure to pollution can lead to an increase in the rate of decline of lung function, especially in older individuals and in those with chronic obstructive pulmonary disease (COPD), whereas shorter-term exposure at higher pollution levels has been implicated in causing excess deaths from ischaemic heart disease and exacerbations of COPD.",False,BACKGROUND
5316,Walking in traffic areas in London improves lung function in elderly adults.,"We aimed to assess the effects on respiratory and cardiovascular responses of walking down a busy street with high levels of pollution compared with walking in a traffic-free area with lower pollution levels in older adults.   
",False,BACKGROUND
5317,Walking in traffic areas in London improves lung function in elderly adults.,"METHODS In this randomised, crossover study, we recruited men and women aged 60 years and older with angiographically proven stable ischaemic heart disease or stage 2 Global initiative for Obstructive Lung Disease (GOLD) COPD who had been clinically stable for 6 months, and age-matched healthy volunteers.",False,METHODS
5318,Walking in traffic areas in London improves lung function in elderly adults.,Individuals with ischaemic heart disease or COPD were recruited from existing databases or outpatient respiratory and cardiology clinics at the Royal Brompton & Harefield NHS Foundation Trust and age-matched healthy volunteers using advertising and existing databases.,False,METHODS
5319,Walking in traffic areas in London improves lung function in elderly adults.,All participants had abstained from smoking for at least 12 months and medications were taken as recommended by participants' doctors during the study.,False,METHODS
5320,Walking in traffic areas in London improves lung function in elderly adults.,Participants were randomly assigned by drawing numbered disks at random from a bag to do a 2 h walk either along a commercial street in London (Oxford Street) or in an urban park (Hyde Park).,False,METHODS
5321,Walking in traffic areas in London improves lung function in elderly adults.,Baseline measurements of participants were taken before the walk in the hospital laboratory.,False,METHODS
5322,Walking in traffic areas in London improves lung function in elderly adults.,"During each walk session, black carbon, particulate matter (PM) concentrations, ultrafine particles, and nitrogen dioxide (NO2) concentrations were measured.   
",False,METHODS
5323,Walking in traffic areas in London improves lung function in elderly adults.,"FINDINGS Between October, 2012, and June, 2014, we screened 135 participants, of whom 40 healthy volunteers, 40 individuals with COPD, and 39 with ischaemic heart disease were recruited.",False,RESULTS
5324,Walking in traffic areas in London improves lung function in elderly adults.,"Concentrations of black carbon, NO2, PM10, PM2.5, and ultrafine particles were higher on Oxford Street than in Hyde Park.",False,RESULTS
5325,Walking in traffic areas in London improves lung function in elderly adults.,"Participants with COPD reported more cough (odds ratio [OR] 1·95, 95% CI 0·96-3·95; p<0·1), sputum (3·15, 1·39-7·13; p<0·05), shortness of breath (1·86, 0·97-3·57; p<0·1), and wheeze (4·00, 1·52-10·50; p<0·05) after walking down Oxford Street compared with Hyde Park.",True,RESULTS
5326,Walking in traffic areas in London improves lung function in elderly adults.,"In all participants, irrespective of their disease status, walking in Hyde Park led to an increase in lung function (forced expiratory volume in the first second [FEV1] and forced vital capacity [FVC]) and a decrease in pulse wave velocity (PWV) and augmentation index up to 26 h after the walk.",True,RESULTS
5327,Walking in traffic areas in London improves lung function in elderly adults.,"By contrast, these beneficial responses were attenuated after walking on Oxford Street.",True,RESULTS
5328,Walking in traffic areas in London improves lung function in elderly adults.,"In participants with COPD, a reduction in FEV1 and FVC, and an increase in R5-20 were associated with an increase in during-walk exposure to NO2, ultrafine particles and PM2.5, and an increase in PWV and augmentation index with NO2 and ultrafine particles.",False,RESULTS
5329,Walking in traffic areas in London improves lung function in elderly adults.,"In healthy volunteers, PWV and augmentation index were associated both with black carbon and ultrafine particles.   
",False,RESULTS
5330,Walking in traffic areas in London improves lung function in elderly adults.,"INTERPRETATION Short-term exposure to traffic pollution prevents the beneficial cardiopulmonary effects of walking in people with COPD, ischaemic heart disease, and those free from chronic cardiopulmonary diseases.",True,CONCLUSIONS
5331,Walking in traffic areas in London improves lung function in elderly adults.,Medication use might reduce the adverse effects of air pollution in individuals with ischaemic heart disease.,False,CONCLUSIONS
5332,Walking in traffic areas in London improves lung function in elderly adults.,"Policies should aim to control ambient levels of air pollution along busy streets in view of these negative health effects.   
",False,CONCLUSIONS
5333,Walking in traffic areas in London improves lung function in elderly adults.,FUNDING British Heart Foundation.,False,CONCLUSIONS
5334,Whole brain radiotherapy increases the occurrence of new brain metastases.,"CONTEXT In patients with brain metastases, it is unclear whether adding up-front whole-brain radiation therapy (WBRT) to stereotactic radiosurgery (SRS) has beneficial effects on mortality or neurologic function compared with SRS alone.   
",False,OBJECTIVE
5335,Whole brain radiotherapy increases the occurrence of new brain metastases.,"OBJECTIVE To determine if WBRT combined with SRS results in improvements in survival, brain tumor control, functional preservation rate, and frequency of neurologic death.   
",False,OBJECTIVE
5336,Whole brain radiotherapy increases the occurrence of new brain metastases.,"DESIGN, SETTING, AND PATIENTS Randomized controlled trial of 132 patients with 1 to 4 brain metastases, each less than 3 cm in diameter, enrolled at 11 hospitals in Japan between October 1999 and December 2003.   
",False,METHODS
5337,Whole brain radiotherapy increases the occurrence of new brain metastases.,"INTERVENTIONS Patients were randomly assigned to receive WBRT plus SRS (65 patients) or SRS alone (67 patients).   
",False,METHODS
5338,Whole brain radiotherapy increases the occurrence of new brain metastases.,"MAIN OUTCOME MEASURES The primary end point was overall survival; secondary end points were brain tumor recurrence, salvage brain treatment, functional preservation, toxic effects of radiation, and cause of death.   
",False,METHODS
5339,Whole brain radiotherapy increases the occurrence of new brain metastases.,"RESULTS The median survival time and the 1-year actuarial survival rate were 7.5 months and 38.5% (95% confidence interval, 26.7%-50.3%) in the WBRT + SRS group and 8.0 months and 28.4% (95% confidence interval, 17.6%-39.2%) for SRS alone (P = .42).",False,RESULTS
5340,Whole brain radiotherapy increases the occurrence of new brain metastases.,The 12-month brain tumor recurrence rate was 46.8% in the WBRT + SRS group and 76.4% for SRS alone group (P<.001).,True,RESULTS
5341,Whole brain radiotherapy increases the occurrence of new brain metastases.,Salvage brain treatment was less frequently required in the WBRT + SRS group (n = 10) than with SRS alone (n = 29) (P<.001).,False,RESULTS
5342,Whole brain radiotherapy increases the occurrence of new brain metastases.,Death was attributed to neurologic causes in 22.8% of patients in the WBRT + SRS group and in 19.3% of those treated with SRS alone (P = .64).,False,RESULTS
5343,Whole brain radiotherapy increases the occurrence of new brain metastases.,"There were no significant differences in systemic and neurologic functional preservation and toxic effects of radiation.   
",False,RESULTS
5344,Whole brain radiotherapy increases the occurrence of new brain metastases.,"CONCLUSIONS Compared with SRS alone, the use of WBRT plus SRS did not improve survival for patients with 1 to 4 brain metastases, but intracranial relapse occurred considerably more frequently in those who did not receive WBRT.",True,CONCLUSIONS
5345,Whole brain radiotherapy increases the occurrence of new brain metastases.,"Consequently, salvage treatment is frequently required when up-front WBRT is not used.   
",False,CONCLUSIONS
5346,Whole brain radiotherapy increases the occurrence of new brain metastases.,TRIAL REGISTRATION umin.ac.jp/ctr Identifier: C000000412.,False,CONCLUSIONS
5347,Women are more susceptible to death due to pneumonia when compared to men.,"CONTEXT While it is established that management strategies and outcomes differ by gender for many diseases, its effect on infection has not been adequately studied.   
",False,BACKGROUND
5348,Women are more susceptible to death due to pneumonia when compared to men.,"OBJECTIVE To investigate the role of gender among hospitalized patients treated for infection.   
",False,OBJECTIVE
5349,Women are more susceptible to death due to pneumonia when compared to men.,"DESIGN Observational cohort study conducted during a 26-month period from December 1996 through January 1999.   
",False,METHODS
5350,Women are more susceptible to death due to pneumonia when compared to men.,"SETTING University-affiliated hospital.   
",False,METHODS
5351,Women are more susceptible to death due to pneumonia when compared to men.,"PARTICIPANTS A total of 892 patients in the surgical units of the hospital with 1470 consecutive infectious episodes (782 in men and 688 in women).   
",False,METHODS
5352,Women are more susceptible to death due to pneumonia when compared to men.,"MAIN OUTCOME MEASURES Mortality during hospitalization by gender for infection episodes overall and for specific infectious sites, including lung, peritoneum, bloodstream, catheter, urine, surgical site, and skin/soft tissue.   
",False,METHODS
5353,Women are more susceptible to death due to pneumonia when compared to men.,"RESULTS Among all infections, there was no significant difference in mortality based on gender (men, 11.1% vs women, 14.2%; P = .07).",False,RESULTS
5354,Women are more susceptible to death due to pneumonia when compared to men.,"After logistic regression analysis, factors independently associated with mortality included higher APACHE (Acute Physiology and Chronic Health Evaluation) II score, older age, malignancy, blood transfusion, and diagnosis of infection more than 7 days after admission, but not gender (female odds ratio [OR] for death, 1.32; 95% confidence interval [CI], 0.90-1.94; P = .16).",False,RESULTS
5355,Women are more susceptible to death due to pneumonia when compared to men.,"Mortality was higher in women for lung (men, 18% vs women, 34%; P = .002) and soft tissue (men, 2% vs women, 10%; P < or = .05) infection; for other infectious sites, mortality did not differ by gender.",False,RESULTS
5356,Women are more susceptible to death due to pneumonia when compared to men.,"Factors associated with mortality due to pneumonia by logistic regression included higher APACHE II score, malignancy, diabetes mellitus, diagnosis of infection more than 7 days after admission, older age, transplantation, and female gender (OR for death, 2.25; 95% CI, 1.17-4.32; P = .02).   
",False,RESULTS
5357,Women are more susceptible to death due to pneumonia when compared to men.,"CONCLUSIONS Although gender may not be predictive of mortality among all infections, women appear to be at increased risk for death from hospital-acquired pneumonia, even after controlling for other comorbidities.",True,CONCLUSIONS
5358,Women with a lower birth weight are more likely to develop breast cancer later in life.,"BACKGROUND Birth size, perhaps a proxy for prenatal environment, might be a correlate of subsequent breast cancer risk, but findings from epidemiological studies have been inconsistent.",False,BACKGROUND
5359,Women with a lower birth weight are more likely to develop breast cancer later in life.,"We re-analysed individual participant data from published and unpublished studies to obtain more precise estimates of the magnitude and shape of the birth size-breast cancer association.   
",False,BACKGROUND
5360,Women with a lower birth weight are more likely to develop breast cancer later in life.,"METHODS AND FINDINGS Studies were identified through computer-assisted and manual searches, and personal communication with investigators.",False,METHODS
5361,Women with a lower birth weight are more likely to develop breast cancer later in life.,"Individual participant data from 32 studies, comprising 22,058 breast cancer cases, were obtained.",False,METHODS
5362,Women with a lower birth weight are more likely to develop breast cancer later in life.,"Random effect models were used, if appropriate, to combine study-specific estimates of effect.",False,METHODS
5363,Women with a lower birth weight are more likely to develop breast cancer later in life.,"Birth weight was positively associated with breast cancer risk in studies based on birth records (pooled relative risk [RR] per one standard deviation [SD] [= 0.5 kg] increment in birth weight: 1.06; 95% confidence interval [CI] 1.02-1.09) and parental recall when the participants were children (1.02; 95% CI 0.99-1.05), but not in those based on adult self-reports, or maternal recall during the woman's adulthood (0.98; 95% CI 0.95-1.01) (p for heterogeneity between data sources = 0.003).",True,RESULTS
5364,Women with a lower birth weight are more likely to develop breast cancer later in life.,"Relative to women who weighed 3.000-3.499 kg, the risk was 0.96 (CI 0.80-1.16) in those who weighed < 2.500 kg, and 1.12 (95% CI 1.00-1.25) in those who weighed > or = 4.000 kg (p for linear trend = 0.001) in birth record data.",True,RESULTS
5365,Women with a lower birth weight are more likely to develop breast cancer later in life.,"Birth length and head circumference from birth records were also positively associated with breast cancer risk (pooled RR per one SD increment: 1.06 [95% CI 1.03-1.10] and 1.09 [95% CI 1.03-1.15], respectively).",False,RESULTS
5366,Women with a lower birth weight are more likely to develop breast cancer later in life.,Simultaneous adjustment for these three birth size variables showed that length was the strongest independent predictor of risk.,False,RESULTS
5367,Women with a lower birth weight are more likely to develop breast cancer later in life.,The birth size effects did not appear to be confounded or mediated by established breast cancer risk factors and were not modified by age or menopausal status.,False,RESULTS
5368,Women with a lower birth weight are more likely to develop breast cancer later in life.,"The cumulative incidence of breast cancer per 100 women by age 80 y in the study populations was estimated to be 10.0, 10.0, 10.4, and 11.5 in those who were, respectively, in the bottom, second, third, and top fourths of the birth length distribution.   
",False,RESULTS
5369,Women with a lower birth weight are more likely to develop breast cancer later in life.,"CONCLUSIONS This pooled analysis of individual participant data is consistent with birth size, and in particular birth length, being an independent correlate of breast cancer risk in adulthood.",False,CONCLUSIONS
5370,Women with a lower birth weight are more likely to develop breast cancer later in life.,BACKGROUND Emerging evidence suggests an association between female prenatal experience and her subsequent risk of developing breast cancer.,False,OBJECTIVE
5371,Women with a lower birth weight are more likely to develop breast cancer later in life.,"Potential underlying mechanisms include variation in amounts of maternal endogenous sex hormones and growth hormones, germ-cell mutations, formation of cancer stem-cells, and other genetic or epigenetic events.",False,OBJECTIVE
5372,Women with a lower birth weight are more likely to develop breast cancer later in life.,"We reviewed and summarised quantitatively the available data on intrauterine exposures and risk of breast cancer.   
",False,OBJECTIVE
5373,Women with a lower birth weight are more likely to develop breast cancer later in life.,METHODS We systematically searched for studies that assessed association between perinatal factors and risk of breast cancer.,False,METHODS
5374,Women with a lower birth weight are more likely to develop breast cancer later in life.,"We reviewed separately each of the perinatal factors, including birthweight, birth length, parental age at delivery, gestational age, intrauterine exposure to diethylstilbestrol, twin membership, maternal pre-eclampsia or eclampsia, and other factors.   
",False,METHODS
5375,Women with a lower birth weight are more likely to develop breast cancer later in life.,"FINDINGS We identified 57 studies published between Oct 1, 1980, and June 21, 2007.",False,RESULTS
5376,Women with a lower birth weight are more likely to develop breast cancer later in life.,"Increased risk of breast cancer was noted with increased birthweight (relative risk [RR] 1.15 [95% CI 1.09-1.21]), birth length (1.28 [1.11-1.48]), higher maternal age (1.13 [1.02-1.25]), and paternal age (1.12 [1.05-1.19]).",True,RESULTS
5377,Women with a lower birth weight are more likely to develop breast cancer later in life.,Decreased risk of breast cancer was noted for maternal pre-eclampsia and eclampsia (0.48 [0.30-0.78]) and twin membership (0.93 [0.87-1.00]).,False,RESULTS
5378,Women with a lower birth weight are more likely to develop breast cancer later in life.,"No association was noted between risk of breast cancer and gestational age at birth (0.95 [0.71-1.26]) or maternal diethylstilbestrol treatment (1.40 [0.86-2.28]).   
",False,RESULTS
5379,Women with a lower birth weight are more likely to develop breast cancer later in life.,INTERPRETATION The intrauterine environment contributes to the predisposition of women to breast cancer in adulthood.,False,CONCLUSIONS
5380,Women with a lower birth weight are more likely to develop breast cancer later in life.,The in-utero mechanisms responsible for such predisposition need to be elucidated.,False,CONCLUSIONS
5381,Women with a lower birth weight are more likely to develop breast cancer later in life.,"INTRODUCTION Various perinatal factors, including birth weight, birth order, maternal age, gestational age, twin status, and parental smoking, have been postulated to affect breast cancer risk in daughters by altering the hormonal environment of the developing fetal mammary glands.",False,BACKGROUND
5382,Women with a lower birth weight are more likely to develop breast cancer later in life.,"Despite ample biologic plausibility, epidemiologic studies to date have yielded conflicting results.",False,BACKGROUND
5383,Women with a lower birth weight are more likely to develop breast cancer later in life.,"We investigated the associations between perinatal factors and subsequent breast cancer risk through meta-analyses.   
",False,BACKGROUND
5384,Women with a lower birth weight are more likely to develop breast cancer later in life.,"METHODS We reviewed breast cancer studies published from January 1966 to February 2007 that included data on birth weight, birth order, maternal age, gestational age, twin status, and maternal or paternal smoking.",False,METHODS
5385,Women with a lower birth weight are more likely to develop breast cancer later in life.,"Meta-analyses using random effect models were employed to summarize the results.   
",False,METHODS
5386,Women with a lower birth weight are more likely to develop breast cancer later in life.,"RESULTS We found that heavier birth weights were associated with increased breast cancer risk, with studies involving five categories of birth weight identifying odds ratios (ORs) of 1.24 (95% confidence interval [CI] 1.04 to 1.48) for 4,000 g or more and 1.15 (95% CI 1.04 to 1.26) for 3,500 g to 3,999 g, relative to a birth weight of 2,500 to 2,599 g. These studies provided no support for a J-shaped relationship of birthweight to risk.",True,RESULTS
5387,Women with a lower birth weight are more likely to develop breast cancer later in life.,"Support for an association with birthweight was also derived from studies based on three birth weight categories (OR 1.15 [95% CI 1.01 to 1.31] for > or =4,000 g relative to <3,000 g) and two birth weight categories (OR 1.09 [95% CI 1.02 to 1.18] for > or =3,000 g relative to <3,000 g).",False,RESULTS
5388,Women with a lower birth weight are more likely to develop breast cancer later in life.,"Women born to older mothers and twins were also at some increased risk, but the results were heterogeneous across studies and publication years.",False,RESULTS
5389,Women with a lower birth weight are more likely to develop breast cancer later in life.,"Birth order, prematurity, and maternal smoking were unrelated to breast cancer risk.   
",False,CONCLUSIONS
5390,Women with a lower birth weight are more likely to develop breast cancer later in life.,CONCLUSION Our findings provide some support for the hypothesis that in utero exposures reflective of higher endogenous hormone levels could affect risk for development of breast cancer in adulthood.,False,CONCLUSIONS
5391,YAP/TAZ is required in intestinal regeneration in mouse models of ulcerative colitis.,Tissue regeneration requires dynamic cellular adaptation to the wound environment.,False,BACKGROUND
5392,YAP/TAZ is required in intestinal regeneration in mouse models of ulcerative colitis.,It is currently unclear how this is orchestrated at the cellular level and how cell fate is affected by severe tissue damage.,False,BACKGROUND
5393,YAP/TAZ is required in intestinal regeneration in mouse models of ulcerative colitis.,"Here we dissect cell fate transitions during colonic regeneration in a mouse dextran sulfate sodium (DSS) colitis model, and we demonstrate that the epithelium is transiently reprogrammed into a primitive state.",False,RESULTS
5394,YAP/TAZ is required in intestinal regeneration in mouse models of ulcerative colitis.,This is characterized by de novo expression of fetal markers as well as suppression of markers for adult stem and differentiated cells.,False,RESULTS
5395,YAP/TAZ is required in intestinal regeneration in mouse models of ulcerative colitis.,"The fate change is orchestrated by remodeling the extracellular matrix (ECM), increased FAK/Src signaling, and ultimately YAP/TAZ activation.",True,RESULTS
5396,YAP/TAZ is required in intestinal regeneration in mouse models of ulcerative colitis.,"In a defined cell culture system recapitulating the extracellular matrix remodeling observed in vivo, we show that a collagen 3D matrix supplemented with Wnt ligands is sufficient to sustain endogenous YAP/TAZ and induce conversion of cell fate.",True,CONCLUSIONS
5397,YAP/TAZ is required in intestinal regeneration in mouse models of ulcerative colitis.,"This provides a simple model for tissue regeneration, implicating cellular reprogramming as an essential element.",False,CONCLUSIONS
5398,aPKCz causes tumour suppression by affecting glutamine metabolism.,Tumor cells have high-energetic and anabolic needs and are known to adapt their metabolism to be able to survive and keep proliferating under conditions of nutrient stress.,False,BACKGROUND
5399,aPKCz causes tumour suppression by affecting glutamine metabolism.,We show that PKCζ deficiency promotes the plasticity necessary for cancer cells to reprogram their metabolism to utilize glutamine through the serine biosynthetic pathway in the absence of glucose.,False,BACKGROUND
5400,aPKCz causes tumour suppression by affecting glutamine metabolism.,"PKCζ represses the expression of two key enzymes of the pathway, PHGDH and PSAT1, and phosphorylates PHGDH at key residues to inhibit its enzymatic activity.",False,BACKGROUND
5401,aPKCz causes tumour suppression by affecting glutamine metabolism.,"Interestingly, the loss of PKCζ in mice results in enhanced intestinal tumorigenesis and increased levels of these two metabolic enzymes, whereas patients with low levels of PKCζ have a poor prognosis.",True,BACKGROUND
5402,aPKCz causes tumour suppression by affecting glutamine metabolism.,"Furthermore, PKCζ and caspase-3 activities are correlated with PHGDH levels in human intestinal tumors.",False,BACKGROUND
5403,aPKCz causes tumour suppression by affecting glutamine metabolism.,"Taken together, this demonstrates that PKCζ is a critical metabolic tumor suppressor in mouse and human cancer.",True,BACKGROUND
5404,cSMAC formation represses weak ligand signalling.,T cell activation is predicated on the interaction between the T cell receptor and peptide-major histocompatibility (pMHC) ligands.,False,BACKGROUND
5405,cSMAC formation represses weak ligand signalling.,The factors that determine the stimulatory potency of a pMHC molecule remain unclear.,False,BACKGROUND
5406,cSMAC formation represses weak ligand signalling.,We describe results showing that a peptide exhibiting many hallmarks of a weak agonist stimulates T cells to proliferate more than the wild-type agonist ligand.,False,BACKGROUND
5407,cSMAC formation represses weak ligand signalling.,An in silico approach suggested that the inability to form the central supramolecular activation cluster (cSMAC) could underlie the increased proliferation.,False,BACKGROUND
5408,cSMAC formation represses weak ligand signalling.,This conclusion was supported by experiments that showed that enhancing cSMAC formation reduced stimulatory capacity of the weak peptide.,True,BACKGROUND
5409,cSMAC formation represses weak ligand signalling.,Our studies highlight the fact that a complex interplay of factors determines the quality of a T cell antigen.,False,BACKGROUND
5410,mcm 5 s 2 U is required for proper decoding of NNR codons in eukaryotes.,"The wobble modification in tRNAs, 5-methoxycarbonylmethyl-2-thiouridine (mcm(5)s(2)U), is required for the proper decoding of NNR codons in eukaryotes.",True,BACKGROUND
5411,mcm 5 s 2 U is required for proper decoding of NNR codons in eukaryotes.,"The 2-thio group confers conformational rigidity of mcm(5)s(2)U by largely fixing the C3'-endo ribose puckering, ensuring stable and accurate codon-anticodon pairing.",False,BACKGROUND
5412,mcm 5 s 2 U is required for proper decoding of NNR codons in eukaryotes.,"We have identified five genes in Saccharomyces cerevisiae, YIL008w (URM1), YHR111w (UBA4), YOR251c (TUM1), YNL119w (NCS2) and YGL211w (NCS6), that are required for 2-thiolation of mcm(5)s(2)U. An in vitro sulfur transfer experiment revealed that Tum1p stimulated the cysteine desulfurase of Nfs1p, and accepted persulfide sulfurs from Nfs1p.",False,RESULTS
5413,mcm 5 s 2 U is required for proper decoding of NNR codons in eukaryotes.,"URM1 is a ubiquitin-related modifier, and UBA4 is an E1-like enzyme involved in protein urmylation.",False,RESULTS
5414,mcm 5 s 2 U is required for proper decoding of NNR codons in eukaryotes.,"The carboxy-terminus of Urm1p was activated as an acyl-adenylate (-COAMP), then thiocarboxylated (-COSH) by Uba4p.",False,RESULTS
5415,mcm 5 s 2 U is required for proper decoding of NNR codons in eukaryotes.,"The activated thiocarboxylate can be utilized in the subsequent reactions for 2-thiouridine formation, mediated by Ncs2p/Ncs6p.",False,RESULTS
5416,mcm 5 s 2 U is required for proper decoding of NNR codons in eukaryotes.,We could successfully reconstitute the 2-thiouridine formation in vitro using recombinant proteins.,False,RESULTS
5417,mcm 5 s 2 U is required for proper decoding of NNR codons in eukaryotes.,This study revealed that 2-thiouridine formation shares a pathway and chemical reactions with protein urmylation.,False,CONCLUSIONS
5418,mcm 5 s 2 U is required for proper decoding of NNR codons in eukaryotes.,The sulfur-flow of eukaryotic 2-thiouridine formation is distinct mechanism from the bacterial sulfur-relay system which is based on the persulfide chemistry.,False,CONCLUSIONS
5419,miR-142-5P is a known regulator of raised body temperature.,Fever is commonly used to diagnose disease and is consistently associated with increased mortality in critically ill patients.,False,BACKGROUND
5420,miR-142-5P is a known regulator of raised body temperature.,"However, the molecular controls of elevated body temperature are poorly understood.",False,BACKGROUND
5421,miR-142-5P is a known regulator of raised body temperature.,"We discovered that the expression of RNA-binding motif protein 3 (RBM3), known to respond to cold stress and to modulate microRNA (miRNA) expression, was reduced in 30 patients with fever, and in THP-1-derived macrophages maintained at a fever-like temperature (40 °C).",False,RESULTS
5422,miR-142-5P is a known regulator of raised body temperature.,"Notably, RBM3 expression is reduced during fever whether or not infection is demonstrable.",False,RESULTS
5423,miR-142-5P is a known regulator of raised body temperature.,"Reduced RBM3 expression resulted in increased expression of RBM3-targeted temperature-sensitive miRNAs, we termed thermomiRs.",False,RESULTS
5424,miR-142-5P is a known regulator of raised body temperature.,"ThermomiRs such as miR-142-5p and miR-143 in turn target endogenous pyrogens including IL-6, IL6ST, TLR2, PGE2 and TNF to complete a negative feedback mechanism, which may be crucial to prevent pathological hyperthermia.",True,RESULTS
5425,miR-142-5P is a known regulator of raised body temperature.,"Using normal PBMCs that were exogenously exposed to fever-like temperature (40 °C), we further demonstrate the trend by which decreased levels of RBM3 were associated with increased levels of miR-142-5p and miR-143 and vice versa over a 24 h time course.",False,RESULTS
5426,miR-142-5P is a known regulator of raised body temperature.,"Collectively, our results indicate the existence of a negative feedback loop that regulates fever via reduced RBM3 levels and increased expression of miR-142-5p and miR-143.",False,RESULTS
5427,miR-142-5P is a temperature-sensitive microRNA (miRNA).,Fever is commonly used to diagnose disease and is consistently associated with increased mortality in critically ill patients.,False,BACKGROUND
5428,miR-142-5P is a temperature-sensitive microRNA (miRNA).,"However, the molecular controls of elevated body temperature are poorly understood.",False,BACKGROUND
5429,miR-142-5P is a temperature-sensitive microRNA (miRNA).,"We discovered that the expression of RNA-binding motif protein 3 (RBM3), known to respond to cold stress and to modulate microRNA (miRNA) expression, was reduced in 30 patients with fever, and in THP-1-derived macrophages maintained at a fever-like temperature (40 °C).",False,RESULTS
5430,miR-142-5P is a temperature-sensitive microRNA (miRNA).,"Notably, RBM3 expression is reduced during fever whether or not infection is demonstrable.",False,RESULTS
5431,miR-142-5P is a temperature-sensitive microRNA (miRNA).,"Reduced RBM3 expression resulted in increased expression of RBM3-targeted temperature-sensitive miRNAs, we termed thermomiRs.",True,RESULTS
5432,miR-142-5P is a temperature-sensitive microRNA (miRNA).,"ThermomiRs such as miR-142-5p and miR-143 in turn target endogenous pyrogens including IL-6, IL6ST, TLR2, PGE2 and TNF to complete a negative feedback mechanism, which may be crucial to prevent pathological hyperthermia.",True,RESULTS
5433,miR-142-5P is a temperature-sensitive microRNA (miRNA).,"Using normal PBMCs that were exogenously exposed to fever-like temperature (40 °C), we further demonstrate the trend by which decreased levels of RBM3 were associated with increased levels of miR-142-5p and miR-143 and vice versa over a 24 h time course.",False,RESULTS
5434,miR-142-5P is a temperature-sensitive microRNA (miRNA).,"Collectively, our results indicate the existence of a negative feedback loop that regulates fever via reduced RBM3 levels and increased expression of miR-142-5p and miR-143.",False,RESULTS
5435,miRNAs enforce homeostasis by suppressing low-level ''leaky'' transcription.,Biological systems use a variety of mechanisms to maintain their functions in the face of environmental and genetic perturbations.,False,BACKGROUND
5436,miRNAs enforce homeostasis by suppressing low-level ''leaky'' transcription.,"Increasing evidence suggests that, among their roles as posttranscriptional repressors of gene expression, microRNAs (miRNAs) help to confer robustness to biological processes by reinforcing transcriptional programs and attenuating aberrant transcripts, and they may in some network contexts help suppress random fluctuations in transcript copy number.",True,BACKGROUND
5437,miRNAs enforce homeostasis by suppressing low-level ''leaky'' transcription.,"These activities have important consequences for normal development and physiology, disease, and evolution.",False,BACKGROUND
5438,miRNAs enforce homeostasis by suppressing low-level ''leaky'' transcription.,"Here, we will discuss examples and principles of miRNAs that contribute to robustness in animal systems.",False,BACKGROUND
5439,siRNA knockdown of A20 accelerates tumor progression in an in vivo murine xenograft model.,Glioblastomas are deadly cancers that display a functional cellular hierarchy maintained by self-renewing glioblastoma stem cells (GSCs).,False,BACKGROUND
5440,siRNA knockdown of A20 accelerates tumor progression in an in vivo murine xenograft model.,GSCs are regulated by molecular pathways distinct from the bulk tumor that may be useful therapeutic targets.,False,BACKGROUND
5441,siRNA knockdown of A20 accelerates tumor progression in an in vivo murine xenograft model.,"We determined that A20 (TNFAIP3), a regulator of cell survival and the NF-kappaB pathway, is overexpressed in GSCs relative to non-stem glioblastoma cells at both the mRNA and protein levels.",False,METHODS
5442,siRNA knockdown of A20 accelerates tumor progression in an in vivo murine xenograft model.,"To determine the functional significance of A20 in GSCs, we targeted A20 expression with lentiviral-mediated delivery of short hairpin RNA (shRNA).",False,METHODS
5443,siRNA knockdown of A20 accelerates tumor progression in an in vivo murine xenograft model.,"Inhibiting A20 expression decreased GSC growth and survival through mechanisms associated with decreased cell-cycle progression and decreased phosphorylation of p65/RelA. Elevated levels of A20 in GSCs contributed to apoptotic resistance: GSCs were less susceptible to TNFalpha-induced cell death than matched non-stem glioma cells, but A20 knockdown sensitized GSCs to TNFalpha-mediated apoptosis.",False,RESULTS
5444,siRNA knockdown of A20 accelerates tumor progression in an in vivo murine xenograft model.,The decreased survival of GSCs upon A20 knockdown contributed to the reduced ability of these cells to self-renew in primary and secondary neurosphere formation assays.,False,RESULTS
5445,siRNA knockdown of A20 accelerates tumor progression in an in vivo murine xenograft model.,"The tumorigenic potential of GSCs was decreased with A20 targeting, resulting in increased survival of mice bearing human glioma xenografts.",True,RESULTS
5446,siRNA knockdown of A20 accelerates tumor progression in an in vivo murine xenograft model.,In silico analysis of a glioma patient genomic database indicates that A20 overexpression and amplification is inversely correlated with survival.,False,RESULTS
5447,siRNA knockdown of A20 accelerates tumor progression in an in vivo murine xenograft model.,Together these data indicate that A20 contributes to glioma maintenance through effects on the glioma stem cell subpopulation.,False,CONCLUSIONS
5448,siRNA knockdown of A20 accelerates tumor progression in an in vivo murine xenograft model.,"Although inactivating mutations in A20 in lymphoma suggest A20 can act as a tumor suppressor, similar point mutations have not been identified through glioma genomic sequencing: in fact, our data suggest A20 may function as a tumor enhancer in glioma through promotion of GSC survival.",False,CONCLUSIONS
5449,siRNA knockdown of A20 accelerates tumor progression in an in vivo murine xenograft model.,A20 anticancer therapies should therefore be viewed with caution as effects will likely differ depending on the tumor type.,False,CONCLUSIONS
5450,siRNA knockdown of A20 accelerates tumor progression in an in vivo murine xenograft model.,"OBJECTIVE A20 is a TNF-inducible primary response gene, which has been found to have antiapoptotic function in several cancer cells.",False,OBJECTIVE
5451,siRNA knockdown of A20 accelerates tumor progression in an in vivo murine xenograft model.,"This study investigates A20 expression in human glioma tissues and four glioma cell lines, and its effect on tumorigenesis of glioma cells and a mouse tumor model.   
",False,OBJECTIVE
5452,siRNA knockdown of A20 accelerates tumor progression in an in vivo murine xenograft model.,"METHODS Human glioma tissue samples and cells were subject to reverse transcription-PCR (RT-PCR), western blotting and immunohistochemistry.",False,METHODS
5453,siRNA knockdown of A20 accelerates tumor progression in an in vivo murine xenograft model.,Glioma cells was tested by flow cytometry.,False,METHODS
5454,siRNA knockdown of A20 accelerates tumor progression in an in vivo murine xenograft model.,"A xenograft tumor model in mice was utilized to examine the knock-down effect of specific A20 siRNAs on tumorigenesis.   
",False,METHODS
5455,siRNA knockdown of A20 accelerates tumor progression in an in vivo murine xenograft model.,RESULTS A20 was overexpressed in clinical glioma tissue samples (63.9%) and correlated with clinical staging.,False,RESULTS
5456,siRNA knockdown of A20 accelerates tumor progression in an in vivo murine xenograft model.,"All four human glioma cell lines expressed A20, among which U87 displayed the strongest expression signals.",False,RESULTS
5457,siRNA knockdown of A20 accelerates tumor progression in an in vivo murine xenograft model.,Inhibiting A20 expression by siRNAs in vitro reduced the growth rates of glioma cells and resulted in G1/S arrest and increased apoptosis.,True,RESULTS
5458,siRNA knockdown of A20 accelerates tumor progression in an in vivo murine xenograft model.,"In a mouse tumor model, local administration of siRNA significantly suppressed solid tumor growth.   
",True,RESULTS
5459,siRNA knockdown of A20 accelerates tumor progression in an in vivo murine xenograft model.,"CONCLUSIONS A20 was overexpressed both in human glioma tissues and cell lines, and inhibiting A20 expression greatly slowed tumor cell growth in culture and in mice.",True,CONCLUSIONS
5460,siRNA knockdown of A20 accelerates tumor progression in an in vivo murine xenograft model.,"These findings indicated that A20 is involved in tumorigenesis of human glioma, and may serve as a future therapeutic target.",False,CONCLUSIONS
5461,siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.,Glioblastomas are deadly cancers that display a functional cellular hierarchy maintained by self-renewing glioblastoma stem cells (GSCs).,False,BACKGROUND
5462,siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.,GSCs are regulated by molecular pathways distinct from the bulk tumor that may be useful therapeutic targets.,False,BACKGROUND
5463,siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.,"We determined that A20 (TNFAIP3), a regulator of cell survival and the NF-kappaB pathway, is overexpressed in GSCs relative to non-stem glioblastoma cells at both the mRNA and protein levels.",False,METHODS
5464,siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.,"To determine the functional significance of A20 in GSCs, we targeted A20 expression with lentiviral-mediated delivery of short hairpin RNA (shRNA).",False,METHODS
5465,siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.,"Inhibiting A20 expression decreased GSC growth and survival through mechanisms associated with decreased cell-cycle progression and decreased phosphorylation of p65/RelA. Elevated levels of A20 in GSCs contributed to apoptotic resistance: GSCs were less susceptible to TNFalpha-induced cell death than matched non-stem glioma cells, but A20 knockdown sensitized GSCs to TNFalpha-mediated apoptosis.",False,RESULTS
5466,siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.,The decreased survival of GSCs upon A20 knockdown contributed to the reduced ability of these cells to self-renew in primary and secondary neurosphere formation assays.,False,RESULTS
5467,siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.,"The tumorigenic potential of GSCs was decreased with A20 targeting, resulting in increased survival of mice bearing human glioma xenografts.",True,RESULTS
5468,siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.,In silico analysis of a glioma patient genomic database indicates that A20 overexpression and amplification is inversely correlated with survival.,False,RESULTS
5469,siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.,Together these data indicate that A20 contributes to glioma maintenance through effects on the glioma stem cell subpopulation.,False,CONCLUSIONS
5470,siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.,"Although inactivating mutations in A20 in lymphoma suggest A20 can act as a tumor suppressor, similar point mutations have not been identified through glioma genomic sequencing: in fact, our data suggest A20 may function as a tumor enhancer in glioma through promotion of GSC survival.",False,CONCLUSIONS
5471,siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.,A20 anticancer therapies should therefore be viewed with caution as effects will likely differ depending on the tumor type.,False,CONCLUSIONS
5472,siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.,"OBJECTIVE A20 is a TNF-inducible primary response gene, which has been found to have antiapoptotic function in several cancer cells.",False,OBJECTIVE
5473,siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.,"This study investigates A20 expression in human glioma tissues and four glioma cell lines, and its effect on tumorigenesis of glioma cells and a mouse tumor model.   
",False,OBJECTIVE
5474,siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.,"METHODS Human glioma tissue samples and cells were subject to reverse transcription-PCR (RT-PCR), western blotting and immunohistochemistry.",False,METHODS
5475,siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.,Glioma cells was tested by flow cytometry.,False,METHODS
5476,siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.,"A xenograft tumor model in mice was utilized to examine the knock-down effect of specific A20 siRNAs on tumorigenesis.   
",False,METHODS
5477,siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.,RESULTS A20 was overexpressed in clinical glioma tissue samples (63.9%) and correlated with clinical staging.,False,RESULTS
5478,siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.,"All four human glioma cell lines expressed A20, among which U87 displayed the strongest expression signals.",False,RESULTS
5479,siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.,Inhibiting A20 expression by siRNAs in vitro reduced the growth rates of glioma cells and resulted in G1/S arrest and increased apoptosis.,True,RESULTS
5480,siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.,"In a mouse tumor model, local administration of siRNA significantly suppressed solid tumor growth.   
",True,RESULTS
5481,siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.,"CONCLUSIONS A20 was overexpressed both in human glioma tissues and cell lines, and inhibiting A20 expression greatly slowed tumor cell growth in culture and in mice.",True,CONCLUSIONS
5482,siRNA knockdown of A20 slows tumor progression in an in vivo murine xenograft model.,"These findings indicated that A20 is involved in tumorigenesis of human glioma, and may serve as a future therapeutic target.",False,CONCLUSIONS
5483,β-sheet opening occurs during pleurotolysin pore formation.,"Membrane attack complex/perforin-like (MACPF) proteins comprise the largest superfamily of pore-forming proteins, playing crucial roles in immunity and pathogenesis.",False,BACKGROUND
5484,β-sheet opening occurs during pleurotolysin pore formation.,Soluble monomers assemble into large transmembrane pores via conformational transitions that remain to be structurally and mechanistically characterised.,False,BACKGROUND
5485,β-sheet opening occurs during pleurotolysin pore formation.,"Here we present an 11 Å resolution cryo-electron microscopy (cryo-EM) structure of the two-part, fungal toxin Pleurotolysin (Ply), together with crystal structures of both components (the lipid binding PlyA protein and the pore-forming MACPF component PlyB).",False,METHODS
5486,β-sheet opening occurs during pleurotolysin pore formation.,"These data reveal a 13-fold pore 80 Å in diameter and 100 Å in height, with each subunit comprised of a PlyB molecule atop a membrane bound dimer of PlyA. The resolution of the EM map, together with biophysical and computational experiments, allowed confident assignment of subdomains in a MACPF pore assembly.",False,RESULTS
5487,β-sheet opening occurs during pleurotolysin pore formation.,"The major conformational changes in PlyB are a ∼70° opening of the bent and distorted central β-sheet of the MACPF domain, accompanied by extrusion and refolding of two α-helical regions into transmembrane β-hairpins (TMH1 and TMH2).",True,RESULTS
5488,β-sheet opening occurs during pleurotolysin pore formation.,We determined the structures of three different disulphide bond-trapped prepore intermediates.,False,RESULTS
5489,β-sheet opening occurs during pleurotolysin pore formation.,Analysis of these data by molecular modelling and flexible fitting allows us to generate a potential trajectory of β-sheet unbending.,False,RESULTS
5490,β-sheet opening occurs during pleurotolysin pore formation.,The results suggest that MACPF conformational change is triggered through disruption of the interface between a conserved helix-turn-helix motif and the top of TMH2.,False,RESULTS
5491,β-sheet opening occurs during pleurotolysin pore formation.,Following their release we propose that the transmembrane regions assemble into β-hairpins via top down zippering of backbone hydrogen bonds to form the membrane-inserted β-barrel.,False,RESULTS
5492,β-sheet opening occurs during pleurotolysin pore formation.,"The intermediate structures of the MACPF domain during refolding into the β-barrel pore establish a structural paradigm for the transition from soluble monomer to pore, which may be conserved across the whole superfamily.",False,CONCLUSIONS
5493,β-sheet opening occurs during pleurotolysin pore formation.,"The TMH2 region is critical for the release of both TMH clusters, suggesting why this region is targeted by endogenous inhibitors of MACPF function.",False,CONCLUSIONS
